<SEC-DOCUMENT>0001193125-24-059407.txt : 20240305
<SEC-HEADER>0001193125-24-059407.hdr.sgml : 20240305
<ACCEPTANCE-DATETIME>20240305171528
ACCESSION NUMBER:		0001193125-24-059407
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		126
FILED AS OF DATE:		20240305
DATE AS OF CHANGE:		20240305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spyre Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001636282
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464312787
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273769
		FILM NUMBER:		24722261

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		6176515940

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aeglea BioTherapeutics, Inc.
		DATE OF NAME CHANGE:	20150311
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>d518298dposam.htm
<DESCRIPTION>POS AM
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:syre="http://www.spy.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>POS AM</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="max-width: auto"><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden103883669" contextRef="P01_01_2023To12_31_2023">POS AM</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden103882519" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">MA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden103882520" contextRef="P01_01_2023To12_31_2023">MA</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2023To12_31_2023" id="ixv-315">0001636282</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2023To12_31_2023" id="ixv-316">false</ix:nonNumeric><ix:footnote id="FN_363400" xml:lang="en-US">Includes $48.5 million in related party expenses for the year ended December 31, 2023 and no related party expenses for the year ended months ended December 31, 2022 and 2021.</ix:footnote></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="syre-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_12_2023To06_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-12</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To04_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2019"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2023To06_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-30</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_10_2015To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-03-10</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2022To05_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-01</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:SoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PerformanceSharesMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:RestructuringActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:RestructuringActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:RestructuringActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PerformanceSharesMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-22</xbrli:startDate> <xbrli:endDate>2023-06-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:FairmountFundsManagementLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonAndParapyreHoldingLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:USBankingInstitutionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-26</xbrli:startDate> <xbrli:endDate>2023-06-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-26</xbrli:startDate> <xbrli:endDate>2023-06-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-07</xbrli:startDate> <xbrli:endDate>2023-07-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-01</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-21</xbrli:startDate> <xbrli:endDate>2021-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PIPTrialMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-27</xbrli:startDate> <xbrli:endDate>2023-07-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">syre:DevelopmentFeeAndRoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:LicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">syre:DevelopmentFeeAndRoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2019_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:LicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-03-01</xbrli:startDate> <xbrli:endDate>2015-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-03-01</xbrli:startDate> <xbrli:endDate>2015-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-01</xbrli:startDate> <xbrli:endDate>2018-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-04-01</xbrli:startDate> <xbrli:endDate>2016-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-06-01</xbrli:startDate> <xbrli:endDate>2018-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2023To02_28_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-01</xbrli:startDate> <xbrli:endDate>2023-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-08</xbrli:startDate> <xbrli:endDate>2023-09-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-29</xbrli:startDate> <xbrli:endDate>2023-09-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">syre:ServiceBasedAwardsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-02-01</xbrli:startDate> <xbrli:endDate>2018-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:SoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:LaboratoryEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputReimbursementRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputReimbursementRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreFundedMay2022WarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:PreFundedMay2022WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:FairmountFundsManagementLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:USBankingInstitutionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AppointOfBoardMembersMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:AppointOfBoardMembersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ParapyreWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PerformanceSharesMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">syre:DevelopmentFeeAndRoyaltyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LicenseMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:SeveranceLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfPreFundedWarrantsMemberusgaapConversionOfStockByUniqueDescriptionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfPreFundedWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:StockCompensationAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:MilestonePaymentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SaleOfStockDecember2023PIPEMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SaleOfStockDecember2023PIPEMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-11</xbrli:startDate> <xbrli:endDate>2023-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2023To12_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-11</xbrli:startDate> <xbrli:endDate>2023-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-11</xbrli:startDate> <xbrli:endDate>2023-12-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_11_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_23_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-23</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002LicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-14</xbrli:startDate> <xbrli:endDate>2023-12-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002LicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-22</xbrli:startDate> <xbrli:endDate>2023-11-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-22</xbrli:startDate> <xbrli:endDate>2023-11-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2023To05_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-05-01</xbrli:startDate> <xbrli:endDate>2023-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_08_2023To12_08_2023_MinimumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-08</xbrli:startDate> <xbrli:endDate>2023-12-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_08_2023To12_08_2023_MaximumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-08</xbrli:startDate> <xbrli:endDate>2023-12-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_08_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2023To11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-11-01</xbrli:startDate> <xbrli:endDate>2023-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_09_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:SeveranceLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:SeveranceLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft"> <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day"> <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_BOARDSEAT"> <xbrli:measure>syre:BOARDSEAT</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_VOTE"> <xbrli:measure>syre:VOTE</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_SUBSIDARY"> <xbrli:measure>syre:SUBSIDARY</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_employee"> <xbrli:measure>syre:employee</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_installment"> <xbrli:measure>syre:installment</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_103881978" toRefs="FN_363400"></ix:relationship><ix:relationship fromRefs="Fact_103881979" toRefs="FN_363400"></ix:relationship><ix:relationship fromRefs="Fact_103881980" toRefs="FN_363400"></ix:relationship></ix:resources></ix:header></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><div style="width: 8.5in; text-align: left; margin-left: auto; margin-right: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="-sec-ix-redline:true;;display:inline;">As filed with the Securities and Exchange Commission on March&#160;5, 2024 </div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="font-weight:bold;display:inline;"><div style="-sec-ix-redline:true;;display:inline;">Registration No.&#160;333-273769 </div></div></div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION</div></div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WASHINGTON, D.C. 20549 </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">POST-EFFECTIVE AMENDMENT <div style="letter-spacing: 0px; top: 0px;;display:inline;">NO</div>. 1 </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 16pt;;font-weight:bold;display:inline;"><div style="font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">TO</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-hidden:hidden103883669;display:inline;">S-1</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER</div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2023To12_31_2023" id="ixv-3216">Spyre Therapeutics, Inc.</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter)</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 412.125px;"/>
<td style="vertical-align: bottom; width: 8.23438px;"/>
<td style="width: 395.641px;"/></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:stateprovnameen" id="ixv-3217">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-3218">46-4312787</ix:nonNumeric></div></div></div></td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8pt;">
<td style="vertical-align: top;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023" id="ixv-3219">221 Crescent Street</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2023To12_31_2023" id="ixv-3220">Building 23</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="P01_01_2023To12_31_2023" id="ixv-3221">Suite 105</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023" id="ixv-3222">Waltham</ix:nonNumeric>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-hidden:hidden103882520;display:inline;">MA</div></div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023" id="ixv-3223">02453</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023" id="ixv-3224">617</ix:nonNumeric>)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-3225">651-5940</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3226">Heidy King-Jones</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Legal Officer and Corporate Secretary</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Spyre Therapeutics, Inc.</div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3227">221 Crescent Street</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3228">Building 23</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3229">Suite 105</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3230">Waltham</ix:nonNumeric>, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-hidden:hidden103882519;display:inline;">MA</div></div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3231">02453</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3232">617</ix:nonNumeric>)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-3233">651-5940</ix:nonNumeric></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="line-height: 6pt; margin: 0pt auto 2pt; border-bottom: 1pt solid rgb(0, 0, 0); width: 171.359px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Ryan A. Murr </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Branden C. Berns </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Melanie E. Neary </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Gibson, Dunn&#160;&amp; Crutcher LLP </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">One Embarcadero Center, Suite 2600 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">San Francisco, CA 94111 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(415) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">393-8373</div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public</div></div>: From time to time after the effective date of this Registration Statement. </div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#8194;&#9746; </div></div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; width: 816px; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 138.719px;"/>
<td style="vertical-align: bottom; width: 8.15625px;"/>
<td style="width: 465.125px;"/>
<td style="vertical-align: bottom; width: 8.15625px;"/>
<td style="width: 171.359px;"/>
<td style="vertical-align: bottom; width: 8.15625px;"/>
<td style="width: 16.3281px;"/></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:entityfilercategoryen" id="ixv-3234">Non-accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2023To12_31_2023" format="ixt:fixed-true" id="ixv-3235">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: 'Times New Roman'; font-size: 8.5pt;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2023To12_31_2023" format="ixt:fixed-false" id="ixv-3236">&#9744;</ix:nonNumeric></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/> </div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXPLANATORY NOTE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics, Inc., a Delaware corporation, filed a Registration Statement on Form&#160;S-1 on October&#160;6, 2023, which was declared effective on November&#160;20, 2023 (as amended and supplemented, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">registration statement</span></span>&#8221;). This Post-Effective Amendment No.&#160;1 to Form&#160;S-1 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Post-Effective Amendment</span></span>&#8221;) is being updated to include the FY23 financial statements, based on our Form&#160;10-K for the year-ended December&#160;31, 2023 filed on February&#160;29, 2024, as well as updating certain other disclosures including those based on the above-mentioned Form&#160;10-K and updated selling stockholder information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information included in this filing amends the registration statement and the prospectus contained therein (and all amendments thereto). No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the registration statement. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED MARCH&#160;5, 2024 </span></span></p> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g81i79.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center">Spyre Therapeutics, Inc. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">18,809,064 Shares </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Stock </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Offered by the Selling Stockholders </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the &#8220;Selling Stockholders&#8221;) of up to (i)&#160;8,864&#160;shares (the &#8220;Merger Common Shares&#8221;) of our common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), (ii)&#160;248,560&#160;shares of Common Stock (the &#8220;Merger Conversion Shares&#8221;) that were issued upon the conversion of 6,214&#160;shares (&#8220;Merger Preferred Shares&#8221;) of our Series&#160;A Preferred Stock, par value $0.0001 per share (the &#8220;Series&#160;A Preferred Stock&#8221;), and (iii)&#160;18,551,640&#160;shares of Common Stock (the &#8220;Private Placement Conversion Shares&#8221;) that were issued upon the conversion of 463,791&#160;shares (the &#8220;Private Placement Preferred Shares&#8221;) of Series&#160;A Preferred Stock. The shares of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221; </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Common Shares and Merger Preferred Shares were issued and sold to former stockholders of Spyre Therapeutics, Inc., a Delaware corporation (&#8220;Spyre&#8221;), in connection with our acquisition (the &#8220;Asset Acquisition&#8221;) of Spyre, which closed on June&#160;22, 2023. The Private Placement Preferred Shares were issued and sold to accredited investors in a private placement (the &#8220;June 2023 PIPE&#8221; and, together with the Asset Acquisition, the &#8220;June 2023 Transactions&#8221;), which closed on June&#160;26, 2023. We are not selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders. </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading &#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares hereunder. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered. </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is traded on The Nasdaq Global Select Market under the symbol &#8220;SYRE.&#8221; On March&#160;4, 2024, the last reported sale price for our Common Stock was $34.97 per share. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold">An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading &#8220;<a href="#tx518298_5">Risk Factors</a>&#8221; beginning on page&#160;12 of this prospectus and any applicable prospectus supplement. </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">We are a &#8220;smaller reporting company&#8221; as defined by <span style="white-space:nowrap">Rule&#160;12b-2</span> of the Exchange Act and are subject to reduced public company reporting requirements. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is &#8195;&#8195;&#8195;&#8195;, 2024 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_4">RISK FACTOR SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_5">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_6">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_7">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_8">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_9">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_10">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_11">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_12">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_13">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_14">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_15">SELLING STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_16">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_17">DESCRIPTION OF CAPITAL STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_18">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_19">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_20">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx518298_21">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this prospectus, unless the context otherwise requires, the terms &#8220;Spyre,&#8221; &#8220;Aeglea BioTherapeutics, Inc.,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Spyre Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the <sup style="font-size:75%; vertical-align:top">&#174;</sup> or TM symbols. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to &#8220;our product candidates,&#8221; &#8220;our programs&#8221; and &#8220;our pipeline&#8221; in this prospectus refer to the research programs with respect to which we have exercised the option to acquire intellectual property license rights to or have the option to acquire intellectual property license rights to pursuant to that certain antibody discovery and option agreement, dated May&#160;25, 2023 and subsequently amended and restated on September&#160;29, 2023, by and among Spyre Therapeutics, LLC, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Parapyre Holding LLC (&#8220;Parapyre&#8221;) (the &#8220;Paragon Agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please be advised that on September&#160;8, 2023, we effected a reverse stock split of our Common Stock at a ratio of <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-25</span></span> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-Reverse Split basis. In addition, on November&#160;28, 2023, we changed our name from &#8220;Aeglea Biotherapeutics, Inc.&#8221; to &#8220;Spyre Therapeutics, Inc.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements, other than statements of historical facts contained in this prospectus, including, without limitation, statements regarding: stockholder approval of the conversion rights of the Series B Preferred Stock; any future payouts under the CVR (as defined herein); our ability to achieve the expected benefits or opportunities and related timing with respect to our acquisition of Spyre Therapeutics, Inc. <span style="white-space:nowrap">(&#8220;Pre-Merger</span> Spyre&#8221;) or to monetize any of our legacy assets, our future results of operations and financial position, business strategy, the length of time that we believe our existing cash resources will fund our operations, our market size, our potential growth opportunities, our preclinical and future clinical development activities, the efficacy and safety profile of our product candidates, the potential therapeutic benefits and economic value of our product candidates, the timing and results of preclinical studies and clinical trials, the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current or potential bank failures, as well as global events, including the ongoing military conflict in Ukraine, conflict in Israel and surrounding areas, and geopolitical tensions in China on our operations, and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements generally relate to future events or our future financial or operating performance. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference are disclosed in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties. We caution you that the risks, uncertainties and other factors referred to in this prospectus may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary may not contain all the information that you should consider before investing in securities. You should read the entire prospectus carefully, including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Company Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we completed the Asset Acquisition pursuant to the Acquisition Agreement (as defined under the section titled &#8220;<span style="font-style:italic">Recent Developments</span>&#8221; below). <span style="white-space:nowrap">Pre-Merger</span> Spyre was a <span style="white-space:nowrap">pre-clinical</span> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount Funds Management LLC (&#8220;Fairmount&#8221;), for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the option to license the intellectual property rights related to four research programs (collectively, the &#8220;Option&#8221;) pursuant to the Paragon Agreement. On July&#160;12, 2023, we exercised the Option with respect to one of these research programs to exclusively license intellectual property rights related to such research program directed to antibodies that selectively bind to &#945;4&#223;7 integrin and methods of using these antibodies, including methods of treating inflammatory bowel disease (&#8220;IBD&#8221;) using the SPY001 program. If this research program is pursued <span style="white-space:nowrap">non-provisionally</span> and matures into issued patents, we would expect those patents to expire no earlier than 2044, subject to any disclaimers or extensions. On December&#160;14, 2023, we exercised the Option under the Paragon Agreement to be granted an exclusive license to all of Paragon&#8217;s rights, title and interest in and to intellectual property rights, including inventions, patents, sequence information and results, under SPY002, Spyre&#8217;s TL1A program, to develop and commercialize antibodies and products worldwide in all therapeutics disorders. The license agreements pertaining to such research programs are currently being finalized. Furthermore, as of the date of this registration statement, the Option remains unexercised with respect to the intellectual property rights related to the two remaining research programs under the Paragon Agreement. For more information on the Paragon Agreement, see discussion under the heading &#8220;<span style="font-style:italic">Paragon Agreement</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, we announced that we entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica Pharma AB (&#8220;Immedica&#8221;) for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments (the &#8220;Immedica APA&#8221;). The sale of pegzilarginase to Immedica supersedes and terminates the license agreement between us and Immedica dated March 2021. See the section titled &#8220;<span style="font-style:italic">Recent Developments</span>&#8221; below for more information regarding the Immedica APA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Asset Acquisition and the entry into the Immedica APA, we have significantly reshaped the business into a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with IBD, including ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease (&#8220;CD&#8221;). Through the Paragon Agreement, our portfolio of novel and proprietary monoclonal antibody product candidates has the potential to address unmet needs in IBD care by improving efficacy, safety, and/or dosing convenience relative to products currently available or product candidates in development. We have engineered our product candidates with the aim to bind potently and selectively to their target epitopes and to exhibit extended pharmacokinetic half-lives through modifications in the Fc domain, that increase affinity to human FcRn and increase antibody recycling. We anticipate that half-life extension will enable less frequent administration as compared to marketed or development-stage monoclonal antibodies (&#8220;mAbs&#8221;) that do not incorporate half-life extension modifications. Nonetheless, the drug and/or device development process is inherently uncertain, our development approach is unproven, the preclinical evidence that supports our proposed development program is preliminary and limited, </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and we have not yet tested any product candidate in humans. In addition to the development of our product candidates as potential monotherapies, we plan to investigate combinations of our proprietary antibodies in preclinical and clinical studies to evaluate whether combination therapy (co-administration or co-formulation of multiple monoclonal antibodies) can lead to greater efficacy, as compared to monotherapies in IBD. We also intend to examine patient selection strategies via complementary diagnostics utilized in our clinical studies to evaluate whether patients can be matched to the optimal therapy based on genetic background and/or other biomarker signatures. We intend to deliver our product candidates through convenient, infrequently dosed, self-administered, subcutaneous (&#8220;SC&#8221;) injection, although the specific delivery mechanism or technology has not been selected given our early stage. Notwithstanding our efforts to develop safe and effective monotherapies and combination therapies, there can be no guarantee that we will be able to develop product candidates that will be found to be safe and effective so as to obtain the necessary regulatory approvals to market our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">On September 8, 2023, we effected the Reverse Split, which resulted in the reverse split of our Common Stock at a ratio of <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-25.</span></span> Readers should note that, except as indicated otherwise, all share numbers related to our Common Stock disclosed in this &#8220;Recent Developments&#8221; section have been adjusted on a post-Reverse Split basis. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we acquired in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), by and among us, Aspen Merger Sub I, Inc., a Delaware corporation and our wholly owned subsidiary, Sequoia Merger Sub II, LLC, a Delaware limited liability company and our wholly owned subsidiary, and <span style="white-space:nowrap">Pre-Merger</span> Spyre, the assets of <span style="white-space:nowrap">Pre-Merger</span> Spyre, a privately held biotechnology company advancing a pipeline of antibody therapeutics through the Paragon Agreement. <span style="white-space:nowrap">Pre-Merger</span> Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Asset Acquisition was structured as a <span style="white-space:nowrap"><span style="white-space:nowrap">stock-for-stock</span></span> transaction pursuant to which all of <span style="white-space:nowrap">Pre-Merger</span> Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from us of 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of Common Stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Common Stock and the Series A Preferred Stock related to the Asset Acquisition were issued to <span style="white-space:nowrap">Pre-Merger</span> Spyre stockholders on July&#160;7, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Asset Acquisition, we entered into a definitive agreement (the &#8220;June 2023 SPA&#8221;) for a PIPE investment (the &#8220;June 2023 PIPE&#8221; and, together with the Asset Acquisition, the &#8220;June 2023 Transactions&#8221;) with existing and new investors (the &#8220;June 2023 Investors&#8221;) to raise approximately $210&#160;million in which the June 2023 Investors were issued 721,452 shares of Series A Preferred Stock at a price of $291.08 per share. The Asset Acquisition was approved by our board of directors and the board of directors and stockholders of <span style="white-space:nowrap">Pre-Merger</span> Spyre. The closings of the June 2023 Transactions were not subject to the approval of our stockholders. Following receipt of stockholder approval of the conversion of Series A Preferred Stock in November 2023, each share of Series A Preferred Stock automatically converted into 40 shares of Common Stock, subject to certain beneficial ownership limitations set by each holder. Except as otherwise required by law (e.g. voting on a change to the authorized shares of Series A <span style="white-space:nowrap">Non-Voting</span> Preferred Stock or the rights of such shares as required by Delaware General Corporation Law (the &#8220;DGCL&#8221;)) and Spyre&#8217;s Certificate of Designation of Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;), the Series A Preferred Stock does not have voting rights. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Acquisition Agreement, Spyre and <span style="white-space:nowrap">Pre-Merger</span> Spyre entered into stockholder support agreements (the &#8220;Support Agreements&#8221;) with certain of Spyre&#8217;s officers and directors, which collectively own an aggregate of less than 1% of the outstanding shares of the Common Stock. The Support Agreements provide that, among other things, each of the parties thereto would vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the approval of the conversion of shares of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules at Spyre&#8217;s stockholders&#8217; meeting held in connection therewith. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the execution of the Acquisition Agreement, certain <span style="white-space:nowrap">Pre-Merger</span> Spyre stockholders as of immediately prior to the Asset Acquisition, and certain of the directors and officers of Spyre as of immediately prior to the Asset Acquisition entered into <span style="white-space:nowrap">lock-up</span> agreements with Spyre and <span style="white-space:nowrap">Pre-Merger</span> Spyre, pursuant to which each such stockholder was subject to a <span style="white-space:nowrap">180-day</span> lockup on the sale or transfer of shares of Common Stock held by each such stockholder at the closing of the Asset Acquisition, including those shares received by such <span style="white-space:nowrap">Pre-Merger</span> Spyre stockholders in the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <span style="white-space:nowrap">non-transferrable</span> contingent value right (a &#8220;CVR&#8221;) was distributed to Spyre stockholders of record as of the close of business on July&#160;3, 2023, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the June 2023 Investors or former stockholders of Pre- Merger Spyre in connection with the June 2023 Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by Spyre for a three-year period, if any, related to the disposition or monetization of certain legacy assets owned by us prior to the Asset Acquisition (the &#8220;Legacy Assets&#8221;) for a period of one year following the closing of the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, we announced that we entered the Immedica APA. The sale of pegzilarginase to Immedica supersedes and terminates the license agreement between us and Immedica dated March 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The milestone payments under the Immedica APA are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the United States Food and Drug Administration (the &#8220;FDA&#8221;), among other events. The upfront payment has been paid and distributed and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to holders of Spyre&#8217;s CVR pursuant to the CVR Agreement that was entered into in connection with the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;7, 2023, we entered into a definitive agreement (the &#8220;December 2023 SPA&#8221;) for a PIPE investment with existing and new investors (the &#8220;December 2023 Investors&#8221;) to raise $180&#160;million, in which transaction the December 2023 Investors were issued an aggregate of 6,000,000 shares of Common Stock at a price of $15.00 per share and 150,000 shares of Series B Preferred Stock at a price of $600.00 per share. The closing of the December 2023 PIPE was not subject to Spyre stockholder approval. Subject to Spyre stockholder approval and certain beneficial ownership limitations set by each holder, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock. We intend to file a definitive proxy statement with the SEC to solicit such stockholder approval, among other matters, at the 2024 annual meeting of stockholders. Except as otherwise required by law (e.g. voting on a change to the authorized shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock or the rights of such shares as required by DGCL) and as specified in our Certificate of Designation of Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (&#8220;Series B Certificate of Designation&#8221;), the Series B Preferred Stock does not have voting rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporation Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were formed as a limited liability company under the laws of the State of Delaware in December 2013 and converted to a Delaware corporation in March 2015. On June&#160;22, 2023, we completed the Asset Acquisition, pursuant to which all of <span style="white-space:nowrap">Pre-Merger</span> Spyre&#8217;s outstanding equity interests were exchanged based on a fixed </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchange ratio of 0.5494488 to 1 for consideration from Spyre of 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of Common Stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. On November&#160;28, 2023, we changed our name from &#8220;Aeglea Biotherapeutics, Inc.&#8221; to &#8220;Spyre Therapeutics, Inc.&#8221; and our Nasdaq ticker symbol from &#8220;AGLE&#8221; to &#8220;SYRE&#8221;. Our principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453, and our telephone number is (617) <span style="white-space:nowrap">651-5940.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, we effected a reverse stock split of our Common Stock at a ratio of <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-25.</span></span> Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-Reverse Split basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Implications of Being a Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company,&#8221; meaning that the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&#160;the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700.0&#160;million. As a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <span style="white-space:nowrap">10-K</span> and smaller reporting companies have reduced disclosure obligations regarding executive compensation. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The Offering </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares Offered by the Selling Securityholders </p></td>
<td>Up to (i) 8,864 shares of Common Stock, (ii) 248,560 shares of Common Stock that were issued upon the conversion of 6,214 shares of Series A Preferred Stock, and (iii) 18,551,640 shares of Common Stock that were issued upon the conversion of 463,791 shares of Series A Preferred Stock. </td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the Offering </p></td>
<td>The selling securityholders will determine when and how they will dispose of the shares of Common Stock and shares of Common Stock that were issued upon the conversion of Series A Preferred Stock registered under this prospectus for resale. </td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares Outstanding </p></td>
<td>As of December&#160;31, 2023, there were 36,057,109 shares of our Common Stock, 437,037 shares of our Series A Preferred Stock and 150,000 shares of our Series B Preferred Stock outstanding. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>We will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. See the section titled &#8220;Use of Proceeds.&#8221; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </p></td>
<td>See the section titled &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Trading Markets and Ticker Symbols </p></td>
<td>Our Common Stock is listed on The Nasdaq Global Select Market under the symbol &#8220;SYRE.&#8221; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of issued and outstanding shares of Common Stock does not include the following, as of December&#160;31, 2023: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">17,481,480 shares of Common Stock issuable upon the conversion of 437,037 shares of Series A Preferred Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">6,000,000 shares of Common Stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">3,029 shares of Common Stock reserved for issuance under our 2015 Equity Incentive Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">4,931,476&#160;shares of Common Stock reserved for issuance under our Amended and Restated 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">6,044,000 shares of Common Stock reserved for issuance under our 2018 Equity Inducement Plan, as amended; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">72,404 shares of Common Stock reserved for issuance pursuant to our 2016 Employee Stock Purchase Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">250,000 shares of Common Stock reserved for issuance upon the exercise of 250,000 <span style="white-space:nowrap">pre-funded</span> warrants to acquire shares of Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">684,407 shares of Common Stock reserved for issuance upon the exercise of 684,407 warrants to acquire shares of Common Stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">121,871 shares of Common Stock reserved for issuance under the Spyre 2023 Equity Incentive Plan, as amended and assumed by us. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-Reverse Split basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information concerning the offering, see the section titled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_4">RISK FACTOR SUMMARY </p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this prospectus and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business. </p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition and Capital Requirements </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will not be able to continue as a going concern if we are unable to raise additional capital when needed. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have never generated any revenue from product sales and may never be profitable. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We anticipate that we will continue to incur significant losses for the foreseeable future. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be able to raise the capital that we need to support our business plans and raising additional capital may cause dilution to our stockholders and restrict our operations. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Discovery, Development and Commercialization </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face competition from companies that have developed or may develop competing programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our programs are in preclinical stages of development and may fail in development or suffer delays. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are substantially dependent on the success of the SPY001 and SPY002 programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to achieve our projected development goals in the time frames we announce and expect. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any drug delivery device used may have its own regulatory development, supply, and other risks. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be successful in building a pipeline of product candidates with commercial value. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our studies and trials may not be sufficient to support regulatory approval of any product candidates. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to successfully develop complementary diagnostics for our therapeutic product candidates, we may not realize their full commercial potential. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have limited experience in developing and commercializing diagnostics and have never applied for or obtained regulatory clearance or approval for any diagnostic tests. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Additional time may be required to obtain regulatory approval for our product candidates and future product candidates because of their status as combination products. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may encounter difficulties enrolling participants in our future clinical trials. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Preliminary or &#8220;topline&#8221; data from our clinical trials may change as more data becomes available. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our future clinical trials may reveal significant adverse events or side effects. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to capitalize on more profitable or potentially successful product candidates. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our future products may not achieve regulatory approval or commercial success. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Certain of our programs may compete with our other programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The FDA may not accept data from clinical trials we conduct at sites outside the United States. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA and comparable foreign regulatory approval processes are lengthy and time-consuming and we may not be able to obtain or may be delayed in obtaining regulatory approvals for our product candidates. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be able to meet requirements for chemistry, manufacturing and control of our programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our product candidates may face competition sooner than anticipated based on rules and regulations that may apply or government decisions with respect to our intellectual property. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Even if we receive regulatory approval, we will be subject to extensive ongoing regulatory obligations. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may face difficulties from healthcare legislative reform measures. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our operations and arrangements with third-parties are subject to healthcare regulatory laws. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be unable to offer products at competitive prices due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may face criminal liability or other consequences for violations of U.S. and foreign trade regulations. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Foreign governments may impose strict price controls, which may adversely affect our revenue. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any accelerated review designations (e.g. fast track designation) we may pursue may not hasten development or regulatory review. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to obtain and protect our patents and other proprietary rights is uncertain. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail in obtaining or maintaining necessary rights to our programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to patent infringement claims or may need to file such claims. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may subject to claims of wrongful hiring of employees or wrongful use of confidential information. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our patents and our ability to protect our products may be impaired by changes to patent laws. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with regulatory requirements. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to identify or interpret relevant third-party patents. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may become subject to claims challenging the inventorship or ownership of our intellectual property. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Patent terms may be inadequate to protect our competitive position of our programs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our technology licensed from various third parties may be subject to retained rights. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Reliance on Third Parties </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to maintain collaborations and licensing arrangements with third parties that we rely on. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Third-parties we rely on for the execution of preclinical studies and clinical trials may fail to carry out their contractual duties. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be unable to use third-party manufacturing sites or our third-party manufacturers may encounter difficulties in production. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may experience difficulties in managing the growth of our organization. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to attract or retain highly qualified personnel. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to operate in foreign markets is subject to regulatory burdens, risks and uncertainties. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our estimates of market opportunity and forecasts of market growth may be inaccurate and our business may not grow at similar rates, or at all. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our employees or third-parties may engage in misconduct or other improper activities. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be impacted by security or data breaches or other improper access to our data. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to comply with privacy and data security regulations. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to comply with environmental, health and safety laws and regulations. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to adverse legislative or regulatory tax changes. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to realize the benefits of our business or product acquisitions or our strategic alliances. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be impacted by the failure of financial institutions. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Common Stock </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may fail to obtain stockholder approval of the conversion of our Series B Preferred Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our certificate of incorporation, Delaware law and certain contracts include anti-takeover provisions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our certificate of incorporation and bylaws contain exclusive forum provisions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We do not anticipate paying any dividends in the foreseeable future. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Future sales of shares by existing stockholders could cause our stock price to decline. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Future sales and issuances of equity and debt could result in additional dilution to our stockholders. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our principal stockholders own a significant percentage of our stock. </p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General Risk Factors </p> <p style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of our Common Stock has historically been volatile and may drop in the future. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We incur significant costs associated with complying with public company reporting requirements. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A lack of analyst coverage may cause a decline in our stock price or trading volume. We may fail to maintain proper and effective internal controls. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_5">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to raise additional capital, and if we are unable to do so when needed, we will not be able to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had $339.6 million of cash, cash equivalents, marketable securities, and restricted cash. We will need to raise additional capital to continue to fund our operations and service our debt obligations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developing our product candidates requires a substantial amount of capital. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all, and such funding may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S. capital markets and the biotechnology sector in general. Competition for additional capital among biotechnology companies may be particularly intense during this present economic downturn. We may be unable to raise capital through public offerings of our Common Stock and may need to turn to alternative financing arrangements. Such arrangements, if we pursue them, could involve issuances of one or more types of securities, including Common Stock, Preferred Stock, convertible debt, warrants to acquire Common Stock or other securities. These securities could be issued at or below the then prevailing market price for our Common Stock. In addition, if we issue debt securities, the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make-whole has been paid. Interest on any newly-issued debt securities and/or newly-incurred borrowings would increase our operating costs and reduce our net income (or increase our net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of our Common Stock, the market price of our Common Stock could be materially and adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional capital when required or on acceptable terms, we may be required to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significantly delay, scale back, or discontinue the development or commercialization of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">file for bankruptcy or cease operations altogether (and face any related legal proceedings). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could have a material adverse effect on our business, operating results, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions placed on the amount of capital we raise or other reasons. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;<span style="font-style:italic">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have never generated any revenue from product sales and may never be profitable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completing research and development of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining regulatory and marketing approvals for our product candidates for which we complete clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">qualify for adequate coverage and reimbursement by government and third-party payors for any product candidates for which we obtain regulatory and marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">marketing, launching, and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">gaining market acceptance of our product candidates as treatment options; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">addressing any competing products and technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implementing internal systems and infrastructure, as needed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">protecting and enforcing our intellectual property rights, including patents, trade secrets, and <span style="white-space:nowrap">know-how;</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining coverage and adequate reimbursement from third-party payors and maintaining pricing for our product candidates that supports profitability; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attracting, hiring, and retaining qualified personnel. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by regulatory authorities to perform clinical and other studies in addition to those that we anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Portions of the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement may be <span style="white-space:nowrap">in-licensed</span> from third parties, which make the commercial sale of such <span style="white-space:nowrap">in-licensed</span> products potentially subject to additional royalty and milestone payments to such third parties. We will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of our product candidates. For instance, if the costs of manufacturing our drug product are not commercially feasible, we will need to develop or procure our drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company with a limited operating history. Since inception, we have incurred significant operating losses. For the years ended December&#160;31, 2023, 2022 and 2021, we reported a net loss of $338.8&#160;million, $83.8 million and $65.8&#160;million, respectively. As of December 31, 2023, we had an accumulated deficit of $764.4&#160;million. We will need to raise substantial additional capital to continue to fund our operations in the future. If our stockholders do not timely approve the conversion of our Series B Preferred Stock, then the holders of our Series B Preferred Stock may be entitled to require us to settle their shares of Series B Preferred Stock for cash at a price per underlying share of Common Stock equal to the last reported closing sale price of Common Stock on the principal trading market on which the Common Stock is listed as of the trading day immediately prior to the date on which a request to convert shares of Series B Preferred Stock into shares of Common Stock is delivered to us by a holder in accordance with the terms of the Series B Certificate of Designation and we fail to deliver such shares of Common Stock, as described in our Series B Certificate of Designation relating to the Series B Preferred Stock. Because the specific timing of the exercise of the cash redemption is not under our control and is dependent the closing sale price of our Common stock at the time of such conversion, we cannot quantify the aggregate amount of the potential cash settlement; however, for illustrative purposes only, if all of our holders of Series B Preferred Stock had delivered requests to convert their shares of Series B Preferred Stock on February 26, 2024 and assuming we were obligated to settle such conversions in cash pursuant to the terms of the Series B Certificate of Designation, a total of $141,480,000 would have been payable to such holders as a result of the cash settlement of all 6,000,000 shares of Common Stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock, at a price of $23.58 per share of Common Stock, which was the closing sale price of our Common Stock on the Nasdaq Global Select Market on February 23, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to complete future milestones and we may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings or entering into strategic collaborations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including conducting preclinical and clinical development of the legacy rare disease clinical studies conducted by us prior to the Asset Acquisition (the &#8220;Legacy Pipeline&#8221;) and the preclinical development of our current IBD pipeline, and providing general and administrative support for our operations. To date, we have funded our operations primarily from the sale and issuance of convertible preferred and common equity securities, <span style="white-space:nowrap">pre-funded</span> warrants, the collection of grant proceeds, and the licensing of our product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates enter more advanced clinical trials. It may be several years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acceptance, pricing, coverage and adequate reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue the preclinical development and initiate the clinical development of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue efforts to discover and develop new product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue the manufacturing of our product candidates or increase volumes manufactured by third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advance our product candidates into larger, more expensive clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiate additional preclinical studies or clinical trials for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek regulatory and marketing approvals and reimbursement for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for ourselves; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek to identify, assess, acquire, and/or develop other product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make milestone, royalty, or other payments under third-party license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek to maintain, protect, and expand our intellectual property portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pay penalties under our registration rights agreement for failing to timely register the applicable securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek to attract and retain skilled personnel; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer <span style="white-space:nowrap">follow-up</span> for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a <span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> comparison of our results of operations may not be a good indication of our future performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial revenue from the sale of our product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of Common Stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our stockholders. For instance, in December 2023, we sold an aggregate of 6,000,000 shares of Common Stock and 150,000 shares of our Series B Preferred Stock in the December 2023 PIPE to the December 2023 Investors for gross proceeds of $180.0&#160;million. Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each holder of Series B Preferred Stock, each share of Series B Preferred Stock will automatically convert into an aggregate of 40 shares of our Common Stock. We are required to solicit the consent of our stockholders with regard to conversion of the shares of our Series B Preferred Stock, which will be voted on at our 2024 annual meeting of stockholders. If our stockholders fail to approve such matters, we may be subject to financial penalties that could materially harm our business, including the forced settlement of shares of Series B Preferred Stock for cash, as described in our Series B Certificate of Designation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot be assured that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially harm our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Discovery, Development and Commercialization </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will complete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trial conduct, regulatory approvals, and marketing than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive therapeutic treatments include those that have already been approved and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accepted by the medical community and any new treatments. Our success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop competing products or if biosimilars enter the market more quickly than we do and are able to gain market acceptance. See the section titled &#8220;Business &#8211; Competition&#8221; for more discussion about our competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because of the competitive landscape for inflammatory and immunology (&#8220;I&amp;I&#8221;) indications, we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development for the same indications as our programs. An increase in the number of approved products for the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number of participants could, among other things, delay our development timeline, which may further harm our competitive position. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our current or future collaborators are unable to complete development of, or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no products on the market, and all of our product candidates are in preclinical stages of development and have not been tested in humans. As a result, we expect it will be many years before we commercialize any product candidate, if ever. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, our product candidates, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our product candidates. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our programs and future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our collaborators may experience delays in initiating or completing clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, any current or future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites deviating from trial protocol or dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory bodies require completion of <span style="white-space:nowrap">non-inferiority</span> or superiority trials, enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment <span style="white-space:nowrap">follow-up</span> at a higher rate than we anticipate; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials of any of our programs may be greater than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to manufacture sufficient quantities of our product candidates for use in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reports from clinical testing of other therapies may raise safety or efficacy concerns about our programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing clinical trials in the United States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;), biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (&#8220;EU&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates. We or our current or future collaborators&#8217; inability to complete development of, or commercialize our product candidates, or significant delays in doing so, could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are substantially dependent on the success of our two most advanced programs, SPY001 and SPY002, and our anticipated clinical trials of such programs may not be successful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize, our two most advanced programs, SPY001 and SPY002. We exercised our Option with respect to the SPY001 and SPY002 programs on July&#160;12, 2023 and December&#160;14, 2023, respectively. We are investing a majority of our efforts and financial resources into the research and development of these programs. We anticipate initiating a Phase 1 clinical trial in healthy volunteers of SPY001 in the first half of 2024 and of SPY002 in the second half of 2024, each subject to the filing of an IND or foreign equivalent and regulatory approval. The success of our programs is dependent on observing a longer half-life of our product candidates in humans than other mAbs currently marketed and in development as we believe this longer half-life </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has the potential to result in a more favorable dosing schedule for our product candidates, assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half-life we have observed in <span style="white-space:nowrap">non-human</span> primates (&#8220;NHPs&#8221;) will translate into an extended half-life of our product candidates in humans. To the extent we do not observe this extended half-life when we dose humans with our product candidates, it would significantly and adversely affect the clinical and commercial potential of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote these programs, or any other programs, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of these product candidates, even if approved. If we are not successful in commercializing our SPY001 or SPY002 programs, or are significantly delayed in doing so, our business will be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our stock price may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of our Phase 1 study, clinical trials in IBD, as well as the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our product candidates may be delayed or never achieved and, as a result, our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any drug delivery device that we potentially use to deliver our product candidates may have its own regulatory, development, supply and other risks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Our product candidates may not be approved or may be substantially delayed in receiving approval if the devices that we choose to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent on those third-party companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to the discovery and development of the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half-life and other properties designed to overcome limitations of existing therapies. Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well-established mechanisms of action. However, the scientific research that forms the basis of our efforts to develop programs using half-life extension technologies, including YTE and LS amino acid substitutions, is ongoing and may not result in viable programs. We have limited clinical data on product candidates utilizing YTE and LS half-life extension technologies, especially in I&amp;I indications, demonstrating whether they are safe or effective for long-term treatment in humans. The long-term safety and efficacy of these technologies and the extended half-life and exposure profile of our programs compared to currently approved products is unknown. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may ultimately discover that utilizing half-life extension technologies for our specific targets and indications and any programs resulting therefrom do not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data regarding the increased half-life properties of our programs and the same results may not be seen in humans. In addition, programs using half-life extension technologies may demonstrate different chemical and pharmacological properties in participants than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, we depend on the availability of NHPs to conduct certain preclinical studies that we are required to complete prior to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. This could cause the cost of obtaining NHPs for our future preclinical studies to increase significantly and, if the shortage continues, could also result in delays to our development timelines. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, we expect to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from day to day for a particular participant, and from participant to participant and from site to site within a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that the FDA will agree with our clinical development plan. We plan to use the data from our planned Phase 1 trials of our SPY001 and SPY002 programs in healthy volunteers to support Phase 2 trials in IBD and other I&amp;I indications. If the FDA requires us to conduct additional trials or enroll additional participants, our development timelines may be delayed. We cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other <span style="font-style:italic">in vivo </span>or <span style="font-style:italic">in vitro </span>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;) and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are researching the potential use of complementary diagnostics in connection with the development of our product candidates, and although we do not currently anticipate such diagnostics would be required for the regulatory approval of any of our product candidates, they may be helpful to maximize the clinical and commercial success of our product candidates and if we fail to develop such complementary diagnostics or obtain regulatory approvals that may be required if they will be used commercially alongside any of our product candidates, our products may not be as competitive or commercially successful as they could be. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A complementary diagnostic is a medical device, often an in vitro device, which provides information that is valuable for the safe and effective use of a corresponding therapeutic drug or biologic product. A complementary diagnostic can be used to identify patients or subsets of patients who are most likely to benefit from the therapeutic product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A complementary diagnostic is generally developed in conjunction with the clinical program for an associated therapeutic product. The development path of a complementary diagnostic may include additional meetings with regulatory authorities, such as a pre-submission meeting and the requirement to submit an investigational device exemption application. In the case of a complementary diagnostic that is designated as &#8220;significant risk device,&#8221; approval of an investigational device exemption by the FDA and IRB is required before such diagnostic is used in conjunction with the clinical trials for a corresponding product candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be successful in developing, validating, obtaining approval of and commercializing a complementary diagnostic, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical device or diagnostic test development. If we choose to develop and seek FDA approval for complementary diagnostic tests on our own, we may require additional personnel. We may rely on third parties for the design, development, testing, validation and manufacture of complementary diagnostic tests for our therapeutic product candidates that may benefit from such tests, the application for and receipt of any required regulatory approvals, and the commercial supply of these complementary diagnostics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we currently plan to focus our complementary diagnostic development program on diagnostics that may help to identity high/better responding patients for our product candidates, we do not believe such complementary diagnostics will be required by regulatory authorities in connection with granting regulatory approval for our product candidates but may aid in clinical trial recruitment, post-approval treatment decisions and maximizing the commercial success of our product candidates. If we or third parties we engage are unable to successfully develop complementary diagnostics for our product candidates, or experience delays in doing so: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to maximize our potential to identify appropriate patients for enrollment in our clinical trials, which may adversely affect the development of our therapeutic product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the FDA or other regulators determine that the safe and effective use of our therapeutic product candidates, if any, depends on the complementary diagnostics we develop then we would have to expend time and resources to obtain regulatory approval of such complementary diagnostics which could cause delays in the commercial launch or success of our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not realize the full commercial potential of any therapeutics that receive marketing approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of any of these events, our business, financial condition, results of operations and prospects could be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have limited experience in developing and commercializing diagnostics and have never applied for or obtained regulatory clearance or approval for any diagnostic tests. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be successful in developing and commercializing therapeutic product candidates in combination with diagnostic candidates, we will need to address a number of scientific, technical, regulatory and logistical challenges. We currently anticipate that we or a collaborator may need to obtain marketing authorization from </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FDA in order to legally market such diagnostics in the United States. As a company, we have little experience in the development of diagnostic tests and may not be successful in developing appropriate diagnostics to pair with any of our therapeutic product candidates that receive marketing approval, and have never applied for or obtained regulatory clearance or approval of any such diagnostic tests. Given our limited experience in developing diagnostic tests, we may rely in part or in whole on third parties for their design, development and manufacture of such tests. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, a company must first submit an application for and receive 510(k) clearance pursuant to a premarket notification submitted under Section&#160;510(k) of the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), de-novo classification, or PMA approval from FDA, unless an exemption applies. The PMA approval pathway, which we expect to pursue for our complementary diagnostic product candidates, requires an applicant to demonstrate the safety and effectiveness of the product based, in part, on valid scientific evidence, including, but not limited to, technical, preclinical, and clinical data. The 510(k) pathway requires a FDA finding that the test is substantially equivalent to a legally marketed predicate device. If no legally marketed predicate can be identified to enable use of the 510(k) pathway, the device is automatically classified under the FDCA into Class III, which generally requires PMA approval. However, for low- to moderate-risk novel devices, FDA allows for the possibility of marketing authorization through the &#8220;<span style="font-style:italic">de novo</span> classification&#8221; process rather than requiring the device to be subject to PMA approval. Products that are approved through a PMA application generally need prior FDA approval before modifications can be made that affect safety or effectiveness, and certain modifications to a 510(k)-cleared device may also require FDA premarket review before the modified product can be marketed. If we are unable to successfully develop, obtain regulatory clearance for and commercialize diagnostics to pair with our therapeutic product candidates, it could adversely impact our ability to develop and generate revenue from our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Additional time may be required to obtain regulatory approval for our product candidates and future product candidates because of their status as combination products.</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may pursue development of combination products that require coordination within the FDA and comparable foreign regulatory authorities for review of its device and biologic components. Although the FDA and comparable foreign regulatory authorities have systems in place for the review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process. Of note, prior clearance or approval of one component of a combination product does not increase the likelihood that FDA will approve a later product combining the previously cleared product or approved active ingredient with a novel active ingredient. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we encounter difficulties enrolling participants in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience difficulties in patient participant enrollment in our future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants who remain in the trial until its conclusion. The enrollment of participants in future trials for any of our programs will depend on many factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if our competitors have ongoing clinical trials for programs that are under development for the same indications as our programs, and participants instead enroll in such clinical trials. Additionally, the number of participants required for clinical trials of our programs may be larger than we anticipate, especially if regulatory bodies require the completion of <span style="white-space:nowrap">non-inferiority</span> or superiority trials. Even if we are able to enroll a sufficient number of participants for our future clinical trials, we may have difficulty maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs or may require us to abandon one or more clinical trials altogether. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preliminary, &#8220;topline&#8221; or interim data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future clinical trials or those of our future collaborators may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While our preclinical studies in NHPs have not shown any such characteristics to date, we have not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting participants to such trials, participants may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early&#8211;stage studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half-life could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment-emergent adverse events could also affect participant recruitment or the ability of enrolled subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, even if we successfully advance our product candidates or any future product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using our product candidates over a multi-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the foregoing events occur or if one or more of the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement prove to be unsafe, our entire pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example, we are initially focused on our most advanced programs, SPY001 and SPY002. As a result, we may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of IBD. However, our programs incorporate advanced antibody engineering to optimize the half-life and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of IBD. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt a biologic that incorporates half-life extension for our targeted indications, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. An extended half-life may make it more difficult for patients to change treatments and there is a perception that half-life extension could exacerbate side effects, each of which may adversely affect our ability to gain market acceptance. Market acceptance of our product candidates will depend on many factors, including factors that are not within our control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any current or future product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing product candidates for the same indication: IBD, and may in the future develop our programs for other I&amp;I indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit our future revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We plan to conduct clinical trials for programs at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may choose to conduct one or more of our future clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates. Even if the FDA accepted such data, it could require us to modify our planned clinical trials to receive clearance to initiate such trials in the United States or to continue such trials once initiated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, conducting international clinical trials presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including our most advanced product candidates, SPY001 and SPY002, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to meet requirements for the chemistry, manufacturing and control of our programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our contract manufacturing partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with an <span style="white-space:nowrap">FDA-licensed</span> reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that any of our product candidates approved as biologics under a BLA should qualify for the <span style="white-space:nowrap">12-year</span> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for <span style="white-space:nowrap">non-biological</span> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as <span style="white-space:nowrap">on-going</span> compliance with current cGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may face difficulties from healthcare legislative reform measures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. See the section titled &#8220;Business &#8211; Government Regulation &#8211; Healthcare Reform&#8221; for a more detailed description of healthcare reform measures that may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. See the section titled &#8220;Business &#8211; Government Regulation &#8211; Other Healthcare Laws and Compliance Requirements&#8221; for a more detailed description of the laws that may affect our ability to operate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices which would seriously harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product candidates are approved and we are found to have improperly promoted off-label uses of those product candidates, we may become subject to significant liability, which would materially adversely affect our business and financial condition. See the sections titled &#8220;Business &#8211; Government Regulation &#8211; Coverage and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Reimbursement&#8221; and &#8220;Business &#8211; Other Government Regulation Outside of the United States &#8211; Regulation in the European Union&#8221; for a more detailed description of the government regulations and third party payor practices that may affect our ability to commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/ or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some countries, particularly member states of the EU, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <span style="white-space:nowrap">low-priced</span> and high-priced member states, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A breakthrough therapy, fast track, or other expedited designation for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable regulatory authorities. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify under one of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. See the section titled &#8220;Business &#8211; Government Regulation &#8211; Expedited Development and Review Programs&#8221; for a more detailed description of the process for seeking expedited designations such as fast track or breakthrough therapy designations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Paragon Agreement to protect the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with us. Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, programs and their uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. We own and have licensed rights to pending patent applications and expect to continue to file patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. However, we may not be able to protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, we may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the United States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any meaningful competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented <span style="white-space:nowrap">know-how,</span> technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and <span style="white-space:nowrap">in-licenses.</span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <span style="white-space:nowrap">in-license,</span> or use these third-party proprietary rights. We may be unable to acquire or <span style="white-space:nowrap">in-license</span> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we do obtain, we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our current and future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our current and future licensors are not the sole and exclusive owners of the patents we <span style="white-space:nowrap">in-license.</span> If other third parties have ownership rights to our current and future <span style="white-space:nowrap">in-licensed</span> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our current and future licensors and us and our partners; and the priority of invention of patented technology. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third party rights. If certain of our product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g. patent infringement or trade secret theft) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds and on the market price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, <span style="white-space:nowrap">know-how</span> or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her <span style="white-space:nowrap">non-competition</span> or <span style="white-space:nowrap">non-solicitation</span> agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of our owned and <span style="white-space:nowrap">in-licensed</span> patent applications and the maintenance, enforcement or defense of our owned and <span style="white-space:nowrap">in-licensed</span> issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in <span style="font-style:italic">Amgen, Inc. v. Sanofi</span> (<span style="font-style:italic">Amgen</span>) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty-six exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that we will be granted U.S. patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally defined antibodies, it is possible that a third party may challenge our patents, when issued, relying on the reasoning in <span style="font-style:italic">Amgen</span> or other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Geopolitical instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for member states of the EU. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Although we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for <span style="white-space:nowrap">non-compliance</span> and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding <span style="white-space:nowrap">co-ownership</span> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we <span style="white-space:nowrap">in-licensed.</span> For example, certain intellectual property we license from the University of Texas at Austin includes inventions that were made with U.S. government support. The U.S. government therefore has certain rights in such inventions under the applicable funding agreements and under applicable law. If other third parties have ownership rights or other rights to our <span style="white-space:nowrap">in-licensed</span> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States <span style="white-space:nowrap">non-provisional</span> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our technology licensed from various third parties may be subject to retained rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current or future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Reliance on Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on collaborations and licensing arrangements with third parties, including our arrangement with Paragon. If we are unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, our business could be negatively impacted. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely on our collaborations and licensing arrangements with third parties, including Paragon, for a substantial portion of our discovery capabilities and <span style="white-space:nowrap">in-licenses.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of our collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates their agreement with us, the research programs with respect to which we have exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Paragon Agreement and development timeline could be adversely affected. If we fail to comply with any of the obligations under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would be time-consuming and expensive and could harm our ability to commercialize our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or provide development or commercialization capabilities that complement our own. We may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require us to incur <span style="white-space:nowrap">non-recurring</span> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our current or future product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we currently rely on foreign CROs and CMOs, including WuXi Biologics, and will likely continue to rely on foreign CROs and CMOs in the future. Foreign CMOs may be subject to U.S. legislation, including the proposed BIOSECURE bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United States and the UK, could also negatively impact our ability to manufacture our product candidates for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture our product candidates. We have not yet caused our product candidates to be manufactured on a commercial scale and may not be able to do so for any of our programs, if approved. We currently have a sole source relationship for our supply of the SPY001 program. If there should be any disruption in such supply arrangement, including any adverse events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are responsible for transporting temperature-controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. See the section titled &#8220;Business &#8211; Manufacturing&#8221; for a more detailed description of our manufacturing plans and assumptions and the factors that may affect the success of our programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a preclinical stage biotechnology company with a limited operating history, and, as of December&#160;31, 2023, we had 30 employees. We have been and will continue to be highly dependent on the research and development, clinical and business development expertise of our executive officers, as well as the other principal members of our management, scientific and clinical team. Any of our management team members may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attracting and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may pursue. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery and nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants, third party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs, other contractors (including sites performing our clinical trials), third party service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fully-remote workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform, deter new customers from products, and negatively impact our ability to grow and operate our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its <span style="white-space:nowrap">pre-change</span> net operating loss carryforwards, or NOLs, and other <span style="white-space:nowrap">pre-change</span> tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. Upon certain events since our conversion from a Delaware limited liability company to a Delaware corporation in 2015, it is possible that we may have triggered an &#8220;ownership change&#8221; limitation. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership (some of which are outside of our control). As a result, if we earn net taxable income, our ability to use our <span style="white-space:nowrap">pre-change</span> NOLs and other <span style="white-space:nowrap">pre-change</span> tax attributes to offset U.S. federal taxable income or taxes may be subject to limitations, which could potentially result in increased future tax liability to us. Our NOLs and other tax attributes arising before our conversion from a Delaware limited liability company to a Delaware corporation in 2015 also may be limited by the Separate Return Limitation Year rule, which could increase our U.S. federal tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, and third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations. See the section titled &#8220;Business &#8211; Government Regulation &#8211; Data Privacy and Security&#8221; for a more detailed description of the laws that may affect our ability to operate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect our stockholders or us. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the United States recently enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. The U.S. Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, we have no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect our effective tax rate, results of operation and general business condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cash held in <span style="white-space:nowrap">non-interest-bearing</span> and interest-bearing accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pursuant to the terms of the December 2023 SPA, we are required to recommend that our stockholders approve the conversion of all outstanding shares of our Series B Preferred Stock into shares of our Common Stock. We cannot guarantee that our stockholders will approve this matter, and if they fail to do so, we may be required to settle such shares in cash and our operations may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the December 2023 SPA, we agreed to use best efforts to obtain the requisite approval for the conversion of all outstanding shares of Series B Preferred Stock issued in the December 2023 PIPE into shares of our Common Stock, as required by the Nasdaq listing rules, at our 2024 annual meeting of stockholders and, if such approval is not obtained at that meeting, to seek to obtain such approval at a stockholders meeting to be held at least every 90 days thereafter until such approval is obtained, which would be time consuming and costly. Additionally, if our stockholders do not timely approve the conversion of our Series B Preferred Stock, then the holders of our Series B Preferred Stock may be entitled to require us to settle their shares of Series B Preferred Stock for cash at a price per share equal to the fair value of the Series B Preferred Stock at such time, as described in our Series B Certificate of Designation relating to the Series B Preferred Stock. If we are forced to settle a significant amount of the Series B Preferred Stock, it could materially affect our results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions in our Certificate of Incorporation and Bylaws may delay or prevent an acquisition or a change in management. These provisions include a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue Preferred Stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Series A Certificate of Designation relating to our Series A Preferred Stock may delay or prevent a change in control of our company. At any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, we may not consummate a Fundamental Transaction (as defined in the Series Certificate of Designation) or any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock. This provision of the Series A Certificate of Designation may make it more difficult for us to enter into any of the aforementioned transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum certain types of actions and proceedings that may be initiated by our stockholders, and our Bylaws designate the federal courts of the United States as the exclusive forum for actions arising under the Securities Act, each of which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any provision of the DGCL, our Certificate of Incorporation or our Bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our Certificate of Incorporation and Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (a &#8220;Federal Forum Provision&#8221;). Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These choice of forum provisions will not apply to claims brought to enforce a duty or liability created by the Exchange Act. These choice of forum provisions may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the specified courts could face additional litigation costs in pursuing any such claim. The specified courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these provisions of our governance documents inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not anticipate that we will pay any cash dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our Common Stock will be your sole source of gain, if any, for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of shares by existing stockholders could cause our stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;7, 2023, we entered into a registration rights agreement (the &#8220;December 2023 RRA&#8221;) with the December 2023 Investors. Pursuant to the December 2023 RRA, we agreed to file a resale registration statement to register the Registrable Securities (as defined in the December 2023 RRA) (the &#8220;Registration Statement&#8221;). This registration statement is being filed in order to satisfy our obligations under the December 2023 RRA. We have agreed to use our commercially reasonable efforts to cause this Registration Statement to be declared effective by the SEC as soon as practicable. If, following receipt of stockholder approval of the Series B Conversion Proposal (as defined in the section titled &#8220;<span style="font-style:italic">Description Of Capital Stock &#8211; Preferred Stock &#8211; Series B Preferred Stock</span>&#8221; below), this Registration Statement is not declared effective prior to, subject to certain limited exceptions pursuant to the December 2023 RRA, the 90<sup style="font-size:75%; vertical-align:top">th</sup> calendar day following the closing date of the December 2023 PIPE (or, in the event the SEC reviews and has written comments to this Registration Statement, the 120<sup style="font-size:75%; vertical-align:top">th</sup> calendar day following such closing date), among other events (each event, a &#8220;Registration Failure&#8221;), then we will be required to make pro rata payments to each Investor of the then outstanding Registrable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities in an amount equal to one percent of the aggregate amount invested by such December 2023 Investor for the Registrable Securities then held by such December 2023 Investor for the initial day of a Registration Failure and for each 30 day period thereafter until the Registration Failure is cured. If this Registration Statement is declared effective, the shares subject to this Registration Statement will no longer constitute restricted securities and may be sold freely in the public markets, subject to lapse on any related contractual restrictions related thereto of any December 2023 Investor and, for shares of Common Stock issuable upon the conversion of Series B Preferred Stock, the approval of our stockholders of such conversion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock in the public market after legal restrictions on resale lapse, the trading price of our Common Stock could decline. In addition, shares of our Common Stock that are subject to our outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales and issuances of equity and debt could result in additional dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that we will need significant additional capital to fund our current and future operations, including to complete potential clinical trials for our product candidates. To raise capital, we may sell Common Stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. As a result, our stockholders may experience additional dilution, which could cause our stock price to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our equity incentive plans, we may grant equity awards and issue additional shares of our Common Stock to our employees, directors and consultants, and the number of shares of our Common Stock reserved for future issuance under certain of these plans will be subject to automatic annual increases in accordance with the terms of the plans. To the extent that new options are granted and exercised, or we issue additional shares of Common Stock in the future, our stockholders may experience additional dilution, which could cause our stock price to fall. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our principal stockholders own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors, officers, 5% stockholders, and their affiliates currently beneficially own a substantial portion of our outstanding voting stock. Therefore, these stockholders have the ability and may continue to have the ability to influence us through this ownership position. These stockholders may be able to determine some or all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our Common Stock that you may believe are in your best interest as one of our stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our Common Stock has historically been volatile, and the market price of our Common Stock may decline in the future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our Common Stock has been, and may continue to be, subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our Common Stock to fluctuate include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of any of our product candidates, if approved, to achieve commercial success; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to maintain our existing third-party license and supply agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations applicable to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory authority decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">introduction of new products, services, or technologies by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed financial and development projections we may provide to the public and the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits, including patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general market or macroeconomic conditions, including global inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in monetary policy, instability in financial institutions and the prospect of a shutdown of the U.S. federal government; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">geopolitical instability, including the ongoing military conflict in Ukraine, conflict in Israel and surrounding areas, and geopolitical tensions in China; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our Common Stock by us or our stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the introduction of technological innovations or new therapies that compete with our potential products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the structure of health care payment systems; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> fluctuations in our financial results. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the capital markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We incur costs and demands upon management as a result of complying with the laws and regulations regulating public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting, and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. These rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules and regulations may also make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our Common Stock and such lack of research coverage may adversely affect the market price of our Common Stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our Common Stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our Common Stock could decrease, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Common Stock may be negatively affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our annual report filing for that year, as required by Section&#160;404 of the Sarbanes-Oxley Act. This requires that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner for each period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may or any subsequent testing by our independent registered public accounting firm may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, it could result in a material misstatement of our financial statements that would not be prevented or detected on a timely basis, which could require a restatement, cause us to be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, cause investors to lose confidence in our financial information, or cause our stock price to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we incur significant legal, accounting, insurance, and other expenses, and our management and other personnel have and will need to continue to devote a substantial amount of time to compliance initiatives resulting from operating as a public company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_6">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_7">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes thereto and other financial information included elsewhere in this prospectus. This discussion contains forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; As used in this prospectus, unless the context suggests otherwise, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;the Company&#8221;. &#8220;Aeglea BioTherapeutics, Inc.&#8221; or &#8220;Spyre&#8221; refers to Spyre Therapeutics, Inc. and its subsidiaries, including Spyre Therapeutics, LLC. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Acquisition of <span style="white-space:nowrap">Pre-Merger</span> Spyre </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we acquired <span style="white-space:nowrap">Pre-Merger</span> Spyre pursuant to the Acquisition Agreement, by and among us, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and our wholly owned subsidiary (&#8220;Second Merger Sub&#8221;), and <span style="white-space:nowrap">Pre-Merger</span> Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into <span style="white-space:nowrap">Pre-Merger</span> Spyre, pursuant to which <span style="white-space:nowrap">Pre-Merger</span> Spyre was the surviving corporation and became our wholly owned subsidiary (the &#8220;First Merger&#8221;). Immediately following the First Merger, <span style="white-space:nowrap">Pre-Merger</span> Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. <span style="white-space:nowrap">Pre-Merger</span> Spyre was a <span style="white-space:nowrap">pre-clinical</span> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the Option to license the <span style="white-space:nowrap">in-process</span> and research development (&#8220;IPR&amp;D&#8221;) rights related to four research programs. On July&#160;12, 2023 we exercised the Option with respect to one of these research programs to exclusively license intellectual property rights related to such research program directed to antibodies that selectively bind to &#945;4&#223;7 integrin and methods of using these antibodies, including methods of treating inflammatory bowel disease (&#8220;IBD&#8221;) using SPY001. If this research program is pursued <span style="white-space:nowrap">non-provisionally</span> and matures into issued patents, we would expect those patents to expire no earlier than 2044, subject to any disclaimers or extensions. On December&#160;14, 2023, we exercised the Option under the Paragon Agreement to be granted an exclusive license to all of Paragon&#8217;s rights, title and interest in and to intellectual property rights, including inventions, patents, sequence information and results, under SPY002, our TL1A program, to develop and commercialize antibodies and products worldwide in all therapeutics disorders. The license agreements pertaining to such research programs are currently being finalized on previously agreed terms. Furthermore, as of the date of the filing of this prospectus, the Option remains unexercised with respect to the IPR&amp;D related to the two remaining research programs under the Paragon Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Asset Acquisition and the entry into the Immedica APA, we have significantly reshaped the business into a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with IBD, including UC and CD. Through the Paragon Agreement, our portfolio of novel and proprietary monoclonal antibody product candidates has the potential to address unmet needs in IBD care by improving efficacy, safety, and/or dosing convenience relative to products currently available or product candidates in development. We have engineered our product candidates with the aim to bind potently and selectively to their target epitopes and to exhibit extended pharmacokinetic half-lives through modifications in the Fc domain, which modifications are designed to increase affinity to human FcRn and increase antibody </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recycling. We anticipate that half-life extension will enable less frequent administration as compared to marketed or development-stage mAbs that do not incorporate half-life extension modifications. Nonetheless, the drug and/or device development process is inherently uncertain, our development approach is unproven, the preclinical evidence that supports our proposed development program is preliminary and limited, and we have not yet tested any product candidate in humans. In addition to the development of our product candidates as potential monotherapies, we plan to investigate combinations of our proprietary antibodies in preclinical and clinical studies in order to evaluate whether combination therapy (co-administration or co-formulation of multiple monoclonal antibodies) can lead to greater efficacy, as compared to monotherapies in IBD. We also intend to examine patient selection strategies via complementary diagnostics utilized in our clinical studies to evaluate whether patients may be matched to the optimal therapy based on genetic background and/or other biomarker signatures. We intend to deliver our product candidates through convenient, infrequently dosed, self-administered, SC injection, although the specific delivery mechanism or technology has not been selected given our early stage. Notwithstanding our efforts to develop safe and effective monotherapies and combination therapies, there can be no guarantee that we will be able to develop product candidates that will be found to be safe and effective so as to obtain the necessary regulatory approvals to market our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Relationship with Paragon and Parapyre </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre each beneficially owns less than 5% of our capital stock through their respective holdings of our Common Stock. Fairmount beneficially owns more than 5% of our capital stock on an as-converted basis, has two seats on our board of directors and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in <span style="white-space:nowrap">Pre-Merger</span> Spyre in order to share profits with certain employees of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, we assumed the rights and obligations of <span style="white-space:nowrap">Pre-Merger</span> Spyre under the Paragon Agreement. Under the Paragon Agreement, we are obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with <span style="white-space:nowrap">mark-up</span> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, <span style="white-space:nowrap">Pre-Merger</span> Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by us through the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December 31, 2023, we recognized $48.5&#160;million in research and development expenses that are due to Paragon under the Paragon Agreement. As of December 31, 2023, $16.6&#160;million was unpaid and owed to Paragon under the Paragon Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023 and December 2023, we exercised our Option for the SPY001 and SPY002 programs, respectively, and the remaining two options for the SPY003 and SPY004 programs remain outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, we assumed the Parapyre Option Obligation which provides for an annual equity grant of warrants to Parapyre, upon the completion of each of the calendar years ending on December 31, 2023 and December 31, 2024, to purchase 1% of the then outstanding shares of our Common Stock, on a fully diluted basis, on the last business day of each applicable calendar year, at the fair market value determined by our board of directors. Under the terms of the Paragon Agreement, an annual equity grant of options will not be made for any calendar year ending after December 31, 2024 regardless of whether the term of the Paragon Agreement has continued beyond such date. On September 29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i) defining that the annual equity grant of options is based on the outstanding shares of our Common Stock, (ii) establishing the grant date as the last business day of each applicable calendar year, and (iii) defining the term of the options granted as ten years. The pro-rated fair value of the Parapyre Option Obligation will be recorded as a liability at each interim reporting period and reclassified </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as permanent equity when settled through the issuance of the related warrants. If the term of the Paragon Agreement ends prior to the end of an applicable calendar year, the equity grant for such calendar year will be pro-rated for such calendar year and effected within five business days of the end of the term. The term of the Paragon Agreement ends upon the earlier of (i)&#160;the effective date of the license agreement for the last research program with respect to which we have exercised our Option, unless an extension is mutually agreed between the parties, or (ii)&#160;120 days following our receipt of deliverables for the last research program with respect to which we have not exercised our Option or such longer period as agreed upon by the parties. As of December 31, 2023, the grant-date fair value of the equity granted to Parapyre on December 29, 2023 was approximately $11.5&#160;million, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition. For the year ended December 31, 2023, $11.4&#160;million was recognized as stock compensation expense related to the Parapyre Option Obligation. The Company&#8217;s obligation for the year ended December 31, 2023 under the Parapyre Option Obligation was settled through the issuance of 684,407 warrants to purchase the Company&#8217;s Common Stock at an exercise price of $21.52 per warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023, we announced that we had entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15&#160;million in upfront cash proceeds and up to $100&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between us and Immedica. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2023, our board of directors appointed Scott Burrows to succeed Jonathan Alspaugh as our Chief Financial Officer effective September&#160;1, 2023. Mr.&#160;Burrows also succeeded Mr.&#160;Alspaugh as our principal financial officer and principal accounting officer on the effective date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;1, 2023, Heidy Abreu King-Jones was appointed as Chief Legal Officer and Corporate Secretary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;6, 2023, our board of directors appointed Dr.&#160;Cameron Turtle, our then-current Chief Operating Officer, as our principal executive officer effective the same day. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;22, 2023, Dr.&#160;Turtle was promoted from Chief Operating Officer to Chief Executive Officer and was appointed to our board of directors. In addition, Jeffrey W. Albers and Laurie Stelzer were appointed to our board of directors to fill the vacancies resulting from the resignations of Hunter Smith and Ivana Magov&#269;evi&#263;-Liebisch, each of which was effective that same day. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;28, 2023, we changed our name from &#8220;Aeglea Biotherapeutics, Inc.&#8221; to &#8220;Spyre Therapeutics, Inc.&#8221; and our Nasdaq ticker symbol from &#8220;AGLE&#8221; to &#8220;SYRE&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 11, 2023, we closed the December 2023 PIPE and sold an aggregate of 6,000,000 shares of Common Stock and 150,000 shares of Series&#160;B Preferred Stock for gross proceeds of $180 million. If our stockholders do not timely approve the conversion of our Series&#160;B Preferred Stock, then the holders of our Series B Preferred Stock may be entitled to require us to settle their shares of Series&#160;B Preferred Stock for cash at a price per underlying share of Common Stock equal to the last reported closing sale price of Common Stock on the principal trading market on which the Common Stock is listed as of the trading day immediately prior to the date on which a request to convert shares of Series B Preferred Stock into shares of Common Stock is delivered to us by a holder in accordance with the terms of the Series&#160;B Certificate of Designation and we fail to deliver such shares of Common Stock, as described in our Series B Certificate of Designation relating to the Series&#160;B Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 19, 2024, our listing of Common Stock was upgraded from The Nasdaq Capital Market to the Nasdaq Global Select Market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 1, 2024, Mark McKenna was appointed to our board of directors to fill the vacancy resulting from the resignation of Alison Lawton, which was effective that same day. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Restructuring </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, we implemented a restructuring plan based on the review of the inconclusive interim results from our Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, as well as our plan to explore strategic alternatives. Under the restructuring plan, our workforce was reduced by 83%, various lab equipment, consumables, and furniture and fixtures were sold, and our corporate headquarters lease in Austin, TX was abandoned. All charges related to the restructuring activities was recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. These estimates form the basis for judgments we make about the carrying values of our assets, liabilities and equity and the amount of revenues and expenses, which are not readily apparent from other sources. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ materially from these estimates under different assumptions or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. The most significant estimates and assumptions that management considers in the preparation of our financial statements relate to accrued research and development costs; the valuation of consideration transferred in acquiring IPR&amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of <span style="white-space:nowrap">Pre-Merger</span> Spyre was comprised of our Common Stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, we considered the per share value of the June 2023 PIPE, which was a financing involving a group of accredited investors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We define our critical accounting policies as those accounting principles generally accepted in the United States that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. Our significant accounting policies are more fully described in Note 2 to our consolidated financial statements as of December&#160;31, 2023 and 2022 and for each of the three years in the period ended December&#160;31, 2023 (the &#8220;2023 Annual Financials&#8221;) appearing elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into license agreements related to our technologies that we have determined are within the scope of Accounting Standards Codification 606. Based on the terms and conditions of our agreements, we identify the goods and services that we promise to transfer to the customer, which may consist of the licensing of technologies, the performance of research and development activities, and/or the supply of products related to our technologies. Based on the nature of the goods and services provided and the customer&#8217;s intended benefit of the arrangement, we evaluate which of the promised goods and services are distinct and, therefore, represent a performance obligation, which may require us to combine certain promised goods and services that are determined to not be distinct from one another. We also evaluate whether an agreement provides the customer an option to purchase future goods or services at a discounted price, or a material right, which would also represent a performance obligation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for the performance obligations, we estimate the amount of consideration promised by the customer, or transaction price, which may include both fixed and variable consideration. Variable consideration, which may consist of various milestone payments based upon the achievement of certain events or conditions, sales-based royalties, or payments contingent on the performance of research and development services, are included in the transaction price only if we expect to receive such consideration and determine it is likely that the inclusion of the variable consideration will not result in a significant reversal in the cumulative amount of revenue recognized under the arrangement. Sales-based royalty and milestone payments that we determine are predominantly related to the license of our intellectual property are excluded from the transaction price we expect to receive until the underlying sales occur. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We allocate the estimated transaction price to the identified performance obligations based on the relative estimated stand-alone selling price (&#8220;SSP&#8221;), of each performance. SSP is based on the observable price of our goods and services, or when SSP is not directly observable, we estimate SSP based on factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. We recognize revenue allocated to each performance obligation either at a <span style="white-space:nowrap"><span style="white-space:nowrap">point-in-time</span></span> or over time in a manner that depicts the transfer of control of the promised goods and services to the customer. For performance obligations that are recognized over time, we estimate the measure of progress associated with the satisfaction of the performance obligation based on an input or output method, which may be based on factors such as costs incurred, labor hours expended, time elapsed, among other measures based on the nature of the performance obligation. The estimates made on an input or output method are subject to change and may result in material changes to revenue that could materially affect our results of operations. Please refer to Note 12, Strategic License Agreements, to our 2023 Annual Financials included elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Accrued research and development costs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record the costs associated with research nonclinical studies, clinical trials, and manufacturing as incurred. These costs are a significant component of our research and development expenses, with a substantial portion of our <span style="white-space:nowrap">on-going</span> research and development activities conducted by third-party service providers, including CROs, CMOs and our related-party Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We accrue for expenses resulting from obligations under the Paragon Agreement and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to us. We record accruals based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. We make significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, a CMO, or an outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, we adjust our accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from our estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our results of operations. However, there have been no material changes in estimates for the periods presented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Impairment of ROU Assets and Leasehold Improvements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to test for impairment of our long-lived assets when events arise that would call into question the recoverability of an asset group. We determined that the abandonment of our leased office space in Austin, Texas would meet this criteria. Accordingly, we tested for impairment using a discounted future cash flow model using estimated cash flows that could be obtained through a hypothetical <span style="white-space:nowrap">sub-letting</span> of the leased space. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Convertible Preferred Stock Issued through PIPE </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. We classified the Series B Preferred Stock outside of stockholders&#8217; equity because, if conversion to common stock is approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#8217;s redemption request. We determined that the conversion and redemption are outside of our control. Additionally, we determined the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Contingent Value Rights Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;3, 2023, we issued a CVR to certain of our securityholders of record as of the close of business on that date (the &#8220;Legacy Stockholders&#8221;), but these were not issued to holders of shares of common stock or preferred stock issued to former stockholders of <span style="white-space:nowrap">Pre-Merger</span> Spyre or the June 2023 Investors in the June 2023 PIPE. Each CVR entitles the holder thereof to receive cash payments in the future calculated on the monetization or disposal of Legacy Assets within the CVR period. Certain contingent payments under the CVR Agreement qualify as derivatives under ASC 815, Derivatives and Hedging, and are recorded as a liability on the balance sheet as of December 31, 2023. The CVR liability is considered a Level&#160;3 instrument that is initially measured at its estimated fair value on the transaction date and subsequently remeasured at each reporting date with changes recorded in the consolidated statement of operations. The determination of the initial and subsequent fair value of the CVR liability requires significant judgment by management. Changes in any of the inputs not related to facts and circumstances existing as of the transaction date may result in a significant fair value adjustment, which can impact the results of operations in the period in which the adjustment is made. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Comparison of the Years Ended December 31, </span><span style="font-weight:bold">2023</span><span style="font-weight:bold"> and </span><span style="font-weight:bold">2022</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022, together with the changes in those items in dollars and as a percentage: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended December 31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Dollar<br/></span><br/><span style="font-weight:bold">Change </span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="10" align="center"><span style="font-weight:bold">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development fee and royalty</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,443</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(62</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">886</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,443</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">89,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired in-process research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of in-process research and development asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,449</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,449</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">243,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">156,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(242,303</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,781</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(157,522</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of forward contract liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,530</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,530</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,130</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,123</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(96,513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(97,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(338,816</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,951</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(254,865</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(110</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(338,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(254,975</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Percentage not meaningful </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Development Fee and Royalty Revenue</span>. For the year ended December&#160;31, 2023, we recognized $0.9 million of revenue in connection with the Immedica Agreement. The revenue generated was attributable to the PEACE Phase 3 trial and drug supply and royalties from an early access program in France. For the year ended December&#160;31, 2022, we recognized $2.3 million of development fee revenue in connection with the Immedica Agreement, which was attributable to the PEACE Phase 3 trial and BLA package. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses</span>. Our research and development expenses incurred during the year ended December 31, 2023 were primarily related to clinical trial costs associated with our Legacy Assets, costs associated with the wind down of those Legacy Assets, and costs associated with furthering our IBD pipeline candidates. Wind down costs included final patient visits, collection and analysis of final patient data, the creation and submission of final research reports, site and pharmacy closeouts, and formally closing the trials with regulatory agencies. Research and development expenses increased by $30.9 million, or 53%, to $89.5 million for the year ended December&#160;31, 2023, from $58.6 million for the year ended December&#160;31, 2022. The increase in research and development expenses was primarily due to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $39.3 million increase in preclinical development and manufacturing expenses for our IBD pipeline candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $11.4 million increase in stock compensation expense related to the Parapyre Option Obligation; partially offset by </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $19.9 million decrease in activities and staff costs associated with the legacy rare disease pipeline we had been advancing prior to the Asset Acquisition. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">External research and development expenses include costs associated with third parties contracted to conduct research and development activities on behalf of the Company, including through Paragon, CROs, CMOs, and third-party laboratories. For the year ended December 31, 2023 and 2022, external research and development costs accounted for $72.7 million and $36.4 million, respectively. The increase in external research and development expenses is primarily due to increases in costs associated with our IBD pipeline candidates and stock compensation expense related to the Parapyre Option Obligation, partially offset by a decrease in activities associated with the Legacy Assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal research and development expenses include compensation and related costs associated our research and development employees, as well as costs associated with the Company&#8217;s on-premises research laboratory. For the year ended December 31, 2023 and 2022, internal research and development costs accounted for $16.8 million and $22.1 million. The decrease in internal research and development expenses is primarily due to a decrease in costs associated with our on-premises research laboratory that was decommissioned, including the elimination of related internal roles, in the first half of 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses</span>. General and administrative expenses increased by $11.4 million, or 40%, to $39.9 million for the year ended December&#160;31, 2023, from $28.5 million for the year ended December&#160;31, 2022. The increase in general and administrative expenses was primarily due to a $9.0 million increase in stock compensation expense, $2.6 million increase in restructuring costs, net of restructuring savings, and an increase in legal and professional service fees of $3.4 million, partially offset by a $2.1 million decrease in legacy commercial readiness activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain on Sale of In-Process Research and Development Asset</span>. Gain on sale of in-process research and development asset during the year ended December 31, 2023 was due to the gain recognized on the sale of pegzilarginase to Immedica. There was no similar gain or loss during the year ended December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acquired In-process Research and Development Expenses</span>. Acquired IPR&amp;D expenses were $130.2 million for the year ended December&#160;31, 2023, as the acquisition of Pre-Merger Spyre was determined by management to be an asset acquisition, in accordance with U.S. GAAP as the product candidates were determined to have no alternative future use. There was no similar expense during the year ended December 31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Forward Contract Liability</span>. Non-cash expenses associated with the change in fair value of the forward contract liability were $83.5 million for the year ended December&#160;31, 2023. This expense was due to the change in fair value of the underlying Series A Preferred Stock between June 22, 2023 and the forward contract&#8217;s settlement on July 7, 2023. There was no similar expense during the year ended December&#160;31, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Years Ended December&#160;31, 2022 and 2021 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&#160;31, 2022 and 2021, together with the changes in those items in dollars and as a percentage: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year&#160;Ended&#160;December&#160;31,</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Dollar<br/>Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%<br/>Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="14" align="center"><span style="font-weight:bold">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,410</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,410</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,069</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,781</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,649</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,132</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">726</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(122</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-94</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,951</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,291</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(141</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-196</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(65,801</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,014</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Percentage not meaningful </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">License and Development Fee Revenue. </span>For the year ended December&#160;31, 2022, we recognized $2.3&#160;million of development fee revenue allocated to the PEACE Phase 3 trial and BLA package of the Immedica Agreement. For the year ended December&#160;31, 2021, we recognized $18.7&#160;million of license and development fee revenue in connection with the Immedica Agreement. The total revenue generated was attributable to $12.0&#160;million allocated to the license and $6.7&#160;million allocated to the PEACE Phase 3 trial and BLA package. Please refer to Note 12, Strategic License Agreements, to the 2023 Annual Financials included elsewhere in this prospectus for additional disclosures around revenue recognition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses</span>. Research and development expenses increased $1.5&#160;million, or 3%, to $58.6&#160;million for the year ended December&#160;31, 2022 from $57.1&#160;million for the year ended December&#160;31, 2021. The change in research and development expenses was due to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $1.1&#160;million increase in expenses associated with pegzilarginase primarily due to a $1.4&#160;million increase related to activities involved in closing the PEACE trial and ramping up the new open-label extension trial for the treatment of patients with Arginase 1 Deficiency, partially offset by a $0.3&#160;million decrease in professional services to support the pegzilarginase program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $2.8&#160;million increase in expense associated with <span style="white-space:nowrap">IND-enabling</span> activities of <span style="white-space:nowrap">AGLE-325</span> for the treatment of patients with Cystinuria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $0.6&#160;million increase in personnel-related expenses, primarily driven by an increase of headcount expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $1.5&#160;million decrease in expenses primarily associated with the completion of <span style="white-space:nowrap">non-clinical</span> toxicology studies in the prior year for pegtarviliase for the treatment of patients with Homocystinuria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $0.6&#160;million decrease due to reduction in preclinical lab work; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $0.9&#160;million decrease in other research and development expenses, primarily related to a reduction of consulting and recruiting activities. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">External research and development expenses include costs associated with third parties contracted to conduct research and development activities on behalf of the Company, including clinical research organizations, clinical manufacturing organizations, and third-party laboratories. For the twelve months ended December 31, 2022 and 2021, external research costs accounted for $36.4 million and $35.0 million, respectively. The increase in external research and development costs is primarily driven by an increase in costs associated with two candidates in the Legacy Pipeline, partially offset by a decrease in costs associated with a third candidate in the Legacy Pipeline as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal research and development expenses include compensation and related costs associated with the Company&#8217;s research and development employees, as well as costs associated with the Company&#8217;s on-premises research laboratory. For the twelve months ended December 31, 2022 and 2021, internal research and development costs accounted for $22.2 million and $22.1 million, respectively. Internal research and development expenses remained flat for the periods presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses</span>. General and administrative expenses increased by $1.2&#160;million, or 4%, to $28.5&#160;million for the year ended December&#160;31, 2022 from $27.3&#160;million for the year ended December&#160;31, 2021. The increase in general and administrative expenses was primarily due to a $0.8&#160;million increase in expense related to our commercial capabilities and infrastructure and $0.4&#160;million increase in expenses related to financing activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a preclinical stage biotechnology company with a limited operating history, and due to our significant research and development expenditures, we have generated operating losses since our inception and have not generated any revenue from the sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception and through December 31, 2023, we have funded our operations by raising an aggregate of approximately $896.2 million of gross proceeds from the sale and issuance of convertible preferred stock and common stock, pre-funded warrants, the collection of grant proceeds, and the licensing of our product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of December 31, 2023, we had an accumulated deficit of $764.4 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our primary use of cash is to fund the development of our product candidates, and advance our pipeline. This includes both the research and development costs and the general and administrative expenses required to support those operations. Since we are a preclinical stage biotechnology company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to increase as we pursue clinical development of our product candidates, prepare for the potential commercialization of our product candidates, and expand our development efforts in our pipeline of nonclinical candidates. Based on current operating plans, we have sufficient resources to fund operations for at least one year from the issuance date of the financial statements included in the 2023 Annual Financials with existing cash, cash equivalents, and marketable securities. We will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Recent Sources of Liquidity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2021, we entered into the Immedica Agreement, pursuant to which Immedica licensed the product rights for commercialization of pegzilarginase in the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. In April 2021, we received an upfront payment of $21.5 million from Immedica. In July </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2021, the Immedica Agreement was modified to include additional development services, up to $3.0 million, to support the PEACE Phase 3 trial and BLA package performance obligation. In July 2023, the Immedica Agreement was terminated through the sale of pegzilarginase to Immedica for $15.0 million in upfront cash proceeds and up to $100.0 million in contingent milestone payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2020, we raised $163.3 million of gross proceeds through an underwritten public offering and an at-the-market offering program. We sold 617,692 shares of Common Stock and pre-funded warrants to purchase up to 544,413 shares of Common Stock in an underwritten public offering for gross proceeds of $138.0 million, resulting in net proceeds of $129.0 million after deducting underwriting discounts, commissions, and offering costs. Additionally, we sold an aggregate of 129,803 shares of Common Stock under an at-the-market offering program for gross proceeds of $25.3 million, resulting in net proceeds of $24.6 million, after deducting underwriting discounts, commissions, and offering costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, we sold 430,107 shares of Common Stock and pre-funded warrants to purchase up to 694,892 shares of Common Stock in a registered direct offering for gross proceeds of $45.0 million, resulting in net proceeds of $42.9 million after deducting placement agent fees and offering costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, we sold 721,452 shares of convertible Series A Preferred Stock in a private placement offering for gross proceeds of $210.0 million before deducting approximately $12.7 million of placement agent and other offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, we sold 6,000,000 shares of Common Stock and 150,000 shares of convertible Series B Preferred Stock for gross proceeds of $180.0 million before deducting approximately $10.9 million of placement agent and other offering expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Recent Developments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2023, our stockholders approved the issuance of shares of our Common Stock upon conversion of Series A Preferred Stock, eliminating the potential requirement to settle shares of Series A Preferred Stock in cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 7, 2023, we entered into the December 2023 SPA for a PIPE investment with the December 2023 Investors to raise $180 million in which the December 2023 Investors were issued an aggregate of 6,000,000 shares of Common Stock at a price of $15.00 per share and 150,000 shares of Series B Preferred Stock at a price of $600.00 per share. See section titled &#8220;<span style="font-style:italic">Liquidity &#8211; Recent Sources of Liquidity</span>&#8221; above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows for the Years Ended December 31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended December 31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents (used in) provided by:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(99,910</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(80,144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(108,393</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">361,077</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate on cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(106</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">152,799</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Used in Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2023 was $99.9 million and reflected a net loss of $338.8 million. Our net loss was offset in part by non-cash expenses of $130.2 million for acquired IPR&amp;D, $83.5 million change in fair value of forward contract liability, $25.7 million in stock-based compensation, $19.0 million change in fair value of CVR liability, $2.6 million impairment loss on lease abandonment, $0.9 million loss on disposal of long-lived assets, and $0.7 million in depreciation and amortization. The net change in operating assets and liabilities of $5.2 million was primarily due to a $4.9 million decrease in accrued and other liabilities, a $3.2 million decrease in prepaid expenses and other assets, a $2.4 million decrease in related party payable, a $2.3 million decrease in operating lease liabilities primarily due to the termination of the Las Cimas lease, and a $0.4 million decrease in development receivables, partially offset by a $0.6 million increase in deferred revenue and a $0.2 million increase in accounts payable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2022 was $80.1 million and reflected a net loss of $83.8 million. Our net loss was offset in part by non-cash expense of $7.1 million for stock-based compensation and $1.6 million for depreciation and amortization. The net change in operating assets and liabilities of $5.5 million was primarily related to a $2.6 million decrease in accounts payable, a $1.1 million increase in prepaid expenses and other assets, a $0.9 million decrease in deferred revenue due to receiving payments under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA filing, a $0.9 million decrease in accrued expenses and other liabilities, and a $0.4 million decrease in operating lease liabilities due to lease payments made during the year, partially offset by a $0.4 million increase in accounts receivable for incremental services provided to Immedica and not yet paid. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash (Used in) Provided by Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the year ended December&#160;31, 2023 was $108.4 million and primarily consisted of $166.8 million in purchases of marketable securities, partially offset by $39.9 million in maturities and sales of marketable securities, $15.0 million in proceeds from the sale of IPR&amp;D assets, and $3.0 million cash assumed from the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities for the year ended December&#160;31, 2022 was $57.0 million and consisted of $96.5 million in maturities and sales of marketable securities, partially offset by $39.5 million in purchases of marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Provided by Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&#160;31, 2023 was $361.1 million, which primarily consisted of the net proceeds from the issuance of the shares of Series A Preferred Stock in the June 2023 PIPE and the issuance of the shares of common stock and Series B Preferred Stock in the December 2023 PIPE. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December 31, 2022 was $42.7 million, which primarily consisted of $42.9 million from the registered direct offering of our common stock and pre-funded warrants in May 2022, net of placement agent fees and offering costs, and $0.2 million from the sale of common stock under our 2016 Employee Stock Purchase Plan, partially offset by $0.4 million in principal payments made on our finance lease obligations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash flows for the Years Ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents (used in) provided by:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(80,144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(53,716</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,619</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,678</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate on cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(106</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(74,957</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash used in operating activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2022 was $80.1&#160;million and reflected a net loss of $83.8&#160;million. The cash impact of our net loss was offset by <span style="white-space:nowrap">non-cash</span> expenses of $7.1&#160;million for stock-based compensation, $1.6&#160;million for depreciation and amortization, $0.4&#160;million for operating lease expense, and $0.1&#160;million for net premium purchase and amortization on marketable securities. The net decrease in operating assets and liabilities of $5.5&#160;million was primarily related to a $2.6&#160;million decrease in accounts payable, a $1.1&#160;million increase in prepaid expenses and other assets, a $0.9&#160;million decrease in deferred revenue due to receiving payments under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA filing, a $0.9&#160;million decrease in accrued expenses and other liabilities, and a $0.4&#160;million decrease in operating lease liabilities due to lease payments made during the year, partially offset by a $0.4&#160;million increase in accounts receivable for incremental services provided to Immedica and not yet paid. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&#160;31, 2021 was $53.7&#160;million and reflected a net loss of $65.8&#160;million. The cash impact of our net loss was offset by <span style="white-space:nowrap">non-cash</span> expenses of $8.0&#160;million for stock-based compensation, $1.6&#160;million for depreciation and amortization, $0.4&#160;million for operating lease expense, and $0.2&#160;million for net premium purchase and amortization on marketable securities. The net change in operating assets and liabilities of $1.8&#160;million was primarily related to a $3.6&#160;million increase in deferred revenue due to receiving a $21.5&#160;million upfront payment under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA submission. Additional offsets included a $1.2&#160;million increase in prepaid expenses and other assets due to advance payments for the Phase 1/2 trial of pegtarviliase and manufacturing activities for the Arginase 1 Deficiency program, a $0.8&#160;million increase in license and development receivable for incremental services provided to Immedica and not yet paid, and a $0.4&#160;million decrease in operating lease liabilities due to lease payments made during the year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash used in investing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the year ended December&#160;31, 2022 was $57.0&#160;million and consisted of $39.5&#160;million in purchases of marketable securities offset by $96.5&#160;million in maturities of marketable securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the year ended December&#160;31, 2021 was $22.6&#160;million and consisted of $133.1&#160;million in purchases of marketable securities and $0.5&#160;million in purchases of property and equipment offset by $111.0&#160;million in maturities of marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash provided by financing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&#160;31, 2022 was $42.7&#160;million, which consisted of $42.9&#160;million from issuance of Common Stock and <span style="white-space:nowrap">pre-funded</span> warrants in a registered direct offering, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2022 RDO, net of offering costs and $0.2&#160;million sale of common stock under our 2016 Employee Stock Purchase Plan offset by $0.4&#160;million in principal payments made on finance lease obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&#160;31, 2021 was $1.4&#160;million, which consisted of $1.9&#160;million in stock option exercises and sale of common stock under our 2016 Employee Stock Purchase Plan offset by $0.5&#160;million in principal payments made on finance lease obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations and Other Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective June 30, 2023, we abandoned our leased corporate headquarters and laboratory space located in Austin, Texas. As a result, we recognized an impairment loss related to the operating right-of-use asset of $0.9 million. On August 7, 2023, we terminated our building lease in Austin, Texas. In exchange for releasing us of all further obligations under the lease, we paid the lessor a $2.0 million termination fee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into agreements in the normal course of business with contract research organizations for clinical trials and contract manufacturing organizations, and with vendors for nonclinical research studies and other services and products for operating purposes. These contractual obligations are cancelable at any time by us, generally upon 30 to 60 days&#8217; prior written notice to the vendor. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Contingent contractual obligations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the Option to license the IPR&amp;D rights related to four research programs. On July 12, 2023 and on December 14, 2023, we exercised the Option with respect to two of these research programs, respectively. The exercise of the Option allows for us to enter into an exclusive license agreement with Paragon for the respective research program. Upon license execution, we expect to be obligated to pay Paragon up to $22.0 million based on specific development, regulatory and clinical milestones for each licensed research program. As of December 31, 2023, none of the $22.0 million obligation was accrued for since the related license agreements are still being negotiated. As of the date of the filing of this prospectus, the Option remains unexercised with respect to the two remaining research programs under the Paragon Agreement. Should the Option for these research programs be exercised and upon entry into license agreements with respect to such research programs, we expect to be obligated to pay Paragon up to $22.0 million per research program based on certain development, regulatory and clinical milestones. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to enter into a SPY001 license agreement (the &#8220;SPY001 License Agreement&#8221;) and a SPY002 license agreement (the &#8220;SPY002 License Agreement&#8221;). Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, we would be obligated to pay Paragon up to $22.0 million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, we expect to pay Paragon a $1.5 million fee for nomination of a development candidate, as applicable, and we expect to be obligated to make a further milestone payment of $2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY003 or SPY004 research programs, we expect to be obligated to make similar payments upon and following the execution of license agreements with respect to these research programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recently Adopted Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update 2020-06, Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), effective as of January 1, 2023 using the modified retrospective method. Among other amendments, ASU 2020-06 eliminates the cash conversion and beneficial conversion feature models in ASC 470-20 that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted earnings-per-share for convertible instruments and contracts </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that may be settled in cash or stock. Additionally, ASU 2020-06 requires the if-converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. We applied ASU 2020-06 to all Series A Preferred Stock and Series B Preferred Stock during fiscal year 2023, and, accordingly, we did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A Preferred Stock and Series B Preferred Stock. The adoption of ASU 2020-06 did not have a material impact on our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Recently Issued Accounting Pronouncements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 &#8211; Segment Reporting. This update is effective beginning with the Company&#8217;s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. This ASU will have no impact on the Company&#8217;s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income tax disclosures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_8">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_9">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates, particularly because our investments are in marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. However, we believe that our exposure to interest rate risk is not significant as the majority of our investments are short-term in duration and have a low risk profile. A hypothetical 10% change in interest rates is not expected to have a material effect on the total market value of our investment portfolio. We have the ability to hold our marketable securities until maturity, and therefore, we would not expect our operating results or cash flows to be materially impacted by a change in market interest rates on our investments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we held $339.6&#160;million in cash, cash equivalents, marketable securities, and restricted cash, predominately all of which was denominated in U.S. dollars, and consisted primarily of investments in money market funds, commercial paper, U.S. government obligations and corporate bonds. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also exposed to market risk related to changes in foreign currency exchange rates as a result of our entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. For the twelve months ended December&#160;31, 2023, a majority of our expenditures were denominated in U.S. dollars. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_10">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Company Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we completed the Asset Acquisition pursuant to the Acquisition Agreement. <span style="white-space:nowrap">Pre-Merger</span> Spyre was a <span style="white-space:nowrap">pre-clinical</span> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the Asset Acquisition, we received the Option pursuant to the Paragon Agreement. On July&#160;12, 2023, we exercised the Option with respect to one of these research programs to exclusively license intellectual property rights related to such research program directed to antibodies that selectively bind to &#945;4&#223;7 integrin and methods of using these antibodies, including methods of treating IBD using the SPY001 program. If this research program is pursued <span style="white-space:nowrap">non-provisionally</span> and matures into issued patents, we would expect those patents to expire no earlier than 2044 subject to any disclaimers or extensions. On December&#160;14, 2023, we exercised the Option under the Paragon Agreement to be granted an exclusive license to all of Paragon&#8217;s rights, title and interest in and to intellectual property rights, including inventions, patents, sequence information and results, under SPY002, our TL1A program, to develop and commercialize antibodies and products worldwide in all therapeutics disorders. The license agreements pertaining to such research programs are currently being finalized. Furthermore, as of the date of this registration statement, the Option remains unexercised with respect to the intellectual property rights related to the two remaining research programs under the Paragon Agreement. For more information on the Paragon Agreement, see discussion under the heading &#8220;<span style="font-style:italic">Paragon Agreement</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, we announced that we entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency, to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica supersedes and terminates the license agreement between us and Immedica dated March 2021. See the section titled &#8220;<span style="font-style:italic">Recent Developments</span>&#8221; below for more information regarding the Immedica APA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Asset Acquisition and the entry into the Immedica APA, we have significantly reshaped the business into a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with IBD, including UC and CD. Through the Paragon Agreement, our portfolio of novel and proprietary monoclonal antibody product candidates has the potential to address unmet needs in IBD care by improving efficacy, safety, and/or dosing convenience relative to products currently available or product candidates in development. We have engineered our product candidates with the aim to bind potently and selectively to their target epitopes and to exhibit extended pharmacokinetic half-lives through modifications in the Fc domain that increase affinity to human FcRn and increase antibody recycling. We anticipate that half-life extension will enable less frequent administration compared to marketed or development-stage mAbs that do not incorporate half-life extension modifications. In addition to development of our product candidates as potential monotherapies, we plan to investigate combinations of our proprietary antibodies in preclinical and clinical studies to evaluate whether combination therapy (co-administration or co-formulation of multiple monoclonal antibodies) can lead to greater efficacy compared to monotherapies in IBD. We also intend to examine patient selection strategies via complementary diagnostics in our clinical studies to evaluate whether patients can be matched to the optimal therapy based on genetic background and/or other biomarker signatures. We intend to deliver our product candidates through convenient, infrequently dosed, self-administered, SC injection, although the specific delivery mechanism or technology has not been selected given our early stage. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to develop next-generation therapeutics for the treatment of IBD, relying on three strategic pillars: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Advancing novel, long-acting antibodies against validated IBD targets, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Evaluating rational therapeutic combinations of our long-acting antibodies, and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Developing genetic- or biomarker-based complementary diagnostics (e.g., a medical device that provides valuable information about whether a treatment might be beneficial, but is not required for the administration of the drug) to match treatment targets to IBD <span style="white-space:nowrap">sub-populations.</span> See the heading &#8220;<span style="font-style:italic">Our Precision Immunology Approach</span>&#8221; below for additional information.</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Half-Life Extension Approach </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A drug&#8217;s half-life is an indicator of how long the therapy remains in the body and is a measure of the period of time it takes for the concentration of a drug in the blood to be reduced by half. The half-life determines how frequently a drug needs to be administered to maintain its therapeutic effect. Technologies that extend half-life for injectable products reduce the frequency of injections, or number of injections per applicable time period, needed to provide a therapeutic benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our antibody programs are engineered to increase FcRn binding in order to prolong the half-life via increased FcRn-mediated endosomal recycling (rather than catabolism) efficiency. Mutagenesis of the antibody Fc domain, such as the YTE and LS mutations, has been shown to increase binding affinity to human FcRn by more than ten-fold and result in &gt;two-fold the half-life in cynomolgus monkeys (Haraya and Tachibana 2022). Additionally, several antibodies incorporating YTE or LS mutations have been tested in humans and exhibit prolonged half-lives, including at least two FDA-approved products (Beyfortus <sup style="font-size:75%; vertical-align:top">&#174;</sup>, Evushield <sup style="font-size:75%; vertical-align:top">&#174;</sup>). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Engineered mAbs with increased half-life have the potential to confer more favorable dosing profiles, including lower dosing frequencies and/or lower required doses administered. In our head-to-head NHP studies, SPY001 and SPY002 exhibited a greater than three-fold and two to three-fold increase in half-life, respectively, relative to comparator antibodies that lack half-life extension modifications. Allometric scaling of the NHP pharmacokinetics to humans support the potential for every other month or quarterly SC dosing for these antibodies, which we believe is a significant improvement over every two week or monthly SC dosing of competitor programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Combination Therapy Approach </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the development of our product candidates as potential monotherapies, we also plan to investigate combinations of our proprietary antibodies in preclinical studies in 2024 and in a clinical study that will include combinations in 2025, subject to approval of an IND or equivalent foreign regulatory submission, to evaluate whether combination therapy (co-administration or co-formulation of multiple monoclonal antibodies) can lead to greater efficacy compared to monotherapies in IBD. This is expected to initially include SPY120, which combines SPY001 (&#945;4&#223;7) and SPY002 (TL1A), following approval of an IND or equivalent foreign regulatory submission anticipated in 2025. This is anticipated to be followed by combinations that include SPY003 (IL-23), SPY130 (a combination of SPY001 and SPY003) and SPY230 (a&#160;combination of SPY002 and SPY003). We believe that combinations targeting distinct pathways could lead to greater efficacy in IBD. To support our plans, this year we intend to evaluate our combination regimens in preclinical <span style="font-style:italic">in vitro</span> and i<span style="font-style:italic">n vivo </span>pharmacology models and to conduct combination toxicology studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Precision Immunology Approach </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We aim to develop genetic- or biomarker-based patient selection approaches such as complementary diagnostics that utilize a genomic or proteomic signature across our portfolio of therapeutics to aid patients and physicians in selecting the optimal treatment regimen. We are in discussions with potential partners to develop patient selection strategies for each of our targets, and if successful, we would intend to evaluate such approaches in Phase 2 studies in IBD patients. Depending on their performance, one or more of such approaches could be utilized in Phase 3 studies and potentially commercially as complementary diagnostics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A complementary diagnostic is a medical device, often an in vitro device, which provides information that is valuable for the safe and effective use of a corresponding therapeutic drug or biologic product. In contrast, a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companion diagnostic is considered <span style="font-style:italic">essential </span>for the safe and effective use of a corresponding drug or biological product. A complementary diagnostic can be used to identify patients or subsets of patients who are most likely to benefit from the therapeutic product, but unlike a companion diagnostic, is not required prior to administration or prescription of a drug. A complementary diagnostic is generally developed in conjunction with the clinical program for an associated therapeutic product and would require additional subgroup analysis as a secondary or exploratory endpoint from patient samples (e.g., blood, saliva) provided in the trial. The development path of a complementary diagnostic may include additional meetings with regulatory authorities, such as a pre-submission meeting and the requirement to submit an investigational device exemption application. As a result, the overall timing and cost of our clinical development program, and ultimately our commercial strategy, may be impacted by our pursuit of complementary diagnostics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercial use of a complementary diagnostic may require additional regulatory approvals, but we do not expect the approval and commercialization of any of our therapeutic product candidates to be dependent on regulatory approval or the commercialization of a diagnostic. A complementary diagnostic could be useful in a commercial setting to facilitate first line use of a therapeutic for patients who are diagnostic-positive and are deemed more likely to respond, as long as diagnostic-negative patients (e.g., false-negatives) are not unduly burdened with access restrictions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Inflammatory Bowel Disease </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. It encompasses two main disorders: UC and CD. UC primarily affects the colon and the rectum. Inflammation occurs in the innermost lining of the colon. Symptoms include bloody diarrhea, abdominal pain, bowel urgency, and frequent bowel movements. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. It is characterized by inflammation that extends through multiple layers of the bowel wall. Symptoms include abdominal pain, diarrhea, weight loss, fatigue, and complications such as strictures or fistulas. Both conditions can significantly impact patients&#8217; quality of life in terms of physical health, emotional well-being, and the unpredictability of symptom onset. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IBD affects millions of individuals worldwide, with increasing prevalence and incidence in both developed and developing countries. In the United States, it is estimated that approximately 2.4&#160;million individuals currently have IBD, with approximately 70,000 patients newly diagnosed every year. Based on research from the Crohn&#8217;s and Colitis Foundation of America, the market for IBD therapeutics is expected to experience steady growth, driven by rising disease prevalence, increasing diagnosis rates, and evolving treatment paradigms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A range of pharmaceutical options exists, including anti-inflammatory drugs, immunosuppressants, and biologics. Treatment plans are often tailored to the individual patient&#8217;s disease severity, location, and response to therapy. In some cases, surgical interventions such as bowel resection or ostomy formation may be necessary to manage complications or improve quality of life. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite available treatments, there remain substantial unmet needs in IBD management, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Inadequate response or loss of response to existing therapies, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Side effects and safety concerns associated with long-term medication use, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Limited options for patients with refractory or severe disease, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adherence to frequent and/or inconvenient dosing regimens. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Portfolio </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing a pipeline of mAbs for the treatment of IBD (UC and CD) in connection with the research programs with respect to which we have exercised the Option to exclusively license all of Paragon&#8217;s right, title, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest in, including all intellectual property license rights to, or have the Option to acquire such intellectual property and other rights to pursuant to the Paragon Agreement and plan to develop patient selection approaches for each program. The following table summarizes the programs that have been exercised to date pursuant to the Paragon Agreement: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g68p81.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other early-stage programs: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SPY003 &#8211; anti-IL-23 mAb </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SPY004 &#8211; novel MOA mAb </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SPY130 &#8211; combination anti-&#945;4&#223;7 and anti-IL-23 mAbs </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SPY230 &#8211; combination anti-TL1A and anti-IL-23 mAbs </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have nominated development candidates for SPY001 and SPY002. We have exercised our Option to license worldwide rights from Paragon for the SPY001 and SPY002 programs and the SPY001 License Agreement and SPY002 License Agreement are currently being finalized with execution expected to occur in the first half of 2024. We continue to hold the Option to license similar rights from Paragon for certain other programs. We expect the SPY003 license to be restricted to IBD, and we expect other potential program licenses related to the Option to be indication agnostic. We additionally have an exclusive option under the agreement for a discovery stage program targeting a novel MOA that also incorporates half-life extension (SPY004). See the section titled &#8220;Paragon Agreement&#8221; for more information on the Paragon Agreement, including the Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we hold the Option to acquire intellectual property license rights related to the SPY003 and SPY004 programs, such Option remains unexercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The drug and/or device development process is inherently uncertain, our development approach is unproven, the preclinical evidence that supports our proposed development program is preliminary and limited, and we have not yet tested any product candidate in humans. Notwithstanding our efforts to develop safe and effective monotherapies and combination therapies, there can be no guarantee that we will be able to develop product candidates that will be found to be safe and effective so as to obtain the necessary regulatory approvals to market our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a discussion of the risks associated with our portfolio, see the section of this prospectus entitled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY001 &#8211; anti-</span><span style="font-style:italic"></span>&#945;<span style="font-style:italic"></span><span style="font-style:italic">4</span><span style="font-style:italic">&#223;</span><span style="font-style:italic">7 mAb </span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, SPY001, is a highly potent, highly selective, and fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the &#945;4&#223;7 integrin being developed for the treatment of IBD (UC and CD). The &#945;4&#223;7 integrin is a protein found on the surface of immune cells known as lymphocytes. This integrin regulates the migration of lymphocytes to the gut where they contribute to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inflammatory process in IBD. By selectively binding to the &#945;4&#223;7 integrin, SPY001 is designed to prevent the interaction of these lymphocytes with <span style="white-space:nowrap">MAdCAM-1,</span> a molecule expressed on endothelial cells lining the blood vessels in the gut. This interaction is responsible for guiding lymphocytes from the bloodstream into the gut tissue, where they cause inflammation. By blocking the interaction between &#945;4&#223;7 integrin and <span style="white-space:nowrap">MAdCAM-1,</span> SPY001 aims to reduce the recruitment of lymphocytes to the gut, leading to a decrease in inflammation. Since it specifically targets the gut immune system, SPY001 is designed to minimize systemic immunosuppressive effects unrelated to IBD pathology. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY001 is being developed by us and our research partners at Paragon. Prior to the closing of the Asset Acquisition, Paragon had sole leadership in conducting <span style="font-style:italic">in vitro</span> and <span style="font-style:italic">in vivo</span> studies for SPY001 clones, including the potency, selectivity, and NHP PK data supporting development candidate nomination for the SPY001 program. Following the closing of the Asset Acquisition and the exercise of the Option with respect to the SPY001 program, Spyre and Paragon established a Joint Development Committee (&#8220;JDC&#8221;) comprised of two employees from Spyre and two employees from Paragon and jointly directed research and development work, with Spyre having final decision rights on the budget for any research program. The JDC is the decision-making body for SPY001 and our other pipeline programs prior to the execution of the SPY001 License Agreement and, in addition to SPY001, we will also control and lead the development process for each of SPY002, non-optioned programs SPY003 and SPY004, and each of the combination programs once the respective license agreements are executed. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY001 preclinical characterization studies were conducted in-house with support from third party vendors. SPY001 demonstrates similar potency and selectivity as vedolizumab in preclinical <span style="font-style:italic">in vitro</span> models including surface plasmon residence (n=5 concentrations, study completed September 2023) and cellular adhesion assays (see Figure&#160;1, n=6 replicates per group, study completed in August 2023). It also incorporates a half-life extending modification resulting in an increase in half-life of &gt;three-fold in Tg276 transgenic mice that express human FcRn (n=5 per group, studies completed in August 2023) and an increase in half-life of &gt;three-fold in NHPs (n=6 per group, studies completed in December 2023), compared to vedolizumab (see Figure 2). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY001 is currently progressing through IND-enabling studies (chemistry, manufacturing, and controls (&#8220;CMC&#8221;) scale-up complete, IND-enabling toxicology studies initiating), and we expect to submit an IND or equivalent foreign regulatory submission and enter a Phase&#160;1 first-in-human (&#8220;FIH&#8221;) study in healthy volunteers in the first half of 2024, pending health agency approval. Interim data from the Phase 1 healthy volunteer study are expected by the end of 2024. If successful, SPY001 would then advance to Phase&#160;2 clinical studies and, pending further success, Phase&#160;3 clinical studies to support global regulatory submissions and commercial approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 1. Potency and selectivity of SPY001 relative to vedolizumab in cellular assays. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g40p53.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 2. Pharmacokinetic concentration-time curves of SPY001 compared to vedolizumab in Tg276 transgenic mice and non-human primates (n=3-5 per group shown, removing primates that developed anti-drug antibodies). </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g82k34.jpg" alt="LOGO"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY002 &#8211; anti-TL1A mAb </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our <span style="white-space:nowrap">co-lead</span> program, SPY002, we have nominated two highly potent, highly selective, and fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (&#8220;TL1A&#8221;), both of which are in preclinical development for the treatment of IBD (UC and CD). TL1A is a protein that plays a role in regulating the immune system and is elevated in the gut tissue of individuals with IBD. TL1A interacts with its receptor, death receptor 3 (&#8220;DR3&#8221;), which is expressed in various immune cells, including T cells. This interaction triggers signaling pathways that contribute to inflammation and immune system activation, leading to IBD symptomology. The SPY002 candidates have been designed to block the interaction between TL1A and DR3 and thereby inhibit the downstream signaling events and dampen the inflammatory response. By neutralizing TL1A, we believe SPY002 candidates have the potential to modulate the immune response in IBD patients, potentially reducing disease activity and promoting mucosal healing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY002 preclinical characterization studies were conducted in-house with support from third party vendors. Our extensive discovery campaign has identified two lead candidates which bind TL1A monomers and trimers and have subnanomolar potency in cellular assays (see Figure&#160;3, n=4 replicates per group per study, studies completed in Q4 2023 and Q1 2024). The candidates also exhibited extended pharmacokinetic half-lives of greater than two to three-fold relative to competitive molecules in clinical development that do not incorporate half-life extending modifications, based on head-to-head preclinical studies in NHPs (see Figure&#160;4, n=5 per group, studies completed in Q4 2023 and Q1 2024). SPY002 candidates are currently progressing through IND-enabling studies (CMC scale-up ongoing) and we expect to submit an IND or equivalent foreign regulatory submission and enter a Phase 1 FIH study in healthy volunteers in the second half of 2024, with one or both of our SPY002 candidates pending additional preclinical data and pending health agency approval. Interim data from the Phase&#160;1 healthy volunteer study are expected in the first half of 2025. If successful, one SPY002 candidate would then advance to Phase&#160;2 clinical studies and, pending further success, Phase&#160;3 clinical studies to support global regulatory submissions and commercial approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 3. Inhibition of TL1-A induced TF-1 cell apoptosis (left) and IFN<span style="FONT-FAMILY:SYMBOL">g</span> secretion in primary human whole blood 1 donor of 4 donors profiled (right). </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g61v60.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 4. Pharmacokinetic concentration-time curves of SPY002 candidates compared to competing anti-TL1A molecules in non-human primates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g518298g08m07.jpg" alt="LOGO"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY003 &#8211; <span style="white-space:nowrap"><span style="white-space:nowrap">anti-IL-23</span></span> mAb </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY003 is a discovery stage program focused on designing antibodies to bind to Interleukin 23 <span style="white-space:nowrap">(&#8220;IL-23&#8221;)</span> and incorporates half-life extending modifications. <span style="white-space:nowrap">IL-23</span> is a cytokine that is produced by immune cells and is involved in immune response regulation. <span style="white-space:nowrap">IL-23</span> promotes the survival, expansion, and activity of Th17 cells. Th17 cells produce inflammatory cytokines, such as <span style="white-space:nowrap">IL-17,</span> which contribute to the inflammation seen in IBD. <span style="white-space:nowrap">IL-23</span> also helps in the recruitment and activation of other immune cells, such as neutrophils, which further contribute to tissue damage in the gut. To date, we have identified several promising clones that meet our target product profile, and we are in the process of narrowing down the potential clones to select a development candidate based on pharmacokinetic performance and CMC developability. We are continuing our preclinical development efforts with the SPY003 program and expect to nominate a development candidate in mid-2024 and move into IND-enabling studies in the second half of 2024. Upon development candidate nomination, we intend to exercise our Option to acquire intellectual property rights for the SPY003 program pursuant to the Paragon Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SPY004 &#8211; novel MOA mAb </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY004 is an undisclosed novel mechanism of action (&#8220;MOA&#8221;) and incorporates half-life extension modifications. Upon development candidate nomination, we intend to exercise our Option to acquire intellectual property rights for the SPY004 program pursuant to the Paragon Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">SPY120 &#8211; combination anti-</span>&#945;<span style="font-style:italic"></span><span style="font-style:italic">4</span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">&#223;7 and anti-TL1A mAbs</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY120 combines SPY001 (anti-&#945;4&#223;7) and SPY002 (anti-TL1A) antibodies, pairing two mechanisms studied in third-party clinical trials targeting non-overlapping sites of action. We are currently evaluating SPY120 in preclinical studies and plan to initiate combination toxicology studies in 2024. We expect to initiate clinical studies for SPY120 in 2025, pending approval of an IND or equivalent foreign regulatory submission anticipated in 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">SPY130 &#8211; combination anti-</span>&#945;<span style="font-style:italic"></span><span style="font-style:italic">4</span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">&#223;7 and anti-IL-23 mAbs</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY130 combines SPY001 (anti-&#945;4&#223;7) and SPY003 (anti-IL-23) antibodies, pairing two commercially validated mechanisms targeting non-overlapping sites of action. We are currently evaluating SPY130 in preclinical studies and plan to initiate combination toxicology studies in 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">SPY230 &#8211; combination anti-TL1A and anti-IL-23 mAbs</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SPY230 combines SPY002 (anti-TL1A) and SPY003 (anti-IL-23) antibodies, pairing two complementary mechanisms of action with potential to address overlapping and non-overlapping triggers of inflammation. We are currently evaluating SPY230 in preclinical studies and plan to initiate combination toxicology studies in 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had 30 employees, all of whom were employed full time. We also engage temporary employees and consultants to augment our existing workforce. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that attracting, motivating, and retaining talent at all levels is vital to continuing our success. We invest in our employees through high-quality benefits, professional development opportunities, and various health and wellness initiatives and offer competitive compensation packages (base salary and incentive plans), </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ensuring fairness in internal compensation practices. The principal purposes of our incentive plans (bonus and equity) are to align with the long-term interests of our stakeholders and stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commercial </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our product candidates. Given our stage of development, we have not yet established a commercial organization or distribution capabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We are currently in the process of novating certain agreements with third parties for the performance of future clinical manufacturing and development activities from Paragon to us. The initial forms of these agreements are generally non-specific master services agreements that allow an entity to begin the process of future manufacturing or development services, respectively. As clinical development activities are commenced by us, the agreements will be revised to provide for the specific deliverables and associated costs that are needed under our development plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#8220;Novation Agreement&#8221;), by and between us, Paragon and WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), we novated (i)&#160;a Biologics Master Services Agreement (the &#8220;WuXi Biologics MSA&#8221;) and (ii)&#160;a Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the recently introduced BIOSECURE Act, which would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern, we have taken several measures to strengthen our supply chain in the event that WuXi Biologics or one of our other manufacturers is impacted. We intend to establish domestic inventory of key materials and are accelerating our clinical resupply campaigns to ensure we have a sufficient stockpile of drug substance in the United States. We will also continue to closely monitor geopolitical risk and implement additional mitigations and supply chain redundancies, as needed. See the risk factor entitled &#8220;<span style="font-style:italic">We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Biologics Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to us by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, we are obligated to pay WuXi Biologics a service fee and all <span style="white-space:nowrap">non-cancellable</span> obligations in the amount specified in each work order associated with the agreement for the provision of services. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. We can terminate the WuXi Biologics MSA or any work order at any time upon 30 days&#8217; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six months&#8217; prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, no </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination or cancellation fees shall be paid by us and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for 30 days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90 days. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cell Line License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to us by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, we received a <span style="white-space:nowrap">non-exclusive,</span> worldwide, sublicensable license to certain of WuXi Biologics&#8217;s <span style="white-space:nowrap">know-how,</span> cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration for the license, we agreed to pay WuXi Biologics a <span style="white-space:nowrap">non-refundable</span> license fee of $150,000. Additionally, if we manufacture all of our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics in an amount equal to a less than one percent of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If we manufacture part of our commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by us upon six months&#8217; prior written notice and our payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii)&#160;by WuXi Biologics for a material breach by us that remains uncured for 60 days after written notice, (iii)&#160;by WuXi Biologics if we fail to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Paragon Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2023, Pre-Merger Spyre entered into the Paragon Agreement with Paragon and Parapyre. Pursuant to the Paragon Agreement, the Option provided for the right to acquire the IPR&amp;D rights related to four research programs from Paragon in accordance with a license agreement to be entered into following each exercise of the Option. Under the Paragon Agreement, the terms of such license agreement would be consistent with the economics and other terms set out in the Paragon Agreement and, in the event of failure to reach an agreement on the definitive terms, the matter would be resolved via arbitration. In consideration for the Option granted under the Paragon Agreement, Pre-Merger Spyre was obligated to pay Paragon an upfront cash amount of $3.0 million in research initiation fees. In addition, Pre-Merger Spyre was obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with mark-up costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Pre-Merger Spyre had incurred total expenses of $19.0 million under the Paragon Agreement since inception, which included the $3.0 million research initiation fee and $16.0 million of historical reimbursable expenses owed to Paragon. As of June 22, 2023, $19.0 million was unpaid and was assumed by us through the Asset Acquisition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Asset Acquisition, we assumed the rights and obligations of Pre-Merger Spyre under the Paragon Agreement, including the Parapyre Option Obligation. For more information on the Parapyre Option Obligation, see the section titled &#8220;<span style="font-style:italic">Our Relationship with Paragon and Parapyre</span><span style="font-style:italic">.</span>&#8221; Pursuant to the Paragon Agreement, on a research program-by-research program basis following the finalization of the research plan for each respective research program, we are required to pay Paragon a nonrefundable fee in cash of $0.8 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 12, 2023 and December 14, 2023, we exercised our Option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expect to enter into the SPY001 License </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement and the SPY002 License Agreement. Our Option available under the Paragon Agreement with respect to the SPY003 and SPY004 programs remains unexercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, we will be obligated to pay Paragon up to $22.0 million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, we expect to pay Paragon a $1.5 million fee for nomination of a development candidate, as applicable, and we expect to be obligated to make a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY003 or SPY004 research programs, we expect to be obligated to make similar payments upon and following the execution of license agreements with respect to these research programs, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to face intense competition from other biopharmaceutical companies that are developing agents for the treatment of inflammatory diseases. If approved for the treatment of patients with <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> IBD, our portfolio of products would compete with TNF antibodies including Humira (AbbVie), Remicade (Johnson&#160;&amp; Johnson), and Simponi (Johnson&#160;&amp; Johnson); Omvoh (Lilly) <span style="white-space:nowrap">IL-12/23</span> and <span style="white-space:nowrap">IL-23</span> antibodies including Stelara (Johnson&#160;&amp; Johnson) and Skyrizi (AbbVie); &#945;4&#223;7 antibody Entyvio (Takeda); JAK inhibitors including Xeljanz (Pfizer), Rinvoq (AbbVie); and S1P1 receptor modulating therapies including Zeposia (Bristol Myers Squibb) and Velsipity (Pfizer). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of several companies with product candidates in development for the treatment of patients with IBD, including Merck&#8217;s <span style="white-space:nowrap">MK-7240,</span> Roche/Roivant&#8217;s <span style="white-space:nowrap">RVT-3101,</span> and Sanofi/Teva&#8217;s <span style="white-space:nowrap">TEV-48574</span> TL1A antibodies; additional <span style="white-space:nowrap">IL-23/IL-23Rs</span> including Tremfya and JNJ-2113 (Johnson&#160;&amp; Johnson); and oral anti-integrin agents including Morphic Therapeutic&#8217;s <span style="white-space:nowrap">MORF-057,</span> and Gilead&#8217;s <span style="white-space:nowrap">GS-1427,</span> and a discovery program at Dice Therapeutics (Lilly). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">United States Biologics Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, biological products are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221; regulation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an independent IRB, or ethics committee at each clinical site before the trial is commenced; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials in accordance with current Good Clinical Practice (&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA Advisory Committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA <span style="white-space:nowrap">pre-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical and Clinical Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to beginning any clinical trial with a product candidate, in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and <span style="font-style:italic">in vitro</span> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <span style="white-space:nowrap">30-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <span style="white-space:nowrap">so-called</span> Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">BLA Submission and Review </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan (&#8220;PSP&#8221;) within sixty days after an <span style="white-space:nowrap"><span style="white-space:nowrap">end-of-Phase</span></span> 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <span style="white-space:nowrap">pre-&#8201;and</span> post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and data demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the <span style="white-space:nowrap">60-day</span> filing date (as compared to ten months under standard review). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Omnibus Reform Act of 2022 the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval <span style="white-space:nowrap">pre-approval</span> of promotional materials, which could adversely impact the timing of the commercial launch of the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Combination Therapy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Combination therapy is a treatment modality that involves the use of two or more drugs to be used in combination to treat a disease or condition. If those drugs are combined in one dosage form, such as one pill, that is known as a fixed dose combination product and it is reviewed pursuant to the FDA&#8217;s Combination Rule at 21&#160;CFR 300.50. The rule provides that two or more drugs may be combined in a single dosage form when each component contributes to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy as defined in the labeling for the drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">But not all combination therapy falls under the category of a fixed dose combination. For example, the FDA recognizes that two drugs in separate dosage forms and in separate packaging, that otherwise might be administered as monotherapy for an indication, also may be used in combination for the same indication. In 2013, the FDA issued guidance to assist sponsors that were developing the range of combination therapies that fall outside the category of fixed dose combinations. That guidance provides recommendations and advice on such topics as: (1) assessment at the outset whether two or more therapies are appropriate for use in combination; (2) guiding principles for nonclinical and clinical development of the combination; (3) options for regulatory pathways to seek marketing approval of the combination; and (4) post-marketing safety monitoring and reporting obligations. Given the wide range of potential combination therapy variations, the FDA indicated it intends to assess each potential combination on a case-by case basis and encouraged sponsors to engage in early and regular consultation with the relevant review division at the agency throughout the development process for its proposed combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulation of Combination Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain therapeutic products are comprised of multiple components, such as drug components and device components, that would normally be subject to different regulatory frameworks by the FDA and frequently regulated by different centers at the FDA. These products are known as combination products. Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established the Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. A combination product with a primary mode of action attributable to the drug or biologic component generally would be reviewed and approved pursuant to the drug or biologic approval processes set forth in the FDCA. In reviewing the NDA or BLA for such a product, however, FDA reviewers </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would consult with their counterparts in the FDA&#8217;s Center for Devices and Radiological Health to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the Quality System Regulation applicable to medical devices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Complementary Diagnostics </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our product candidates may depend, in part, on the development and commercialization of a complementary diagnostic. Complementary diagnostics can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Complementary diagnostics are regulated as medical devices by the FDA. The level of risk associated with a new diagnostic test combined with available controls to mitigate risk determines whether a complementary diagnostic device requires Premarket Approval (&#8220;PMA&#8221;) from the FDA or if it can be cleared by the agency through the 510(k) premarket notification process based on a showing of substantial equivalence to a commercially available device. The use of the complementary diagnostic device will be stipulated in the labeling of the therapeutic product, and vice versa. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on post-approval clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal of the FDA to permit the import or export of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mandated modification of promotional materials and labeling and the issuance of corrective information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such <span style="white-space:nowrap">off-label</span> uses are common across medical specialties. Physicians may believe that such <span style="white-space:nowrap">off-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <span style="white-space:nowrap">off-label</span> use of their products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Biosimilars and Reference Product Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an <span style="white-space:nowrap">FDA-approved</span> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an <span style="white-space:nowrap">FDA-approved</span> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <span style="white-space:nowrap">six-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <span style="white-space:nowrap">FDA-issued</span> &#8220;Written Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the <span style="white-space:nowrap">COVID-19</span> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the <span style="white-space:nowrap">12-year</span> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed below, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Healthcare Laws and Compliance Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221; the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Data Privacy and Security </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA <span style="white-space:nowrap">non-compliance.</span> A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the Federal Trade Commission Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain state laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household &#8212; unless it is subject to HIPAA &#8212; and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the CPRA expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Coverage and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a <span style="white-space:nowrap"><span style="white-space:nowrap">plan-by-plan</span></span> basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost- containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition, beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Government Regulation Outside of the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation in the European Union </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">European Data Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United States, on July 10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation No.&#160;536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection regulation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the Data Protection Act 2018 (the &#8220;DPA 2018&#8221;)), the DPA 2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5 million or 4% of global turnover. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the United States, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework and the UK Extension. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Drug and Biologic Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the former regime, which will expire after a transition period of three years as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an <span style="white-space:nowrap">&#8220;opt-out&#8221;</span> from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July 19, 2023, the EC published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i) documentation which was previously assessed will not be reassessed, (ii) templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii) there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Drug Marketing Authorization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA. To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210 days, excluding time taken to provide any additional information or data required by the MHRA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August 30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January 1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK or Great Britain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Centralized Authorization Procedure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional EEA Member States. The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Decentralized Authorization Procedure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technical innovation, or if their authorization would be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Risk Management Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">MA Validity Period </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAs have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA. Conversion refers to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Norther Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January 31, 2020 and ending on December 31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining member states of the EU, the three year period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Advanced Therapy Medicinal Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, medicinal products, including ATMPs are subject to extensive pre- and post-market regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exceptional Circumstances/Conditional Approval </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Data and Market Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another non-cumulative <span style="white-space:nowrap">one-year</span> period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant <span style="white-space:nowrap">pre-clinical</span> or clinical studies were carried out in relation to the new indication. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant <span style="white-space:nowrap">pre-trial</span> tests or clinical trials (when examining an application by another applicant for or holder of MA for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Orphan Designation and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a MA, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EMA&#8217;s Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) reassesses the orphan drug designation of a product in parallel with the review for a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA and approval by the EC. Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten years of market exclusivity in the orphan indication. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the UK, following the post-Brexit transition period, a system for incentivizing the development of orphan medicines was introduced. Overall, the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained. Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK-wide orphan MA can only be considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines in rare diseases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January 1, 2021 have been adopted as UK PIPs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PRIME Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small-and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">medium-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling <span style="white-space:nowrap">non-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A <span style="white-space:nowrap">kick-off</span> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase IV safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More generally, <span style="white-space:nowrap">non-compliance</span> with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sales and Marketing Regulations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute <span style="white-space:nowrap">off-label</span> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. <span style="white-space:nowrap"><span style="white-space:nowrap">Direct-to-consumer</span></span> advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern Ireland. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Corruption Legislation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act 2010. Due to the Bribery Act 2010&#8217;s far-reaching territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bribery Act 2010 is comprised of four offenses that cover (i) individuals, companies and partnerships that give, promise or offer bribes, (ii) individuals, companies and partnerships that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships that bribe foreign public officials, and (iv) companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten years and in some cases both. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulations in the UK and Other Markets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK formally left the EU on January&#160;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UK government has adopted the Medicines and Medical Devices Act 2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Properties and Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a fully remote company and do not maintain physical corporate offices. Our employees work remotely. We believe these arrangements support our current needs. We maintain a mailing address at 221 Crescent St., Building 23, Suite 105, Waltham, MA. As we expand, we believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_11">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of eight directors and is divided into three classes. Each class serves for three years, with the terms of office of the respective classes expiring in successive years. Directors in Class&#160;I will stand for election at our Annual Meeting expected to be held in June 2026. The terms of office of directors in Class&#160;II and Class&#160;III do not expire until the annual meetings of stockholders held in 2024 and 2025, respectively. Peter Harwin and Tomas Kiselak were designated by entities affiliated with Fairmount. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current directors, and their ages, occupations and length of board service as of January 31, 2024, are provided in the table below. Additional biographical descriptions of each director are set forth in the text below the table. These descriptions include the primary individual experience, qualifications, qualities and skills of each of our directors. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:53%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name of Director</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Principal Occupation</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Director<br/>Since</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"><span style="font-weight:bold">Class&#160;I Directors:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Mark McKenna</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">44</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Investment Officer and Managing Director, McKenna Capital Partners; Chairman, Apogee Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2024</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cameron Turtle</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">34</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer of Spyre Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laurie Stelzer (1)(2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer of ReNAgade Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Class&#160;II Directors:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Russell J. Cox (1)(3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">President and Chief Executive Officer, Epirium Bio, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2015</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jeffrey W. Albers (2)(3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">52</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chairman of Blueprint Medicines Corporation and Venture Partner at Atlas Venture</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Tomas Kiselak (3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">37</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Managing Member, Fairmount Funds Management LLC; Director, Dianthus Therapeutics, Inc.; Director, Viridian Therapeutics, Inc.; Director, Apogee Therapeutics, Inc.; and Director, Paragon Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Class&#160;III Directors:</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Peter Harwin (1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">37</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Managing Member, Fairmount Funds Management LLC; Director, Cogent Biosciences, Inc.; Director, Viridian Therapeutics, Inc.; Director, Apogee Therapeutics, Inc.; and Director, Paragon Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Michael Henderson (2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">34</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer of Apogee Therapeutics, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2023</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the nominating and corporate governance committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the audit committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the compensation committee. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cameron Turtle, DPhil</span>. Dr.&#160;Turtle joined us as Chief Operating Officer in June 2023, and was appointed as our Chief Executive Officer and director in November 2023. Prior to joining the Company, Dr.&#160;Turtle was an advisor </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to <span style="white-space:nowrap">Pre-Merger</span> Spyre from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma (NASDAQ: BBIO), a biotechnology company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics (NASDAQ: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, where he worked with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40, and the Biocom Life Sciences Catalyst Award. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&#160;Turtle is qualified to serve on our board of directors due to his experience as a leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Russell J. Cox</span>. Mr.&#160;Cox has served as a director since June 2015 and has served as Chair of our board of directors since January 2019. Mr.&#160;Cox has served as President and Chief Executive Officer of Epirium Bio, Inc. since July 2019. Mr.&#160;Cox previously served as Chief Executive Officer at Vital Therapies, Inc. from January 2018 to January 2019. Additionally, Mr.&#160;Cox served as Executive Vice President and Chief Operating Officer at Jazz </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceuticals plc, a publicly traded biopharmaceutical company, from May 2014 to January 2018, where he also served as Executive Vice President and Chief Commercial Officer from March 2012 to May 2014 and as Senior Vice President, Sales and Marketing from July 2010 until February 2012. Prior to that, Mr.&#160;Cox served in a variety of senior management roles since joining Jazz Pharmaceuticals, Inc. (the predecessor to Jazz Pharmaceuticals plc) in July 2010. From January 2009 to January 2010, he served as Senior Vice President and Chief Commercial Officer of Ipsen Group, a publicly traded pharmaceutical company, and from 2007 until December 2008, he served as Vice President of Marketing at Tercica, Inc. (acquired by Ipsen Group), a biotechnology company. From 2003 to 2007, Mr.&#160;Cox was with Scios Inc. (acquired by Johnson and Johnson in 2003), where he also served as Vice President, Marketing. Prior to 2003, Mr.&#160;Cox was with Genentech, Inc. for 12 years, where he was a Product Team Leader responsible for the Growth Hormone franchise and led numerous product launches as a Group Product Manager. Mr.&#160;Cox currently serves on the boards of directors of Epirium Bio, Inc. and Gossamer Bio, Inc. Mr.&#160;Cox received a B.S. in Biomedical Science from Texas A&amp;M University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Cox is qualified to serve on our board of directors due to his commercial and operating experience in the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jeffrey W. Albers</span>. Mr.&#160;Albers has over 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. He is currently Chairman of Blueprint Medicines Corporation (Nasdaq: BPMC), a global precision therapy company, since January 2023, and Venture Partner at Atlas Venture, a venture capital firm focused on investment in biotechnology companies, since January 2023. Mr.&#160;Albers served as Chief Executive Officer, President and Chairman of Blueprint Medicines from June 2021 to April 2022, Executive Chairman from April 2022 to December 2022 and as Chief Executive Officer, President and Director from July 2014 to June 2021. Prior to joining Blueprint Medicines in July 2014, Mr.&#160;Albers was President of Algeta ASA, a Norwegian biotechnology company from January 2012 to April 2014, where he oversaw the commercial and business functions. Prior to Algeta ASA, from July 2005 to November 2011, Mr.&#160;Albers was at Genzyme Corporation, a biotechnology company that is now a wholly-owned subsidiary of Sanofi S.A., most recently as Vice President of the U.S. hematology and oncology business unit. In addition to Blueprint Medicines, Mr.&#160;Albers serves on the board of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR) and several private companies, and previously served on the board of directors of Magenta Therapeutics, Inc. (which later became Dianthus Therapeutics, Inc. (Nasdaq: DNTH)) from July 2017 to September 2023. Mr.&#160;Albers received a B.S. from Indiana University and an M.B.A. and a J.D. from Georgetown University. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that Mr.&#160;Albers is qualified to serve on our board of directors due to his extensive leadership experience in the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mark McKenna</span>. Mr. McKenna has served as a director since February 2024. Mr. McKenna currently serves as Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases, since June 2023. Mr. McKenna most recently served as the President and Chief Executive Officer and as a member of the board of directors of Prometheus Biosciences, Inc., a clinical stage biotechnology company, from September 2019 to June 2023, when Prometheus was acquired by Merck &amp; Co., Inc., and as Chairman of the board of Prometheus from August 2021 to June 2023. Prior to Prometheus, he served as President of Salix Pharmaceuticals, Inc., a pharmaceutical company and wholly-owned subsidiary of Bausch Health Companies, Inc., from March 2016 through August 2019. Prior to Salix, Mr. McKenna spent more than a decade in various roles with Bausch + Lomb, also a division of Bausch Health Companies, Inc., most recently as Senior Vice President and General Manager of its U.S. Vision Care business. Before joining Bausch + Lomb, he held several positions with Johnson &amp; Johnson. Mr. McKenna has served as chair of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE) since August 2023. Mr. McKenna received a B.S. in Marketing from Arizona State University and an M.B.A. from Azusa Pacific University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that Mr. McKenna is qualified to serve on our board of directors due to his extensive experience as an executive officer in the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Laurie Stelzer</span>. Ms.&#160;Stelzer has served as Chief Financial Officer of ReNAgade Therapeutics, Inc., a biotechnology company focused on RNA therapeutics, since September 2023. Prior to joining ReNAgade, Ms.&#160;Stelzer served as Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial-stage targeted oncology company (&#8220;Mirati&#8221;), from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms.&#160;Stelzer served as Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. (acquired by Pfizer Inc.), a biopharmaceutical company, from March 2020 until the completion of Pfizer&#8217;s acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms.&#160;Stelzer served as Chief Financial Officer at Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharma technology platform company, from June 2015 to March 2020, where she led the Finance, Information Technology, Business Development, Project Management and Site Operations organizations. Prior to joining Halozyme Therapeutics, Ms.&#160;Stelzer held senior management roles at Shire Plc (acquired by Takeda Pharmaceutical), including Senior Vice President of Finance, Division Chief Financial Officer for the Regenerative Medicine Division and Head of Investor Relations. Previously, she also worked at Amgen, Inc. (Nasdaq: AMGN), a global biopharmaceutical company, for 15 years, serving in positions of increasing responsibility in the areas of Finance, Treasury, Global Accounting and International/Emerging Markets. Ms.&#160;Stelzer has served as a member of the board of directors of PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company, since 2020, Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company, from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals, a clinical-stage neurology company from 2020 to 2021. Ms.&#160;Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Ms.&#160;Stelzer is qualified to serve on our board of directors because of her financial expertise and experience within the biopharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Peter Harwin</span>. Peter Harwin has served as a director since June 2023. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he <span style="white-space:nowrap">co-founded</span> in April 2016. Prior to Fairmount, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a director of Viridian Therapeutics, Inc. (Nasdaq: VRDN), Apogee Therapeutics, Inc. (Nasdaq: APGE) and Paragon Therapeutics, Inc. Mr.&#160;Harwin holds a B.B.A. from Emory University. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Harwin is qualified to serve on our board of directors because of his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tomas Kiselak</span>. Tomas Kiselak has served as a director since June 2023. Mr.&#160;Kiselak is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he <span style="white-space:nowrap">co-founded</span> in April 2016. Prior to Fairmount, Mr.&#160;Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr.&#160;Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE), Dianthus Therapeutics, Inc. (Nasdaq: DNTH) as well as several private companies. He received a B.S. in neuroscience and economics from Amherst College. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&#160;Kiselak is qualified to serve on our board of directors because of his experience advising biotechnology companies and as a manager of funds specializing in the area of life sciences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Michael Henderson, M.D</span>. Michael Henderson, M.D. has served as a director since June 2023. Dr.&#160;Henderson is Chief Executive Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September 2022 as well as a member of its board of directors since June 2023. Dr.&#160;Henderson is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy. He has overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date. Prior to joining Apogee, Dr.&#160;Henderson served as Chief Business Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company, from January 2020 to September 2022, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies and running business development and operations. Prior to holding that position, he spent two years serving as BridgeBio&#8217;s Senior Vice President, Asset Acquisition, Strategy and Operations, where he was responsible for business development, strategy and operations. Dr.&#160;Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr.&#160;Henderson also served as the Chief Executive Officer of a number of BridgeBio&#8217;s subsidiaries. Prior to BridgeBio, Dr.&#160;Henderson worked at McKinsey&#160;&amp; Company, a global management consulting firm, from January 2015 to April 2016 and prior to that, he <span style="white-space:nowrap">co-founded</span> PellePharm, Inc., a biotechnology company, in August 2011. Dr.&#160;Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company focused on the healthcare industry, since February 2021. Dr.&#160;Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&#160;Henderson is qualified to serve on our board of directors because of his experience in business leadership, drug development, and commercial strategy in the area of life sciences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors determines the independence of our directors by applying the applicable rules, regulations and listing standards of Nasdaq. These provide that a director is independent only if the board affirmatively determines that the director does not have a relationship with us which, in the opinion of the board of directors, would interfere with the exercise of his or her independent judgment in carrying out the responsibilities of a director. They also specify various relationships that preclude a determination of director independence. Such relationships may include employment, commercial, accounting, family and other business, professional and personal relationships. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applying these standards, the board reviews the independence of our directors, taking into account all relevant facts and circumstances. After considering the foregoing factors, our board of directors has determined that the following members of our board are currently independent as determined under applicable rules, regulations and listing standards of Nasdaq: Mr.&#160;Russell Cox, Ms.&#160;Laurie Stelzer, Mr.&#160;Jeffrey&#160;W. Albers, Mr.&#160;Peter Harwin, Mr.&#160;Tomas Kiselak and Dr.&#160;Michael Henderson. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All members of our audit committee, compensation committee and nominating and corporate governance committee must be independent directors under the applicable rules, regulations and listing standards of Nasdaq. Members of the audit committee also must satisfy the independence criteria set forth in Rule <span style="white-space:nowrap">10A-3</span> under the Exchange Act. Members of the compensation committee also must satisfy the independence criteria set forth in Rule 10C under the Exchange Act, and related Nasdaq listing standards with respect to their affiliation with us and any consulting, advisory or other fees they may have received from us. Our board of directors has determined that all members of our audit committee, compensation committee and nominating and corporate governance committee are independent and satisfy the relevant SEC, Exchange Act and Nasdaq independence requirements for such committees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The names of our current executive officers, their ages as of January 31, 2024, and their positions are shown below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:59%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Position</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cameron Turtle, DPhil(1)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">34</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Scott Burrows</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Heidy King-Jones</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">41</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Legal Officer and Corporate Secretary</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="5"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(1)&#8194;&#8201;&#8202;For Dr.&#160;Turtle&#8217;s biographical information, see &#8220;Directors&#8221; above.</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors chooses executive officers, who then serve at the board&#8217;s discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Scott Burrows.</span> Mr.&#160;Burrows joined as our Chief Financial Officer in September 2023. Prior to becoming Chief Financial Officer, Mr.&#160;Burrows most recently served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (&#8220;Arcutis&#8221;) (Nasdaq: ARQT) where he helped lead Arcutis through a successful initial public offering, several further equity and debt financings, and the transition to a fully integrated commercial-stage company. Prior to Arcutis, Mr.&#160;Burrows was the head of international investor relations for Shire, plc based in Switzerland. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury and investor relations. Mr.&#160;Burrows began his career at Arthur Andersen as a consultant. He earned his B.A. and M.B.A. from the University of California, Los Angeles, and is a licensed C.P.A. (inactive). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Heidy King-Jones.</span> Ms.&#160;King-Jones joined as our Chief Legal Officer and Corporate Secretary in September 2023. Ms.&#160;King-Jones most recently served as the Chief Legal Officer and Corporate Secretary at Provention Bio, Inc. through various financings, the approval of Tzield<sup style="font-size:75%; vertical-align:top">&#174;</sup>, the companies successful transition from clinical-stage to commercial-stage as well as its acquisition by Sanofi in April 2023. Prior to her leadership role at Provention Bio, she was a Senior Vice President, General Counsel and Corporate Secretary at Axcella Health Inc. where she was responsible for Axcella&#8217;s corporate legal function and strategy. From 2013 to 2018, she held positions of increasing responsibility in the legal department at Sarepta Therapeutics, Inc., including overseeing all Corporate Law matters as Senior Director, Corporate Law. While at Sarepta, she served as a member of the company&#8217;s commercial readiness working group and was responsible for the development of the compliance program, contract and other legal work for the launch of its first product, Exondys 51<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Ms.&#160;King-Jones began her legal career in the Securities&#160;&amp; Public Companies Practice Group at Ropes&#160;&amp; Gray LLP, where she represented private and publicly traded companies in the pharmaceutical, utility and technology industries. She holds a J.D. and LL.M in International and Comparative Law from Cornell Law School, and a B.A. from Dartmouth College. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among our directors and executive officers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_12">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section provides an overview of the material components of our executive compensation program each for our Chief Executive Officer, other individuals who served as principal executive officer during any part of fiscal year 2023, and each of our two other most highly compensated executive officers (collectively, our &#8220;Named Executive Officers&#8221; or &#8220;NEOs&#8221;) during fiscal year 2023. The compensation provided to our Named Executive Officers for fiscal year 2023 is set forth in detail in the Summary Compensation Table and other tables that follow in this section, as well as the accompanying footnotes and narratives relating to those tables. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Named Executive Officers for fiscal year 2023 were: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Title</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Turtle</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Burrows</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidy King-Jones</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Legal Officer and Corporate Secretary<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Goldberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former President and Chief Executive Officer<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Alspaugh</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Financial Officer<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In connection with the Asset Acquisition, Dr.&#160;Turtle was appointed Chief Operating Officer of the Company effective June&#160;22, 2023. On November&#160;22, 2023, Dr.&#160;Turtle was promoted to Chief Executive Officer of the Company. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Burrows was appointed Chief Financial Officer of the Company effective September&#160;1, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;King-Jones was appointed Chief Legal Officer and Corporate Secretary effective September&#160;1, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Goldberg&#8217;s employment with the Company as President and Chief Executive Officer was terminated effective May&#160;16, 2023, and he was succeeded by Mr.&#160;Alspaugh as the principal executive officer. Mr.&#160;Alspaugh&#8217;s employment with the Company was terminated effective August&#160;31, 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding all plan and <span style="white-space:nowrap">non-plan</span> compensation awarded to, earned by or paid to each of our Named Executive Officers for the fiscal years ended December&#160;31, 2023 and 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bonus<br/>($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br/>Awards<br/>($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Awards</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span><br/>Incentive Plan<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br/>Compensation<br/>($)<sup style="font-size:75%; vertical-align:top">(4)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Turtle</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">272,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,500,492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,919,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Burrows</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">154,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,452,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,767,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,551,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidy King-Jones</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,356,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,588,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Legal Officer and Corporate&#160;Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Goldberg</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">248,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">581,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">830,207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Former President and Chief Executive&#160;Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">54,616</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,774,952</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2,917</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,832,485</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Alspaugh</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">329,767</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">735,647</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,059,923</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">234,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,360,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Former Chief Financial&#160;Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">425,001</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">443,285</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">130,560</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">12,994</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,011,840</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For 2023, the amounts reported in this column include: (i)&#160;discretionary annual bonuses of $141,000 for Mr.&#160;Turtle, $60,700 for Mr.&#160;Burrows, and $62,700 for Ms.&#160;King-Jones; (ii)&#160;a <span style="white-space:nowrap">sign-on</span> bonus for Mr.&#160;Burrows </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
in connection with the commencement of his employment with the Company during 2023 of $115,000; (iii)&#160;retention bonuses totaling $168,247 for Mr.&#160;Alspaugh in accordance with his June&#160;21, 2023 incentive agreement, as described in more detail under &#8220;<span style="font-style:italic">Narrative Disclosure to Summary Compensation Table&#8212;Transaction and Retention Bonuses</span>&#8221; below; and (iv)&#160;transaction success bonuses totaling $567,400 for Mr.&#160;Alspaugh, as described in more detail under &#8220;<span style="font-style:italic">Narrative Disclosure to Summary Compensation Table&#8212;Transaction and Retention Bonuses</span>&#8221; below. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reported in this column represent the aggregate grant date fair value of restricted stock units (&#8220;RSUs&#8221;) granted to our NEOs, as computed in accordance with ASC 718 based on the closing price of our common stock on the applicable date of grant. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reported in this column represent the aggregate grant date fair value of stock options granted to our NEOs, as computed in accordance with ASC 718. See Note 15 to our consolidated financial statements included herein for the fiscal year ended December 31, 2023 for more information regarding the assumptions used in calculating the grant date fair value of stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reported in this column for 2023 include: (i)&#160;matching contributions under our 401(k) plan made during 2023 of $5,203 to Mr.&#160;Turtle, $1,517 to Mr.&#160;Burrows, $5,092 to Mr.&#160;Goldberg, and $13,200 to Mr.&#160;Alspaugh, (ii)&#160;severance payments and benefits totaling $563,384 for Mr.&#160;Goldberg and $211,617 for Mr.&#160;Alspaugh as described in more detail under &#8220;<span style="font-style:italic">Narrative Disclosure to Summary Compensation Table&#8212;Separation Agreements</span>&#8221; below; (iii)&#160;consulting fees of $9,875 paid to Mr.&#160;Alspaugh during 2023 as described in more detail under &#8220;<span style="font-style:italic">Narrative Disclosure to Summary Compensation Table&#8212;Separation Agreements</span>&#8221; below; and (iv)&#160;housing allowances and home office expense reimbursements for Mr.&#160;Goldberg. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative Disclosure to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2023, our compensation committee adopted a compensation philosophy to frame future compensation decisions for the Company. Under this philosophy, compensation positioning is used to attract and retain key employees for the Company&#8217;s continued success and growth. While market data is helpful to the compensation committee in setting compensation framework and guiding decisions, other factors such as general market practices, Company strategy, tenure, performance and criticality are also considered. The compensation philosophy serves as the foundation to reinforce the Company&#8217;s business strategy and desired culture, while balancing internal and external alignment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Peer Group </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2023, our compensation committee, in consultation with Alpine, its independent compensation consultant, established a peer group that focuses on U.S.-based, <span style="white-space:nowrap">pre-clinical</span> or early clinical biopharma companies (with priority places on companies with a similar therapeutic focus) with a market capitalization ranging from $250M to $2B and less than 100 employees. The peer group, which was used in making compensation decisions in connection with Dr.&#160;Turtle&#8217;s promotion to Chief Executive Officer, includes the following companies: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:31%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACELYRIN, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arcellx, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kymera Therapeutics, Inc.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aclaris Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Astria Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morphic Holding, Inc.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allakos Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pliant Therapeutics, Inc.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alpine Immune Sciences, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celldex Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RAPT Therapeutics, Inc.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IGM Biosciences, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ventyx Biosciences, Inc.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Apogee Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janux Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vera Therapeutics, Inc.</p></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Elements of Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Base Salary </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each NEOs base salary is a fixed annual amount that is intended to compensate the NEO for performing specific job responsibilities and is based on the NEO&#8217;s level of experience and requisite skills. Our compensation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee annually evaluates and approves (or recommends to the board of directors for approval for our Chief Executive Officer) each NEO&#8217;s base salary. The base salaries for the NEOs hired during 2023 were established in connection with their appointments, and Dr.&#160;Turtle&#8217;s base salary was subsequently adjusted in connection with his promotion. The table below sets forth the base salary as of December&#160;31, 2023 for each NEO that was employed with us at such time: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Named Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Base&#160;Salary</span><br/><span style="font-weight:bold">as&#160;of&#160;12/31/2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Turtle</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">625,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Burrows</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">455,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidy King-Jones</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">470,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Annual Bonus Program </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the strategic process and the Asset Acquisition, our compensation committee and the board of directors determined not to utilize an annual bonus program for 2023. Instead, our compensation committee determined that each NEO who was employed as of the payment date would receive an annual bonus for 2023 equal to their target bonus, <span style="white-space:nowrap">pro-rated</span> for any partial years of service. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Long-Term Incentive Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his appointment as Chief Operating Officer of the Company, on June&#160;22, 2023, Dr.&#160;Turtle received an initial grant of stock options to purchase 47,297,197 shares of our common stock (1,891,887 shares following our reverse stock split), which vest in equal monthly installments through the fourth anniversary of the grant date. As a result of his promotion to Chief Executive Officer, on November&#160;22, 2023, Dr.&#160;Turtle received an additional grant of stock options to purchase 374,000 shares of our common stock, which vest as to 25% on the first anniversary of the grant date and in equal monthly installments thereafter through the fourth anniversary of the grant date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his appointment as Chief Financial Officer of the Company, (i)&#160;on September&#160;1, 2023, Mr.&#160;Burrows received an initial grant of stock options to purchase 10,121,441 shares of our common stock (404,857 shares following our reverse stock split), which vest as to 25% on the first anniversary of the grant date and in equal monthly installments thereafter through the fourth anniversary of the grant date, and (ii)&#160;on December&#160;22, 2023, Mr.&#160;Burrows received an initial grant of 134,953 RSUs, which vest in equal annual installments through the fourth anniversary of the grant date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with her appointment as Chief Legal Officer of the Company, on September&#160;1, 2023, Ms.&#160;King-Jones received an initial grant of stock options to purchase 13,495,255 shares of our common stock (539,810 shares following our reverse stock split), which vest as to 25% on the first anniversary of the grant date and in equal monthly installments thereafter through the fourth anniversary of the grant date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Company&#8217;s annual grants, Mr.&#160;Alspaugh received a grant of stock options to purchase 640,000 shares of our common stock (15,999 shares following our reverse split), which vest in equal monthly installments through the fourth anniversary of the grant date. In connection with the Asset Acquisition, on June&#160;22, 2023, Mr.&#160;Alspaugh receive a grant of stock options to purchase 19,787,969 shares of our common stock (791,518 shares following our reverse split), which vest in equal monthly installments through the fourth anniversary of the grant date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transaction and Retention Bonuses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Asset Acquisition, the Company entered into an incentive agreement with Mr.&#160;Alspaugh that provided for (i)&#160;a retention bonus equal to Mr.&#160;Alspaugh&#8217;s annual salary <span style="white-space:nowrap">pro-rated</span> for the period of time between </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
April&#160;15, 2023 and the earlier of October&#160;25, 2023 or a termination of employment by the Company without cause and (ii)&#160;a transaction bonus equal to (A) 0.5% of the equity value of the Company in a transaction if the equity value is greater than or equal to $15&#160;million but less than $20&#160;million or (B)&#160;1.0% of the equity value of the Company in a transaction if the equity value is greater than or equal to $20&#160;million. In accordance with the incentive agreement, in connection with the Asset Acquisition, Mr.&#160;Alspaugh received a transaction bonus of $274,400, and in connection with his separation, he received a retention bonus of $168,247. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, our compensation committee approved a bonus to Mr.&#160;Alspaugh of $293,000 in recognition of the successful consummation of the transaction to sell assets relating to pegzilarginase to Immedica. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Offer Letters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with their appointments (and, for Dr.&#160;Turtle, his promotion to Chief Executive Officer), we entered into offer letters with each of Dr.&#160;Turtle, Mr.&#160;Burrows and Ms.&#160;King-Jones (collectively, the &#8220;Offer Letters&#8221;). The Offer Letters provide for an initial base salary, target bonus opportunity and stock option grant. Under the Offer Letters, the NEOs are eligible for certain payments or benefits upon certain terminations of employment, as described under &#8220;<span style="font-style:italic">Additional Narrative Disclosure&#8212;Potential Payments Upon Termination or Change in Control</span>&#8221; below. Mr.&#160;Burrow&#8217;s Offer Letter also provides for a <span style="white-space:nowrap">sign-on</span> bonus of $115,000, which is subject to repayment in the event of a termination for cause or resignation without good reason prior to September&#160;1, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Dr.&#160;Turtle, Mr.&#160;Burrows and Ms.&#160;King-Jones are also party to our standard employee invention assignment, confidentiality and <span style="white-space:nowrap">non-competition</span> agreement, which, among other things, provides standard protections regarding our ownership of intellectual property, the confidentiality of our proprietary information, <span style="white-space:nowrap">non-competition</span> and <span style="white-space:nowrap">non-solicitation.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Separation Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jeffrey M. Goldberg </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his termination in May 2023, Mr.&#160;Goldberg entered into a separation agreement that provided for the following severance benefits in consideration for a release of claims: (i)&#160;$600,000, reflecting 12&#160;months of base salary;&#160;(ii)&#160;$300,000, reflecting 100% of his annual target bonus; (iii)&#160;$15,801, reflecting the estimated amount of his premiums under COBRA for 12&#160;months; (iv)&#160;$50,000 as an additional severance payment; and (v)&#160;accelerated vesting of 667,756 stock options, representing the stock options that would have vested within the <span style="white-space:nowrap">12-month</span> period following the termination date, which had a value of $1,636,002 on the date of termination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jonathan Alspaugh </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his termination in August 2023, Mr.&#160;Alspaugh entered into a separation and consulting agreement and general release of claims (the &#8220;Separation Agreement&#8221;) that provided for the following severance benefits in consideration for a release of claims: (i)&#160;aggregate severance payments of $623,000 payable in installments over 12 months; (ii) $15,801, reflecting the estimated amount of fully subsidized COBRA coverage for up to 12&#160;months; (iii)&#160;a retention bonus of $168,247; (iv)&#160;accelerated vesting of all stock options that were scheduled to vest during the <span style="white-space:nowrap">12-month</span> period following the last day of the consulting period described below; (v)&#160;extension of the post-termination exercise period of outstanding stock options to six months; and (vi)&#160;the opportunity to earn potential transaction bonuses in the event the Company consummates any sale, licensing, disposition or monetization transaction relating to pegtarviliase or any of the Company&#8217;s legacy development-stage assets prior to June&#160;23, 2024, which had not become earned as of December&#160;31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Separation Agreement also provides that Mr.&#160;Alspaugh will provide consulting services to the Company through February&#160;29, 2024 (which consulting period may be extended by mutual agreement of the parties or may be earlier terminated by Mr.&#160;Alspaugh, by the Company for cause or as a result of Mr.&#160;Alspaugh&#8217;s death or disability). During the consulting period, Mr.&#160;Alspaugh will receive a consulting fee of $500 per hour and will continue to vest in any outstanding stock options. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at December&#160;31, 2023 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information regarding outstanding stock options, RSUs and restricted stock held by each Named Executive Officer as of December&#160;31, 2023. The equity awards reflected below give effect to our <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-25</span></span> reverse stock split on September&#160;8, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:30%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Exercise<br/>Price ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br/>of Shares<br/>or Units<br/>of Stock<br/>That<br/>Have Not<br/>Vested&#160;(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market<br/>Value of<br/>Shares or<br/>Units of<br/>Stock That<br/>Have Not<br/>Vested ($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Turtle</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/22/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,655,402</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/22/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/22/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/22/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">508,073</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,933,731</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Burrows</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">404,857</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/1/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/22/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">134,953</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,904,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidy King-Jones</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">539,810</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/1/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Goldberg</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Alspaugh</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/6/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,534</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7/5/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/17/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,685</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/23/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,467</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/22/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/23/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,665</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/22/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/21/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">692,579</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/22/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The market value was determined by multiplying the number of shares by $21.52, the closing price of our common stock as reported on the Nasdaq Capital Market on December&#160;29, 2023, the last trading day of 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These stock options vest in equal monthly installments through the fourth anniversary of the grant date, subject to the NEO&#8217;s continued service. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These stock options vest as to 25% on the first anniversary of the grant date and in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to the NEO&#8217;s continued service. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In connection with the Asset Acquisition, outstanding shares of restricted common stock of <span style="white-space:nowrap">Pre-Merger</span> Spyre were assumed by the Company and converted into restricted common stock and restricted Series A preferred stock, which was subsequently converted to restricted and unrestricted common stock on November&#160;24, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These shares of restricted common stock vest in equal monthly installments through November&#160;22, 2026, subject to the NEO&#8217;s continued service. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These RSUs vest in equal annual installments through the fourth anniversary of the grant date, subject to the NEO&#8217;s continued service. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Narrative Disclosure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Retirement Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a <span style="white-space:nowrap">tax-qualified</span> 401(k) defined contribution plan that provides eligible U.S. employees, including our NEOs, with an opportunity to save for retirement on a <span style="white-space:nowrap">tax-advantaged</span> basis. Eligible employees may make voluntary contributions from their eligible pay, up to certain applicable annual limits set by the Code. We provide matching contributions equal to 100% of the first 3% of eligible compensation contributed by each employee, and 50% of the next 2% of eligible compensation contributed by each employee. All company matching contributions are immediately and fully vested. We do not maintain, and have not historically maintained, any <span style="white-space:nowrap">non-qualified</span> deferred compensation or defined benefit pension plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential Payments Upon Termination or Change in Control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Offer Letters, in the event each NEO that is a current executive officer is terminated by the Company without &#8220;cause&#8221; or as a result of a resignation for &#8220;good reason&#8221; (collectively, an &#8220;Involuntary Termination&#8221;), such NEO will, subject to the execution of a release in favor of the Company, receive: (i)&#160;severance payments equal to 12 months of base salary and any earned but unpaid annual bonus for the preceding year; (ii)&#160;up to 12 months of partially subsidized COBRA coverage; and (iii)&#160;accelerated vesting of any time-based equity awards scheduled to vest in the 12 months following such termination. However, if the Involuntary Termination is within three months before or 12 months after a change in control of the Company, the NEO will instead receive: (A)&#160;severance payments equal to 18 months of base salary, any earned but unpaid annual bonus for the preceding year, and the target annual bonus for the year of termination; (B)&#160;up to 18 months of fully subsidized COBRA continuation coverage; and (C)&#160;full acceleration of all equity awards (with performance-based awards determined in accordance with the terms of the applicable award agreement or, if not specified in such award agreement, based on the greater of target or, if determinable, actual performance). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in the Offer Letters: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Cause&#8221; generally means (i)&#160;the NEO&#8217;s dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii)&#160;the NEO&#8217;s conviction or plea of no contest to a felony or misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&#160;the NEO&#8217;s failure to perform his or her duties or responsibilities, subject to a <span style="white-space:nowrap">30-day</span> cure period; (iv)&#160;the NEO&#8217;s gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v)&#160;the NEO&#8217;s violation of any material provision of any agreement with the Company or any written Company policies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Good Reason&#8221; generally means (i)&#160;a material diminution in the NEO&#8217;s base salary or target bonus (excluding <span style="white-space:nowrap"><span style="white-space:nowrap">across-the-board</span></span> reductions of less than 10%); (ii) a material geographic relocation or requirement to change the NEO&#8217;s remote work location; (iii)&#160;a material reduction in the NEO&#8217;s duties, authority or responsibilities; (iv)&#160;the failure of the Company to obtain the assumption of the Offer Letter by a successor; or (v)&#160;the material breach of any agreement between the NEO and the Company, in each case, subject to standard notice and cure periods. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information for the fiscal year ended December&#160;31, 2023 regarding all compensation awarded to, earned by or paid to each person who served as a <span style="white-space:nowrap">non-employee</span> director for some portion of 2023. Employees who served on our board during 2023 did not receive additional compensation for such service. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees&#160;Earned<br/>or Paid&#160;in<br/>Cash ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Option<br/>Awards&#160;($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey W. Albers<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">427,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">433,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell J. Cox</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">112,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">633,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">746,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Harwin<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">633,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">661,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Henderson<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">633,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">660,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">633,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">658,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">V. Bryan Lawlis, Ph.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alison Lawton</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">633,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">696,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivana Magov&#269;evi&#263;-Liebisch, Ph.D.<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">633,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">696,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armen Shanafelt, Ph.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunter C. Smith<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">633,508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">711,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcio Souza<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,077</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,077</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurie Stelzer<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">427,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">434,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported in this column represent the aggregate grant date fair value of the awards granted to our <span style="white-space:nowrap">non-employee</span> directors during the year ended December&#160;31, 2023, as computed in accordance with Accounting Standards Codification Topic 718 (&#8220;ASC 718&#8221;). The assumptions used in calculating the grant date fair value of the awards reported in the Option Awards column are set forth in See Note 15 to our consolidated financial statements included herein for the fiscal year ended December 31, 2023. Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the <span style="white-space:nowrap">non-employee</span> directors from the awards. As of December&#160;31, 2023, our <span style="white-space:nowrap">non-employee</span> directors held the following number of outstanding stock options: (i)&#160;Mr.&#160;Albers, 50,000; (ii) Mr.&#160;Cox, 86,228; (iii)&#160;Mr.&#160;Harwin, 78,000; (iv) Dr.&#160;Henderson, 78,000; (v) Mr.&#160;Kiselak, 78,000; (vi) Dr.&#160;Lawlis, 0; (vii)&#160;Ms.&#160;Lawton, 83,208; (viii) Dr.&#160;Magov&#269;evi&#263;-Liebisch, 84,412; (ix) Dr.&#160;Shanafelt, 0; (x), Mr.&#160;Smith. 73,620; (xi)&#160;Mr.&#160;Souza, 0; and (xii)&#160;Ms.&#160;Stelzer, 50,000. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Albers and Ms.&#160;Stelzer were appointed to our board of directors effective as of November&#160;22, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In connection with the Asset Acquisition, effective as of June&#160;22, 2023, Drs. Lawlis and Shanafelt and Mr.&#160;Souza resigned from our board of directors and Messrs. Harwin and Kiselak and Dr.&#160;Henderson were appointed to our board of directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Magov&#269;evi&#263;-Liebisch and Mr.&#160;Smith resigned from our board of directors effective as of November&#160;22, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our <span style="white-space:nowrap">non-employee</span> directors receives compensation pursuant to the <span style="white-space:nowrap">non-employee</span> director cash and equity compensation program adopted by our board of directors. This program provides for the following annual cash retainers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:85%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Cash Retainer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Retainers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-Chair</span> Member</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Retainers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-Chair</span> Member</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Retainers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-Chair</span> Member</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, each <span style="white-space:nowrap">non-employee</span> director who initially joins our board of directors receives an initial grant of stock options to purchase 50,000 shares of our common stock; however, Messrs. Harwin and Kiselak and Dr.&#160;Henderson did not receive an initial grant as a result of their appointments in connection with the Asset Acquisition. The initial stock option grants vest in equal monthly installments over three years. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, and in lieu of grants made in connection with the 2023 annual meeting, each <span style="white-space:nowrap">non-employee</span> director serving immediately following the Asset Acquisition (including Messrs. Harwin, Henderson and Kiselak) received a grant of stock options to purchase 1,950,000 shares of our common stock (or 78,000 shares following our reverse stock split) in June 2023, which stock options vest in equal monthly installments over one year or, if earlier, upon the date of the 2024 annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <span style="white-space:nowrap">non-employee</span> director who is serving as of the date of the annual meeting in 2024 will receive a grant of stock options to purchase 20,000 shares of our common stock. Annual stock option grants vest in equal monthly installments over one year or, if earlier, upon the next annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, all <span style="white-space:nowrap">non-employee</span> directors are reimbursed their reasonable travel expenses incurred in attending board and committee meetings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_13">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our Common Stock as of February 15, 2024 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our Named Executive Officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our directors and executive officers as a group; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person, or group of affiliated persons, who is known by us to beneficially owner of greater than 5.0% of our Common Stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The column entitled &#8220;Shares Beneficially Owned&#8221; is based on a total of 36,149,011 shares of our Common Stock outstanding as of February 15, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our Common Stock. Shares of our Common Stock subject to options that are currently exercisable or exercisable within 60 days of February 15, 2024 are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Due to the conversion limitations on the Series A Preferred Stock and Series B Preferred Stock, shares of underlying Common Stock have been excluded from beneficial ownership set forth below. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Spyre Therapeutics, Inc., 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;beneficially&#160;owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Name and address of beneficial owner</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">5% Stockholders:</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">FMR LLC (1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,206,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,606,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities associated with Venrock Healthcare Capital<br/>Partners (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,372,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities associated with RTW Investments, LP (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,232,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Entities associated with Avoro Capital Advisors (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,125,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commodore Capital Master LP (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,884,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Named Executive Officers and Directors:</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jonathan Alspaugh (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">342,058</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Scott Burrows (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jeffrey M. Goldberg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Heidy King-Jones (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Russell J. Cox (10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jeffrey W. Albers (11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Laurie Stelzer (12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,555</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Mark McKenna (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Peter Harwin (14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">842,959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Tomas Kiselak (15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">842,959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Michael Henderson, M.D. (16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cameron Turtle, DPhil (17)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,113,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">All current executive officers and directors as a group<br/>(10 persons) (18)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,603,892</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> </div> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than one percent. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares of Common Stock listed in the table above are held by funds and accounts managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based solely upon a Schedule 13G/A filed on February 14, 2024. Represents shares of Common Stock held by Perceptive Life Sciences Master Fund, Ltd (&#8220;Perceptive Fund&#8221;). The address of Perceptive Fund is 51 Astor Place, 10th Floor, New York, NY 10003. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based solely upon a Schedule 13G/A filed on February 14, 2024. Represents shares of Common Stock held by Venrock Healthcare Capital Partners III, LP (&#8220;VHCP III&#8221;), VHCP III Co-Investment Holdings III, LLC (&#8220;VHCP III Co&#8221;) and Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP EG&#8221;). VHCP Management III, LLC (&#8220;VHCPM&#8221;) is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM and VHCPM EG. The address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based solely upon a Schedule 13G filed on February 13, 2024. Represents shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities LTD (collectively, the &#8220;RTW Funds&#8221;). RTW Investments, LP (&#8220;RTW&#8221;), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The address and principal office of RTW is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based solely upon a Schedule 13G filed on February 14, 2024. Represents shares of Common Stock held by Avoro Capital Advisors LLC (&#8220;Avoro&#8221;). The address of Avoro is 110 Greene Street, Suite 800, New York, NY 10012. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based solely upon a Schedule 13G/A filed on February 14, 2024. Represents shares of Common Stock held by Commodore Capital Master LP (&#8220;Commodore Capital&#8221;). Commodore Capital LP is the investment manager to Commodore Capital and may be deemed to beneficially own the shares held by Commodore Capital. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i)&#160;7,254 shares of Common Stock held by Mr.&#160;Alspaugh and (ii)&#160;options exercisable for 334,804&#160;shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 2,917 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 2,625 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i)&#160;280 shares of Common Stock held by Mr.&#160;Cox and (ii)&#160;options exercisable for 66,728&#160;shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 34,360 shares of Common Stock held by Sessions LLC, which may be deemed to be indirectly beneficially owned by Mr.&#160;Albers, and (ii)&#160;options exercisable for 5,555 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 5,555 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 2,222 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 378,421 shares of Common Stock held by Fairmount Healthcare Fund II L.P. (&#8220;Fund II&#8221;) that may be deemed to be beneficially owned by Mr.&#160;Harwin; (ii)&#160;406,038 shares of Common Stock held by Mr.&#160;Harwin; and (iii)&#160;options exercisable for 58,500 shares of Common Stock within 60 days of February&#160;15, 2024. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 378,421 shares of Common Stock held by Fund II that may be deemed to be beneficially owned by Mr.&#160;Kiselak; (ii)&#160;406,038 shares of Common Stock held by Mr.&#160;Kiselak; and (iii)&#160;options exercisable for 58,500 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents options exercisable for 58,500 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 746,907 shares of Common Stock held by Dr.&#160;Turtle and (ii)&#160;options exercisable for 366,301 shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(18)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i) 1,972,044 shares of Common Stock and (ii)&#160;options exercisable for 631,848&#160;shares of Common Stock within 60 days of February 15, 2024. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_14">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in the &#8220;Related Party Transactions&#8221; section of our 2023 Annual Proxy, below we describe the transactions to which we were a party since January&#160;1, 2021, in which the amount involved exceeded the lesser of $120,000 and 1% of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the prior two completed fiscal years and in which our directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of our Common Stock, or other persons as may be required to be disclosed pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K,</span> had a direct or indirect material interest: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On May&#160;5, 2022, we entered into a placement agent agreement with JonesTrading Institutional Services LLC, as placement agent, relating to a registered direct offering of an aggregate of 430,107 shares of our Common Stock at a public purchase price of $40.00 per share and <span style="white-space:nowrap">pre-funded</span> warrants to purchase up to 694,892 shares of our Common Stock at a public purchase price of $39.99 per <span style="white-space:nowrap">pre-funded</span> warrant with an exercise price of $0.0025 per share. This registered direct offering closed on May&#160;9, 2022. Pursuant to this offering, on the closing date: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">i.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Baker Brothers Life Sciences, L.P. and 667, L.P. (together, the &#8220;Baker Funds&#8221;) purchased 251,351 and 29,898 <span style="white-space:nowrap">pre-funded</span> warrants to purchase Common Stock, respectively, for an aggregate purchase price of approximately $11.2&#160;million; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">ii.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Averill Master Fund, Ltd., an entity affiliated with Suvretta, purchased 250,000 <span style="white-space:nowrap">pre-funded</span> warrants to purchase Common Stock for an aggregate purchase price of approximately $10.0&#160;million; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">iii.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Nantahala purchased 132,071 <span style="white-space:nowrap">pre-funded</span> warrants to purchase Common Stock for an aggregate purchase price of approximately $5.3&#160;million. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On March&#160;16, 2021, we entered into a registration rights agreement (the &#8220;Baker RRA&#8221;) with the Baker Funds, pursuant to which the Baker Funds are entitled to certain resale registration rights with respect to shares of our Common Stock held by the Baker Funds (the &#8220;Baker Registrable Securities&#8221;). Under the Baker RRA, following a request by the Baker Funds, we are obligated to file a resale registration statement on Form <span style="white-space:nowrap">S-3,</span> or other appropriate form, covering Baker Registrable Securities. Under the Baker RRA, the Baker Funds also have the right to up to two underwritten public offerings or block trades per calendar year, but no more than three underwritten public offerings and eight block trades in total, to effect the sale or distribution of their Baker Registrable Securities, subject to specified exceptions, conditions and limitations. The Baker RRA also includes customary indemnification obligations in connection with registrations conducted pursuant to the Baker RRA. The rights of the Baker Funds under the Baker RRA terminate automatically upon the earlier to occur of the following events: (i)&#160;all Baker Registrable Securities covered by the Baker RRA have been sold pursuant to an effective registration statement; (ii)&#160;all Baker Registrable Securities covered by the Baker RRA have been sold pursuant to Rule 144 under the Securities Act (&#8220;Rule 144&#8221;), or other similar rule; (iii)&#160;at any time after the Baker Funds are no longer our affiliate, all Baker Registrable Securities covered by the Baker RRA may be resold by the Baker Funds without limitations as to volume or manner of sale pursuant to Rule 144; or (iv)&#160;ten (10) years after the date of the Baker RRA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other than the executive officer and director compensation arrangements discussed above under &#8220;Executive Compensation,&#8221; below we describe the transactions to which we were a party since the date of our 2023 Annual Proxy, in which the amount involved exceeded the lesser of $120,000 and 1% of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the prior two completed fiscal years and in which our directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of our Common Stock, or other persons as may be required to be disclosed pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K,</span> had a direct or indirect material interest. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In connection with the Asset Acquisition, we assumed the rights and obligations of <span style="white-space:nowrap">Pre-Merger</span> Spyre under the Paragon Agreement. Under the Paragon Agreement, we are obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
incurred with <span style="white-space:nowrap">mark-up</span> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, <span style="white-space:nowrap">Pre-Merger</span> Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by us through the Asset Acquisition. Furthermore, following our amendment and restatement of the Paragon Agreement on September&#160;29, 2023, we are obligated to provide certain equity grants to Parapyre pursuant to the Parapyre Option Obligation. Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, we expect to be obligated to pay Paragon up to $22.0 million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and SPY002 License Agreement, we expect to pay Paragon a $1.5 million fee for nomination of a development candidate and we expect to be obligated to make a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY003 or SPY004 research programs, we expect to be obligated to make similar payments upon and following the execution of license agreements with respect to the these research programs, respectively. For additional detail regarding our arrangements with Paragon and Parapyre, see the sections titled &#8220;<span style="font-style:italic">Paragon Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Our Relationship with Paragon and Parapyre</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In July 2023 and December 2023, we exercised our option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expect to enter into the SPY001 License Agreement and the SPY002 License Agreement. Our option available under the Paragon Agreement with respect to the SPY003 and SPY004 programs remains unexercised. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In connection with the June 2023 Transactions, we issued to Fairmount (i) 378,421 shares of Common Stock and 265,263 shares of Series A Preferred Stock in exchange for shares of <span style="white-space:nowrap">Pre-Merger</span> Spyre based on a fixed exchange ratio of 0.5494488 to 1 pursuant to the Asset Acquisition and (ii) 257,661 shares of Series A Preferred Stock at a price of $291.08 per share pursuant to the June 2023 PIPE. On June&#160;22, 2023, we also entered into a registration rights agreement (the &#8220;June 2023 RRA&#8221;) with the June 2023 Investors, including Fairmount, pursuant to which the June 2023 Investors are entitled to certain resale registration rights with respect to shares of our Common Stock held by such investors. For additional detail regarding the June 2023 Transactions, see &#8220;<span style="font-style:italic">Prospectus Summary &#8211; Recent Developments.</span>&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In connection with the December 2023 PIPE, we issued (i) 16,667 shares of Series B Preferred Stock to Fairmount, (ii) 1,666,666 shares of Common Stock to entities associated with FMR LLC, (iii) 710,000 shares of Common Stock and 18,083 shares of Series B Preferred Stock to Perceptive Life Sciences Master Fund, Ltd., (iv) 250,000 shares of Common Stock and 35,417 shares of Preferred Stock to entities associated with Venrock Healthcare Capital Partners, (v) 515,000 shares of Common Stock and 12,125 shares of Series B Preferred Stock to entities associated with RTW Investments, LP, (vi) 235,000 shares of Common Stock and 5,792 shares of Series B Preferred Stock to Deep Track Biotechnology Master Fund, Ltd., and (vii) 50,000 shares of Common Stock and 1,250 shares of Series B Preferred Stock to Commodore Capital Master LP, at a price of $15.00 per share of Common Stock and $600.00 per share of Series B Preferred Stock. On December&#160;7, 2023, we also entered into the December 2023 RRA with the December 2023 Investors, including the above-named investors, pursuant to which the December 2023 Investors are entitled to certain resale registration rights with respect to shares of our Common Stock held by such investors. For additional detail regarding the December 2023 PIPE and the December 2023 RRA, see &#8220;<span style="font-style:italic">Prospectus Summary &#8211; Recent Developments</span>&#8221; and &#8220;<span style="font-style:italic">Risk Factors&#8212;Future sales of shares by existing stockholders could cause our stock price to decline</span>,&#8221; respectively. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In November 2023, we entered into a consulting agreement with Mr. McKenna, pursuant to which Mr. McKenna agreed to provide consulting services to us as a senior advisor to the executive management </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
team. As compensation for such consulting services, Mr. McKenna was granted non-qualified stock options to purchase up to 477,000 shares of Common Stock under the 2016 Plan, vesting over 4 years with an exercise price of $10.39 per share. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Review, Approval or Ratification of Transactions with Related Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of our Common Stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and approval of our audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. The policy provides that, subject to limited exceptions, any transaction, arrangement or relationship or series of similar transactions, arrangements or relationships in which (1) the aggregate amount involved since the beginning of the Company&#8217;s last completed fiscal year exceeds or is expected to exceed $120,000, (2) the Company or any of our subsidiaries is a participant, and (3) any related person has or will have a direct or indirect interest, will be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the material facts and other factors it deems appropriate, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_15">SELLING STOCKHOLDERS </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate of 18,809,064 shares of our Common Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we entered into the June 2023 SPA, pursuant to which we sold an aggregate of 721,452 shares of our Series&#160;A Preferred Stock, each of which automatically converted into 40&#160;shares of Common Stock, subject to stockholder approval and certain beneficial ownership limitations set by each holder, pursuant to the Series&#160;A Certificate of Designation, at an aggregate purchase price of approximately $210&#160;million. Also on June&#160;22, 2023, we completed our acquisition of Spyre in accordance with the Acquisition Agreement, pursuant to which we issued an aggregate of 517,809 shares of Common Stock and 364,887 shares of Series&#160;A Preferred Stock to certain of the Selling Stockholders. This prospectus covers the resale or other disposition by the Selling Stockholders or their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this prospectus of up to the total number of shares issued to the Selling Stockholders pursuant to the Acquisition Agreement or issuable upon the conversion of the Series&#160;A Preferred Stock sold pursuant to the June 2023 SPA or Acquisition Agreement. This prospectus covers the resale or other disposition by the Selling Stockholders or their transferees of up to the total number of Merger Common Shares, Merger Conversion Shares and Private Placement Conversion Shares issued to the Selling Stockholders pursuant to the Acquisition Agreement or the June 2023 SPA. Throughout this prospectus, when we refer to the &#8220;Selling Stockholders,&#8221; we are referring to the purchasers under the June 2023 SPA, certain of the securityholders under the Acquisition Agreement and certain of our employees listed in the table below. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other <span style="white-space:nowrap">successors-in</span> interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan of Distribution&#8221; herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office or other material relationship with us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders, the number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will be owned after this offering by the Selling Stockholders assuming all of the shares registered for resale hereby are sold. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling Stockholders, provided that Resale Shares issued upon conversion of Series&#160;A Preferred Stock may only be offered after such shares of Series&#160;A Preferred Stock are converted to Common Stock pursuant to the terms of the Series&#160;A Certificate of Designation. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth below, which has been adjusted to reflect the effects of the Reverse Split as applicable, is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Series A Preferred Stock and Merger Common Shares in connection with the PIPE and the Asset Acquisition. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 36,149,011&#160;shares of Common Stock outstanding as of February&#160;15, 2024. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of Selling<br/>Stockholders(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common<br/>Stock<br/>Beneficially<br/>Owned<br/>Before<br/>Offering&#160;(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common<br/>Stock that<br/>May<br/>Be Offered<br/>Pursuant&#160;to<br/>Prospectus</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common Stock<br/>Beneficially<br/>Owned After<br/>Offering (2)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage<br/>(%)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,606,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,717,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">888,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Venrock Healthcare Capital Partners&#160;III, L.P. (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,372,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,827,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">545,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with RTW Investments, LP (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,232,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,717,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">515,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avoro Life Sciences Fund LLC (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,125,597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,827,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">297,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commodore Capital Master LP (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,834,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,717,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Growth Company Commingled Pool (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,376,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">916,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">460,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd. (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,218,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,717,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harry Turtle (10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,113,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,099,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,070,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">704,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">366,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund, LP (11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">937,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with EcoR1 Capital (12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">887,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">199,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Driehaus Capital Management (USVI) LLC (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">800,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">113,773</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with BVF Partners L.P. (14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Franklin Biotechnology (15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P. (16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">687,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affinity Healthcare Fund, LP (17)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">651,326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">548,246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">479,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">455,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel CEMF Investments Ltd. (18)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">412,240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">412,240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Aisling Capital (19)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">411,205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">343,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust : Fidelity Growth Company K6 Fund (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">332,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">294,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stempoint Capital (20)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">279,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">176,901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salthill Investors (Bermuda) L.P. (21)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">214,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">214,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salthill Partners, L.P. (21)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Pharmaceuticals Portfolio (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">148,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with Logos Global (22)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">343,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Spencer (23)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janet Gunzner-Toste (24)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,061</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Justin LaFountaine (25)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">112,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Healthcare Partners 2023 Fund, LLC (26)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68,720</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68,720</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sessions LLC (27)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and investment power with respect to their shares of Common Stock. Unless an address is provided below, the address for the holder is 221 Crescent Street, Building 23, Suite 105, Waltham MA 02453. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">&#8220;Beneficial ownership&#8221; is a term broadly defined by the SEC in Rule&#160;13d-3 under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;888,919 shares of Common Stock held by Perceptive Life Sciences Master Fund, Ltd (&#8220;Perceptive Fund&#8221;) and (ii)&#160;1,717,760 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Perceptive Fund. The address of Perceptive is 51 Astor Place, 10th Floor, New York, NY 10003. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;1,299,120 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP EG&#8221;), (ii)&#160;457,336 shares of Common Stock held by VHCP EG, (iii)&#160;480,480 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP&#160;III&#8221;), (iv)&#160;79,691 shares of Common Stock held by VHCP III, (v)&#160;2 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by VHCP Co-Investment Holdings III, LLC (&#8220;VHCP III Co&#8221;), and (vi)&#160;56,085 shares of Common Stock held by VHCP III Co. VHCP Management III, LLC (&#8220;VHCPM&#8221;) is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCP EG. Dr.&#160;Bong Koh and Nimish Shah are the voting members of VHCPM and VHCPM EG. The address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY&#160;10018. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of an aggregate of (i)&#160;1,717,760 shares of Common Stock held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities Ltd (collectively, the &#8220;RTW Funds&#8221;) and (ii)&#160;515,000 shares of Common Stock held by the RTW Funds. RTW Investments, LP (&#8220;RTW&#8221;), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr.&#160;Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The address and principal office of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr.&#160;Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;1,827,680 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Avoro Life Sciences Fund LLC and (ii)&#160;297,917 shares of Common Stock held by Avoro Life Sciences Fund LLC. Avoro Capital Advisors LLC (&#8220;Avoro&#8221;) is the investment advisor for Avoro Life Sciences Fund LLC. Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro and may be deemed to have investment discretion and voting power over the shares held by Avoro. Mr.&#160;Aghazadeh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. The address of Avoro Life Sciences Fund LLC is 110 Greene Street, Suite 800, New&#160;York, NY 10012. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 1,717,760 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Commodore Capital Master LP and (ii) 116,324 shares of Common Stock held by Commodore Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act of 1940 (&#8220;Fidelity Funds&#8221;) advised by Fidelity Management &amp; Research Company LLC (&#8220;FMR Co. LLC&#8221;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#8217; Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds&#8217; Boards of Trustees. The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 1,717,760 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Deep Track Biotechnology Master Fund, Ltd. (&#8220;Deep Track Biotech&#8221;). Deep Track Capital, LP (&#8220;Deep Track Capital&#8221;) and David Kroin have shared voting power and shared dispositive power over the shares held by the Deep Track Biotech. Mr. Kroin may be considered a control person for Deep Track Capital. The address of Deep Track Capital and Mr. Kroin is 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830, and the address for Deep Track Biotech is 190 Elgin Avenue, George Town, KY1-9001, Cayman Islands. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 733,147 shares of Common Stock held by Dr. Turtle and (ii) options exercisable for 366,301 shares of Common Stock within 60 days of February 15, 2024 and (iii) 13,760 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Harry Turtle. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 687,080 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Cormorant Global Healthcare Master Fund, LP (&#8220;Cormorant Global Healthcare&#8221;) and (ii) 250,000 shares of Common Stock held by Cormorant Global Healthcare. Cormorant Global Healthcare GP, LLC (&#8220;Global Healthcare GP&#8221;) is the general partner of Cormorant Global Healthcare. Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare. Bihua Chen serves as the managing member of both Global Healthcare GP and Cormorant Asset Management, LP and accordingly may be deemed to have voting and dispositive power with respect to shares held by Cormorant Global Healthcare. Each of Global Healthcare GP, Cormorant Asset Management, LP and Ms. Chen disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The principal address for the Cormorant Asset Management, LP entities is 200 Clarendon Street 52nd Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;39,520 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by EcoR1 Capital Fund, L.P. (&#8220;Capital&#8221;), (ii)&#160;647,560 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by EcoR1 Capital Fund Qualified, L.P. (&#8220;Qualified&#8221;), and (iii)&#160;199,996 shares of Common Stock held by Capital and Qualified. EcoR1 Capital LLC (&#8220;EcoR1&#8221;) is the general partner and investment advisor of Capital and Qualified, which disclaims beneficial ownership of the shares. Oleg Nodelman is the control person of EcoR1 Capital. EcoR1 Capital is the general partner and investment advisor of EcoR1 and Qualified, which disclaims beneficial ownership of the shares. Mr.&#160;Nodelman, EcoR1, Capital and Qualified each disclaim beneficial ownership of the shares except to the extent of their pecuniary interest therein. The address of each of EcoR1, Capital, Qualified and Mr.&#160;Nodelman is 357 Tehama Street&#160;#3, San Francisco, CA 94103. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;507,720 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Driehaus Life Sciences Master Fund, L.P. (&#8220;Driehaus Master Fund&#8221;), (ii)&#160;84,131 shares of Common Stock held by Driehaus Master Fund, (iii)&#160;179,360 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Driehaus Life Sciences (QP) Fund, L.P. (&#8220;Driehaus QP Fund&#8221;), and (iv)&#160;29,642 shares of Common Stock held by Driehaus QP Fund. Driehaus Capital Management (USVI) LLC is the general partner of both Driehaus Life Sciences Master Fund, L.P. and Driehaus Life Sciences (QP) Fund, L.P. By virtue of such relationship, Driehaus Capital Management (USVI) LLC may be deemed to have beneficial ownership over such securities. Driehaus Capital Management LLC is the investment advisor to both Driehaus Life Sciences Master Fund, L.P. and Driehaus Life Sciences (QP) Fund. Driehaus Capital Management LLC exercises voting and investment power through portfolio managers comprised of Michael Caldwell and Alex Munns, each of whom disclaims beneficial ownership of the shares held by Driehaus Life Sciences Master Fund, L.P. and Driehaus Life Sciences (QP) Fund, L.P.. The address for these entities is c/o&#160;Driehaus Capital Management LLC, 25&#160;East Erie Street, Chicago,&#160;IL 60611. </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;367,080 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Biotechnology Value Fund, L.P. (&#8220;BVF LP&#8221;), (ii)&#160;278,240 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Biotechnology Value Fund&#160;II, L.P. (&#8220;BVF2 LP&#8221;), (iii)&#160;32,360 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Biotechnology Value Trading Fund OS LP (&#8220;BVF OS&#8221;), and (iv)&#160;9,400 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by MSI BVF SPV, LLC (&#8220;MSI BVF&#8221; and together with BVF LP, BVF2 LP and BVF OS, the &#8220;BVF Entities&#8221;). BVF I GP LLC (&#8220;BVF GP&#8221;), as general partner of BVF LP, may be deemed to beneficially own the shares beneficially owned by BVF LP. BVF II GP LLC (&#8220;BVF2 GP&#8221;), as general partner of BVF2 LP, may be deemed to beneficially own the shares beneficially owned by BVF2 LP. BVF Partners OS Ltd. (&#8220;Partners OS&#8221;), as general partner of BVF OS, may be deemed to beneficially own the shares beneficially owned by BVF OS. BVF GP Holdings LLC (&#8220;BVF GPH&#8221;), as the sole member of BVF GP and BVF2 GP, may be deemed to beneficially own the shares beneficially owned in the aggregate by BVF GP and BVF2 GP. BVF Partners L.P. (&#8220;Partners&#8221;), as investment manager of BVF LP, BVF2 LP, BVF OS and MSI BVF, and the sole member of Partners OS, may be deemed to beneficially own the shares beneficially owned in the aggregate by the BVF Entities. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the shares beneficially owned by Partners. Mark&#160;N. Lampert as director and officer of BVF Inc., may be deemed to beneficially own the shares beneficially owned by BVF Inc. Each of BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc. and Mark N. Lampert disclaims beneficial ownership of securities beneficially owned by the BVF Entities. The address of each of these entities is 44&#160;Montgomery Street, Suite 4000, San Francisco, CA&#160;94104. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;220,000 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Franklin Strategic Series&#160;&#8211; Franklin Biotechnology Discovery Fund (&#8220;Franklin Strategic&#8221;) and (ii)&#160;467,080 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Franklin Templeton Investment Funds&#160;&#8211; Franklin Biotechnology Discovery Fund (&#8220;Franklin Templeton&#8221;). The address of the Franklin entities is c/o Franklin Advisers, Inc., One Franklin Parkway, San Mateo, CA&#160;94403. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 687,080&#160;shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by RA Capital Healthcare Fund,&#160;L.P. (&#8220;RACHF&#8221;). RA Capital Management, L.P. is the investment manager for RACHF. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the managing members. Each of Mr. Kolchinsky and Mr.&#160;Shah may be deemed to have voting and investment power over the ordinary shares held by RACHF. Mr.&#160;Kolchinsky and Mr.&#160;Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The principal business address of these persons and entities is 200&#160;Berkeley Street, 18th&#160;Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;103,080 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Affinity Healthcare Fund, LP (the &#8220;Affinity Fund&#8221;) and (ii)&#160;548,246 shares of Common Stock held by Affinity Fund. Affinity Asset Advisors, LLC (the &#8220;Affinity Advisor&#8221;) is the investment manager of Affinity Fund and exercises investment discretion with regard to the shares of Common Stock owned by Affinity Fund. Affinity Fund and Affinity Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of such shares of Common Stock owned by Affinity Fund. Affinity Advisor may be deemed to be the beneficial owner of such shares of Common Stock owned by Affinity Fund by virtue of its position as investment manager of Affinity Fund. The address of each of these entities is 767&#160;3rd&#160;Avenue, Floor&#160;15, New York, NY 10017. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(18)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 412,240&#160;shares of Common Stock issued upon conversion of Series&#160;A Preferred Stock held by Citadel CEMF Investments Ltd. (&#8220;Citadel CEMF&#8221;). Citadel Advisors LLC (&#8220;Citadel Advisors&#8221;) is the portfolio manager of Citadel CEMF. Citadel Advisors Holdings&#160;LP (&#8220;Citadel Holdings&#8221;) is the sole member of Citadel Advisors. Citadel GP LLC (&#8220;Citadel GP&#8221;) is the General Partner of Citadel Holdings. Kenneth Griffin owns a controlling interest in Citadel GP LLC. Mr.&#160;Griffin, as the owner of a controlling interest in Citadel GP LLC, may be deemed to have shared power to vote and/or shared power to dispose of the securities held by Citadel CEMF. This disclosure shall not be construed as an admission that Mr.&#160;Griffin or any of the Citadel related entities listed above is the beneficial owner of any of the Company&#8217;s securities </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
other than the securities actually owned by such person (if any). The address of Citadel CEMF is Southeast Financial Center, 200&#160;S.&#160;Biscayne Blvd., Suite&#160;3300, Miami, FL 33131. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(19)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;343,560 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held directly by Aisling Capital&#160;V, LP (&#8220;Aisling&#160;V&#8221;) and held indirectly by Aisling Capital Partners&#160;V, LP (&#8220;Aisling GP&#160;V&#8221;), as general partner of Aisling&#160;V, Aisling Capital Partners&#160;V LLC (&#8220;Aisling Partners&#160;V&#8221;), as general partner of Aisling GP&#160;V, and each of the individual managing members of Aisling Partners&#160;V and (ii)&#160;67,645&#160;shares of Common Stock held directly by Aisling Capital&#160;IV, LP (&#8220;Aisling&#160;IV&#8221;) and held indirectly by Aisling Capital Partners&#160;IV, LP (&#8220;Aisling GP&#160;IV&#8221;), as general partner of Aisling&#160;IV, Aisling Capital Partners&#160;IV LLC (&#8220;Aisling Partners&#160;IV&#8221;), as general partner of Aisling GP&#160;IV, and each of the individual managing members of Aisling Partners&#160;IV. The individual managing members (collectively, the &#8220;Managers&#8221;) of Aisling Partners&#160;IV and Aisling Partners&#160;V are Dr.&#160;Andrew Schiff and Steve Elms. Aisling GP&#160;IV, Aisling GP&#160;V, Aisling Partners&#160;IV, Aisling Partners V and the Managers share voting and dispositive power over the shares directly held by Aisling&#160;V and Aisling&#160;IV. Each of Aisling GP&#160;IV, Aisling GP&#160;V, Aisling Partners&#160;IV, Aisling Partners&#160;V and the Managers may be deemed to be the beneficial owner of the securities listed above only to the extent of its pecuniary interest therein. The above information shall not be deemed an admission that any of Aisling GP&#160;IV, Aisling GP&#160;V, Aisling Partners&#160;IV, Aisling Partners V or any of the Managers is the beneficial owner of any securities reported herein. The address of the principal business offices of each of these entities and persons is 489&#160;Fifth Avenue, 10th&#160;Floor, New York, NY 10017. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(20)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;103,080 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by StemPoint Capital Master Fund LP (&#8220;StemPoint Fund&#8221;), (ii)&#160;87,530&#160;shares of Common Stock held by Jefferies Strategic Investments, LLC (&#8220;JSI&#8221;) and (iii)&#160;89,371&#160;shares of Common Stock held by Titan Biotech Dislocation Fund SP (&#8220;TBDF&#8221;). StemPoint Capital LP (&#8220;Stempoint&#8221;) serves as investment advisor to StemPoint Fund and JSI, and as sub-advisor to TBDF. StemPoint exercises voting and investment power over the shares held by each of StemPoint Fund and JSI pursuant to investment management agreements and StemPoint exercises investment power over the shares held by TBDF pursuant to its sub-advisory agreement. StemPoint hereby disclaims beneficial ownership of the shares held by StemPoint Fund, JSI and TBDF. The total number of shares that StemPoint exercises investment power over is 176,901, as of September&#160;22, 2023. The total number of shares that StemPoint exercises voting and investment power over is 87,530, as of September&#160;22, 2023. The address of these funds and accounts is 520&#160;Madison Avenue, 19th&#160;Floor, New York, NY 10022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(21)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;214,280&#160;shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Salthill Investors (Bermuda) L.P. (&#8220;Salthill Investors&#8221;) and (ii)&#160;197,960 shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Salthill Partners, L.P. (&#8220;Salthill Partners&#8221;). Wellington Management Company LLP (&#8220;Wellington Management&#8221;), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the investment adviser to Salthill Partners and Salthill Investors (collectively, the &#8220;Wellington Entities&#8221;). Wellington Management is an indirect subsidiary of Wellington Management Group LLP (&#8220;Wellington Group&#8221;). Wellington Group and Wellington Management may be deemed beneficial owners with shared voting and investment power over the shares held by the Wellington Entities. The address of these entities is c/o Wellington Management Company LLP, 280&#160;Congress Street, Boston, MA 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(22)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;343,560 shares of Common Stock issued upon the conversion of Series A Preferred Stock held by Logos Opportunities Fund IV LP (&#8220;Logos Opportunities&#8221;) and (ii)&#160;254,000 shares of Common Stock held by Logos Global Master Fund LP (&#8220;Global Fund&#8221;). Logos Opportunities IV GP LLC (&#8220;Logos Opportunities GP&#8221;) is the general partner of Logos Opportunities. Logos Global Management LP (&#8220;Logos Global&#8221;) is the investment advisor to Global Fund. Logos Global Management GP LLC (&#8220;Logos Global GP&#8221;) is the general partner of Logos Global. Arsani William and Graham Walmsley are the members of Logos Opportunities GP and Mr. William is a control person of Logos Global and Logos Global GP. Mr. William and Mr. Walmsley each disclaim beneficial ownership of these shares, except to the extent of each&#8217;s pecuniary interest in such shares, if any. The principal address of Logos Opportunities and Global Fund is 1 Letterman Drive, Building&#160;C, Suite&#160;C3-350, San Francisco, CA 94129. </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(23)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;88,240&#160;shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock, (ii)&#160;3,547 shares of Common Stock and (iii)&#160;44,061 shares of Common Stock issuable upon the exercise of options that are or will become exercisable within 60&#160;days of the date hereof, held by Dr.&#160;Spencer. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(24)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;88,240&#160;shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock, (ii)&#160;3,147&#160;shares of Common Stock and (iii)&#160;44,061 shares of Common Stock issuable upon the exercise of options that are or will become exercisable within 60&#160;days of the date hereof, held by Dr.&#160;Gunzner-Toste. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(25)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;72,080&#160;shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock, (ii)&#160;2,970 shares of Common Stock and (iii)&#160;37,305 shares of Common Stock issuable upon the exercise of options that are or will become exercisable within 60&#160;days of the date hereof, held by Mr.&#160;LaFountaine. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(26)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 68,720&#160;shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Wedbush Healthcare Partners 2023&#160;Fund, LLC. The address for Wedbush Healthcare Partners 2023&#160;Fund, LLC is Wedbush Center, 1000&#160;Wilshire Blvd., Los Angeles, CA 90017. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(27)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 34,360&#160;shares of Common Stock issued upon the conversion of Series&#160;A Preferred Stock held by Sessions LLC. The address for Sessions LLC is 96&#160;Fairbanks Ave, Wellesley, MA 02481. </p></td></tr></table> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Relationship with the Selling Stockholders </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the June 2023 SPA, on June&#160;22, 2023, in connection with the PIPE, we entered into the June 2023 RRA on June&#160;22, 2023 with certain Selling Stockholders. Andrew Spencer is our SVP, Preclinical R&amp;D, Janet Gunzner-Toste is our SVP, Operations and Justin LaFountaine is our VP, Corporate Development. Wedbush PacGrow served as lead financial advisor to our board of directors with respect to the Asset Acquisition. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Registration Rights Agreements </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our June 2023 RRA, we agreed to prepare and file with the SEC a registration statement that permits the resale or other disposition, by purchasers under the June 2023 SPA, certain of the Selling Stockholders, of shares of Common Stock issued upon conversion of the Series A Preferred Stock issued to such investors pursuant to the June 2023 SPA and Acquisition Agreement and, subject to certain exceptions, use commercially reasonable efforts to keep the registration statement of which this prospectus forms a part effective under the Securities Act for so long as such securities registered for resale thereunder retain their character as Registrable Securities (as defined in the June 2023 RRA). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our December 2023 RRA, we agreed to prepare and file with the SEC a registration statement that permits the resale or other disposition of the December 2023 Investors&#8217; shares of Common Stock issued and shares of Common Stock issued upon conversion of the Series B Preferred Stock issued to such December 2023 Investors pursuant to the December 2023 SPA and, subject to certain exceptions, use commercially reasonable efforts to keep the registration statement of which this prospectus forms a part effective under the Securities Act for so long as such securities registered for resale thereunder retain their character as Registrable Securities (as defined in the December 2023 RRA). This registration statement is being filed in order to satisfy our obligations under the December 2023 RRA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also agreed, among other things, to indemnify the Selling Stockholders and the December 2023 Investors and each of their respective officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents, each person who controls any such Selling Stockholder or December&#160;2023 Investors and the officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents of each such controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the June 2023 RRA and the December 2023 RRA, respectively. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_16">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the Resale Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling Stockholders or their donees, pledgees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to, bear all fees and expenses incident to our obligation to register the Resale Shares. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the case of the Private Placement Conversion Shares and Merger Conversion Shares, may only be offered after such shares are converted to Common Stock pursuant to the terms of the Series A Certificate of Designation, directly or through one or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agent&#8217;s commissions. The Resale </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling Resale Shares </p> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exchange distribution in accordance with the rules of the applicable exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a combination of any such methods of sale; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144, as permitted by that rule, or Section&#160;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA <span style="white-space:nowrap">IM-2121.01.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with sales of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume. The Selling Stockholders may also sell Resale Shares short and if such short sale takes place after the date that this registration statement is declared effective by the SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions and to return borrowed Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221; within the meaning of Section&#160;2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule <span style="white-space:nowrap">10b-5</span> under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder has informed us that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Resale Shares. Upon us being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i)&#160;the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares involved, (iii)&#160;the price at which such the Resale Shares were sold, (iv)&#160;the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&#160;that such broker-dealer(s) did not conduct any investigation to verify the information set out in this prospectus, and (vi)&#160;other facts material to the transaction. In no event shall any broker-dealer receive fees, commissions and markups, which, in the aggregate, would exceed eight percent (8.0%). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some U.S. states, the Resale Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states the Resale Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration statement, of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the Resale Shares pursuant to the June 2023 RRA, including, without limitation, SEC filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that each Selling Stockholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the June 2023 RRA, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against certain civil liabilities set forth in the June 2023 RRA, including liabilities under the Securities Act, that may arise from any written information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related registration rights agreements, or we may be entitled to contribution. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_17">DESCRIPTION OF CAPITAL STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description summarizes the material terms of our capital stock, as well as other material terms of our amended and restated certificate of incorporation (&#8220;Certificate of Incorporation&#8221;) and amended and restated bylaws (&#8220;Bylaws&#8221;) and certain provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Certificate of Incorporation and Bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K, to which this exhibit is also appended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 400,000,000 shares of Common Stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share (&#8220;Preferred Stock&#8221;), of which 1,086,341 shares have been designated as Series A Preferred Stock, $0.0001 par value per share and 150,000 shares have been designated as Series B Preferred Stock, $0.0001 par value per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February 15, 2024, there were 36,149,011 shares of our Common Stock, 437,037 shares of Series A Preferred Stock and 150,000 shares of Series B Preferred Stock outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation authorizes the issuance of up to 400,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividend rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to our Certificate of Incorporation, holders of a majority of the shares of our Common Stock are able to elect all of our directors. Our Certificate of Incorporation establishes a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No preemptive or similar rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Right to receive liquidation distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <span style="white-space:nowrap">winding-up,</span> the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of our Certificate of Incorporation, our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 10,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations or restrictions, in each case without further vote or action by our stockholders. Subject to any certificates of designation, our board of directors can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. We have no current plan to issue any shares of Preferred Stock other than the shares of our Series A Preferred Stock and shares of our Series B Preferred Stock that were issued in connection with the June 2023 Transactions and the December 2023 PIPE, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Series A Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-if-converted-to-common-stock</span></span></span></span> basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Series A Certificate of Designation, amend or repeal any provision of, or add any provision to, our Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules (the &#8220;Series A Conversion Proposal&#8221;) or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Series A Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Series A Conversion Proposal, each share of Series A Preferred Stock automatically converted into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Series B Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain holders of our Common Stock, Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-if-converted-to-common-stock</span></span></span></span> basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders of a majority of the then outstanding shares of the Series B Preferred Stock alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, our Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the conversion of the Series B Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules (the &#8220;Series B Conversion Proposal&#8221;), each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our Series A Preferred Stock and Series B Preferred Stock are entitled to certain rights with respect to the registration of such securities as further provided under the heading &#8220;<span style="font-style:italic">Selling Stockholders &#8211; Registration Rights Agreements</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Provisions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Delaware law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&#160;203 of the DGCL regulating corporate takeovers. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1)&#160;shares owned by persons who are directors and also officers and (2)&#160;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section 203 defines a &#8220;business combination&#8221; to include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any merger or consolidation involving the corporation and the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certificate of Incorporation and Bylaw Provisions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Board of Directors vacancies</span></span>. Our Certificate of Incorporation and Bylaws authorize our board of directors to fill vacant directorships, including newly created seats unless the board of directors determines that any such vacancies shall be filled by the stockholders. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Classified board</span></span><span style="font-style:italic">. </span>Our Certificate of Incorporation provides that our board is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Stockholder action; special meetings of stockholders</span></span><span style="font-style:italic">. </span>Our Certificate of Incorporation and Bylaws provide that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws. Further, our Certificate of Incorporation and Bylaws provide that special meetings of our stockholders may be called only by a majority of our entire board of directors, the chairperson of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Advance notice requirements for stockholder proposals and director nominations</span></span><span style="font-style:italic">. </span>Our Bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">No cumulative voting</span></span>. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide for cumulative voting. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Directors removed only for cause</span></span>. Our Certificate of Incorporation provides that stockholders may remove directors only for cause. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Amendment of charter provisions</span></span>. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders of at least <span style="white-space:nowrap">two-thirds</span> of our outstanding Common Stock, provided that if <span style="white-space:nowrap">two-thirds</span> of our entire board of directors approves such an amendment, then only the approval of a majority of holders is required. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Issuance of Preferred Stock</span></span>. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of Preferred Stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Choice of forum</span></span>. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, our Bylaws also provide that the federal district courts of the United States is the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions will not apply to claims brought to enforce a duty or liability created by the Exchange Act. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock, Class A Preferred Stock and Class B Preferred Stock is Equiniti Trust Company, LLC (previously known as American Stock Transfer&#160;&amp; Trust Company LLC). The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is (800) <span style="white-space:nowrap">937-5449.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exchange Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on The Nasdaq Global Select Market under the symbol &#8220;SYRE.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_18">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters, including the legality of the securities offered, has been passed upon for us by Gibson, Dunn&#160;&amp; Crutcher LLP, San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_19">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Spyre Therapeutics, Inc. as of December&#160;31, 2023 and 2022 and for each of the three years in the period ended December&#160;31, 2023 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc., as of June&#160;22, 2023 included in this prospectus have been so included in reliance on the report (which contains an emphasis of matter relating to the basis of presentation as described in Note 1 and an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx518298_20">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an Internet site (<span style="text-decoration:underline">http://www.sec.gov</span>) that contains reports, proxy and information statements, and various other information about us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about us is also available at our website at http://www.aeglea.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. However, the information on our website is not a part of this prospectus and is not incorporated by reference into this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <span style="white-space:nowrap">S-1</span> with the SEC relating to the securities covered by this prospectus. This prospectus is a part of the registration statement and does not contain all of the information in the registration statement. Whenever a reference is made in this prospectus to a contract or other document of ours, please be aware that the reference is only a summary and that you should refer to the exhibits that are part of the registration statement for a copy of the contract or other document. You may review a copy of the registration statement through the SEC&#8217;s website or our website. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="syre:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" id="hidden103883038" contextRef="P01_01_2023To12_31_2023">Accrued interest receivable on available-for-sale debt securities</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="hidden103884648" contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="hidden103884635" contextRef="PAsOn12_31_2023">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="hidden103884638" contextRef="PAsOn12_31_2023">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction name="syre:OtherCommitmentRoyaltyPercentage" id="hidden103884640" contextRef="PAsOn04_30_2023" unitRef="Unit_pure" decimals="2">0.01</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="syre-20231231.xsd"/></ix:references></ix:header></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SPYRE THERAPEUTICS, INC. </div></div></div><div id="tx518298_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 95%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consolidated Financial Statements for each of the three years in the period ended December&#160;31, 202</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">3</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_22">Report of Independent Registered Public Accounting Firm (ID 238 PricewaterhouseCoopers LLP)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_23">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_24">Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_25">Consolidated Statements of Comprehensive Loss</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_26">Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_27">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_28">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-10</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO STATEMENT OF ASSETS ACQUIRED AND LIABILITIES ASSUMED FROM SPYRE THERAPEUTICS, INC. BY AEGLEA BIOTHERAPEUTICS, INC. </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;">
<tr>
<td style="width: 95%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-style:italic;display:inline;">Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. as of June&#160;22, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_29" style="-sec-ix-redline:true;;display:inline;">Report of Independent Registered Public Accounting Firm (ID 238 PricewaterhouseCoopers LLP)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">F-47</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_30" style="-sec-ix-redline:true;;display:inline;">Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc.</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">F-49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin518298_31" style="-sec-ix-redline:true;;display:inline;">Notes to Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc.</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">F-50</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Stockholders of Spyre Therapeutics, Inc. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion on the Financial Statements </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Spyre Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, and the related consolidated statements of operations, of comprehensive loss, of changes in convertible preferred stock and stockholders&#8217; equity and of cash flows for each of the three years in the period ended December&#160;31, 2023, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023 in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical Audit Matters </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i)&#160;relates to accounts or disclosures that are material to the consolidated financial statements and (ii)&#160;involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Value Right (CVR) Liability </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As described in Notes 1, 2, 3, and 8 to the consolidated financial statements, in connection with the asset acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right was distributed to certain legacy stockholders of record as of the close of business on July&#160;3, 2023 entitling holders of the contingent value right to </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">receive certain cash payments from proceeds received by the Company related to the disposition or monetization of the Company&#8217;s legacy assets. Management determined that certain contingent payments under the Contingent Value Rights (CVR) Agreement qualified as derivatives, and as such, were recorded as a liability on the balance sheet. For derivative financial instruments accounted for as liabilities, the derivative instrument is initially recorded by management at its fair value and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date. The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. The CVR liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of regulatory success, estimated reimbursement rates compared to the reimbursement target, and risk-adjusted discount rates. The CVR liability as of December&#160;31, 2023 was $42.7&#160;million and the Company recognized an increase in the CVR liability of $19.0&#160;million for the year ended December&#160;31, 2023 related to the change in fair value between the issuance of the CVR and December&#160;31, 2023. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal considerations for our determination that performing procedures relating to the valuation of the CVR liability is a critical audit matter are (i)&#160;the significant judgment by management when developing the fair value estimate of the CVR liability; (ii)&#160;a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to the estimated probabilities of regulatory success, estimated reimbursement rates compared to the reimbursement target, and risk-adjusted discount rates; and (iii)&#160;the audit effort involved the use of professionals with specialized skill and knowledge. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others (i)&#160;reading and evaluating the terms of the CVR Agreement; (ii)&#160;testing management&#8217;s process for developing the fair value estimate of the CVR liability; (iii)&#160;evaluating the appropriateness of the probability weighted discounted cash flow method used by management; (iv)&#160;testing the completeness and accuracy of underlying data used by management in the probability weighted discounted cash flow method; and (v)&#160;evaluating the reasonableness of the significant assumptions used by management related to the estimated probabilities of regulatory success, estimated reimbursement rates compared to the reimbursement target, and risk-adjusted discount rates. Evaluating management&#8217;s assumptions related to estimated probabilities of regulatory success and estimated reimbursement rates compared to the reimbursement target involved evaluating whether the assumptions used by management were reasonable considering the consistency with (i)&#160;external market and industry data and (ii)&#160;evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i)&#160;the appropriateness of the probability weighted discounted cash flow method and (ii)&#160;the reasonableness of the risk-<div style="letter-spacing: 0px; top: 0px;;display:inline;">adjusted </div>discount rate assumption. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ PricewaterhouseCoopers LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Austin, Texas </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;29, 2024 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2014. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3 </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents<br/></a></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_23" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Spyre Therapeutics, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:81%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td colspan="8" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CURRENT ASSETS</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12025">188,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12030">34,863</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12038">150,384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12043">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12051">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NontradeReceivablesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12056">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12064">2,251</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12069">6,172</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12091">341,528</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12096">62,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12104">322</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12109">1,553</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12117">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12122">3,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12132">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12137">3,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12146">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12151">683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL ASSETS</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12173">341,859</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12178">71,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td colspan="8" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CURRENT LIABILITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12216">896</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12221">677</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12229">1,390</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12234">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12242">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12247">625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12255">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12260">517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12268">13,108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12273">12,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party accounts payable and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12281">16,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12286">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12308">31,978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12313">14,656</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12336">41,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12341">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12350">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12355">4,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12363">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12368">2,179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL LIABILITIES</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12390">73,288</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12395">20,839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and Contingencies (Note 9)</div></td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-12415"></ix:nonFraction></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true" id="ixv-12420"></ix:nonFraction></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12428"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12429">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12430">150,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12431">no</ix:nonFraction> shares authorized as of December&#160;31, 2023 and December&#160;31, 2022, respectively; <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12432"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12433">150,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12434"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12435">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and December&#160;31, 2022, respectively.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12439">84,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12444">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">STOCKHOLDERS&#8217; EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12461"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12462">0.0001</ix:nonFraction></ix:nonFraction> par value; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12465">1,086,341</ix:nonFraction></div></div> and <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12467">no</ix:nonFraction></div> shares authorized as of December&#160;31, 2023 and December&#160;31, 2022, respectively; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12468"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12469">437,037</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12470"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12471">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and December&#160;31, 2022, respectively.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12475">184,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12480">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12485"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12486">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12487">8,763,659</ix:nonFraction> shares and <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12489">10,000,000</ix:nonFraction></div> authorized as of December&#160;31, 2023 and December&#160;31, 2022, respectively; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12490"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12491"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12492"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-12493">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and December&#160;31, 2022.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12497">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12502">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12507"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12508">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12509">400,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12510">20,000,000</ix:nonFraction> shares authorized as of December&#160;31, 2023 and December&#160;31, 2022, respectively; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12511"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12512">36,057,109</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12513"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-12514">2,614,014</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and December&#160;31, 2022, respectively.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12518">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12523">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12532">763,191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12537">475,971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive income (loss)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12545">302</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-12550">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-12558">764,414</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-12563">425,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL STOCKHOLDERS&#8217; EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12585">184,016</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12590">50,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12612">341,859</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12617">71,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_24" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Spyre Therapeutics, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:69%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">License</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12712">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12717">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12722">12,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development fee and royalty</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12730">886</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12735">2,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12740">6,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12768">886</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12773">2,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12778">18,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development <div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_103881978">89,504</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_103881979">58,579</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_103881980">57,069</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12820">39,946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12825">28,531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12830">27,319</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12839">130,188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12844">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12849">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain on sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12858">16,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12863">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-12868">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12896">243,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12901">87,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12906">84,388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-12934">242,303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-12939">84,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-12944">65,649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other (expense) income:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12987">6,147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12992">837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-12997">111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of forward contract liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13005">83,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-13010">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-13015">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other expense, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13023">19,130</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13028">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13033">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other (expense) income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13061">96,513</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13066">830</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13071">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13099">338,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13104">83,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13109">65,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit (expense)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13117">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13122">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13127">141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13155">338,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13160">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13165">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-13193"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-13194">49.12</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-13199"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-13200">24.86</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-13205"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-13206">25.02</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average common shares outstanding, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-13214"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-13215">6,897,065</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-13220"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-13221">3,371,231</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-13226"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-13227">2,629,784</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Includes $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-13235">48.5</ix:nonFraction>&#160;million in related party expenses for the year ended December&#160;31, 2023 and <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2022To12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-13236"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2021To12_31_2021_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-13237">no</ix:nonFraction></ix:nonFraction> related party expenses for the year ended months ended December&#160;31, 2022 and 2021. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_25" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Spyre Therapeutics, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Comprehensive Loss </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13305">338,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13310">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13315">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13338">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13343">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13348">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain (loss) on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13356">313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13361">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13366">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13394">338,440</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13399">83,843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13404">65,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_26" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Spyre Therapeutics, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series B</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/> Preferred<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series A</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/> Preferred<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comprehensive</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Loss) Income</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-13615">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-13620">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-13628">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-13633">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13638">1,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13643">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13648">415,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13653">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13658">276,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13663">139,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13691">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13738">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13747">1,903</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13760">1,903</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13795">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-13808">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13847">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13856">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13895">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13904">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13947">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-13952">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14024">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14029">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14037">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14042">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14047">1,974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14052">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14057">425,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14062">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14067">341,809</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14072">83,941</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in connection with registered direct offering, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14164">430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14169">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14174">42,873</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14187">42,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14215">204</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14262">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14271">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14284">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14319">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14332">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14371">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14380">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14419">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14428">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14471">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14476">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14548">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14553">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14561">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14566">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14571">2,614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14576">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14581">475,971</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14586">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14591">425,624</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14596">50,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:31%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series B</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/> Preferred<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series A</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/> Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comprehensive</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Loss) Income</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with private placement, net of financing costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14857">721</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14862">197,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14887">197,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14909">365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14914">189,741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14939">189,741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock into common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14961">649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-14966">202,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14971">25,972</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14976">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-14981">202,175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-14994">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with private placement, net of financing costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15003">150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15008">84,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with private placement, net of financing costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15074">6,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15083">84,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15096">84,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with the asset acquisition of Spyre</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15125">518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15130">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15135">3,767</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15148">3,768</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfPreFundedWarrantsMemberusgaapConversionOfStockByUniqueDescriptionAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15178">905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15227">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15236">405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15249">405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR distribution to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:ContingentValueRightDistributionToCommonStockholders" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15286">29,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:ContingentValueRightDistributionToCommonStockholders" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15299">29,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15336">14,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15349">14,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Parapyre Option Obligation warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15386">11,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15399">11,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15440">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15449">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15490">313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15499">313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15544">338,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15549">338,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balances&#8212;December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15623">150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15628">84,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15638">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15643">184,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15648">36,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15653">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15658">763,191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15663">302</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15668">764,414</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15673">184,016</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-8 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_27" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Spyre Therapeutics, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM OPERATING ACTIVITIES</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15824">338,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15829">83,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15834">65,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15857">744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15862">1,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15867">1,576</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15875">25,675</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15880">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15885">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15894">130,188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15899">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15904">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15912">18,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15917">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To12_31_2021_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15922">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of forward contract liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15930">83,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15935">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15940">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain on sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15949">16,449</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15954">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15959">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease ROU asset and leasehold improvement impairment loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-15967">2,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15972">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15977">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on disposal of long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-15985">915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15990">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-15995">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net (accretion of discount) amortization of premium on marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16003">2,318</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16008">327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16013">548</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of operating lease assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16021">220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16026">397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16031">425</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16039">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16044">426</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16049">335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16072">3,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16077">1,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16082">1,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16090">218</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16095">2,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16100">1,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16108">575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16113">880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16118">3,576</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16126">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16131">440</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16136">815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16144">2,326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16149">435</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16154">404</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16162">4,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16167">843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16172">373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16180">2,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16185">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16190">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16218">99,910</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16223">80,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16228">53,716</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM INVESTING ACTIVITIES</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash assumed from asset acquisition of Spyre</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16272">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16277">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16282">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research&#160;&amp; development asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16291">15,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16296">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16301">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16309">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16314">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16319">573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from the sale of property plant and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16327">475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16332">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16337">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16345">166,803</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16350">39,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16355">133,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturities and sales of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16363">39,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16368">96,546</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16373">111,033</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16401">108,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16406">57,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16411">22,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH FLOWS FROM FINANCING ACTIVITIES</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with private placement, net of placement and other offering costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16456">197,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16461">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16466">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in connection with private placement, net of placement and other offering costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16475">84,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16480">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16485">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock in connection with private placement, net of placement and other offering costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16493">84,555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16498">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16503">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of contingent value rights liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16511">5,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16516">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16521">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants in registered direct offering, net of offering costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16530">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16535">42,874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16540">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from employee stock plan purchases and stock option exercises</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16548">405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16553">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16558">1,903</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on finance lease obligation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16566">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16571">418</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16576">510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16604">361,077</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16609">42,678</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16614">1,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of exchange rate on cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16642">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16647">106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16652">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16680">152,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16685">19,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-16690">74,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16714">36,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16719">16,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16724">91,937</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">End of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16752">189,215</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16757">36,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16762">16,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental Disclosure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> Investing and Financing Information:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of forward contract liability and issuance of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16808">189,741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16813">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16818">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock into common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16827">202,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16832">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16837">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leased assets obtained in exchange for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:LeasedAssetsObtainedInExchangeForLeaseObligations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-16845">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:LeasedAssetsObtainedInExchangeForLeaseObligations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16850">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:LeasedAssetsObtainedInExchangeForLeaseObligations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-16855">872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-9 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin518298_28" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Spyre Therapeutics, Inc. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882084" id="ixv-16873"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. The Company and Basis of Presentation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc., (&#8220;Spyre&#8221; or the &#8220;Company&#8221;) is a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with inflammatory bowel disease. The Company was formed as a Limited Liability Company (&#8220;LLC&#8221;) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. On November&#160;27, 2023, the Company completed its corporate rebranding, changing the name of the Company to Spyre Therapeutics, Inc. The Company operates in one segment and has its principal offices in Waltham, Massachusetts. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company effected a reverse stock split of its Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to the Company&#8217;s Common Stock disclosed in these financial statements have been adjusted on a post-Reverse Split basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. As a result, in April 2023, the Company implemented a restructuring plan resulting in an approximate <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_12_2023To06_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-16881">83</ix:nonFraction>% reduction of the Company&#8217;s existing headcount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets of Spyre Therapeutics, Inc. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Pre-Merger</div> Spyre&#8221;) as disclosed in Note 7 and 8, a privately held biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). The asset acquisition was accomplished through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> reverse triangular merger whereby a wholly owned subsidiary of the Company merged with and into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, which existed at the time the Acquisition Agreement was entered into, became a wholly owned subsidiary of the Company in accordance with the terms of the Acquisition Agreement. Immediately following this merger, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre merged with an into a second wholly subsidiary of the Company (&#8220;Merger Sub&#8221;) in accordance with the terms of the Acquisition Agreement and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre ceased to exist. Subsequently, Aeglea BioTherapeutics, Inc. was renamed Spyre Therapeutics, Inc. and is a different entity than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, which ceased to exist upon merging with Merger Sub. The transaction was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of <ix:nonFraction name="syre:FixedExchangeRatio" contextRef="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="7" scale="0" format="ixt:num-dot-decimal" id="ixv-16892">0.5494488</ix:nonFraction> to 1 for consideration from the Company of <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16893">517,809</ix:nonFraction> shares of common stock and <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16894">364,887</ix:nonFraction> shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-16896">0.0001</ix:nonFraction> per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16897">40</ix:nonFraction> to 1 basis), in addition to the assumption of outstanding and unexercised stock options to purchase <ix:nonFraction name="syre:OutstandingAndUnexercisedStockOptions" contextRef="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16898">2,734</ix:nonFraction> shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Asset Acquisition&#8221;). The common stock and Series A Preferred Stock related to the Asset Acquisition were issued to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre stockholders on July&#160;7, 2023. For additional information, see Note 8. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock (the &#8220;Series A PIPE&#8221;) to a group of investors (the &#8220;Series A Investors&#8221;). The Company sold an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16901">721,452</ix:nonFraction> shares of Series A Preferred Stock (the &#8220;Series A PIPE Securities&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-16902">210.0</ix:nonFraction>&#160;million before deducting approximately $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-16903">12.7</ix:nonFraction>&#160;million of placement agent and other offering expenses. For additional information, see Note 11. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882084" continuedAt="TextSelectionAppend_103882084_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882084_1" continuedAt="TextSelectionAppend_103882084_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882084_2" continuedAt="TextSelectionAppend_103882084_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882084_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right (&#8220;CVR&#8221;) was distributed to stockholders of record of the Company as of the close of business on July&#160;3, 2023 (the &#8220;Legacy Stockholders&#8221;), but was not distributed to the holders of shares of common stock or Series A Preferred Stock issued to the former stockholders of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre or Investors in the Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by the Company for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="syre:AssetAcquisitionStockholderPaymentPeriod" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" format="ixt-sec:duryear" id="ixv-16924">3</ix:nonNumeric>-year</div> period related to the disposition or monetization of its legacy assets for a period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> following the closing of the Asset Acquisition. For additional information, see Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2023, the Company&#8217;s stockholders approved the conversion of the Company&#8217;s Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock to Common Stock. For additional information, see Note 11. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company completed a private placement of shares of common stock and Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_11_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-16930">0.0001</ix:nonFraction> per share (&#8220;Series B Preferred Stock&#8221;) (convertible on a <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn12_11_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16931">40</ix:nonFraction> to 1 basis) (collectively, the &#8220;December 2023 PIPE&#8221;) to a group of investors (the &#8220;December 2023 PIPE Investors&#8221;). The Company sold an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_11_2023To12_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16932">6,000,000</ix:nonFraction> shares of Common Stock and <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-16933">150,000</ix:nonFraction> shares of Series B Preferred Stock (the &#8220;December 2023 PIPE Securities&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-16934">180.0</ix:nonFraction>&#160;million before deducting approximately $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-16935">10.9</ix:nonFraction>&#160;million of placement agent and other offering expenses. For additional information, see Note 11. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a preclinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its inception and through December&#160;31, 2023, the Company has funded our operations by raising an aggregate of approximately $<ix:nonFraction name="syre:ProceedsFromRaisingCapital" contextRef="P03_10_2015To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-16942">896.2</ix:nonFraction>&#160;million of gross proceeds from the sale and issuance of convertible preferred stock and common stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, the collection of grant proceeds, and the licensing of its product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of December&#160;31, 2023, Spyre had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-16944">764.4</ix:nonFraction>&#160;million, and cash, cash equivalents, and marketable securities of $<ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-16945">339.3</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on current operating plans, the Company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements with existing cash, cash equivalents, and marketable securities. Spyre will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company. </div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16947"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882089" id="ixv-16953"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882528" id="ixv-16956"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude> </div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882528" continuedAt="TextSelectionAppend_103882528_1"><ix:continuation id="TextSelection_103882089" continuedAt="TextSelectionAppend_103882089_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_1" continuedAt="TextSelectionAppend_103882089_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_2" continuedAt="TextSelectionAppend_103882089_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_3" continuedAt="TextSelectionAppend_103882089_4"><ix:continuation id="TextSelectionAppend_103882528_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#8217;s financial statements relate to the valuation of consideration transferred in acquiring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research&#160;&amp; development (&#8220;IPR&amp;D&#8221;); the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was comprised of shares of the Company&#8217;s Common Stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the Series A PIPE securities, <div style="letter-spacing: 0px; top: 0px;;display:inline;">which</div> was a financing event involving a group of accredited investors. </div></ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16990"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16996"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All investments have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any unrealized losses from declines in fair value below the amortized cost basis as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882089_4" continuedAt="TextSelectionAppend_103882089_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_5" continuedAt="TextSelectionAppend_103882089_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_6" continuedAt="TextSelectionAppend_103882089_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_7" continuedAt="TextSelectionAppend_103882089_8"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17035"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consisted of money market accounts held by financial institutions as collateral for the Company&#8217;s obligations under a credit agreement and a facility lease for the Company&#8217;s corporate headquarters in Austin, Texas. The lease was terminated in August 2023 and the cash was subsequently unrestricted. Remaining restricted cash balances relate to the Company&#8217;s operations in the United Kingdom. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17041"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company&#8217;s two U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17047">250,000</ix:nonFraction> per depositor. As of December&#160;31, 2023 and 2022, balances at the Company&#8217;s U.S. banking institutions exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17048"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. </div><ix:nonNumeric name="syre:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17054"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:59%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen" id="ixv-17066">5 years</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen" id="ixv-17071">5 years</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen" id="ixv-17076">3 years</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen" id="ixv-17081">3 years</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shorter of remaining lease term or estimated useful life</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17086"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. The Company recognized a $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17092">2.6</ix:nonFraction>&#160;million impairment loss for the year ended December&#160;31, 2023 related to its leased office space in Austin, Texas (see Note 17 for additional information). There were no impairments of long-lived assets for the years ended December&#160;31, 2022 and 2021. </div></ix:nonNumeric><ix:nonNumeric name="syre:AccruedResearchAndDevelopmentExpensePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882409" id="ixv-17093"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Research and Development Costs </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_103882409" continuedAt="TextSelectionAppend_103882409_1"><ix:continuation id="TextSelectionAppend_103882089_8" continuedAt="TextSelectionAppend_103882089_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_9" continuedAt="TextSelectionAppend_103882089_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_10" continuedAt="TextSelectionAppend_103882089_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_11" continuedAt="TextSelectionAppend_103882089_12"><ix:continuation id="TextSelectionAppend_103882409_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>development expenses, with a substantial portion of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> research and development activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for expenses resulting from obligations under the Paragon Agreement and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. Historically, the Company has not experienced any material deviations between accrued and actual research and development expenses. </div></ix:continuation><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17124"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Company&#8217;s restructuring, as described in Note 17, the Company had lease agreements with lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. As allowed under Topic 842, the Company elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for any leases involving real estate and office equipment classes of assets and, as a result, accounted for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. The Company also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103883358" id="ixv-17136"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses fair value measurements to record fair value adjustments to certain financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_103883358" continuedAt="TextSelectionAppend_103883358_1"><ix:continuation id="TextSelectionAppend_103882089_12" continuedAt="TextSelectionAppend_103882089_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_13" continuedAt="TextSelectionAppend_103882089_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_14" continuedAt="TextSelectionAppend_103882089_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_15" continuedAt="TextSelectionAppend_103882089_16"><ix:continuation id="TextSelectionAppend_103883358_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three levels of inputs that may be used to measure fair value are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto">
<tr>
<td style="width:9%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.</td></tr></table></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments carried at fair value include cash equivalents and marketable securities. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </div></ix:continuation><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103883359" id="ixv-17190"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License revenue </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_103883359" continuedAt="TextSelectionAppend_103883359_1"><ix:continuation id="TextSelectionAppend_103882089_16" continuedAt="TextSelectionAppend_103882089_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_17" continuedAt="TextSelectionAppend_103882089_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_18" continuedAt="TextSelectionAppend_103882089_19"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103883359_1" continuedAt="TextSelectionAppend_103883359_2"><ix:continuation id="TextSelectionAppend_103882089_19" continuedAt="TextSelectionAppend_103882089_20"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s contracts may be modified for changes in the customer&#8217;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude> </div></ix:continuation></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_103883359_2" continuedAt="TextSelectionAppend_103883359_3"><ix:continuation id="TextSelectionAppend_103882089_20" continuedAt="TextSelectionAppend_103882089_21"><div></div></ix:continuation></ix:continuation></div><div><div style="line-height:normal;background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_103883359_3" continuedAt="TextSelectionAppend_103883359_4"><ix:continuation id="TextSelectionAppend_103882089_21" continuedAt="TextSelectionAppend_103882089_22"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_22" continuedAt="TextSelectionAppend_103882089_23"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_23" continuedAt="TextSelectionAppend_103882089_24"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_24" continuedAt="TextSelectionAppend_103882089_25"><ix:continuation id="TextSelectionAppend_103883359_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">an adjustment to revenue on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis. The cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above. </div></ix:continuation><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17263"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#8217;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17270"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the cost of stock-based awards granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. </div></ix:nonNumeric><ix:nonNumeric name="syre:TemporaryEquityPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17278"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock Issued through PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company classified the Series B Preferred Stock outside of stockholders&#8217; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock on the last trading day prior to the holder&#8217;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#8217;s control. Additionally, the Company determined the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882089_25" continuedAt="TextSelectionAppend_103882089_26"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_26" continuedAt="TextSelectionAppend_103882089_27"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_27" continuedAt="TextSelectionAppend_103882089_28"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_28" continuedAt="TextSelectionAppend_103882089_29"><ix:nonNumeric name="syre:InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17303"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">&#160;</div><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Milestone Proceeds </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes contingent milestone proceeds associated from the sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development assets in earnings once the achievement of the milestone becomes probable and payment to the Company is contractually required. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17312"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17321"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Value Rights </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#8217;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882089_29" continuedAt="TextSelectionAppend_103882089_30"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_30" continuedAt="TextSelectionAppend_103882089_31"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_31" continuedAt="TextSelectionAppend_103882089_32"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_32" continuedAt="TextSelectionAppend_103882089_33"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17347"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2023 and 2022, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2023, 2022, or 2021. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17355"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#8217;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#8217;s functional currency and the reporting currency. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882253" id="ixv-17363"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the cash conversion and beneficial conversion feature models in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20</div> that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted earnings-per-share for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> requires the if-converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> to all Series A Preferred Stock and Series B Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A Preferred Stock and Series B Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-07,</div> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 &#8211; Segment Reporting. This update is effective beginning with the Company&#8217;s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_103882253" continuedAt="TextSelectionAppend_103882253_1"><ix:continuation id="TextSelectionAppend_103882089_33" continuedAt="TextSelectionAppend_103882089_34"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_34" continuedAt="TextSelectionAppend_103882089_35"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882089_35" continuedAt="TextSelectionAppend_103882089_36"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882089_36"><ix:continuation id="TextSelectionAppend_103882253_1"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-09,</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. This ASU will have no impact on the Company&#8217;s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income <div style="letter-spacing: 0px; top: 0px;;display:inline;">tax</div> disclosures. </div></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882090" id="ixv-17405"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882531" id="ixv-17409">The following tables sets forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair <div style="letter-spacing: 0px; top: 0px;;display:inline;">value</div> hierarchy (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_103882531"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:58%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17486">150,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17491">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17496">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17501">150,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17509">32,843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17514">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17519">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17524">32,843</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17532">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17537">16,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17542">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17547">16,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17555">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17560">104,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17565">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17570">104,141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17578">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17583">33,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17588">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17593">33,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17627">183,491</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17632">153,462</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17637">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17642">336,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17695">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17700">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17705">42,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17710">42,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17744">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17749">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17754">42,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17759">42,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17861">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17866">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17871">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17876">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17884">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17889">23,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17894">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17899">23,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17907">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17912">4,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17928">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17933">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17938">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17943">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17977">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17982">31,603</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17987">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17992">46,853</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds on quoted prices in active markets for identical asset or liabilities. The Level&#160;2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level&#160;1 and Level&#160;2 during the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-18023">no</ix:nonFraction> financial liabilities outstanding measured at fair value. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Forward Contract Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company entered into a contract for the issuance of <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18029">364,887</ix:nonFraction> shares of Series A Preferred Stock as part of the consideration transferred. This forward contract was classified as a liability because the underlying preferred shares were contingently redeemable. Further, the forward contract </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882090" continuedAt="TextSelectionAppend_103882090_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882090_1" continuedAt="TextSelectionAppend_103882090_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882090_2" continuedAt="TextSelectionAppend_103882090_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882090_3" continuedAt="TextSelectionAppend_103882090_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">liability was considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability and was initially measured at its estimated fair value on the transaction date based on the underlying price per share on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis of the Series A PIPE Securities issued in the Series A PIPE. Subsequent remeasurement of the fair value of the forward contract liability through its settlement date was based on the market price of the Company&#8217;s Common Stock, which represents the redemption value of the Series A Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the forward contract at the transaction date, June&#160;22, 2023, was $<ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18049">106.2</ix:nonFraction>&#160;million. The liability was settled with the issuance of the Series A Preferred Stock on July&#160;7, 2023 for $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18050">189.7</ix:nonFraction>&#160;million. For the year ended December&#160;31, 2023, $<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-18051">83.5</ix:nonFraction>&#160;million was recorded as Other (expense) income in the consolidated statements of operations in connection with the change in fair value of the forward contract liability. There was <ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt-sec:numwordsen" id="ixv-18052"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt-sec:numwordsen" id="ixv-18053">no</ix:nonFraction></ix:nonFraction> similar expense for the year ended December&#160;31, 2022 and 2021. </div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882702" id="ixv-18054"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the forward contract liability for the periods presented (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Forward&#160;Contract<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of June&#160;22, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18078">106.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P06_23_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-18086">83.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A Preferred Stock on July&#160;7, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P06_23_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18094">189.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="ixv-18110">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVR Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right was distributed to the Legacy Stockholders, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the Investors or former stockholders of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre in connection with the Transactions. Holders of the CVR will be entitled to receive certain cash payments from proceeds received by the Company for a <ix:nonNumeric name="syre:AssetAcquisitionStockholderPaymentPeriod" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen" id="ixv-18127">three-year</ix:nonNumeric> period, if any, related to the disposition or monetization of the Company&#8217;s legacy assets for a period of <ix:nonNumeric name="syre:AssetAcquisitionCashPaymentThresholdPeriod" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen" id="ixv-18128">one year</ix:nonNumeric> following the closing of the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June&#160;22, 2023, as a Common Stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability will be recognized as a component of Other income (expense) in the consolidated statement of operations and comprehensive loss in each reporting period. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of regulatory success, and discount rates, which represent a Level&#160;3 measurement within the fair value hierarchy. <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882529" id="ixv-18130">The significant inputs used to estimate the fair value of the CVR liability were as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_103882529"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:82%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated cash flow dates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2/28/24&#8201;-&#8201;06/22/26</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated probability of success</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18155">39</ix:nonFraction>% - <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18156">100</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated reimbursement rate compared to reimbursement target</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18162">81</ix:nonFraction>% - <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18163">100</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-adjusted discount rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-18169">5.91</ix:nonFraction>% - <ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-18170">6.32</ix:nonFraction>%</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value between the issuance of the CVR and December&#160;31, 2023 was a $<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-18172">19.0</ix:nonFraction>&#160;million increase, and was primarily driven by changes in the expected timing of achievement of certain milestones, changes in the likelihood of certain milestones related to the approval received from the European Medicines Agency by Immedica Pharma AB (&#8220;Immedica&#8221;), partially offset by a change in the likelihood of a successful disposition of pegtarviliase and updates to expenses and deductions. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882090_4" continuedAt="TextSelectionAppend_103882090_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882090_5" continuedAt="TextSelectionAppend_103882090_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882090_6" continuedAt="TextSelectionAppend_103882090_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882090_7"><ix:continuation id="TextSelection_103882702"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the CVR liability for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:88%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CVR&#160;Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18215">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at CVR issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18223">29,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in the fair value of the CVR liability since issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-18231">18,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18239">5,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18255">42,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882325" id="ixv-18265"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Cash Equivalents and Marketable Securities </div></div><ix:nonNumeric name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18268"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18362">150,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18367">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18372">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18377">150,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18385">24,950</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18390">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18395">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18400">24,955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18408">10,965</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18413">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18418">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18423">10,966</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18457">186,563</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18462">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18467">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18472">186,569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="4" style="height:6pt"/>
<td colspan="4" style="height:6pt"/>
<td colspan="4" style="height:6pt"/>
<td colspan="4" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18531">79,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18536">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18541">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18546">79,186</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18554">32,984</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18559">81</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18564">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18569">33,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18577">21,846</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18582">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18587">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18592">21,877</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18600">16,147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18605">110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18610">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18615">16,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18649">150,101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18654">284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18659">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18664">150,384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;&#8199;&#8199;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18784">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18789">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18794">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18799">15,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18807">7,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18812">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18817">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18822">7,020</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18830">3,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18835">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18840">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18845">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18879">26,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:CashEquivalentsUnrealizedGains" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18884">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:CashEquivalentsUnrealizedLosses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18889">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18894">26,005</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18947">16,644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18952">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18957">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18962">16,621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18970">3,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18975">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18980">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18985">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18993">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18998">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19003">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19008">495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19042">20,877</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19047">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19052">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19057">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_103882325" continuedAt="TextSelectionAppend_103882325_1"><div></div></ix:continuation></div><div><div style="line-height:normal;background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_103882325_1" continuedAt="TextSelectionAppend_103882325_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882325_2" continuedAt="TextSelectionAppend_103882325_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882325_3" continuedAt="TextSelectionAppend_103882325_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882325_4"><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19105"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2023 and 2022, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:46%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19208">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19213">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19218">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19223">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19228">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19233">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19241">9,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19246">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19251">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19256">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19261">9,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19266">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19274">4,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19279">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19284">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19289">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19294">4,831</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19299">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19345">14,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19350">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19355">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19360">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19365">14,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19370">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:46%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19509">17,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19514">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19519">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19524">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19529">17,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19534">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19542">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19547">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19552">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19557">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19562">3,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19567">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19575">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19580">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19585">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19590">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19595">3,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19600">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19646">25,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19651">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19656">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19661">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19666">25,166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19671">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect they will be required to sell the securities before recovery of the unamortized cost basis. As of December&#160;31, 2023 and 2022, an allowance for credit losses had <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-19713"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" contextRef="PAsOn12_31_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-19714">no</ix:nonFraction></ix:nonFraction>t</div> been recognized. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December&#160;31, 2023 and 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-19716">0.3</ix:nonFraction>&#160;million unrealized gains on marketable securities for the year ended December&#160;31, 2023. There were <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-19717"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-19718">no</ix:nonFraction></ix:nonFraction> realized gains on marketable securities for the year ended December&#160;31, 2023, 2022 and 2021. Interest on marketable securities is included in interest income. Accrued interest receivable on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt <div style="-sec-ix-hidden:hidden103883038;display:inline;">securities</div> totaled $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-19722">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-19723">0.1</ix:nonFraction>&#160;million as of December&#160;31, 2023 and 2022, respectively, and is excluded from the estimate of credit losses. </div><ix:nonNumeric name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19724"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19763">115,784</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19768">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in 1 &#8211; 2 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19776">34,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19781">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19803">150,384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19808">20,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current assets. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-23 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19836"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and Equipment, Net </div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19839"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19878">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19883">2,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19891">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19896">520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19904">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19909">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19917">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19922">121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19930">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19935">4,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19957">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19962">7,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19970">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-19975">4,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-19997">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20002">3,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2023, 2022, and 2021 was $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To12_31_2023_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20019">0.7</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20020">1.4</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20021">1.4</ix:nonFraction>&#160;million, respectively. All of the Company&#8217;s long-lived assets were located in the United States. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Assets </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. As a result, the Company implemented a restructuring plan resulting in an approximate <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_12_2023To06_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-20027">83</ix:nonFraction>% reduction of the Company&#8217;s existing headcount by June&#160;30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20029">0.5</ix:nonFraction>&#160;million. After recording the disposal of all the Company&#8217;s property and equipment net of proceeds, the Company recorded a $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-20030">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-20031">0.2</ix:nonFraction>&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. </div></ix:nonNumeric><ix:nonNumeric name="syre:AccruedAndOtherCurrentLiabilitiesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20032"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued and Other Current Liabilities </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20035"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20074">4,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20079">4,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AccruedContractedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20087">7,092</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AccruedContractedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20092">6,972</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20100">1,474</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20105">946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20113">488</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20118">330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20140">13,108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20145">12,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882326" id="ixv-20161"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Related Party Transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC (&#8220;Parapyre&#8221;) each beneficially own less than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-20165">5</ix:nonFraction>% of the Company&#8217;s capital stock through their respective holdings of the Company&#8217;s common stock. Fairmount Funds Management </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-24</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882326" continuedAt="TextSelectionAppend_103882326_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882326_1" continuedAt="TextSelectionAppend_103882326_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882326_2" continuedAt="TextSelectionAppend_103882326_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882326_3" continuedAt="TextSelectionAppend_103882326_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LLC (&#8220;Fairmount&#8221;) beneficially owns more than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn12_31_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-20183">5</ix:nonFraction>% of the Company&#8217;s capital stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, has <ix:nonFraction name="syre:RelatedPartyTransactionNumberOfBoardSeats" contextRef="PAsOn12_31_2023_AppointOfBoardMembersMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_BOARDSEAT" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-20185">two</ix:nonFraction> seats on the Board and beneficially owns more than <ix:nonFraction name="syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" contextRef="PAsOn12_31_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-20186">5</ix:nonFraction>% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre had incurred total expenses of $<ix:nonFraction name="syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20191">19.0</ix:nonFraction>&#160;million under the Paragon Agreement since inception, which included the $<ix:nonFraction name="syre:ResearchInitiationFees" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20192">3.0</ix:nonFraction>&#160;million research initiation fee and $<ix:nonFraction name="syre:ReimbursableResearchCosts" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20193">16.0</ix:nonFraction>&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $<ix:nonFraction name="syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition" contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20194">19.0</ix:nonFraction>&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company recognized expenses related to services provided by Paragon subsequent to the Asset Acquisition totaling $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2023To12_31_2023_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20196">48.5</ix:nonFraction>&#160;million, which included $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20197">11.4</ix:nonFraction>&#160;million of stock-based compensation expense, and were recorded as Research and development expenses in the consolidated statements of operations. As of December&#160;31, 2023, $<ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20198">16.6</ix:nonFraction>&#160;million was unpaid and was included in Related party accounts payable and other current liabilities on the Company&#8217;s consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company made payments totaling $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2023To12_31_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20200">39.5</ix:nonFraction>&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;12, 2023 and December&#160;14, 2023, the Company exercised the Option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expects to enter into the SPY001 License Agreement and the SPY002 License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, the Company will be obligated to pay Paragon up to $<ix:nonFraction name="syre:AmountToBePaidUnderAgreement" contextRef="PAsOn12_14_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20203">22.0</ix:nonFraction>&#160;million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, we expect to pay Paragon a $<ix:nonFraction name="syre:NominationFee" contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20204">1.5</ix:nonFraction>&#160;million fee for nomination of a development candidate, as applicable, and the Company expects to be obligated to make a further milestone payment of&#8201;$<ix:nonFraction name="syre:PaymentOfMilestone" contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20205">2.5</ix:nonFraction>&#160;million upon the first dosing of a human patient in a Phase 1 trial. </div><ix:nonNumeric name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20206"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of expenses related to the Paragon Agreement recognized within research and development expenses, which were ultimately settled in cash (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:RelatedPartyTransactionReimbursableCosts" contextRef="P01_01_2023To12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20254">37.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:RelatedPartyTransactionReimbursableCosts" contextRef="P01_01_2022To12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="ixv-20259">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:RelatedPartyTransactionReimbursableCosts" contextRef="P01_01_2021To12_31_2021_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="ixv-20264">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Paragon Agreement, the Company is obligated to issue Parapyre a stock option grant on the last business day of 2023 and 2024 (the &#8220;Parapyre Option Obligation&#8221;). See Note 15 for additional information. </div><ix:nonNumeric name="syre:ScheduleOfBalancesDueToAffiliatesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20271"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of Related party accounts payable and other current liabilities (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20305">16.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="ixv-20310">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party accounts payable and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20332">16.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:fixed-zero" id="ixv-20337">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-25</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882326_4" continuedAt="TextSelectionAppend_103882326_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882326_5" continuedAt="TextSelectionAppend_103882326_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882326_6" continuedAt="TextSelectionAppend_103882326_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882326_7"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December 2023 PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The December 2023 Investors included Fairmount, a related party. Fairmount&#8217;s participation in the December 2023 PIPE was approved by the Company&#8217;s board of directors. Fairmount&#8217;s investment accounted for $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SaleOfStockDecember2023PIPEMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20377">10.0</ix:nonFraction>&#160;million of the $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20378">180.0</ix:nonFraction>&#160;million gross proceeds raised in the December 2023 PIPE. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Mark McKenna Option Grant </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;1, 2024, the Board appointed Mark McKenna as a Class&#160;I director. Mr.&#160;McKenna and the Company are parties to a consulting agreement, pursuant to which Mr.&#160;McKenna agreed to continue to provide consulting services as an independent contractor to the Company, with an effective date of August&#160;1, 2023 (the &#8220;Vesting Commencement Date&#8221;). As compensation for Mr.&#160;McKenna&#8217;s consulting services, on November&#160;22, 2023, he was granted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20383">477,000</ix:nonFraction> shares of the Company&#8217;s common stock under the Company&#8217;s equity incentive plan with an exercise price of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-20384">10.39</ix:nonFraction> per share, which vest as to <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-20385">25</ix:nonFraction>% on the one year anniversary of the Vesting Commencement Date and thereafter vest and become exercisable in <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" contextRef="PAsOn11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_installment" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20386">48</ix:nonFraction>th equal monthly installments, subject to Mr.&#160;McKenna&#8217;s continued service to the Company through each applicable vesting date. For the twelve months ended December&#160;31, 2023, the Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20387">0.1</ix:nonFraction>&#160;million in stock-based compensation expense related to Mr.&#160;McKenna&#8217;s consulting agreement. There was no such expense for the twelve months ended December&#160;31, 2022 and 2021. </div></ix:continuation><ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103883857" id="ixv-20388"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Asset Acquisition </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, pursuant to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was the surviving corporation and became the Company&#8217;s wholly owned subsidiary (the &#8220;First Merger&#8221;). Immediately following the First Merger, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Asset Acquisition, the Company determined that Aeglea was the acquirer for accounting purposes under ASC 805. The primary factors considered were a) the relative voting rights in the combined entity not resulting in a change of control, b) legacy members of the Company&#8217;s Board of Directors maintained control of the Board of Directors, and c) the only change in the composition of senior management was the appointment of a new Chief Operating Officer. Next, the Company considered whether the Asset Acquisition should be defined as a business under ASC 805. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">805-10-55-5A</div></div></div> through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">55-5C</div> describe a screen test to determine whether an acquired set of assets and activities is not a business. We determined that substantially all (greater than 90%) of the fair value of the assets acquired were concentrated in a single asset, Spyre&#8217;s Option to license intellectual property rights related to SPY001, SPY002, SPY003 and SPY004 pursuant to the Paragon Agreement. Accordingly, the Company treated the Asset Acquisition as an asset acquisition for accounting purposes. Even if the transaction would have failed the screen test, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre lacked the financial resources to have inputs, processes, and outputs to constitute a business under ASC 805. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company completed the Asset Acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, in accordance with the terms of the Acquisition Agreement. Under the terms of the Acquisition Agreement, the Company issued <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20407">517,809</ix:nonFraction> shares of Common Stock and <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20408">364,887</ix:nonFraction> shares of Series A Preferred Stock to former <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre security holders. In addition, outstanding and unexercised stock options to purchase <ix:nonFraction name="syre:OutstandingAndUnexercisedStockOptions" contextRef="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20410">2,734</ix:nonFraction> shares of common stock were assumed from the Amended and Restated Spyre 2023 Equity Incentive Plan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-26</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103883857" continuedAt="TextSelectionAppend_103883857_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103883857_1" continuedAt="TextSelectionAppend_103883857_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103883857_2" continuedAt="TextSelectionAppend_103883857_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103883857_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the acquisition date, the Company recorded forward contracts to represent the obligation to issue shares of the Company&#8217;s Common Stock and shares of Series A Preferred Stock. The forward contract related to the Common Stock was recorded as Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital as the instrument is indexed to the Company&#8217;s Common Stock. The forward contract related to the Series A Preferred Stock was recorded as a liability, as the underlying stock has a cash redemption feature. On July&#160;7, 2023, both the shares of Common Stock and Series A Preferred Stock were issued and the forward contract liability associated with the Series A Preferred Stock was settled accordingly. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the Option to exclusively license IPR&amp;D. The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing the entire portfolio of individual treatments to create combination treatments that simultaneously address different mechanisms of irritable bowel disease with a single treatment. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20431">113.2</ix:nonFraction>&#160;million which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20432">364,887</ix:nonFraction> shares of Series A Preferred Stock (<ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20433">14,595,480</ix:nonFraction> shares of Common Stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20435">517,809</ix:nonFraction> shares of Common Stock, valued at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-20436">291.08</ix:nonFraction> per share and $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-20437">7.277</ix:nonFraction> per share, respectively. </div><ix:nonNumeric name="us-gaap:AssetAcquisitionTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20438"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20462">110.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by the Company</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20470">3.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20486">113.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20520">130.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20528">3.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:AssumedLiabilities" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20536">20.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20552">113.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="syre:OptionAgreementTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103883037" id="ixv-20562"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Paragon Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2023, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre entered into the Paragon Agreement with Paragon and Parapyre. Pursuant to the Paragon Agreement, the Option provided for the right to acquire the intellectual property rights related to four research programs from Paragon in accordance with a license agreement to be entered into following each exercise of the Option. Under the Paragon Agreement, the terms of such license agreement would be consistent with the economics and other terms set out in the Paragon Agreement and, in the event of failure to reach an agreement on the definitive terms, the matter would be resolved via arbitration. In consideration for the Option granted under the Paragon Agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was obligated to pay Paragon an upfront cash amount of&#8201;$<ix:nonFraction name="syre:ResearchInitiationFees" contextRef="P05_01_2023To05_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20568">3.0</ix:nonFraction>&#160;million in research initiation fees. In addition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-27</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103883037" continuedAt="TextSelectionAppend_103883037_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103883037_1" continuedAt="TextSelectionAppend_103883037_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103883037_2" continuedAt="TextSelectionAppend_103883037_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103883037_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre had incurred total expenses of $<ix:nonFraction name="syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20592">19.0</ix:nonFraction>&#160;million under the Paragon Agreement since inception, which included the $<ix:nonFraction name="syre:ResearchInitiationFees" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20593">3.0</ix:nonFraction>&#160;million research initiation fee and $<ix:nonFraction name="syre:ReimbursableResearchCosts" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20594">16.0</ix:nonFraction>&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $<ix:nonFraction name="syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition" contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20595">19.0</ix:nonFraction>&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. Furthermore, the Paragon Agreement provided for an annual equity grant of options to purchase <ix:nonFraction name="syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-20596">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year, during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Asset Acquisition, the Company assumed the rights and obligations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre under the Paragon Agreement, including the Parapyre Option Obligation. Pursuant to the Paragon Agreement, on a research <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">program-by-research</div></div> program basis following the finalization of the research plan for each respective research program, the Company is required to pay Paragon a nonrefundable fee in cash of $<ix:nonFraction name="syre:NonrefundableResearchInitiationFeeForOneProgramPaidInCash" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20601">0.8</ix:nonFraction>&#160;million. For the year ended December&#160;31, 2023, the Company incurred $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2023To12_31_2023_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20602">48.5</ix:nonFraction>&#160;million, in costs reimbursable to Paragon, which were recorded as Research and development expenses in the consolidated statements of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company made payments totaling $<ix:nonFraction name="syre:LicenseAgreementMilestonePayments" contextRef="P01_01_2023To12_31_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20604">39.5</ix:nonFraction>&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;12, 2023 and December&#160;14, 2023, the Company exercised the Option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expects to enter into the SPY001 License Agreement and the SPY002 License Agreement. Our Option available under the Paragon Agreement with respect to the SPY003 and SPY004 programs remains unexercised. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, the Company will be obligated to pay Paragon up to $<ix:nonFraction name="syre:AmountToBePaidUnderAgreement" contextRef="PAsOn12_14_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20607">22.0</ix:nonFraction>&#160;million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, the Company expects to pay Paragon a $<ix:nonFraction name="syre:NominationFee" contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20608">1.5</ix:nonFraction>&#160;million fee for nomination of a development candidate, as applicable, and the Company expects to be obligated to make a further milestone payment of&#8201;$<ix:nonFraction name="syre:PaymentOfMilestone" contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20609">2.5</ix:nonFraction>&#160;million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY003 or SPY004 research programs, the Company expects to be obligated to make similar payments upon and following the execution of license agreements with respect to these research programs, respectively. </div></ix:continuation><ix:nonNumeric name="us-gaap:LesseeFinanceLeasesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882530" id="ixv-20610"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Company&#8217;s restructuring, as described in Note 17, the Company leased certain office space, laboratory facilities, and equipment. These leases required monthly lease payments that were subject to annual increases throughout the lease term. Certain of these leases also included renewal options at the election of the Company to renew or extend the lease for an additional <div style="-sec-ix-hidden:hidden103884648;display:inline;">three</div> to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-20615">five years</ix:nonNumeric>. These optional periods were not considered in the determination of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has both operating and finance leases. Variable lease expense for these leases primarily consisted of common area maintenance and other operating costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, the Company entered into a lease agreement (the &#8220;Las Cimas Lease&#8221;) for its corporate headquarters and laboratory space located in Austin, Texas. The Las Cimas Lease included approximately <ix:nonFraction name="us-gaap:AreaOfLand" contextRef="PAsOn04_30_2019" unitRef="Unit_sqft" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-20619">30,000</ix:nonFraction> square feet and commenced on April&#160;30, 2019, with an expiration on April&#160;30, 2028. The Company posted a customary letter of credit in the amount of $<ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="PAsOn04_30_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20620">1.5</ix:nonFraction>&#160;million as security, which is subject to automatic reductions per the terms of the Las Cimas Lease. A tenant allowance of up to $<ix:nonFraction name="us-gaap:TenantImprovements" contextRef="PAsOn04_30_2019_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20621">1.0</ix:nonFraction>&#160;million was provided by the lessor and fully reimbursed to the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $<ix:nonFraction name="syre:OperatingLeaseTerminationFeeAmount" contextRef="PAsOn08_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-20623">2.0</ix:nonFraction>&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease including terminating the associated letter of credit. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-28</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882530" continuedAt="TextSelectionAppend_103882530_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882530_1" continuedAt="TextSelectionAppend_103882530_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882530_2" continuedAt="TextSelectionAppend_103882530_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882530_3"><ix:nonNumeric name="syre:AssetsAndLiabilitiesLesseeTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20640"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s recognition of its operating and finance leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:31%"/>
<td style="vertical-align:bottom;width:3%"/>
<td style="width:52%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-20705">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20710">3,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="-sec-ix-hidden:hidden103884638;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-20722">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20727">597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total leased assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:OperatingAndFinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-20751">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:OperatingAndFinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20756">4,027</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-20809">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20814">625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="-sec-ix-hidden:hidden103884635;display:inline;">Accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-20825">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20830">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-20855">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20860">4,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:OperatingAndFinanceLeaseLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-20884">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:OperatingAndFinanceLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-20889">4,645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20907"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating and finance leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-20957">0.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear" id="ixv-20962">5.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-20970">0.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear" id="ixv-20975">0.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero" id="ixv-20994">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-20999">10.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero" id="ixv-21007">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21012">10.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the lease costs pertaining to the Company&#8217;s operating leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21061">455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21066">910</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21071">991</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21079">471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21084">472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21089">519</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21117">926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21122">1,382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21127">1,510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21150">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21151">0.9</ix:nonFraction>&#160;million, respectively, and was included within net cash used in operating activities in the cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had no operating or finance lease obligations. </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103881902" id="ixv-21153"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Convertible Preferred Stock and Stockholders&#8217; Equity </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue <ix:nonFraction name="syre:SharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21157">410,000,000</ix:nonFraction> shares of capital stock of which <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21158">400,000,000</ix:nonFraction> shares are designated as Common Stock and <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21159">10,000,000</ix:nonFraction> shares are designated as preferred stock, all with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21160">0.0001</ix:nonFraction> per share. Each holder of Common Stock is entitled to <ix:nonFraction name="syre:NumberOfCommonStockVotingRightsHeldPerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-21161">one</ix:nonFraction> vote for each share of Common Stock held. The Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-29</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_103881902" continuedAt="TextSelectionAppend_103881902_1"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_103881902_1" continuedAt="TextSelectionAppend_103881902_2"><div><div style="line-height:normal;background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103881902_2" continuedAt="TextSelectionAppend_103881902_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Common Stock are entitled to receive dividends out of funds legally available if the board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that the board of directors may determine. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, <ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21186">no</ix:nonFraction> Common Stock dividends had been declared by the board of directors. As of December&#160;31, 2023 there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21187">437,037</ix:nonFraction> shares of Series A preferred stock and <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21188">150,000</ix:nonFraction> shares of Series B preferred stock outstanding. There were no shares of Series A preferred stock or shares of Series B preferred stock outstanding as of December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registered Direct Offering </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued and sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21194">430,107</ix:nonFraction> shares of Common Stock at an offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21195">40.00</ix:nonFraction> per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn05_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21197">694,892</ix:nonFraction> shares of Common Stock at an offering price of $<ix:nonFraction name="syre:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21198">39.9975</ix:nonFraction> per warrant (representing the price per share of Common Stock sold in the offering minus the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21199">0.0025</ix:nonFraction> exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> The net proceeds to the Company from this offering were approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21201">42.9</ix:nonFraction>&#160;million, after deducting placement agent fees and offering costs of $<ix:nonFraction name="syre:PlacementAgentFeesAndOfferingCosts" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21202">2.1</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">June 2023 PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2023, in connection with the Asset Acquisition, the Company issued and sold <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21208">721,452</ix:nonFraction> shares of Series A Preferred Stock at approximately $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21209">291.08</ix:nonFraction> per share through a private placement to a group of accredited investors. The net proceeds from this offering were approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21210">197.3</ix:nonFraction>&#160;million, after deducting placement agent fees and offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21211">12.7</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December 2023 PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the Company issued and sold <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21217">6,000,000</ix:nonFraction> shares of Common Stock at an offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21218">15.00</ix:nonFraction> per share and <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21219">150,000</ix:nonFraction> shares of Series B Preferred Stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21220">600</ix:nonFraction> per share through a private placement to a group of accredited investors. The net proceeds from this offering were approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21221">169.1</ix:nonFraction>&#160;million, after deducting placement agent fees and offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21222">10.9</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Warrants </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company settled its 2023 obligations under the Parapyre Option Obligation by issuing Parapyre <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_ParapyreWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21228">684,407</ix:nonFraction> warrants to purchase the Company&#8217;s common stock, less the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_ParapyreWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21229">21.52</ix:nonFraction> per share exercise price of each warrant. As of December&#160;31, 2023, none of the warrants issued under the Parapyre Option Obligation have been exercised. See Note 15 for additional information on the Parapyre Option Obligation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase shares of Common Stock in underwritten public offerings at the offering price of the Common Stock, less the $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21237">0.0025</ix:nonFraction> per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#8217; equity within additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of Common Stock may not be exercised if the holder&#8217;s ownership of the Common Stock would exceed <ix:nonFraction name="syre:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21239">4.99</ix:nonFraction>% (&#8220;Maximum Ownership Percentage&#8221;) or <ix:nonFraction name="syre:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21240">9.99</ix:nonFraction>% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of <ix:nonFraction name="syre:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" contextRef="P05_01_2022To05_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21241">19.99</ix:nonFraction>% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective <ix:nonNumeric name="syre:ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" contextRef="P05_01_2022To05_31_2022" format="ixt-sec:durday" id="ixv-21242">61</ix:nonNumeric> days after the notice is received by the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-30</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103881902_3" continuedAt="TextSelectionAppend_103881902_4"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103881902_4" continuedAt="TextSelectionAppend_103881902_5"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103881902_5" continuedAt="TextSelectionAppend_103881902_6"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103881902_6" continuedAt="TextSelectionAppend_103881902_7"><ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21259"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase Common Stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:45%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Warrants<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_PreFundedMay2022WarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21308">0.0025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_PreFundedMay2022WarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21313">250,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21346">250,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Asset Acquisition and the PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Designation, holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to-Common</div></div></div></div> Stock basis, and in the same form as, dividends actually paid on shares of Common Stock. Except as provided in the Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules (the &#8220;Conversion Proposal&#8221;) or at any time while at least <ix:nonFraction name="syre:PreferredStockRemainsIssuedAndOutstandingPercentage" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21375">30</ix:nonFraction>% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company held a stockholders&#8217; meeting to submit the following matters to its stockholders for their consideration: (i)&#160;the approval of the Conversion Proposal, and (ii)&#160;if deemed necessary or appropriate by the Company or as otherwise required by law or contract, the approval of an amendment to the Certificate of Incorporation to authorize sufficient shares of Common Stock for the conversion of the Series A Preferred Stock issued pursuant to the Acquisition Agreement. In connection with these matters, the Company filed with the SEC a definitive proxy statement and other relevant materials. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock automatically converted into <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21379">40</ix:nonFraction> shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between <ix:nonFraction name="syre:BeneficiallyHoldersOwnedPercentage" contextRef="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21380">0.0</ix:nonFraction>% and <ix:nonFraction name="syre:BeneficiallyHoldersOwnedPercentage" contextRef="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-21381">20.0</ix:nonFraction>%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </div></ix:continuation><ix:continuation id="TextSelectionAppend_103881902_7" continuedAt="TextSelectionAppend_103881902_8"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-31 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103881902_8" continuedAt="TextSelectionAppend_103881902_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103881902_9" continuedAt="TextSelectionAppend_103881902_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103881902_10" continuedAt="TextSelectionAppend_103881902_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103881902_11" continuedAt="TextSelectionAppend_103881902_12"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;26, 2023, the Company completed a private placement of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21403">721,452</ix:nonFraction> shares of Series A PIPE Securities in exchange for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21404">210.0</ix:nonFraction>&#160;million, or net proceeds of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21405">197.3</ix:nonFraction>&#160;million, after deducting placement agent and other offering costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P07_07_2023To07_07_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21407">364,887</ix:nonFraction> shares of Series A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition that closed on June&#160;22, 2023 which settled the related forward contract liability. For additional information, see Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2023, the Company&#8217;s stockholders approved the Conversion Proposal, among other matters, at a special meeting of stockholders. As a result of the approval of the Conversion Proposal, all conditions that could have required cash redemption of the Series A Preferred Stock were satisfied. Since the Series A Preferred Stock is no longer redeemable, the associated balances of the Series A Preferred Stock were reclassified from mezzanine equity to permanent equity during the fourth quarter of 2023. In addition, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P10_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-21409">649,302</ix:nonFraction> shares of Series A Preferred Stock automatically converted to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P10_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21410">25,972,080</ix:nonFraction> shares of Common Stock; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21411">437,037</ix:nonFraction> shares of Series A Preferred Stock did not automatically convert and remain outstanding as of December&#160;31, 2023 due to beneficial ownership limitations. This conversion was recorded as a reclassification between Series A Preferred Stock and Common Stock based on the historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> contributed capital amount, inclusive of any forward-contract valuation adjustments, of the Series A Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;8, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock with the Secretary of State of the State of Delaware (the &#8220;Series B Certificate of Designation&#8221;) in connection with the December 2023 PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Series B Certificate of Designation, holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to-Common</div></div></div></div> Stock basis, and in the same form as, dividends actually paid on shares of Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed to use its best efforts to obtain stockholder approval of the conversion of all issued and outstanding Series B Preferred Stock into shares of Common Stock in accordance with the Nasdaq Stock Market Rules (the &#8220;Series B Conversion Proposal&#8221;) at its 2024 annual meeting of stockholders, which the Company agreed to hold no later than May&#160;15, 2024. The Series B Preferred Stock is recorded outside of stockholders&#8217; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock per share of Common Stock underlying the Series B Preferred Stock, on the last trading day prior to the holder&#8217;s redemption request. As of December&#160;31, 2023, the redemption value of the Company&#8217;s outstanding Series B Preferred Stock was $<ix:nonFraction name="us-gaap:PreferredStockRedemptionAmount" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21427">129.1</ix:nonFraction>&#160;million based on the closing stock price of the Company&#8217;s Common Stock on December&#160;31, 2023 of $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21428">21.52</ix:nonFraction> per share. The Company has determined that the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-32</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103881902_12" continuedAt="TextSelectionAppend_103881902_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103881902_13" continuedAt="TextSelectionAppend_103881902_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103881902_14" continuedAt="TextSelectionAppend_103881902_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103881902_15"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Series B Conversion Proposal, each share of Series B Preferred Stock will automatically convert into <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn12_08_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21446">40</ix:nonFraction> shares of the Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between <ix:nonFraction name="syre:BeneficiallyHoldersOwnedPercentage" contextRef="P12_08_2023To12_08_2023_MinimumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21447">0</ix:nonFraction>% and <ix:nonFraction name="syre:BeneficiallyHoldersOwnedPercentage" contextRef="P12_08_2023To12_08_2023_MaximumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-21448">19.99</ix:nonFraction>%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, as part of the December 2023 PIPE, the Company completed a private placement of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21450">150,000</ix:nonFraction> shares of Series B Preferred Stock in exchange for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21451">90.0</ix:nonFraction>&#160;million. </div></ix:continuation><ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882327" id="ixv-21452"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Strategic License Agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immedica Pharma AB License and Development Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2021, the Company entered into an exclusive license and supply agreement with Immedica Pharma AB (&#8220;Immedica&#8221;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Deliver an exclusive, sublicensable, license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (the &#8220;License&#8221;) to develop and commercialize pegzilarginase (the &#8220;Product&#8221;) in the territory comprising the members states of the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#8220;Territory&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#8220;PEACE Trial&#8221;) and related Biologics License Application (&#8220;BLA&#8221;) package to file with the United States Food and Drug Administration (&#8220;FDA&#8221;), which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">iii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Perform a Pediatric Investigation Plan trial (&#8220;PIP Trial&#8221;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company and Immedica formed a Joint Steering Committee (&#8220;JSC&#8221;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#8217;s participation in the JSC does not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement do not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Finally, Immedica will bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#8217;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Phase 3 Trial and BLA package performance obligation in exchange for the reimbursement of up to $<ix:nonFraction name="us-gaap:ReimbursementFromLimitedPartnershipInvestment" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21484">3.0</ix:nonFraction>&#160;million of the actual costs incurred in relation to such incremental services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payment of $<ix:nonFraction name="syre:NonRefundablePaymentReceived" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21487">21.5</ix:nonFraction>&#160;million and Immedica agreed to provide payment of <ix:nonFraction name="syre:PercentageOfPaymentForCostIncurredInPIPTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21488">50</ix:nonFraction>% of the Company&#8217;s costs incurred in performing the PIP Trial up to a maximum of $<ix:nonFraction name="syre:CostsIncurredInPerformingTheTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21489">1.8</ix:nonFraction>&#160;million. In addition, the Company has the ability to receive additional payments under the agreement of up to approximately $<ix:nonFraction name="syre:AdditionalUpfrontPaymentAbilityToReceived" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21490">120.8</ix:nonFraction>&#160;million in regulatory and commercial milestone payments, assuming an exchange rate of $<ix:nonFraction name="syre:MilestonePaymentsExchangeRate" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21491">1.07</ix:nonFraction> to &#8364;1.00. The Company is also entitled to receive royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-20&#160;percent</div> range on net sales of the Product in the Territory. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-33</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882327" continuedAt="TextSelectionAppend_103882327_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882327_1" continuedAt="TextSelectionAppend_103882327_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882327_2" continuedAt="TextSelectionAppend_103882327_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882327_3" continuedAt="TextSelectionAppend_103882327_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that Immedica meets the definition to be accounted for as a customer because the Company is delivering intellectual property and other services within the Company&#8217;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in making these determinations, the Company considered the following factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and were conducting the ongoing PEACE Trial. Accordingly, the Company is not promising, nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The License represents functional intellectual property given the functionality of the License is not expected to change substantially as a result of the company&#8217;s ongoing activities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The services necessary to complete the PEACE Trial, BLA package and PIP Trial could be performed by other parties. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that Immedica was not obligated to purchase any minimum amount or quantities of the Product, the supply of the Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#8217;s option to purchase the Product does not create a material right as the expected pricing is not at a discount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the upfront fixed payment amount of $<ix:nonFraction name="syre:UpfrontPayment" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21540">21.5</ix:nonFraction>&#160;million must be included in the transaction price. Additionally, the Company determined at inception of the arrangement that <ix:nonFraction name="syre:PercentageOfPaymentForCostIncurredInPIPTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21541">50</ix:nonFraction>% of the estimated costs to be incurred in relation to the PIP Trial exceeded $<ix:nonFraction name="syre:CostsIncurredInPerformingTheTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21542">1.8</ix:nonFraction>&#160;million and included the full reimbursement amount of $<ix:nonFraction name="syre:CostsIncurredInPerformingTheTrial" contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21543">1.8</ix:nonFraction>&#160;million in the transaction price. Upon subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluation</div> due to changing facts and circumstances, the Company determined the estimated costs are now less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized to date. Additionally, upon the modification of the agreement in July 2021, the Company determined that the estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeds the maximum allowable reimbursement of $<ix:nonFraction name="us-gaap:ReimbursementFromLimitedPartnershipInvestment" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21545">3.0</ix:nonFraction>&#160;million. Therefore, the Company included an estimated total of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21546">3.6</ix:nonFraction>&#160;million that will be due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21547">25.1</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has allocated $<ix:nonFraction name="syre:AllocatedAmountOfTransactionPrice" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21549">9.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="syre:AllocatedAmountOfTransactionPrice" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21550">3.5</ix:nonFraction>&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#8220;SSP&#8221;), which was based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $<ix:nonFraction name="syre:AllocationPriceTotal" contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21551">12.0</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain regulatory approvals, which might not be achieved. The Company determined that the royalties and commercial milestone payments relate predominantly to the license of intellectual property and are therefore excluded from the transaction price under the sales-&#8201;or usage-based royalty exception of ASC 606. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price as necessary. The Company </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-34</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882327_4" continuedAt="TextSelectionAppend_103882327_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882327_5" continuedAt="TextSelectionAppend_103882327_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882327_6" continuedAt="TextSelectionAppend_103882327_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882327_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">will recognize the royalties and commercial milestone payments as revenue when the associated sales occur, and relevant sales-based thresholds are met. The Company assessed the arrangement with Immedica and concluded that a significant financing component does not exist. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> necessary for Immedica to benefit from the License in June 2021 and recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21572">12.0</ix:nonFraction>&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations will be recognized over time using an input method of costs incurred related to the performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2023 and 2022, the Company recognized revenue of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21574">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21575">2.3</ix:nonFraction>&#160;million, respectively, related to the PEACE Trial and BLA package performance obligation using a cost to cost model. The Company recognized revenue of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21576">6.7</ix:nonFraction>&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model and $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21577">12.0</ix:nonFraction>&#160;million related to the transfer of the License for the year ended December&#160;31, 2021. As of December&#160;31, 2022, the Company recorded deferred revenue of $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21578">2.7</ix:nonFraction>&#160;million associated with the license and supply agreement with Immedica, of which $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21579">0.5</ix:nonFraction>&#160;million was classified as current. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica for $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21581">15.0</ix:nonFraction>&#160;million in upfront cash proceeds and up to $<ix:nonFraction name="syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21582">100.0</ix:nonFraction>&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was <ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-21583">zero</ix:nonFraction> as it was internally developed. Accordingly, the Company recognized a $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21584">16.4</ix:nonFraction>&#160;million gain within Gain on Sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which is comprised of $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21586">15.0</ix:nonFraction>&#160;million in upfront cash proceeds and the reimbursement of $<ix:nonFraction name="syre:PrepaidExpenseValueOfExpectedRecoveries" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21587">1.8</ix:nonFraction>&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> manufacturing costs that was contingent upon a favorable opinion being received by the CHMP, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities totaling $<ix:nonFraction name="syre:DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21589">0.4</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will reduce the CVR liability and will be distributed to CVR holders pursuant to the CVR Agreement resulting from the Asset Acquisition. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Contract Balances from Customer Contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div><ix:nonNumeric name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21594"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21667">2,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:ContractWithCustomerLiabilityAdditions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-21672">575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-21677">3,271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-21682">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had <ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21685"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21686">no</ix:nonFraction></ix:nonFraction> contract assets during the years ended December&#160;31, 2023 and 2022. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-35 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21698"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">&#160;</div><div style="font-weight:bold;display:inline;">13. Sale of Pegzilarginase to Immedica </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica for $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21704">15.0</ix:nonFraction>&#160;million in upfront cash proceeds and up to $<ix:nonFraction name="syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21705">100.0</ix:nonFraction>&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was <ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-21706">zero</ix:nonFraction> as it was internally developed. Accordingly the Company recognized a $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21707">16.4</ix:nonFraction>&#160;million gain within Gain on sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which is comprised of $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21709">15.0</ix:nonFraction>&#160;million in upfront cash proceeds and the reimbursement of $<ix:nonFraction name="syre:PrepaidExpenseValueOfExpectedRecoveries" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21710">1.8</ix:nonFraction>&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> manufacturing costs that was contingent upon a favorable opinion being received by the Committee for Medicinal Products for Human Use, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities totaling $<ix:nonFraction name="syre:DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21712">0.4</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. Accordingly, the Company will recognize any future milestone payments once the contingency is resolved and payment is contractually required. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to CVR holders pursuant to the CVR Agreement resulting from the Asset Acquisition. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882411" id="ixv-21714"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Novation of Manufacturing Agreements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#8220;Novation Agreement&#8221;), by and between the Company, Paragon and WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), the Company novated (i)&#160;a Biologics Master Services Agreement (the &#8220;WuXi Biologics MSA&#8221;) and (ii)&#160;a Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;). </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Biologics Master Services Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to the Company by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, the Company is obligated to pay WuXi Biologics a service fee and all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> obligations in the amount specified in each work order associated with the agreement for the provision of services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. The Company can terminate the WuXi Biologics MSA or any work order at any time upon <ix:nonNumeric name="syre:OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durmonth" id="ixv-21725">30</ix:nonNumeric> days&#8217; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon <ix:nonNumeric name="syre:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durwordsen" id="ixv-21726">six months</ix:nonNumeric> prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, <ix:nonFraction name="syre:OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-21727">no</ix:nonFraction> termination or cancellation fees shall be paid by the Company and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for <ix:nonNumeric name="syre:OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday" id="ixv-21728">30</ix:nonNumeric> days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least <ix:nonNumeric name="syre:OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday" id="ixv-21729">90</ix:nonNumeric> days. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cell Line License Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to the Company by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, the Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable license to certain of WuXi Biologics&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-36</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882411" continuedAt="TextSelectionAppend_103882411_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882411_1" continuedAt="TextSelectionAppend_103882411_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882411_2" continuedAt="TextSelectionAppend_103882411_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882411_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the license, the Company agreed to pay WuXi Biologics a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> license fee of $<ix:nonFraction name="syre:OtherCommitmentNonRefundableLicenseFeeAmount" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21756">0.2</ix:nonFraction>&#160;million. Additionally, if the Company manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics of less than <div style="-sec-ix-hidden:hidden103884640;display:inline;">one</div> percent of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by the Company upon <ix:nonNumeric name="syre:OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durwordsen" id="ixv-21759">six months</ix:nonNumeric> prior written notice and our payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii)&#160;by WuXi Biologics for a material breach by the Company that remains uncured for <ix:nonNumeric name="syre:OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday" id="ixv-21760">60</ix:nonNumeric> days after written notice, (iii)&#160;by WuXi Biologics if the Company fails to make a payment and such failure continues for <ix:nonNumeric name="syre:OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" contextRef="P04_01_2023To04_30_2023" format="ixt-sec:durday" id="ixv-21761">30</ix:nonNumeric> days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy. </div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882314" id="ixv-21762"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Stock-Based Compensation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2015 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, the Company adopted the 2015 Equity Incentive Plan (&#8220;2015 Plan&#8221;), administered by the board of directors, and provides for the Company to sell or issue share of Common Stock or restricted Common Stock, or to grant incentive stock options or nonqualified stock options for the purchase of Common Stock, to employees, members of the board of directors and consultants of the Company. Under the terms of the 2015 Plan, the exercise prices, vesting and other restrictions may be determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21770">100</ix:nonFraction>% of the fair market value of the share of common stock on the date of grant, the term of stock options may not be greater than <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P03_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-21771">ten years</ix:nonNumeric> for all grants, and for grantees holding more than <ix:nonFraction name="syre:GranteesWithMoreThanFiveYearsVestingTermPercent" contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21772">10</ix:nonFraction>% of the total combined voting power of all classes of stock, the term may not be greater than <ix:nonNumeric name="syre:MaximumVestingTermForMoreThanTenPercentGrantees" contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-21773">five years</ix:nonNumeric>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted options under the 2015 Plan until April 2016 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="P01_01_2023To12_31_2023_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21776">3,029</ix:nonFraction> shares of Common Stock are subject to options outstanding under the 2015 Plan and will become available under the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) to the extent the options are forfeited or lapse unexercised. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Plan became effective in April 2016 and serves as the successor to the 2015 Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan provides for an initial reserve of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21782">44,000</ix:nonFraction> shares of Common Stock, plus <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21783">20,395</ix:nonFraction> shares of Common Stock remaining under the 2015 Plan, and any share awards that subsequently are forfeited or lapse unexercised under the 2015 Plan. The shares reserved exclude shares of Common Stock reserved for issuance under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the 2016 Plan was amended to increase the number of shares of Common Stock reserved for issuance thereunder by <ix:nonFraction name="syre:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21785">70,384</ix:nonFraction> shares, extend the term of the 2016 Plan through August&#160;7, 2028, and provide for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-37</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882314" continuedAt="TextSelectionAppend_103882314_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_1" continuedAt="TextSelectionAppend_103882314_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_2" continuedAt="TextSelectionAppend_103882314_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882314_3" continuedAt="TextSelectionAppend_103882314_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>the remaining term of the plan equal to (a) <ix:nonFraction name="syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-21807">4.0</ix:nonFraction>% of the number of issued and outstanding shares of Common Stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board each year (the &#8220;Evergreen Provision&#8221;). As a result of the operation of each of these provisions, on January&#160;1, 2023, 2022, and 2021, an additional <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21808">104,561</ix:nonFraction>, <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21809">78,968</ix:nonFraction>, and <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21810">76,735</ix:nonFraction> shares, respectively, became available for issuance under the 2016 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the 2016 Plan was amended to (i)&#160;increase the number of shares of Common Stock reserved for issuance thereunder by <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P11_01_2023To11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21812">4,481,152</ix:nonFraction> shares, (ii)&#160;revise the annual limit on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director compensation from <ix:nonFraction name="syre:ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21814">4,000</ix:nonFraction> shares to (a) $<ix:nonFraction name="syre:ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" contextRef="PAsOn11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21815">750,000</ix:nonFraction> in total value or (b) $<ix:nonFraction name="syre:ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" contextRef="PAsOn11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21816">1,000,000</ix:nonFraction> in the year of the director&#8217;s initial service as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director or in any year a director serves as chairman of the Board of Directors, in either case, applicable to fees paid in both cash and equity, (iii)&#160;remove the fixed termination date of the 2016 Plan and, (iv)&#160;revise the Evergreen Provision from <ix:nonFraction name="syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21818">4</ix:nonFraction>% to <ix:nonFraction name="syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" contextRef="P11_01_2023To11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21819">5</ix:nonFraction>% of issued and outstanding shares of Common Stock on December&#160;31 of the preceding calendar year and to include shares issuable upon the exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants and the conversion of outstanding shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in the calculation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the total number of shares reserved for issuance under the 2016 Plan was <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21823">5,019,177</ix:nonFraction>, of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21824">3,294,962</ix:nonFraction> shares were subject to outstanding option awards and restricted unit awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Equity Inducement Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the board of directors approved and adopted the 2018 Equity Inducement Plan (&#8220;2018 Plan&#8221;), which became effective on the same date. The board of directors approved an initial reserve of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21830">44,000</ix:nonFraction> shares of Common Stock to be used exclusively for individuals who were not previously employees or directors, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employment,</div> as an inducement material to the individual entering into employment with the Company. Nonqualified stock options or restricted stock units may be granted under the 2018 Plan at the discretion of the Compensation Committee or the board of directors. The Company did not seek stockholder approval of the 2018 Plan pursuant to Nasdaq Rule 5635(c)(4). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2023, the 2018 Plan was amended to increase the number of shares of Common Stock reserved for issuance by <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P01_01_2023To12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-21833">6,000,000</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions (&#8220;service-based&#8221; awards), performance conditions (&#8220;performance-based&#8221; awards), and market conditions (&#8220;market-based&#8221; awards). Service-based awards granted under the 2018 Plan, 2016 Plan, and 2015 Plan generally vest over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-21835">four years</ix:nonNumeric> and expire after <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-21836">ten years</ix:nonNumeric>, although awards have been granted with vesting terms less than <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-21837">four years</ix:nonNumeric>. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21839">153,865</ix:nonFraction> service-based restricted stock units (&#8220;RSUs&#8221;) during the year ended December&#160;31, 2023 to certain employees under the 2018 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the total number of shares reserved for issuance under the 2018 Plan was <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21841">6,044,000</ix:nonFraction>, of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21842">5,350,595</ix:nonFraction> shares were subject to outstanding awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Spyre 2023 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Spyre Equity Plan&#8221;) and its outstanding and unexercised stock options, which were converted to options to purchase 2,734 shares of Common Stock. The acquisition-date fair value of these grants will be recognized as an expense on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> basis over the vesting period. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-38</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882314_4" continuedAt="TextSelectionAppend_103882314_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_5" continuedAt="TextSelectionAppend_103882314_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_6" continuedAt="TextSelectionAppend_103882314_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882314_7" continuedAt="TextSelectionAppend_103882314_8"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of warrants for Parapyre to purchase <ix:nonFraction name="syre:ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-21870">1</ix:nonFraction>% of the then outstanding shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of warrants is based on the outstanding shares of the Company&#8217;s Common Stock, (ii)&#160;establishing the grant date as the last business day of 2023 and 2024, and (iii)&#160;defining the term of the warrants granted as <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_09_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen" id="ixv-21874">ten years</ix:nonNumeric>. The Company determined that the 2023 and 2024 grants are two separate grants, as there would be no obligation for the 2024 grant had the Company exercised or terminated all of the options under the Paragon Agreement prior to December&#160;31, 2023. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, a liability related to the Parapyre Option Obligation was recorded pursuant to the amended Paragon Agreement during 2023 interim periods. The Company determined that the grant date of the award was December&#160;31, 2023, as all terms of the award, including number of shares and exercise price, were known by all parties. Accordingly, the Company measured the grant-date fair value of the warrants granted at approximately $<ix:nonFraction name="syre:ClassOfWarrantOrRightGrantDateFairValue" contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21875">11.5</ix:nonFraction>&#160;million as an equity-classified award, of which $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21876">0.1</ix:nonFraction>&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition on June&#160;22, 2023. For the year ended December&#160;31, 2023, $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-21877">11.4</ix:nonFraction>&#160;million was recognized as stock compensation expense related to the Parapyre Option Obligation. There was <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21878"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21879">no</ix:nonFraction></ix:nonFraction> similar expense for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the unamortized expense related to the Parapyre Option Obligation was <ix:nonFraction name="syre:ClassOfWarrantOrRightUnamortizedExpense" contextRef="PAsOn12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-21881">nil</ix:nonFraction>. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21882"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option activity for the year ended December&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Under</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-21988">405,082</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-21993">113.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear" id="ixv-21998">6.72</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22003">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22011">8,776,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22016">9.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22032">46,246</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22037">8.22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22053">637,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22058">43.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22095">8,497,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22100">12.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-22105">8.40</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22110">98,928</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options vested and expected to vest as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22139">8,497,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22144">12.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-22149">8.40</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22154">98,928</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options exercisable as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22183">1,065,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22188">24.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-22193">5.62</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22198">13,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s Common Stock as of the reporting date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2023, 2022, and 2021, the weighted-average grant date fair value of options granted was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22222">9.67</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22223">1.80</ix:nonFraction>, and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22224">4.96</ix:nonFraction>, per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2023, and 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22225">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22226">0.7</ix:nonFraction>&#160;million, respectively. <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-22227">No</ix:nonFraction> options were exercised in the year ended December&#160;31, 2022. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-39</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882314_8" continuedAt="TextSelectionAppend_103882314_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_9" continuedAt="TextSelectionAppend_103882314_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_10" continuedAt="TextSelectionAppend_103882314_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882314_11" continuedAt="TextSelectionAppend_103882314_12"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22248">477,000</ix:nonFraction> stock options issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2023. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22250"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22251">no</ix:nonFraction></ix:nonFraction> stock options issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2022 and 2021. For the years ended December&#160;31, 2023, 2022 and 2021, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22253"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22254"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22255">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options vested in the period. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Employee Stock Purchase Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;) became effective in April 2016. A total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22262">6,600</ix:nonFraction> shares of Common Stock <div style="letter-spacing: 0px; top: 0px;;display:inline;">were </div>reserved for issuance under the 2016 ESPP. Eligible employees may purchase shares of Common Stock under the 2016 ESPP at <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22264">85</ix:nonFraction>% of the lower of the fair market value of the Common Stock as of the first or the last day of each offering period. Employees are limited to contributing <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22265">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22266">25,000</ix:nonFraction> of stock during any calendar year. The 2016 ESPP will terminate <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-22267">ten years</ix:nonNumeric> from the first purchase date under the plan, unless terminated earlier by the board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the 2016 ESPP was amended to provide for an automatic annual increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the year equal to (a) <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" contextRef="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22269">1.0</ix:nonFraction>% of the number of issued and outstanding shares of Common Stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board of directors each year. As a result of the operation of this provision, on January&#160;1, 2023, 2022 and 2021, an additional <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22270">26,140</ix:nonFraction>, <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22271">19,742</ix:nonFraction>, and <ix:nonFraction name="syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" contextRef="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22272">19,184</ix:nonFraction> shares, respectively, became available for issuance under the 2016 ESPP. As of December&#160;31, 2023, the reserve remaining and available for future issuance under the 2016 ESPP was <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22273">72,404</ix:nonFraction> shares. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023, the 2016 ESPP was amended to increase the maximum shares purchased during any one period from <ix:nonFraction name="syre:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22275">80</ix:nonFraction> shares to <ix:nonFraction name="syre:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" contextRef="P02_01_2023To02_28_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22276">400</ix:nonFraction> shares or a lesser amount determined by the board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, stock-based compensation expense related to the 2016 ESPP plan was di minimis. For the years ended 2022 and 2021, stock-based compensation expense related to the 2016 ESPP plan was $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22278">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22279">0.2</ix:nonFraction>&#160;million, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Common Stock Units </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2020, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22285">9,128</ix:nonFraction> restricted stock units to certain employees, with vesting terms subject to regulatory, commercial, and clinical milestones, in addition to a service condition. As of December&#160;31, 2023 <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22286">none</ix:nonFraction> of these restricted stock units had vested and all restricted stock units were forfeited since the performance milestones were not met within the required time frame. <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22287">No</ix:nonFraction> stock-based compensation expense was recognized on these awards. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22289">153,865</ix:nonFraction> service-based restricted stock units during the year ended December&#160;31, 2023. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22290"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22291">no</ix:nonFraction></ix:nonFraction> restricted stock units granted during the years ended December&#160;31, 2022 and 2021. </div><ix:nonNumeric name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-22292"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average&#160;Grant</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22331">5,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22336">203.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22344">153,865</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22349">18.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-22357">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-22362">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22370">5,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22375">203.25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22396">153,865</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22401">18.17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no restricted stock units granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2023, 2022, and 2021. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-40</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882314_12" continuedAt="TextSelectionAppend_103882314_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_13" continuedAt="TextSelectionAppend_103882314_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882314_14" continuedAt="TextSelectionAppend_103882314_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882314_15" continuedAt="TextSelectionAppend_103882314_16"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-22437"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:48%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22538">2,910</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22543">11,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22548">2,591</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22553">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22558">2,723</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22563">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22571">11,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22576">109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22581">4,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22586">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22591">5,315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22596">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22642">14,237</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22647">11,437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22652">7,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22657">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22662">8,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22667">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22708"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22709"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22710">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> related tax benefits were recognized for the years ended December&#160;31, 2023, 2022, and 2021 (see Note&#160;18). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards contain both performance and service-based vesting conditions. <ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2023_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22713"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2021_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22714"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2022_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22715">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> expense was recognized for the unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards with only a performance condition for the years ended December&#160;31, 2023, 2022, and 2021. The performance-based vesting conditions represent specific performance targets. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable of achievement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had an aggregate of $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22719">64.4</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense for options outstanding, which is expected to be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-22720">3.5</ix:nonNumeric> years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#8217;s stock-based awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Volatility </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Company was privately held through April 2016 and transitioned from a clinical stage company to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage company in 2023, it alone does not have the relevant company-specific historical data to support its expected volatility. As such, the Company has used an average of expected volatilities based on the volatilities of a representative group of publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. Subsequent to the Company&#8217;s initial public offering, it began to consider the Company&#8217;s own historic volatility. However, due to the transition from a clinical stage company to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage company, the Company still uses peer company data to assist in this analysis. For purposes of identifying comparable companies, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company intends to consistently apply this process using the same or </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-41</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_103882314_16" continuedAt="TextSelectionAppend_103882314_17"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_103882314_17" continuedAt="TextSelectionAppend_103882314_18"><div><div style="line-height:normal;background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882314_18"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>similar comparable entities until a sufficient amount of historical information regarding the volatility of the Company&#8217;s own share price post transition becomes available. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has never paid dividends on its Common Stock and has no plans to pay dividends on its Common Stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen" id="ixv-22767"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen" id="ixv-22768"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen" id="ixv-22769">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction>. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Valuation of Stock Options and 2016 ESPP </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the stock options granted under the the Company&#8217;s equity incentive plans, as well as the shares available for purchase under the 2016 ESPP were determined using the Black-Scholes option-pricing model. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103883869" id="ixv-22775">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: </ix:nonNumeric></div><ix:continuation id="TextSelection_103883869"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Options Granted</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-22839">5.88</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-22844">6.00</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-22849">5.99</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22857">107</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22862">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22867">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22875">4.37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22880">2.93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22885">0.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22893">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22898">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22903">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2016 ESPP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-22927">0.49</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-22932">0.49</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-22937">0.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22945">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22950">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22955">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22963">4.99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22968">1.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22973">0.08</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22981">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22986">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22991">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-22993"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">16. Defined Contribution Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. During the years ended December&#160;31, 2023, 2022, 2021, the Company provided $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22997">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22998">0.6</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22999">0.6</ix:nonFraction>&#160;million, respectively, in contributions to the plan. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882413" id="ixv-23000"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">17. Restructuring Charges </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Severance and Stock Compensation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the Company implemented a restructuring plan resulting in an approximate <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_12_2023To06_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-23009">83</ix:nonFraction>% reduction of the Company&#8217;s existing headcount by June&#160;30, 2023. The Company recognized restructuring expenses consisting of cash severance payments and other employee-related costs of $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23010">6.4</ix:nonFraction>&#160;million during the year ended December&#160;31, 2023. Cash payments for employee related restructuring charges of $<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23011">5.3</ix:nonFraction>&#160;million were paid as of December&#160;31, 2023. In addition, the Company recognized $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23012">1.0</ix:nonFraction>&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> stock-based compensation </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-42</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882413" continuedAt="TextSelectionAppend_103882413_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882413_1" continuedAt="TextSelectionAppend_103882413_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882413_2" continuedAt="TextSelectionAppend_103882413_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882413_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">expense related to the accelerated vesting of stock-based awards for certain employees. The Company recorded these restructuring charges based on each employee&#8217;s role to the respective research and development and general and administrative operating expense categories on its consolidated statements of operations and comprehensive loss. </div><ix:nonNumeric name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23031"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:53%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beginning&#160;Balance<br/> December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charges</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ending&#160;Balance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Severance liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23085">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23090">6,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2023To12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23095">5,325</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23100">1,123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Assets </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23107">0.5</ix:nonFraction>&#160;million. After recording the disposal of all the Company&#8217;s property and equipment net of proceeds, the Company recorded a $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-23108">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-23109">0.2</ix:nonFraction>&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> Asset and Leasehold Improvement Impairment </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&#160;30, 2023, the Company abandoned its leased office space in Austin, Texas. As a result, the Company recognized an impairment loss of $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P06_30_2023To06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23117">0.9</ix:nonFraction>&#160;million related to the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and $<ix:nonFraction name="us-gaap:ImpairmentOfLeasehold" contextRef="P06_30_2023To06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23120">1.7</ix:nonFraction>&#160;million related to leasehold improvements. On August&#160;7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $<ix:nonFraction name="syre:OperatingLeaseTerminationFeeAmount" contextRef="PAsOn08_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23121">2.0</ix:nonFraction>&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All charges related to the restructuring activities were recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. <ix:nonNumeric name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103884050" id="ixv-23123">A summary of the charges related to the restructuring activities is as follows (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_103884050"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:48%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance<br/> Related<br/> Expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/> Compensation<br/> Expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss on<br/> Disposal&#160;of<br/> Long&#160;Lived<br/> Assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Asset<br/> Impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Restructuring<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23192">3,182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23197">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23202">749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23207">1,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23212">5,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23220">3,266</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23225">870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23230">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23235">1,175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23240">5,493</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23280">6,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23285">993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23290">931</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23295">2,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23300">10,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882085" id="ixv-23334"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">18. Income Taxes </div></div><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23337"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:63%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23385">338,942</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23390">84,113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23395">65,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23403">126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23408">162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23413">280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23441">338,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23446">83,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23451">65,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-43</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_103882085" continuedAt="TextSelectionAppend_103882085_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882085_1" continuedAt="TextSelectionAppend_103882085_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882085_2" continuedAt="TextSelectionAppend_103882085_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882085_3" continuedAt="TextSelectionAppend_103882085_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company recognized no provision or benefit from income taxes. For both the years ended December&#160;31, 2022 and 2021, the Company recognized an income tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23493">0.1</ix:nonFraction>&#160;million, related to foreign subsidiaries income tax expense and the Texas margins tax. <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_103882087" id="ixv-23494">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_103882087"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:64%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax provision derived by applying the federal statutory rate to income before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23542">71,151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23547">17,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23552">13,789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on forward contract valuation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23560">17,541</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23565">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23570">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired IPR&amp;D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23578">27,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23583">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23588">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on CVR revaluation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23596">3,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23601">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23606">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23614">4,472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23619">1,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23624">1,002</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23632">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23637">3,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23642">3,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23650">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23655">640</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="syre:IncomeTaxReconciliationTaxCostCredit" contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23660">152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of tax rate on foreign jurisdiction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23668">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23673">42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23678">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in the valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23686">17,839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23691">20,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23696">16,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23724">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-23729">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23734">141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23756"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the deferred tax assets and liabilities consist of the following (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23806">74,454</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23811">68,917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized 174 R&amp;D costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23819">22,532</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23824">11,097</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23832">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23837">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23845">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23850">566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23858">579</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23863">668</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23871">4,246</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23876">3,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23884">21,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23889">21,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23897">1,631</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23902">1,631</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23910">88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23915">190</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23937">125,491</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23942">108,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23961">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23966">676</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-23988">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23993">676</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24001">125,491</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24006">107,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-24028">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-24033">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24050">17.8</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24051">20.6</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24052">16.9</ix:nonFraction>&#160;million during the years ended December&#160;31, 2023, 2022, and 2021, respectively, primarily due to continuing loss from operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24054">354.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24055">328.2</ix:nonFraction>&#160;million, respectively. For both the years ended December&#160;31, 2023 and 2022, the Company had U.S. tax credit carryforwards and state tax credit carryforwards of $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24056">21.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24057">1.6</ix:nonFraction>&#160;million, respectively. Of the net operating loss and tax credit carryforwards $<ix:nonFraction name="syre:OperatingLossCarryforwardsSetToExpireIfNotUtilized" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24058">58.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="syre:TaxCreditCarryforwardsSetToExpireIfNotUtilized" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24059">21.9</ix:nonFraction>&#160;million, respectively, will expire in 2033, if not utilized. Any remaining net operating loss will carry forward indefinitely and can be </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-44</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_103882085_4" continuedAt="TextSelectionAppend_103882085_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882085_5" continuedAt="TextSelectionAppend_103882085_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103882085_6" continuedAt="TextSelectionAppend_103882085_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103882085_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">utilized to offset up to 80% of the taxable income in any tax year. The net operating loss and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or tax credits are utilized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. If the Company has experienced an ownership change at any time since its formation, utilization of the NOL or research and development credit carryforwards would be subject to an annual limitation under Section&#160;382 or 383 of the Internal Revenue Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> rate, and then could be subject to additional adjustments, as required. Additionally, the separate return limitation year (&#8220;SRLY&#8221;) rules may apply to losses of the Company&#8217;s <ix:nonFraction name="syre:NumberOfDomesticSubsidiaries" contextRef="PAsOn12_31_2023" unitRef="Unit_SUBSIDARY" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-24079">eight</ix:nonFraction> wholly owned U.S. subsidiary corporations. The SRLY rules limit the consolidated group&#8217;s use of a subsidiary corporation&#8217;s net operating losses to the amount of income generated by the subsidiary corporation after it becomes a member of the group. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Additionally, the Company does <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-24080"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-24081">no</ix:nonFraction></ix:nonFraction>t expect any unrecognized tax benefits to change significantly over the next twelve months. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2019 and subsequent years. However, due to NOL and tax attribute carryovers, the taxing authorities have the ability to adjust the NOLs and other tax attributes related to closed years. As of December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-24083">no</ix:nonFraction> amounts recorded for uncertain tax positions. As of December&#160;31, 2023, undistributed earnings of the Company&#8217;s incorporated foreign subsidiaries are immaterial. Under the Global Intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-Taxed</div> Income (&#8220;GILTI&#8221;) provisions of the 2017 Tax Cuts and Jobs Act, U.S. income taxes have been incurred on the undistributed earnings of the foreign subsidiaries and therefore, the tax impact upon distribution is limited to state income and withholding taxes and is not material. </div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24085"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">19. Net Loss Per Share </div></div><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24088"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company computes net loss attributable per common stockholder using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. The Company considers convertible preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for Common Stock and participating security considering a participating security&#8217;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock and Series B Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock and the Series B Preferred Stock were excluded from the calculation of basic net loss per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding during the period, without consideration of potential dilutive securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. </div></ix:nonNumeric></ix:nonNumeric><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-45 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24104"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-dilutive</div> for the periods presented: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Options to purchase Common Stock</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24189">2,583,226</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8199;&#8201;<ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24199">346,331</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8199;&#8201;<ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24209">264,858</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Unvested restricted stock units</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24224">4,240</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24234">6,983</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24244">7,975</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Outstanding Parapyre Warrants</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24259">5,625</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-24269">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-24279">&#8212;</ix:nonFraction>&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24283"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Weighted average Common Shares</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24368">6,201,954</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24378">2,307,668</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24388">1,956,933</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24403">695,111</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24413">1,063,563</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24423">672,851</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Total basic and diluted weighted average shares</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24438"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24439">6,897,065</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24449"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24450">3,371,231</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24460"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24461">2,629,784</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-46 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc"></a></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin518298_29" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors of Aeglea BioTherapeutics, Inc. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinion </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying statement of assets acquired and liabilities assumed from Spyre Therapeutics, Inc. (&#8220;Spyre&#8221;) by Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221;) as of June&#160;22, 2023, including the related notes (collectively referred to as the &#8220;financial statement&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In our opinion, the accompanying financial statement presents fairly, in all material respects, the assets acquired and liabilities assumed from Spyre by Aeglea as of June&#160;22, 2023 in accordance with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors&#8217; Responsibilities for the Audit of the Financial Statement section of our report. We are required to be independent of Aeglea and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statement has been prepared assuming that Aeglea will continue as a going concern. As discussed in Note 1 to the financial statement, holders of Aeglea Series A Preferred Stock are entitled to require Aeglea to settle their shares of Series A Preferred Stock for cash, and the cash redemption is not in Aeglea&#8217;s control, and Aeglea has stated that substantial doubt exists about it&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The financial statement does not include any adjustments that might result from the outcome of the uncertainty. Our opinion is not modified with respect to this matter. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emphasis of Matter </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As described in Note 1 to the accompanying financial statement, the financial statement was prepared in connection with Aeglea&#8217;s acquisition of Spyre in accordance with a Securities and Exchange Commission (SEC) waiver received by Aeglea, for the purpose of Aeglea complying with Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the SEC&#8217;s Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> The financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. Our opinion is not modified with respect to this matter. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Responsibilities of Management for the Financial Statement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management is responsible for the preparation and fair presentation of the financial statement in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statement that is free from material misstatement, whether due to fraud or error. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In preparing the financial statement, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Aeglea&#8217;s ability to continue as a going concern for one year after the date the financial statement is available to be issued. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-47</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Auditors&#8217; Responsibilities for the Audit of the Financial Statement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our objectives are to obtain reasonable assurance about whether the financial statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditors&#8217; report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In performing an audit in accordance with US GAAS, we: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise professional judgment and maintain professional skepticism throughout the audit. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identify and assess the risks of material misstatement of the financial statement, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Aeglea&#8217;s internal control. Accordingly, no such opinion is expressed. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statement. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Aeglea&#8217;s ability to continue as a going concern for a reasonable period of time. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit. </div></div><div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ PricewaterhouseCoopers LLP </div></div><div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Austin, Texas </div></div><div style="text-indent: -2%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October&#160;6, 2023 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div> <div id="fin518298_30" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Statement of Assets Acquired and Liabilities Assumed </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands) </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:88%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS ACQUIRED</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24697">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24713">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets acquired</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24729">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES ASSUMED</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24760">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24776">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities assumed</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24792">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net liabilities assumed</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-24813">17,012</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">See accompanying notes to the Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Aeglea BioTherapeutics, Inc. </div></div> <div id="fin518298_31" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Statement of Assets Acquired and Liabilities Assumed </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc. </div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" continuedAt="TextSelection_103884331" id="ixv-24843"> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Description of the Business and Summary of Significant Accounting Policies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221;, the &#8220;Company&#8221;, and &#8220;our&#8221;) acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets from Spyre Therapeutics, Inc (&#8220;Spyre&#8221;), a privately held biotechnology company advancing a pipeline of antibody therapeutics through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, Aeglea effected a reverse stock split of its Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P09_08_2023To09_08_2023" id="ixv-24850">1-for-25</ix:nonNumeric></div></div> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this statement have been adjusted on a post-Reverse Split basis. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction (the &#8220;Asset Acquisition&#8221;) was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of <ix:nonFraction name="syre:FixedExchangeRatio" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="7" scale="0" format="ixt:num-dot-decimal" id="ixv-24854">0.5494488</ix:nonFraction> to 1 for consideration from Aeglea of <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24855">517,809</ix:nonFraction> shares of common stock and <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24856">364,887</ix:nonFraction> shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-24858">0.0001</ix:nonFraction> per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24859">40</ix:nonFraction> to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase <ix:nonFraction name="syre:OutstandingAndUnexercisedStockOptions" contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-24860">2,734</ix:nonFraction> shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Aeglea common stock and the Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option (the &#8220;Option&#8221;) to exclusively license certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;). The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing a portfolio of combination treatments that simultaneously address different mechanisms of irritable bowel disease. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-24864">113.2</ix:nonFraction>&#160;million, which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-24865">364,887</ix:nonFraction> shares of Series A Preferred Stock (<ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-24866">14,595,480</ix:nonFraction> shares of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-24868">517,809</ix:nonFraction> shares of common stock, valued at $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-24869">291.08</ix:nonFraction> per share and $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-24870">7.277</ix:nonFraction> per share, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Agreement provided for an annual equity grant of options to purchase <ix:nonFraction name="syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-24872">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Option, at the fair market value determined by the board of directors of Spyre (the &#8220;Parapyre Option Obligation&#8221;). In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of common stock of the Company on the same terms. For additional information, see Note&#160;3. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div></ix:exclude></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_103884331" continuedAt="TextSelectionAppend_103884331_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_103884331_1" continuedAt="TextSelectionAppend_103884331_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103884331_2" continuedAt="TextSelectionAppend_103884331_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_103884331_3" continuedAt="TextSelectionAppend_103884331_4"><ix:nonNumeric name="us-gaap:AssetAcquisitionTableTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-24893"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24917">109,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24925">3,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24941">113,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24975">130,188</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24983">3,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-24991">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-25007">113,176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">730-10-25-2(c),</div></div></div> intangible assets used in research and developmental activities acquired in an asset acquisition should be expensed at the acquisition date if there is no alternative future use in other R&amp;D projects or otherwise (i.e., if they have no economic value). The Company determined that product candidates pertaining to Spyre had no alternative future use at the time of acquisition and recorded $<ix:nonFraction name="syre:AcquiredInProcessResearchAndDevelopment" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25021">130.2</ix:nonFraction>&#160;million to Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> Research and Development Expenses as of the date of acquisition. The difference between this amount and the $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25023">113.2</ix:nonFraction>&#160;million cost to acquire Spyre represents the net liabilities assumed of $<ix:nonFraction name="syre:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25024">17.0</ix:nonFraction>&#160;million. </div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" continuedAt="TextSelection_103882704" id="ixv-25025"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of acquiring Spyre, and based on the criteria in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#8217;s full financial statements are not material to the Company&#8217;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> and Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#8217;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#8217;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#8217;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5<div style="display:inline;">1</div></div></ix:exclude></div></ix:nonNumeric></ix:continuation> </div> </div> <ix:continuation id="TextSelection_103882704" continuedAt="TextSelectionAppend_103882704_1"><ix:continuation id="TextSelectionAppend_103884331_4" continuedAt="TextSelectionAppend_103884331_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_103884331_5" continuedAt="TextSelectionAppend_103884331_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103884331_6" continuedAt="TextSelectionAppend_103884331_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_103882704_1" continuedAt="TextSelectionAppend_103882704_2"><ix:continuation id="TextSelectionAppend_103884331_7" continuedAt="TextSelectionAppend_103884331_8"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option to exclusively license IPR&amp;D. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-25064">83</ix:nonFraction>%, retaining approximately <ix:nonFraction name="syre:NumberOfEmployeesRetained" contextRef="P04_01_2023To04_30_2023" unitRef="Unit_employee" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-25065">10</ix:nonFraction> employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-25067">721,452</ix:nonFraction> shares of Series A Preferred Stock for an aggregate purchase price of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25068">210.0</ix:nonFraction>&#160;million before deducting approximately $<ix:nonFraction name="syre:PlacementAgentAndOtherOfferingExpenses" contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25069">12.7</ix:nonFraction>&#160;million placement agent and other offering expenses. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5<div style="display:inline;">2</div></div></ix:exclude></div></ix:continuation></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_103882704_2" continuedAt="TextSelectionAppend_103882704_3"><ix:continuation id="TextSelectionAppend_103884331_8" continuedAt="TextSelectionAppend_103884331_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_103884331_9" continuedAt="TextSelectionAppend_103884331_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_103884331_10" continuedAt="TextSelectionAppend_103884331_11"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_103884331_11"><ix:continuation id="TextSelectionAppend_103882704_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div> </ix:continuation><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25094"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#8217;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of the Company&#8217;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25100"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;22</div>, 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">023,</div> Spyre held $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25108">3.0</ix:nonFraction>&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#8217;s insured limit were $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25109">2.8</ix:nonFraction>&#160;million. </div> </ix:nonNumeric><ix:nonNumeric name="syre:AccruedLiabilitiesPolicyTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25110"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Liabilities</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. </div> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="syre:AccruedLiabilitiesTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25116"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Accrued liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $<ix:nonFraction name="syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25121">19.0</ix:nonFraction>&#160;million under the Paragon Agreement since inception, inclusive of a $<ix:nonFraction name="syre:ResearchInitiationFees" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25122">3.0</ix:nonFraction>&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $<ix:nonFraction name="syre:ReimbursableResearchCosts" contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25123">16.0</ix:nonFraction>&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $<ix:nonFraction name="syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition" contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25124">19.0</ix:nonFraction>&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25125"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="syre:AccruedOptionCostPayable" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-25149">18,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-25157">917</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProgramRightsObligations" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-25165">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-25181">20,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5<div style="display:inline;">3</div></div></div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25201"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Parapyre Option Obligation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre to purchase <ix:nonFraction name="syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-25205">1</ix:nonFraction>% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. The Parapyre Option Obligation is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liabilities. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> who provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing services within Research and development expenses. As of June&#160;22, 2023, the estimated liability of the Parapyre Option Obligation was $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextRef="PAsOn06_22_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-25208">0.1</ix:nonFraction>&#160;million and was included in accrued liabilities. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25209"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Related Party Transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC each beneficially owns less than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-25213">5</ix:nonFraction>% of the Company&#8217;s capital stock through their respective holdings of Common Stock and Series A Preferred Stock of the Company. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-25214">5</ix:nonFraction>% of our capital stock, has <ix:nonFraction name="syre:RelatedPartyTransactionNumberOfBoardSeats" contextRef="PAsOn06_22_2023" unitRef="Unit_BOARDSEAT" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-25215">two</ix:nonFraction> seats on the Company&#8217;s board of directors and beneficially owns more than <ix:nonFraction name="syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-25216">5</ix:nonFraction>% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount has appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P06_22_2023To06_22_2023" escape="true" id="ixv-25217"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Subsequent Events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s management has evaluated subsequent events up to October&#160;6, 2023, the date the Statement of Assets Acquired and Liabilities Assumed from Spyre, Inc. was available to be issued. There have been no subsequent events that require recognition or disclosure in this financial statement except for the following described below. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-25222">517,809</ix:nonFraction> shares of common stock and <ix:nonFraction name="syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-25223">364,887</ix:nonFraction> shares of Series&#160;A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2023, the Company filed a preliminary proxy statement with the SEC to solicit approval of the conversion of the Series A Preferred Stock into shares of Common Stock in connection with the Asset acquisition, among other matters, at a special meeting of stockholders. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company&#8217;s Board of Directors approved a reverse stock split of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-25226">0.0001</ix:nonFraction> per share, at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="ixv-25229">1-for-25</ix:nonNumeric></div></div> and a reduction in the total number of authorized shares of Common Stock from <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-25230">500,000,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-25231">20,000,000</ix:nonFraction> shares. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durwordsen" id="ixv-25233">ten years</ix:nonNumeric>. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement on a go forward basis. The Company determined that these amendments would not have materially impacted the liability as of June&#160;22, 2023. </div> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5<div style="display:inline;">4</div></div></div> </div> </div> </div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;13.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Expenses of Issuance and Distribution </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expenses payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form <span style="white-space:nowrap">S-1</span> (other than underwriting discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item listed is estimated, except for the SEC registration fee: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">149,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;14.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Indemnification of Officers and Directors </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section&#160;145 of the DGCL are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the DGCL, the Registrant&#8217;s Certificate of Incorporation contains provisions that eliminate the personal liability of its directors for monetary damages for any breach of fiduciary duties as a director, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of the director&#8217;s duty of loyalty to the Registrant or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">under Section&#160;174 of the DGCL (regarding unlawful dividends and stock purchases); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the DGCL, the Registrant&#8217;s Bylaws provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the DGCL, subject to very limited exceptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Registrant may indemnify its other employees and agents as set forth in the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to very limited exceptions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights conferred in the Bylaws are not exclusive. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant&#8217;s Certificate of Incorporation and Bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The indemnification provisions in the Registrant&#8217;s Certificate of Incorporation, Bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the Registrant&#8217;s directors and executive officers for liabilities arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant currently carries liability insurance for its directors and officers. Two of the Registrant&#8217;s directors, Peter Harwin and Tomas Kiselak, are also indemnified by their employer with regard to their service on the Registrant&#8217;s board of directors. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;15.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Recent Sales of Unregistered Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, we entered into the June 2023 SPA, pursuant to which we sold an aggregate of 721,452 shares of our Series A Preferred Stock, which will automatically convert into 40 shares of Common Stock, subject to stockholder approval and certain beneficial ownership limitations set by each holder, pursuant to the Series A Certificate of Designation, at an aggregate purchase price of approximately $210&#160;million. The shares issued pursuant to the June 2023 SPA were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section&#160;4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the June 2023 Investors represented that it was an &#8220;accredited investor,&#8221;; as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The shares of Series A Preferred Stock issued pursuant to the June 2023 SPA have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on June&#160;22, 2023, we completed our acquisition of <span style="white-space:nowrap">Pre-Merger</span> Spyre in accordance with the Acquisition Agreement, pursuant to which we issued an aggregate of 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock to certain of the Selling Stockholders. Such issuances were exempt from registration pursuant to Section&#160;4(a)(2) of the Securities Act and Regulation D promulgated thereunder. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;7, 2023, we entered into the December 2023 SPA, pursuant to which we sold an aggregate of 6,000,000 shares of our Common Stock and 150,000 shares of our Series B Preferred Stock, which will automatically convert into 40 shares of Common Stock, subject to stockholder approval and certain beneficial ownership limitations set by each holder, pursuant to the Series B Certificate of Designation, at an aggregate purchase price of $180.0&#160;million. The Private Placement Preferred Shares were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section&#160;4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the December 2023 Investors represented that it was an &#8220;accredited investor,&#8221;; as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The Private Placement Preferred Shares have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective December 29, 2023, we issued to one of our existing investors a warrant to purchase up to an aggregate of up to 684,407 shares of Common Stock, with an exercise price equal to $21.52 per share and an expiration date of December 29, 2033. Such issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;16.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits and Financial Statement Schedules </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">(a)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">Exhibits</span> </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:89%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">EXHIBIT<br/>NUMBER</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">DESCRIPTION OF EXHIBIT</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex21.htm">Agreement and Plan of Merger, dated June&#160;22, 2023, by and among the Company, Aspen Merger Sub&#160;I, Inc., Sequoia Merger Sub&#160;II, LLC and Spyre Therapeutics, Inc. (incorporated by reference to Exhibit&#160;2.1 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex31.htm">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312524023071/d518298dex32.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit&#160;3.2 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.3*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex33.htm">Certificate of Designations of Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (incorporated by reference to Exhibit&#160;3.3 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.4*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex34.htm">Certificate of Designations of Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (incorporated by reference to Exhibit&#160;3.4 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex41.htm">Form of Registration Rights Agreement (December 2023 PIPE) (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.2*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex42.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit&#160;4.2 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.3*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex43.htm">Securities Purchase Agreement, dated December&#160;7, 2023, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto (incorporated by reference to Exhibit&#160;4.3 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.4*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex44.htm">Form of Registration Rights Agreement, by and among the Company and certain purchasers (June 2023 PIPE) (incorporated by reference to Exhibit&#160;4.4 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.5*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex45.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrants 2022 (incorporated by reference to Exhibit&#160;4.5 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="d518298dex51.htm">Opinion of Gibson, Dunn&#160;&amp; Crutcher LLP</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1*#</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex101.htm">Biologics Master Services Agreement, effective June&#160;20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2*#</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex102.htm">Cell Line License Agreement, effective June&#160;20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex103.htm">Novation Agreement, dated September&#160;19, 2023, by and between Paragon Therapeutics, Inc., the Company and WuXi Biologics (Hong Kong) Limited (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:6%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">EXHIBIT<br/>NUMBER</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">DESCRIPTION OF EXHIBIT</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312524023071/d518298dex104.htm">Amended and Restated Offer Letter, dated November&#160;22, 2023 and as amended on February&#160;1,&#160;2024, by and between the Company and Cameron Turtle (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5*#</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex105.htm">Amended and Restated Antibody Discovery and Option agreement, dated September&#160;29, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, LLC (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex107.htm">2015 Equity Incentive Plan and forms of award agreements (incorporated by reference to Exhibit&#160;10.6 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex107.htm">Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, As Amended and Restated Effective November&#160;21, 2023 (incorporated by reference to Exhibit&#160;10.7 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312524055961/d518298dex108.htm">Spyre Therapeutics, Inc. 2016 Employee Stock Purchase Plan, as amended by the First Amendment on January 31, 2024 (incorporated by reference to Exhibit&#160;10.8 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1010.htm">Spyre Therapeutics, Inc. 2018 Equity Inducement Plan and the First Amendment, Second Amendment, Third Amendment and Fourth Amendment thereto (incorporated by reference to Exhibit&#160;10.9 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1011.htm">Form of Stock Option Agreement under the Amended and Restated 2018 Equity Inducement Plan (incorporated by reference to Exhibit&#160;10.10 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1012.htm">Spyre Therapeutics, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.11 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1013.htm">Form of Stock Restriction Agreement (incorporated by reference to Exhibit&#160;10.12 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1014.htm">Form of Severance Agreement (incorporated by reference to Exhibit&#160;10.13 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1015.htm">Separation and Consulting Agreement and General Release of Claims by and between the Company and Jonathan Alspaugh, dated as of September&#160;22, 2023 (incorporated by reference to Exhibit&#160;10.14 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15*&#8224;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1016.htm">Offer Letter, dated August&#160;10, 2023, by and between the Company and Scott Burrows (incorporated by reference to Exhibit&#160;10.15 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1017.htm">Asset Purchase Agreement, dated July&#160;27, 2023, by and between the Company and Immedica Pharma AB (incorporated by reference to Exhibit&#160;10.16 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex1018.htm">Lease Termination Agreement dated August&#160;7, 2023, between the Company and Las Cimas Owner LP (incorporated by reference to Exhibit&#160;10.17 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">EXHIBIT<br/>NUMBER</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">DESCRIPTION OF EXHIBIT</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312524023071/d518298dex1019.htm">2024 Form of Indemnification Agreement (incorporated by reference to Exhibit&#160;10.18 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19*&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312524055961/d518298dex1019.htm">Offer Letter, dated August 18, 2023, by and between the Company and Heidy King-Jones (incorporated by reference to Exhibit&#160;10.19 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312524055961/d518298dex1020.htm">Consulting Agreement by and between the Company and Mark McKenna, effective August 1, 2023 (incorporated by reference to Exhibit&#160;10.20 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;21.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523302158/d518298dex211.htm">Subsidiaries of the Registrant (incorporated by reference to Exhibit&#160;21.1 to the Company&#8217;s registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on March&#160;1, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex231.htm">Consent of PricewaterhouseCoopers LLP</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex232.htm">Consent of PricewaterhouseCoopers LLP</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d518298dex51.htm">Consent of Gibson, Dunn&#160;&amp; Crutcher LLP (included in Exhibit 5.1)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636282/000119312523302158/d518298ds1.htm#sig">Power of Attorney (included on the signature page to the registration statement)</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1636282/000119312523277992/d541146dexfilingfees.htm">Filing Fee Table (incorporated by reference to Exhibit&#160;107 to the Company&#8217; registration statement on <span style="white-space:nowrap">Form&#160;S-1/A</span> filed with the SEC on November&#160;15, 2023). </a></td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Previously filed. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates a management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Portions of this exhibit have been omitted pursuant to Item&#160;601(b)(10)(iv) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left"><span style="font-weight:bold">(b)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial statement schedules </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;17.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Undertakings </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The undersigned Registrant hereby undertakes: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; in the effective registration statement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <span style="font-style:italic">bona fide</span> offering thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. <span style="font-style:italic">Provided, however</span>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on March&#160;5, 2024. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">SPYRE THERAPEUTICS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle, DPhil</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Turtle, DPhil</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</p></td></tr>
</table></div> <div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">KNOW ALL PERSONS BY THESE PRESENTS</span>, that each person whose signature appears below hereby constitutes and appoints Dr.&#160;Cameron Turtle and Mr.&#160;Scott Burrows, as his or her true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule&#160;462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Title</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Cameron Turtle, DPhil</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Cameron Turtle, DPhil</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer&#160;&amp; Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Scott Burrows</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Scott Burrows</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Financial Officer and Principal Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Russell J. Cox</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Chairman of the Board</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Jeffrey W. Albers</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Jeffrey W. Albers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Peter Harwin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Michael Henderson, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Title</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Mark McKenna</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Mark McKenna</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Laurie Stelzer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Laurie Stelzer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">March&#160;5, 2024</td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:10%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:89%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">*By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Cameron Turtle, DPhil</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Cameron Turtle, DPhil</td></tr>
</table> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">*** </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d518298dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g518298g0305152730469.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;Gibson, Dunn &amp; Crutcher LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;One Embarcadero Center, Suite 2600</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;San Francisco, CA 94111-3715</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;Tel 415.393.8200</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;gibsondunn.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Client: 06759-00003</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;5, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spyre
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221 Crescent Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building 23, Suite
105 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Spyre Therapeutics, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#8195;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Spyre
Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), in connection with the preparation and filing with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) of a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (the &#147;<U>Registration Statement</U>&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), relating to the resale from time to time by the selling stockholders
named therein of up to 18,809,064 shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at the
opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the specimen common stock certificates and such other documents, corporate
records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination, we have assumed the genuineness of all signatures, the
legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares are
validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of this opinion as an exhibit to the
Registration Statement, and we further consent to the use of our name under the caption &#147;Legal Matters&#148; in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we
are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Abu Dhabi &#149; Beijing &#149; Brussels &#149; Century City &#149; Dallas &#149; Denver &#149; Dubai &#149; Frankfurt &#149; Hong Kong &#149;
Houston &#149; London &#149; Los Angeles </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Munich &#149; New York &#149; Orange County &#149; Palo Alto &#149; Paris &#149; Riyadh &#149; San
Francisco &#149; Singapore &#149; Washington, D.C. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g518298g0305152730761.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d518298dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form&nbsp;S-1 of Spyre Therapeutics, Inc. of our report dated February&nbsp;29, 2024 relating
to the financial statements of Spyre Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;5, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d518298dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form S-1 of Spyre Therapeutics, Inc. of our report dated October 6, 2023 relating to the
Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. by Aeglea BioTherapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such
Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;5, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>syre-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-March-2024 [02:06:26] {AM}-->
<schema targetNamespace="http://www.spy.com/20231231" elementFormDefault="qualified" xmlns:syre="http://www.spy.com/20231231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.spy.com/role/Cover" id="Cover">
<link:definition>1001 - Document - Cover</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical" id="ConsolidatedStatementsOfOperationsParenthetical">
<link:definition>1005 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
<link:definition>1006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" id="ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity">
<link:definition>1007 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1008 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" id="StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<link:definition>1009 - Statement - Statement of Assets Acquired and Liabilities Assumed</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentation" id="TheCompanyAndBasisOfPresentation">
<link:definition>1010 - Disclosure - The Company and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies">
<link:definition>1011 - Disclosure - Description of the Business and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1012 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1013 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecurities" id="CashEquivalentsAndMarketableSecurities">
<link:definition>1014 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1015 - Disclosure - Property and Equipment, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilities" id="AccruedAndOtherCurrentLiabilities">
<link:definition>1016 - Disclosure - Accrued and Other Current Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilities" id="AccruedLiabilities">
<link:definition>1017 - Disclosure - Accrued Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1018 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisition" id="AssetAcquisition">
<link:definition>1019 - Disclosure - Asset Acquisition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ParagonAgreement" id="ParagonAgreement">
<link:definition>1020 - Disclosure - Paragon Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/Leases" id="Leases">
<link:definition>1021 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquity" id="ConvertiblePreferredStockAndStockholdersEquity">
<link:definition>1022 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreements" id="StrategicLicenseAgreements">
<link:definition>1023 - Disclosure - Strategic License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedica" id="SaleOfPegzilarginaseToImmedica">
<link:definition>1024 - Disclosure - Sale of Pegzilarginase to Immedica</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NovationOfManufacturingAgreements" id="NovationOfManufacturingAgreements">
<link:definition>1025 - Disclosure - Novation of Manufacturing Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>1026 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DefinedContributionPlan" id="DefinedContributionPlan">
<link:definition>1027 - Disclosure - Defined Contribution Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringCharges" id="RestructuringCharges">
<link:definition>1028 - Disclosure - Restructuring Charges</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1029 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1030 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1031 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1032 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1033 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1034 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1035 - Disclosure - Fair Value Measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables" id="CashEquivalentsAndMarketableSecuritiesTables">
<link:definition>1036 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1037 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables" id="AccruedAndOtherCurrentLiabilitiesTables">
<link:definition>1038 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>1039 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisitionTables" id="AssetAcquisitionTables">
<link:definition>1040 - Disclosure - Asset Acquisition (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesTables" id="LeasesTables">
<link:definition>1041 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityTables" id="ConvertiblePreferredStockAndStockholdersEquityTables">
<link:definition>1042 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreementTables" id="StrategicLicenseAgreementTables">
<link:definition>1043 - Disclosure - Strategic License Agreement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>1044 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesTables" id="RestructuringChargesTables">
<link:definition>1045 - Disclosure - Restructuring Charges (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1046 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1047 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1048 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
<link:definition>1049 - Disclosure - Accrued Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails" id="TheCompanyAndBasisOfPresentationDetails">
<link:definition>1050 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
<link:definition>1051 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" id="SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
<link:definition>1052 - Disclosure - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<link:definition>1053 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails" id="FairValueMeasurementsNarrativeDetails">
<link:definition>1054 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails" id="FairValueMeasurementsChangesInForwardContractLiabilityDetails">
<link:definition>1055 - Disclosure - Fair Value Measurements - Changes in Forward Contract Liability (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" id="FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails">
<link:definition>1056 - Disclosure - Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails" id="FairValueMeasurementsChangesInCvrLiabilityDetails">
<link:definition>1057 - Disclosure - Fair Value Measurements - Changes in CVR Liability (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" id="CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails">
<link:definition>1058 - Disclosure - Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" id="CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<link:definition>1059 - Disclosure - Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails" id="CashEquivalentsAndMarketableSecuritiesNarrativeDetails">
<link:definition>1060 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" id="CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails">
<link:definition>1061 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<link:definition>1062 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails" id="PropertyAndEquipmentNetNarrativeDetails">
<link:definition>1063 - Disclosure - Property and Equipment, Net - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails" id="AccruedAndOtherCurrentLiabilitiesDetails">
<link:definition>1064 - Disclosure - Accrued and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails" id="RelatedPartyTransactionsNarrativeDetails">
<link:definition>1065 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" id="RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails">
<link:definition>1066 - Disclosure - Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" id="RelatedPartyTransactionsRelatedPartyAccountsPayableDetails">
<link:definition>1067 - Disclosure - Related Party Transactions - Related Party Accounts Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisitionNarrativeDetails" id="AssetAcquisitionNarrativeDetails">
<link:definition>1068 - Disclosure - Asset Acquisition - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails" id="AssetAcquisitionAssetAcquisitionCostDetails">
<link:definition>1069 - Disclosure - Asset Acquisition - Asset Acquisition Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ParagonAgreementDetails" id="ParagonAgreementDetails">
<link:definition>1070 - Disclosure - Paragon Agreement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesNarrativeDetails" id="LeasesNarrativeDetails">
<link:definition>1071 - Disclosure - Leases - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" id="LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails">
<link:definition>1072 - Disclosure - Leases - Operating and Financing Leases Presented in Balance Sheet (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" id="LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails">
<link:definition>1073 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/LeasesLeaseCostDetails" id="LeasesLeaseCostDetails">
<link:definition>1074 - Disclosure - Leases - Lease Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails" id="ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails">
<link:definition>1075 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" id="ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<link:definition>1076 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails" id="StrategicLicenseAgreementNarrativeDetails">
<link:definition>1077 - Disclosure - Strategic License Agreement - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails" id="StrategicLicenseAgreementChangesInContractLiabilitiesDetails">
<link:definition>1078 - Disclosure - Strategic License Agreement - Changes in Contract Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails" id="SaleOfPegzilarginaseToImmedicaDetails">
<link:definition>1079 - Disclosure - Sale of Pegzilarginase to Immedica (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NovationOfManufacturingAgreementsDetails" id="NovationOfManufacturingAgreementsDetails">
<link:definition>1080 - Disclosure - Novation of Manufacturing Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockBasedCompensationNarrativeDetails" id="StockBasedCompensationNarrativeDetails">
<link:definition>1081 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails" id="StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails">
<link:definition>1082 - Disclosure - Stock-Based Compensation - Employee and Non-Employee Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails" id="StockBasedCompensationEmployeeRestrictedStockActivityDetails">
<link:definition>1083 - Disclosure - Stock-Based Compensation - Employee Restricted Stock Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" id="StockBasedCompensationStockBasedCompensationExpenseDetails">
<link:definition>1084 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails" id="StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails">
<link:definition>1085 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DefinedContributionPlanDetails" id="DefinedContributionPlanDetails">
<link:definition>1086 - Disclosure - Defined Contribution Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesNarrativeDetails" id="RestructuringChargesNarrativeDetails">
<link:definition>1087 - Disclosure - Restructuring Charges - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails" id="RestructuringChargesChangesInAccruedRestructuringBalanceDetails">
<link:definition>1088 - Disclosure - Restructuring Charges - Changes in Accrued Restructuring Balance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" id="RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails">
<link:definition>1089 - Disclosure - Restructuring Charges - Charges Related to the Restructuring Activities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails" id="IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails">
<link:definition>1090 - Disclosure - Income Taxes - (Loss) Income Before Income Tax Expense by Jurisdiction (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesNarrativeDetails" id="IncomeTaxesNarrativeDetails">
<link:definition>1091 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
<link:definition>1092 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition>1093 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
<link:definition>1094 - Disclosure - Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails" id="NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails">
<link:definition>1095 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails">
<link:definition>1096 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1097 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" id="AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails">
<link:definition>1098 - Disclosure - Accrued Liabilities - Accrued and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails" id="AccruedLiabilitiesAdditionalInformationDetails">
<link:definition>1099 - Disclosure - Accrued Liabilities - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1100 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="syre-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="syre-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="syre-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="syre-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesANonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_SeriesANonVotingConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesBNonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_SeriesBNonVotingConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="DevelopmentFeeAndRoyaltyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_DevelopmentFeeAndRoyaltyMember" substitutionGroup="xbrli:item" />
<element name="AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AcquiredInProcessResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConversionOfPreFundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ConversionOfPreFundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ConversionOfSeriesANonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="ContingentValueRightDistributionToCommonStockholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ContingentValueRightDistributionToCommonStockholders" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesNewIssuesOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_StockIssuedDuringPeriodSharesNewIssuesOne" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValueNewIssuesOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_StockIssuedDuringPeriodValueNewIssuesOne" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="ContingentValueRightLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ContingentValueRightLiabilityMember" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LeasedAssetsObtainedInExchangeForLeaseObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_LeasedAssetsObtainedInExchangeForLeaseObligations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" substitutionGroup="xbrli:item" />
<element name="AccruedAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AccruedAndOtherCurrentLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedLiabilitiesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AccruedLiabilitiesTextBlock" substitutionGroup="xbrli:item" />
<element name="OptionAgreementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OptionAgreementTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedResearchAndDevelopmentExpensePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_TemporaryEquityPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AccruedLiabilitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfBalancesDueToAffiliatesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AssetsAndLiabilitiesLesseeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AssetsAndLiabilitiesLesseeTableTextBlock" substitutionGroup="xbrli:item" />
<element name="CompanyAndBasisOfPresentationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_CompanyAndBasisOfPresentationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SpyreTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_SpyreTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="CompanyAndBasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_CompanyAndBasisOfPresentationLineItems" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionStockholderPaymentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AssetAcquisitionStockholderPaymentPeriod" substitutionGroup="xbrli:item" />
<element name="FixedExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_FixedExchangeRatio" substitutionGroup="xbrli:item" />
<element name="OutstandingAndUnexercisedStockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OutstandingAndUnexercisedStockOptions" substitutionGroup="xbrli:item" />
<element name="ProceedsFromRaisingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ProceedsFromRaisingCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Spyre2023EquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_Spyre2023EquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="CashEquivalentsAndMarketableSecuritiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_CashEquivalentsAndMarketableSecuritiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CashEquivalentsAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_CashEquivalentsAndMarketableSecuritiesLineItems" substitutionGroup="xbrli:item" />
<element name="USBankingInstitutionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_USBankingInstitutionMember" substitutionGroup="xbrli:item" />
<element name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LaboratoryEquipmentMember" substitutionGroup="xbrli:item" />
<element name="SoftwareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_SoftwareMember" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionCashPaymentThresholdPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AssetAcquisitionCashPaymentThresholdPeriod" substitutionGroup="xbrli:item" />
<element name="MeasurementInputProbabilityOfSuccessMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_MeasurementInputProbabilityOfSuccessMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputReimbursementRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_MeasurementInputReimbursementRateMember" substitutionGroup="xbrli:item" />
<element name="CashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_CashEquivalentsUnrealizedGains" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashEquivalentsUnrealizedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_CashEquivalentsUnrealizedLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" substitutionGroup="xbrli:item" />
<element name="AccruedContractedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_AccruedContractedResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairmountFundsManagementLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_FairmountFundsManagementLlcMember" substitutionGroup="xbrli:item" />
<element name="ParagonAndParapyreHoldingLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ParagonAndParapyreHoldingLlcMember" substitutionGroup="xbrli:item" />
<element name="ParagonTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ParagonTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="AppointOfBoardMembersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_AppointOfBoardMembersMember" substitutionGroup="xbrli:item" />
<element name="ConsultingAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ConsultingAgreementMember" substitutionGroup="xbrli:item" />
<element name="MilestonePaymentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_MilestonePaymentsMember" substitutionGroup="xbrli:item" />
<element name="OwnershipInterestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_OwnershipInterestMember" substitutionGroup="xbrli:item" />
<element name="ParagonAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ParagonAgreementMember" substitutionGroup="xbrli:item" />
<element name="SaleOfStockDecember2023PIPEMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_SaleOfStockDecember2023PIPEMember" substitutionGroup="xbrli:item" />
<element name="SPY002LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_SPY002LicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="StockCompensationAndResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_StockCompensationAndResearchAndDevelopmentExpenseMember" substitutionGroup="xbrli:item" />
<element name="ReimbursableCostsUnderParagonAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ReimbursableCostsUnderParagonAgreementMember" substitutionGroup="xbrli:item" />
<element name="AmountToBePaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_AmountToBePaidUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" substitutionGroup="xbrli:item" />
<element name="NominationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_NominationFee" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_PaymentOfMilestone" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReimbursableResearchCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ReimbursableResearchCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RelatedPartyExpensesIncurredPriorToAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RelatedPartyExpensesUnpaidPriorToAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RelatedPartyTransactionNumberOfBoardSeats" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_RelatedPartyTransactionNumberOfBoardSeats" substitutionGroup="xbrli:item" />
<element name="ResearchInitiationFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ResearchInitiationFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionReimbursableCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_RelatedPartyTransactionReimbursableCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" substitutionGroup="xbrli:item" />
<element name="PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" substitutionGroup="xbrli:item" />
<element name="ParapyreOptionObligationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ParapyreOptionObligationMember" substitutionGroup="xbrli:item" />
<element name="AssumedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AssumedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CollaborativeArrangementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_CollaborativeArrangementAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_LicenseAgreementMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonrefundableResearchInitiationFeeForOneProgramPaidInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLeaseTerminationFeeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_OperatingLeaseTerminationFeeAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LeaseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LeaseAssetsAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingAndFinanceLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_OperatingAndFinanceLeaseRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LeaseLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LeaseLiabilityAbstract" substitutionGroup="xbrli:item" />
<element name="LeaseLiabilityCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LeaseLiabilityCurrentAbstract" substitutionGroup="xbrli:item" />
<element name="LeaseLiabilityNoncurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LeaseLiabilityNoncurrentAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingAndFinanceLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_OperatingAndFinanceLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseWeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LeaseWeightedAverageDiscountRateAbstract" substitutionGroup="xbrli:item" />
<element name="LeaseWeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LeaseWeightedAverageRemainingLeaseTermAbstract" substitutionGroup="xbrli:item" />
<element name="BeneficiallyHoldersOwnedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_BeneficiallyHoldersOwnedPercentage" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" substitutionGroup="xbrli:item" />
<element name="MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" substitutionGroup="xbrli:item" />
<element name="MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" substitutionGroup="xbrli:item" />
<element name="NumberOfCommonStockVotingRightsHeldPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_NumberOfCommonStockVotingRightsHeldPerShare" substitutionGroup="xbrli:item" />
<element name="OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" substitutionGroup="xbrli:item" />
<element name="PlacementAgentFeesAndOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_PlacementAgentFeesAndOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreferredStockRemainsIssuedAndOutstandingPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_PreferredStockRemainsIssuedAndOutstandingPercentage" substitutionGroup="xbrli:item" />
<element name="SharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_SharesAuthorized" substitutionGroup="xbrli:item" />
<element name="ParapyreWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ParapyreWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PreFundedMay2022WarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_PreFundedMay2022WarrantsMember" substitutionGroup="xbrli:item" />
<element name="PreFundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_PreFundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="GlobalRightsToPegzilarginaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_GlobalRightsToPegzilarginaseMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_LicenseAgreementsMember" substitutionGroup="xbrli:item" />
<element name="PeaceTrialAndBLAPackageMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_PeaceTrialAndBLAPackageMember" substitutionGroup="xbrli:item" />
<element name="PIPTrialMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_PIPTrialMember" substitutionGroup="xbrli:item" />
<element name="AdditionalUpfrontPaymentAbilityToReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AdditionalUpfrontPaymentAbilityToReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AllocatedAmountOfTransactionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AllocatedAmountOfTransactionPrice" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AllocationPriceTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AllocationPriceTotal" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CostsIncurredInPerformingTheTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_CostsIncurredInPerformingTheTrial" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePaymentsExchangeRate" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_MilestonePaymentsExchangeRate" substitutionGroup="xbrli:item" />
<element name="NonRefundablePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_NonRefundablePaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfPaymentForCostIncurredInPIPTrial" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_PercentageOfPaymentForCostIncurredInPIPTrial" substitutionGroup="xbrli:item" />
<element name="PrepaidExpenseValueOfExpectedRecoveries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_PrepaidExpenseValueOfExpectedRecoveries" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_UpfrontPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ImmedicaPharmaABMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ImmedicaPharmaABMember" substitutionGroup="xbrli:item" />
<element name="ChangeInContractWithCustomerLiabilityRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ChangeInContractWithCustomerLiabilityRollForward" substitutionGroup="xbrli:item" />
<element name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ContractWithCustomerLiabilityAdditions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherCommitmentNonRefundableLicenseFeeAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_OtherCommitmentNonRefundableLicenseFeeAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentRoyaltyPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_OtherCommitmentRoyaltyPercentage" substitutionGroup="xbrli:item" />
<element name="ServiceBasedAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ServiceBasedAwardsMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEighteenEquityInducementPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_TwoThousandAndEighteenEquityInducementPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndFifteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_TwoThousandAndFifteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndSixteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndSixteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_TwoThousandAndSixteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ClassOfWarrantOrRightGrantDateFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClassOfWarrantOrRightUnamortizedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ClassOfWarrantOrRightUnamortizedExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GranteesWithMoreThanFiveYearsVestingTermPercent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_GranteesWithMoreThanFiveYearsVestingTermPercent" substitutionGroup="xbrli:item" />
<element name="IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" substitutionGroup="xbrli:item" />
<element name="MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" substitutionGroup="xbrli:item" />
<element name="MaximumVestingTermForMoreThanTenPercentGrantees" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_MaximumVestingTermForMoreThanTenPercentGrantees" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" substitutionGroup="xbrli:item" />
<element name="NonEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_NonEmployeesMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" substitutionGroup="xbrli:item" />
<element name="EmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_EmployeesMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="SeveranceLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_SeveranceLiabilityMember" substitutionGroup="xbrli:item" />
<element name="RestructuringActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_RestructuringActivitiesMember" substitutionGroup="xbrli:item" />
<element name="NumberOfDomesticSubsidiaries" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_NumberOfDomesticSubsidiaries" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsSetToExpireIfNotUtilized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxCreditCarryforwardsSetToExpireIfNotUtilized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_IncomeTaxesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_IncomeTaxesLineItems" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxReconciliationTaxCostCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_IncomeTaxReconciliationTaxCostCredit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AssetAcquisitionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_AssetAcquisitionMember" substitutionGroup="xbrli:item" />
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfEmployeesRetained" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_NumberOfEmployeesRetained" substitutionGroup="xbrli:item" />
<element name="PlacementAgentAndOtherOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syre_PlacementAgentAndOtherOfferingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedOptionCostPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syre_AccruedOptionCostPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_AccruedLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccruedLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syre_AccruedLiabilitiesLineItems" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>syre-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-March-2024 [02:06:26] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.spy.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StatementOfAssetsAcquiredAndLiabilitiesAssumed" roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails" roleURI="http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedOptionCostPayable" xlink:label="loc_SYRE_AccruedOptionCostPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_SYRE_AccruedOptionCostPayable" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProgramRightsObligations" xlink:label="loc_us-gaap_ProgramRightsObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_ProgramRightsObligations" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_NontradeReceivablesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="28" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_SYRE_AcquiredInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_SYRE_AcquiredInProcessResearchAndDevelopment" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNet" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="13" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_SYRE_AcquiredInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SYRE_AcquiredInProcessResearchAndDevelopment" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_SYRE_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SYRE_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments" use="optional" order="35" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xlink:label="loc_SYRE_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SYRE_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xlink:label="loc_SYRE_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SYRE_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_SYRE_IncomeTaxReconciliationTaxCostCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SYRE_IncomeTaxReconciliationTaxCostCredit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="12" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>syre-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-March-2024 [02:06:26] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#Cover" roleURI="http://www.spy.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.spy.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StatementOfAssetsAcquiredAndLiabilitiesAssumed" roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#TheCompanyAndBasisOfPresentationDetails" roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsNarrativeDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsChangesInForwardContractLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsChangesInCvrLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesNarrativeDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#PropertyAndEquipmentNetNarrativeDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AssetAcquisitionNarrativeDetails" roleURI="http://www.spy.com/role/AssetAcquisitionNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AssetAcquisitionAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ParagonAgreementDetails" roleURI="http://www.spy.com/role/ParagonAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#LeasesNarrativeDetails" roleURI="http://www.spy.com/role/LeasesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails" roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StrategicLicenseAgreementNarrativeDetails" roleURI="http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SaleOfPegzilarginaseToImmedicaDetails" roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationNarrativeDetails" roleURI="http://www.spy.com/role/StockBasedCompensationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationEmployeeRestrictedStockActivityDetails" roleURI="http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails" roleURI="http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringChargesNarrativeDetails" roleURI="http://www.spy.com/role/RestructuringChargesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringChargesChangesInAccruedRestructuringBalanceDetails" roleURI="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" roleURI="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://www.spy.com/role/IncomeTaxesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedLiabilitiesAdditionalInformationDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1923" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_DocumentType_102" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine1_110" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine2_111" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine3_112" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressCityOrTown_113" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressStateOrProvince_114" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressPostalZipCode_115" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_CityAreaCode_116" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityCentralIndexKey_128" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_AmendmentFlag_130" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_DocumentInformationTable_1918" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1918" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1919" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1919" xlink:to="loc_dei_AddressTypeDomain_1920" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1920_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1919" xlink:to="loc_dei_AddressTypeDomain_1920_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1920" xlink:to="loc_dei_BusinessContactMember_1921" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_ContactPersonnelName_1925" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityRegistrantName_107" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityIncorporationStateCountryCode_108" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityTaxIdentificationNumber_109" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_LocalPhoneNumber_117" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityFilerCategory_123" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntitySmallBusiness_124" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityEmergingGrowthCompany_125" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2703" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2703" xlink:to="loc_us-gaap_AssetsAbstract_2169" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2167" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2168" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2678" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_2721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_2721" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2873" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_AssetsCurrent_2892" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2679" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2720" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2874" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2891" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_Assets_2969" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2703" xlink:to="loc_us-gaap_StatementTable_2101" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2102" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2102" xlink:to="loc_us-gaap_ClassOfStockDomain_2165" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2165_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2102" xlink:to="loc_us-gaap_ClassOfStockDomain_2165_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2165" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2166" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2165" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2680" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2165" xlink:to="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2719" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2703" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2170" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_2171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_2171" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_2675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_2675" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2723" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2871" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2894" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_2967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_2967" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_LiabilitiesCurrent_2981" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_2676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_2676" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2722" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2872" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_Liabilities_2893" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2968" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2980" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3024" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_2172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_PreferredStockValue_2172" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_CommonStockValue_2674" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2724" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2870" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2895" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_StockholdersEquity_2966" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3029" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2690" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_StatementTable_2144" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2145" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2145" xlink:to="loc_us-gaap_ClassOfStockDomain_2146" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2145" xlink:to="loc_us-gaap_ClassOfStockDomain_2146_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2146" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2147" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2146" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2689" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2146" xlink:to="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2712" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3028" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3061" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockSharesIssued_3062" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3087" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2148" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_2688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_2688" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_2713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_2713" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2877" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2888" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2971" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2978" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3026" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2732" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_StatementTable_2191" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2191" xlink:to="loc_srt_ProductOrServiceAxis_2192" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2192" xlink:to="loc_srt_ProductsAndServicesDomain_2136" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2136_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2192" xlink:to="loc_srt_ProductsAndServicesDomain_2136_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_2137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2136" xlink:to="loc_us-gaap_LicenseMember_2137" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DevelopmentFeeAndRoyaltyMember" xlink:label="loc_syre_DevelopmentFeeAndRoyaltyMember_2696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2136" xlink:to="loc_syre_DevelopmentFeeAndRoyaltyMember_2696" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2191" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2664" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2664" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2187" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2187_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2664" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2187_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2187" xlink:to="loc_us-gaap_ForwardContractsMember_2188" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_2195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_InvestmentIncomeNet_2195" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3305" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2734" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2862" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2899" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2962" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_NetIncomeLoss_2985" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_EarningsPerShareBasic_3021" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3032" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_RevenuesAbstract_2189" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2189" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2193" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2665" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2194" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2663" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_2733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_2733" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2863" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_OperatingExpenses_2900" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_OperatingIncomeLoss_2731" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3058" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3065" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2625" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2625" xlink:to="loc_us-gaap_StatementTable_2284" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2284" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2285" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2285" xlink:to="loc_us-gaap_RelatedPartyDomain_2272" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2285" xlink:to="loc_us-gaap_RelatedPartyDomain_2272_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_2273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2272" xlink:to="loc_us-gaap_RelatedPartyMember_2273" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2625" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2274" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2869" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2869" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2270" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2628" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2754" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2847" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2869" xlink:to="loc_us-gaap_StatementTable_2174" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2174" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2175" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2175" xlink:to="loc_us-gaap_EquityComponentDomain_2176" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2176_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2175" xlink:to="loc_us-gaap_EquityComponentDomain_2176_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_PreferredStockMember_2177" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_CommonStockMember_2671" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2726" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2848" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_RetainedEarningsMember_2912" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2673" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2673" xlink:to="loc_us-gaap_ClassOfStockDomain_2265" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2673" xlink:to="loc_us-gaap_ClassOfStockDomain_2265_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2265" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2266" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2265" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2631" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2174" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2725" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2725" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2267" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2267_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2725" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2267_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2267" xlink:to="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2268" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfPreFundedWarrantsMember" xlink:label="loc_syre_ConversionOfPreFundedWarrantsMember_2629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2267" xlink:to="loc_syre_ConversionOfPreFundedWarrantsMember_2629" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2869" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2271" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2627" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockholdersEquity_2755" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2846" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2914" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2952" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2993" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3014" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3039" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3054" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3069" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_syre_StockIssuedDuringPeriodSharesNewIssuesOne_3082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodSharesNewIssuesOne_3082" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_syre_StockIssuedDuringPeriodValueNewIssuesOne_3091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodValueNewIssuesOne_3091" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_3104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_3104" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3109" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_3122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_3122" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_3125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_3125" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3137" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3140" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightDistributionToCommonStockholders" xlink:label="loc_syre_ContingentValueRightDistributionToCommonStockholders_3151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_ContingentValueRightDistributionToCommonStockholders_3151" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3154" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3165" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3168" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3176" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_NetIncomeLoss_3179" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2661" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" xlink:to="loc_us-gaap_NetIncomeLoss_2141" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2202" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_ShareBasedCompensation_2658" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_2736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_2736" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2860" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2902" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_2960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_AssetImpairmentCharges_2960" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2987" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3020" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3033" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3057" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2138" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2695" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2709" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2880" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2885" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2974" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_2975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_2975" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2708" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_StatementTable_2197" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2197" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2198" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2199" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2199_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2199_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2199" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2200" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2199" xlink:to="loc_us-gaap_ForwardContractsMember_2659" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_2140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_2140" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2693" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2711" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2878" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2887" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2972" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2977" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2139" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2694" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2710" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_2879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_2879" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_2886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_2886" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2973" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_2976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_2976" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3027" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2861" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2901" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_2961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_2961" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_2961" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2142" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_2151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" xlink:to="loc_us-gaap_StockIssued1_2151" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_2686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_2686" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_syre_LeasedAssetsObtainedInExchangeForLeaseObligations_2715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" xlink:to="loc_syre_LeasedAssetsObtainedInExchangeForLeaseObligations_2715" use="optional" order="53" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1929" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1929" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1929" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CompanyAndBasisOfPresentationLineItems" xlink:label="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CompanyAndBasisOfPresentationTable" xlink:label="loc_syre_CompanyAndBasisOfPresentationTable_2325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_CompanyAndBasisOfPresentationTable_2325" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2326" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2326" xlink:to="loc_us-gaap_EquityComponentDomain_2332" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2332_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2326" xlink:to="loc_us-gaap_EquityComponentDomain_2332_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2332" xlink:to="loc_us-gaap_CommonStockMember_2333" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2610" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2610" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2610" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_2335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334" xlink:to="loc_us-gaap_PrivatePlacementMember_2335" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2766" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2766" xlink:to="loc_us-gaap_ClassOfStockDomain_2336" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2336_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2766" xlink:to="loc_us-gaap_ClassOfStockDomain_2336_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2336" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2337" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2336" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2608" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_PlanNameAxis_2838" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2838" xlink:to="loc_us-gaap_PlanNameDomain_2327" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2327_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2838" xlink:to="loc_us-gaap_PlanNameDomain_2327_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_Spyre2023EquityIncentivePlanMember" xlink:label="loc_syre_Spyre2023EquityIncentivePlanMember_2328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2327" xlink:to="loc_syre_Spyre2023EquityIncentivePlanMember_2328" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2919" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2919" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2329" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2329_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2919" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2329_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_2330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2329" xlink:to="loc_syre_SpyreTherapeuticsIncMember_2330" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2767" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FixedExchangeRatio" xlink:label="loc_syre_FixedExchangeRatio_2837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_FixedExchangeRatio_2837" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2920" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2948" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_2996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_2996" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OutstandingAndUnexercisedStockOptions" xlink:label="loc_syre_OutstandingAndUnexercisedStockOptions_3012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_OutstandingAndUnexercisedStockOptions_3012" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3041" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3052" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3071" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod_3080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_AssetAcquisitionStockholderPaymentPeriod_3080" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3102" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ProceedsFromRaisingCapital" xlink:label="loc_syre_ProceedsFromRaisingCapital_3111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_ProceedsFromRaisingCapital_3111" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3120" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3127" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" xlink:to="loc_srt_RangeAxis_2119" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2119" xlink:to="loc_srt_RangeMember_2120" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2120_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2119" xlink:to="loc_srt_RangeMember_2120_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2120" xlink:to="loc_srt_MaximumMember_2121" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2700" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2700" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2700" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_USBankingInstitutionMember" xlink:label="loc_syre_USBankingInstitutionMember_2123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122" xlink:to="loc_syre_USBankingInstitutionMember_2123" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_2681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" xlink:to="loc_us-gaap_CashFDICInsuredAmount_2681" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2718" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2583" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2583" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2418" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2418" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2419" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2419" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2419" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LaboratoryEquipmentMember" xlink:label="loc_syre_LaboratoryEquipmentMember_2421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_syre_LaboratoryEquipmentMember_2421" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2582" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_us-gaap_ComputerEquipmentMember_2784" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SoftwareMember" xlink:label="loc_syre_SoftwareMember_2825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_syre_SoftwareMember_2825" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2422" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2358" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2358" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2351" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2340" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2340" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2340" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2344" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2607" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2607" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2607" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2346" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2605" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2769" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2768" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2768" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2768" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2348" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2836" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2836" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2836" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2350" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_CommercialPaperMember_2604" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2770" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2835" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2922" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2601" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2601" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2352" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2127" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2127" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2128" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2128_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2127" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2128_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_2129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2128" xlink:to="loc_syre_SpyreTherapeuticsIncMember_2129" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2672" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2672" xlink:to="loc_us-gaap_ClassOfStockDomain_2130" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2130_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2672" xlink:to="loc_us-gaap_ClassOfStockDomain_2130_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2130" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2131" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2706" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2706" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2132" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2132_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2706" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2132_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2132" xlink:to="loc_us-gaap_ForwardContractsMember_2133" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2132" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2699" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2153" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2684" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2716" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2876" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod_2889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_syre_AssetAcquisitionStockholderPaymentPeriod_2889" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_2970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_2970" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2979" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3025" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2581" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2581" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2443" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2577" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2788" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2581" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2424" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2424" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2425" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2425" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2440" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2440_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2425" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2440_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2440" xlink:to="loc_us-gaap_ForwardContractsMember_2441" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2943" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2943" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_srt_RangeAxis_2428" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2428" xlink:to="loc_srt_RangeMember_2447" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2447_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2428" xlink:to="loc_srt_RangeMember_2447_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2447" xlink:to="loc_srt_MaximumMember_2448" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2447" xlink:to="loc_srt_MinimumMember_2575" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2580" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2580" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2580" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2435" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2785" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2785" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2785" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2437" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2585" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2824" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2824" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2438" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2438_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2824" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2438_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_syre_MeasurementInputProbabilityOfSuccessMember_2439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2438" xlink:to="loc_syre_MeasurementInputProbabilityOfSuccessMember_2439" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MeasurementInputReimbursementRateMember" xlink:label="loc_syre_MeasurementInputReimbursementRateMember_2578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2438" xlink:to="loc_syre_MeasurementInputReimbursementRateMember_2578" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2438" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2787" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2929" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2943" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2487" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2682" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2682" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2157" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2683" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2717" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2875" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2682" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2159" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2159" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2160" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2160" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2154" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2160" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2154_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2154" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2155" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_2360" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsUnrealizedGains" xlink:label="loc_syre_CashEquivalentsUnrealizedGains_2599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_syre_CashEquivalentsUnrealizedGains_2599" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsUnrealizedLosses" xlink:label="loc_syre_CashEquivalentsUnrealizedLosses_2772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_syre_CashEquivalentsUnrealizedLosses_2772" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2833" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2354" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2354" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2355" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2355" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2355" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2357" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_CommercialPaperMember_2602" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2771" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2834" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2923" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2361" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2598" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2773" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2832" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2289" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2622" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2757" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2163" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2163" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2164" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2164" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2164" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_CommercialPaperMember_2287" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2624" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2756" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2845" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2312" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2616" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_2761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_2761" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2291" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2291" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2292" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2292" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2292" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2294" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" xlink:label="loc_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag_2296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag_2296" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_2295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_2295" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2620" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_2758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_2758" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2844" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2298" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2298" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2299" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2299" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2299" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LaboratoryEquipmentMember" xlink:label="loc_syre_LaboratoryEquipmentMember_2311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_syre_LaboratoryEquipmentMember_2311" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2617" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_us-gaap_ComputerEquipmentMember_2760" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SoftwareMember" xlink:label="loc_syre_SoftwareMember_2842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_syre_SoftwareMember_2842" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2916" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2313" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2615" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2762" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2364" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2364" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2364" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_2366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_2366" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2597" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2597" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2367" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2597" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2367_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2367" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2368" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2367" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2596" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2369" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2595" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2775" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2831" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_652" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_OwnershipAxis_627" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_627" xlink:to="loc_srt_OwnershipDomain_628" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_628_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_627" xlink:to="loc_srt_OwnershipDomain_628_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonTherapeuticsIncMember" xlink:label="loc_syre_ParagonTherapeuticsIncMember_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_syre_ParagonTherapeuticsIncMember_629" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FairmountFundsManagementLlcMember" xlink:label="loc_syre_FairmountFundsManagementLlcMember_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_syre_FairmountFundsManagementLlcMember_630" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAndParapyreHoldingLlcMember" xlink:label="loc_syre_ParagonAndParapyreHoldingLlcMember_2008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_syre_ParagonAndParapyreHoldingLlcMember_2008" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_631" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_632" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_632_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_632_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OwnershipInterestMember" xlink:label="loc_syre_OwnershipInterestMember_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_OwnershipInterestMember_633" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAgreementMember" xlink:label="loc_syre_ParagonAgreementMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_ParagonAgreementMember_635" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_636" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_syre_ReimbursableCostsUnderParagonAgreementMember_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_636" xlink:to="loc_syre_ReimbursableCostsUnderParagonAgreementMember_637" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MilestonePaymentsMember" xlink:label="loc_syre_MilestonePaymentsMember_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_MilestonePaymentsMember_638" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AppointOfBoardMembersMember" xlink:label="loc_syre_AppointOfBoardMembersMember_2684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_AppointOfBoardMembersMember_2684" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SPY002LicenseAgreementMember" xlink:label="loc_syre_SPY002LicenseAgreementMember_3127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_SPY002LicenseAgreementMember_3127" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SaleOfStockDecember2023PIPEMember" xlink:label="loc_syre_SaleOfStockDecember2023PIPEMember_3148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_SaleOfStockDecember2023PIPEMember_3148" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConsultingAgreementMember" xlink:label="loc_syre_ConsultingAgreementMember_3176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_ConsultingAgreementMember_3176" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_RangeAxis_641" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_641" xlink:to="loc_srt_RangeMember_642" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_642_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_641" xlink:to="loc_srt_RangeMember_642_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MaximumMember_643" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MinimumMember_644" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" xlink:to="loc_us-gaap_RelatedPartyDomain_646" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_646_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" xlink:to="loc_us-gaap_RelatedPartyDomain_646_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_646" xlink:to="loc_us-gaap_RelatedPartyMember_647" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_CounterpartyNameAxis_648" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_648" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_648" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_3037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_VestingAxis_3037" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_3037" xlink:to="loc_us-gaap_VestingDomain_2442" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2442_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_3037" xlink:to="loc_us-gaap_VestingDomain_2442_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2442" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2443" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3302" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_3304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303" xlink:to="loc_us-gaap_PrivatePlacementMember_3304" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:label="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_654" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:label="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ResearchInitiationFees" xlink:label="loc_syre_ResearchInitiationFees_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_ResearchInitiationFees_657" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableResearchCosts" xlink:label="loc_syre_ReimbursableResearchCosts_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_ReimbursableResearchCosts_658" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AmountToBePaidUnderAgreement" xlink:label="loc_syre_AmountToBePaidUnderAgreement_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_AmountToBePaidUnderAgreement_663" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensation_666" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_3192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_3192" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NominationFee" xlink:label="loc_syre_NominationFee_3225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_NominationFee_3225" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PaymentOfMilestone" xlink:label="loc_syre_PaymentOfMilestone_3239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_PaymentOfMilestone_3239" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3248" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3259" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3267" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3278" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_3294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_3294" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3301" use="optional" order="58" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_679" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_679" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" xlink:to="loc_us-gaap_RelatedPartyDomain_671" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" xlink:to="loc_us-gaap_RelatedPartyDomain_671_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_673" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_673" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_674" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_674_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_673" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_674_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_syre_ReimbursableCostsUnderParagonAgreementMember_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_674" xlink:to="loc_syre_ReimbursableCostsUnderParagonAgreementMember_675" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_676" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyTransactionReimbursableCosts" xlink:label="loc_syre_RelatedPartyTransactionReimbursableCosts_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_679" xlink:to="loc_syre_RelatedPartyTransactionReimbursableCosts_680" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_691" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_691" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" xlink:to="loc_us-gaap_RelatedPartyDomain_685" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" xlink:to="loc_us-gaap_RelatedPartyDomain_685_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_685" xlink:to="loc_us-gaap_RelatedPartyMember_686" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_687" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_687" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_688" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_688_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_687" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_688_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_syre_ReimbursableCostsUnderParagonAgreementMember_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_688" xlink:to="loc_syre_ReimbursableCostsUnderParagonAgreementMember_689" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_2175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_691" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_2175" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1872" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionTable_1871" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_PlanNameAxis_1874" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1874" xlink:to="loc_us-gaap_PlanNameDomain_1875" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1875_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1874" xlink:to="loc_us-gaap_PlanNameDomain_1875_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_1876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1875" xlink:to="loc_syre_ParapyreOptionObligationMember_1876" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_Spyre2023EquityIncentivePlanMember" xlink:label="loc_syre_Spyre2023EquityIncentivePlanMember_2604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1875" xlink:to="loc_syre_Spyre2023EquityIncentivePlanMember_2604" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_2598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_2598" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_2598" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_2598" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599" xlink:to="loc_us-gaap_CommonStockMember_2600" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2626" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2626" xlink:to="loc_us-gaap_ClassOfStockDomain_2601" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2601_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2626" xlink:to="loc_us-gaap_ClassOfStockDomain_2601_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2601" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2602" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2920" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2920" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2605" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2605_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2920" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2605_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_2606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2605" xlink:to="loc_syre_SpyreTherapeuticsIncMember_2606" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2607" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OutstandingAndUnexercisedStockOptions" xlink:label="loc_syre_OutstandingAndUnexercisedStockOptions_2625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_OutstandingAndUnexercisedStockOptions_2625" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2913" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_2919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_2919" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_3061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_3061" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_720" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionTable_716" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_716" xlink:to="loc_us-gaap_AssetAcquisitionAxis_717" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_717" xlink:to="loc_us-gaap_AssetAcquisitionDomain_718" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_718_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_717" xlink:to="loc_us-gaap_AssetAcquisitionDomain_718_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_718" xlink:to="loc_syre_SpyreTherapeuticsIncMember_719" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_723" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_724" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssumedLiabilities" xlink:label="loc_syre_AssumedLiabilities_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_syre_AssumedLiabilities_725" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParagonAgreementDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_748" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" xlink:to="loc_us-gaap_RelatedPartyDomain_731" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_731_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" xlink:to="loc_us-gaap_RelatedPartyDomain_731_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_731" xlink:to="loc_us-gaap_RelatedPartyMember_732" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_733" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_733" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_734" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_734_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_733" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_734_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAgreementMember" xlink:label="loc_syre_ParagonAgreementMember_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_syre_ParagonAgreementMember_735" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_738" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_PlanNameAxis_739" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_739" xlink:to="loc_us-gaap_PlanNameDomain_740" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_740_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_739" xlink:to="loc_us-gaap_PlanNameDomain_740_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_740" xlink:to="loc_syre_ParapyreOptionObligationMember_741" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_RangeAxis_742" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_742" xlink:to="loc_srt_RangeMember_743" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_742" xlink:to="loc_srt_RangeMember_743_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_CounterpartyNameAxis_745" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_745" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_745" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonTherapeuticsIncMember" xlink:label="loc_syre_ParagonTherapeuticsIncMember_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" xlink:to="loc_syre_ParagonTherapeuticsIncMember_747" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ResearchInitiationFees" xlink:label="loc_syre_ResearchInitiationFees_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_ResearchInitiationFees_749" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableResearchCosts" xlink:label="loc_syre_ReimbursableResearchCosts_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_ReimbursableResearchCosts_751" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:label="loc_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LicenseAgreementMilestonePayments" xlink:label="loc_syre_LicenseAgreementMilestonePayments_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_LicenseAgreementMilestonePayments_759" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2317" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2317" xlink:to="loc_srt_RangeAxis_2318" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2318" xlink:to="loc_srt_RangeMember_2341" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2341_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2318" xlink:to="loc_srt_RangeMember_2341_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2341" xlink:to="loc_srt_MinimumMember_2342" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2341" xlink:to="loc_srt_MaximumMember_2606" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2319" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_2612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_AreaOfLand_2612" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_2764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_SecurityDeposit_2764" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaap_TenantImprovements_2840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_TenantImprovements_2840" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLeaseTerminationFeeAmount" xlink:label="loc_syre_OperatingLeaseTerminationFeeAmount_2918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_syre_OperatingLeaseTerminationFeeAmount_2918" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_2950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_OperatingLeasePayments_2950" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2997" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2372" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2373" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2373" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2373" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_2375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374" xlink:to="loc_us-gaap_PrivatePlacementMember_2375" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2594" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2594" xlink:to="loc_us-gaap_EquityComponentDomain_2376" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2594" xlink:to="loc_us-gaap_EquityComponentDomain_2376_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2376" xlink:to="loc_us-gaap_CommonStockMember_2446" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2376" xlink:to="loc_us-gaap_PreferredStockMember_2576" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_srt_RangeAxis_2776" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2776" xlink:to="loc_srt_RangeMember_2449" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2776" xlink:to="loc_srt_RangeMember_2449_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2449" xlink:to="loc_srt_MaximumMember_2450" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2449" xlink:to="loc_srt_MinimumMember_2574" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2830" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2830" xlink:to="loc_us-gaap_ClassOfStockDomain_2458" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2458_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2830" xlink:to="loc_us-gaap_ClassOfStockDomain_2458_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2458" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2459" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2458" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2569" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2924" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2924" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2429" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2924" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2429_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreWarrantsMember" xlink:label="loc_syre_ParapyreWarrantsMember_2430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2429" xlink:to="loc_syre_ParapyreWarrantsMember_2430" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2947" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2947" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2431" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2431_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2947" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2431_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2431" xlink:to="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2432" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SharesAuthorized" xlink:label="loc_syre_SharesAuthorized_2433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_SharesAuthorized_2433" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2579" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2786" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2823" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="loc_syre_NumberOfCommonStockVotingRightsHeldPerShare_2942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_NumberOfCommonStockVotingRightsHeldPerShare_2942" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_3000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_DividendsCommonStock_3000" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3009" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3044" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3050" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3072" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3079" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_3094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_3094" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3101" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3112" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_syre_PlacementAgentFeesAndOfferingCosts_3119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_PlacementAgentFeesAndOfferingCosts_3119" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3128" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3135" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3142" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_3156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_3156" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" xlink:label="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice_3163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice_3163" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_3170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_3170" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:label="loc_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_3175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_3175" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:label="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_3180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_3180" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_3185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_3185" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_BeneficiallyHoldersOwnedPercentage" xlink:label="loc_syre_BeneficiallyHoldersOwnedPercentage_3190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_BeneficiallyHoldersOwnedPercentage_3190" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3195" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3199" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3203" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaap_PreferredStockRedemptionAmount_3206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockRedemptionAmount_3206" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_3209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_3209" use="optional" order="58" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2507" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2547" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2801" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2801" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2496" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2496" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2505_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2496" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2505_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreFundedMay2022WarrantsMember" xlink:label="loc_syre_PreFundedMay2022WarrantsMember_2506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" xlink:to="loc_syre_PreFundedMay2022WarrantsMember_2506" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreFundedWarrantsMember" xlink:label="loc_syre_PreFundedWarrantsMember_2548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" xlink:to="loc_syre_PreFundedWarrantsMember_2548" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2510" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2510" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2510" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ImmedicaPharmaABMember" xlink:label="loc_syre_ImmedicaPharmaABMember_2512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511" xlink:to="loc_syre_ImmedicaPharmaABMember_2512" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2546" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2546" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2546" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PeaceTrialAndBLAPackageMember" xlink:label="loc_syre_PeaceTrialAndBLAPackageMember_2514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" xlink:to="loc_syre_PeaceTrialAndBLAPackageMember_2514" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PIPTrialMember" xlink:label="loc_syre_PIPTrialMember_2545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" xlink:to="loc_syre_PIPTrialMember_2545" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LicenseAgreementsMember" xlink:label="loc_syre_LicenseAgreementsMember_2804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" xlink:to="loc_syre_LicenseAgreementsMember_2804" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2739" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2739" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2497" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2497_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2739" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2497_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2497" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2498" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2813" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2813" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2813" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GlobalRightsToPegzilarginaseMember" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember_2500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499" xlink:to="loc_syre_GlobalRightsToPegzilarginaseMember_2500" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_2501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_2501" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonRefundablePaymentReceived" xlink:label="loc_syre_NonRefundablePaymentReceived_2549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_NonRefundablePaymentReceived_2549" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:label="loc_syre_PercentageOfPaymentForCostIncurredInPIPTrial_2803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_PercentageOfPaymentForCostIncurredInPIPTrial_2803" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CostsIncurredInPerformingTheTrial" xlink:label="loc_syre_CostsIncurredInPerformingTheTrial_2814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_CostsIncurredInPerformingTheTrial_2814" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AdditionalUpfrontPaymentAbilityToReceived" xlink:label="loc_syre_AdditionalUpfrontPaymentAbilityToReceived_2934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_AdditionalUpfrontPaymentAbilityToReceived_2934" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MilestonePaymentsExchangeRate" xlink:label="loc_syre_MilestonePaymentsExchangeRate_2940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_MilestonePaymentsExchangeRate_2940" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_UpfrontPayment" xlink:label="loc_syre_UpfrontPayment_3007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_UpfrontPayment_3007" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_3045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_3045" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3048" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AllocatedAmountOfTransactionPrice" xlink:label="loc_syre_AllocatedAmountOfTransactionPrice_3074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_AllocatedAmountOfTransactionPrice_3074" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AllocationPriceTotal" xlink:label="loc_syre_AllocationPriceTotal_3077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_AllocationPriceTotal_3077" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3096" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3099" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3114" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_3117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_3117" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_3130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_3130" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_3133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_3133" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3144" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3147" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PrepaidExpenseValueOfExpectedRecoveries" xlink:label="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_3158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_3158" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xlink:label="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_3161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_3161" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2504" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2504" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2212" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2212_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2504" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2212_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2212" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2213" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2654" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2654" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2654" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GlobalRightsToPegzilarginaseMember" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember_2215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214" xlink:to="loc_syre_GlobalRightsToPegzilarginaseMember_2215" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2216" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_2652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_2652" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2742" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2858" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PrepaidExpenseValueOfExpectedRecoveries" xlink:label="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_2903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_2903" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xlink:label="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_2959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_2959" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_us-gaap_PlanNameAxis_2379" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2379" xlink:to="loc_us-gaap_PlanNameDomain_2380" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2380_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2379" xlink:to="loc_us-gaap_PlanNameDomain_2380_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:label="loc_syre_TwoThousandAndFifteenEquityIncentivePlanMember_2381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndFifteenEquityIncentivePlanMember_2381" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_2593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_2593" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_2777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_2777" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_2829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_2829" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2946" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_us-gaap_AwardTypeAxis_2585" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2404" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ServiceBasedAwardsMember" xlink:label="loc_syre_ServiceBasedAwardsMember_2589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_syre_ServiceBasedAwardsMember_2589" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2781" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_us-gaap_PerformanceSharesMember_2827" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_srt_TitleOfIndividualAxis_2778" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2778" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2778" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonEmployeesMember" xlink:label="loc_syre_NonEmployeesMember_2383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382" xlink:to="loc_syre_NonEmployeesMember_2383" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2826" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2384" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2384_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_2385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2384" xlink:to="loc_syre_ParapyreOptionObligationMember_2385" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2386" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2592" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:label="loc_syre_GranteesWithMoreThanFiveYearsVestingTermPercent_2779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_GranteesWithMoreThanFiveYearsVestingTermPercent_2779" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:label="loc_syre_MaximumVestingTermForMoreThanTenPercentGrantees_2828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_MaximumVestingTermForMoreThanTenPercentGrantees_2828" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2927" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2944" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2999" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_3010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_3010" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:label="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_3043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_3043" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_3049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_3049" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3073" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares_3078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares_3078" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount_3095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount_3095" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount_3100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount_3100" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3113" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3118" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3129" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3134" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" xlink:label="loc_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding_3143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding_3143" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3148" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightGrantDateFairValue" xlink:label="loc_syre_ClassOfWarrantOrRightGrantDateFairValue_3157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ClassOfWarrantOrRightGrantDateFairValue_3157" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3162" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensation_3171" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightUnamortizedExpense" xlink:label="loc_syre_ClassOfWarrantOrRightUnamortizedExpense_3174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ClassOfWarrantOrRightUnamortizedExpense_3174" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3181" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3184" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3191" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_3194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_3194" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3200" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3202" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_3207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_3207" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_3208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_3208" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:label="loc_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_3212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_3212" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3213" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3216" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3217" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3219" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3220" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3221" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3222" use="optional" order="64" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" xlink:to="loc_us-gaap_AwardTypeAxis_2224" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217" xlink:to="loc_us-gaap_RestrictedStockMember_2218" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" xlink:to="loc_srt_TitleOfIndividualAxis_2650" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2650" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2650" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EmployeesMember" xlink:label="loc_syre_EmployeesMember_2220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219" xlink:to="loc_syre_EmployeesMember_2220" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2237" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2645" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2743" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2857" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2225" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2649" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2745" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2856" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2817" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2817" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xlink:to="loc_us-gaap_PlanNameAxis_2463" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2463" xlink:to="loc_us-gaap_PlanNameDomain_2464" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2464_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2463" xlink:to="loc_us-gaap_PlanNameDomain_2464_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_2465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2464" xlink:to="loc_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_2465" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2567" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2567" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2466" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2466_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2567" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2466_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2466" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2467" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2466" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2566" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xlink:to="loc_srt_TitleOfIndividualAxis_2794" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2794" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2794" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EmployeesMember" xlink:label="loc_syre_EmployeesMember_2470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" xlink:to="loc_syre_EmployeesMember_2470" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonEmployeesMember" xlink:label="loc_syre_NonEmployeesMember_2564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" xlink:to="loc_syre_NonEmployeesMember_2564" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2817" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2471" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" xlink:to="loc_us-gaap_PlanNameAxis_2233" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2233" xlink:to="loc_us-gaap_PlanNameDomain_2226" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2226_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2233" xlink:to="loc_us-gaap_PlanNameDomain_2226_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2226" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2227" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" xlink:to="loc_us-gaap_AwardTypeAxis_2647" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2229" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2230" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2648" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2746" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2855" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2235" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2235" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2236" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2236" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2238" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2238_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2236" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2238_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2238" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2239" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2238" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2644" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2240" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_SeveranceCosts1_2642" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_2748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_PaymentsForRestructuring_2748" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_2854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_2854" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2906" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2958" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_2988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_2988" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_3019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_3019" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLeaseTerminationFeeAmount" xlink:label="loc_syre_OperatingLeaseTerminationFeeAmount_3034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_syre_OperatingLeaseTerminationFeeAmount_3034" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2518" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2518" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2519" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2519" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2520" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2520_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2519" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2520_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeveranceLiabilityMember" xlink:label="loc_syre_SeveranceLiabilityMember_2521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2520" xlink:to="loc_syre_SeveranceLiabilityMember_2521" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_2522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_RestructuringReserve_2522" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_2543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_RestructuringCharges_2543" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_2805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_PaymentsForRestructuring_2805" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2474" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2474" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2475" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2475_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2474" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2475_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RestructuringActivitiesMember" xlink:label="loc_syre_RestructuringActivitiesMember_2476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2475" xlink:to="loc_syre_RestructuringActivitiesMember_2476" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2563" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2477" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2477_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2477_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2477" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2478" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2477" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2562" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_SeveranceCosts1_2479" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2561" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2797" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_2816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_2816" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_2911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_RestructuringCosts_2911" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2541" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_2526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_2526" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2526" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2527" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2527" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2529" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2529_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2527" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2529_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_2530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2529" xlink:to="loc_us-gaap_ForeignCountryMember_2530" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2529" xlink:to="loc_us-gaap_DomesticCountryMember_2539" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2529" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2808" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2528" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2540" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2807" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2811" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" xlink:label="loc_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized_2936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized_2936" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" xlink:label="loc_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized_2939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized_2939" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfDomesticSubsidiaries" xlink:label="loc_syre_NumberOfDomesticSubsidiaries_3003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_syre_NumberOfDomesticSubsidiaries_3003" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3006" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesLineItems" xlink:label="loc_syre_IncomeTaxesLineItems_2643" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesTable" xlink:label="loc_syre_IncomeTaxesTable_2242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_syre_IncomeTaxesTable_2242" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_IncomeTaxesTable_2242" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2243" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2243" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2244" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2243" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2244_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2244" xlink:to="loc_us-gaap_DomesticCountryMember_2245" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2244" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2641" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2246" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xlink:label="loc_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount_2640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount_2640" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2749" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xlink:label="loc_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount_2853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount_2853" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2907" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_syre_IncomeTaxReconciliationTaxCostCredit_2957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_syre_IncomeTaxReconciliationTaxCostCredit_2957" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2989" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3018" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3035" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesLineItems" xlink:label="loc_syre_IncomeTaxesLineItems_2634" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2264" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2632" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2753" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2849" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2910" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2954" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2992" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3015" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3038" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesTable" xlink:label="loc_syre_IncomeTaxesTable_2258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_syre_IncomeTaxesTable_2258" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_IncomeTaxesTable_2258" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2259" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2259" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2262" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2262_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2259" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2262_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2262" xlink:to="loc_us-gaap_DomesticCountryMember_2263" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2262" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2633" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2181" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2668" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2728" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2867" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3318" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3318" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3312" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3312" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3313" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3313" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3313" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3315" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3316" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreWarrantsMember" xlink:label="loc_syre_ParapyreWarrantsMember_3317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" xlink:to="loc_syre_ParapyreWarrantsMember_3317" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3318" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3319" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1806" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionTable_1802" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_1802" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1803" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1803" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1804" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1804_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1803" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1804_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_1805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1804" xlink:to="loc_syre_SpyreTherapeuticsIncMember_1805" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_1809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_1809" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_1810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_1810" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1813" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FixedExchangeRatio" xlink:label="loc_syre_FixedExchangeRatio_1817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_FixedExchangeRatio_1817" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1824" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1824" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1825" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1825_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1824" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1825_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionMember" xlink:label="loc_syre_AssetAcquisitionMember_1826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_syre_AssetAcquisitionMember_1826" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_1838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_syre_SpyreTherapeuticsIncMember_1838" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1827" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1827" xlink:to="loc_us-gaap_ClassOfStockDomain_1828" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1827" xlink:to="loc_us-gaap_ClassOfStockDomain_1828_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1828" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1829" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1830" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1830" xlink:to="loc_us-gaap_EquityComponentDomain_1831" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1831_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1830" xlink:to="loc_us-gaap_EquityComponentDomain_1831_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1831" xlink:to="loc_us-gaap_CommonStockMember_1832" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" xlink:to="loc_us-gaap_CommonStockMember_1855" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_PlanNameAxis_1850" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1850" xlink:to="loc_us-gaap_PlanNameDomain_1851" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1850" xlink:to="loc_us-gaap_PlanNameDomain_1851_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_Spyre2023EquityIncentivePlanMember" xlink:label="loc_syre_Spyre2023EquityIncentivePlanMember_1852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_syre_Spyre2023EquityIncentivePlanMember_1852" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_1859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_syre_ParapyreOptionObligationMember_1859" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" xlink:to="loc_us-gaap_PrivatePlacementMember_1862" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1863" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_USBankingInstitutionMember" xlink:label="loc_syre_USBankingInstitutionMember_1865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" xlink:to="loc_syre_USBankingInstitutionMember_1865" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OutstandingAndUnexercisedStockOptions" xlink:label="loc_syre_OutstandingAndUnexercisedStockOptions_1823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_OutstandingAndUnexercisedStockOptions_1823" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1836" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_1839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_1839" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfEmployeesRetained" xlink:label="loc_syre_NumberOfEmployeesRetained_1844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_NumberOfEmployeesRetained_1844" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_syre_PlacementAgentAndOtherOfferingExpenses_1847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_PlacementAgentAndOtherOfferingExpenses_1847" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_Cash_1849" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesLineItems" xlink:label="loc_syre_AccruedLiabilitiesLineItems_1958" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesTable" xlink:label="loc_syre_AccruedLiabilitiesTable_1957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_AccruedLiabilitiesTable_1957" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" xlink:to="loc_us-gaap_RelatedPartyDomain_1964" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" xlink:to="loc_us-gaap_RelatedPartyDomain_1964_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1964" xlink:to="loc_us-gaap_RelatedPartyMember_1965" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syre_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1966" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1966" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1967" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1967_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1966" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1967_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAgreementMember" xlink:label="loc_syre_ParagonAgreementMember_1968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1967" xlink:to="loc_syre_ParagonAgreementMember_1968" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ResearchInitiationFees" xlink:label="loc_syre_ResearchInitiationFees_1960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_ResearchInitiationFees_1960" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableResearchCosts" xlink:label="loc_syre_ReimbursableResearchCosts_1961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_ReimbursableResearchCosts_1961" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1884" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_SubsequentEventTable_1883" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1885" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1886" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1886_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1886_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1886" xlink:to="loc_us-gaap_SubsequentEventMember_1887" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1889" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1889" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1890" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1890_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1889" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1890_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_1891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1890" xlink:to="loc_syre_SpyreTherapeuticsIncMember_1891" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1892" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1892" xlink:to="loc_us-gaap_ClassOfStockDomain_1893" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1892" xlink:to="loc_us-gaap_ClassOfStockDomain_1893_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1893" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1894" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" xlink:to="loc_us-gaap_CommonStockMember_1897" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_srt_RangeAxis_1901" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1901" xlink:to="loc_srt_RangeMember_1902" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1901" xlink:to="loc_srt_RangeMember_1902_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MaximumMember_1903" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MinimumMember_1904" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_PlanNameAxis_1906" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1906" xlink:to="loc_us-gaap_PlanNameDomain_1907" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1906" xlink:to="loc_us-gaap_PlanNameDomain_1907_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_1908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1907" xlink:to="loc_syre_ParapyreOptionObligationMember_1908" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="1.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>syre-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-March-2024 [02:06:26] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3" xml:lang="en-US">Entity Address, Address Line Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine3" xml:lang="en-US">Entity Address, Address Line Three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xlink:to="lab_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series A Non Voting Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series A Non Voting Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series A non voting convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series B Non Voting Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:to="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SeriesBNonVotingConvertiblePreferredStockMember" xml:lang="en-US">Series B Non Voting Convertible Preferred Stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">TOTAL ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Marketable securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Estimated Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Total marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xml:lang="en-US">Nontrade Receivables, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xml:lang="en-US">Development receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="lab_us-gaap_NontradeReceivablesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies (Note 9)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Deferred revenue, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Non-current CVR liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">TOTAL LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Total accrued and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Deferred revenue, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">CVR liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Non-current operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value; 400,000,000 and 20,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 36,057,109 shares and 2,614,014 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 150,000 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Series B non-voting convertible preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Series B non-voting convertible preferred stock, authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Series B non-voting convertible preferred stock, issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Series B non-voting convertible preferred stock, outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForwardContractsMember" xml:lang="en-US">Forward Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForwardContractsMember" xml:lang="en-US">Forward Contract Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForwardContractsMember" xml:lang="en-US">Forward Contracts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DevelopmentFeeAndRoyaltyMember" xlink:label="loc_syre_DevelopmentFeeAndRoyaltyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_DevelopmentFeeAndRoyaltyMember" xml:lang="en-US">Development Fee And Royalty [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_DevelopmentFeeAndRoyaltyMember" xml:lang="en-US">Development fee and royalty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DevelopmentFeeAndRoyaltyMember" xlink:to="lab_syre_DevelopmentFeeAndRoyaltyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share, basic (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision or benefit from income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (expense) income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of forward contract liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Change in fair value of derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Acquired In Process Research And Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Acquired in-process research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_syre_AcquiredInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AcquiredInProcessResearchAndDevelopment" xml:lang="en-US">Acquired in process research and development</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Gain on sale of in-process research and development asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Gain on sale of in-process research and development asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Total diluted weighed average shares (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Total basic weighed average shares (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyMember" xml:lang="en-US">Related Party [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyMember" xml:lang="en-US">Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other comprehensive income (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized gain (loss) on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xml:lang="en-US">Stock Conversion Description [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xml:lang="en-US">Stock Conversion Description [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xml:lang="en-US">Conversion of Stock, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xml:lang="en-US">Conversion of Stock, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfPreFundedWarrantsMember" xlink:label="loc_syre_ConversionOfPreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ConversionOfPreFundedWarrantsMember" xml:lang="en-US">Conversion Of Pre-Funded Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ConversionOfPreFundedWarrantsMember" xml:lang="en-US">Conversion Of Pre-Funded Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ConversionOfPreFundedWarrantsMember" xlink:to="lab_syre_ConversionOfPreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ConversionOfPreFundedWarrantsMember" xml:lang="en-US">Conversion Of Pre-Funded Warrants</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Conversion Of Series A Non-Voting Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Conversion Of Series A Non-Voting Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xlink:to="lab_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US">Conversion Of Series A Non-Voting Convertible Preferred Stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Issuance of Parapyre Option Obligation warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightDistributionToCommonStockholders" xlink:label="loc_syre_ContingentValueRightDistributionToCommonStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ContingentValueRightDistributionToCommonStockholders" xml:lang="en-US">Contingent Value Right Distribution To Common Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ContingentValueRightDistributionToCommonStockholders" xml:lang="en-US">CVR distribution to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ContingentValueRightDistributionToCommonStockholders" xlink:to="lab_syre_ContingentValueRightDistributionToCommonStockholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ContingentValueRightDistributionToCommonStockholders" xml:lang="en-US">Contingent value right distribution to common stockholders.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issued as part of consideration transferred in acquisition (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock Issued During Period Shares Common Stock And Pre Funded Warrants Registered Direct Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:to="lab_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock Issued During Period Shares Common Stock And Pre Funded Warrants Registered Direct Offering</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock upon conversion (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_syre_StockIssuedDuringPeriodSharesNewIssuesOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_StockIssuedDuringPeriodSharesNewIssuesOne" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_StockIssuedDuringPeriodSharesNewIssuesOne" xml:lang="en-US">Issuance of common stock in connection with private placement, net of financing costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="lab_syre_StockIssuedDuringPeriodSharesNewIssuesOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_StockIssuedDuringPeriodSharesNewIssuesOne" xml:lang="en-US">Stock Issued During Period, Shares, New Issues, One</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:to="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Issuance of common stock in connection with the asset acquisition of Spyre (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:to="lab_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xml:lang="en-US">Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock upon conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Issuance of common stock in connection with employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_syre_StockIssuedDuringPeriodValueNewIssuesOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_StockIssuedDuringPeriodValueNewIssuesOne" xml:lang="en-US">Stock Issued During Period, Value, New Issues, One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_StockIssuedDuringPeriodValueNewIssuesOne" xml:lang="en-US">Issuance of common stock in connection with private placement, net of financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="lab_syre_StockIssuedDuringPeriodValueNewIssuesOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_StockIssuedDuringPeriodValueNewIssuesOne" xml:lang="en-US">Stock Issued During Period, Value, New Issues, One</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:to="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xml:lang="en-US">Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Issuance of common stock in connection with the asset acquisition of Spyre</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ContingentValueRightLiabilityMember" xml:lang="en-US">Contingent Value Right Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ContingentValueRightLiabilityMember" xml:lang="en-US">CVR liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ContingentValueRightLiabilityMember" xlink:to="lab_syre_ContingentValueRightLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ContingentValueRightLiabilityMember" xml:lang="en-US">Contingent Value Right Liability</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xml:lang="en-US">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">End of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Finance Lease, Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Principal payments on finance lease obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xml:lang="en-US">Payments for Derivative Instrument, Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xml:lang="en-US">Payment of contingent value rights liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock in connection with private placement, net of placement and other offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Net proceeds from sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:to="lab_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants in public offering net of offering costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from issuance of Series A non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from issuance of Series B non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from issuance of private placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Gross proceeds received in private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from employee stock plan purchases and stock option exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash Acquired from Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash assumed from asset acquisition of Spyre</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xml:lang="en-US">Purchases of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from Sale of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from sale of in-process research &amp; development asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xml:lang="en-US">Proceeds from sale of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of property plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Net (accretion of discount) amortization of premium on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Lease ROU asset and leasehold improvement impairment loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of long-lived assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of long-lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Development receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Amortization of operating lease assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of Series A non-voting convertible preferred stock into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_syre_LeasedAssetsObtainedInExchangeForLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LeasedAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Leased Assets Obtained In Exchange For Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LeasedAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Leased assets obtained in exchange for lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:to="lab_syre_LeasedAssetsObtainedInExchangeForLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LeasedAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Leased assets obtained in exchange for lease obligations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xml:lang="en-US">ASSETS ACQUIRED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xml:lang="en-US">LIABILITIES ASSUMED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xml:lang="en-US">Total liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Net liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">The Company and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xml:lang="en-US">Description of the Business and Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xml:lang="en-US">Description of the business and summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Description of the Business and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:label="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">Accrued And Other Current Liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xml:lang="en-US">The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesTextBlock" xlink:label="loc_syre_AccruedLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedLiabilitiesTextBlock" xml:lang="en-US">Accrued Liabilities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AccruedLiabilitiesTextBlock" xml:lang="en-US">Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedLiabilitiesTextBlock" xlink:to="lab_syre_AccruedLiabilitiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedLiabilitiesTextBlock" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Asset Acquisition [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Asset Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OptionAgreementTextBlock" xlink:label="loc_syre_OptionAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OptionAgreementTextBlock" xml:lang="en-US">Option Agreement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OptionAgreementTextBlock" xml:lang="en-US">Paragon Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OptionAgreementTextBlock" xlink:to="lab_syre_OptionAgreementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OptionAgreementTextBlock" xml:lang="en-US">Option agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xml:lang="en-US">Lessee, Finance Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Convertible Preferred Stock and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Strategic License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Sale of Pegzilarginase to Immedica</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Novation of Manufacturing Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Defined Contribution Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring and Related Activities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="loc_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xml:lang="en-US">Accrued Research And Development Expense [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xml:lang="en-US">Accrued Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:to="lab_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xml:lang="en-US">Accrued research and development expense policy.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Contingent Value Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" xml:lang="en-US">In-Process Research And Development Assets, Contingent Consideration, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" xml:lang="en-US">Contingent Milestone Proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" xlink:to="lab_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" xml:lang="en-US">In-Process Research And Development Assets, Contingent Consideration, Policy</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncement/Recently Issued Accounting Pronouncement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TemporaryEquityPolicyPolicyTextBlock" xlink:label="loc_syre_TemporaryEquityPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TemporaryEquityPolicyPolicyTextBlock" xml:lang="en-US">Temporary Equity, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TemporaryEquityPolicyPolicyTextBlock" xml:lang="en-US">Convertible Preferred Stock Issued through PIPE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TemporaryEquityPolicyPolicyTextBlock" xlink:to="lab_syre_TemporaryEquityPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TemporaryEquityPolicyPolicyTextBlock" xml:lang="en-US">Temporary Equity, Policy</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesPolicyTextBlock" xlink:label="loc_syre_AccruedLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedLiabilitiesPolicyTextBlock" xml:lang="en-US">Accrued Liabilities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AccruedLiabilitiesPolicyTextBlock" xml:lang="en-US">Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedLiabilitiesPolicyTextBlock" xlink:to="lab_syre_AccruedLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedLiabilitiesPolicyTextBlock" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Useful Lives of Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule of estimated useful lives of property plant and equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Significant Inputs used to Estimate the Fair Value of Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Changes in Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xml:lang="en-US">Available-for-Sale Securities in an Unrealized Loss Position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xml:lang="en-US">Contractual Maturities of Marketable Securities at Estimated Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xml:lang="en-US">Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xlink:label="loc_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xml:lang="en-US">Schedule Of Balances Due To Affiliates [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xml:lang="en-US">Related Party Accounts Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xlink:to="lab_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xml:lang="en-US">Schedule of balances due to affiliates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Expenses related to Related Party which were Settled in Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xml:lang="en-US">Asset Acquisition [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xml:lang="en-US">Asset Acquisition Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xml:lang="en-US">Summary of Asset Acquisition Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_syre_AssetsAndLiabilitiesLesseeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssetsAndLiabilitiesLesseeTableTextBlock" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AssetsAndLiabilitiesLesseeTableTextBlock" xml:lang="en-US">Supplemental Balance Sheet Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_syre_AssetsAndLiabilitiesLesseeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssetsAndLiabilitiesLesseeTableTextBlock" xml:lang="en-US">Assets And Liabilities, Lessee</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Weighted-Average Remaining Lease Term/Discount Rates and Lease Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Pre-funded Warrants for Common Stock Issued and Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Changes in Contract Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US">Employee Restricted Stock Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Stock-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Employee and Non-Employee Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Weighted-Average Assumptions Used in Calculating Fair Value of Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Charges Related to the Restructuring Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Changes in Accrued Restructuring Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Effective Income Tax Rate Reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">(Loss) Income Before Income Tax Expense by Jurisdiction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Reconciliation of Basic and Diluted Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CompanyAndBasisOfPresentationTable" xlink:label="loc_syre_CompanyAndBasisOfPresentationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CompanyAndBasisOfPresentationTable" xml:lang="en-US">Company and Basis of Presentation [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_CompanyAndBasisOfPresentationTable" xml:lang="en-US">Company and Basis of Presentation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable" xlink:to="lab_syre_CompanyAndBasisOfPresentationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CompanyAndBasisOfPresentationTable" xml:lang="en-US">Company and basis of presentation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SpyreTherapeuticsIncMember" xml:lang="en-US">Spyre Therapeutics, Inc. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_SpyreTherapeuticsIncMember" xml:lang="en-US">Spyre Therapeutics, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SpyreTherapeuticsIncMember" xlink:to="lab_syre_SpyreTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SpyreTherapeuticsIncMember" xml:lang="en-US">Spyre Therapeutics, Inc.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CompanyAndBasisOfPresentationLineItems" xlink:label="loc_syre_CompanyAndBasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CompanyAndBasisOfPresentationLineItems" xml:lang="en-US">Company and Basis of Presentation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_CompanyAndBasisOfPresentationLineItems" xml:lang="en-US">Company and Basis of Presentation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems" xlink:to="lab_syre_CompanyAndBasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CompanyAndBasisOfPresentationLineItems" xml:lang="en-US">Company and basis of presentation.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xml:lang="en-US">Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xml:lang="en-US">Shares transferred as equity interest in asset acquisition (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xml:lang="en-US">Number of shares transferred as equity interest in asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:to="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xml:lang="en-US">Asset acquisition consideration transferred equity interest issued and issuable, shares.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssetAcquisitionStockholderPaymentPeriod" xml:lang="en-US">Asset Acquisition, Stockholder Payment Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AssetAcquisitionStockholderPaymentPeriod" xml:lang="en-US">Asset acquisition, stockholder payment period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionStockholderPaymentPeriod" xlink:to="lab_syre_AssetAcquisitionStockholderPaymentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssetAcquisitionStockholderPaymentPeriod" xml:lang="en-US">Asset Acquisition, Stockholder Payment Period</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, cash equivalents, and marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FixedExchangeRatio" xlink:label="loc_syre_FixedExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_FixedExchangeRatio" xml:lang="en-US">Fixed Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syre_FixedExchangeRatio" xml:lang="en-US">Fixed exchange ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_FixedExchangeRatio" xml:lang="en-US">Fixed exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_FixedExchangeRatio" xlink:to="lab_syre_FixedExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_FixedExchangeRatio" xml:lang="en-US">Fixed exchange ratio.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OutstandingAndUnexercisedStockOptions" xlink:label="loc_syre_OutstandingAndUnexercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OutstandingAndUnexercisedStockOptions" xml:lang="en-US">Outstanding and Unexercised Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OutstandingAndUnexercisedStockOptions" xml:lang="en-US">Number of outstanding and unexercised stock options to purchase (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OutstandingAndUnexercisedStockOptions" xlink:to="lab_syre_OutstandingAndUnexercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OutstandingAndUnexercisedStockOptions" xml:lang="en-US">Outstanding and unexercised stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Conversion basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ProceedsFromRaisingCapital" xlink:label="loc_syre_ProceedsFromRaisingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ProceedsFromRaisingCapital" xml:lang="en-US">Proceeds From Raising Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ProceedsFromRaisingCapital" xml:lang="en-US">Proceeds from raising capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ProceedsFromRaisingCapital" xlink:to="lab_syre_ProceedsFromRaisingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ProceedsFromRaisingCapital" xml:lang="en-US">Proceeds From Raising Capital</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Employee workforce, termination percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_Spyre2023EquityIncentivePlanMember" xlink:label="loc_syre_Spyre2023EquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_Spyre2023EquityIncentivePlanMember" xml:lang="en-US">Spyre 2023 Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_Spyre2023EquityIncentivePlanMember" xml:lang="en-US">Spyre 2023 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_Spyre2023EquityIncentivePlanMember" xlink:to="lab_syre_Spyre2023EquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_Spyre2023EquityIncentivePlanMember" xml:lang="en-US">Spyre 2023 equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" xml:lang="en-US">Cash Equivalents And Marketable Securities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" xml:lang="en-US">Cash Equivalents And Marketable Securities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesTable" xml:lang="en-US">Cash equivalents and marketable securities.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xml:lang="en-US">Cash Equivalents And Marketable Securities [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xml:lang="en-US">Cash Equivalents And Marketable Securities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CashEquivalentsAndMarketableSecuritiesLineItems" xml:lang="en-US">Cash equivalents and marketable securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC insured amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairments of long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_USBankingInstitutionMember" xlink:label="loc_syre_USBankingInstitutionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_USBankingInstitutionMember" xml:lang="en-US">U.S. Banking Institution [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_USBankingInstitutionMember" xml:lang="en-US">U.S. Banking Institution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_USBankingInstitutionMember" xlink:to="lab_syre_USBankingInstitutionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_USBankingInstitutionMember" xml:lang="en-US">U.S. Banking Institution [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and office equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LaboratoryEquipmentMember" xlink:label="loc_syre_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LaboratoryEquipmentMember" xlink:to="lab_syre_LaboratoryEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SoftwareMember" xlink:label="loc_syre_SoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SoftwareMember" xml:lang="en-US">Software [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_SoftwareMember" xml:lang="en-US">Software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SoftwareMember" xlink:to="lab_syre_SoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SoftwareMember" xml:lang="en-US">Software</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property Plant And Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful lives of the property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Financial Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total financial assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Fair value of liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial paper</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xml:lang="en-US">Corporate Bond Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xml:lang="en-US">Corporate bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xml:lang="en-US">U.S. government agency securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">US Treasury Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">U.S. government treasury securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" xml:lang="en-US">Asset Acquisition, Cash Payment, Threshold Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" xml:lang="en-US">Asset acquisition, cash payment, threshold period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:to="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssetAcquisitionCashPaymentThresholdPeriod" xml:lang="en-US">Asset Acquisition, Cash Payment, Threshold Period</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Changes in the fair value of the CVR liability since issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial liabilities measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Issuance of Series A Preferred Stock on July 7, 2023</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative liability, measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Risk-adjusted discount rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_syre_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement Input, Probability Of Success [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Estimated probability of success</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_syre_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement Input, Probability Of Success</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MeasurementInputReimbursementRateMember" xlink:label="loc_syre_MeasurementInputReimbursementRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MeasurementInputReimbursementRateMember" xml:lang="en-US">Measurement Input, Reimbursement Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MeasurementInputReimbursementRateMember" xml:lang="en-US">Estimated reimbursement rate compared to reimbursement target</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MeasurementInputReimbursementRateMember" xlink:to="lab_syre_MeasurementInputReimbursementRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MeasurementInputReimbursementRateMember" xml:lang="en-US">Measurement Input, Reimbursement Rate</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair value at CVR issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xml:lang="en-US">Marketable securities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Gross Unrealized Gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Gross Unrealized Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Amortized Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xml:lang="en-US">Cash equivalents:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Estimated Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Amortized Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsUnrealizedGains" xlink:label="loc_syre_CashEquivalentsUnrealizedGains" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CashEquivalentsUnrealizedGains" xml:lang="en-US">Cash Equivalents Unrealized Gains</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_CashEquivalentsUnrealizedGains" xml:lang="en-US">Gross Unrealized Gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsUnrealizedGains" xlink:to="lab_syre_CashEquivalentsUnrealizedGains" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CashEquivalentsUnrealizedGains" xml:lang="en-US">Cash equivalents unrealized gains.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsUnrealizedLosses" xlink:label="loc_syre_CashEquivalentsUnrealizedLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CashEquivalentsUnrealizedLosses" xml:lang="en-US">Cash Equivalents Unrealized Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syre_CashEquivalentsUnrealizedLosses" xml:lang="en-US">Gross Unrealized Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CashEquivalentsUnrealizedLosses" xlink:to="lab_syre_CashEquivalentsUnrealizedLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CashEquivalentsUnrealizedLosses" xml:lang="en-US">Cash equivalents unrealized losses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xml:lang="en-US">Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xml:lang="en-US">12 Months or Longer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Less Than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Total, fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xml:lang="en-US">Unrealized Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xml:lang="en-US">12 Months or Longer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Less Than 12 Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xml:lang="en-US">Accrued interest receivable on available-for-sale debt securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" xlink:label="loc_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" xml:lang="en-US">Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" xml:lang="en-US">Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" xlink:to="lab_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" xml:lang="en-US">Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xml:lang="en-US">Debt securities, available-for-sale, allowance for credit loss, excluding accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xml:lang="en-US">Realized gains or losses on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xml:lang="en-US">Unrealized gains or losses on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government Agencies Debt Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xml:lang="en-US">Due in 1 - 2 years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xml:lang="en-US">Due in one year or less</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedContractedResearchAndDevelopmentCosts" xlink:label="loc_syre_AccruedContractedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedContractedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued Contracted Research And Development Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AccruedContractedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued contracted research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedContractedResearchAndDevelopmentCosts" xlink:to="lab_syre_AccruedContractedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedContractedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued contracted research and development costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional and consulting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FairmountFundsManagementLlcMember" xlink:label="loc_syre_FairmountFundsManagementLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_FairmountFundsManagementLlcMember" xml:lang="en-US">Fairmount Funds Management LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_FairmountFundsManagementLlcMember" xml:lang="en-US">Fairmount Funds Management LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_FairmountFundsManagementLlcMember" xlink:to="lab_syre_FairmountFundsManagementLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_FairmountFundsManagementLlcMember" xml:lang="en-US">Fairmount Funds Management LLC.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAndParapyreHoldingLlcMember" xlink:label="loc_syre_ParagonAndParapyreHoldingLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ParagonAndParapyreHoldingLlcMember" xml:lang="en-US">Paragon and Parapyre Holding LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syre_ParagonAndParapyreHoldingLlcMember" xml:lang="en-US">Paragon and Parapyre Holding LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonAndParapyreHoldingLlcMember" xlink:to="lab_syre_ParagonAndParapyreHoldingLlcMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonTherapeuticsIncMember" xlink:label="loc_syre_ParagonTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ParagonTherapeuticsIncMember" xml:lang="en-US">Paragon Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ParagonTherapeuticsIncMember" xml:lang="en-US">Paragon Therapeutics Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonTherapeuticsIncMember" xlink:to="lab_syre_ParagonTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ParagonTherapeuticsIncMember" xml:lang="en-US">Paragon therapeutics, Inc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AppointOfBoardMembersMember" xlink:label="loc_syre_AppointOfBoardMembersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AppointOfBoardMembersMember" xml:lang="en-US">Appoint Of Board Members [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AppointOfBoardMembersMember" xml:lang="en-US">Appoint Of Board Members</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AppointOfBoardMembersMember" xlink:to="lab_syre_AppointOfBoardMembersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AppointOfBoardMembersMember" xml:lang="en-US">Appoint Of Board Members</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConsultingAgreementMember" xlink:label="loc_syre_ConsultingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ConsultingAgreementMember" xml:lang="en-US">Consulting Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ConsultingAgreementMember" xml:lang="en-US">Consulting Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ConsultingAgreementMember" xlink:to="lab_syre_ConsultingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ConsultingAgreementMember" xml:lang="en-US">Consulting Agreement</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MilestonePaymentsMember" xlink:label="loc_syre_MilestonePaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MilestonePaymentsMember" xml:lang="en-US">Milestone Payments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MilestonePaymentsMember" xml:lang="en-US">Milestone Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MilestonePaymentsMember" xlink:to="lab_syre_MilestonePaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MilestonePaymentsMember" xml:lang="en-US">Milestone Payments</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OwnershipInterestMember" xlink:label="loc_syre_OwnershipInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OwnershipInterestMember" xml:lang="en-US">Ownership Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OwnershipInterestMember" xml:lang="en-US">Ownership Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OwnershipInterestMember" xlink:to="lab_syre_OwnershipInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OwnershipInterestMember" xml:lang="en-US">Ownership Interest</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAgreementMember" xlink:label="loc_syre_ParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ParagonAgreementMember" xml:lang="en-US">Paragon Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ParagonAgreementMember" xml:lang="en-US">Paragon Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParagonAgreementMember" xlink:to="lab_syre_ParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ParagonAgreementMember" xml:lang="en-US">Paragon agreement.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SaleOfStockDecember2023PIPEMember" xlink:label="loc_syre_SaleOfStockDecember2023PIPEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SaleOfStockDecember2023PIPEMember" xml:lang="en-US">Sale Of Stock, December 2023 PIPE [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_SaleOfStockDecember2023PIPEMember" xml:lang="en-US">Sale Of Stock, December 2023 PIPE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SaleOfStockDecember2023PIPEMember" xlink:to="lab_syre_SaleOfStockDecember2023PIPEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SaleOfStockDecember2023PIPEMember" xml:lang="en-US">Sale Of Stock, December 2023 PIPE</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SPY002LicenseAgreementMember" xlink:label="loc_syre_SPY002LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SPY002LicenseAgreementMember" xml:lang="en-US">SPY002 License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_SPY002LicenseAgreementMember" xml:lang="en-US">SPY002 License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SPY002LicenseAgreementMember" xlink:to="lab_syre_SPY002LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SPY002LicenseAgreementMember" xml:lang="en-US">SPY002 License Agreement</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">Stock Compensation And Research And Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">Stock Compensation And Research And Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:to="lab_syre_StockCompensationAndResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">Stock Compensation And Research And Development Expense</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_syre_ReimbursableCostsUnderParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ReimbursableCostsUnderParagonAgreementMember" xml:lang="en-US">Reimbursable Costs Under Paragon Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ReimbursableCostsUnderParagonAgreementMember" xml:lang="en-US">Reimbursable Costs Under Paragon Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ReimbursableCostsUnderParagonAgreementMember" xlink:to="lab_syre_ReimbursableCostsUnderParagonAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ReimbursableCostsUnderParagonAgreementMember" xml:lang="en-US">Reimbursable costs under paragon agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AmountToBePaidUnderAgreement" xlink:label="loc_syre_AmountToBePaidUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AmountToBePaidUnderAgreement" xml:lang="en-US">Amount To Be Paid Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AmountToBePaidUnderAgreement" xml:lang="en-US">Contingent obligation based on milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AmountToBePaidUnderAgreement" xlink:to="lab_syre_AmountToBePaidUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AmountToBePaidUnderAgreement" xml:lang="en-US">Amount to be paid under agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Percentage of ownership by noncontrolling owner</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:label="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xml:lang="en-US">Minority Interest Ownership Percentage By Noncontrolling Owners Held In Third Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xml:lang="en-US">Percentage of ownership held in third party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:to="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xml:lang="en-US">Minority interest ownership percentage by noncontrolling owners held in third party.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NominationFee" xlink:label="loc_syre_NominationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_NominationFee" xml:lang="en-US">Nomination Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_NominationFee" xml:lang="en-US">Nomination fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NominationFee" xlink:to="lab_syre_NominationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_NominationFee" xml:lang="en-US">Nomination fee.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PaymentOfMilestone" xlink:label="loc_syre_PaymentOfMilestone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PaymentOfMilestone" xml:lang="en-US">Payment Of Milestone</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PaymentOfMilestone" xml:lang="en-US">Milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PaymentOfMilestone" xlink:to="lab_syre_PaymentOfMilestone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PaymentOfMilestone" xml:lang="en-US">Payment of milestone.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableResearchCosts" xlink:label="loc_syre_ReimbursableResearchCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ReimbursableResearchCosts" xml:lang="en-US">Reimbursable Research Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ReimbursableResearchCosts" xml:lang="en-US">Reimbursable research costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ReimbursableResearchCosts" xlink:to="lab_syre_ReimbursableResearchCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ReimbursableResearchCosts" xml:lang="en-US">Reimbursable research costs.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xml:lang="en-US">Related Party Expenses Incurred Prior To Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xml:lang="en-US">Related party expenses incurred prior to asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:to="lab_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xml:lang="en-US">Related party expenses incurred prior to asset acquisition.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xml:lang="en-US">Related Party Expenses Unpaid Prior To Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xml:lang="en-US">Related party expenses unpaid prior to asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:to="lab_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xml:lang="en-US">Related party expenses unpaid prior to asset acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related party transaction amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:label="loc_syre_RelatedPartyTransactionNumberOfBoardSeats" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" xml:lang="en-US">Related Party Transaction, Number Of Board Seats</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" xml:lang="en-US">Number of board seats held by related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:to="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_RelatedPartyTransactionNumberOfBoardSeats" xml:lang="en-US">Related Party Transaction, Number Of Board Seats</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ResearchInitiationFees" xlink:label="loc_syre_ResearchInitiationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ResearchInitiationFees" xml:lang="en-US">Research Initiation Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ResearchInitiationFees" xml:lang="en-US">Research initiation fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ResearchInitiationFees" xlink:to="lab_syre_ResearchInitiationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ResearchInitiationFees" xml:lang="en-US">Research initiation fees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xml:lang="en-US">Number of monthly installments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:to="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyTransactionReimbursableCosts" xlink:label="loc_syre_RelatedPartyTransactionReimbursableCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_RelatedPartyTransactionReimbursableCosts" xml:lang="en-US">Related Party Transaction Reimbursable Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_RelatedPartyTransactionReimbursableCosts" xml:lang="en-US">Reimbursable costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RelatedPartyTransactionReimbursableCosts" xlink:to="lab_syre_RelatedPartyTransactionReimbursableCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_RelatedPartyTransactionReimbursableCosts" xml:lang="en-US">Related party transaction, reimbursable costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTable" xml:lang="en-US">Asset Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTable" xml:lang="en-US">Asset Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xml:lang="en-US">Asset Acquisition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xml:lang="en-US">Asset Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Cost to acquire asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Cost to acquire asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xml:lang="en-US">Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable Shares Of Common Stock On An As-converted Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xml:lang="en-US">Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:to="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xml:lang="en-US">Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xml:lang="en-US">Asset acquisition, contingent consideration, liability, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage Of Annual Equity Grant Of Options To Purchase Outstanding Shares Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage of annual equity grant of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:to="lab_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage of annual equity grant of options to purchase outstanding shares of common stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ParapyreOptionObligationMember" xml:lang="en-US">Parapyre Option Obligation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ParapyreOptionObligationMember" xml:lang="en-US">Parapyre Option Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParapyreOptionObligationMember" xlink:to="lab_syre_ParapyreOptionObligationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ParapyreOptionObligationMember" xml:lang="en-US">Parapyre Option Obligation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Consideration transferred in Series A Preferred Stock and Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Consideration transferred in Series A Preferred Stock and common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xml:lang="en-US">Transaction costs incurred by the Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xml:lang="en-US">Transaction costs incurred by Aeglea</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssumedLiabilities" xlink:label="loc_syre_AssumedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssumedLiabilities" xml:lang="en-US">Assumed Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syre_AssumedLiabilities" xml:lang="en-US">Assumed liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssumedLiabilities" xlink:to="lab_syre_AssumedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssumedLiabilities" xml:lang="en-US">Assumed liabilities.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CollaborativeArrangementAbstract" xlink:label="loc_syre_CollaborativeArrangementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CollaborativeArrangementAbstract" xml:lang="en-US">Collaborative Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CollaborativeArrangementAbstract" xlink:to="lab_syre_CollaborativeArrangementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CollaborativeArrangementAbstract" xml:lang="en-US">Collaborative Arrangement [Abstract]</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LicenseAgreementMilestonePayments" xlink:label="loc_syre_LicenseAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LicenseAgreementMilestonePayments" xml:lang="en-US">License Agreement, Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LicenseAgreementMilestonePayments" xml:lang="en-US">Milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LicenseAgreementMilestonePayments" xlink:to="lab_syre_LicenseAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LicenseAgreementMilestonePayments" xml:lang="en-US">License Agreement, Milestone Payments</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:label="loc_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xml:lang="en-US">Nonrefundable Research Initiation Fee For One Program Paid In Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xml:lang="en-US">Nonrefundable research initiation fee for one program paid in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:to="lab_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xml:lang="en-US">Nonrefundable research initiation fee for one program paid in cash.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfLand" xml:lang="en-US">Area of Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfLand" xml:lang="en-US">Area of land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, operating lease, renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating lease, payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLeaseTerminationFeeAmount" xlink:label="loc_syre_OperatingLeaseTerminationFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OperatingLeaseTerminationFeeAmount" xml:lang="en-US">Operating Lease, Termination Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OperatingLeaseTerminationFeeAmount" xml:lang="en-US">Termination fee amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OperatingLeaseTerminationFeeAmount" xlink:to="lab_syre_OperatingLeaseTerminationFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OperatingLeaseTerminationFeeAmount" xml:lang="en-US">Operating Lease, Termination Fee Amount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Letter of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaap_TenantImprovements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TenantImprovements" xml:lang="en-US">Tenant Improvements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TenantImprovements" xml:lang="en-US">Tenant improvement allowance (up to)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseAssetsAbstract" xlink:label="loc_syre_LeaseAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LeaseAssetsAbstract" xml:lang="en-US">Lease, Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LeaseAssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LeaseAssetsAbstract" xlink:to="lab_syre_LeaseAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LeaseAssetsAbstract" xml:lang="en-US">Lease, Assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_syre_OperatingAndFinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OperatingAndFinanceLeaseRightOfUseAsset" xml:lang="en-US">Operating And Finance Lease Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_syre_OperatingAndFinanceLeaseRightOfUseAsset" xml:lang="en-US">Total leased assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="lab_syre_OperatingAndFinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OperatingAndFinanceLeaseRightOfUseAsset" xml:lang="en-US">Operating and financing lease right of use asset.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseLiabilityAbstract" xlink:label="loc_syre_LeaseLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LeaseLiabilityAbstract" xml:lang="en-US">Lease Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LeaseLiabilityAbstract" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LeaseLiabilityAbstract" xlink:to="lab_syre_LeaseLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LeaseLiabilityAbstract" xml:lang="en-US">Lease Liability</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseLiabilityCurrentAbstract" xlink:label="loc_syre_LeaseLiabilityCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LeaseLiabilityCurrentAbstract" xml:lang="en-US">Lease Liability, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LeaseLiabilityCurrentAbstract" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LeaseLiabilityCurrentAbstract" xlink:to="lab_syre_LeaseLiabilityCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LeaseLiabilityCurrentAbstract" xml:lang="en-US">Lease Liability, Current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseLiabilityNoncurrentAbstract" xlink:label="loc_syre_LeaseLiabilityNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LeaseLiabilityNoncurrentAbstract" xml:lang="en-US">Lease Liability, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LeaseLiabilityNoncurrentAbstract" xml:lang="en-US">Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LeaseLiabilityNoncurrentAbstract" xlink:to="lab_syre_LeaseLiabilityNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LeaseLiabilityNoncurrentAbstract" xml:lang="en-US">Lease Liability, Noncurrent</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingAndFinanceLeaseLiabilities" xlink:label="loc_syre_OperatingAndFinanceLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OperatingAndFinanceLeaseLiabilities" xml:lang="en-US">Operating And Finance Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_syre_OperatingAndFinanceLeaseLiabilities" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OperatingAndFinanceLeaseLiabilities" xlink:to="lab_syre_OperatingAndFinanceLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OperatingAndFinanceLeaseLiabilities" xml:lang="en-US">Operating and Finance lease Liabilities.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseWeightedAverageDiscountRateAbstract" xlink:label="loc_syre_LeaseWeightedAverageDiscountRateAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LeaseWeightedAverageDiscountRateAbstract" xml:lang="en-US">Lease, Weighted Average Discount Rate [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LeaseWeightedAverageDiscountRateAbstract" xml:lang="en-US">Discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_syre_LeaseWeightedAverageDiscountRateAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LeaseWeightedAverageDiscountRateAbstract" xml:lang="en-US">Lease, Weighted Average Discount Rate</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:label="loc_syre_LeaseWeightedAverageRemainingLeaseTermAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LeaseWeightedAverageRemainingLeaseTermAbstract" xml:lang="en-US">Lease, Weighted Average Remaining Lease Term [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LeaseWeightedAverageRemainingLeaseTermAbstract" xml:lang="en-US">Lease term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_syre_LeaseWeightedAverageRemainingLeaseTermAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LeaseWeightedAverageRemainingLeaseTermAbstract" xml:lang="en-US">Lease, Weighted Average Remaining Lease Term</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class Of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_BeneficiallyHoldersOwnedPercentage" xlink:label="loc_syre_BeneficiallyHoldersOwnedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_BeneficiallyHoldersOwnedPercentage" xml:lang="en-US">Beneficially Holders Owned Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_BeneficiallyHoldersOwnedPercentage" xml:lang="en-US">Beneficially holders owned percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_BeneficiallyHoldersOwnedPercentage" xlink:to="lab_syre_BeneficiallyHoldersOwnedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_BeneficiallyHoldersOwnedPercentage" xml:lang="en-US">Beneficially holders owned percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price per warrant (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants to purchase shares (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Offering Price Of Warrants Or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xml:lang="en-US">Offering price of warrant (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:to="lab_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xml:lang="en-US">Class of warrant or right offering price of warrants or rights.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:label="loc_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xml:lang="en-US">Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xml:lang="en-US">Revised ownership percentage, period to take effect after notice</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:to="lab_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xml:lang="en-US">Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Dividends, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Common stock dividends declared</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:to="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xml:lang="en-US">Maximum ownership percentage for outstanding warrants to purchase shares of common stock to be exercised.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" xlink:label="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" xml:lang="en-US">Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised Upon Written Notice</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" xml:lang="en-US">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised upon written notice</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" xlink:to="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" xml:lang="en-US">Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised Upon Written Notice</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="loc_syre_NumberOfCommonStockVotingRightsHeldPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_NumberOfCommonStockVotingRightsHeldPerShare" xml:lang="en-US">Number Of Common Stock Voting Rights Held Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_NumberOfCommonStockVotingRightsHeldPerShare" xml:lang="en-US">Number of votes for common stock holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NumberOfCommonStockVotingRightsHeldPerShare" xlink:to="lab_syre_NumberOfCommonStockVotingRightsHeldPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_NumberOfCommonStockVotingRightsHeldPerShare" xml:lang="en-US">Number of common stock voting rights held per share.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xml:lang="en-US">Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xml:lang="en-US">Ownership percentage for outstanding warrants to purchase shares of common stock to be exercised to certain holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:to="lab_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xml:lang="en-US">Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_syre_PlacementAgentFeesAndOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PlacementAgentFeesAndOfferingCosts" xml:lang="en-US">Placement Agent Fees And Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PlacementAgentFeesAndOfferingCosts" xml:lang="en-US">Placement agent fees and offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PlacementAgentFeesAndOfferingCosts" xlink:to="lab_syre_PlacementAgentFeesAndOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PlacementAgentFeesAndOfferingCosts" xml:lang="en-US">Placement agent fees and offering costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaap_PreferredStockRedemptionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionAmount" xml:lang="en-US">Preferred Stock, Redemption Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionAmount" xml:lang="en-US">Preferred stock, redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionAmount" xlink:to="lab_us-gaap_PreferredStockRedemptionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred stock, redemption per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:label="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xml:lang="en-US">Preferred Stock Remains Issued and Outstanding Percentage.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xml:lang="en-US">Preferred stock issued and outstanding percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:to="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xml:lang="en-US">Preferred stock remains issued and outstanding percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Aggregate purchase price for stock sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Public offering price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SharesAuthorized" xlink:label="loc_syre_SharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SharesAuthorized" xml:lang="en-US">Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_SharesAuthorized" xml:lang="en-US">Shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SharesAuthorized" xlink:to="lab_syre_SharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SharesAuthorized" xml:lang="en-US">Shares authorized.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreWarrantsMember" xlink:label="loc_syre_ParapyreWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ParapyreWarrantsMember" xml:lang="en-US">Parapyre Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ParapyreWarrantsMember" xml:lang="en-US">Parapyre Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syre_ParapyreWarrantsMember" xml:lang="en-US">Outstanding Parapyre Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ParapyreWarrantsMember" xlink:to="lab_syre_ParapyreWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ParapyreWarrantsMember" xml:lang="en-US">Parapyre Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreFundedMay2022WarrantsMember" xlink:label="loc_syre_PreFundedMay2022WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PreFundedMay2022WarrantsMember" xml:lang="en-US">Pre Funded, May 2022 Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PreFundedMay2022WarrantsMember" xml:lang="en-US">May 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PreFundedMay2022WarrantsMember" xlink:to="lab_syre_PreFundedMay2022WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PreFundedMay2022WarrantsMember" xml:lang="en-US">Pre Funded, May 2022 Warrants</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreFundedWarrantsMember" xlink:label="loc_syre_PreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PreFundedWarrantsMember" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PreFundedWarrantsMember" xml:lang="en-US">Pre-Funded Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PreFundedWarrantsMember" xlink:to="lab_syre_PreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PreFundedWarrantsMember" xml:lang="en-US">Pre-Funded Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of warrants outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of shares sold in private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GlobalRightsToPegzilarginaseMember" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_GlobalRightsToPegzilarginaseMember" xml:lang="en-US">Global Rights To Pegzilarginase [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_GlobalRightsToPegzilarginaseMember" xml:lang="en-US">Global Rights To Pegzilarginase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_GlobalRightsToPegzilarginaseMember" xlink:to="lab_syre_GlobalRightsToPegzilarginaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_GlobalRightsToPegzilarginaseMember" xml:lang="en-US">Global Rights To Pegzilarginase</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LicenseAgreementsMember" xlink:label="loc_syre_LicenseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_LicenseAgreementsMember" xml:lang="en-US">License Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_LicenseAgreementsMember" xml:lang="en-US">License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_LicenseAgreementsMember" xlink:to="lab_syre_LicenseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_LicenseAgreementsMember" xml:lang="en-US">License agreements.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PeaceTrialAndBLAPackageMember" xlink:label="loc_syre_PeaceTrialAndBLAPackageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PeaceTrialAndBLAPackageMember" xml:lang="en-US">Peace Trial And B L A Package [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PeaceTrialAndBLAPackageMember" xml:lang="en-US">PEACE Trial and BLA Package</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PeaceTrialAndBLAPackageMember" xlink:to="lab_syre_PeaceTrialAndBLAPackageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PeaceTrialAndBLAPackageMember" xml:lang="en-US">Peace Trial And BLA Package Member.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PIPTrialMember" xlink:label="loc_syre_PIPTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PIPTrialMember" xml:lang="en-US">P I P Trial [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PIPTrialMember" xml:lang="en-US">PIP Trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PIPTrialMember" xlink:to="lab_syre_PIPTrialMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PIPTrialMember" xml:lang="en-US">PIP trial.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AdditionalUpfrontPaymentAbilityToReceived" xlink:label="loc_syre_AdditionalUpfrontPaymentAbilityToReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AdditionalUpfrontPaymentAbilityToReceived" xml:lang="en-US">Additional Upfront Payment Ability To Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AdditionalUpfrontPaymentAbilityToReceived" xml:lang="en-US">Additional upfront payment to be received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AdditionalUpfrontPaymentAbilityToReceived" xlink:to="lab_syre_AdditionalUpfrontPaymentAbilityToReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AdditionalUpfrontPaymentAbilityToReceived" xml:lang="en-US">Additional upfront payment ability to received.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AllocatedAmountOfTransactionPrice" xlink:label="loc_syre_AllocatedAmountOfTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AllocatedAmountOfTransactionPrice" xml:lang="en-US">Allocated Amount Of Transaction Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AllocatedAmountOfTransactionPrice" xml:lang="en-US">Allocated amount of modified transaction price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AllocatedAmountOfTransactionPrice" xlink:to="lab_syre_AllocatedAmountOfTransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AllocatedAmountOfTransactionPrice" xml:lang="en-US">Allocated amount of transaction price.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AllocationPriceTotal" xlink:label="loc_syre_AllocationPriceTotal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AllocationPriceTotal" xml:lang="en-US">Allocation Price Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AllocationPriceTotal" xml:lang="en-US">Allocation for stand-alone selling prices</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AllocationPriceTotal" xlink:to="lab_syre_AllocationPriceTotal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AllocationPriceTotal" xml:lang="en-US">Allocation price total.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Carrying value of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xml:lang="en-US">Contract assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Deferred revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CostsIncurredInPerformingTheTrial" xlink:label="loc_syre_CostsIncurredInPerformingTheTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_CostsIncurredInPerformingTheTrial" xml:lang="en-US">Costs Incurred In Performing The Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_CostsIncurredInPerformingTheTrial" xml:lang="en-US">Maximum amount of costs to reimburse</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_CostsIncurredInPerformingTheTrial" xlink:to="lab_syre_CostsIncurredInPerformingTheTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_CostsIncurredInPerformingTheTrial" xml:lang="en-US">Costs incurred in performing the pip trial.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:to="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xlink:label="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Derecognition Of Nonfinancial Assets And Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xml:lang="en-US">Derecognition of nonfinancial assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xlink:to="lab_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Derecognition Of Nonfinancial Assets And Liabilities, Net</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MilestonePaymentsExchangeRate" xlink:label="loc_syre_MilestonePaymentsExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MilestonePaymentsExchangeRate" xml:lang="en-US">Milestone Payments Exchange Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MilestonePaymentsExchangeRate" xml:lang="en-US">Milestone payments exchange rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MilestonePaymentsExchangeRate" xlink:to="lab_syre_MilestonePaymentsExchangeRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MilestonePaymentsExchangeRate" xml:lang="en-US">Milestone payments exchange rate.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonRefundablePaymentReceived" xlink:label="loc_syre_NonRefundablePaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_NonRefundablePaymentReceived" xml:lang="en-US">Non Refundable Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_NonRefundablePaymentReceived" xml:lang="en-US">Non refundable payment received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NonRefundablePaymentReceived" xlink:to="lab_syre_NonRefundablePaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_NonRefundablePaymentReceived" xml:lang="en-US">Non refundable payment received.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:label="loc_syre_PercentageOfPaymentForCostIncurredInPIPTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PercentageOfPaymentForCostIncurredInPIPTrial" xml:lang="en-US">Percentage Of Payment For Cost Incurred In P I P Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PercentageOfPaymentForCostIncurredInPIPTrial" xml:lang="en-US">Percentage of payment for cost incurred in trial</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:to="lab_syre_PercentageOfPaymentForCostIncurredInPIPTrial" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PercentageOfPaymentForCostIncurredInPIPTrial" xml:lang="en-US">Percentage of payment for cost incurred in pip trial.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PrepaidExpenseValueOfExpectedRecoveries" xlink:label="loc_syre_PrepaidExpenseValueOfExpectedRecoveries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PrepaidExpenseValueOfExpectedRecoveries" xml:lang="en-US">Prepaid Expense, Value Of Expected Recoveries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PrepaidExpenseValueOfExpectedRecoveries" xml:lang="en-US">Contingent reimbursement of pre-paid manufacturing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PrepaidExpenseValueOfExpectedRecoveries" xlink:to="lab_syre_PrepaidExpenseValueOfExpectedRecoveries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PrepaidExpenseValueOfExpectedRecoveries" xml:lang="en-US">Prepaid Expense, Value Of Expected Recoveries</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xml:lang="en-US">Reimbursement from Limited Partnership Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xml:lang="en-US">Reimbursement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:to="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xml:lang="en-US">Estimated amount incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_UpfrontPayment" xlink:label="loc_syre_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_UpfrontPayment" xml:lang="en-US">Upfront Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_UpfrontPayment" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_UpfrontPayment" xlink:to="lab_syre_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_UpfrontPayment" xml:lang="en-US">Upfront payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ImmedicaPharmaABMember" xlink:label="loc_syre_ImmedicaPharmaABMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ImmedicaPharmaABMember" xml:lang="en-US">Immedica Pharma A B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ImmedicaPharmaABMember" xml:lang="en-US">Immedica Pharma AB</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ImmedicaPharmaABMember" xlink:to="lab_syre_ImmedicaPharmaABMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ImmedicaPharmaABMember" xml:lang="en-US">Immedica Pharma AB</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ChangeInContractWithCustomerLiabilityRollForward" xlink:label="loc_syre_ChangeInContractWithCustomerLiabilityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ChangeInContractWithCustomerLiabilityRollForward" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ChangeInContractWithCustomerLiabilityRollForward" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_syre_ChangeInContractWithCustomerLiabilityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ChangeInContractWithCustomerLiabilityRollForward" xml:lang="en-US">Change In Contract With Customer, Liability</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContractWithCustomerLiabilityAdditions" xlink:label="loc_syre_ContractWithCustomerLiabilityAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ContractWithCustomerLiabilityAdditions" xml:lang="en-US">Contract With Customer, Liability, Additions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ContractWithCustomerLiabilityAdditions" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ContractWithCustomerLiabilityAdditions" xlink:to="lab_syre_ContractWithCustomerLiabilityAdditions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ContractWithCustomerLiabilityAdditions" xml:lang="en-US">Contract With Customer, Liability, Additions</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xml:lang="en-US">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xml:lang="en-US">Deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentNonRefundableLicenseFeeAmount" xlink:label="loc_syre_OtherCommitmentNonRefundableLicenseFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentNonRefundableLicenseFeeAmount" xml:lang="en-US">Other Commitment, Non-Refundable License Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentNonRefundableLicenseFeeAmount" xml:lang="en-US">Non-refundable license fee amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentNonRefundableLicenseFeeAmount" xlink:to="lab_syre_OtherCommitmentNonRefundableLicenseFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentNonRefundableLicenseFeeAmount" xml:lang="en-US">Other Commitment, Non-Refundable License Fee Amount</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xml:lang="en-US">Right to terminate agreement by counterparty, material breach, uncured period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xlink:to="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xml:lang="en-US">Right to terminate agreement by counterparty, payments not received, period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xlink:to="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xml:lang="en-US">Right to terminate agreement or work order, prior written notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xlink:to="lab_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement, Prior Written Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xml:lang="en-US">Right to terminate agreement, prior written notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xlink:to="lab_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Agreement, Prior Written Notice Period</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xml:lang="en-US">Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xml:lang="en-US">Right to terminate work order by counterparty, reasonable cause, termination amount payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xlink:to="lab_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xml:lang="en-US">Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xml:lang="en-US">Right to terminate work order, material breach, uncured period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xlink:to="lab_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xml:lang="en-US">Right to terminate work order, reasonable cause, prior written notice period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xlink:to="lab_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xml:lang="en-US">Right to terminate work order, unusual or infrequent cause, period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xlink:to="lab_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xml:lang="en-US">Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRoyaltyPercentage" xlink:label="loc_syre_OtherCommitmentRoyaltyPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OtherCommitmentRoyaltyPercentage" xml:lang="en-US">Other Commitment, Royalty Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OtherCommitmentRoyaltyPercentage" xml:lang="en-US">Royalty percentage (less than)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OtherCommitmentRoyaltyPercentage" xlink:to="lab_syre_OtherCommitmentRoyaltyPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OtherCommitmentRoyaltyPercentage" xml:lang="en-US">Other Commitment, Royalty Percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Options to purchase Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PerformanceSharesMember" xml:lang="en-US">Performance Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PerformanceSharesMember" xml:lang="en-US">Performance Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Unvested restricted stock units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ServiceBasedAwardsMember" xlink:label="loc_syre_ServiceBasedAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ServiceBasedAwardsMember" xml:lang="en-US">Service Based Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ServiceBasedAwardsMember" xml:lang="en-US">Service Based Awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ServiceBasedAwardsMember" xlink:to="lab_syre_ServiceBasedAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ServiceBasedAwardsMember" xml:lang="en-US">Service-based awards.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">Two Thousand And Eighteen Equity Inducement Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">2018 Equity Inducement Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:to="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">2018 equity inducement plan.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">Two Thousand And Fifteen And Two Thousand And Sixteen Equity Incentive Plan And Two Thousand And Eighteen Equity Inducement Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">2018 Plan, 2016 Plan and 2015 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:to="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xml:lang="en-US">Two thousand and fifteen and two thousand and sixteen equity incentive plan and two thousand and eighteen equity inducement plan.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:label="loc_syre_TwoThousandAndFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TwoThousandAndFifteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Fifteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TwoThousandAndFifteenEquityIncentivePlanMember" xml:lang="en-US">2015 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:to="lab_syre_TwoThousandAndFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TwoThousandAndFifteenEquityIncentivePlanMember" xml:lang="en-US">Two thousand and fifteen equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand And Sixteen Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">2016 Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two thousand and sixteen employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Sixteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xml:lang="en-US">2016 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:to="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TwoThousandAndSixteenEquityIncentivePlanMember" xml:lang="en-US">Two thousand and sixteen equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:label="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xml:lang="en-US">Annual Percentage Of Additional Shares Which Equals To Issued And Outstanding Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xml:lang="en-US">Annual percentage of additional shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:to="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xml:lang="en-US">Annual percentage of additional shares which equals to the issued and outstanding shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Liability assumed in asset acquisition related to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" xlink:label="loc_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" xml:lang="en-US">Class Of Warrant Or Right, Annual Grant, Percentage Of Common Stock Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" xml:lang="en-US">Percentage of annual grant of common stock outstanding for warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" xlink:to="lab_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" xml:lang="en-US">Class Of Warrant Or Right, Annual Grant, Percentage Of Common Stock Outstanding</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightGrantDateFairValue" xlink:label="loc_syre_ClassOfWarrantOrRightGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ClassOfWarrantOrRightGrantDateFairValue" xml:lang="en-US">Class Of Warrant Or Right, Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ClassOfWarrantOrRightGrantDateFairValue" xml:lang="en-US">Warrant grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ClassOfWarrantOrRightGrantDateFairValue" xlink:to="lab_syre_ClassOfWarrantOrRightGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ClassOfWarrantOrRightGrantDateFairValue" xml:lang="en-US">Class Of Warrant Or Right, Grant Date Fair Value</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightUnamortizedExpense" xlink:label="loc_syre_ClassOfWarrantOrRightUnamortizedExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ClassOfWarrantOrRightUnamortizedExpense" xml:lang="en-US">Class Of Warrant Or Right, Unamortized Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ClassOfWarrantOrRightUnamortizedExpense" xml:lang="en-US">Warrant unamortized expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ClassOfWarrantOrRightUnamortizedExpense" xlink:to="lab_syre_ClassOfWarrantOrRightUnamortizedExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ClassOfWarrantOrRightUnamortizedExpense" xml:lang="en-US">Class Of Warrant Or Right, Unamortized Expense</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Shares reserved for issuance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Expense recognized for unvested employee and non-employee awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted average period over which unrecognized compensation is expected to be recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized stock-based compensation expense for options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Tax benefits recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:label="loc_syre_GranteesWithMoreThanFiveYearsVestingTermPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_GranteesWithMoreThanFiveYearsVestingTermPercent" xml:lang="en-US">Grantees With More Than Five Years Vesting Term Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_GranteesWithMoreThanFiveYearsVestingTermPercent" xml:lang="en-US">Grantees with more than five years vesting term, percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:to="lab_syre_GranteesWithMoreThanFiveYearsVestingTermPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_GranteesWithMoreThanFiveYearsVestingTermPercent" xml:lang="en-US">Grantees with more than five years vesting term, percent.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Increase In Common Stock Capital Shares Reserved For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Increase in common stock reserved for issuance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Increase in common stock capital shares reserved for future issuance.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:label="loc_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xml:lang="en-US">Maximum Number of Shares Purchased Under Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xml:lang="en-US">Maximum shares purchased under employee stock purchase plan (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:to="lab_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xml:lang="en-US">Maximum number of shares purchased under employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:label="loc_syre_MaximumVestingTermForMoreThanTenPercentGrantees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_MaximumVestingTermForMoreThanTenPercentGrantees" xml:lang="en-US">Maximum Vesting Term For More Than Ten Percent Grantees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_MaximumVestingTermForMoreThanTenPercentGrantees" xml:lang="en-US">Maximum vesting term for more than ten percent grantees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:to="lab_syre_MaximumVestingTermForMoreThanTenPercentGrantees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_MaximumVestingTermForMoreThanTenPercentGrantees" xml:lang="en-US">Maximum vesting term for more than ten percent grantees.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Additional Annual Percentage Increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xml:lang="en-US">Additional annual percentage increase of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:to="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xml:lang="en-US">Share based compensation arrangement by share based payment award additional annual percentage increase.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Additional Number Of Shares Available For Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xml:lang="en-US">Additional common stock available for issuance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:to="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, additional number of shares available for grant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Awards granted, vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xml:lang="en-US">Percentage of fair market value of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Shares, granted to employees (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Equity instruments other than options, vested (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Awards granted, expiration period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based payment award, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Annual Fair Market Value Per Employee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xml:lang="en-US">Maximum purchase value per employee under employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:to="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum annual fair market value per employee.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xml:lang="en-US">Percentage of discount through payroll deductions to eligible employees to purchase common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Additional shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Initial reserves of common stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Available for issuance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Intrinsic value of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding option awards (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, ending balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xml:lang="en-US">Shares subject to options outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Stock option vested (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Percentage of market value of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Stock option issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Annual Limit For Non-Employee Director Compensation, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" xml:lang="en-US">Annual limit for non-employee director compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" xlink:to="lab_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Annual Limit For Non-Employee Director Compensation, Amount</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Non-Employee Director Compensation, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" xml:lang="en-US">Non-employee director compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" xlink:to="lab_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Non-Employee Director Compensation, Amount</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" xml:lang="en-US">Share-Based Payment Arrangement, Plan Terms, Annual Limit For Non-Employee Director Compensation, Number Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" xml:lang="en-US">Annual limit for non-employee director compensation (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" xlink:to="lab_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" xml:lang="en-US">Share-Based Payment Arrangement, Plan Terms, Annual Limit For Non-Employee Director Compensation, Number Of Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonEmployeesMember" xlink:label="loc_syre_NonEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_NonEmployeesMember" xml:lang="en-US">Non Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_NonEmployeesMember" xml:lang="en-US">Non- Employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NonEmployeesMember" xlink:to="lab_syre_NonEmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_NonEmployeesMember" xml:lang="en-US">Non-employees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Options vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options exercisable (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Options exercisable (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Shares Issuable Under Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Options vested and expected to vest (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options vested and expected to vest (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Unvested (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Unvested (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Forfeited (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Granted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Unvested (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Unvested (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Vested (in dollars per share))</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EmployeesMember" xlink:label="loc_syre_EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_EmployeesMember" xml:lang="en-US">Employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_EmployeesMember" xml:lang="en-US">Employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_EmployeesMember" xlink:to="lab_syre_EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_EmployeesMember" xml:lang="en-US">Employees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand Eighteen Equity Inducement Plan And Two Thousand Sixteen Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xml:lang="en-US">Two thousand eighteen equity inducement plan and two thousand sixteen employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined contribution plan, contribution amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xml:lang="en-US">Total consideration from disposal of long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="loc_us-gaap_ImpairmentOfLeasehold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xml:lang="en-US">Impairment of Leasehold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xml:lang="en-US">Impairment on leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLeasehold" xlink:to="lab_us-gaap_ImpairmentOfLeasehold" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xml:lang="en-US">Operating Lease, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xml:lang="en-US">Lease asset impairment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xml:lang="en-US">Lease Asset Impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments for Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Cash payments for employee related restructuring charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Cash severance payments and other employee-related costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Related Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xml:lang="en-US">Non-cash stock-based compensation expense related to accelerated vesting of stock-based awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeveranceLiabilityMember" xlink:label="loc_syre_SeveranceLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_SeveranceLiabilityMember" xml:lang="en-US">Severance Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_SeveranceLiabilityMember" xml:lang="en-US">Severance Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_SeveranceLiabilityMember" xlink:to="lab_syre_SeveranceLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_SeveranceLiabilityMember" xml:lang="en-US">Severance liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Restructuring Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Beginning Balance December 31, 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Ending Balance December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RestructuringActivitiesMember" xlink:label="loc_syre_RestructuringActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_RestructuringActivitiesMember" xml:lang="en-US">Restructuring Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_RestructuringActivitiesMember" xml:lang="en-US">Restructuring Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_RestructuringActivitiesMember" xlink:to="lab_syre_RestructuringActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_RestructuringActivitiesMember" xml:lang="en-US">Restructuring activities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">Restructuring Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">Total Restructuring Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xml:lang="en-US">Income Tax Contingency [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xml:lang="en-US">Income Tax Contingency [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">U.S</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfDomesticSubsidiaries" xlink:label="loc_syre_NumberOfDomesticSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_NumberOfDomesticSubsidiaries" xml:lang="en-US">Number Of Domestic Subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_NumberOfDomesticSubsidiaries" xml:lang="en-US">Number of domestic subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NumberOfDomesticSubsidiaries" xlink:to="lab_syre_NumberOfDomesticSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_NumberOfDomesticSubsidiaries" xml:lang="en-US">Number Of Domestic Subsidiaries</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" xlink:label="loc_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire If Not Utilized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" xml:lang="en-US">Net operating loss carryforwards, set to expire if not utilized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" xlink:to="lab_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire If Not Utilized</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" xlink:label="loc_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" xml:lang="en-US">Tax Credit Carryforwards, Set To Expire If Not Utilized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" xml:lang="en-US">Tax credit carryforwards, set to expire if not utilized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" xlink:to="lab_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" xml:lang="en-US">Tax Credit Carryforwards, Set To Expire If Not Utilized</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Increase in valuation primarily due to operation losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesTable" xlink:label="loc_syre_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_IncomeTaxesTable" xml:lang="en-US">Income Taxes [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_IncomeTaxesTable" xml:lang="en-US">Income Taxes [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_IncomeTaxesTable" xlink:to="lab_syre_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_IncomeTaxesTable" xml:lang="en-US">Income taxes.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesLineItems" xlink:label="loc_syre_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_IncomeTaxesLineItems" xml:lang="en-US">Income Taxes [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_IncomeTaxesLineItems" xml:lang="en-US">Income Taxes [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_IncomeTaxesLineItems" xlink:to="lab_syre_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_IncomeTaxesLineItems" xml:lang="en-US">Income taxes line items.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xlink:label="loc_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Value Added Liability, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xml:lang="en-US">Loss on CVR revaluation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xlink:to="lab_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Contingent Value Added Liability, Amount</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xlink:label="loc_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Forward Contract Liability, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xml:lang="en-US">Loss on forward contract valuation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xlink:to="lab_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Forward Contract Liability, Amount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in the valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Other permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Tax provision derived by applying the federal statutory rate to income before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Acquired IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effect of tax rate on foreign jurisdiction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_syre_IncomeTaxReconciliationTaxCostCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_IncomeTaxReconciliationTaxCostCredit" xml:lang="en-US">Income Tax Reconciliation Tax Cost Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_IncomeTaxReconciliationTaxCostCredit" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_IncomeTaxReconciliationTaxCostCredit" xlink:to="lab_syre_IncomeTaxReconciliationTaxCostCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_IncomeTaxReconciliationTaxCostCredit" xml:lang="en-US">Income tax reconciliation tax cost (credit).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred tax assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Capitalized 174 R&amp;D costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Depreciable assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xml:lang="en-US">Weighted average pre-funded warrants (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Weighted average common shares (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xml:lang="en-US">Organization consolidation and presentation of financial statements.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionMember" xlink:label="loc_syre_AssetAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssetAcquisitionMember" xml:lang="en-US">Asset Acquisition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AssetAcquisitionMember" xml:lang="en-US">Asset Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionMember" xlink:to="lab_syre_AssetAcquisitionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssetAcquisitionMember" xml:lang="en-US">Asset acquisition.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xml:lang="en-US">Organization consolidation and presentation of financial statements.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Asset Acquisition Assets Acquired and Liabilities Assumed Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Asset Acquisition, net liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Asset acquisition assets acquired and liabilities assumed net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfEmployeesRetained" xlink:label="loc_syre_NumberOfEmployeesRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_NumberOfEmployeesRetained" xml:lang="en-US">Number of Employees Retained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_NumberOfEmployeesRetained" xml:lang="en-US">Number of employees retained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_NumberOfEmployeesRetained" xlink:to="lab_syre_NumberOfEmployeesRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_NumberOfEmployeesRetained" xml:lang="en-US">Number of employees retained.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_syre_PlacementAgentAndOtherOfferingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_PlacementAgentAndOtherOfferingExpenses" xml:lang="en-US">Placement Agent And Other Offering Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_PlacementAgentAndOtherOfferingExpenses" xml:lang="en-US">Placement agent and other offering expenses in private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_PlacementAgentAndOtherOfferingExpenses" xlink:to="lab_syre_PlacementAgentAndOtherOfferingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_PlacementAgentAndOtherOfferingExpenses" xml:lang="en-US">Placement agent and other offering expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' equity, reverse stock split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedOptionCostPayable" xlink:label="loc_syre_AccruedOptionCostPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedOptionCostPayable" xml:lang="en-US">Accrued Option Cost Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syre_AccruedOptionCostPayable" xml:lang="en-US">Accrued option cost payable to Paragon</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedOptionCostPayable" xlink:to="lab_syre_AccruedOptionCostPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedOptionCostPayable" xml:lang="en-US">Accrued option cost payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProgramRightsObligations" xlink:label="loc_us-gaap_ProgramRightsObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProgramRightsObligations" xml:lang="en-US">Program Rights Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProgramRightsObligations" xml:lang="en-US">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProgramRightsObligations" xlink:to="lab_us-gaap_ProgramRightsObligations" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesTable" xlink:label="loc_syre_AccruedLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedLiabilitiesTable" xml:lang="en-US">Accrued Liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedLiabilitiesTable" xlink:to="lab_syre_AccruedLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedLiabilitiesTable" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesLineItems" xlink:label="loc_syre_AccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syre_AccruedLiabilitiesLineItems" xml:lang="en-US">Accrued Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syre_AccruedLiabilitiesLineItems" xlink:to="lab_syre_AccruedLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syre_AccruedLiabilitiesLineItems" xml:lang="en-US">Accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Reduction in the total number of authorized shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>syre-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-March-2024 [02:06:26] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#Cover" roleURI="http://www.spy.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.spy.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.spy.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StatementOfAssetsAcquiredAndLiabilitiesAssumed" roleURI="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#TheCompanyAndBasisOfPresentation" roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurements" roleURI="http://www.spy.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecurities" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecurities" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#PropertyAndEquipmentNet" roleURI="http://www.spy.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedAndOtherCurrentLiabilities" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedLiabilities" roleURI="http://www.spy.com/role/AccruedLiabilities" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactions" roleURI="http://www.spy.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AssetAcquisition" roleURI="http://www.spy.com/role/AssetAcquisition" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ParagonAgreement" roleURI="http://www.spy.com/role/ParagonAgreement" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#Leases" roleURI="http://www.spy.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConvertiblePreferredStockAndStockholdersEquity" roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StrategicLicenseAgreements" roleURI="http://www.spy.com/role/StrategicLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SaleOfPegzilarginaseToImmedica" roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedica" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#NovationOfManufacturingAgreements" roleURI="http://www.spy.com/role/NovationOfManufacturingAgreements" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensation" roleURI="http://www.spy.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DefinedContributionPlan" roleURI="http://www.spy.com/role/DefinedContributionPlan" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringCharges" roleURI="http://www.spy.com/role/RestructuringCharges" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxes" roleURI="http://www.spy.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#NetLossPerShare" roleURI="http://www.spy.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SubsequentEvents" roleURI="http://www.spy.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementTables" roleURI="http://www.spy.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesTables" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedAndOtherCurrentLiabilitiesTables" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactionsTables" roleURI="http://www.spy.com/role/RelatedPartyTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AssetAcquisitionTables" roleURI="http://www.spy.com/role/AssetAcquisitionTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#LeasesTables" roleURI="http://www.spy.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConvertiblePreferredStockAndStockholdersEquityTables" roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StrategicLicenseAgreementTables" roleURI="http://www.spy.com/role/StrategicLicenseAgreementTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationTables" roleURI="http://www.spy.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringChargesTables" roleURI="http://www.spy.com/role/RestructuringChargesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesTables" roleURI="http://www.spy.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#NetLossPerShareTables" roleURI="http://www.spy.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedLiabilitiesTables" roleURI="http://www.spy.com/role/AccruedLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#TheCompanyAndBasisOfPresentationDetails" roleURI="http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsNarrativeDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsChangesInForwardContractLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#FairValueMeasurementsChangesInCvrLiabilityDetails" roleURI="http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesNarrativeDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" roleURI="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#PropertyAndEquipmentNetNarrativeDetails" roleURI="http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" roleURI="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AssetAcquisitionNarrativeDetails" roleURI="http://www.spy.com/role/AssetAcquisitionNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AssetAcquisitionAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ParagonAgreementDetails" roleURI="http://www.spy.com/role/ParagonAgreementDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#LeasesNarrativeDetails" roleURI="http://www.spy.com/role/LeasesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" roleURI="http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" roleURI="http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#LeasesLeaseCostDetails" roleURI="http://www.spy.com/role/LeasesLeaseCostDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails" roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" roleURI="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StrategicLicenseAgreementNarrativeDetails" roleURI="http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StrategicLicenseAgreementChangesInContractLiabilitiesDetails" roleURI="http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SaleOfPegzilarginaseToImmedicaDetails" roleURI="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#NovationOfManufacturingAgreementsDetails" roleURI="http://www.spy.com/role/NovationOfManufacturingAgreementsDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationNarrativeDetails" roleURI="http://www.spy.com/role/StockBasedCompensationNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails" roleURI="http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationEmployeeRestrictedStockActivityDetails" roleURI="http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails" roleURI="http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DefinedContributionPlanDetails" roleURI="http://www.spy.com/role/DefinedContributionPlanDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringChargesNarrativeDetails" roleURI="http://www.spy.com/role/RestructuringChargesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringChargesChangesInAccruedRestructuringBalanceDetails" roleURI="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" roleURI="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails" roleURI="http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://www.spy.com/role/IncomeTaxesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#AccruedLiabilitiesAdditionalInformationDetails" roleURI="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="syre-20231231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_1918" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1918" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1919" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1919" xlink:to="loc_dei_AddressTypeDomain_1920" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1920" xlink:to="loc_dei_BusinessContactMember_1921" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1918" xlink:to="loc_dei_DocumentInformationLineItems_1923" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_DocumentType_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityRegistrantName_107" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityIncorporationStateCountryCode_108" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityTaxIdentificationNumber_109" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine1_110" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine2_111" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressAddressLine3_112" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressCityOrTown_113" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressStateOrProvince_114" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityAddressPostalZipCode_115" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_CityAreaCode_116" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_LocalPhoneNumber_117" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityFilerCategory_123" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntitySmallBusiness_124" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityEmergingGrowthCompany_125" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_EntityCentralIndexKey_128" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_AmendmentFlag_130" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1923" xlink:to="loc_dei_ContactPersonnelName_1925" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2100" xlink:to="loc_us-gaap_StatementTable_2101" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2102" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2102" xlink:to="loc_us-gaap_ClassOfStockDomain_2165" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2165" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2166" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2165" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2680" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2165" xlink:to="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2719" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2101" xlink:to="loc_us-gaap_StatementLineItems_2703" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2703" xlink:to="loc_us-gaap_AssetsAbstract_2169" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2167" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2168" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2678" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_2721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_2721" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2873" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2167" xlink:to="loc_us-gaap_AssetsCurrent_2892" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2679" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2720" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2874" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2891" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2169" xlink:to="loc_us-gaap_Assets_2969" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2703" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2170" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_2171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_2171" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_2675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_2675" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2723" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2871" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2894" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_2967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_2967" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2170" xlink:to="loc_us-gaap_LiabilitiesCurrent_2981" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_2676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_2676" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2722" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2872" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_Liabilities_2893" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2968" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2980" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3024" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_2172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_PreferredStockValue_2172" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_CommonStockValue_2674" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2724" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2870" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2895" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3024" xlink:to="loc_us-gaap_StockholdersEquity_2966" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2677" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3029" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2143" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2143" xlink:to="loc_us-gaap_StatementTable_2144" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2144" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2145" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2145" xlink:to="loc_us-gaap_ClassOfStockDomain_2146" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2146" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2147" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2146" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2689" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2146" xlink:to="loc_syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember_2712" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2144" xlink:to="loc_us-gaap_StatementLineItems_2690" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2148" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_2688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_2688" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_2713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_2713" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2877" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2888" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2971" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2978" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3026" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3028" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3061" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockSharesIssued_3062" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2690" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3087" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_2190" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2190" xlink:to="loc_us-gaap_StatementTable_2191" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2191" xlink:to="loc_srt_ProductOrServiceAxis_2192" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2192" xlink:to="loc_srt_ProductsAndServicesDomain_2136" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_2137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2136" xlink:to="loc_us-gaap_LicenseMember_2137" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DevelopmentFeeAndRoyaltyMember" xlink:label="loc_syre_DevelopmentFeeAndRoyaltyMember_2696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2136" xlink:to="loc_syre_DevelopmentFeeAndRoyaltyMember_2696" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2191" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2664" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2664" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2187" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2187" xlink:to="loc_us-gaap_ForwardContractsMember_2188" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2191" xlink:to="loc_us-gaap_StatementLineItems_2732" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_RevenuesAbstract_2189" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2189" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2193" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2665" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2194" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2663" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_2733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_2733" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2863" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2665" xlink:to="loc_us-gaap_OperatingExpenses_2900" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_OperatingIncomeLoss_2731" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_2195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_InvestmentIncomeNet_2195" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3305" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2734" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2864" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2862" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2899" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2962" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_NetIncomeLoss_2985" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_EarningsPerShareBasic_3021" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3032" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3058" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2732" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3065" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_2283" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2283" xlink:to="loc_us-gaap_StatementTable_2284" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2284" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2285" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2285" xlink:to="loc_us-gaap_RelatedPartyDomain_2272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_2273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2272" xlink:to="loc_us-gaap_RelatedPartyMember_2273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2284" xlink:to="loc_us-gaap_StatementLineItems_2625" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2625" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2274" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2149" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2149" xlink:to="loc_us-gaap_NetIncomeLoss_2150" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2149" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2687" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_2152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2687" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_2152" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2687" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2685" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2149" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2714" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2173" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2173" xlink:to="loc_us-gaap_StatementTable_2174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2174" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2175" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2175" xlink:to="loc_us-gaap_EquityComponentDomain_2176" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_PreferredStockMember_2177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_CommonStockMember_2671" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2726" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2848" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_2912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2176" xlink:to="loc_us-gaap_RetainedEarningsMember_2912" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2673" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2673" xlink:to="loc_us-gaap_ClassOfStockDomain_2265" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2265" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2266" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2265" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2631" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2174" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2725" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2725" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2267" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2267" xlink:to="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2268" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfPreFundedWarrantsMember" xlink:label="loc_syre_ConversionOfPreFundedWarrantsMember_2629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2267" xlink:to="loc_syre_ConversionOfPreFundedWarrantsMember_2629" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2174" xlink:to="loc_us-gaap_StatementLineItems_2869" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2869" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2270" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2628" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2754" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2847" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_2913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_2913" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_2269" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2953" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2869" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2271" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2627" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockholdersEquity_2755" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2846" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering" xlink:label="loc_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering_2914" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2952" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2993" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3014" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3039" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3054" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3069" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_syre_StockIssuedDuringPeriodSharesNewIssuesOne_3082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodSharesNewIssuesOne_3082" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="loc_syre_StockIssuedDuringPeriodValueNewIssuesOne_3091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodValueNewIssuesOne_3091" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_3104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_3104" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3109" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_3122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan_3122" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan" xlink:label="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_3125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan_3125" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3137" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3140" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightDistributionToCommonStockholders" xlink:label="loc_syre_ContingentValueRightDistributionToCommonStockholders_3151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_syre_ContingentValueRightDistributionToCommonStockholders_3151" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3154" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3165" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3168" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3176" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_NetIncomeLoss_3179" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3186" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3189" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_3196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2630" xlink:to="loc_us-gaap_StockholdersEquity_3196" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2196" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2196" xlink:to="loc_us-gaap_StatementTable_2197" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2197" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2198" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2199" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2199" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2200" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2199" xlink:to="loc_us-gaap_ForwardContractsMember_2659" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2197" xlink:to="loc_us-gaap_StatementLineItems_2661" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" xlink:to="loc_us-gaap_NetIncomeLoss_2141" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2202" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_ShareBasedCompensation_2658" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_2736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_2736" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2860" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2902" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_2960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_AssetImpairmentCharges_2960" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2987" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3020" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3033" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3057" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2692" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2138" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2695" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2709" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2880" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2885" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2974" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_2975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3066" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_2975" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2201" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2708" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_2140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_2140" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2693" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2711" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2878" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2887" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2972" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2660" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2977" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2139" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2694" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2710" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_2879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_2879" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts" xlink:label="loc_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_2886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts_2886" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2973" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_2976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_2976" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2735" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3027" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2861" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2901" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_2961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_2961" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_2961" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2142" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_2961" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2691" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2661" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_2151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" xlink:to="loc_us-gaap_StockIssued1_2151" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_2686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_2686" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeasedAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_syre_LeasedAssetsObtainedInExchangeForLeaseObligations_2715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2986" xlink:to="loc_syre_LeasedAssetsObtainedInExchangeForLeaseObligations_2715" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1927" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1927" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1928" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1929" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1929" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1933" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract_1932" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_1934" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_1931" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1935" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1938" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract_1937" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1939" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1936" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1940" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_1930" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1941" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/TheCompanyAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2387" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2387" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2388" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1792" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1792" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1793" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2275" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2275" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2277" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2277" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2278" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecurities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2279" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2389" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2389" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedAndOtherCurrentLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2281" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedAndOtherCurrentLiabilitiesTextBlock" xlink:label="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock_2282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2281" xlink:to="loc_syre_AccruedAndOtherCurrentLiabilitiesTextBlock_2282" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1943" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesTextBlock" xlink:label="loc_syre_AccruedLiabilitiesTextBlock_1944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1943" xlink:to="loc_syre_AccruedLiabilitiesTextBlock_1944" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_347" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_347" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_348" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisition">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_350" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_350" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_351" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParagonAgreement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2391" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OptionAgreementTextBlock" xlink:label="loc_syre_OptionAgreementTextBlock_2392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2391" xlink:to="loc_syre_OptionAgreementTextBlock_2392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2393" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_2394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2393" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_2394" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2103" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2104" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2395" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2395" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2396" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SaleOfPegzilarginaseToImmedica">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2397" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2397" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2398" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NovationOfManufacturingAgreements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2300" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_2301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2300" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_2301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2105" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2105" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2106" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DefinedContributionPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2302" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_2303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2302" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_2303" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringCharges">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2304" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2304" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2305" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2306" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2306" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2307" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2399" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2399" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2400" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1879" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1879" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1880" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2308" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2309" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_UseOfEstimates_2759" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2843" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_2915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_2915" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2951" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2994" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3013" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3040" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="loc_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock_3053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock_3053" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_3070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_3070" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3081" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3092" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3103" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3110" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TemporaryEquityPolicyPolicyTextBlock" xlink:label="loc_syre_TemporaryEquityPolicyPolicyTextBlock_3121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_syre_TemporaryEquityPolicyPolicyTextBlock_3121" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock" xlink:label="loc_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock_3126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock_3126" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_3136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_3136" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_3141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_3141" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3150" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_3155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_3155" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3164" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2308" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3169" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_377" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesPolicyTextBlock" xlink:label="loc_syre_AccruedLiabilitiesPolicyTextBlock_1796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_377" xlink:to="loc_syre_AccruedLiabilitiesPolicyTextBlock_1796" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2107" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_2108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2107" xlink:to="loc_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_2108" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2401" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2401" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2402" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2401" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2590" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2401" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2780" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2405" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2405" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2405" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2588" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2405" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2782" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2407" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2409" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2409" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2410" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2411" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2411" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock" xlink:label="loc_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock_2587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2411" xlink:to="loc_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock_2587" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_2323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2322" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_2323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2109" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_syre_AssetsAndLiabilitiesLesseeTableTextBlock_2110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2109" xlink:to="loc_syre_AssetsAndLiabilitiesLesseeTableTextBlock_2110" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2109" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2702" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2111" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2111" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_2112" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_2114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2113" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_2114" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2115" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2115" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2116" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2115" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2701" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2115" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2704" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2115" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2883" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_417" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_417" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_418" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_417" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_419" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2413" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2413" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2413" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2586" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2413" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2783" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3307" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3307" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3307" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3309" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1798" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_1799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1798" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_1799" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1946" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1946" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2324" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CompanyAndBasisOfPresentationTable" xlink:label="loc_syre_CompanyAndBasisOfPresentationTable_2325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2324" xlink:to="loc_syre_CompanyAndBasisOfPresentationTable_2325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2326" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2326" xlink:to="loc_us-gaap_EquityComponentDomain_2332" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2332" xlink:to="loc_us-gaap_CommonStockMember_2333" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2610" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2610" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_2335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2334" xlink:to="loc_us-gaap_PrivatePlacementMember_2335" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2766" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2766" xlink:to="loc_us-gaap_ClassOfStockDomain_2336" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2336" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2337" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2336" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2608" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_PlanNameAxis_2838" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2838" xlink:to="loc_us-gaap_PlanNameDomain_2327" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_Spyre2023EquityIncentivePlanMember" xlink:label="loc_syre_Spyre2023EquityIncentivePlanMember_2328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2327" xlink:to="loc_syre_Spyre2023EquityIncentivePlanMember_2328" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2919" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2919" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2329" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_2330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2329" xlink:to="loc_syre_SpyreTherapeuticsIncMember_2330" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CompanyAndBasisOfPresentationLineItems" xlink:label="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationTable_2325" xlink:to="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2767" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FixedExchangeRatio" xlink:label="loc_syre_FixedExchangeRatio_2837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_FixedExchangeRatio_2837" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2920" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2948" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_2996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_2996" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OutstandingAndUnexercisedStockOptions" xlink:label="loc_syre_OutstandingAndUnexercisedStockOptions_3012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_OutstandingAndUnexercisedStockOptions_3012" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3041" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3052" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3071" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod_3080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_AssetAcquisitionStockholderPaymentPeriod_3080" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3102" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ProceedsFromRaisingCapital" xlink:label="loc_syre_ProceedsFromRaisingCapital_3111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_syre_ProceedsFromRaisingCapital_3111" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3120" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CompanyAndBasisOfPresentationLineItems_2949" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3127" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2117" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2117" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" xlink:to="loc_srt_RangeAxis_2119" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2119" xlink:to="loc_srt_RangeMember_2120" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2120" xlink:to="loc_srt_MaximumMember_2121" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2700" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2700" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_USBankingInstitutionMember" xlink:label="loc_syre_USBankingInstitutionMember_2123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2122" xlink:to="loc_syre_USBankingInstitutionMember_2123" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2118" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_2681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" xlink:to="loc_us-gaap_CashFDICInsuredAmount_2681" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2705" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2718" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2417" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2417" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2418" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2418" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2419" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2419" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LaboratoryEquipmentMember" xlink:label="loc_syre_LaboratoryEquipmentMember_2421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_syre_LaboratoryEquipmentMember_2421" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2582" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_us-gaap_ComputerEquipmentMember_2784" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SoftwareMember" xlink:label="loc_syre_SoftwareMember_2825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2420" xlink:to="loc_syre_SoftwareMember_2825" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2418" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2583" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2422" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2338" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2338" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2340" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2340" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2343" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2344" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2607" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2607" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2346" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2605" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2345" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2769" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2768" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2768" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2347" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2348" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2836" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2836" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2350" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_CommercialPaperMember_2604" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2770" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2835" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2349" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2922" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2339" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_2358" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2358" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2351" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2921" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2601" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2601" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2352" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2125" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2125" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2127" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2127" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2128" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_2129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2128" xlink:to="loc_syre_SpyreTherapeuticsIncMember_2129" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2672" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2672" xlink:to="loc_us-gaap_ClassOfStockDomain_2130" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2130" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2131" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2706" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2706" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2132" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2132" xlink:to="loc_us-gaap_ForwardContractsMember_2133" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2132" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2699" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2126" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2153" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2684" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2716" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2876" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionStockholderPaymentPeriod" xlink:label="loc_syre_AssetAcquisitionStockholderPaymentPeriod_2889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_syre_AssetAcquisitionStockholderPaymentPeriod_2889" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionCashPaymentThresholdPeriod" xlink:label="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_2970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_syre_AssetAcquisitionCashPaymentThresholdPeriod_2970" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2979" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2881" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3025" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_2423" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_2423" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2424" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2424" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2425" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2425" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2440" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaap_ForwardContractsMember_2441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2440" xlink:to="loc_us-gaap_ForwardContractsMember_2441" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2424" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2581" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2581" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2443" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2577" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2788" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2442" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2822" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2426" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2426" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_srt_RangeAxis_2428" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2428" xlink:to="loc_srt_RangeMember_2447" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2447" xlink:to="loc_srt_MaximumMember_2448" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2447" xlink:to="loc_srt_MinimumMember_2575" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2580" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2580" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2434" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2435" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2785" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2785" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2436" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2437" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2824" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2824" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2438" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_syre_MeasurementInputProbabilityOfSuccessMember_2439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2438" xlink:to="loc_syre_MeasurementInputProbabilityOfSuccessMember_2439" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MeasurementInputReimbursementRateMember" xlink:label="loc_syre_MeasurementInputReimbursementRateMember_2578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2438" xlink:to="loc_syre_MeasurementInputReimbursementRateMember_2578" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2438" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2787" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2929" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2929" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2444" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2585" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2427" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2943" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2943" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2487" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_2158" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract_2158" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2159" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2159" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2160" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2160" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2154" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContingentValueRightLiabilityMember" xlink:label="loc_syre_ContingentValueRightLiabilityMember_2155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2154" xlink:to="loc_syre_ContingentValueRightLiabilityMember_2155" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2159" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2682" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2682" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2157" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2683" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2717" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2875" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2156" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2890" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2353" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2353" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2354" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2354" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2355" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2355" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2357" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_CommercialPaperMember_2602" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2771" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2834" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2356" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2923" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2354" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_2360" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsUnrealizedGains" xlink:label="loc_syre_CashEquivalentsUnrealizedGains_2599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_syre_CashEquivalentsUnrealizedGains_2599" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsUnrealizedLosses" xlink:label="loc_syre_CashEquivalentsUnrealizedLosses_2772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_syre_CashEquivalentsUnrealizedLosses_2772" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_2359" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2833" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2603" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2361" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2598" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2773" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2600" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2832" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2162" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2162" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2163" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2164" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2164" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_CommercialPaperMember_2287" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2624" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2756" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2286" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2845" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2163" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2289" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2622" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_2288" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2757" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2626" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2312" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2616" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_2761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_2623" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_2761" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2290" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2290" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2291" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2291" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2292" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2292" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2293" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2294" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesTable_2291" xlink:to="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag" xlink:label="loc_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag_2296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag_2296" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_2295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_2295" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2620" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_2758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_2758" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CashEquivalentsAndMarketableSecuritiesLineItems_2621" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_2844" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2488" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2488" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2489" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2488" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2557" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2488" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2799" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2297" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2297" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2298" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2299" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LaboratoryEquipmentMember" xlink:label="loc_syre_LaboratoryEquipmentMember_2311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_syre_LaboratoryEquipmentMember_2311" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2617" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_us-gaap_ComputerEquipmentMember_2760" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SoftwareMember" xlink:label="loc_syre_SoftwareMember_2842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_syre_SoftwareMember_2842" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2310" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2916" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2298" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2313" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2615" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2619" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2762" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2362" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2362" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2364" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2364" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_2366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2365" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_2366" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2597" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2597" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2367" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2367" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2368" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2367" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2596" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2363" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2369" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2595" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2775" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2774" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2831" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2314" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2314" xlink:to="loc_us-gaap_AccruedSalariesCurrent_2315" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedContractedResearchAndDevelopmentCosts" xlink:label="loc_syre_AccruedContractedResearchAndDevelopmentCosts_2614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2314" xlink:to="loc_syre_AccruedContractedResearchAndDevelopmentCosts_2614" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2314" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2763" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2314" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2841" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_2314" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2917" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_625" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_625" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_OwnershipAxis_627" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_627" xlink:to="loc_srt_OwnershipDomain_628" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonTherapeuticsIncMember" xlink:label="loc_syre_ParagonTherapeuticsIncMember_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_syre_ParagonTherapeuticsIncMember_629" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FairmountFundsManagementLlcMember" xlink:label="loc_syre_FairmountFundsManagementLlcMember_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_syre_FairmountFundsManagementLlcMember_630" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAndParapyreHoldingLlcMember" xlink:label="loc_syre_ParagonAndParapyreHoldingLlcMember_2008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_628" xlink:to="loc_syre_ParagonAndParapyreHoldingLlcMember_2008" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_631" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_632" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OwnershipInterestMember" xlink:label="loc_syre_OwnershipInterestMember_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_OwnershipInterestMember_633" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAgreementMember" xlink:label="loc_syre_ParagonAgreementMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_ParagonAgreementMember_635" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_syre_ReimbursableCostsUnderParagonAgreementMember_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_636" xlink:to="loc_syre_ReimbursableCostsUnderParagonAgreementMember_637" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MilestonePaymentsMember" xlink:label="loc_syre_MilestonePaymentsMember_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_MilestonePaymentsMember_638" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AppointOfBoardMembersMember" xlink:label="loc_syre_AppointOfBoardMembersMember_2684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_AppointOfBoardMembersMember_2684" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SPY002LicenseAgreementMember" xlink:label="loc_syre_SPY002LicenseAgreementMember_3127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_SPY002LicenseAgreementMember_3127" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SaleOfStockDecember2023PIPEMember" xlink:label="loc_syre_SaleOfStockDecember2023PIPEMember_3148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_SaleOfStockDecember2023PIPEMember_3148" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConsultingAgreementMember" xlink:label="loc_syre_ConsultingAgreementMember_3176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_632" xlink:to="loc_syre_ConsultingAgreementMember_3176" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_RangeAxis_641" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_641" xlink:to="loc_srt_RangeMember_642" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MaximumMember_643" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_642" xlink:to="loc_srt_MinimumMember_644" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_645" xlink:to="loc_us-gaap_RelatedPartyDomain_646" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_646" xlink:to="loc_us-gaap_RelatedPartyMember_647" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_srt_CounterpartyNameAxis_648" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_648" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_649" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_3037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_VestingAxis_3037" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_2442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_3037" xlink:to="loc_us-gaap_VestingDomain_2442" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2442" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2443" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3302" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3302" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_3304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3303" xlink:to="loc_us-gaap_PrivatePlacementMember_3304" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_652" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_653" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyTransactionNumberOfBoardSeats" xlink:label="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_RelatedPartyTransactionNumberOfBoardSeats_654" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty" xlink:label="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty_655" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_656" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ResearchInitiationFees" xlink:label="loc_syre_ResearchInitiationFees_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_ResearchInitiationFees_657" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableResearchCosts" xlink:label="loc_syre_ReimbursableResearchCosts_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_ReimbursableResearchCosts_658" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_659" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_660" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AmountToBePaidUnderAgreement" xlink:label="loc_syre_AmountToBePaidUnderAgreement_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_AmountToBePaidUnderAgreement_663" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensation_666" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_3192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_3192" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NominationFee" xlink:label="loc_syre_NominationFee_3225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_NominationFee_3225" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PaymentOfMilestone" xlink:label="loc_syre_PaymentOfMilestone_3239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_PaymentOfMilestone_3239" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3248" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3259" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3267" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3278" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_3294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments_3294" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_652" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3301" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_668" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_668" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_670" xlink:to="loc_us-gaap_RelatedPartyDomain_671" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_673" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_673" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_674" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_syre_ReimbursableCostsUnderParagonAgreementMember_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_674" xlink:to="loc_syre_ReimbursableCostsUnderParagonAgreementMember_675" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_676" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_676" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_677" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_677" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_678" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_669" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_679" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyTransactionReimbursableCosts" xlink:label="loc_syre_RelatedPartyTransactionReimbursableCosts_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_679" xlink:to="loc_syre_RelatedPartyTransactionReimbursableCosts_680" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_682" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_682" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_684" xlink:to="loc_us-gaap_RelatedPartyDomain_685" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_685" xlink:to="loc_us-gaap_RelatedPartyMember_686" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_687" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_687" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_688" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableCostsUnderParagonAgreementMember" xlink:label="loc_syre_ReimbursableCostsUnderParagonAgreementMember_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_688" xlink:to="loc_syre_ReimbursableCostsUnderParagonAgreementMember_689" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_683" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_691" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_2175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_691" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_2175" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1870" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1870" xlink:to="loc_us-gaap_AssetAcquisitionTable_1871" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_PlanNameAxis_1874" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1874" xlink:to="loc_us-gaap_PlanNameDomain_1875" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_1876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1875" xlink:to="loc_syre_ParapyreOptionObligationMember_1876" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_Spyre2023EquityIncentivePlanMember" xlink:label="loc_syre_Spyre2023EquityIncentivePlanMember_2604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1875" xlink:to="loc_syre_Spyre2023EquityIncentivePlanMember_2604" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_2598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_2598" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_2598" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2599" xlink:to="loc_us-gaap_CommonStockMember_2600" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2626" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2626" xlink:to="loc_us-gaap_ClassOfStockDomain_2601" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2601" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2602" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2920" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2920" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2605" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_2606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2605" xlink:to="loc_syre_SpyreTherapeuticsIncMember_2606" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1871" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_1872" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1873" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_1877" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_2607" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OutstandingAndUnexercisedStockOptions" xlink:label="loc_syre_OutstandingAndUnexercisedStockOptions_2625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_OutstandingAndUnexercisedStockOptions_2625" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2913" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_2919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_2919" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_3061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1872" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_3061" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_715" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_715" xlink:to="loc_us-gaap_AssetAcquisitionTable_716" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_716" xlink:to="loc_us-gaap_AssetAcquisitionAxis_717" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_717" xlink:to="loc_us-gaap_AssetAcquisitionDomain_718" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_718" xlink:to="loc_syre_SpyreTherapeuticsIncMember_719" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_716" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_721" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_722" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_723" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_724" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssumedLiabilities" xlink:label="loc_syre_AssumedLiabilities_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_syre_AssumedLiabilities_725" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_720" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_726" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ParagonAgreementDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CollaborativeArrangementAbstract" xlink:label="loc_syre_CollaborativeArrangementAbstract_728" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_CollaborativeArrangementAbstract_728" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_730" xlink:to="loc_us-gaap_RelatedPartyDomain_731" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_731" xlink:to="loc_us-gaap_RelatedPartyMember_732" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_733" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_733" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_734" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAgreementMember" xlink:label="loc_syre_ParagonAgreementMember_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_syre_ParagonAgreementMember_735" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_StockCompensationAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_734" xlink:to="loc_syre_StockCompensationAndResearchAndDevelopmentExpenseMember_738" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_PlanNameAxis_739" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_739" xlink:to="loc_us-gaap_PlanNameDomain_740" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_740" xlink:to="loc_syre_ParapyreOptionObligationMember_741" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_RangeAxis_742" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_742" xlink:to="loc_srt_RangeMember_743" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_srt_CounterpartyNameAxis_745" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_745" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonTherapeuticsIncMember" xlink:label="loc_syre_ParagonTherapeuticsIncMember_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746" xlink:to="loc_syre_ParagonTherapeuticsIncMember_747" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_729" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_748" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ResearchInitiationFees" xlink:label="loc_syre_ResearchInitiationFees_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_ResearchInitiationFees_749" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_750" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableResearchCosts" xlink:label="loc_syre_ReimbursableResearchCosts_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_ReimbursableResearchCosts_751" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_752" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_753" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash" xlink:label="loc_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash_754" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_755" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LicenseAgreementMilestonePayments" xlink:label="loc_syre_LicenseAgreementMilestonePayments_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_748" xlink:to="loc_syre_LicenseAgreementMilestonePayments_759" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2316" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2316" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2317" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2317" xlink:to="loc_srt_RangeAxis_2318" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2318" xlink:to="loc_srt_RangeMember_2341" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2341" xlink:to="loc_srt_MinimumMember_2342" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2341" xlink:to="loc_srt_MaximumMember_2606" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2317" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2319" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_2612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_AreaOfLand_2612" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_2764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_SecurityDeposit_2764" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaap_TenantImprovements_2840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_TenantImprovements_2840" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLeaseTerminationFeeAmount" xlink:label="loc_syre_OperatingLeaseTerminationFeeAmount_2918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_syre_OperatingLeaseTerminationFeeAmount_2918" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_2950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2613" xlink:to="loc_us-gaap_OperatingLeasePayments_2950" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2491" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseAssetsAbstract" xlink:label="loc_syre_LeaseAssetsAbstract_2492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2491" xlink:to="loc_syre_LeaseAssetsAbstract_2492" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseAssetsAbstract_2492" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2493" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_2554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseAssetsAbstract_2492" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_2554" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseAssetsAbstract_2492" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2800" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingAndFinanceLeaseRightOfUseAsset" xlink:label="loc_syre_OperatingAndFinanceLeaseRightOfUseAsset_2815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseAssetsAbstract_2492" xlink:to="loc_syre_OperatingAndFinanceLeaseRightOfUseAsset_2815" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseLiabilityAbstract" xlink:label="loc_syre_LeaseLiabilityAbstract_2555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2491" xlink:to="loc_syre_LeaseLiabilityAbstract_2555" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseLiabilityCurrentAbstract" xlink:label="loc_syre_LeaseLiabilityCurrentAbstract_2495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseLiabilityAbstract_2555" xlink:to="loc_syre_LeaseLiabilityCurrentAbstract_2495" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseLiabilityCurrentAbstract_2495" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2494" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseLiabilityCurrentAbstract_2495" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2552" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseLiabilityCurrentAbstract_2495" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2738" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseLiabilityNoncurrentAbstract" xlink:label="loc_syre_LeaseLiabilityNoncurrentAbstract_2551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseLiabilityAbstract_2555" xlink:to="loc_syre_LeaseLiabilityNoncurrentAbstract_2551" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseLiabilityNoncurrentAbstract_2551" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2370" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingAndFinanceLeaseLiabilities" xlink:label="loc_syre_OperatingAndFinanceLeaseLiabilities_2802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseLiabilityAbstract_2555" xlink:to="loc_syre_OperatingAndFinanceLeaseLiabilities_2802" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2480" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:label="loc_syre_LeaseWeightedAverageRemainingLeaseTermAbstract_2481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2480" xlink:to="loc_syre_LeaseWeightedAverageRemainingLeaseTermAbstract_2481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseWeightedAverageRemainingLeaseTermAbstract_2481" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_2559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseWeightedAverageRemainingLeaseTermAbstract_2481" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_2559" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LeaseWeightedAverageDiscountRateAbstract" xlink:label="loc_syre_LeaseWeightedAverageDiscountRateAbstract_2560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2480" xlink:to="loc_syre_LeaseWeightedAverageDiscountRateAbstract_2560" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseWeightedAverageDiscountRateAbstract_2560" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2490" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_LeaseWeightedAverageDiscountRateAbstract_2560" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2556" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/LeasesLeaseCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_2483" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_2484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2483" xlink:to="loc_us-gaap_OperatingLeaseCost_2484" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_2558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2483" xlink:to="loc_us-gaap_VariableLeaseCost_2558" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_2798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2483" xlink:to="loc_us-gaap_LeaseCost_2798" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2371" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2371" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2372" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2373" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2373" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_2375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2374" xlink:to="loc_us-gaap_PrivatePlacementMember_2375" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2594" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2594" xlink:to="loc_us-gaap_EquityComponentDomain_2376" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2376" xlink:to="loc_us-gaap_CommonStockMember_2446" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2376" xlink:to="loc_us-gaap_PreferredStockMember_2576" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_srt_RangeAxis_2776" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2776" xlink:to="loc_srt_RangeMember_2449" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2449" xlink:to="loc_srt_MaximumMember_2450" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2449" xlink:to="loc_srt_MinimumMember_2574" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2830" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2830" xlink:to="loc_us-gaap_ClassOfStockDomain_2458" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2458" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_2459" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesBNonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2458" xlink:to="loc_syre_SeriesBNonVotingConvertiblePreferredStockMember_2569" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2924" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2924" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2429" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreWarrantsMember" xlink:label="loc_syre_ParapyreWarrantsMember_2430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2429" xlink:to="loc_syre_ParapyreWarrantsMember_2430" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2947" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2947" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2431" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_2431" xlink:to="loc_syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember_2432" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2372" xlink:to="loc_us-gaap_ClassOfStockLineItems_2997" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SharesAuthorized" xlink:label="loc_syre_SharesAuthorized_2433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_SharesAuthorized_2433" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2579" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2786" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2823" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfCommonStockVotingRightsHeldPerShare" xlink:label="loc_syre_NumberOfCommonStockVotingRightsHeldPerShare_2942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_NumberOfCommonStockVotingRightsHeldPerShare_2942" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_3000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_DividendsCommonStock_3000" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3009" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3044" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3050" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3072" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3079" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights" xlink:label="loc_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_3094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights_3094" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3101" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3112" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PlacementAgentFeesAndOfferingCosts" xlink:label="loc_syre_PlacementAgentFeesAndOfferingCosts_3119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_PlacementAgentFeesAndOfferingCosts_3119" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3128" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3135" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3142" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised" xlink:label="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_3156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised_3156" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice" xlink:label="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice_3163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice_3163" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders" xlink:label="loc_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_3170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders_3170" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice" xlink:label="loc_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_3175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice_3175" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreferredStockRemainsIssuedAndOutstandingPercentage" xlink:label="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_3180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_PreferredStockRemainsIssuedAndOutstandingPercentage_3180" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_3185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_3185" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_BeneficiallyHoldersOwnedPercentage" xlink:label="loc_syre_BeneficiallyHoldersOwnedPercentage_3190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_syre_BeneficiallyHoldersOwnedPercentage_3190" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3195" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3199" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3203" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaap_PreferredStockRedemptionAmount_3206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockRedemptionAmount_3206" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_3209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2997" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_3209" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2485" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2485" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2801" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2801" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2496" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2496" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreFundedMay2022WarrantsMember" xlink:label="loc_syre_PreFundedMay2022WarrantsMember_2506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" xlink:to="loc_syre_PreFundedMay2022WarrantsMember_2506" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PreFundedWarrantsMember" xlink:label="loc_syre_PreFundedWarrantsMember_2548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2505" xlink:to="loc_syre_PreFundedWarrantsMember_2548" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2801" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2507" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_2550" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2547" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2508" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2508" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2510" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2510" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ImmedicaPharmaABMember" xlink:label="loc_syre_ImmedicaPharmaABMember_2512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2511" xlink:to="loc_syre_ImmedicaPharmaABMember_2512" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2546" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2546" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PeaceTrialAndBLAPackageMember" xlink:label="loc_syre_PeaceTrialAndBLAPackageMember_2514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" xlink:to="loc_syre_PeaceTrialAndBLAPackageMember_2514" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PIPTrialMember" xlink:label="loc_syre_PIPTrialMember_2545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" xlink:to="loc_syre_PIPTrialMember_2545" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_LicenseAgreementsMember" xlink:label="loc_syre_LicenseAgreementsMember_2804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2513" xlink:to="loc_syre_LicenseAgreementsMember_2804" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2739" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2739" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2497" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2497" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2498" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2813" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2813" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GlobalRightsToPegzilarginaseMember" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember_2500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2499" xlink:to="loc_syre_GlobalRightsToPegzilarginaseMember_2500" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2509" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_2501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_2501" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonRefundablePaymentReceived" xlink:label="loc_syre_NonRefundablePaymentReceived_2549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_NonRefundablePaymentReceived_2549" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfPaymentForCostIncurredInPIPTrial" xlink:label="loc_syre_PercentageOfPaymentForCostIncurredInPIPTrial_2803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_PercentageOfPaymentForCostIncurredInPIPTrial_2803" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_CostsIncurredInPerformingTheTrial" xlink:label="loc_syre_CostsIncurredInPerformingTheTrial_2814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_CostsIncurredInPerformingTheTrial_2814" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AdditionalUpfrontPaymentAbilityToReceived" xlink:label="loc_syre_AdditionalUpfrontPaymentAbilityToReceived_2934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_AdditionalUpfrontPaymentAbilityToReceived_2934" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MilestonePaymentsExchangeRate" xlink:label="loc_syre_MilestonePaymentsExchangeRate_2940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_MilestonePaymentsExchangeRate_2940" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_UpfrontPayment" xlink:label="loc_syre_UpfrontPayment_3007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_UpfrontPayment_3007" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_3045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_3045" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_3048" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AllocatedAmountOfTransactionPrice" xlink:label="loc_syre_AllocatedAmountOfTransactionPrice_3074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_AllocatedAmountOfTransactionPrice_3074" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AllocationPriceTotal" xlink:label="loc_syre_AllocationPriceTotal_3077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_AllocationPriceTotal_3077" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3096" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3099" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3114" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_3117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_3117" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_3130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_3130" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_3133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_3133" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3144" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3147" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PrepaidExpenseValueOfExpectedRecoveries" xlink:label="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_3158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_3158" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xlink:label="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_3161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2935" xlink:to="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_3161" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2451" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ChangeInContractWithCustomerLiabilityRollForward" xlink:label="loc_syre_ChangeInContractWithCustomerLiabilityRollForward_2452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2451" xlink:to="loc_syre_ChangeInContractWithCustomerLiabilityRollForward_2452" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ChangeInContractWithCustomerLiabilityRollForward_2452" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2453" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ContractWithCustomerLiabilityAdditions" xlink:label="loc_syre_ContractWithCustomerLiabilityAdditions_2573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ChangeInContractWithCustomerLiabilityRollForward_2452" xlink:to="loc_syre_ContractWithCustomerLiabilityAdditions_2573" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_2789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ChangeInContractWithCustomerLiabilityRollForward_2452" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_2789" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ChangeInContractWithCustomerLiabilityRollForward_2452" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2821" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2502" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2502" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2504" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2504" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2212" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2212" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2213" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2654" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2654" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GlobalRightsToPegzilarginaseMember" xlink:label="loc_syre_GlobalRightsToPegzilarginaseMember_2215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2214" xlink:to="loc_syre_GlobalRightsToPegzilarginaseMember_2215" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2503" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_2216" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_2652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_2652" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_2742" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2858" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PrepaidExpenseValueOfExpectedRecoveries" xlink:label="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_2903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_syre_PrepaidExpenseValueOfExpectedRecoveries_2903" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet" xlink:label="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_2959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2740" xlink:to="loc_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet_2959" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NovationOfManufacturingAgreementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod_2321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod_2321" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod_2611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod_2611" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable_2765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable_2765" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod_2839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod_2839" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod_2926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod_2926" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentNonRefundableLicenseFeeAmount" xlink:label="loc_syre_OtherCommitmentNonRefundableLicenseFeeAmount_2945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentNonRefundableLicenseFeeAmount_2945" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRoyaltyPercentage" xlink:label="loc_syre_OtherCommitmentRoyaltyPercentage_2998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRoyaltyPercentage_2998" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod_3011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod_3011" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod_3042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod_3042" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod" xlink:label="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod_3051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2320" xlink:to="loc_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod_3051" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2377" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2377" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_us-gaap_PlanNameAxis_2379" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2379" xlink:to="loc_us-gaap_PlanNameDomain_2380" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndFifteenEquityIncentivePlanMember" xlink:label="loc_syre_TwoThousandAndFifteenEquityIncentivePlanMember_2381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndFifteenEquityIncentivePlanMember_2381" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEquityIncentivePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_2593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndSixteenEquityIncentivePlanMember_2593" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_2777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndEighteenEquityInducementPlanMember_2777" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember" xlink:label="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_2829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember_2829" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2380" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2946" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_us-gaap_AwardTypeAxis_2585" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2404" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ServiceBasedAwardsMember" xlink:label="loc_syre_ServiceBasedAwardsMember_2589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_syre_ServiceBasedAwardsMember_2589" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2781" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2403" xlink:to="loc_us-gaap_PerformanceSharesMember_2827" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_srt_TitleOfIndividualAxis_2778" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2778" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonEmployeesMember" xlink:label="loc_syre_NonEmployeesMember_2383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2382" xlink:to="loc_syre_NonEmployeesMember_2383" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2826" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2384" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_2385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2384" xlink:to="loc_syre_ParapyreOptionObligationMember_2385" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2378" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2386" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2592" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_GranteesWithMoreThanFiveYearsVestingTermPercent" xlink:label="loc_syre_GranteesWithMoreThanFiveYearsVestingTermPercent_2779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_GranteesWithMoreThanFiveYearsVestingTermPercent_2779" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumVestingTermForMoreThanTenPercentGrantees" xlink:label="loc_syre_MaximumVestingTermForMoreThanTenPercentGrantees_2828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_MaximumVestingTermForMoreThanTenPercentGrantees_2828" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2927" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2944" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2999" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_3010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_3010" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares" xlink:label="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_3043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares_3043" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_3049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant_3049" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3073" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares_3078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares_3078" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount_3095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount_3095" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount" xlink:label="loc_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount_3100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount_3100" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3113" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3118" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3129" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3134" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding" xlink:label="loc_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding_3143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding_3143" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_3148" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightGrantDateFairValue" xlink:label="loc_syre_ClassOfWarrantOrRightGrantDateFairValue_3157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ClassOfWarrantOrRightGrantDateFairValue_3157" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3162" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensation_3171" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ClassOfWarrantOrRightUnamortizedExpense" xlink:label="loc_syre_ClassOfWarrantOrRightUnamortizedExpense_3174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ClassOfWarrantOrRightUnamortizedExpense_3174" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3181" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3184" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_3191" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_3194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_3194" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3200" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3202" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_3207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee_3207" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_3208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease_3208" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan" xlink:label="loc_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_3212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan_3212" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3213" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3216" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3217" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3219" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3220" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3221" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2928" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3222" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2455" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2456" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2455" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2791" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2819" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2932" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2572" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2790" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2820" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2457" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2570" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2792" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2818" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2933" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2931" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2941" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3001" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3001" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2460" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3001" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2568" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3001" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2793" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_3008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2454" xlink:to="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_3008" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_3008" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2468" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_3008" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2565" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_3008" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2795" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2222" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2222" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" xlink:to="loc_us-gaap_AwardTypeAxis_2224" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2224" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2217" xlink:to="loc_us-gaap_RestrictedStockMember_2218" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" xlink:to="loc_srt_TitleOfIndividualAxis_2650" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2650" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EmployeesMember" xlink:label="loc_syre_EmployeesMember_2220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2219" xlink:to="loc_syre_EmployeesMember_2220" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2223" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2237" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2645" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2743" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2857" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2904" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2744" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2225" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2649" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2745" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2856" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2651" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2905" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2461" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2461" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xlink:to="loc_us-gaap_PlanNameAxis_2463" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2463" xlink:to="loc_us-gaap_PlanNameDomain_2464" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_2465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2464" xlink:to="loc_syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember_2465" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2567" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2567" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2466" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2467" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2466" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2566" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xlink:to="loc_srt_TitleOfIndividualAxis_2794" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2794" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EmployeesMember" xlink:label="loc_syre_EmployeesMember_2470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" xlink:to="loc_syre_EmployeesMember_2470" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NonEmployeesMember" xlink:label="loc_syre_NonEmployeesMember_2564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2469" xlink:to="loc_syre_NonEmployeesMember_2564" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2817" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2817" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2471" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2231" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2231" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" xlink:to="loc_us-gaap_PlanNameAxis_2233" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2233" xlink:to="loc_us-gaap_PlanNameDomain_2226" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2226" xlink:to="loc_syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember_2227" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" xlink:to="loc_us-gaap_AwardTypeAxis_2647" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2228" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2229" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2230" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2648" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2746" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2747" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2855" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DefinedContributionPlanDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2515" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_2516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2515" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_2516" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2234" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2234" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2235" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2235" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2236" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2236" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2238" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2238" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2239" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2238" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2644" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2235" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_2240" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_SeveranceCosts1_2642" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_2748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_PaymentsForRestructuring_2748" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_2854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_2854" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_2906" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2958" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_2988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_2988" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_3019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_3019" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLeaseTerminationFeeAmount" xlink:label="loc_syre_OperatingLeaseTerminationFeeAmount_3034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2646" xlink:to="loc_syre_OperatingLeaseTerminationFeeAmount_3034" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2517" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2517" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2518" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2518" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2519" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2519" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2520" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeveranceLiabilityMember" xlink:label="loc_syre_SeveranceLiabilityMember_2521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2520" xlink:to="loc_syre_SeveranceLiabilityMember_2521" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2518" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_2522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_RestructuringReserve_2522" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_2543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_RestructuringCharges_2543" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_2805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_PaymentsForRestructuring_2805" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_2812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2544" xlink:to="loc_us-gaap_RestructuringReserve_2812" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2472" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2474" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2474" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2475" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RestructuringActivitiesMember" xlink:label="loc_syre_RestructuringActivitiesMember_2476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2475" xlink:to="loc_syre_RestructuringActivitiesMember_2476" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2563" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2477" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2477" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2478" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2477" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2562" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2473" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_SeveranceCosts1_2479" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2561" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2797" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_2816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_2816" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_2911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2796" xlink:to="loc_us-gaap_RestructuringCosts_2911" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2523" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2523" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2524" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2523" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2542" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2523" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2806" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2525" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_2526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2525" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_2526" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2526" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2527" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2527" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2529" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_2530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2529" xlink:to="loc_us-gaap_ForeignCountryMember_2530" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2529" xlink:to="loc_us-gaap_DomesticCountryMember_2539" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2529" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2808" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2526" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_2541" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2528" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2540" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2807" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2811" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized" xlink:label="loc_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized_2936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized_2936" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized" xlink:label="loc_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized_2939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized_2939" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfDomesticSubsidiaries" xlink:label="loc_syre_NumberOfDomesticSubsidiaries_3003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_syre_NumberOfDomesticSubsidiaries_3003" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2541" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3006" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2241" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesTable" xlink:label="loc_syre_IncomeTaxesTable_2242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2241" xlink:to="loc_syre_IncomeTaxesTable_2242" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesTable_2242" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2243" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2244" xlink:to="loc_us-gaap_DomesticCountryMember_2245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2244" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2641" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesLineItems" xlink:label="loc_syre_IncomeTaxesLineItems_2643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesTable_2242" xlink:to="loc_syre_IncomeTaxesLineItems_2643" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2246" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount" xlink:label="loc_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount_2640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount_2640" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2749" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount" xlink:label="loc_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount_2853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount_2853" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2907" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxReconciliationTaxCostCredit" xlink:label="loc_syre_IncomeTaxReconciliationTaxCostCredit_2957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_syre_IncomeTaxReconciliationTaxCostCredit_2957" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2989" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3018" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2643" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3035" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2257" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesTable" xlink:label="loc_syre_IncomeTaxesTable_2258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2257" xlink:to="loc_syre_IncomeTaxesTable_2258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesTable_2258" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2259" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2259" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2262" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2262" xlink:to="loc_us-gaap_DomesticCountryMember_2263" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2262" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2633" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_IncomeTaxesLineItems" xlink:label="loc_syre_IncomeTaxesLineItems_2634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesTable_2258" xlink:to="loc_syre_IncomeTaxesLineItems_2634" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2264" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2632" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2753" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2849" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2910" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2954" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2992" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3015" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_2180" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3038" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2181" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2669" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2668" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2728" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_IncomeTaxesLineItems_2634" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2867" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3311" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3311" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3312" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3312" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3313" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3313" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3315" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3316" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreWarrantsMember" xlink:label="loc_syre_ParapyreWarrantsMember_3317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3314" xlink:to="loc_syre_ParapyreWarrantsMember_3317" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3312" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3318" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3318" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3319" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3321" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3321" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_3322" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_3323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3321" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_3323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3321" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3321" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3325" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1801" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_1802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1801" xlink:to="loc_us-gaap_AssetAcquisitionTable_1802" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1802" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1803" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1803" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1804" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_1805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1804" xlink:to="loc_syre_SpyreTherapeuticsIncMember_1805" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_1806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_1802" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_1806" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_1807" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1808" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_1809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_1809" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_1810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_1810" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1813" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_1806" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1812" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="loc_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1815" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract_1815" xlink:to="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1824" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1824" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1825" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionMember" xlink:label="loc_syre_AssetAcquisitionMember_1826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_syre_AssetAcquisitionMember_1826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_1838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1825" xlink:to="loc_syre_SpyreTherapeuticsIncMember_1838" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1827" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1827" xlink:to="loc_us-gaap_ClassOfStockDomain_1828" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1828" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1829" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1830" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1830" xlink:to="loc_us-gaap_EquityComponentDomain_1831" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1831" xlink:to="loc_us-gaap_CommonStockMember_1832" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_PlanNameAxis_1850" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1850" xlink:to="loc_us-gaap_PlanNameDomain_1851" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_Spyre2023EquityIncentivePlanMember" xlink:label="loc_syre_Spyre2023EquityIncentivePlanMember_1852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_syre_Spyre2023EquityIncentivePlanMember_1852" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_1859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1851" xlink:to="loc_syre_ParapyreOptionObligationMember_1859" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1853" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1854" xlink:to="loc_us-gaap_CommonStockMember_1855" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1860" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1861" xlink:to="loc_us-gaap_PrivatePlacementMember_1862" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1863" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_USBankingInstitutionMember" xlink:label="loc_syre_USBankingInstitutionMember_1865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1864" xlink:to="loc_syre_USBankingInstitutionMember_1865" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1819" xlink:to="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1816" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_FixedExchangeRatio" xlink:label="loc_syre_FixedExchangeRatio_1817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_FixedExchangeRatio_1817" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1818" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1821" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_1822" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_OutstandingAndUnexercisedStockOptions" xlink:label="loc_syre_OutstandingAndUnexercisedStockOptions_1823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_OutstandingAndUnexercisedStockOptions_1823" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_1833" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis_1835" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1836" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock" xlink:label="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock_1837" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_syre_AcquiredInProcessResearchAndDevelopment_1839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AcquiredInProcessResearchAndDevelopment_1839" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_1842" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1843" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_NumberOfEmployeesRetained" xlink:label="loc_syre_NumberOfEmployeesRetained_1844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_NumberOfEmployeesRetained_1844" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1845" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1846" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_PlacementAgentAndOtherOfferingExpenses" xlink:label="loc_syre_PlacementAgentAndOtherOfferingExpenses_1847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_syre_PlacementAgentAndOtherOfferingExpenses_1847" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1848" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1820" xlink:to="loc_us-gaap_Cash_1849" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1950" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedOptionCostPayable" xlink:label="loc_syre_AccruedOptionCostPayable_1951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_syre_AccruedOptionCostPayable_1951" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1952" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProgramRightsObligations" xlink:label="loc_us-gaap_ProgramRightsObligations_1953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_us-gaap_ProgramRightsObligations_1953" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1950" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1954" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1956" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesTable" xlink:label="loc_syre_AccruedLiabilitiesTable_1957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1956" xlink:to="loc_syre_AccruedLiabilitiesTable_1957" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1963" xlink:to="loc_us-gaap_RelatedPartyDomain_1964" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaap_RelatedPartyMember_1965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1964" xlink:to="loc_us-gaap_RelatedPartyMember_1965" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_AccruedLiabilitiesTable_1957" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1966" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1966" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1967" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParagonAgreementMember" xlink:label="loc_syre_ParagonAgreementMember_1968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1967" xlink:to="loc_syre_ParagonAgreementMember_1968" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AccruedLiabilitiesLineItems" xlink:label="loc_syre_AccruedLiabilitiesLineItems_1958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_AccruedLiabilitiesTable_1957" xlink:to="loc_syre_AccruedLiabilitiesLineItems_1958" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition_1959" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ResearchInitiationFees" xlink:label="loc_syre_ResearchInitiationFees_1960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_ResearchInitiationFees_1960" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ReimbursableResearchCosts" xlink:label="loc_syre_ReimbursableResearchCosts_1961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_ReimbursableResearchCosts_1961" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition" xlink:label="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syre_AccruedLiabilitiesLineItems_1958" xlink:to="loc_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition_1962" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1882" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1882" xlink:to="loc_us-gaap_SubsequentEventTable_1883" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1885" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1885" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1886" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1886" xlink:to="loc_us-gaap_SubsequentEventMember_1887" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1889" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1889" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1890" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SpyreTherapeuticsIncMember" xlink:label="loc_syre_SpyreTherapeuticsIncMember_1891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1890" xlink:to="loc_syre_SpyreTherapeuticsIncMember_1891" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1892" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1892" xlink:to="loc_us-gaap_ClassOfStockDomain_1893" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1893" xlink:to="loc_syre_SeriesANonVotingConvertiblePreferredStockMember_1894" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1895" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1896" xlink:to="loc_us-gaap_CommonStockMember_1897" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_srt_RangeAxis_1901" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1901" xlink:to="loc_srt_RangeMember_1902" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MaximumMember_1903" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1902" xlink:to="loc_srt_MinimumMember_1904" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_PlanNameAxis_1906" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1906" xlink:to="loc_us-gaap_PlanNameDomain_1907" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_ParapyreOptionObligationMember" xlink:label="loc_syre_ParapyreOptionObligationMember_1908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1907" xlink:to="loc_syre_ParapyreOptionObligationMember_1908" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1883" xlink:to="loc_us-gaap_SubsequentEventLineItems_1884" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="syre-20231231.xsd#syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1888" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1898" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1899" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1900" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1884" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1905" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g518298g0305152730469.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g0305152730469.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 *P# 2(  A$! Q$!_\0
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M*/\ %J?,)?PH?(ZF_P#^0=<_]<F_D:AT7_D!:?\ ]>T?_H(HHKE_Y=_,Z?\
MEY\CG/$/_(4G_P!P?RIO@_\ X^Y/I117>_\ =WZ(XO\ E_\ ,[.O-/'O_(<A
M^@HHK++OX_R-,?\ P3O;?_D")_UP_I6!X;_Y"A_ZY'^8HHJ(?!,N?QP-C7_^
M/2U_Z_(/_1@K$\0_\A63_=6BBJPW3Y_H3B.OR_4Z]/N+]*R_#O\ R"/^V\W_
3 *-:BBN9?PWZK]3H?QKT?Z'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g518298g0305152730761.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g0305152730761.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! .H# 2(  A$! Q$!_\0
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M1114%A1110 4444 %%%% !24M)0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %)2TE "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !2444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g518298g08m07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g08m07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:N4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :GFR(         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  (0   %(          !                          $
M!2    (0                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (0     %)G:'1L;VYG   %(     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "$     !29VAT
M;&]N9P  !2     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     $X0DE-! P     #$8    !    H    $    '@  !X    #"H
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ML277BN&S8-_H:;O3WOT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&"5"4E:8L<$G,S=R=9*7)C0V.$=3=O&(Q]'_Q  < 0$  04! 0
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M) *3)RJFNP9C@S.65H=]7%(LY52.0E0DT;2Q8(!,4;M')D'LZNA]WN,C/EG
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MGW?7']^>T_Y1I'^CW&[^#]?]JGGZ'G^?Z?K3[OKC^_/:?\HTC_1[C=_!^O\
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MM+^3Z1_H]_;_ )?I[MW\'Z_[5//T/\T^[ZX_EO3:?\GTCG__ $]CC=_!^O\
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M"."%>.,-.)##$$"%:R\664022TR*,&TE;A+Y"VFFD-N+4OP3Y<I56< JK$G
MV@'(8G 4^6X^@)K#C_>O'&F3)/Q!$%9I)V/"K&B*Q+._N*#C+D#SKTQ4Y&3<
M9'S$44/(1<H$/(@'A$BF!%A&,H($*%+%?>'*&*8<0\.2*Z\.^TM#K;JFUI5D
MP9205(()!!&#D=Q@X((\P<$>E52(\+M%*C12H<2QN KPOYI*I.5=3E67G# C
MXUW_ &@UY*3Z3_X5)1G/BWG&%J\L93WP[GOE"DJ0K..^,*QVQG.,XSR=O8Y
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M^WMW[XQCWQV[\#G'&,^OE^6?TS4@$@E06QWV@G'IY8YP<?(^8JRKALRB:_0
M]=[57ZF-*%- 1Y5CG(>#'-/?\\,@AKE3@\EF.Y1V0,,EU[.5([([9SG%R.*2
M7/AHSXSPH+=L9S@$#&03DCBLVRTW4M29TTW3[W4'A0RW*65K-<O:PC@33I$C
M.D3-E5<*P+*PXQ77G:%#_:8>E)L\(NX%!)DQJJF7B\6(F,5G'E)#PJC4R1 #
M:,J==*8&<9;;;<4I>,IQC-0MYMAE*%8P6&X_=RHSC(R,GC;DC)('<U3[!?\
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MO7F@>C;:^^-Q;U-O+%:U?4RML:!N![\CJHF=NTL93-6:KD9,34^UI&?CFHB
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M4&[73A]MD];423O,<=#V^0JM<,L\5*/!DR8$X1"QV9020>CF!8Y9C!V2$%*
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MWS#C:V[."!RI.01C$.R.IZGT[6D_L*A8%V]F+!48Y'4J3&EF@6E!29296TR
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MR@QW4RC!G6/<J[8\;>#Z]N]/+>UYN=EHRZ2=0-M.O'M96MIB&!E42593)$S
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M:4#O$A?(2,K&]+C2]7W(&S:LO$SK+9U4/B)RRY%*FM?["KLY4[([7Y.=A6Y
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M;K-<MD$U8<M@ER.#G!5(7G=],:WK5[?W-GJ-M)X,2NR7A2-%;:Q 4&-8PIX
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M(4G*L8WVB:>^GZUKU\MC=7#G68;33-UU=^$EN]LAE!B>?P60R%V)=6(W8#8
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M7)_:=TOH/3-UH?\ T]+.UMJ5A=W$\%Y<Q75Q'+#J5Q;HY\.-6A'A(@4;GCF
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M_'-<JC8]?GYAC*]3"<.=V49\\)[^.%^WXL8[Y[8SW^N?USR61'W;E5MY4OD
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MBH(!&" 1Z'D5YL@!*4I2A1\J4KR4K+2,Y4K\/XE9[>ZOPI]\^_MC'TY 50"
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MGMWQ63O-&>W9:<]_I^+'O^7M[_K[<M5C5SY)_7'^..*4QG&?IG&?[,_I]?\
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MO( <%DN84>W9>YR)"H !SC!,AYBW5>NQQ<O/V"(A8D!;23I66/'CXP)1#S3
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MOD%DX6>:*2*(>&TAW%69LX!QPHP?,G: 2U>D?9+KVI]/=>:+?Z88Q.INX/?
MR89K62.0Y)4 A)9RI)R"HX((!VJ:XK8U-U[1:@&TE@2JU"MUP5A#F'D,C0D.
M'&,-(>P,%AY#;0J$)=2&*EQ*<+2,QA6&DZN.229%EF):60;Y&*LA9V)9F*N
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MKFZMXM26+V;?[T\,2PW2@DG#3QA26+]G=7(4@?\ $ ;#HG7='UWJS18.O(+
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M=F+/L^Y6I.KI "QL$ZZB[M9MU[<EK?%UI88DT]L2R-$(R,Z P"J?KZ_2H?\
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M^^>W;Z\M8).!R?7D_,]O+S-=23M"Y&,G: 2H.[L%QG!8GRS7I^J?;\\>W?\
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M@>J],:@FH].Z+>>/IKR3:?9"8Z;,TU@T_L\8F2PDV[FB64,L23B)U4!9,,&
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M\+!DE'[P\2JXSN\N*BMU:]!-)NVD;)6HS9.WX6KA.1TX-3)&ZE7:K8E(XK"
M'DMW9B?L8+0Z2WF<#0MEB6<C..,X1C*^^<_2]9EL;E;CV:UDF]X"9T=9$W#E
ME*.$))&<LC8SP,<5W?1OVGZAT_KT.L/I>CW%^EK>6R7\=M)IMU&MY;&VE=7T
MF:RC>81Y97EAERYW2*^:G3HZJ6VAZZA*=<)*J2A-8##@84FI5^9K$9BMQ0K
M,,P_%3MDM)B)!@=KTRR$R[@Y"L-NMLL94I.=7<O%-,TL0<!RSL'97.]B6;W@
MB9 \AM&,=R*\YUB[L+[4+F]L(+ZVAN',CI?SPSS>*22Y62""V4JQ.X?NPW)!
M["LQ\L5KJ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*TD]?%BQ%]9O3&U9YNK#
M5H4"'/I(B;'T]5R[0.RS]HQ-?=LI!NXM1['LL;5I4,V JD9*U&PZ_P *M#S$
M&%(S%BGX],2J#@_'Z^OU'J*W;<5-.*5J^^*61?A^G]Y-:@JC)U<C:'3VBSR%
M@L,O&S$3..=0VGQM;Y@(*/KD@).AE7IV'(M1<A9JZN!A(A;L9&6DJ1>##S=,
M*M?VR/RLDLD+CGB/PHW9EP/O@/(!D[3[N1P<[+1%ZCEU_1EZ9GTY+Q;D/*M_
M%(Z^S+;:H\X00E'9V4)LW.%4Y)R% K9C%8+Q%QV#T,-G?)"_.MBNK>&07Z*/
MF$#O.-,./,I>\TM.K9:6XC"5J;1G.4XPLYY P#V'? ^>3_.M6A<HAEV^(54R
M;/N;R 7V?P[L[?ABJAQ55.*4XI3BE4^3;(<$=0(IA!64.?++(;6\RA_TU>DI
MQEMT=UU&%]O-MM]E2D]\8=1G\7,>Z69H)1;&$7)1A ;A7:$2$$#>(W1\8SRK
MJ1Z^52-FY?%5VB# R"(A9"@.3L+(ZACP 2A SG'%6I2JT?!UF*@Y4X8TF,#8
M$^;!!7'M/M,8\&5+%),E'$/)2GNYG!66\KSY(0GMCQUFA:=<:9I=M8W,L#W5
MO"8#/;J1F$RO*%(E:0')=@QQR,8P02<W4[J&_OIKR**2..>3QO"F<.5E*A<A
MD2+*J -JE>,Y.>*Q%/526T_)DVW7H)4S4C"5R=QURPGU'FB'7,K-M-&:QEM#
M4OGLX7*UO*FPIYSU2 5@S#CBI#47=I)TT\VJZ3;2W-BFZXU+2K9C[0L3;C->
M62L6\9PJDM:!0TAR4;.%'26U[;=41VVDZ]=QVVI +!I?4%YEH2\8)@L]8F&9
M1"V5@MKPL!:*(XY UNF$S34[-!7.$ L,!(LGQ<HWE\8AC.4Y5GRRAYMYA[L^
M,4,\RZP2*0VT0(0T\.0PT\TXA/1Z9J=GJMG#>V4GB07*+*BNI2:,$ [)HCAX
M95R0\;@.IR"!7+ZCIMYI-Y/97UN]O<6TCQ2ID.BN#R4D7W)4(VNDT9,;JP*Y
M!S714Z)$4YF19BBY@A,G(&29*I63(E%X*-=<>>RPHS+GH-Y=<6O#;>$IRK.5
M*PK.>_-D9"V/0<'OSCOGG/?/;%:6STZ"Q]H,32NUQ,9F::1Y CGN(D9MD:^9
M 7!;WCR359+KX,@R^*?YFB$L.C$"DH8='?'>2M+K#S2V<H=97AQ6%-KQE.4_
MA[>.58R$A'8*.01@'@@8XR3W Y]?GS67)#'*A25$D5TFBF61 Z7$4X8-%/$^
MZ)XP&P$V!2!A@U1:D>GNPZW>=E^FRS#TS#KCQ)NK;2T5,:DEW%9RXI$?&CYS
M)Z_,?7E6$'5(EB+&6XLHJO2B\K9=N"0'._/&<%>/+Y9 )[\\\94XK@)>B[[1
MC)=]#ZC'I88EI>G=3+W'3EP<DD6UJI6;1WD8G,FER11;B));2XP4:,_3[LVV
MP'4-NE&]*I5=,OW^S5Y&MX]\>18"GS8,9P69&BKXY7(N!M*9@C"I1AI1PU@>
MD5OD9KZV?4(S2#(<*Z*$#$*>[L& !*YP&[@J"5.3Y9(KBNC.JNH+;K/K2VZ[
MM],Z637;S28>EK*:ZGFM[J728ECO5M-;>TM].N?:"AD@A:2"^;,FVQ*'>=CM
MMO(=1@9*R&X==BXL)9Q3@,<=*.MCMH4ZZ^D<##K[Z&6L>JIMIKR\<9PI;?MG
MA8\D @@[B#D@8 YY&"1Q\3Z@&O:KZ_AT^UNKZ=I#:V]K+/XEO;S71=XT9@J+
M#EIER!N\-<A=QS[IJY8:45+!C&X9<9;*8;?;;=8=8>0EU&%IP\T]V<9<RE2<
MJ:<3A;2_)I?XTJ[4NNTX\^<\^AP/($?C67'(LJJZEMCQPNN^)X7_ 'L2R$-&
MYW#!)&#@C'GWJL<HJY3BE.*4XI7GR,WGUO=7=_.<KSY9[X[IPG\/Z>V.WM_X
M^_)!.1SD+V! P.<GRR?Q_MBG8OO<</\ >&6Y\O7CC_QQZ]^:^, C89PQE&5-
M]NV>ZLXRKV[9SG.,X]\_GGZ_QY X<N,@G.<=N3GM]>7H*D@%0C %0  I&0 .
M .<YP !DY)\^YK&%^T3J#:3+3&Q-=U*XX'SA0CT_!1LB8$\GS\2 3GQE& D(
M]164OB/LNI^F%XQ[<O0W5W;DF"ZEBSD,$("L"""&4@@@@G@\?"MMI^N:MI9!
MT^_NK7OD1SRA3G@AE+E64@D%6!!!/%7C4Z; TB!BJS7!WQ(2$%;#C!'S3)%8
MX[7?*4*,D7RSB,X[]L+))=6E&$MI4EM"$IMEF9F8GE_O< >OPX[U@7=Q->W#
MW-S(997;<20J@'C[H4*!C'Q_GFZ>4U9IQ2G%*<4IQ2G%*<4IQ2M,'Q*MB4;%
MS>UUMZ/KE,AJMH6Y;5T)L>;V?N;4DUL_J!F7IV@/=/M&M6E+#4;3(NRE 7)C
MWB@Q\S*62Z#;%I)-7JLF]6),@=48^OEGZY_0UM8TXEI&HM5H9I"]9LHUQ1TM
M:W<RC+FOVDUB+PW2%Y;QAO*ZHG&(%66\81E0&?'&$]N*FLC\4J$7Q$(O;$OT
M?=00VI+;2Z7,LZJO9LW+7FDRE^C#:4'3K$_<8*/AH>ZT,J-L$U#)= @K(]+R
M(<!(.M2!=;GAVE@+K0X)/H/GYCUX_/@5DV*;M0T\98$WUK[R,5=?WF 5;(P0
M2,8QG)Y'GFKIA2I/3=H)*\83G&FM:8QC"O+'C^QT/X9[]L?5'CG..WX<YRGO
MGMWS,N?$?/)W'/S\ZR-8_P#[MJ0R3B^NADDDG$[C+$\ECW8GDG)\ZSGRW6NI
MQ2G%*<4KC.._;^&<9_PXI1*<)[]N^>^>^<YSWS__ %_#\N0!CS)^9)_G2NMQ
ME#OCYX[^/?./X9SV]_[?;MC/Y=\_KP0#W\CD'S!^![_T/G3^GD>1GUP?,>7I
MDU@[85".9F6+[KPIF"OXC#;+^24JS 7$!GU5,U^VMMH6O#&<X6F,FV$*D8%]
MQ;C&70GSP3-!J6DO)<'4=.E6SU'"G=@,FH.H(6VN$8%1N10HN!^\1> <#!Z+
M2M8MHK==*UF.2XT69GB1XR3-H\DIW&]M4W(&4.VZ6W8B&8Y+8?#"J4':(=R$
M*#?0[!6R&);!LU4D$XS+PA_HJ<4EW"&/ERHXU+3A,1*C+4'*@XR^,XEQ+K+6
M5I&JQZE$ZO$;6_MY)(;ZS<C=#-&0&,9SEXF&"DF,.,D9P36+K6AW.CS0*94G
MT_4 SZ+JD(WPZC"N!O8=K>120LL+[9(F]UP.YRX.XIUI*U8RG.<KQG&<=O\
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M+([#+793CKSR\I:9:0GOY..*2A.<X[YQ[< $]JB1Q&K.QP$5G8G_ ,4&6)]
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M1.P7*2_'KSK<F+BZ8.P)@HMJ=L9LP.Z0HM!T7&# ,.S2J0,^OPY\N_X#RQZ
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MON*D(=Y:5-Y+BW@SR,?3=6F6<:;K:K;ZFA\.&7E;._A0,RRVI/'M) W3(0I
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MF\O+5C&$*=6RQ$6Y24MF*RW'SF!STLR$IRUK<3]-R0Z;K%R]UIAF+:;JTJ>
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MMM&%+6ZXK"&TIRI6<)QG/'XX^([CX_A4$ @@YP1@X[X/!Q\:LR/^(]T1[.J
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M1D=C@GYUY!?B:]&YLO*P MZV.1.P8T8;,0K'37U-OR\6#-+D6X8Z1C&-/.G
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M[9_$52(+XFO1Q9X6)L==O.R9VOST:!,P4[#=-/4[+0TW#2@C)\9+Q$I':=*
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MRJ,\C\?/^?Z$'COSCL9][-UK1]U:XNNJ-EUT&VZ[V16)NEW>JR>7LQMCJMB
M(B9R%/\ E'V",AR<<20*_P"B^R[Z3JO%:%X]E.X],BKP%'&B0 P1D)9$!&8#
M&;QW2AD<5E+3*,9SWPE#;3>$XRI7MA.$]U*SC&5.V,_+YFM9,3U.=($[NND=
M3 .W+8T5?H WIAH,-*:BVU!1=T(1<*]=S;;6&9O7<=+SU)")F8(<S;<3\UJ
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M4 $)1G5]XCF[A23W*%-R#S!=MAP9EABW1P2:M/(-JLG88B953CGMG'//X]L
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*BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g518298g40p53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g40p53.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1NT4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :Y3,P         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "J@  !6     & &< -  P
M '  -0 S     0                         !              5@   "
MJ@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MJ@    !29VAT;&]N9P  !6     &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   JH     4F=H=&QO;F<
M  5@     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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ML>]@K:!<S\ZO:US=MGNM?2WU&?\ ;E:SZ^@93:;VGIG39>:=E0=;Z;MCGZV
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M[GC3TZ_TGN>LF_H6:<A[JL/I7HR=K74NW.!W
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(J325&_O5SAV[E/($F>WTPM#L-8T%AUGS*;=G7+LC7TXD:TDL470@KJVY+,
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M@GQ[L\2^5+2T.GNN-QJ-94%&G4CU82J&E;T9)M31GL F9WD[FL2RLP9CVLQ
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MM;?L6N7VK6V:,.MFK>@M1:T'?2@BA]:M##87L]1)5F9I#[DFZYTM,GUHD97
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MMS]WA]_[S_#^..7_ !5_:/\ )G/O+L_#M6_KG+?V"Y';0_*V_P!WA_J<<O\
MBK^T?Y,>\NS\.U;^NDM_8+CMH?E;?[O#_4XY?\5?VC_)G'O+L_#M6?R?SYRW
M]@_^KD]M#\K<^O\ N\/]3_KCE_Q5_:/\F<^\NS\.U9^N<M_8/CMH?E;G[O#_
M %..7_%7]H_R8]Y=GX=JW]<Y;_R_\ O_ -OY>1VT/RMO]WA_1_SG_P ?JQR_
MXJ_M'^3'O+L_@CM6_KG+<_\ Y"QQVT/C+;_=X1_^9..7_%7]H_R8]Y=GX=JW
M^7^?.6_L%_U\=M#\K;^K^[P_U/\ ICE_Q5_:/\F/>79^':M_726_L%QVT/RM
MO]WA_J<<O^*O[1_DQ[R[/P[5OE_;G+?_ %_8+_V<=M#\K;Y_^'A_P]I_SQR_
MXJ_M'^3'O+L_#M6?KG+?V#Y/;0_*W/W>'^IQR_XJ_M'^3'O+L_#M6_KI+?V"
MY';0_*V_W>'^IQR_XJ_M'^3./>79^':L_7.6_L'_ &?^_P!\]M#\K<_=X?ZG
M\WV]SE_Q5_:/\F<^\NS\.U;^NDM_8+D=M#\K;_=X?ZG'+_BK^T?Y,X]Y=GX=
MJS]<Y;_R_P# /_O_ "\GMH?E;G[O#^C_ )S]OJQR_P"*O[1_DSGWEV?AVK?U
MTEO[!<CMH?E;?[O#_4XY?\5?VC_)CWEV?AVK?UTEO[!<=M#\K;_=X?ZG'+_B
MK^T?Y,>\NS\.U;^NDM_8+CMH?E;?[O#_ %..7_%7]H_R8]Y=GX=JW]<Y;^P7
M';0_*V_W>'^IQR_XJ_M'^3'O+L_#M6_KG+?V"X[:'Y6W^[P_U..7_%7]H_R9
MQ[R[/P[5GZYRW[_U#_Q?X^3VT/RMS]WA]W[S_'^&.7_%7]H_R9V IU;&Y%KJ
M;!UXV$[*XP^7%2F2/2*2'EGSV:M7<.8-EU?/TXQHL\;Z9QG.?B8SC&,T.*?8
M?3DLE^/FAX8E0GZRL[$#ZPK?FP"WQ"\?4Q/\.T?XYL/F-E6.,91#?WB<]@ZE
M[ERVAE1?6^L8A'K$K"+0&,=@QUPPB4]C(?+QL7=R><UAV(U<M>N\;7#O31<0
M'B,D0*F"!2/.!KE5N4<:L$O0-=TKKKFDAV ?9VII:UN:S-KFI3PZR:!I1%!;
MUO#;*4.L:.\T11%24. 4'<<9IF60K\P $ !N07!X)*OSVCCZ#S]'O!&:HGGC
M!WG#;[MV#,G'4&1LZU[JLNL /K4U>6.CW!LF'/I!% ^;$APMC*#4?=Z,&\D>
MO7#M[$QX!;,9,M\O&B^6Z>V97Z+U\^NI6&7=1&UHVVLFU(JG2U9ECF?V:9FA
MCD!8Q*H59VD'JH>TCDY29V#L.8SQ)V=G+=Y'('(^'/O^''C)--?$ [1N.R>.
MB7Y&(5IVK:W9N4*2G(*;_D-2Z,? R>;=CVZN9%@CO)GC;=.KT8;]K-T-;:T6
M;*N=1VNS%/5'IW4C5GJ#VZ?[D&AV)"98!?._Y$9UA'I%?2!YMF;T0?8B&X[O
MG&OU9._T^T=_=Y/#%/2]_?S]/PXY]_CD<^(]-_&>M2*P\Q=]F5+6RE*6=2';
MZX.LHN'DY4C8V%^JEDH5]I&;?=%E7<>4VL)-TB?:E8HR8:1Q%/<<Y9DUE<.4
M-B>B*DLR4*MRT+]6_I:6U:9836(V]4V?5HK&!*/9BIC*3,WJGYP9 .#3[00"
MQ [65V3CGD=C%?G$^//O\>[SX.;N9>(MVMBE4=RQTWZ]0>SNRG5037<C4&4L
M7>@ZEVB%M4:8N<',IDZLB2HGQ8& (1P^'F:0,D7-R5TW$(104@[.Z)#\%NFM
M1-<TCU]E8JZO;O9B#WD62YZU/81T9((%K1&-I+)EC> R(D<2EVF<K&2U0ED"
MR<JI= ".WD+PRE@3R>1V\'G@^?  !.68T#<1"R^KU07W,1R+(G.*1A5JR<5$
M1)HF@U>'H4/E)=A&@:&YN0D-$E7+A 0*1W+&'?I0:)9>O%-?B<ML:25=K=U\
M#%DKWYZD3S.BDK'.T2-+(1'&I( +N0B#R3VJ/%Y6Y16/O*ACP#\1R>!Y/YAY
M.0[:^+IU9^SUD')!'[WAA"JS='B)3"934Q)O8/M>Q$D7BM6G!<0%D"Q1^S,%
MFSE%^%U33FH;='VA**($EVK%?=GHW;>K5CCDU\ZW([[PSQ7%-;NUL8EMQO,Z
M(BLB,I63S X/<DQ0%A:]=."2'';V\@KP>'/ /'/T_#W_ %<YD3;Q2.O3T&S4
M90V_GEE/KWDW7%MU_;5*16O3:SH9$A]@RIGM#M".1^H,#7Y4=-2,CS(/E*()
MVGGW&Q+&X_2T>D]DLC SZX54U\6S;8FXHH>R3SM5A;UB@;U)+*- L?I]QD'N
M["&-7K+QX#$]Q7L ^?R "?'/N ()//N.>]U/[RNKIZ22SN)8$/>(#8G(>QBS
MN,U]&3>D@<P:EK-G<7&N&T3E13!G$L=Q.*-B1D,\>,E\&MWS5!BQVPDP2IW&
MA6CO8M+6F4M-'K0LMF6,QBQ>JUY7!FA3L]$33%8W56'I]I+-Y8DD+1F1A[N[
MD 'W GX'SSQ[^?=B6^*1U/BC9R[3-3*6I:P"@9T+Q"(DM(U9(\[0NWZ%&UV
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M.G*.TO6HX)YYI&N;&U2K_P!V:9B]BQ(L:GL>&!% )5>&9JA*02."SM(RJI(
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MM&"),A@LN[CY$?S+G^3^S%:K5$V,+2/<>E;,M>2$0/%4GNRSUU+L]RLD-:9
MX2%C*JKV!9$<TBR.UF*'PH8<,#SRP4 G@<'EE/Q !^D<9AJ?>OM*AV@MZ!W
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M9Q]7//.00!^#C1J'V^C<QLNSY[41:M+\J>H:F*ZQ,:'H.)=EYBG/;5^QI\2
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M5NB^\JRS2/)+-+8[BYD)7M8 +RO)@0 ,&+%F#ER> .3QP!]0 'P_SR273'K
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M[A/'H]EU^FU%K1=.VY*=19=57^[>U<PQAKVO1]KWQV#V\SCUZ%>$*Y;D3E?
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M%[#Q"@V)5]KF;51DG)D2N&WQVQQ=LIE,@3;92>%<IMU":KM5JVW2D[S<&HM
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M%-<*+[8Y=NW)]A;LW;+!I[4TD\I X7OD8L0B\GM1>>U%Y(5 %'@84!0%'N
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M]U%%%W#ITNN[=N55G3I=9PLHKO:LV9[EB6U:E::Q.YDEE?CN=S[R>  /@
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M@W47^&X(JH84VPLZ>KII8204>.,(ZJ98SN^,8XQE,/B?_P!6!X*']_\ 2O\
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MAVX!?1)5'YAJXRDDHR.?\"?U<?ZYM$?W,ZL%8"RM)C>U>+5X0=.F3.7[&]$
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MNJKOMFS=N6=A:GNVY#+9L.9)9"%7N;@ <*@55"J JJH "@ #Q@  <#W#]/\
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MKG??.NN,[[[:Z:XSGSVVVQKCSSG&. "?<.?S9*JS'M52S'D@*"3P 23P.3X
M)/T $GP,\G&1GSK>.;XJ07J?4,#CM(3ROY-81*ZXBC-![5FK-W$9:P(F/L%N
MP=9'JZ1P835+ !N"8PJ81/:#\X3:"=DWJA!AZ'T3TN=E:GFV->S%6%.7V=B1
M )3.&KNX#??601._8Z(8R_'<WS>T^G=-=.=/ZFHV\^4W7=1TM->]ABT"4H4K
M3;.1MA6;8V8TL/#8DJ5M4EHPV(D-9[<D*&5G B>R.G.QW;J[ZAJJRX=U@KH6
MSL.MX/.$3EAW^VCXLHG+(P,.Z%  . P2V""8)_A_AX&2-%&)C4:LWT*,V3_"
M[=/GKFMTM&W;K2[:U(:]F> )6UID9?2E>/MD>S8I*9%[>'[$*=P;L8KP3;N:
M/Y,:MRV5Z]W&PHFS.:*Z?I":Q-[$97-46I]UL^GE%KT/3%CT:KPB;O\ 2=X^
MUCLW13O@_P#+.[7J7%L;9SGT:O[?G.Z6OEC.-<[Y'0#1;;.?/&=L:HXQ_ML:
M[?[7F,1T\I\-N9A]/;2K\_H[[/ _2<Q2/DLB\"3K^]Q_O>ET[JPQ_P#=]7;E
M1\?PB3[O'OS]9CO>A7&<YMKJRQVSY8].E#VF1QICZ>>_KW[ C<J9^_R3SHGC
MZ8SZ_KG&(]30#_F>V;_^X5$__P!<_'\<@7/DO7_[@ZYE'//GJG10\CZ.!TE-
MQ^?D^_W>//XS$>]&_P"]S>W6)'&<X\U$NM%E**:XQ]?WNBO9S*><Y^[/J^[&
M<YQ]<8Y(FT //W/VQ^H[6H ?TC4<Y(V'R7@\_P!E>MFX'X+=:Z8 GCXE>B 0
M/CXY]WQR+,2@]O9[/V,'C][=(M+F"P:#'S"8WK(YVF+/!@K8Z9,AD2S['Z28
M647;$6V9,87=*[%AYV/HN]$$L([D-M-/1^Y5:236[XTGL6(XR^V40$HE;M7U
M&U)B=05;TD ^8T<A4GR$[S8;7IX=#Z:Q;Z5^4X].6=IM*E8S];HNMD]GKZ5H
M(?:).C6I6($>!_8:Z1@5YJMQHV<]RPRE^Q7>/^,+UP_Z+\\_^)OFI]HT'_HO
M9_\ SBO_ -SYPOW3^2__ *']9?\ ;G5?I_\ X'SG[%=X_P",+UP_Z+\\_P#B
M;Y/M&@_]&;3_ .<5_P#NC'W3^2__ *(=9?\ ;G5?_LC./L5WC_C"]</^B_//
M_B;X]HT'_HO:?_.*_P#W/C[I_)?_ -#^LO\ MSJC_P#\0/U?Q^CG[%=X_P",
M+UQ_Z,$\_P#B;X]HT'_HS:<__P XK<?K^X_^6/NG\E__ $/ZRY__ *YU7^/]
MB/\ +)4!DBR @4@?>L21Q$<R2,D18]82-?E4VR6A!Z/%.2!=P,8NG>%EVK!<
MJ369H;IMU7[S=/9PIIW*%W,:LD99BBNP=U0D]JLX5 [!> S!$#$$A5!X'!V6
MKO8L-4BE@JM-*U:&>9;$T-=I&,,4TZ0UTGECC*I),D$"R."ZPQA@B]ERG+..
M,8XQCC&.,8XQCC&.,8XQGS9=QI!6,M[S"C:6H&3V41D="I=>IZQ/]8VE2PL8
M(D@X;.6/82)V&FC=<V,NSK*3I!5X6!GF^H%2+"H*\KN4BRQY9C)X^)O'8ELC
M5$^.7-4E9'XAK+F,5CDHLBZ:-MVR%3WR'<C%*AN;KE.!=QB57VHEEJ=A(6KK
MI%2YRF 6=0Y(F%%/DV,D/T!5CSCKF'<QOKS8_6UJ[DTH>D(E:[F4$YM,3CU]
MH\,6H3D-A^UMF5)SQZNH0;2:X@,2LTLDCA:2Q0+Z6B&6,FKQC/RIO\/3??.-
MLXTTVWSC77??;/IQG/EKHGKNIOMGR\L:Z:;[[9^FNNVV<8RQGS45'V*M1[I
MH?=G;"2I5K(9561^\NT]<6=(&$1!&YI3G9"1,Z,5=6-5D)+]=Y 'L: 116:Q
M5^Q'2)FSDM;0>0(Q4X:7%%F,E>?[$>*;KU_IHE5?32J;^$R_JM!I38]EVAV4
M0H":IV"<B[_>5-7=7?DBD.K970=H)/J[:/12>Q,R^#Z"!FHS&-V,SGP&L[Y\
M'[H-G?7&F^:-9>K7&WJQC/VDD7TQMY8\_P"SY8XQEN/&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC-0W[,GM?TK:$O$^>3@B%G<QM/7'JW7E#UDH.C#5/7RSZU7
M1]V.;):8QY[[JZZ_P\TW4-Z36Z/:W8?-B"C.:P'O:VZ&*J@^DO8>)0/B2!G9
M_)UHZ_4G772>EN<#7W=Y0&T9O"QZF"=;6VE<^.$AUL%J5S[@J$GW9DU90QI7
M-<P. L?++6%P^.1='?'GYK8!B&@[9QOG/[[91QNWV75WV\]]U%-]]LYVVSGF
M5JJ*:S6:_7(>4HTJM0'XM[/"D18\^27*EF)\DDD^<U?5>]FZGZGZAZCL<B;>
M[O:;9U/'S#L+LUH1@#P%B641HH^:JJ%4  9G',_-!CC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,9T<DC@:7 B<:D+39^%,-LM"+/1T\8[.&^VVN^4\.Q[AH]0SG;3
M7/K;N$5,>7EC?RSG&6,^=_PXE943[R2(JZ(5HS)#F=_5W9D&BUK0"9H#9/7C
M^KC$ME0-H%MV=3)1[B;VJQ@0H*\'8:QZLXN'/V0/A=D3(>+),?5]OC_IG6^)
M0UFLXO\ E,/<VI5/9L4)>1I]#^L5*]>XE/>ZG7QVL+%J:E0LPTBTR7BY(B_V
M4DX&<S&S^KR(-F2;IMY4OJBV>NF/M\?M]OSY]$L&9K#X3#F#GYSEPQBT?9KY
MD:^KJ0_&;"6B*OSUSH1,:.#/KTV^:+Z%BFJS[XZFI%]C;#E5C(F>(!.)S!*$
M:/:_N:'=?C)NTZNCKZV9X<0BD:C<<>RMF[D+-U,"=96U&8DZE(Q@O$!IV6Q/
M )$@>;-=2PTR\$*;L97;UI[CW;95N5*@ZG\P5DLCF48C KK++B-:JOYUUU6Z
M(O[>>=D'Q=A6L.DSQJ=[0-'D)$VZ/'1&OW8YD*BFT($'"RK++\^/L?M^K]'Z
M\C'V3OGN_;'>WP=A':+H*RZE149W>DY&-S!KVNK&_MI0?VZUW*U4CF\>@T:!
MOP>J8Q9V5^</%UFFV67L<)?&<I[ZLCS]7'VX_AGU%<9..,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQE27C&]?;![#=;HF @<C(QK[-VM$39IT@:;C1;E P]2@PQ P
MS6>C-GR3<M+6Q1!QJ^U3&9'K+J-E]E4E6W8=%;.OJ]I-+8A6;U:<T: J2RE!
M[0Y1@K]I*0E2.WY_=QW#SSZQ\C_RD5/DRZDM[FWTZG427M7+K$A66."W6DFG
MKS++5EEKV5^^F'V>>,1AY(Y/FO\ -,<N')6T),]?*[(WG;<EJWJ+"XY#ZL9E
M6ITX]O#NW. @=I'W#6*O(8WWGA:#2@F/<-P@VMFSB>70ME^1:.&<(6;[R2Z]
M9H=C:6G3BM;FQ--:9#&@HZ*&20R#U$F/H+9B5AWM9(KT050AK ;TLW?[#7=%
M;79[-]3K'Z_V]ZWMFUCP07-)\GB;"Q);@UT-&5'K;#J2LDJ@I:@>EHP(HO9I
M=DD@I:M[2U5+NU77F+U@ \/NCZ;Z[1VT*A(PA[VO:,L2=H_+V7%8JS-QGKE4
M>^2,>2+M#KQE)6\ZM: 2DE%R9467 -GSY5-"YK;4>NV$UF7?7;FQDK6UG&L9
MFC94K2S%)-C:^;(4* Q&"M8B25%979!Y\CVFTVF\MS;#;7;>PNV'#2W-A9EL
MV9#SP.YY6=NT<]J)W!57A550 !.D5U6[8.18P4>[]RJ!B10]D*'Q/K?USZ^U
MG$0HH>V39LA !M9T4O@X.&LFB235BAJ<V]HV2110^'JECSTC[/5AF:/113.Q
M9FEV&POV9G9B2SR&M+11G)/)/9Y))(//C#[6\<R'Z^%4#]'/)'Z\[A/HZ8<^
M6TC[O=[)(IG'^NY_+!"H:FIY[>>V-4JTJJ$:H8SC.VF/@93WTUV\]-\*:);Z
M4'<J !'IM)%Q[B*DLI^KGVFS,#Q]8\\>>?..SSSWO^L ?P _AG.W0*$KY]3_
M +'=[GV<YSOMZ>['8,/C*F<_3?T1N:!--<:ZYSKA!/71MY9]>4,J:Z;ZR-[,
M!PNOT8^')TU!SQ_^)"X_3QS]?'/+TQ^,_P"VP_P(SQ[>'G5:N?-U>'>IUMC'
MEIE3OWV]1]&/OSC&&=P-=<^>?KG.^N^WTQC&<8^G W]H?@TM(/=_]PZAO=[O
MPJ;8],?C.?\ \1_\F&4D4C0GAO27Q<[[H6*=KNU[^\8U#DED(TSNFV8R?<6$
MUQ(][G!?G"!-@UI2Q_&(\WB#UT/)60[6>[NI,V(/CZ8)VU8=O=VG4B=)4;4N
MMU8I23$%VI4Y8EK'TO8G&O</5B$LK3 ,M<=O;$56,R<MZ/L?E3ZHVG1-+Y/K
M5M6T5%*4440BA5_3UTL\U=!(L*S!^9(0\GK%I!5')YFL^K=K_J=U0_\ '-WF
M_P#2 ]R?^VKG$_VAN?\ FFD_[/Z7^ASSCTQ]+_F]1_YN?XX_U.ZH?^.;O-_Z
M0'N3_P!M7']H+G_FFD_[/Z7^AQZ:_2__ %DG\V/]3NJ'_CF[S?\ I >Y/_;5
MQ_:&Y_YII/\ L_I?Z''IK]+_ /62?S8_U.ZH?^.;O-_Z0'N3_P!M7']H;G_F
MFD_[/Z7^AQZ:_2__ %DG\V3=CX5M&P(2.LG1=ZS B1P9H\/FBLD.NVPQFBR0
M<FI$>>$#9XLNDAJJ1,F'[TH3=[K/7[MPZ756WTLCF21Y&"*9'9RL:)'&"S%B
M$CC"I&@)X5$541>%4  #*P.!Q]'CR23^DGR?SGSG;\HQCC&.,8XQCC&.,8XQ
MCC&.,9\W_>HH6==\2(]>UKD'0*+_ )+9P^)1@9(]HK3TWBI_KZ'>N-56MZQ/
MYHK7=9VL8LQB.C]5&AKLM>1<G.G\UUA4=@VK(^G_ $^W.7.=L);M4U;O+HC8
MJ$J61$%!PB*DY-4UB6P4>,Y":&HEH6#%TZ+,6FQ5E>$$&^"4<$GF0=RW;'CL
M=,#!2[?#)^W^F=#U=[*V;=J615P]6K1ZW2[,<Q+!>9&2CTS@$NCV2N1.C^-S
M"/N&Y@,14VW9D/L7:,,K>>)BWZ3K6-+:,3&1K&3"XQCC&>/**.==],I)YT4V
MSOOIE/7.N^^V?/;;?7R\MMML_7.V<9SG/USGC&8U.?Z29A_:M(/\DN^,95SX
M#O\ 6@>A']PYE]W]LDAXQEM_&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC(V]B_
MYMJTE72>WKVGEY0M9^VU^NZD?K=,G;)93?7[LM,KP@:/=9VQG3;4DFCMC/QL
M8YS'4O,[:'6KY.PW]!I5'O-75B7<3,?''9W4(HGYX\2@>\\9ZA\F?%!.O.IG
M':.GN@-['6E(^:NRZH:KT=24'WB8)O[5F'@A@:K.#PAR27.GSR_'&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC,?E4LBL$CAF8S>2Q^&Q&.,%RLAE,J,CH]' (M
MKKZW)(R<+N68P6P;Z?OEWCYT@W1U_?**:X^O&,^>/PJVE>33L)BQ(9<],R."
M*";'/U'0K#NE6]M6_3C%8?"JOT2-4[#.K=<R+3 B P..Q59])+XLX?%62F?;
M%)L_.8F"C&2J[Z!.B%/V>"G=U^']U>[*RNV$EG1WY56-,V1W(FIL7\N",G4.
MI>3P7>876''"46;0J6"S90X 1:,1Z$=?MLH[I,99G1EI5U;E=C)'6#,H&C8E
MT_ABL3/PTW7<A@QB(+_)"<*.P:1"PQ:+D(ZJVU8_+%AR+7VFK1T+4="7+%VN
MQFW=]--]<Z;ZZ[Z;8\MM=]<;:[8_1G7.,XSC^3..,8]&GJQOZ-?7C7T8V]./
M5C3S\_3C;R\\:^?U]/GY>?U\N,93'XGW]6!X*']_]*_]%>\>,9<]QC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8SYK/W2$WE=O=?(-U\JVTW,(F;66Q^S9-&TI"J
M"8V*.*EL5=6=7;IM'+9P;F,ZLF5-2D) .=_DVK."RV4FMV3:,-R37T7Y/1'5
MN6-C9K"6+TVJPR>GZCPNJ&U9L@D$)#7K1$3R %^Z>").3*5/01:*0=,W.JIK
MHI1U=K2U>I@"/[1M=BR/:M^S2)(A@BU-1(I[-D"3MGMT:X4-8]6*R7H7TI-U
M'!JEM#LY.F783M3'ZEAT!93]QJW?1"HXL(BXL(M!Z29>G=H(;$DV.J\]L%#1
M.4VD<V<$S#IL"U"1H+SF\W*VYK5;70&AK)+4UAH 2)K<SR,_KW6\%RI/WBN?
MO59.%0&3OE?GV>::62Q9EDGL3.TDTTSM)))([%I)))'+/))(Y+R2.Q>1R68D
MG)8=BFDU+PL6"A$!,SE\XF]<2!W@6:AP9(8P@UEPN9OL.E)9(P'QUR T(_;C
M4V&'>,O=--'NS-!31?.LUQA29Y)["0*(+,8[DF<NT]:>%>!%')P%9U+%BO@_
M-[B"!#<_ ?$']1!^D?;WYN\4[=/Q@]Z^%NPCQVS;N70=\L/<O1;A9+118>[<
M"GA 8NX:*;;(+*CW[QFHIIMLV<KI9T4VPF 5F56#@,0'4,%8 \!@'"L 1Y 9
M58 ^0#XR<]_E.,<8QQC*J:JZ%51 O$5M/N8,Z\R@!.9\#T&_E6<RZOW@A<X^
MVFR$[.;Q-C*'18<VEP?6OV Y\P (2)1PU?[2#VZ+LNJ^ZFUO;,_3U73M?ADB
M@?N-80V%<1J(#703-$J,8G]H+AG,?!7T^2$[<][ZR0M!]S=;&6@K0^U1P.MD
M&N[,TRN9V436 0EEQ'Q(@ "H>2;5N<MF!CC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&?+[:MK=<>P?B(YL&Q LCC)^L[!JNOJ<(18+X>TB4D2L:D#3<DO9S
MZQ+,F-EOGPVRVSEQ%&HP0.>QD$W $HNP;3O1]ABQ]/\ E_Q_SRY/OK2%A7Q7
M(&+"['ZZ0>IP\LBTRM01V.JB06A")PVB$J!G@\6DK%E<56QQ2$E'#)5K(0TE
M;FD"+M0.Z;J--QVS=ZQG;=#:=84K4LN B)U24S"22VYA-@HWK?$L0"C:Z'F1
M\=:8@%=P=.=V*VC ]FY%N9(99,I%AF^E<G/G$10KYMLTT8R;/&,<8QQC,6G/
M]),P_M6D'^27?&,JY\!W^M ]"/[AS+_.20\8RV_C&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQD;37E(^UT%'XSZF]84S-)4ZT^N<:E[+DT?C !7/_DZ;IBH7,T]
M<Y\M]M'>V-/WOQ><Q/\ WGJ^A%[UU6CNW&'T3;2W7J5S] (AHW1]/#^.!SSZ
MA1/W,^2#J"QQQ+U7UQHM1$WNYI=+:G9;79(/QE>YO=$QXY : =WGMR27.GSR
M_'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC,,L2.1B70:5QJ:OB(R)&0C]E(B(
MB82&OR3$0HCML]=,YM%#4=DD7501UV4P9#'13YEKKLJB]0SC.V&,H(\-W#-Q
MVR$P^N[1DUT"*1@5J@+BNV(=J>W?:"G;5-2HM&G< T,)6H*_(!5\R'#VCTFV
MC<$L2Q)8'T4? -/=1_963[L9+WN#UJ[@7K=!&2Q*(U&_KB-U4?AU6;*=V>T7
M7:7#K +O!Y9E94@8432JJ;Q44Y15&-0)28RILR:L6Y4$Y"O3A]HJQEH$!%'P
M<(B B6DD#4M'1@"SEAQOKIJD<E#44T0/FM<ILAVN_P T*INGOKP/9>O"^-O:
M-O/X.C&9;QC'&,I@\3_^K \%#^__ )5_HKWCQC+G^,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQGJOGS08Q>$B#A)HP'M7#YZ[7WPF@U:-$=W#EPLIMY8T2013W54W
MS]-=-<[9^F.2JLS*J@LS$*J@<DL3P !\22> ,N1123RQPQ(TDLTB111J.6>2
M1@B(H^+,Q"@?$D#*&^AT#$]].PUT=\+8BHZ35@%FTIA'7B/2P:S,"WQ'1BTC
M9F9*#2";IJMK H,T&5O'TU$L(B9U(K^<IML.2K=WIW>_G?1T:6AJRM'8$$<N
MPDB8HP)8R^F&7@CUYRT[D,>ZO%0')"D9W7RA31U-A0Z.JNCT>AZ9TTK1$&*W
MU%*XL=4; $?A]^T+Z^&0EBU'74QSPHR^$:,&AA[,2''LA0L<W29CQHUH@Q'L
M6B&F$T&K-FU32;M6Z.F,:)(()Z))Z8QKIKC&,8YPK,SL7=F9F)+,Q+,Q/DDD
M\DDGWDGDYP.>[RG&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,9\S]C2.M^TG<@I6O387]J ]JVT%;=BC$KK^J*[B<=E?5 S&G,R8P*R
M)"!,=D(Q(-&8\=OJV"U ^AYH\J^DM=6I I%(3DK49'@G\XX\_I]WY_C]7'/&
M6K^)H!S*.MHL /8L3$P)WE1*%<Q\S%X1,8S([ ULD&M' DN!V7(8U %8L\52
M7R9=2)^X<,6R7NX>**V E$F2K)SNO#U-F7E.3*+2Z,0F%V#6=P2V 6+%:[KZ
M#5[#PLJ9!8J?PB&:UU*YA&)$@\C\B E-I(F_'%U-WVP.0QX"=!$!R+&3OXQG
MJ/WB8]B]?JI.ETF+1P\418M'#]ZLFV1W6W29L6B:SMZZ4UTSHW:-4E7#E;.B
M*">ZF^NN6,^?FNN_5_7=84FA,ULJ9=0X](NUP2*M#<OH=O64LIBLC?3PQ=,,
MJ!P2[)UD[A,@M"13.-.59R<=A)8U9Y</14(4UCI^O9(19'_'_+_#G-SR/O=W
M90H.G3<+\.>T.U3.S^J\'L68W'7%O4-5\1;2R7Q@@H='MH;9,O$R=+5%LBRE
M.F6;5P-V'R%FP8.5UV;G&C)S.? :VVV\'[H-MMIE/;-&LLYTSG&V=?YY)%],
MYU_>YSY?H^G&,MQXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9&VI_0>N[LO,<8
MRHF-D%>U,Q<9^NNS:$PAI+R":.<X\\:HGK-*MEL8_>^X:J>7UQGG,:?BQO>J
M;OO6*SK=/&WP[:%!;DH'YK&UF5N/'<G'O!)]0ZQ[M=T%\EFD)"M9UO4O6-B,
M>&$N_P!_-I:[2 ?%]=TG3EC)\^E*I\!@,DESI\\OQQC'&,<8QQC'&,<8QQC'
M&,<8QQC'&,<8S4][ JYD].63'K=@SRS*Q-1$N.G, 'Q U/GTMCCIMLD1",X;
M'&1$_(G3Q';.B T.Q<D55/3EHG\;33;5C*X^E;&DX;V!EH>BIKW2"A)G',.I
M'3O9*H[=^QC%Q!QHF/1M:)6O=\$8V*"=1P)KH);0XI8TC&O!F/)B&9;C<N,,
M9JWQ- 1HUV#KEX$IUMV<;Q>A)>=EU0FX;*)D#KR.IS0>IK<+9J/MZJ@Z1@EJ
MQ*1K(E@VG$\DS(/E&-A6;801P59'V]_T_5[OA_CER5;DA!FNX$7CZHUP!*PN
M+$@BX9%VW#K"'P-BZ&JB4"&<OT!JC)5'=@B]SEVFUV2T<YRMKOGC)S\V18L-
MJ. R^SK"-MX["8* )262F7&BRVK(4+;[N%\H-&J:[T@^7].K8<+'MW)(J06;
M#AS5T^=-VZC&:(AG="B9]/(97T9+R9X3G@J-NP!Q6&21M#<GY;5&M[ :](RU
M9AJ%%V0]IK?2RL0UZZ2*I17=)\KIKNNW158R WB<NFKCN#X*6K=RW7VU[_2K
M;;5)9-7.NOYK%X8]6<:;9SC'Z,Y^GG_+QC+IN,8XQCC&.,8XQCC&.,8XQCC&
M.,8XQE8/B\6W**\Z:2>OJU4TVN7M%+(9U9J)E\79-1S++H-MXN[5\DL9<ZMF
M4;7-K.7*&N=F?FDOMMKC7SYTW25:.;<16K _NFJBFVEH_ )30R(// Y,WI^#
M[P",[/H>1-;M9^IID62+I.C-O(D=>Y)=LCQT^GXF4^'4[ZWKIITX)-2"TW:0
MC<30ZV47%.LM"5)04)TQB.51!0,/:.LIZIKEW8UGI@Q(7^-,8PH5DII0@?+.
M-L9W<DR3MPIG917;;.EV%V797K5Z<\RVIWF8<\A0Q^:@_P#9C3M11\%4#X9Q
MSR22R/+,[2RRN\LLKDL\DLC%Y)'8DDL[LS,22222<W=S#RG'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8R@7LSV2J!#MK!83?'3VE
MT[RC<VB;2$VO"[HM;>Z(J*D<OC F/N?MS3W6')..9-YD\.=%*U.6>P$$TI1&
MQDEPL(D0UV^9'V]_CW?;X?7QDUO%&"M'?6*4OCPFSIO"7KJ)Q2<UW @P"5-"
M$6*3R+%BTC>1 K3%VNI$<&-@6P:-,DXFY%*$Y"EH96!,]MY?'&3G5^$N D4+
MZJ+U](X.[@*]?V?+8PV#_+!0@!Z]1L:,R!K$F86K*@'*"8I,S$GKXL5:119E
M()K#I9(!AI^**,-&K('Q^W^9^WC+..,G'&,QPU#HC)&9 =(HM'#X\NNV=%6!
MH&,*,R;IDDD@S<D&KYJN@]7:(H((MEG.BJB"2*2:6VFB>F-6,]::IIHP:6HI
M)Z)))1,\FDDGKKHFFGH'=ZZ)IZ:XQKIIIKC&NNNN,:ZZXQC&,8QC'&,J]\![
M^M ]"/N_\1S+[O[9)#_W^GT_1].0/\S_ (XRV[DXQQC'&,<8QQC'&,<8QQC'
M&,<8QQC'W??QC(W]5\_,ZN>S?;&/C6?8]I6)G.,^>,L#\\.IQST[Y^N^ND48
M@4]=ON].F,:^>F-<YYCI'[[J7O\ GG:[/;[/R>?O=G8V!6X/Q'LB5P/J  \
M9ZA\KO\ =>K8-"O^SZ4Z7Z1Z9 /@^T:[I[7MLR5_W6;<6-BQ7R06//GD"2'.
MGSR_'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC.DDI=V CQPXQCIN7/0XE^2:Q
M:-9"XD,B<,FRKA(*#S(S,> ?-B6Z>&C#YR>#C/=*I8>DF:'K7T8SYFO"UKZN
M]>[0V15S636#2:-5?9ZUX)2B-=30U]@9>8=1"+ZAK9/U5V9LFV3K@TUCT;=3
MIA*J=BC@C<L>D%CE3L9<2]W"%V1^G[#G^/T_FS:7C")Z?E2@4=(R<HO+"\+F
M)V&H.=X3749=P'W0@A8\'F,[P!*'#U20J#P2>VK:3.3L9!#D=,1()( 9!Q*X
M\L.9/V_-]O=_PR_"J2"1:KJV*H#7@= G 8<01$$1+,"0%)/8Z.<IC7X(>FDP
M"O&.BN&KH2Q239CETMV;9/1%'37#&:\[(]=8KV:@;&!RV1S6,-!$G&3001A)
MS(=TE)P#4AI'7A1JJW=CSK$&4?(2,>,)-E4&LE# 9 RW:&0@M^T8R)53>'(E
M6!FO1SNX74WJV'F858)^+2&&[Z3*9VS#.GK3I,D:=3UI,-&8J!OZI'"RRD(;
MPYR:;3 >D\3GB@A5<.HR/HY^Q^K[?YY5/V1\,CHKT>[W>#O.^JO7J-T]+9EW
M=D\4DQH+()R87*QY+K7<IO08LC*92>:)):E![-WA5LW1<>M#73*V4MMT]F3G
MU'<8QQC'&,<8QQC'&,<8QQC'&,<8QQC*H+4'*=A/%?Z^5^IHW?P+H]1TE[*2
MMOOY+M=[CO-V<J>HF+YMMYI8(1^*QV?3(4KMCXK)RHP>)>2FR.Z?45F%#I:_
M..5GW5Z/7QGW'V.B([5EE(_W9)9887'^\ 0?'/.^>85.G8ZJ]ZS[C9&[.#X4
MT-5$]:@R\?AI8O7-H) ? EUL1')'(M?YR^:''&,<8QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC/FG[:@+%DW;JRF,W"P !$F]STEO*
M+;KUYW ,16"04VUB4>%A;[;QJ&(56PDUFQ%.+MK&&#9<+$#XV!J ]89\%%PH
M"0$6/M]O\_X99YXJT:5FW3N5P=@@_-GYK,ZZBD4@36+[3$=:,F.2M@R%5Y)
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MVMXU)!$^5A%PSJTX,<@;4.>E3=Y(F-;TJGV$G<EI1&?F!J1<D#$U%7JR>!J
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M$EP+@B/<6[1&H'X(XO3+VQ5XR"A*-.WNY)E<^FW!Y(#5XX".>.Y2& X8$VQ
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MX_E:)6+JBFD73L7*804,&E<,LE<'&R>?=$GSAFOZ,[IZ<RZF.V=0Z(SLAO\
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M/T8Q^<SUO_C!4C_!_P#*O _X?N_\_?P_P?IXQC\YGK?G[NP-(Y\OO_HK0/\
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M'MZ]D3I";!_F@@_IDHT3]HD.<XU>ZL9JFROW/+TBFD^[?RR.U!UTA +L/UB
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;CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g518298g61v60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g61v60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?N4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :WP8H         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  (0   %&          !                          $
M!1@   (0                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (0     %)G:'1L;VYG   %&     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "$     !29VAT
M;&]N9P  !1@    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #84    !    H    $$   '@  !YX   #6D
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $$ H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /2,K$OOMWML=6 -
MHV6%IB=W[C]J#^R\K4'*O(.@'K1 T_X+^2M-4\GJ!Q\AE/V:^T/$^K6S<P<Z
M.=/\E*TB115]/R:]L7V.VO#_ '6DS C8[]%_-_G;5$=+R@1.5<YH &TW<Q^\
MX4_G*Y@WNR<+'R'C:^ZIECFQ$%S0\B#\4=*T\1<W]FY!:UIOM]I)W>L9,[='
M'TOHMV*(Z5D#C)O'(_GSP?\ K2T;+JJ@#8X-G02>3_)_>53(ZOAX[Z_5<YK+
M-T/+'Q[8T'M]V[<CJD&9VL_1A9TVVW?ZCWNWEICUG"-H<W:S8QNS=O\ >GMP
M,JQP(OLK <YS@RT^[='C5[=NWV*#?K%TQUCZ]UDL<UHBJP[BYH>-H8QSOSOS
MDJ^OXME=3F5VN=:6  5V!H+W-K_G'UL^CN2HJJ8Z'[.ZW[+RML'*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X  0 !! ,! 0             '! 4&" (#"0$*_\0 3A
M  8! P($! ,$!@<%!0D  0(#! 4&!P ($1(A"1,4,14B05$68I$7,F%Q(SB!
MH;&W&"0E0G3A\!E2=L'1)B<S4Y(U-U18<H>7U_'_Q  < 0$  @,! 0$
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MA<\D9\\<\]7_ /'FL^-#"98(2W4MCTX5F,D3M+?V%Y?)<!70$VWA6JDRX/\
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M\6:?C/2S[.OWAPC0X:/CV31H,_*/W35V9-X^,DT(55%*ZMM8/:/<I92@F65
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M0Y1*<.LH\")3_,41*(& 1 >P\& !#[" #[Z 8/<GX$YI7'TZ'_R4_P#Z _\
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MD\D9!(RB?253I5%+/4;SH;3UAECBUN^9G$;6T=O=6_ADL,232S1QND8&=VT
M$'G!X/%T_6N@-8NGM='Z(O;F(%$_;&K]70:-HT@=AB:W-S;VMS=QJO\ JM1X
M><AF5L5KOMEMWB#2\'=4J[(9(@(T+ _];_JAXDPV%T\E%IY9(Q<!Y,,LX0?G
M62D7*;F)$SX@IHBJHW$K6]JFJ=%VJ0R7!$K"-75-(L;K5I1"0I5)$@N8XVE4
M9#ACE2"'.2%KZ!UITATMI$VC0:,.GK^+4;&.34A<]33BXTZ1(PT?LDC709H9
M\^Y*K+XR#<V"PJ<5<;[Z)=R#N8GLAV05A 1<6&8D9QF(]8B84X^>V9/4TT^>
M.$TFX$$>. X#7';JCHPH)8=.ZD"L 5__ ,=N;>0^6&C7J"/PSQR B^O>OGIZ
M?Z:N3XE]H714LK9\2VO=6U6[5"N5Y'[3,/*C=E53.X\ U%6?L4[EI>D0E8R3
M>G%!I4E<ZPW=/I%9.)C>I1^1+J%A#[;L+(RSB-364F&S*3N3&/24C_6KE3,V
M*Z;VM-ZDZ<>=GMM,UR69XW5/:-/MU1692%$C2:S=,B @*_[N5_#+*%(X/L^B
MI=.Z;U(7>D=!_9W?F&PU#PTT+]J7^H;6@E#HVGRF:UBB=2RRRF+8%)+%@23^
MB'$<:2'QQ1(E*SOKFG&52N,4[9)O49%_94FL.T;%G73ULY=MW+F5\KUR[E)R
MX374<&5*NL!P5-YNX9GN;B1D6-7=BL<:A$0DEBH7 VA<D*H PH P,5\8U*=K
MC4+V8V0TY[BZEG-CM"K:H[9$$2 !8TCR$"* JA<#%2AK55.FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2M+O$*_JB93_X_&'^;U"TI6Z.E*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*XB8H#P)B@(<<@(AR'/8.W//<?;[Z4K[R B( ("(>X<]P_F&
ME*TOP/\ UL]]W_B7;Q_D;#:4K='2E-*4TI32E-*4'V'GV^NE*P2P72#@I6"A
MWY7YGDZOY$:*$!-2#158J+ARHD>091SA@S42;-'+E;UCIN*#9$[A8"H\'UFJ
MGPY'9E58PV\ET51C .0S D#(SA3Y#N0*L06$]VCRQ>R[(4WR>T7,,$BH1D-&
MDCJS%AD(%!+-[JACP-8KUE*^90MTOAS;T=FT5@'GH<GYCD(T).OX]45;)'/5
MZPQ.(-+3E &RP/#,W!C053(HS=6,KQ=9"%=W;>&.T5I]3,D@;W[>"($22!CB
M,L5#,MN>0S@ N,X(4,X]7INC:;I5A::[U-$7CO(VN-"T&.9(Y]45)!'[5JZ!
MO:;+2"ZL$G"I+>,C):-E6<2-B_;KCW%KA6R-8QY9;_)) 6?R;=W!K-?YQ41*
M8X.IR1(95DQ$%%@3B8=**AF292(M8]!%(A"Z;F]N;I=I801;L1VD.%MT][ D
M"J<&0QC!+%W()RY/-<[6>J=6UC$#R1:=IL+J+;2=,0VNEV8['V:W!8R84D/=
M7#27+KQ)*PR3J/M%W(6ZS63<PYS!&76AU;%]@!-G,Y,ED6T'#QS=S- [CEGK
MJ!@DFTDW:,FE@D% >O6WPV;B4D2$131<ONGJ>EQV_L"V\\5S<7D(810E7<LH
M4>[&C,Q!)V$  [HV'D0/4=8=%:?H]ETL= U6'7KK6($DDM+)X[F4W$IC*[4M
MWE=LEV0!D#;HY,\@JN$WW>YDK,]H7QSM"ITK*KJD3%Q>UX-.0G%(U4 !E/0U
M?E74;!4^!6Y!1A=,J2#).2;JF7JM&N0$\@;METQ$L"ZGK-U%I]E[I$LS/&LK
M)R\21Q#VR_F"D[(;-3'&Y474T*N,T9M)T;I50W4#+K.M[V Z8TR;P;:W!4>[
MKNLQD^S2(V4:QM&:YC92+CPR=M:E[G=AN6W6%+AE[,^1Y^U9(9%8N646T6?6
MXL0T,\*M)FF[--)L2.V;=F51,L?CNH8TB6KA1-ZY;2S1HY34KWG55CHL&_0]
M#U+51$<2)=726TEXH+8:"QMB;4*1AHQ?33.%++*0S$CZ;]DWVAWR=:Z/89Z?
MZ=T K?HUO;V,5DTRRV[^&FH:O;'VB65I&\)9IGY544 %B3Z>;1MK^)J+B#%T
MDZQK$+WE2G0;FQ62UP[6:M;N849%4=O#2,LF\<Q95%BD<(Q[(S5-BB9!FJ11
M=%553@R:I+?Q&Z]FFLXYV,QT^1=LD#2/N\(QQ^Z6B)VEERA"ED(7;CY7U[JM
MS>]7Z^T=^TUN=;U,V_@3-)!X)Q$@CE9B98]BB-)B290H<A2<#? 2II(F*3I
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M#^8\?]>X?KI2O@G('N<H<=AY, <#]NXZ4K2_Q"3 ;:'E,2B!@%_C#N @(?\
MWO4+ZAR&E*W2TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI7PQBE#DQ@*'W,(
M '?L'<>W<>VE ">PS\J^ <@^QBC_ ",'_KJ"0.Y \N3CGTI@^G;O7$54^#<*
M$$2@/(=0"(#P(]P >?H/;W'@="0.Y SG&>,X[_AYU PQX.2O?'.,XY_O\ZP-
M.\E5O!J7\ FBJDC&LN:>YA?@AF3HSM-$2G"8-*&.9RR<,SD",^1<A#GX;JD6
M"0%9#()8R-VS8&RV[CD8&,<^;9SG':K?LCFR]M$D83QO V9.\N5W #C!W#)
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M<,AQK6J7IQ/66Q/%HZ%B5#]<_G]9YQZU+^Q3*[_-&<=\-[DL2Y;PHZ>7?!;
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MUZ>N5TZW0RW%[J$D&F6D4:@L7>:^FM^!M_TY).%')%8P]W=V5\F12G8"N8,
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MTML^ Z7A.2RLVHT)7H".D;A'-E(^$B/AB1$6%7K[EF3S <.3K)I)2)@(F?I
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M28. 5YJ?VK5!D@DV:I)H((D(FFBD4J:29" !0*F0A2E*4H !2E "@4H
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MFCW$>R80;%)7TR+ES./YATDB9;JZ(!J5Q<0F<:98PV4KCPE]X@N4)FD,D>\
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M4O(1+[459SO#?Q6UM"Q9<K[7"_;(H3"E9CY5M8IQT_NEF; ;RY^V"E*.T.H
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MV[ZI8Y)/))/) R%_V# 'NCR')]2:^6A0H 7@ 8QY$_[CZL?,]OADDUV]@]N
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ML>..@1,Z::7P8SL8@A4_,45*";(G+A0SD_4N(*!I\1MNWC!(/GG(SSWP#SW
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M?CD #W#7JT4(JJ.RJ%  P,  #"C"J.. H  X  KSS'<Q;MN)/XG-?51$$E!
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MN) TI +90;MJ#"H%50M38!2E  * %  X      ]N  .P!P =OX:K5W@ !@#
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MSV:;5N*]3+.!$96621%N1G\VZ9^UC[0/M Z?A:XZ4CM-6=T$[SVUUI73T2L
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MY=#)^2(F2M%>C7S5XL9T^BWS9E&LR(R;-(CI$[A10?7UQ^E?I(;\^6';C@>
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MY;*I/7*<DR63,PD_--\4;NS  A='4/4:*D U;5)HXU,8,MX9UC60 -E9<J"
M 5/#)MS&5QS@! =N&B&X,53*J6VDJ2!G<PSG. V0<\@YK)JU@3"-6>%DH"@P
MD6X0EI&=3<$1=G*C*R<5*03Y1)-RLLFBV+#3,Q&MHTA"1#!G)OTHYHV(Y<">
MF^L:K>1I#-?7,L8BV@R,@4DRDRY .X2+-&NYR,R$ [Y H(/'%@'8HX9@< 94
M9R<X_P")."<^8!!!K-,=8LQEBQ*>:8TI5;I+6PRI9R<9UF&:PK)[*^@9QY'9
MVC-%!LF<K!DT1*DW2303Z#G!,%UG!U,[B[O+LQ&[N)9_!B$,7BN7V1ABP52>
M0H8G /88 P !4*J*2%4 CW3@8[8\QP>",')SY$U).J]94TI32E-*4TI32E-*
M5Q.)@(82  G H](#V 3<=@Y'[C]Q /XA[Z4^OK->$>X?8+NWSMN+L><I&D[;
M$7[@8JG0UCK.]3Q&<+6.3Q;3;'8)&B,;;3<)V*H8[=S4:TL4J^?I$9O60R\O
M+ FNY;N!.J^OK\JC\?R^O\\_#W;2*)4R%-^\4A0'OSW   >_U_GI4CL/K^GZ
M"OBBR:7'F&Z>>1#Y3#[!R/[H#] ^OO\ 32GU^-:7^(,J1;:%E,Z9NLOQ#&1?
M80$#%R]0@, @( 8!*/N @ @/N&E*W4TI5$]+U$#WY B@A]N. $>>X?0/IW^H
M=PUB\GAC)R1@DJ!RVT%L!C[JG /+$ ^N0 8P#G(_TN ?(;AMR0.3R1V\LY]1
MYI4#=+6\>UF\35H^)2#-G;I+R)5S<W[^%3:K/I$\*Q;3=^L1$SNWC- A(Z%K
MH2<K*'%,J;1ZN9%0_P UTS[2]-ZPDN8.A^GM=ZJEM)4MKDV\5I9V%I<^(]OX
MESJ6HW=GX8#QY>&)962,K*$*2JS?9=7^R[5Q<Z'"UQ9PSZEI.F2K;6D4EQ="
M,6<0FN)[.R@GFCA1TD62\G6.W9XV43$JP63*?>\^;BF3IRUJJN!\;2":A6%G
MG3&2R)8F9Q\LKJO5YXFW?5I%=-,_3*V:-BI0J)D',5&JE63?-NQ<6G7,\OA7
MNH].Z*%+J\6EB?5+^WY8;#=74-O;1R$ ,9;3VF/#91C_ !#F7VG]"]'.H:Z;
MK77X6!FL4S;]-V<PVLHNKF+>^JRQ*5S#;2^S*^89Y"8Y(J[R83PWMVHEXOK>
MES-V?5Z-L-YFU'X+VJVVF9BV#EVYD$0>"HVD;'*%1$B<FX3!RJ!TP.Y,F0A4
MKUKTC8W]QIR:W?2]1W<4JFWN.H+N.\M[&-VP%@LCL@2&(-M5C$71!A@"<"F>
MK^J.K]2TS1Q>V6@VU[/%IUK'96HT:SM%:3PDEDGMXV&P*=Q(=@>6"EF.>_8)
MF=AF/;33+,6 DJF2&,_K"C:5Z02>G@%2HJR<:Y!-%-U&K@8"%5*F0R+A)RT5
M*)VXF-[;5=-32K][.$V[QX5E]FVA06'\!1"0KCL5&?7/()J_:1TU+TKU9J&D
MRWXU"5"LQF;W9@C*&(FB8F6)U .5DY"X/8YJ?LBYXPSC1J8U[RA2JLN?H,V9
M2<]'DE7IR'(IY$=#E6/)R3DX%Z2-&+1PY5$0(DD8YB@-:*WGD.4A=QV/&!R.
MY8X QWR37GM.Z:ZAUC TO1]4NP1GQK:QGDA1,9+R3>'X,<6W)=W=5"9;(QFM
M%]PV3MQ&<<2WZ/VX4U_CVK-ZY*/G.3LI(/J1,VR*10!>0CL>TR19N+&T3D(X
MRJ0V>X1D"W .MK%LUEUR2+'KZ=#86U[:RZA(95,ZHT$:F3:VTE6=@5C<*X7*
M(SDKDG@ 'Z'T=IW1O2G4>ER=:W<6MW*2DGIWI^:#4K>.5T9(9M4OH':V MI6
M60V5O+-*TRJ)  NQMM-J&,Y;#6#J+1+46'"W1\,V6MSZ%!51K,VAV*KJ<FEG
MBY"NY1_)/55',C,O.'$J^.X>"5,JA$B4-2N8[R]N+B&-XHFE811NRMLA#'P\
M;6957!VJG!1552N1D^+ZUUNWU_J?5M3LWO!IT]TZZ;!J&Q)K2TA BBLXT3$:
MP0(B&)(\A$D"9)%2G><F4V@1AI.RS3=D58P-X]B0BSF6FGW/R1L)%-B*R$N_
M5$Q02:1[9RN;D1 G'(A42-W;  []R5QGS!R>X]#R>V*\)J>JV.D0^-?S"(.0
ML,!#">YD)PL5M%CQ)Y'/ 2)6/';SK2S+F*[1N60K<K?:Q/4^B1<^@_@:E%E1
M7O\ *INC,FKZ5M3@ZKF,KC8(TK@K*':(NY<@' SEVV<B=@I?@G6U61&&YC@
M@@KQ@C^$G')]?,9()Q7S;J/IBYZ^BL6U>TETS2+34(;J+24F'[0U !E#3:C(
M"T$, 0-MM8G:<J58CQ 8DWSK<!'5^$CH>)CFL3&,6#5DRCF28-F[1LW03210
M(@GP1,J29"I@!>3<!\PB;D1YSL79F;))8GWL'N<Y\Q]=L5]4@MX;:".UMH+>
MWMH8UBABM4,<:1HH2-$!5&VJ@"KN ; ][FLCUC6^FE*:4II2FE*L,NUBY-G(
MQ<LV(^CG[5PTD6;A$5FSED[0,V<-E4Q(8JJ2Z)U2')P8#@8Q3!P8 &<D,K!M
MC)E@=P7@9)).0 !\2/4>1$QR-!()$8J\;).D@R6C=7 0J%!;=N&5 !/GCSJ'
M,"X+PM@6M2]<PA66%9KDO-/IR719/9*45=3"H%0447?2KY\^$&R"*;1JT*MZ
M=DV1*W:H(I%Z1W3W\E^RRS7*W)5%C$BR(X5%[*2A*C&/,@@\MS7;Z@UWJ#7;
MN&[U^XN)[J""*"'VN"2*3P8U58P$=$)7;C#!27)_B8GF.\A5O:#8+S+O,DN,
M:KWTL"ZCYUK-SZ;.33ASUJ1%RI(PYI!N!56U/E9< E'+7XDQKTC( FY0CW"P
M&YQZAL(':#]JVT36LOAM&;F)6CD$0N<-EO=_=A91W4C!SG KJ:5!US;V%M<:
M79:JEA<W*S6UY!8SB&2Z,JPJD5QX0!E-P%C$6\$SQA"N\$5G%XM^WMM,UI>[
MVZBMY^M2[LU:)-3K)JO'S,O7!CG8((G=)E%R[JUI\L4G!% &.ET7!"@"Z*NH
M?6].MW6"34;6-YY8XQ'X\>XRRNHBC9<G8SOM"*P!=RJJ"Q%4]/T7J^>"\;3=
M*UF:![)FO!;V5U();+3[MGEN)$6,LT%I=PMXTP!B@>-O$9=AQ&IL/[.X:3-6
M'5?Q_%2U/(_N@QBLR=K+0;)RS@&SF==-OB:;YG#LT*Y608*NTPC88L!658LK
M$(J(.VMOK<$,S02:E;1W"V[W$EO+<1QN+>$.99F1W!,<89FED/N*)"'/O8JU
M!J/6=Q BVSZE=VMU<)8PF"!;Y);LW,^HQVD.8IU:X>ZU"]<6T0\=@\V4,;MF
MK3HVTEA376,DEZ<E3*@T8W-U7EKJ]73I,<$:@A%V)NZ6GU9&LQ(Q"R:#59H]
M91_P]\HD0GD22Q7-637;%&FD;5+,,+5;J0^/'DV\Y!CF(!)*2<&-L8;AP22,
MY/\ ];W%U#J)M-:-SJEQ+HEM-!IT8CO+N&?P)K",00)%<W:7 VO;JLEPL@Y7
M(K)8[:?M[2<.YN,Q973.IP9%P^>-P=H)N$YZ,LL?(I)-COTD4$'D?=+0F9N@
MBB@"E@?KD*FLX56+TUO[B:%$]IS''C #[U#83.&CW C"H1R?=5,'A15&7JWJ
MEHH[675K]8[<(L<>U(2I@:.2)71PK[TEM;9/W@RIB16P(R%Y!M V]IR2TC^R
M.NKK.$E$EA4.Z4;^4N*QW2!&2TB+4J+I59PNY3(B1-V[?/'3HJB[YZJIG[;<
M8 \5LC&"2>,8 QQQ@<<>G&!P3]7]3/$(3K%X8U"JNSPDE(0JZEI1AR0UO;!2
M6)4(@& IQ3-MFNW5H[!^GB6$.^*J*@.U7\N]<J*&0!MYKM:0F'!GXD0 44_6
M"J9%%9VBD )O'0+A?7(01B9@@8MM)]T$\G  R 3SQW."3P*V'K3JD(T8U>YV
M&R73U"16R-[*LOC["0H[R<N1AG\]W%7 ^S[;PM'RD2KC"*]!,-V+1^ 2,R9=
MP@Q:>A3X<FDP=-SN6@ A*+-EDEII/DDT>0(8P#C[9<9#>*VX8QP!MP> ,>GE
MZ X!%4QU'K>^!VO6)MO:_!;PK<-_WS;KC)6!6RQ['<"G_P 97L=C(J+8PS!G
M&1C1)C'1[9%DQ9MR$3;M&;5(B#9L@D3@B:**)"II)D "D(4I0 "@&JI)))))
M))))[DGO]?SKCNS22/([%WD8N[$Y)8\D^N23\ORS<M*QII2FE*" #[]^!Y_M
MTI32E   YX[<CS_;I2M,\S;=<LY2SMC;(C7*E"2Q1CPL+)M<.7+%]FLR*EY9
MS#M:1R(WGH/+-,C'%J:UY9M$T(UJJ-LB<?RZ3NV1\6_FGC=2-5&,Y[>@^1_O
MZ5$6-O#K@XNF6''.:+\[RG1SX7PKMPI,94B7;"4Y7<-8%L4W9J4TF;S1,C?C
M:9O4@_DHM&VVN GJ9&3;*NL6A*NS:R,^A+J'Z_O71L4P9CG;KG+?#C'%D=8(
MRIL+K@J51:V6_P"0<E2@/Y?"4&N_4-:,FV>W6I5!14@&19KS2K-F7E-F@@D/
M1I4UZ6J& I1$>?H';^/;_P ]/7X G\!FH/(QZ\#YG@?K4=4]8A[ADY,O/42?
M@S&Y#CCKI=9$H>_N/ _3CL/?69!"1GR8$CY9(^7E^8JY/&RVMBY'NR1S!3_^
MDI4Y^9SC&> <X[5F$U(MXEDYD72A4F[-HZ<KJJ*H(I)(MTC+J***N%D4R$(1
M(3&,8Y2%* B<Q2\F#$*'(3/O.RJHY))SP  #G)/;^U55CDD<)"C23.!%!$H!
M,LTC*L<2#MXCL<+N(7/=AY_GHW4[K$Y.KYER'7)*42O648*-Q]B9[&"NT<8Z
MP8WD5Y1*9,J@91ZG;<]S$8]DXF!9 A*JT*.CK._49Q,"=RI]!T#1?:K^RLRJ
M+;6!FN]5EF&%BDCV"196*LJ1V8,2G=@-+(R(&D95K[[9VVF]$2=-+K=K:WEC
MI-X;B[L2R%^JNL+VWCC&BP+.\*2VG3T3#VFX8QP>W&:" W(/B)MSLGJU)V_;
M6:/)X\<QV1\GYP,I(&GFOK&ZMGM1E' $9.A>D)*-:UCUN#Y*;<.FZ)D5FTM)
M'9DDIL41\IUOK=R^HR6ERCV\L/B6FG6 6,DV\GOK?NJ,W[MQ(LP< L(2B[1M
M11XOJ&2+K/K75=9F!T?0[.U07D\Y1S8V&GJ(;?3H([5YE:XO+B-HDCC8*))>
M9-BM(-VJT]B,7PS>DQ /+QD:4,O.6!%CY:4I-V"9,=60L<^\,;T$*R55,4B
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M3BH]< *XD1(*;9#SO3'3$72]I<VD%W<74=S<27 :Y.YD,C%BH&2 JYP/4<D
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MU#I^JW<EC )UEBMQ<1EX'C1HMZQS[)&&&,;O&K 8R6[<5. % H<!V  X /L
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M@X-SQV'L(@/;^(" _P PYX$.P]ATI7$B2:8F,0O2)NX\";CG[@41$I>?<>D
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MIJ[B<H>X_P"/\/\ U#]=*9^OK]*M4D[B(EDXDI9XVCXYBBJ[=OGJY&[)FV1
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M0;0ZJIKTAW&;5,U6G/%(W0;8,S43$^8J_B*TX$M#7+F,)?+F/KAC*QVF$N[
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M23A-NJ[M#"7>1\T[J4>9P=K5UWDN>8649 P5AH,'_P @_ ?S&?QQSQ4^./\
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M@?XR?3%7V*&M33<7<:A"O$V\E*-U%&J<>Z(WEV;IS&320JMP4*F_;O4WL?)
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MF$14P/05S3C8Y%-%))@R22;!PW33:H$30#S"+<(D*F!4@\U--7Y +_2$(?\
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/*:4II2FE*:4II2FE*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g518298g68p81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g68p81.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1-B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q ;(5'H         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ "4S,P  0 ! )3,S  !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             !F0  !9D    & &< -@ X
M '  .  Q     0                         !              69   !
MF0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MF0    !29VAT;&]N9P  !9D    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   9D     4F=H=&QO;F<
M  69     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( *P"6P,!$0 "$0$#$0'_Q  ?  $
M @,  P$! 0          !@<!!0@$"0H# @O_Q !=$  ! P0  @8'!0,##0X"
M"P % P0&  $"!PC6$107(9:7$A,Q05576 D5%E%6&6%Q(H&A&!HE)B<U-C<X
MD;'3\ HC)$-$1D=V=Y6XP<;A=-$H4U1F9X6&AZ6U\?_$ !T! 0 " @,! 0
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M#:+)''(QD"R.Z,X"\.()M].0LP]'#$GF.0.,FM26Y,;N@"$JJLJDG?(6SZ*
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M&*$/(\<C<-E60XP2Q=%8[.7(<UYDD #.,G ,Y)"J*RKO#,@SG "NP&[VGKY
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M!3S (Y;N63@%BH]0&!C^CG!_I\[#X%"E4Y,.&Z_U00T8S>B3EF1B1:B, Q@
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M.W*+I9^_R<Y\ZFW!MV  PV#.Q@Y8N&7.&W%VW9YG./4*QP(]I7'7M.[^<"H
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M]+BUGH]T:NM3TR:2:**[BN=/B1Y+=S',H2XO(9<HX*DF, D>B2.=;O\ :D\
MWU'QCP]/>4ZVOQ0Z2?FJ;ZRW_?5S?\0WE<ZOQ+OO;_END?\ $*?M2> ;ZCXQ
MX=GO*=/Q0Z2?FJ;ZRW_?4_B&\KF<?B7?9Z_\MTC_ (A3]J3P#?4?&/#T]Y3I
M^*'23\U3?66_[ZG\0WE<Y_\ ,N^Y<C_AND?\0_O^RG[4G@&^H^,>'I[RG3\4
M.DGYJF^LM_WU9_B%\KG_ '+OOZ[I'_$:?M2> ;ZCHQX=GO*=/Q0Z2?FJ;ZRW
M_?4_B%\KG_<N^_KND?\ $:?M2> ;V_U1\8Z/S_#T]Y3I^*'23\U3?66_[ZL?
MQ#>5O_N7??K\]TC'/Y_PABG[4G@&^H^+^'I[RG3\4.DGYJF^LM_WU!Y!O*V>
MKH7??UW2/^(5>VCN*_AZXDG<B8Z0V8*V [B3<:ZD2(T;(&&0MN74>(CE%KFQ
M S%2SI1@\PPLWR6RQNAE=2V%LL+Y<=J&C:GI0B;4+1[83EQ$7:-MYC"EP.&[
MXVAUSG'7RSSKJ?2GR?\ 3#H3'9R]*=#GTB/4'GCLVFGLYA.]L(VG51:W,Y4Q
MB:,G>%!W>B3@XZ'KC*Z=2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I5>[$VMK/4S 46V;
M-XS"&!DK@%#O)(3;#4WY11LX=Y-&>2^6.2F:3%LZ>.U,+>J9L6Z[MVHBV245
MQV;:TNKQG2U@EG:-#)((D+E4!"[FP.0+%54=;,5506(%<QHW1_7.D,MQ!H>E
MWVJ36MN;JYCLH'G:&W#I'Q)-@(4-*\<<8/I22ND<89V"F'C^(KA]-'8-'!VU
MM?$#^P!@^10(6B<'JO)".-)/<Q!$1AZ?3?[[29$;B.FZ2Y;%F^LPP<]7<6PN
M?3-2CCN)7L[E8[9VBN',; 1/&5$BN<?]667B=83<N\C<N>1FZ&=+[6UU6]GZ
M/ZQ#:://-9:M.]I,L5G/;-$MQ#<''+S5I(?.>3);F2(S&/>F=8(XIN&:1#9.
M3#[IUD3%0T C)92\;R06HT#1T@ZN/2*/%,E+)V9."%_NO/).ZG]E,\!:N-GZ
MF#;*;Z1JD30H]C=H\\IBA4Q.&DE1=Q11C.X)Z8^AZ8]'G5]QT#Z;V4UC!<]&
M=<@N-3O&L;")[*=9+J\ACXS01*%W&5(?RX!Q^0!G4\)2X\G'BAX<TT(8I;<N
MNTF\^Q?8PJ]Y$P2P/6#D;!BR8_')3'HR"DK78%TE<4<A"Z2R9#%MZA7T(G2=
M3S.#8W.;;;Q_R3'A[UWIN./^L7TDQG>""N<BH'H)TSWZFIZ-:R7T@PG5/\"F
M)M/.83<VYF(!Y74'Y:V92PN$*M"7W+F'/N-GAI0O ONG9H*58;$V:*U.&5C#
MML1P92@R#>2!@J;LHNV5'AW(YJC=L1LFO@]5)BL6";I-WZU/870=4(N2]I)#
MYK:/>R"564M"DBQ,(\!MT@=B&3D5V/O*[<5R47DPZ;N-6\XT.[L#HVAW'2"Z
M6_CD@,EA;74=G,+4A)%FN4FD8/#E#$()^,T9CVG=B.+'1RPF /)5L&'00QLN
M[O\ "L;/3",N2+_%O(W45262=!BA$5FU>&6UF#5YB^ZHH16P%66^\\%6N%;Z
M/J >Y6*VGN$M,<:6."4*N8A,01(B/N$9W%=N[8"^-F&K5N/)_P!*5N-7CL-'
MU+5;;0]GX0O;33KY(82UE'?LK1W,$-P'BMG,TD9B$BPJ;@IP"LAF8+?^E)//
M7>KH]L^&E]AL'!]F\A[$TU6.MWL5<=5D;%1ECGZ=GX57HR(L>]VV0O9THC9K
M>RU42:=?PVXNY;2=+9A$5F:,B,K,NZ)@W9D'R6ZB?1SNY5QEUT1Z3V.DQZ]>
M:%J=MHTJ6DD>I2VLB6KQWZ<2RE$I&.%=+_B9?\6[?DPW$]&K?K2KKM*4I2E>
M,]>-!S-V0(.F[)@P;+O'KUVLFW:M&C5+-=RZ<N%<L$D&[='#-5993+%-)/#+
M//*V.-[VR 20 "23@ <R2>H >LFL$@ D\@!DGV 5S?'.,3ARE:)M8-L9/+&/
M:]>[:(XE8Q,H[G?6+-5F@C/1^$BCPJY:)FEWR*45."^N#Y?FF]QBZY?[L)=4
MO:UG7;E/E.(QAE;\H>>P[6.&'\X'FG+<!D54L\39PWR5+G*L/0'\X9 RI_FD
M<FYXS@XHVW'8H\UIKZ:X:[!0([.B_$-B[";PV:TUM'X-'.'?8Q+7,@>3*7L(
MO,$A\E-E[QAJPC;82[;-"<@=,5CR]@^*Q2WS3$CKO9U00<X8S(SM/&)%"(60
ME0-V3D$A<[1D[:_.3L1M@4N9>4CA%58G*$LP#<R=N![3C/+G*Y7Q/;C$(Z,+
M .'Z.$A.^WNN1D5CDGW"9AVWAQ&81U.5RYN;U[AIB1!6">KHZVD)N5.%Y^DG
M]W1UW@G9$L]'"7,5MXCQ@9VS"'+,L0:(A6VIB3BJ3Q&VA<(>;#K )J1FD'#(
MB&)"H4-(5?)&6RO#(&P9)RW4/:0#W!6I6Q2E*4I2E*4I2E*4I7$VYN+$_K[<
M3S3$,@\"D<I%ZZ#[(1$;!W$WU1(MF-S!.4#<8CHP0[A<F:;!EXW.+YXF4"9B
M)B!3V015D]*HI%UWP[;BME>+BN[JI<QY2/B+&0%.Z8AU**=W+"L2%8@<L'7D
MG*R<-50L%#8>0(7R3Z,8*D,PQSR0!D ]?*);*XS-@0/^J%E+;3L(=:RX:60(
MA/UY3NIS#-J/T2&HH?M\LRBT$[+C\0)&QHJ6I@1HHAM(18_(V.;!!XSP=-U\
MI):H_ 4RN'G+!-L6^/E*T2EFXBN 2NXGAG"G.,C%1:X9>*>&NV( MF3:_P#B
MUD.%V%20&V@;QEAC(]4J7XR,&YXOJ]37;M/?:NPXS%H#JQ<]DC><P6;MW)^-
M[DQ-?<>;@+ !D+$RLI/G*P-XYB4EA$FA*.!HSD R.1\URHDX@X/#9WDV_(=3
MM:+;N])RY4( PW*RMR&<2-QS*;?RNY0B9^4K<U?.,A0 2V1R*E>9QF/DN.;"
M.!WD\E.KW#'5QL7NMUJ@^)EZ):5SLKI5X0:N Q>(N(\)&Q)782 @J5U\Z0E\
MF1<"VF&<HQB[US@QPR+3<0BR9D!B$BE,(@E ((<,Q;9D!\HN"?1W $U@W& 6
M*80B0H0V68Q]8*D +N )7TFR!SP<"I-(N+61Z_A6\"&P-*F%MEZ3!!9,\UWJ
MR1*;$8R(!*XV</QPPUF).,09$$)27B\I$2LK(P@T='W4>=KM71M%\&L1BMLK
MO$$E'#E)7?(O#*LK!6&T,^X^DI4*Q+!N84@XRTY19-T9+Q@-L1MVX$$@[BJ8
M&58,2 !CK.1GK*&R&TNB$4E>+6['&3QL'(;,;K6<79V-"VI*S6Z]DT;+W;V<
M^INM9)*RE\/3]7AZ7HVUW78[+G.UF7/MVDC/]E7@Y /M /Q&:DE1K-*4I2E*
M4I2E?"_]I1W<7FV_^N>PK?O_ ,:VP/\ 1[>GW=]Z]WZ"?Z.6W^ON_P#WWK],
M/X,_+R2Z3_\ N>MCV'_.,WPQUY]7,UP9T7_?W=U^_O\ 9T6M[>CI[[>SNO[;
MWM?NKN->^X/S\N1Y\^K '7C/,=7(]9(/*G3WWZ>GV6Z+^[O[NGH_+OZ??_GM
M2F>9!SU#U\O9U=0'//K^?F,5F]OX_P +='1_#V>SO]E^[V^ZE9(_7^H8Q^KJ
MZN?4>77ZJQ;OM;V7O[>_HZ;V[[VMT7Z???HZ>ZE8'/'43C.#ZQ@XZ\^L]?+]
M6*SW?Z?;[[7[[]%OY_R_.U*SR_V]?K!YG _;[/:*Q?\ AW^R]^CV]/MZ.G\O
M=T]W1W?E2L']7/J)QUYZ\9]GJSRQR]E9Z?;>W?;V^^U[]%O9[?X>[V='=?II
M6<]9',=?K!.!U=?ZO5U8Y'-?1)_N??I_&'$[T_IK5W_]I-O\_P#'HM;\K5Y?
MY2_\5H_^LO?_ .MK7QK_  O\_@WH+GU7VOCJ/N-*^/Z^7S#%?3=7D]?#=*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E<3\86M=I2E]IK8&FP9<S.-:2":)6N&?P*SIK')
M]"WT8/6L"V0_ QDKFZQNS11?YR-D]CZML7Z0>3-,WPA3G=%NK2);ZVOI$CM[
MJ. _E%N=IEMYUEC].U625,>EE>$RR [2\)Q(/3_)SK>@V$7272.DMU;6VE:Y
M9Z8Q\YAU8I)>Z3J<-]:'SK18KN^MQ&1*SPBREBO%S"UQ8R"*Y6@=(_9RN86I
MHV4RB<IH%XA#M$X;&A:#(H8%D9II$6JE'W,<+IR82&9M$W:K3KRI>'2-W=45
MBZC[X&H0>J+<EJ'2<7'X1ABM_P G//J)M9R41T@OW!D65#"[L2H;:$GB4;RL
MJRA5QV[I3Y9TU,=*[&PTIFMM2U+I8=%U-Y;>VGATSI1.&NTO+9K"XN9)#&K\
M);?4K*/;<&.\BNA#$JRI_P#9Q 2$!CD'4V>3;Y1;1X?48PNRCF+)7(M'=T1_
M=H68N$FL@1<>KPD$=:L'X-L0;+.F;ATLV/,7>>"J>NG2:5+B6X%JAXU]+>,C
M2;@$FL9;"2$;HB,F*5F61E8!@H:-ER#QT/EGO(=7O=5&A6[^?]*+GI#/;RWI
ME46][T9O.B]UIJ-)9LFXV=Y)-#=O"ZQRI&DEI-$&5IWKC@B1U\_N?:;,?(RE
MUJC>FOGIX%'E!SEM(MWS"(RQW/0:QN1R@DU)QC.(M&C!$T3D+\JLMF2+FUW-
MW&+FFZU]KE>&UJAA%YI]RL<D@8&/3X)X%MI!'%"A243L6,:1*@&U(P,;>*UK
MRH/K$0M)-#A:PCU_HKK$5K=W@F1[/HMINHZ?'I-TMK96$$D%^-1DDF:U@LXK
M=4$%M:HFPI X/]GX<AI )([[O^])8'VYI[;.11W!BCQL0?:MU]/-9/V#_ ]L
M8^:=JRV-3MV\<DW!]3,7(&O6VC102J@%8WS](TF62(6&R&2RO;+8+A0RI=W5
MO>*RF.UCC4036Z@((@'B.QB'!D;EM4\K]MJ4-U9#HL+?3[GH[TCZ/""/58(W
MABU[6-)UV*:$VFBVEK&NG7VDQQQP): 3V<G#DD6Y5[J;\G'V<Z'X;RAPW<1!
MC&Y;K<=J3;[56$C7SV8P</LB6[&&X1,@N:LK #]EYH;"/"N&$B:KLU&A! 6T
M+,6[K&0Z3L9A.UDC2PW3WMD1.RK!<26L%J_&41XN8L6\<BH>$0VY2Y1BM23R
MS.;T:E/T;AEO=.UJ;I%T<D759XHM-U2YT73M&G.H0I:[=8LRNF6MU';DV4B2
M+) ]Q+;RNAM1'A&(Q@JG,X9/<4Y@ V?Q+;AC%GT<;9,[RC?,3+@1HQ_FJ27Q
MS9Q-Z]9NLGBJ"_WRDSLW79,\,_2QU#K2S)P)[;\A)::58S%93NX.G3)(SKZ
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M/Y3OE6_I^C^W_,MK[,>WV5G]BIP*]/3^&-A_E_C&,_ZNGX^](O?6W]5CK/\
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MFX*TN\A#V:_\DVMVNEZ7>VL\=[>:I=:\!8[M.M(]/TS0+N6RNM3U2_GU40V
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MNV)B3))F-7(0AO66V*0C FKM><4FU&<\(</JNO1B7$%()6'*ZS2S'G5(&YT
M=5N2(;;EBB9&SMHMJY@U*P>=@FAA&Y+:'X.'"G0P1L0(Y9U"WC*B;>>"JD2<
MUW\9>0B7E@\0D.A(/Y/>2"4(JWC2;N$4 E9@4Y$IPCS+MS!!091AGF^W')QB
M"FN-O8L/C-MK22'0DCK;8(W>N&FP(1R<9S1.0:F<E[1-K.C3YR\".1^RQ@$F
M4<+!0HY:"*]3&*8RZZRS]O-;6-VX:LX=##Q20-NV0#>44>EF,D !B=XR?1Q@
MP-PZKO95*,).&!D-E"=H8DD$.!G( *]6":L]+</$?B0GNL7R&B66Q==N81)Y
M9LMYC*AVIHWJ2:Q:9E\92[BI"4(24B9#2>"&(DX'8306P=,'3"9N" =M@_ M
M:S%!M20<8I('58QM,C2HR@J&"[0I5U;.PD'*8/)JGQ)LLAX6]=K%SN"!&#<]
MI;<2&4KC=C!!)'55^\/6RC6W]-P;8\@#- 923L'SE5N-N^N&)-F1DD+&RF/?
M>:21*T8F@QBSE\8L0PN]QCYP;BZ457MFKG3/&(I7C!)"D=>,C(!*MCEN0DJV
M.6X'%6Q.9(U<@ D'JZC@D9&>>U@-RY]1%7-5564I2E*4I2E*5\+WVE'^5[MJ
MW_WSV%>_N[NU:?\ O[_9_-[N^U>[]!/]'+;_ %]W_P"^]?I?_!G_ .B;2!_X
MGK9/JY#49?7SZOV>KF*X.OW7Z/;T_GTWM;_VZ;V_+W]_LM7<:]_/(XZ\^W)
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MMXPTK$DJ6)5/2" A5*[<;026(QS8DGV5V-# 9B-Q@2#/2HA-BPY%5%U*"@L
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MBOK2_P!/L=4L;H6MPEW:/+9ZA;W-NTMI=1I/;3<,212 [6VLZM"&O")H9A-
MLY8Q,DS(@GT2,- S>83#&&NI' @*48A<K+PO([E&34JC()! >+D)0:[)IV;M
MG2KA9\V;N4[SK.H-!);M,K)(LT9<P0&=8KF0RW$*3\/C1PS2$L\2.$.6 4*S
M \H_E#Z62Z9<Z5+J$,D-W%J-M)<OINFG4DLM7NVOM3T^WU,6@OK73[Z[=YI[
M.WGC@8N\:HL3O&WAH<&W#\VCK>*HP]YB$;:[A>JD6OXFD>6>,(U_,<YY%A5W
M%R=U\E6$G4S?J$,E+OWB=^J.W"S2UD:R=;U$RF8S@R&YGO">%%_E%S#YO,^-
MF,-$-H3&Q>L*#SJU_*3TO>]?4&U*,W3ZSJFOM)YC9 '5-8TT:1J$^S@;-LU@
M!$L.WA1-^4B1)/2KP+<$O#Q=[*GJ\7//,9@VVNB3&OYY-GX-DYW?9ZEM O'@
M3L\L)C1R5LG[@6\+@F;!ZB,RNR:*H)9K>MG^'=2VPJ)HU,#6;(ZV]NLC#3]O
MF:22",/+'"RAU21F4OZ3!B!BW^,_IB(["-+^UC.G/T?:":+2M+BNI(^BW#;0
M;:\NH[1;B]M-/DB2>*VNY)HFG'%D5V"[96IPL:162307B:RR">P0NT/4*G3N
M22DRC^M\=2C""N/WA;UC=*"8V$*CLK]0<*7N06;YO[]9J@:M?@EA, 3;O:Y$
M<>>#)=&]=?D<B;DF3=\H?)!"@"N/7IYTH1F=-057;2+K0MRVMH&&FWFM'I#<
M0J>#R=M6)N5F'Y5!B%'$/H5!!7 KP[!!V(T:#F3>R'9K]W$+[.V$N8"6T^1+
M$=<8@"R\D5?!$XMD<)M62(Q9LDHS<YI.L%U/]]OL/K^IR,6>6$[O.]Z^:VP2
M3SY46[,J+$%D,W#0L7!(905QU5RUQY5.F5U.9Y[K37W_ (<XT(T+1DMKK\9(
M;>#6S>6Z6*Q737XM8))6G61EEC#1E!Z->>9X(^'0XT29.XD;:H9?CEL5Q#3N
M< <I."V3-B&Q)K$9;F&D#'*30\W,";PNK&S%W8QMDMFV9(-FBBJ"F(]>U.-B
MPG1C_@Y0R6]O)P9+6W6UMYH-\3<&>.!%C$L>USC+$M@U5;>5#IG:R-+'J-K(
MX_!4EN;G2=*NQ87>B:9#HVEZCIPN;.46.I6FG016RWML(YY H>5Y) KB5+\*
MNCU\,TKQ)P@CG.IOL>R3&12(99"6;#B#J"2E^R4&E&BX])U&7J[%DT8*MFXA
M2Z;P4FS>(HKX4C5K\<Q,"?-X+;THXFS#;3K<0J0R,&VS*&)8$N,JY920>/7I
M[TI4AAJ",PTK2]%W2V=E/OT_1]1CU:PAE6>"1)FCOHDFDDE5WN!F*<R1,R&5
MZET=KW2B$D3@S$QB\F!1F8DYF124_+#QM\-%- 8W-\8D1 B^43'B639DU1Q5
MP3PPPS5RQS<+KK*TW=_<WQBX[)M@1DB2***&.-6<R.%2)$4;G8L3CK.!A0 -
M#I#TIUCI.]D=5EMS'IT$MO8VUG96FGVEK%//)=3B*VLX88E,UQ*\LC%2Q)"@
MA%15MVM.NNUK#087(PQ:/'&+<F$/#'X8P-=8>L:D!91JJQ(,7*?3;TV[MHNL
MW6PZ;>DFIE;IMTUD$J0P."""".L$'((_4:P0""",@@@CV@\B*YHA'!OI6%F<
M#;AG)9^NA A>KF;':4C=;!#,M?QTFU*Q*-H!9"FY&Y)Q)TBZN$+.6SB0WL6+
M*%2Y1P\]>G>]U*Z[1M0;S(>&NPEV!#-E>?I#&0,+Z(P!BJE@C4Y])O1" .=P
M" Y5<'EZ)SM)R1D\Z@[[@DAHN;:E)ZO(OM3177KCB-/D<($^QC\G>2W?LAB\
M@>/&:Z0MT&=B6>3 ^,Q%FF3IL*%+1YJ%014 C' ZP7;E)5D D:3@ ;QN4+"K
M* 1D$$Y4Y!YD-GY1J!MU#1E#PU3BD[>1)E(/L(P.8P<X&,=0Q?L#T'K+6C^%
MD(>&<CE=?:P4U#%$UBC\@F-A;@N).OT,LB"[EP\*%2@,4[+F7BZY$FLR14>+
MJJ6OG>AYI) X8YWR<5N0&7 ('5R  8@ # SRJU8T0KM&-B%%YYPI()Z_7E1S
MJS#\= RH;D&DH8:>$YO!1',:79H/V63\&59' SS)LYP42NY%F1H\JP6OCZQJ
M_9-G2.6"R*>>-88J<J2#@C(.#@@@C(]H)!^8D5,@,,, 1D'!&1D$$? @$?.*
MV3END[;.&JUKW1<H*MU;8WOCE=)9/)-2ULK=^-[X97M:]N^U^^U8'(@^RLGF
M"/;7.)GA5UL3A.DX,.*3Z(,>'MNT:ZN,PV8OP<F"MVD'(:ZLDX-8)K+$<7,3
M*/ASOK2>=U\E\E\KV5M;*VP+F0-*Y"/QSF0.N5)WA^KEC# $5484*QKEAPN2
M$,01Z)7K]?HDCG4]OIV,N6&KFAPI+)2\U%*U)K%3TED+DF?7D.<?E<8ZX>(W
MP2N9QP"S(RT30<)62PM=GG;'TVB=ZKXK R%0JB5=C*JX7;E6P!SQS13R^?VU
M+8,)DL=C;E).3G#+S/KY,1461X9-2M]< =8H"""02-3<9LD27P*N?Q8C/!>Q
M>U7"4J22_20<%'TVS<DRV2V6:!-!^_'.T%![Q9OE(W$AD:0D992A&/1V%.'M
MV]6 O(>S -1X*;0F#A6#@Y]+<&W[MW626YGVY-= U35M*4KG/8G#% MBRLW,
MU)!LR$FY?'1T1GN>M]@GH:TGT:$?>6(L9)V8Y;)')PP;F"K%I(0U@\J;CWRC
M%([@U2:I-[TN'10FV-U5BR<1%<HQQDJ3[=HRIRI(SC-5-"K,6RRE@%;:Q7<H
MS@'XGF,,/4:L#76H8%JE>4*00/\ <:$M<Q5P1'HN5E!S7"%0&*ZSC;,4U5RS
MQ'L1\0A@ ?BV1O?'-1JHYSODLNIE>#RO(%WG.W=@XYG>[2,2?62S$_V5)(U3
M=M&-Q4D>KT45!@>H!548^:MBXUQ%W.S1.W%6[J\T"P20ZX8.[/%L66$7D\@C
M,F+-U!]K]74=*EHB%52>96]<@DBLAA>V#A2U\<1N&8L^@7$A&!G<JLH.>OJ8
M\NJL[!O#_P X*4'LP2">7ZU%0Z?:!@.QG.RWQO.2,2.V-4C=,2XE'9$_!D,X
M*+(R\FW9BG3/+%42_P UYS(TUR;.^#M5L[31OG:S=*^,DF=.&!M(CD,JAAD;
MR%&2/6/07D?9\YJ+1*Y<G.701L0<':"3@$<QG<<D<^?S#$!'<(L"&1./1%O-
M=NYH0@V%D&N#"T\7R-ZU(@H^9BC7&$+8#TQXL:YC$@, "(9R-?B'XM[FW78Y
M631R3F;ERS/MC],,KC9Z+AF#>ESR2&4$'.01U]=1$"!54,^%(*'=S3 (]'ER
M&"01U$==7U ()&]90\%!8BT79@(^V509X/'KHF_<K.G3@@2)E";Y5=\4+F"C
MMZ5+DWJRKLB3>NWKE3-9?/*]+NTC%VQECSP  /4  ,      8   JQ55%"J,
M =7KZSDDD\R2222>9))/.IA4:E2E*4I2E*4I7RE\6/V;W%?Q([WV1M74\, F
MH66V#M<<R?OYO%P;E1V%W'L4<0PS'E"+9XGBDZ1SQPSS2M@KC:V:>5\;]-_5
M.BO2K1M*T:"SO)Y4G26X=E6WED7;)*SJ=R*0<@C(SRK[8\B7EJ\G_0KH!I^@
M=(-3O+74[>^U.>6&'3+^Y01W5Y)-$1-;P/&Q:-E) ;*GD<'.>;[?8S\?'RVB
MGF9!O9TWZ;?WYM^[_P"5=C_'OHY_29_ZI/X*]:'\);R2?GJ__P#H6J=63D?Y
M,/F^RLV^QGX][?\ 1M%?=_TF0:UO\UC/OO>_YT_'OHY_29_ZI/X*R/X2WDD]
M>MZ@>K_L/5/9[/-O7^WU4_8S\?'RWBO[O[ID&[O_ .:MT^_V_N_*GX]]'/Z3
M/_5)_!3^4OY)?SWJ'S?\A:KR_P#XXSZ^OYO96+_8S\>]_P#HVBOF;!ORZ.C^
M_-K='3W]_P"_V=-/Q[Z.?TF?^J3^"L'^$MY)#_VWJ _]#U4^K&/\F&0#SY]?
M/ESK:!/L6N.DB8&,"L.AD?&O7[1L_./-A19\U$,UEL$W)%=F*(/"3M-FCEFO
MDV8M'#I?T/013RSRQM:$G3WH\J.R37$KJK%8Q;2J78 D(&=0JEC@98@#.3RJ
MBZ_A-^2J&VN)8-2U.\FCAD>&TCT?4(I+F14)2!);B**"-I&P@DF=44G>S #
M^HOA)X2=7\'VKV6O=>LL71-UBW>S:;O6Z29^;R#!+T%"1'/')2[9BWOFHB%"
MHK9LQ#/*Z:>2[M9Z^>>1:UK5WK=XUU=-A1E8(%),=O%G(1!ZV/(NY&YVYG "
MJ/A#RA^4/7O*/KTNLZS+PX4+Q:9I<3L;/2[,ME8( 0N^5\*US=,HEN9!N8)&
ML44?4M<170Z4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*IK1'^!!S_MEXC/_ !";/I2KEI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*56Y77;@H1>$,=B;(%XNULEK#Q1P8W'-+9='^\LT%@3A5)''H_DX
MYKJY6Z;].=ZF'P,;$/SE<G_;4"N3G>X^8$8_V&M?V6.OFGMCQ$'Y<K/$^A'W
M?OK&SZ<G>'V?-_?)IV6.OFGMCQ$'Y<IQ/H1]W[ZSL/;?XCPT[+'7S3VQXB#\
MN4XGT(^[]]-GTW^(^RG98Z^:>V/$0?ERG$^A'W?OIL^F_P 1]E.RQU\T]L>(
M@_+E.)]"/N_?39]-_B/LIV6.OFGMCQ$'Y<IQ/T<?=^^FP]M_B/LIV6.OFGMC
MQ$'Y<IQ/T<?=^^FSZ;_$?93LL=?-/;'B(/RY3B?0C[OWTV?3?XC[*=ECKYI[
M8\1!^7*<3Z$?=^^FSZ;_ !'V4[+'7S3VQXB#\N4XGT(^[]]-A[;_ !'AIV6.
MOFGMCQ$'Y<IQ/H1]W[Z;#VW^(\-.RQU\T]L>(@_+E.)^CC[OWTV'MO\ $>&G
M98Z^:>V/$0?ERG$_1Q]W[Z;/IO\ $?93LL=?-/;'B(/RY3B?0C[OWTV'MO\
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DCE:^/K%L\$4L,E,LKXIX6O;&U9YD^KYAU5,<A[?G/7^VO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g518298g81i79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g81i79.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[14^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %2*^5! X0DE-!"4      !                      .$))300Z
M  #O    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    & $$ 4 !$ "T ,@
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 )3,S  !  ( E,S,  $  CA"24T$)@      #@
M           _@   .$))300-       $    'CA"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))301$       0     @   D    )      #A"24T$'@
M    !      X0DE-!!H      T$    &              ".   "1P    8
M9 !S '  ,  P #,    !                          $
M D<   ".                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   ".     %)G:'1L;VYG   "1P    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    C@    !29VAT
M;&]N9P   D<    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     "N\    !    C    "(   &D   WR   "M,
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "( C ,!
M(@ "$0$#$0'_W0 $  G_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,6%Q=H&6L<'P)2@R-#8W.$%%676'D9>FM=;_Q  < 0  !P$!
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M%Q!3KCS#1.7PW%+S@@9Y/@G$BGJJBE,QIY6B-13RTLVT*>I3S@++$=P/JN
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JSU$Q!DE>VYMJJBBP 4*B*J(J@*J*JJ H P:J% "BP'8#'?\ J/@\?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g518298g82k34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518298g82k34.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GR^5U8X0DE-! 0      $T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0 !%"97)N<RP@0G)A
M;F1E;B!#+@ X0DE-!"4      !"YI];QU]?MWA3X3[@_,JR>.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&CF\:         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE- _(       H  /_______P  .$))300-       $    >#A"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              =P   3D          $
M         0             $Y    =P                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   =P     4F=H=&QO;F<   3D    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   '<     %)G:'1L;VYG   $Y     -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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MFU_2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4K'!T0<5(T+A\18D,V*B<A<E)K(T-D-$4V2"DJ2ETO_:  P# 0 "$0,1 #\
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M"2A4!*\#2CP"W5#I[G 2LDDC)+2"70AY+S&YW$;++:>(&BT['8^0TCLKB?\
MM$/9;'R)<K"9/JV*Z36M&9)'+)CX4H=)#B=\)?L\DD;CBW(V0Q]W(X<5L5F?
MC ;C&6-X6P:?A":V:[GW]I1K*PETD']L=2FD*M-VXDR6LJU=O'$CIN.A0:$;
M)S8NFDDL8R?GMD43.<G\@AX0YN<3-]GQM1 <#1=G2"%\/$'.<7QDDEI;NVR=
M[7=_]E+)<;'BQ=4GCU0Z'V>U_(QLC3<:/3<;3=>S8L+'/VMV3QEV,^1D[RZ%
ML8C!WMK@/2[YN;;9T77=H'6&HE9+;EHT/%42OQ^XQDTPA-\+223%[>6+>H$L
M<!(5EPR1*[<,X1Y!6 SN13CGBCN+4:K5_E[>\R6F?('V=F0\S&%X]K$JVL<3
MPGB#@02\%GL\3:<*Y./V"T&36\S39]7UF+3=&TKM!EZI,S0<8OFRM*'&X8+9
M,V.":+)X3W;WY,9;Q-+@.,516_M+)6+V%9Z;:=5M65?J$WM.ES-J825J81K:
MT:CJ#RRV"3<R\Q26=.1J,F_BI:.8&9VJ0M3!G\D3,O7FZ,H5!.[]'C,$<T62
M;DCQY0RFO<P3R",-X6.=()&VTNXHV1N)+6O<6K;E_AMBMTG3\@:W//JF9I&G
M:S*T84/\N,&I:E%@0:=CY,>=+EG5X6RB:?&R<2&-S(IQ#([@XC9;/VGVPI.F
MVF00T*V>VBO7S6];")C+!;U4'$#L*B35Y1GBUU[1F>P9@8IO# T<,82K.73Q
MJ_;6)%).#3,NOG&A1=_"UV=3)(9I0]PC #H9 S@[P2B$%P)<.*4 .!8:?2ZA
M_A'@X^I8.+EZ_)C0YV%G302Q8^-.U^9C9<6"S%FE=E_8H&R.G/?2RSC[.8W1
M2@2 AM66]J$!E*$YKFHCS<?*T/7ETO)XE];IOY.^?%TDJ,K 5=_%Z^<0Y5ZY
M(1DHNY7O[^@(N'*1*VT2),%>HM\)T(D9#GYI9_S4T3.][N,AL4(D[QS9).+V
MQP@&-LQ!(<YP;P$Z#OX5/PWZICZEG2Z?EX.9K.F8K&8V$8'/T/3IM0@DSGQ9
MG?,CSFB./&9BQY4DDCPZ-CPX ]K'E;M#;O(7BB9BPBZ+JJV[GY*4Q*%97-Y(
M66W1^JZC<(<#[ KBD*Q9Q(#88DD]%-F<Q+!']-47ADG2Z7F!@8T&G:J>^=+E
M8\6"Z)[FD1M?D3@25)Q4X!A,9MK>(AQ;LQ=+([ Z+H/97MX_(F_G6I:;V8['
MZG#G112-TK$RM?S].R98</)>1)+D,@[^#(9-%$X&-SHV$12$5&T<H-I:EY*<
MD/-C65YU17-F<4**$=)VIZPD:4;<#1G6CNZ/#(0<BPD5AGI=O-S9)*4ADU2-
MB@V5.Z,H8 P,2;!TQPXVY<T.9)*2SBCD=CO<YH+BX%C>!A:7-:X NMPV"T,;
ML;IFM=E.RSH&9&'K&;HO;C6'2PX4.3#E#L\9L]@DDDFC<UY@A?&P1-DV+7N:
M ;.+=P>T&NESI?)BKU6NEI2M=TSM*YZUVC6)Z=<.'A-?; 9T=1XW>2=6B(MV
MO(N%??DY.K2\W%1R@.(CW]T\1<N$\^-I+()L%\Q#F294;)H?8XV!\/>4]K'O
M<T%MBI&,<X;D 6%UNS_\*X(]1[)9F:W)U3[;KNAZ=G:)E8@Q6D:KI<6M!Q,<
MLG 70->&QR<$SXV"41M:>$9 X\\C;1!7CD9;=_6:U2]<BMSUK3E$AJ?$["O[
M6$ZUI4;7XC56J5)TWB4'[-\C*2-O?$365FWDI%.7'NS6,=/]?4<.)^/ALP6M
M;*=.RYLI[G,B)<<[):'?U'@/<U@#&L9Q.+ T@&W!O*[:=CL.&#LOC]G\;&QW
MY^AY':/4G963CXH)Q];UK%[N)^5/&UXB9!'''%&7.<UL;J+G\(B_9>4&[(?6
M%X5@[O9U;:THG..8C[ _MRWR;$QE Y%Q5/AU4J\>O21']B@J\^,A4)-:39MH
M@B LSME$' N&O:&E:<,['+F1?9ADZ"QT?""'?:,$2SGO!(.%H<XB0%KC1NQ0
M:?=8G8#0I]<T=K\9T6#)J7\-,',QVPRO=([M%HDN3D 2?;XB(W2POMK8K((+
M3&0&OE9K#G#:87:5-T)*:]DK$E#6VBZ@M=[7G+Y/S+B[VNBM+>[LAYJ1I 5V
M4K3-P[28BA,6N+M[V/*>Q-X$8AND+KAY&GM9COR&2MX'!\K8SW8>V)N1P!O"
M)72,?S)(C+!7"7<1I?.M:[!Z<S3W:SC:F87Y>GZUKV#I[(F.QVX>GZG-I&#B
MY;V9$C\7-R<>%L[8Y6EI#V /D+BX9@V[OK;56Y(&U)K5.H*/K;-Z3J,>^O(V
MB7@(!.XZZY/7B9F$*]#3L611^S7U)$)E;QZL8:<(J9K*/VXHL).)Y,<-17R^
M\0*%[.:*VY5Q\^H!\R?D)D/>[[ AHVW L$T-J(!%>XUSH#+4!-3?(KBZE<;+
M+6'7EI9)7P91UJFV3]5 ;+K:<MU/>N(R4;+(R_S>EY* 5ETHF17<G(W<-V;U
M1TJU%PICCID_"*(<6BS1%%PN^8\=^0^B$%\8+@ YMD\Q9;?B17*]QRV/BHAZ
MTVYN"CZ,X\DIMN^>M_V?Q$/RLV%;.0UNM]NC%2U*F:P6G:O34D9-JK +SLO>
M3R:[XJ[B(K#%F=RO"S"CML1KD+"Z9S0#1>18WH$[>0LFO,?)2' ,!(NA= @[
M[^?7QJO=LKFK%KV3MJ^Z;D*GM:_SUQO$=J_9NWJW5G(P^FM&Z@M&JHY[*TN8
M9"I(D?7RZ3S]>=H;A5X;8;<[IM,JJLJ; B62MW;6 N<.7$T D@N=9;?2@WKY
M\B2HX[/"P5=&]J%;GIS/3GT.W-8OGI7;56A[O;=<;%W-/T^\<FZ#Q9H;.S;=
MDY!XA%5JVO:[M&]-;;;$)Q*I/;CL2-E-7L;!&L9%[ 5N)^5(%NYL<NV02NQL
M#[!L4QSB0W^[D!M6S1O>UGJ %#W2-HD--N H=-[OJ=]AL=MN9YR)B-[WFD<0
MMAW>+^4;/LK5VT)W6CB.VA9269J$\RW/'T=6$"^0$3 .[56XQC+E:P5O=PZ5
ME5:HM%+6P<6-I+M,PF)G>;B@1S#>E%UD&Q?78\K-@$*YD->QSW)%[C<-)L5^
MM'S6&KCR_P"1%?A]K,[C%:D<,:?<-ZZ0<R%&2O=>G7]UHF@+#NR O46L\L;E
M2"B_=&+*M.X%%V^F$GR:E@C[6U+[O%IW; Q_W"[DTFVUL2&T#6^]T:ZC;QIW
MI;]_A-75$GF+L675L.72N>ZN*0YQ;1KFN+QNQ>(U2XUG1Y2]:T9T.8GK(TV[
M:[MKNA+V!:7CYA9=W$/FLS+,7C]2JD@@EFFM$EK^>RO#-U(8([EE\+@ZZ!O@
MN@>8-B^E7=<71#(X"VE@'@7'G9Y"P+(%U0(&]]%('0.^MW[<I^Z(6R4N)KNR
M:8T9%I$G)U.STVNSKVU51S*UP9NE3MBD+5&L8N90*A(KA/H%GX)5O)1*T>NN
MJW:5DC;&UCVDT]SF@$406FKL4#TNN1!!Z7(>:HB_-NX\:-V/\;CP4>I3G7N&
MU5:-M>G=?P4A$ M0ZU9!>P%ANUIK%_<ZPE]C;3B&VO:]9*_:;HVHKB0H=.EV
MU4*ZG*R\>6R7D(J5;P9H\,KL<MV=L:O<T"+'"0=ZXF^U9VY40-R[QMT0;% @
MU8L75;;[U0W/7HI-VODLI4M-:(Y"OC5135=S^:K[:TW'C..(ZMP]ZI4FM7[#
M6G<BTA'QXTVRG%/K:I+#!M'JD78!<.&<5(M!1-B;#QO=&/O"Z!JW$$;"S1->
M9\AM2.DIH=6Q W;9KGOPBS6W.O(V%%*%YY[Y6N\'"3.FT0BX!_HR&V@QCZI:
MCK-Y'>S.N3!58^Y.9\E;JJE(C;G"L0@YN/G7M_G(2PL(AS!.%H]L7*<>,,<+
M)),@:*!:>$U]VCQ!VYL$ ;;5:"4$$D;TVR2 ?:%[@[@B]Q1WL>^RU^7_ ""3
MO^J-@/'6N5*]NKCM#VC6VNVTG86%;J4MN#?O'VA4B5VVJX<O3RLOK^/OSI"8
MGH L*G,2*EAJL?'1:[-&3=SW$%/A+'4RR74/_LP30HT+(! /(4[?IA,LUBG,
M]KD;\:&]\QN=VD<1]G8D$].T>5VYFNR"52P.HM"<ULXL=!N:=%D;'7Z'=I=;
MD5P)C(>TL&@2YYR)?1E,W;8H)]"O)^61:OWM@BG;V6AY)PV4PF*(<@:YWPC;
M9YY\(O<;F@=SMSO(R24FB?+<58XF 'G>P<:WW("D%$\D>0:%LL#]X]T_;].Q
M.Y]7:1CKE7Z/<*R>;M]PV5%52YM(!Y([%LT=.L*#%R!X>0L+9!M'KWWWJ':)
M."0$JACNXCLT.#Q9%@50:#?W00"+^"MWDE^T1PFNIO<\- <1%@U\;\%B6T<[
M]\I2&[7-1K>HG4/I*&Y5W.8"=2M2CFQ5;CAN)#7T=7(Y>+F_=H^<M<.X\YY.
MN$G<=$RC<[LM?>HJ),T9$.X#PZCPU0WLM+N1!Y50',\QLG>D %M7O=N\'!NV
MX\;OD.6ZO*S<R=Y5E:S:\=-M4_A5K][7C&IZ]1-MWU.=JH:DJ.U!<0FN*R[4
MG5!@E;>QKMJM$Q=(*MPS4&LZ9$[N4:UY.S88QOPNX:H<F[\5 7P^6P',]:!*
MJZ60[%S;!H\W4"T'E=WXV10%C<TK/U!R]W78G<AN9T6E.M5VJW<-XZ1UT_?S
MKV]5UUR5U7IM-9K09!-TC$L82M66\%L:C*5A'SFV($LYR+P"S!!X]F6.-@IG
M%9LF^1 =L??7/P^*HQSWD<5.HC=O,<6Q)Z@$\K!V]P6Y0/@'Z _/_?\ 7FJ.
M9^'Z_7]*6VN<E$PB81,(F$3")A%\*!V0?42^I?4/K#Q!]$?S&_HC^81P2 "3
MO_G;Z*"+K<C<';R-U[CR/EY[J ?+W=NP]+SE%?ZQ=0%HL4P2=1#19Z;;9ZZ;
M23;GB@]^J%BI;&=<U-6 %7W5W)6.N2%8 9=L$FZC^FBQNAA8\62US)Y7PQ4'
MF4/C#8R+X0YDDD?$UU;\!+_9V!Y+V_8GL[I7:*;-Q-5O2\?A+I.T0S,'&CTP
M M'VC)BS@UN5CCB(DQ\9WVN1W!W-AK@8V;.VSL")WYQ]MJNWY^JHVZ]:OI&T
MN/:MBHTM$ZI-=ZA)N&]/MU3AE7%GLEJN5G?1RR5[;F:1E881*Z@,7<<H55#H
M0X\$N!G0.TZ.=H@EECS."4.)CR(1Q-=M$V.)G%QQN#RXO'M-<+/K]&T+2\GL
MYVMP&Z7!GC2-/U3)TGM0W$U%N5JAQ)(V2Y,6;)-_+H<(8ULCT\0_:I<J>%K'
MVX,?G;B?S!LG(V\;4ITI3J?6B:C=JU2PN82^!:%)BYISDY%&?U5JG',S&H)X
MF+0.E8I 6[IW85Y.)(T[B'*XZ^=I3<*'&E;,^1N3#Q!AB>QL;6-8[A<7"C,7
M/<',:2&L$;O[Z7 [<]@X.Q6'V:S7ZC)J+NT>%@ZM&&XSV1X.'G843HL?*E+B
MQF?'-]H9/B %T#&12/(,S&J.4'S=V76;3LNC5*D,;HZ0NO-.RJO]E;+E!0AX
M/CY9JZ@G#PI8ND.%F<1)1TLLV@8 4UP@CD0(K+2*1G+@<C=-B= V:7(,1)PP
M&QQ6]WVHR^V"9*'=B,%SMK%  .H+OXO\-L7/Q-.RLG5'X\<DW8S2F08^'WG>
M_P#%#LMC)7GOPTR0'&(<2YO>B@UK7-I9WH_-RV[0FHHU4U_2XBF,HK12UP?7
M'9C*KVID]W;46%L8&IL3)PR<)86T C*,8\Z"TVRD[,\*^9P37WILDBZP/T^.
M"P9Y9G%\XID3G-+89"PE[@;:'<)>*8> %O$;7 U?L -'QW?:<K.?E9&;K>)I
MOV#3&YF*UFAZE'I\S\F5LI? Z0.F>!P$1B-O%0<2L(&]I5M!MJS3^P76EJV,
MANF-V98:K#14_?YUK'UK5;E1E.FGE:QK><DT9B:DA3+$$1C30D3& XE9^5:D
M24;DV3I$)RLF!N:YS<<XX,A8R-SG3,8ZFB25@X6<6_M&1QH,;O2]!/\ POTA
MNL=I<.#M!DR8/9271\+*><")F3F9>K9#<=TN)BC)#9L6!KA*^1DCGO86N$?M
M NNEG[2)]*;0UY5XO5R8U&XO:G7Y&=>3\JG/5BVVG4Y]I%AIA%>O(45H]C&J
MJ,6^A%;<G.H-_.GWC=A&G0%6\6CM=!D/.2>*!KBV/NPTSQMF[KB8Z^]+7.WX
M^[<PFF N<37/A_A;++H7:'4),Z>#-T/3\C7,1N4R%V'JNAXNNX^AOU#!C;F_
M:7RA\LKS 8&O:(O:;PO:]6'$>U,G5ZG892Q:7)!W9N_U>RJU0))W)<'[?:%C
M>UQG,2:'X.QEYZ'A'3$ZC:=U]&VUE9G2K6(ADRR2R)5[_P D/>1QMR(GL>Q\
MO?=[$.#NV![XRXS!D<CA37,F,999+C0=7H<S^"^%%K$./A]HG9.BNA[3329H
MP,)KIO\ AS3':F&Q1NSR8ILUK6]SCY63C3MXQ;'/!8JC8_:$;%V!0IV!I>MH
MZF7E/47(.W6>;M-JGZNP@FFJI%>I_*&OSRM,;S,K-R+MRA-,F=GAZT>$.W-%
M3/D/"JG0QQ:3##/"R?*=*UV1B-#(6-E<YLW"YW&6/X:C%MN,R V"P.!7*TS^
M'&!%J4>1G9\V5@8VJ=CL7N,7&#YG_P#$L;LI\<K1*X1M@;$Z"9S#)[9:!T"O
MZ\[3V^STU[.J>I\^K)W;9=RU%'V<DO.OHF/N?S@U'8Y&20M<BQ9RCL\<XDDR
M2\@5&.>.UG#-,Z"?GE*<M8L/%^V]H(GVS'QSE.PPT<4D19,QD=@EO/<6XT!9
M(6EI^B:"=6_B3CZC'-%B:'INJRX!CA[U\4V'JW#!&R&1T;'RNC'"ULCFM;8<
M\<(VQA8_:CRT72J=8&^I8*1DEXZ?D]@UQK;YIZM6(VO;=7T^JM$N8BF/4$HN
M8DV#U['REP4K#=R0J<.R1?NA/Y=H=&&1(]K<IWW7ACB &RN&*^<M]M[7%X--
MX6"0AU/Y$!W?P?X.XTVNZEI4FMY6-BX&1AQ8>H?RN!L;9INSHUYHEX<PR L#
M!%,V!LI9&))GEK&EK;(4W1O.6W1!5!K?Y8U">\_-^UJ91)8I]A-GH>L-/TZ[
M,J9&+0D3)/QK3!)S,RS. 9KF"=GS(Q3I).,>N5B;0Q=/;BR2]W_6BT3!<QX;
M89DRYPA+GN)%.+*:>(CA +A;FTNAE]D>S.+V6RY9-*[C58OX3=E=6QG N<S+
MUW5NUV1IV=J$]O C[S!E C+B&A[6. MP#O=R7YAR#NQ7RSZVL>U&5 AN)\C8
M#UI)&V:?G/GBAORBU<\RQ+;:F65CGQ(:6.P2F#UIPBZC#.FS,P^>=RVKI^EM
M,>/%E=TV>74&1B5QCFB;CNQ<A_"XQR!E\8:0TR!S2+H'9:W97L'AY&FXL&KQ
MX;-5SNWV!A#.9/#F8\>F#0=1S)(WR8F='$YKIH8G%OVJ,@LHD40[F+YC[HU7
M>]XO)Q@&P9"P<B+!J+7U=3FM@R]2J,'0M:P-V>B2NU37UDE#N74<^9@,M&0:
M[U_)O9UY,G;0< W<.*OTS!DCP(X9.Y<-.9-D.'=M<^63*E8!QR3,8T@#[KBW
MV.'@#N/:L_8#0-2TCL[DXN0_#BQNRN'JNN 10G(R)L_6=2TR".,3ZB0^2(X[
M))8R(2V Q/ >9 %-V8Y$REQT?QRVS"0\Q6%=J;*U0U>5N6?/VKR(9VE:2%^P
M<K1RL>,JV;K,#%32<)FCY-D9)=XQ,BJFGG!GQF8^3/ 91,(G.8'?VG@L<0%6
M _<T>K:&VZ^*:SIXT?4<S2_M RG8TSF-G8*8^-SB&%A)/%L!Q"SPDC>S2\W%
M/D+MS:4_6X+;D5KMH&P^->L^2%95H*%E8)PL=>'9V#ZL3J%CDY$TH]9'%@_:
MS,<$:W '#MFM'&,@WD'>-\+>$%H<6\9;R&[F[]/(CS]U4N6R6WBS51@W8V))
M-'D-OUK<;J%4?R-W=3XB J][NLX^;;;YA,BZ7OYE *Z+ 0G+W\&^R= S#U(I
M@67CZ6T"Q5<BRA59JBR]GC4$A0HKI0VR8(@_=IML0<2!XQEX-F[%D6-NN]&Q
MA,TEN (#2\ 6:NG .]QH6#X5U!NMZYY&\F)K3W#1:Q5FW1$5<-J?),WN5?8U
M4E5MC1I*GMYVG$RE<8.%+,BU?+Q3!P!'[7^9- (*K""WD -7Q0B26A]W[H((
MH^R!TW_N!LG<#I:R!\Q;'9!O[U;CD22.8'2MNOA=T7CYL'E>WTUJK?$'7]XS
M9&W']6W[!=<B-QT:6UOM^TSU&B%Z<.O6 7>?G*N]D;>Z^5FJ\B2CM#02SBO/
MD4I218$8G_9S))&1PAKRUK@VZ )&_*[%<^*CN?!(^^,<9-<3F N)H>U6_('D
M;!VO;H=U.;66^MN['X\[>M["!@)+=^K75MB4*8O3K[0C/;!!5>*M\-6K-0[4
M[5L=5G)Z-F&#5$C"R6F'<(R<58HF<D63Y1@VPF-HF;'8#'53P0X $U]X;;>&
MQVHBP5;C<(G$@D@NV((W VYT0#0HW1.X)YJ/M]YW[77@E-C:7J-0LNHG,I;E
MX6X.X"U7.24JU!J-*D)B<DZC3)Q.V%J3JZ6"R5N6V%6X.SLJ(G5T59&KS1YI
MJ*%OLY+@V9MNXFM  ;NYQVW-ML[;7[7B!NH[X42W< $T+.S1X $\SS -#8#9
M2GY \G2:1K6N-J/DXJ1U1:H.W$E)!J#Y=Z%I_!T^V#K0D0\\2#-6*MWS<FZD
M0'$>5X]L4_4T&:C<YUVR^..%TDDD?";AH^>Q#7'F?NW9^7B19TG"UCZV?SH7
M0 )IU?=NMK.Q(&YL*)"_/?>]3LDXE;=0-Y:O:UDFU!V.TJ]2M2*KB\L]4,]@
M6*2KUWE)IQ6F[9&9=!$PU"7BY2?EJYU8TK"+E9*)-G$+;!<=B+%7RL@&J)^-
MU?/95=+[)#:!! YBMZ(WL5=^'N-TK?C.3G)Z,WVSKTO-:FE9G=&M^-:&NXV-
M?6=QJ6A/MH2&^;-)669C#RRDU-S(P%-;5N/<QTS7F]Z=I5M5N2NI.731G?N8
M.%QX7BN+< W[/" .0 <2ZR"#0OF19QB26P+;T)'B#9)K<T.0HC?AY7M15>6F
MWY[>$'$/)-C#K,K-J/5=CC(64L:6MW=M9<N-JZBME[@&B4M'OUXJ<B:[&@YA
MY:1>))@@-<EE9(L:[<+8Q%$(S;2#QFP6D$C@:X>0%V2=_'E2S/D>2=P131=@
MU9<.= [#SWH#GNI!Z\Y.<@)2P41[:U=1V?5>QN0<1I2CW2ITVW4]>VQS:B[+
ML-ON$"A,;!MB#RNA9*?%UZI3/G&;6-%O.R[5HM%.8&1=0^)E?T^*P"7<6];B
MKIHH4>HZ_!8VRD_?X2#0!&UV#8YGF10W-['985#GGR%EX6R6JLUK3;B&I$;%
MSDRTFD[@#N<)/\MMR\<8EA#OXZ87;1B8PNO(2SNYAXUDR$E#2+=&-5:2K9:"
MLV%E'O ZSX#E;>*JZW8!Y;"[WI0Z5UD,+:!=L3L:-79]_/>SM6]JY]B\YMX4
M*#NL.Y8:ND-C:GD]OJW1"OT;;MN9V2MZQC:=-,I9A7*\\7'7%:DVEK-&3]YN
M=VD8VO2L<48R%LA7BB4='<--%EAIX:XJ;[1YCS.U@ "_+96;+LX//M GERH
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M\5664<4U?>=_^X>%?EM[E'<LY\+>N]M'OY5UZ>)]R]C9QP19Q41!LZQ6&L5
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M8/\ [/\ 4?8'Q^S_ %5R>!WA]1^ZGA/AY\QR\>:Y_E2Z,^/SOD.OM^8^P/\
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M7LN6Z;J&+CZ3D]G=*QXNS#(<>1L7:/![2Y6?F967"]W&QLF(YLAD9WCI99#
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M/*ZKW^%*S[-OXK<V)D;7#^UD1X@#1WY438Z#97_I7:-7WIJ^C[;J*;QO7+S
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M2321,():'MB?;G6\DA?7/X@]LOX7:\WLY%I_9S(FS=,PC!J$FD&#0M(G?W;
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M3.'L9INKS#$T?98:(<.69'! >7C6_ERV/GO_ *4L,*5UJE(9-0J@"*8D,!P
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MVXP#=I9I=Q58([YO N%GR[Z+35,E$F044#O+!&Z6:.-C2]\CFL8P4>)[K#
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M=35LY^<[#[S,R<HXV)#!"W(E?*,>.-H)A@$KW]U&UY<YL;.%H<2Z@25FP6Z
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M2F%]N872Q:. <$!<@B9-5,BJ?1O&0Q#E\93)F\0E,4Q1*)3%'PF 0$!ZSFM
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M?T[Z$O8AF;IF4^^[;'+0O@9-$YSO,!LAY#VCO9Y 6#5/^!>TDDCH\3$AU$M
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M-%N++O2%T=OYTE6L;6OW4EUM$S=V;^4B)8DRO (@Y>,5Y9M(M)Z=2;^%>OH
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ML;HU585G'@\A"%V!59)=83] 4$T6DJLJ<3"( 4"E$1[ .N\POPLR*S)BY+
M22^"1H ',DEH  ZWR7/S>SNOZ;((M0T/5\&4\H\O3LS'?X?<EA8[GY+*R#]B
MZ("C9XU<$'X'0<(JE']!DSF#ZA^OZLUR"" 003R!V)Z[#GRW7)DBDB-2QOC/
MA(QS#_Y +T>,G_S%_>#_ )Y"HN/-3 0 5" (^@!XR]B/V '?KBP.9I/]?'P7
MF=2+!D0JCQZT:)F431*=RX21(994P$22 RARE%10X@4A 'Q',( 4!'(:0]W
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MQ@<! 2]^@AV&2P.<XMYM(V:/O; EU>/]NU]-]E9I=; QKG/$C'!K 2\GB#:
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M0[U  (=)S&/F*Q!'S$5R' !#+#E3X\I,.3-&QS&W"VS$31W>#_3=Q;@AQ=5
MEM4LNC=H]<T&G:5GY6)Q&42L;D.;C2M>]X+9<8=ZR8D4:?!PGV?:V &#3\?-
M[:V<&<:'WU,NX),0 FL-_-Y+95=\I, !%I![#9K,=F5U-3P@D*LO,75HT2Z%
M.,,1--'-IN=C3M#<S CC>WV3DXG"R1]W[3X;,+R.?$UD3CU=U7HH^T79?5(S
M!VG[-.,[VNX-7[,9/\DS(Y+)#\C#DBRM-S1;GN<.YQ9'[ R BQTJ<F[IKU-2
M.Y"Z4N&K$VH+ ILBKH/MMZ:>+%3$47#FSU6++;:BQ\SP>:M=J-7FB28J">1.
M1,ZIH.GQRN:<'+9*QHL0R%D&2\$[-[J20M>ZP;;%+(\[>QN J-[&X>J/#NRG
M:'"UF,2M,^FZH_'T#M"T6VQ#C9N3)@YK]@UC=.S\I[RYA[L.+V,Q3[.?8O(;
M:<;NVW[J_!^^K<IL=^YUU.:^DH:7B99#RBHS2+)[!2$DW<PC-)&&0C'$F9K.
MG65D$Y1'WE,Q6^_V@QM-PSA18!R?M#L6(Y<>1'+&(I0T4 9&-+39=Q!H,8 '
M=FC2[_\ %+2^Q^D2=F,/L[C:IB:A'H+3KN!JC)&SPY<E.#I.\CC:9I27O>Z%
MIQGCA?"2QPXMH9?Z(>G7H'I]GI\/U9YY?*1R%>"YPI3")A$PB81?GQ]J]N;>
ME(VRWUGI2<L=A_"QQWDZU::G6=;<M[Q-:.8R%Y?GCN0M=;<:*=:H.7M$G+1R
M<+&5K8;NM$E$*.X91T\E7YJV,Y!ZW_)5)H'GS)L"_GOX5S\15=-\],.LI5:X
MHX</7:YX&'.L[D8WY&?N531Z!E%GL0** Q3M4YC*NHPR29F#@ZK44R"GUA2.
MO*NGZ^O?[U<^%*_.A_I+.M[E=N"#ZRUUI9G$%K29&S7):!K>MYJ.90SHT9$(
MKVB3O%KK]CK<0>0=MTTI/6<1;+0H\!-FXBD8I9T\1)Y>[]?7Y=5^A6M]_-^$
M['O_ *ICP[]/@#5( ^'I\.OAA%6L(J9,PT588M_"3D<REX>4:+L9*,DFJ#U@
M_9.4S).&KMHY(H@X;KI&,FJDJ0Q#D$2F 0'"'?UZ]<E%]2K[8T3X3ZZ:.MM:
ME;G _P"#.0D46^Q*.R2\1O(U[9I5=-G:X5J3PE:4^VNV4@S13\B)M:R)6T.#
MD*5?/W$T? >=?'EL-ST67=>;HU_LH[B/@YI-I9V!"'F*-/H.J[>X#QD W@G*
MA-(L9Q@!3>-,KH6BL<Y%,RC)ZY1Z4$K6LJ <AO0I@-\0]![^'Q]0]/3"+ZPB
M81,(F$3")A$PB81,(F$3")A$PBQ["ZZIM9E[+8:Y4Z_!3MO>$D+-+1,!%1TG
M8'S4BR;9W./F+=!U,.$B*F(@M(*N%2)F$@' IC :9G/G;C1S2Y$C,-Q?"TS/
M<UH>27,8TDM:WVC;6AH)J[*VI=1U'*@AQ<G.R\C&QFEF#!DS220X'$;=]GC<
MXMB:\@.(8T T+!)5S>X^]$ KMJ4P@'0>8<RG?7KZ^,>@]>A .A /4 Z$1RH+
M3NWO65T=1/YD'PY;^8*U&.F9=NX2?_PII6@@['8<'3G?/?XX[M6C-1W(AU+7
MJV@V90Y3><$U3JW*BX P^(Q5@D(UQY_C$ $P*#V(@ ]@8.PS-R<EI/=9$T3_
M .R0/>.!W,.%. ]D]+ Z+JX6O:YIE_R[6-4P :#A@YD^.XM&Y'$R0/KI[+@5
MB5YPPXY$."\)IVOUAP<H=/*4YF:*X:B/0&! E+F*^"(B >'MN9+P"/C*)3 '
M>U'J.H'V,C.?D#D1)$QP<!R'&_CJMB=B35#8KIM[<=J6.[QVJ3Y;@" _5,;"
MUC8\[AU*#(#CX$NMIIX-MW[C<48%HF!ZUM#D35G %\")HO>-WDT6H=^@IQ]X
MD;A&G\!?H@5TT=$,'],INLJ[4IFNK['A3M%>Q-!&&. V]IT0B>;\B">:S-[8
MY4LC9<_1.R^I$ V)^S^#AV3S).EMPGDFK/\ 4HGI1-TPW'_=T6X(K6.6.T?"
MGXRIM;K2]0W!IX!$#)@Y59TNK2J_A$.C"G+I&5()BB(' JI+.SL:0-+]&Q(S
M8XCB9.1"\@<P3*_(8&G8T& \0!!V-CV@T.>0NS.QVF@$$%NE96=IQ-D'>2>?
M46%M<F" 'B]HOH%CL"\BN%>]N3D)4*%MG?%9D:%!W.-MLB-&UG,Z^N#TT:W>
M,Q0++$V19:YXQ;R"RC/WJJN!;/$TWC==NZ125)T\#6\;3)7Y.%ISF3OB,-9.
M4W*8P/(M[ ,>&0&@0\B:G-<6$%I(7J^R'\0>SO8?4L[6="[(&34Y]&U#3,:+
M6=19JVF-=FQMC?++ <#$D:]C;,);*07&G"K#]D\%'EBF*$<D5R#=BU:,VYW;
ME1VNHDT1!N4ZKE81675.5,#JK+&,HJ<XJ''LPAGGB27.<>&G.+@&MX0"XV[8
M>R+.^WQ7RN60RR.>X-XW_P!1[F@-:7RDO<QH% -C)+6@"FBFC8*M9"QIA$PB
M81,(F$3")A%K@]I?RILW#G4.OMYQDO3VU/K6YJPTV=7;-M'5&GY.[TR4A+.T
M3K-1N>YW;"CI3 V8T!,2,8M)Q$Q)UB)G$8658O2^,7YJ.OJ_6WAOS!7J]EA;
MAOW"[6%Z-(ZNE?GC*[5M8OM/S-#LM/.G8]P7N901>675[5CK^P7UHB\*VVC-
M5%DA!RVQ4[,^9%$BHF%Z*#\J'3Y?KR WV52=>T%I;ZNS\OK[4^Z-H3D=O>9T
M#7Z#7*I%UR\W6SUS7T=M.P3<##[(GZ4W9U*,HKQU,(R]G?U]:<+')I03%^I-
MP!))Z]>MNJ7\M[_/UXC?WUO5O._7NWMGUBBU&G;'/4;RQ:DI&YI&!BFFM+1<
ME-81.ZI#6[(Y9]6WM+3$ZOF$;"[=RE38U=1Y'S]=96!Y/P3U@!+\:W.WQ^//
MW<^BUK^V!N$9KOE1P0V99F*S^C5W7O,:/E"K,PD(M6Q3D#IYI3V[R.5 2J$7
MDT5RF<G143:(@HLH9) 5%![N@:9FZGF!F&T'NJ?([B#71L<YK20207$MX@UK
M02=]N5_6OX0=C.T/;#7LQFA\#8M.Q\7*U&6;-9BQ,QCG0-_I ASG3@![VF-I
M< PN!!:WBVW<)J@2A\1^.E6*A[N=AJ*E.7:0IBD?Y1F89M.2BBQ#&,<'"TC)
M.E7 G,)S+G4,<1,(CFCJDSY]1SI)'-<\Y,S7%@IMQO,=-%#9H: -NEKQ?;+(
M.5VL[23F1TO%K>I-[Q\O?%XCRY8@X2D-XV$,' >%HX.$   *46:"\TF$3")A
M$PB81,(F$3")A$PB816E=:C5KO79&M7*!C+-7I-$Z+^%EV"$@R=$\!S (MUD
MS@"R9@\U!8G@606*55%5)0I3@4?X_P!>O'Q6I/A_N/>CU]NV6H&K]A3^MZ->
M&\"OJ[9]DE)#8<9' ,B(M]=W>SG1:R,E7F[;S);6UG%,[4LC'$CKH .&K(7Y
M>OC[OCX)9N@.@Y\_G9L[?Y6TG6FWZ+M6,=/ZI, JZBW(,)^O2;5Q#6RKRGA$
MRD3::Q(%1F(&23\)O^COVJ15TR^\-%7+4Z:YB ^.WA>WG^7QVL^64,*4PB81
M,(F$3")A$PBISY!!P@H1<PBD B*A!Z,4X"4/HB4P" @'?H'78#\!^ 8!=8+3
MPD'F:(_7UX=(XCQ L?(US3SB<6.W_P"X?7RL':U@O2+ZGK?A%8U#Y*!HWV--
MNCMX4K5)NF219QBWOAD6W@3\+IXD[,"A2>%58B_0B<JHAL3]Z>"2=Y=4;7-+
MBX@M V LN)]D7OM54*76UAV8^3#ERWR32RZ?BQ-ED=Q2,BCC:(VO<XV2UM#K
M>U\PI"!\ _0'Q^/Z\UURAL /!<X1,(F$3")A%^:3VRD?L=#D-K&U4"/VW!RK
M+24LV@G^L1YONU=^6-I=WL@VXY1KWB/L*I0&K;,]((S378FUHRRQYRV!BM&Q
M+F.J=D3</7B/E1]>:C;?8^?Y>/Y=*)VW7Z-::1PG5JZ1VR?QKM.!ATG4;*2)
MIB2CUTF"!%F<A+G47-*OFZH'2>2)G"YGSDJKHRIQ6$1*?U5S81:#_P#2*)"O
MMO9X[0:R^K=OW^3?-D&U<M.N49E2GZHD0E(-=>W;?/&V>!8)4YVS*M#M#3<9
M:F7RXZ8>7$H.!2>$)Z]>O%;U:UW\WH3L1$?DIAV(E\(^C9/ZO[@'U[#U['OL
M2*MX1,(N! ! 0'U 0$!#\P_'"+'5]U+KG9:;0;K4HR:>QHB>'F@*K'66"6'U
M!S7[/&*LI^"=D$ ,1U$R3-<A@ Q5 '"BA54/<>2Q:37&\J"H*FM-K$N\&GZD
MHV\VYIA9-,#=E:0VU:V@SML<F!  A7-Q@]F/!,(F.L'P,3E0K:O'W#:_*[V^
MJP-2>07).G;FV*ERDU[':_T@HS;_ (/;#46$M?8V*?(.44CA/6VL1[H[9@]9
MG<.7TE;(6K(-722";-!)'WPB!-[W_+E\?@>8%]%.2IWVE7N.3EZ5:H"V12H
M))*O2C.79=CU_-G<L55DDEB]AXT5#$5)WT<A1],)8'KUZ]ZNW"E,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6F;VSCV=C-/Z)
MDZ/97=5VFWY&PS?54EY_'2&K?SN?:UV4R=I7.X\H:S;M6U*!4J"UE$CUS7Y>
M9DYI.(A(6/</G_B1*!SO]^>W^/=NI)^R]V))[4X7:FNDU:I^Y33Y;8$=.3MB
M@-.UYXYG*YLRX5B819(Z"AX+44S7F$I#/&55M](C&L9=:XC&VA4AG<HL<2#G
M?3W>-<CUY<_<.FU9M7"Q>3=VNQTC<ETU?L&;Y"S7(6"O-=A*A,NJM,V74T/I
MBPUI.!ML;.5^;@I"FQKM5,\JP,_83[UG*M5P)$),W#U\U%$'8 7S\JY>'Y;>
M:MO7OL_*;K2TU]PSOMUGM/TJ+<J5?1MA:T]S5&ELDM)QG'JPVV2FVT TLTVG
M-ZP8/FRM6DI%2MM;!9+/.(L@]\B6$(3<[D"]_.N@WN_D/@%^9?VDM2XOZYYI
M06F=!P/%RL)U#6V]HF[:[T31I&K[!I\Y::UILNO%]X.#/G$#*RH/IB9F=<JQ
M43&$CF)I4ZI'2YESE]+V3FR(-8AD@E,8:0Z9I?W;'Q1W*6O)(:YK@QP(-_-?
M8?X)965C=ML9L>HSZ;ARZ9J\N?+$Y_#(S$PWY,$,D; 2\23Q-CH@\(>7$M )
M'[6*E&(PM9@89  *C$1+"*3 "^  )'-4F9?"'0!X>D0\(E#PB7H2^G6>;<\2
M/D>+]J65V_4F1Q/OW)^*^3Y,AFR)YG.+G2S2R.<;MSY'N<YQL [N).XO=7#D
M+ F$3")A$PB81,(F$3")A$PB81=2Q3&)]#^D ]AWUU\!#H>^NP]?4 $/J]>N
MP$A\ME8=%J]AK:EB4GIN&F33<RXF4/DFNOJ_[DH\*F#ENM[W:K*#TG:27D*$
M!D9$"J)F!9,401**^7ZW?KG9\*WLO9NA:Q?9%O;X9])Z[VE&-2MH39]+.@QL
MC=NDJ"Z45.(+IK1-QK1U@ SBN6=E)1QBBH=H#%X9)Z@3KX;<]KOT/#?RI6-'
M[SM.KY%C5>3$?$5I-XX;1\!NJNE<IZIMCI=3RFS2<3=F=/=7V1T(=%BK"^?5
MYZMXB0]K=KJ$CT"6?"_EROS//GY&N8Y"5*"Z+E(JS=4BR1P 2*)F Q#E$ $#
M%,'H8H@("4P"(& 0$!$! <*5VX1,(F$3")A$PBX\)?7T#U'L?SC\,** -];N
M_->5)HFB90R92E\?B]"%*7^D(^HC\3"'8^HC@G;87\?\;=2AXG$%[B[A% 'D
M!R 'E7^RO7CZ*4PB81,(F$3"+0YRIXN<T[+>^9U,UIKBN[*J?,IQK%Q1N0$I
MRANNIY3BF37%5@HNLM":[B:Y+R<LUU_L9E/;B@%-=3<4K<Y:T/H.WIM6B"+Q
M=Z]>_JJU?S._GXUL#1\N>ZWEU]@]BX6)CY*24F9%E&1[1_++)D15DWC5HDBZ
MD54D@!--5\N11RHFF )D,J)" !2@&%;U^RC?S4V1M337%O?FW]/DJ*ERU=J+
M86PF!;L$BM!HDI52F+*[<&CXI$'4J](WC#DCHQ1_%LW;U1#WV2;-4E2JE!VL
M^ _+?EY]3S\%IP_T@+G#J[5?"C<_&"]U/<K?8._=:5:.U]>V&IK*XTO,3[VU
M1DTK6C[3*F2LM[''Q5=?/Y6#*NK(1[-Q'N7")&[Y$^.8M/'W^O7^E^A^O"48
M"$$H>$/DF/Z#KP]=-$@'T_3W^GXA\<*56,(F$3")A$PB^!33-\2%'L?$/H'J
M( (=C]H]#\?^08180M/'35%FEU;,A73U"X+^(5;IKV3DZ%:EC_2$BCR6JSF-
M/+BDH85"HS:<FU,(F*HW.50X&*"!ZV_+?RY]2K0?P7(#5\9(R</LVN;6K<4S
M<R"L1MB+"KVAM'L4E'#CR=BT.)68K^2W(8W4IK:1=+&)VI( )O0E\@>=>._G
MMM\_?LL6:+]H'J/<5,/=7T!L&AP+216A9.S3E6E):A,)5HW:NG*+F\5]J^C(
MAJ1J]9N2O;:WJY54EP4*F'@6*D0$5?U]_OW'^15J:5;MU8N,4TG*G8(:S0S\
MHG9RT!*,)F-<D#KLR#^-<.6BI>C (^6L80^ @!@$,(#?KUZY;*XL*4PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+43[0&\RM;W!K6"W/
M2;O=^$MBUAL]K>XJC\9G?*)M);T6>59AK%GL"H0=0OMD@("%C'L[9JE+,JZ$
M-)7&/2C+&_;)!'MY)U]^W0;^N?NZ*/']=]O=M[OE=J2/LY"[=+Q!T^GO"NKU
M2]LHJ=B$85]1(?5TTG0X:WV"-U5(6;6E>\,'K^W3>LF]3F;;38ULP;URR/Y.
M*)&QP-?<&I!ZWO\ /U^0G+A2NEQ_[!;T[_FC^@#X1'Z(_7T;K]/A'\P#\,(O
MRU^U/L#*R<Y..&G"[9T]L!S<IRTPK76]*K4)';0TDK*S_'R$.AM"::WZRO)9
M:WJ6@L]75)O7M3418Q*S9J$LAXU#;N!CORYG01RF!PAGR"\$M!9CPOF>UQ -
MVUA %$%Q;9:"7#T79C&S\O4WMP\U^"V#2M9R)WM/"Y\<.!+D.8#1+SPPD-;=
M<3MZ:"X?J.8)"BT12,8QQ(40$YS>,QO4>C";HOQ#KT   /@4    -(/#P'@4
M' $#K7G77QY[]3S7G "  YQ>X !SCS) WO\ <[D;G<KV84IA$PB81,(F$3")
MA$PB81,(F$3")A$PBI<Q"Q,]'/XJ9C(^7C91FJPD(Z3:H/6#]DN4Q%FCQHX3
M50<ME2G,51%5,Y#E$0$.APBA7?\ 7.W./E2L$[QXLJTA08F-=2;G3UB51D7%
M<2:)&776U58IM&2.P:D IE/F'. O"+ID,TK\E63J)  ^O7KQ4 5ZZ=.:D5J/
M;E/V?#J)P4U).K#7Q1CKA7[-$FK5XK,QY)%3LK=4UT&;J">*E,*C<?="1C](
M/>8AR]8F2<')Z/EUZ^_HLO84IA$PB81,(F$3")A$PB81,(F$3"+\ROMA-ESM
M?Y7:UJ[W9#BJTP^A3SS6+F^6/,CC155+.ML.PLG3Z,)Q/HEL<6.Q#&,&*$H:
M^N4&R$:E%DJZ"1BSJCAM_CZ?3GX?DJ[V3N.8%$57GL2=NAZGWK]'6OU/-I54
M5\XKCS*W!'!<LC(2_FE-%M1!096620E9+QA]('\F@C(NP$'#Y)-THJ0"FJO<
MD=+^/KF55;+7(*X5V>J5HAXRPUJT0TG7K# 3;!M*0TW!S3)>.EHB6C'J2[.1
MC))@Y<,W[%VBJV=M5E6ZZ9TE#E$I7YO?])MBEUN$4![E#OY$L;:USN7;"JO)
MMK#-A9LDTG$G+-M([0;5)D)C$00E7]WT@V46.DQ3O;MPLG!O2#P]>?4^/+HO
MTB5SKYOPG0=!\E1_IT =#[JEW\/3X]]_;\<(/5^@JSA$PB81,(F$3")A%\G(
M10IB*$(<A@$IBG*!RF ?00,4P" @/U@/H.$5!K53J]-C A:C6X"K0X.'+L(F
MN0T=!Q@.WBAEG;D&$6W:M07=+&%5PMY7FK*")U3G,(CA/06(K%QJU1,RKRR0
ML(YUQ<'YC*NKGJJ4?ZZLCQP<1$R\NYJZ[!G9#"/0F2M+"<:J" "LV4 H )17
MN'NYW]+ \[OP"MTM;Y+4%)0L%>*EN^'03,#:(V&P-K^\>6 AY9!O=19R-:DW
M!4^RD%YKV*%8P +B0 QCJ"2CXWZH[_E5?F5[4>2D# )@EM^G732[LGA36?V^
M-2DJ0980['W?8=56FZF@W,;L$33SZ!='#PB9DF)@+A!X?GSVZK/,#8H&T1S>
M7KDS%3T2[3*JUE(:0:2D<Y3,'8';O6*R[=8O0@/B34,'J'0CA2JSA$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:W_ &E'(S<G'+6NKG^C/D].
MY;)W)&:_<O5=)[#Y#R\="GH]WM3Y] :FUI8:E/6-^DI5&R;YRK8V+.'A%)&3
M,WD%VB+0Y1[O7^^2S[PVO.Q-E<>Z/=MKN5WE]FCV4)UVYTM<N/:ZYH^V3D:Q
M,?4M_G[1:ZOU&M&0$&5G7QI@@%FVHH,I%LW2*!UZ^[E\OGR\-S84H\*R^%#
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MX"/F*[!2T7!O"*&CR+*D',[5X>?H]>O7DIT84KK5,<B:ADR"H<I#"4@==G,
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3PB81,(F$3")A$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971707600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Spyre Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4312787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Heidy King-Jones<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968614032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 188,893<span></span>
</td>
<td class="nump">$ 34,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">150,384<span></span>
</td>
<td class="nump">20,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Development receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,251<span></span>
</td>
<td class="nump">6,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">341,528<span></span>
</td>
<td class="nump">62,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">341,859<span></span>
</td>
<td class="nump">71,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">CVR liability</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">13,108<span></span>
</td>
<td class="nump">12,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">16,584<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,978<span></span>
</td>
<td class="nump">14,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current CVR liability</a></td>
<td class="nump">41,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">73,288<span></span>
</td>
<td class="nump">20,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 400,000,000 and 20,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 36,057,109 shares and 2,614,014 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">763,191<span></span>
</td>
<td class="nump">475,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">302<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(764,414)<span></span>
</td>
<td class="num">(425,624)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">184,016<span></span>
</td>
<td class="nump">50,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">341,859<span></span>
</td>
<td class="nump">71,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">184,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 150,000 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.</a></td>
<td class="nump">84,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971526448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">36,057,109<span></span>
</td>
<td class="nump">2,614,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">36,057,109<span></span>
</td>
<td class="nump">2,614,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series B non-voting convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Series B non-voting convertible preferred stock, authorized (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series B non-voting convertible preferred stock, issued (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series B non-voting convertible preferred stock, outstanding (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">1,086,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">437,037<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">437,037<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">8,763,659<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968841776">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">$ 18,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">89,504<span></span>
</td>
<td class="nump">58,579<span></span>
</td>
<td class="nump">57,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,946<span></span>
</td>
<td class="nump">28,531<span></span>
</td>
<td class="nump">27,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">130,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,449)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,189<span></span>
</td>
<td class="nump">87,110<span></span>
</td>
<td class="nump">84,388<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(242,303)<span></span>
</td>
<td class="num">(84,781)<span></span>
</td>
<td class="num">(65,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,147<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,130)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(96,513)<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(338,816)<span></span>
</td>
<td class="num">(83,951)<span></span>
</td>
<td class="num">(65,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (338,790)<span></span>
</td>
<td class="num">$ (83,815)<span></span>
</td>
<td class="num">$ (65,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (49.12)<span></span>
</td>
<td class="num">$ (24.86)<span></span>
</td>
<td class="num">$ (25.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (49.12)<span></span>
</td>
<td class="num">$ (24.86)<span></span>
</td>
<td class="num">$ (25.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,897,065<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,897,065<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contract Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of forward contract liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (83,530)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=syre_DevelopmentFeeAndRoyaltyMember', window );">Development fee and royalty</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">$ 6,739<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $48.5 million in related party expenses for the year ended December 31, 2023 and no related party expenses for the year ended months ended December 31, 2022 and 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=syre_DevelopmentFeeAndRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=syre_DevelopmentFeeAndRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971663216">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 89,504<span></span>
</td>
<td class="nump">$ 58,579<span></span>
</td>
<td class="nump">$ 57,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 48,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $48.5 million in related party expenses for the year ended December 31, 2023 and no related party expenses for the year ended months ended December 31, 2022 and 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971503408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (338,790)<span></span>
</td>
<td class="num">$ (83,815)<span></span>
</td>
<td class="num">$ (65,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (338,440)<span></span>
</td>
<td class="num">$ (83,843)<span></span>
</td>
<td class="num">$ (65,832)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962679184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Conversion Of Series A Non-Voting Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Non-Voting Convertible Preferred Stock</div></th>
<th class="th"><div>Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</div></th>
<th class="th">
<div>Series A Non-Voting Convertible Preferred Stock </div>
<div>Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Conversion Of Series A Non-Voting Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Conversion Of Pre-Funded Warrants</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Conversion Of Series A Non-Voting Convertible Preferred Stock</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 139,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">$ (276,008)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,801)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">83,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(341,809)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering', window );">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering', window );">Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs</a></td>
<td class="nump">42,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock in connection with employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock in connection with employee stock purchase plan</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (83,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">2,614,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 50,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(425,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Series B Non-Voting Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,972,000<span></span>
</td>
<td class="nump">905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (202,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs</a></td>
<td class="nump">197,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract</a></td>
<td class="nump">189,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Issuance of common stock in connection with private placement, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueNewIssuesOne', window );">Issuance of common stock in connection with private placement, net of financing costs</a></td>
<td class="nump">84,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock in connection with the asset acquisition of Spyre (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock in connection with the asset acquisition of Spyre</a></td>
<td class="nump">3,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan', window );">Issuance of common stock in connection with exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ContingentValueRightDistributionToCommonStockholders', window );">CVR distribution to common stockholders</a></td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Issuance of Parapyre Option Obligation warrants</a></td>
<td class="nump">11,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (338,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(338,790)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,037<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">36,057,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 184,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,927<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 763,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="num">$ (764,414)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ContingentValueRightDistributionToCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value right distribution to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ContingentValueRightDistributionToCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Common Stock And Pre Funded Warrants Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodSharesNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, New Issues, One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodSharesNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues, One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622960047312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (338,790)<span></span>
</td>
<td class="num">$ (83,815)<span></span>
</td>
<td class="num">$ (65,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">25,675<span></span>
</td>
<td class="nump">7,111<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">130,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="num">(16,449)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Lease ROU asset and leasehold improvement impairment loss</a></td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net (accretion of discount) amortization of premium on marketable securities</a></td>
<td class="num">(2,318)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease assets</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="num">(335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Development receivables</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="num">(815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">218<span></span>
</td>
<td class="num">(2,641)<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,245<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
<td class="num">(1,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">575<span></span>
</td>
<td class="num">(880)<span></span>
</td>
<td class="nump">3,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,326)<span></span>
</td>
<td class="num">(435)<span></span>
</td>
<td class="num">(404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(4,891)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Related party payable</a></td>
<td class="num">(2,402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(99,910)<span></span>
</td>
<td class="num">(80,144)<span></span>
</td>
<td class="num">(53,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash assumed from asset acquisition of Spyre</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of in-process research &amp; development asset</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property plant and equipment</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(166,803)<span></span>
</td>
<td class="num">(39,500)<span></span>
</td>
<td class="num">(133,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">39,900<span></span>
</td>
<td class="nump">96,546<span></span>
</td>
<td class="nump">111,033<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(108,393)<span></span>
</td>
<td class="nump">57,008<span></span>
</td>
<td class="num">(22,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series A non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs</a></td>
<td class="nump">197,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of Series B non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs</a></td>
<td class="nump">84,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in connection with private placement, net of placement and other offering costs</a></td>
<td class="nump">84,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Payment of contingent value rights liability</a></td>
<td class="num">(5,786)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts', window );">Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,874<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from employee stock plan purchases and stock option exercises</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligation</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
<td class="num">(510)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">361,077<span></span>
</td>
<td class="nump">42,678<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</a></td>
<td class="nump">152,799<span></span>
</td>
<td class="nump">19,436<span></span>
</td>
<td class="num">(74,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">36,416<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
<td class="nump">91,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">189,215<span></span>
</td>
<td class="nump">36,416<span></span>
</td>
<td class="nump">16,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre</a></td>
<td class="nump">189,741<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Series A non-voting convertible preferred stock into common stock</a></td>
<td class="nump">202,178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LeasedAssetsObtainedInExchangeForLeaseObligations', window );">Leased assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative liability</a></td>
<td class="nump">18,986<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contract Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative liability</a></td>
<td class="nump">$ 83,530<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LeasedAssetsObtainedInExchangeForLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leased assets obtained in exchange for lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LeasedAssetsObtainedInExchangeForLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants in public offering net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622964248032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Assets Acquired and Liabilities Assumed<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Total current assets</a></td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accrued liabilities</a></td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net liabilities assumed</a></td>
<td class="num">$ (17,012)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622967600176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. The Company and Basis of Presentation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc., (&#8220;Spyre&#8221; or the &#8220;Company&#8221;) is a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with inflammatory bowel disease. The Company was formed as a Limited Liability Company (&#8220;LLC&#8221;) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. On November&#160;27, 2023, the Company completed its corporate rebranding, changing the name of the Company to Spyre Therapeutics, Inc. The Company operates in one segment and has its principal offices in Waltham, Massachusetts. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company effected a reverse stock split of its Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to the Company&#8217;s Common Stock disclosed in these financial statements have been adjusted on a post-Reverse Split basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. As a result, in April 2023, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#8217;s existing headcount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets of Spyre Therapeutics, Inc. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Pre-Merger</div> Spyre&#8221;) as disclosed in Note 7 and 8, a privately held biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). The asset acquisition was accomplished through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> reverse triangular merger whereby a wholly owned subsidiary of the Company merged with and into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, which existed at the time the Acquisition Agreement was entered into, became a wholly owned subsidiary of the Company in accordance with the terms of the Acquisition Agreement. Immediately following this merger, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre merged with an into a second wholly subsidiary of the Company (&#8220;Merger Sub&#8221;) in accordance with the terms of the Acquisition Agreement and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre ceased to exist. Subsequently, Aeglea BioTherapeutics, Inc. was renamed Spyre Therapeutics, Inc. and is a different entity than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, which ceased to exist upon merging with Merger Sub. The transaction was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from the Company of 517,809 shares of common stock and 364,887 shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $0.0001 per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a 40 to 1 basis), in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Asset Acquisition&#8221;). The common stock and Series A Preferred Stock related to the Asset Acquisition were issued to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre stockholders on July&#160;7, 2023. For additional information, see Note 8. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock (the &#8220;Series A PIPE&#8221;) to a group of investors (the &#8220;Series A Investors&#8221;). The Company sold an aggregate of 721,452 shares of Series A Preferred Stock (the &#8220;Series A PIPE Securities&#8221;) for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million of placement agent and other offering expenses. For additional information, see Note 11. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right (&#8220;CVR&#8221;) was distributed to stockholders of record of the Company as of the close of business on July&#160;3, 2023 (the &#8220;Legacy Stockholders&#8221;), but was not distributed to the holders of shares of common stock or Series A Preferred Stock issued to the former stockholders of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre or Investors in the Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by the Company for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-year</div> period related to the disposition or monetization of its legacy assets for a period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> following the closing of the Asset Acquisition. For additional information, see Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2023, the Company&#8217;s stockholders approved the conversion of the Company&#8217;s Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock to Common Stock. For additional information, see Note 11. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, the Company completed a private placement of shares of common stock and Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $0.0001 per share (&#8220;Series B Preferred Stock&#8221;) (convertible on a 40 to 1 basis) (collectively, the &#8220;December 2023 PIPE&#8221;) to a group of investors (the &#8220;December 2023 PIPE Investors&#8221;). The Company sold an aggregate of 6,000,000 shares of Common Stock and 150,000 shares of Series B Preferred Stock (the &#8220;December 2023 PIPE Securities&#8221;) for an aggregate purchase price of approximately $180.0&#160;million before deducting approximately $10.9&#160;million of placement agent and other offering expenses. For additional information, see Note 11. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a preclinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its inception and through December&#160;31, 2023, the Company has funded our operations by raising an aggregate of approximately $896.2&#160;million of gross proceeds from the sale and issuance of convertible preferred stock and common stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, the collection of grant proceeds, and the licensing of its product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of December&#160;31, 2023, Spyre had an accumulated deficit of $764.4&#160;million, and cash, cash equivalents, and marketable securities of $339.3&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on current operating plans, the Company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements with existing cash, cash equivalents, and marketable securities. Spyre will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970952992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Description of the Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of the Business and Summary of Significant Accounting Policies</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Description of the Business and Summary of Significant Accounting Policies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, Aeglea BioTherapeutics, Inc. (&#8220;Aeglea&#8221;, the &#8220;Company&#8221;, and &#8220;our&#8221;) acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Acquisition Agreement&#8221;), the assets from Spyre Therapeutics, Inc (&#8220;Spyre&#8221;), a privately held biotechnology company advancing a pipeline of antibody therapeutics through a research and development option agreement (&#8220;Paragon Agreement&#8221;) with Paragon Therapeutics (&#8220;Paragon&#8221;). Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, Aeglea effected a reverse stock split of its Common Stock at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> (the &#8220;Reverse Split&#8221;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this statement have been adjusted on a post-Reverse Split basis. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction (the &#8220;Asset Acquisition&#8221;) was structured as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stock-for-stock</div></div> transaction pursuant to which all of Spyre&#8217;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from Aeglea of 517,809 shares of common stock and 364,887 shares of Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock, par value of $0.0001 per share (&#8220;Series A Preferred Stock&#8221;) (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Aeglea common stock and the Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option (the &#8220;Option&#8221;) to exclusively license certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;). The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing a portfolio of combination treatments that simultaneously address different mechanisms of irritable bowel disease. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $113.2&#160;million, which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and 517,809 shares of common stock, valued at $291.08 per share and $7.277 per share, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Option, at the fair market value determined by the board of directors of Spyre (the &#8220;Parapyre Option Obligation&#8221;). In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of common stock of the Company on the same terms. For additional information, see Note&#160;3. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div>  <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">730-10-25-2(c),</div></div></div> intangible assets used in research and developmental activities acquired in an asset acquisition should be expensed at the acquisition date if there is no alternative future use in other R&amp;D projects or otherwise (i.e., if they have no economic value). The Company determined that product candidates pertaining to Spyre had no alternative future use at the time of acquisition and recorded $130.2&#160;million to Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> Research and Development Expenses as of the date of acquisition. The difference between this amount and the $113.2&#160;million cost to acquire Spyre represents the net liabilities assumed of $17.0&#160;million. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of acquiring Spyre, and based on the criteria in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#8217;s full financial statements are not material to the Company&#8217;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> and Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#8217;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#8217;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#8217;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option to exclusively license IPR&amp;D. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#8217;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of the Company&#8217;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;22</div>, 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">023,</div> Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#8217;s insured limit were $2.8&#160;million. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Liabilities</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the business and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622969882720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#8217;s financial statements relate to the valuation of consideration transferred in acquiring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research&#160;&amp; development (&#8220;IPR&amp;D&#8221;); the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was comprised of shares of the Company&#8217;s Common Stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the Series A PIPE securities, <div style="letter-spacing: 0px; top: 0px;;display:inline;">which</div> was a financing event involving a group of accredited investors. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All investments have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any unrealized losses from declines in fair value below the amortized cost basis as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consisted of money market accounts held by financial institutions as collateral for the Company&#8217;s obligations under a credit agreement and a facility lease for the Company&#8217;s corporate headquarters in Austin, Texas. The lease was terminated in August 2023 and the cash was subsequently unrestricted. Remaining restricted cash balances relate to the Company&#8217;s operations in the United Kingdom. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company&#8217;s two U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000 per depositor. As of December&#160;31, 2023 and 2022, balances at the Company&#8217;s U.S. banking institutions exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shorter of remaining lease term or estimated useful life</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. The Company recognized a $2.6&#160;million impairment loss for the year ended December&#160;31, 2023 related to its leased office space in Austin, Texas (see Note 17 for additional information). There were no impairments of long-lived assets for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Research and Development Costs </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>development expenses, with a substantial portion of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> research and development activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for expenses resulting from obligations under the Paragon Agreement and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. Historically, the Company has not experienced any material deviations between accrued and actual research and development expenses. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Company&#8217;s restructuring, as described in Note 17, the Company had lease agreements with lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. As allowed under Topic 842, the Company elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for any leases involving real estate and office equipment classes of assets and, as a result, accounted for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. The Company also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses fair value measurements to record fair value adjustments to certain financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three levels of inputs that may be used to measure fair value are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto">
<tr>
<td style="width:9%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.</td></tr></table></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments carried at fair value include cash equivalents and marketable securities. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License revenue </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s contracts may be modified for changes in the customer&#8217;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">an adjustment to revenue on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis. The cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#8217;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the cost of stock-based awards granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock Issued through PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company classified the Series B Preferred Stock outside of stockholders&#8217; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock on the last trading day prior to the holder&#8217;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#8217;s control. Additionally, the Company determined the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">&#160;</div><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Milestone Proceeds </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes contingent milestone proceeds associated from the sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development assets in earnings once the achievement of the milestone becomes probable and payment to the Company is contractually required. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Value Rights </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#8217;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2023 and 2022, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2023, 2022, or 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#8217;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#8217;s functional currency and the reporting currency. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the cash conversion and beneficial conversion feature models in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20</div> that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted earnings-per-share for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> requires the if-converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> to all Series A Preferred Stock and Series B Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A Preferred Stock and Series B Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-07,</div> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 &#8211; Segment Reporting. This update is effective beginning with the Company&#8217;s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-09,</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. This ASU will have no impact on the Company&#8217;s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income <div style="letter-spacing: 0px; top: 0px;;display:inline;">tax</div> disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622974644400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables sets forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair <div style="letter-spacing: 0px; top: 0px;;display:inline;">value</div> hierarchy (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:58%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183,491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">336,953</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;31,603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;46,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures the fair value of money market funds on quoted prices in active markets for identical asset or liabilities. The Level&#160;2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level&#160;1 and Level&#160;2 during the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had no financial liabilities outstanding measured at fair value. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Forward Contract Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company entered into a contract for the issuance of 364,887 shares of Series A Preferred Stock as part of the consideration transferred. This forward contract was classified as a liability because the underlying preferred shares were contingently redeemable. Further, the forward contract </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">liability was considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability and was initially measured at its estimated fair value on the transaction date based on the underlying price per share on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis of the Series A PIPE Securities issued in the Series A PIPE. Subsequent remeasurement of the fair value of the forward contract liability through its settlement date was based on the market price of the Company&#8217;s Common Stock, which represents the redemption value of the Series A Preferred Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the forward contract at the transaction date, June&#160;22, 2023, was $106.2&#160;million. The liability was settled with the issuance of the Series A Preferred Stock on July&#160;7, 2023 for $189.7&#160;million. For the year ended December&#160;31, 2023, $83.5&#160;million was recorded as Other (expense) income in the consolidated statements of operations in connection with the change in fair value of the forward contract liability. There was no similar expense for the year ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the forward contract liability for the periods presented (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Forward&#160;Contract<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of June&#160;22, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A Preferred Stock on July&#160;7, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(189.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVR Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-transferable</div> contingent value right was distributed to the Legacy Stockholders, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the Investors or former stockholders of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre in connection with the Transactions. Holders of the CVR will be entitled to receive certain cash payments from proceeds received by the Company for a three-year period, if any, related to the disposition or monetization of the Company&#8217;s legacy assets for a period of one year following the closing of the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June&#160;22, 2023, as a Common Stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability will be recognized as a component of Other income (expense) in the consolidated statement of operations and comprehensive loss in each reporting period. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of regulatory success, and discount rates, which represent a Level&#160;3 measurement within the fair value hierarchy. The significant inputs used to estimate the fair value of the CVR liability were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated cash flow dates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2/28/24&#8201;-&#8201;06/22/26</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated probability of success</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">39% - 100%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated reimbursement rate compared to reimbursement target</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">81% - 100%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-adjusted discount rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5.91% - 6.32%</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value between the issuance of the CVR and December&#160;31, 2023 was a $19.0&#160;million increase, and was primarily driven by changes in the expected timing of achievement of certain milestones, changes in the likelihood of certain milestones related to the approval received from the European Medicines Agency by Immedica Pharma AB (&#8220;Immedica&#8221;), partially offset by a change in the likelihood of a successful disposition of pegtarviliase and updates to expenses and deductions. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the CVR liability for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CVR&#160;Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at CVR issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in the fair value of the CVR liability since issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,786</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622974640880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Cash Equivalents and Marketable Securities </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,955</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79,186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;&#8199;&#8199;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;20,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2023 and 2022, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect they will be required to sell the securities before recovery of the unamortized cost basis. As of December&#160;31, 2023 and 2022, an allowance for credit losses had <div style="letter-spacing: 0px; top: 0px;;display:inline;">not</div> been recognized. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December&#160;31, 2023 and 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were $0.3&#160;million unrealized gains on marketable securities for the year ended December&#160;31, 2023. There were no realized gains on marketable securities for the year ended December&#160;31, 2023, 2022 and 2021. Interest on marketable securities is included in interest income. Accrued interest receivable on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt <div style="-sec-ix-hidden:hidden103883038;display:inline;">securities</div> totaled $0.9&#160;million and $0.1&#160;million as of December&#160;31, 2023 and 2022, respectively, and is excluded from the estimate of credit losses. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in 1 &#8211; 2 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current assets. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970677664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Property and Equipment, Net </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2023, 2022, and 2021 was $0.7&#160;million, $1.4&#160;million, and $1.4&#160;million, respectively. All of the Company&#8217;s long-lived assets were located in the United States. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Assets </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. As a result, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#8217;s existing headcount by June&#160;30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $0.5&#160;million. After recording the disposal of all the Company&#8217;s property and equipment net of proceeds, the Company recorded a $0.7&#160;million and $0.2&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622974448608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedAndOtherCurrentLiabilitiesTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Accrued and Other Current Liabilities </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622972353952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedLiabilitiesTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Accrued liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622972423776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Related Party Transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC each beneficially owns less than 5% of the Company&#8217;s capital stock through their respective holdings of Common Stock and Series A Preferred Stock of the Company. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than 5% of our capital stock, has two seats on the Company&#8217;s board of directors and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount has appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div> <span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Related Party Transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parapyre Holding LLC (&#8220;Parapyre&#8221;) each beneficially own less than 5% of the Company&#8217;s capital stock through their respective holdings of the Company&#8217;s common stock. Fairmount Funds Management </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LLC (&#8220;Fairmount&#8221;) beneficially owns more than 5% of the Company&#8217;s capital stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, has two seats on the Board and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Asset Acquisition, the Company assumed the rights and obligations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, which included the $3.0&#160;million research initiation fee and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company recognized expenses related to services provided by Paragon subsequent to the Asset Acquisition totaling $48.5&#160;million, which included $11.4&#160;million of stock-based compensation expense, and were recorded as Research and development expenses in the consolidated statements of operations. As of December&#160;31, 2023, $16.6&#160;million was unpaid and was included in Related party accounts payable and other current liabilities on the Company&#8217;s consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company made payments totaling $39.5&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;12, 2023 and December&#160;14, 2023, the Company exercised the Option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expects to enter into the SPY001 License Agreement and the SPY002 License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, we expect to pay Paragon a $1.5&#160;million fee for nomination of a development candidate, as applicable, and the Company expects to be obligated to make a further milestone payment of&#8201;$2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of expenses related to the Paragon Agreement recognized within research and development expenses, which were ultimately settled in cash (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Paragon Agreement, the Company is obligated to issue Parapyre a stock option grant on the last business day of 2023 and 2024 (the &#8220;Parapyre Option Obligation&#8221;). See Note 15 for additional information. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of Related party accounts payable and other current liabilities (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party accounts payable and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December 2023 PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The December 2023 Investors included Fairmount, a related party. Fairmount&#8217;s participation in the December 2023 PIPE was approved by the Company&#8217;s board of directors. Fairmount&#8217;s investment accounted for $10.0&#160;million of the $180.0&#160;million gross proceeds raised in the December 2023 PIPE. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Mark McKenna Option Grant </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;1, 2024, the Board appointed Mark McKenna as a Class&#160;I director. Mr.&#160;McKenna and the Company are parties to a consulting agreement, pursuant to which Mr.&#160;McKenna agreed to continue to provide consulting services as an independent contractor to the Company, with an effective date of August&#160;1, 2023 (the &#8220;Vesting Commencement Date&#8221;). As compensation for Mr.&#160;McKenna&#8217;s consulting services, on November&#160;22, 2023, he was granted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options to purchase 477,000 shares of the Company&#8217;s common stock under the Company&#8217;s equity incentive plan with an exercise price of $10.39 per share, which vest as to 25% on the one year anniversary of the Vesting Commencement Date and thereafter vest and become exercisable in 48th equal monthly installments, subject to Mr.&#160;McKenna&#8217;s continued service to the Company through each applicable vesting date. For the twelve months ended December&#160;31, 2023, the Company recognized $0.1&#160;million in stock-based compensation expense related to Mr.&#160;McKenna&#8217;s consulting agreement. There was no such expense for the twelve months ended December&#160;31, 2022 and 2021. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970044832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Asset Acquisition</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Parapyre Option Obligation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. The Parapyre Option Obligation is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liabilities. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> who provided <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing services within Research and development expenses. As of June&#160;22, 2023, the estimated liability of the Parapyre Option Obligation was $0.1&#160;million and was included in accrued liabilities. </div> <span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Asset Acquisition </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger Sub&#8221;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, pursuant to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was the surviving corporation and became the Company&#8217;s wholly owned subsidiary (the &#8220;First Merger&#8221;). Immediately following the First Merger, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Asset Acquisition, the Company determined that Aeglea was the acquirer for accounting purposes under ASC 805. The primary factors considered were a) the relative voting rights in the combined entity not resulting in a change of control, b) legacy members of the Company&#8217;s Board of Directors maintained control of the Board of Directors, and c) the only change in the composition of senior management was the appointment of a new Chief Operating Officer. Next, the Company considered whether the Asset Acquisition should be defined as a business under ASC 805. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">805-10-55-5A</div></div></div> through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">55-5C</div> describe a screen test to determine whether an acquired set of assets and activities is not a business. We determined that substantially all (greater than 90%) of the fair value of the assets acquired were concentrated in a single asset, Spyre&#8217;s Option to license intellectual property rights related to SPY001, SPY002, SPY003 and SPY004 pursuant to the Paragon Agreement. Accordingly, the Company treated the Asset Acquisition as an asset acquisition for accounting purposes. Even if the transaction would have failed the screen test, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre lacked the financial resources to have inputs, processes, and outputs to constitute a business under ASC 805. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company completed the Asset Acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre, in accordance with the terms of the Acquisition Agreement. Under the terms of the Acquisition Agreement, the Company issued 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock to former <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre security holders. In addition, outstanding and unexercised stock options to purchase 2,734 shares of common stock were assumed from the Amended and Restated Spyre 2023 Equity Incentive Plan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the acquisition date, the Company recorded forward contracts to represent the obligation to issue shares of the Company&#8217;s Common Stock and shares of Series A Preferred Stock. The forward contract related to the Common Stock was recorded as Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital as the instrument is indexed to the Company&#8217;s Common Stock. The forward contract related to the Series A Preferred Stock was recorded as a liability, as the underlying stock has a cash redemption feature. On July&#160;7, 2023, both the shares of Common Stock and Series A Preferred Stock were issued and the forward contract liability associated with the Series A Preferred Stock was settled accordingly. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the Option to exclusively license IPR&amp;D. The Company determined that the Option to license IPR&amp;D was a single asset as the Company&#8217;s strategy relies on developing the entire portfolio of individual treatments to create combination treatments that simultaneously address different mechanisms of irritable bowel disease with a single treatment. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the cost to acquire the asset was $113.2&#160;million which was recorded as acquired IPR&amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of Common Stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis) and 517,809 shares of Common Stock, valued at $291.08 per share and $7.277 per share, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by the Company</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622969951472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paragon Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OptionAgreementTextBlock', window );">Paragon Agreement</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Paragon Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2023, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre entered into the Paragon Agreement with Paragon and Parapyre. Pursuant to the Paragon Agreement, the Option provided for the right to acquire the intellectual property rights related to four research programs from Paragon in accordance with a license agreement to be entered into following each exercise of the Option. Under the Paragon Agreement, the terms of such license agreement would be consistent with the economics and other terms set out in the Paragon Agreement and, in the event of failure to reach an agreement on the definitive terms, the matter would be resolved via arbitration. In consideration for the Option granted under the Paragon Agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was obligated to pay Paragon an upfront cash amount of&#8201;$3.0&#160;million in research initiation fees. In addition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, which included the $3.0&#160;million research initiation fee and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. Furthermore, the Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year, during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Asset Acquisition, the Company assumed the rights and obligations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre under the Paragon Agreement, including the Parapyre Option Obligation. Pursuant to the Paragon Agreement, on a research <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">program-by-research</div></div> program basis following the finalization of the research plan for each respective research program, the Company is required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million. For the year ended December&#160;31, 2023, the Company incurred $48.5&#160;million, in costs reimbursable to Paragon, which were recorded as Research and development expenses in the consolidated statements of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company made payments totaling $39.5&#160;million to Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;12, 2023 and December&#160;14, 2023, the Company exercised the Option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expects to enter into the SPY001 License Agreement and the SPY002 License Agreement. Our Option available under the Paragon Agreement with respect to the SPY003 and SPY004 programs remains unexercised. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, the Company expects to pay Paragon a $1.5&#160;million fee for nomination of a development candidate, as applicable, and the Company expects to be obligated to make a further milestone payment of&#8201;$2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY003 or SPY004 research programs, the Company expects to be obligated to make similar payments upon and following the execution of license agreements with respect to these research programs, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OptionAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OptionAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971797440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Company&#8217;s restructuring, as described in Note 17, the Company leased certain office space, laboratory facilities, and equipment. These leases required monthly lease payments that were subject to annual increases throughout the lease term. Certain of these leases also included renewal options at the election of the Company to renew or extend the lease for an additional <div style="-sec-ix-hidden:hidden103884648;display:inline;">three</div> to five years. These optional periods were not considered in the determination of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has both operating and finance leases. Variable lease expense for these leases primarily consisted of common area maintenance and other operating costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, the Company entered into a lease agreement (the &#8220;Las Cimas Lease&#8221;) for its corporate headquarters and laboratory space located in Austin, Texas. The Las Cimas Lease included approximately 30,000 square feet and commenced on April&#160;30, 2019, with an expiration on April&#160;30, 2028. The Company posted a customary letter of credit in the amount of $1.5&#160;million as security, which is subject to automatic reductions per the terms of the Las Cimas Lease. A tenant allowance of up to $1.0&#160;million was provided by the lessor and fully reimbursed to the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $2.0&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease including terminating the associated letter of credit. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s recognition of its operating and finance leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="-sec-ix-hidden:hidden103884638;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total leased assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="-sec-ix-hidden:hidden103884635;display:inline;">Accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating and finance leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the lease costs pertaining to the Company&#8217;s operating leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities during the years ended December&#160;31, 2023 and 2022 was $0.5&#160;million and $0.9&#160;million, respectively, and was included within net cash used in operating activities in the cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had no operating or finance lease obligations. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622967166432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders' Equity</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Convertible Preferred Stock and Stockholders&#8217; Equity </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 410,000,000 shares of capital stock of which 400,000,000 shares are designated as Common Stock and 10,000,000 shares are designated as preferred stock, all with a par value of $0.0001 per share. Each holder of Common Stock is entitled to one vote for each share of Common Stock held. The Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Common Stock are entitled to receive dividends out of funds legally available if the board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that the board of directors may determine. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, no Common Stock dividends had been declared by the board of directors. As of December&#160;31, 2023 there were 437,037 shares of Series A preferred stock and 150,000 shares of Series B preferred stock outstanding. There were no shares of Series A preferred stock or shares of Series B preferred stock outstanding as of December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registered Direct Offering </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued and sold 430,107 shares of Common Stock at an offering price of $40.00 per share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase up to 694,892 shares of Common Stock at an offering price of $39.9975 per warrant (representing the price per share of Common Stock sold in the offering minus the $0.0025 exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> The net proceeds to the Company from this offering were approximately $42.9&#160;million, after deducting placement agent fees and offering costs of $2.1&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">June 2023 PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2023, in connection with the Asset Acquisition, the Company issued and sold 721,452 shares of Series A Preferred Stock at approximately $291.08 per share through a private placement to a group of accredited investors. The net proceeds from this offering were approximately $197.3&#160;million, after deducting placement agent fees and offering costs of $12.7&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December 2023 PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the Company issued and sold 6,000,000 shares of Common Stock at an offering price of $15.00 per share and 150,000 shares of Series B Preferred Stock at $600 per share through a private placement to a group of accredited investors. The net proceeds from this offering were approximately $169.1&#160;million, after deducting placement agent fees and offering costs of $10.9&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Warrants </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company settled its 2023 obligations under the Parapyre Option Obligation by issuing Parapyre 684,407 warrants to purchase the Company&#8217;s common stock, less the $21.52 per share exercise price of each warrant. As of December&#160;31, 2023, none of the warrants issued under the Parapyre Option Obligation have been exercised. See Note 15 for additional information on the Parapyre Option Obligation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase shares of Common Stock in underwritten public offerings at the offering price of the Common Stock, less the $0.0025 per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#8217; equity within additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of Common Stock may not be exercised if the holder&#8217;s ownership of the Common Stock would exceed 4.99% (&#8220;Maximum Ownership Percentage&#8221;) or 9.99% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of 19.99% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase Common Stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Warrants<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Asset Acquisition and the PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Designation, holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to-Common</div></div></div></div> Stock basis, and in the same form as, dividends actually paid on shares of Common Stock. Except as provided in the Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules (the &#8220;Conversion Proposal&#8221;) or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company held a stockholders&#8217; meeting to submit the following matters to its stockholders for their consideration: (i)&#160;the approval of the Conversion Proposal, and (ii)&#160;if deemed necessary or appropriate by the Company or as otherwise required by law or contract, the approval of an amendment to the Certificate of Incorporation to authorize sufficient shares of Common Stock for the conversion of the Series A Preferred Stock issued pursuant to the Acquisition Agreement. In connection with these matters, the Company filed with the SEC a definitive proxy statement and other relevant materials. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock automatically converted into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0.0% and 20.0%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;26, 2023, the Company completed a private placement of 721,452 shares of Series A PIPE Securities in exchange for gross proceeds of $210.0&#160;million, or net proceeds of $197.3&#160;million, after deducting placement agent and other offering costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued 364,887 shares of Series A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition that closed on June&#160;22, 2023 which settled the related forward contract liability. For additional information, see Note 3. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2023, the Company&#8217;s stockholders approved the Conversion Proposal, among other matters, at a special meeting of stockholders. As a result of the approval of the Conversion Proposal, all conditions that could have required cash redemption of the Series A Preferred Stock were satisfied. Since the Series A Preferred Stock is no longer redeemable, the associated balances of the Series A Preferred Stock were reclassified from mezzanine equity to permanent equity during the fourth quarter of 2023. In addition, 649,302 shares of Series A Preferred Stock automatically converted to 25,972,080 shares of Common Stock; 437,037 shares of Series A Preferred Stock did not automatically convert and remain outstanding as of December&#160;31, 2023 due to beneficial ownership limitations. This conversion was recorded as a reclassification between Series A Preferred Stock and Common Stock based on the historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> contributed capital amount, inclusive of any forward-contract valuation adjustments, of the Series A Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;8, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Voting</div> Convertible Preferred Stock with the Secretary of State of the State of Delaware (the &#8220;Series B Certificate of Designation&#8221;) in connection with the December 2023 PIPE. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Series B Certificate of Designation, holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-if-converted-to-Common</div></div></div></div> Stock basis, and in the same form as, dividends actually paid on shares of Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#8217;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">winding-up</div> of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has agreed to use its best efforts to obtain stockholder approval of the conversion of all issued and outstanding Series B Preferred Stock into shares of Common Stock in accordance with the Nasdaq Stock Market Rules (the &#8220;Series B Conversion Proposal&#8221;) at its 2024 annual meeting of stockholders, which the Company agreed to hold no later than May&#160;15, 2024. The Series B Preferred Stock is recorded outside of stockholders&#8217; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock per share of Common Stock underlying the Series B Preferred Stock, on the last trading day prior to the holder&#8217;s redemption request. As of December&#160;31, 2023, the redemption value of the Company&#8217;s outstanding Series B Preferred Stock was $129.1&#160;million based on the closing stock price of the Company&#8217;s Common Stock on December&#160;31, 2023 of $21.52 per share. The Company has determined that the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Series B Conversion Proposal, each share of Series B Preferred Stock will automatically convert into 40 shares of the Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;11, 2023, as part of the December 2023 PIPE, the Company completed a private placement of 150,000 shares of Series B Preferred Stock in exchange for gross proceeds of $90.0&#160;million. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622969896064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Strategic License Agreements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Strategic License Agreements </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immedica Pharma AB License and Development Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2021, the Company entered into an exclusive license and supply agreement with Immedica Pharma AB (&#8220;Immedica&#8221;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">i.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Deliver an exclusive, sublicensable, license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (the &#8220;License&#8221;) to develop and commercialize pegzilarginase (the &#8220;Product&#8221;) in the territory comprising the members states of the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#8220;Territory&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">ii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#8220;PEACE Trial&#8221;) and related Biologics License Application (&#8220;BLA&#8221;) package to file with the United States Food and Drug Administration (&#8220;FDA&#8221;), which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">iii.</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Perform a Pediatric Investigation Plan trial (&#8220;PIP Trial&#8221;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company and Immedica formed a Joint Steering Committee (&#8220;JSC&#8221;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#8217;s participation in the JSC does not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement do not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Finally, Immedica will bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#8217;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Phase 3 Trial and BLA package performance obligation in exchange for the reimbursement of up to $3.0&#160;million of the actual costs incurred in relation to such incremental services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> payment of $21.5&#160;million and Immedica agreed to provide payment of 50% of the Company&#8217;s costs incurred in performing the PIP Trial up to a maximum of $1.8&#160;million. In addition, the Company has the ability to receive additional payments under the agreement of up to approximately $120.8&#160;million in regulatory and commercial milestone payments, assuming an exchange rate of $1.07 to &#8364;1.00. The Company is also entitled to receive royalties in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-20&#160;percent</div> range on net sales of the Product in the Territory. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that Immedica meets the definition to be accounted for as a customer because the Company is delivering intellectual property and other services within the Company&#8217;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in making these determinations, the Company considered the following factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and were conducting the ongoing PEACE Trial. Accordingly, the Company is not promising, nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The License represents functional intellectual property given the functionality of the License is not expected to change substantially as a result of the company&#8217;s ongoing activities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The services necessary to complete the PEACE Trial, BLA package and PIP Trial could be performed by other parties. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that Immedica was not obligated to purchase any minimum amount or quantities of the Product, the supply of the Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#8217;s option to purchase the Product does not create a material right as the expected pricing is not at a discount. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the upfront fixed payment amount of $21.5&#160;million must be included in the transaction price. Additionally, the Company determined at inception of the arrangement that 50% of the estimated costs to be incurred in relation to the PIP Trial exceeded $1.8&#160;million and included the full reimbursement amount of $1.8&#160;million in the transaction price. Upon subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluation</div> due to changing facts and circumstances, the Company determined the estimated costs are now less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized to date. Additionally, upon the modification of the agreement in July 2021, the Company determined that the estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeds the maximum allowable reimbursement of $3.0&#160;million. Therefore, the Company included an estimated total of $3.6&#160;million that will be due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $25.1&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has allocated $9.6&#160;million and $3.5&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#8220;SSP&#8221;), which was based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $12.0&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potential regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain regulatory approvals, which might not be achieved. The Company determined that the royalties and commercial milestone payments relate predominantly to the license of intellectual property and are therefore excluded from the transaction price under the sales-&#8201;or usage-based royalty exception of ASC 606. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price as necessary. The Company </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">will recognize the royalties and commercial milestone payments as revenue when the associated sales occur, and relevant sales-based thresholds are met. The Company assessed the arrangement with Immedica and concluded that a significant financing component does not exist. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> necessary for Immedica to benefit from the License in June 2021 and recognized $12.0&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations will be recognized over time using an input method of costs incurred related to the performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2023 and 2022, the Company recognized revenue of $0.9&#160;million and $2.3&#160;million, respectively, related to the PEACE Trial and BLA package performance obligation using a cost to cost model. The Company recognized revenue of $6.7&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model and $12.0&#160;million related to the transfer of the License for the year ended December&#160;31, 2021. As of December&#160;31, 2022, the Company recorded deferred revenue of $2.7&#160;million associated with the license and supply agreement with Immedica, of which $0.5&#160;million was classified as current. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was zero as it was internally developed. Accordingly, the Company recognized a $16.4&#160;million gain within Gain on Sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which is comprised of $15.0&#160;million in upfront cash proceeds and the reimbursement of $1.8&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> manufacturing costs that was contingent upon a favorable opinion being received by the CHMP, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities totaling $0.4&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will reduce the CVR liability and will be distributed to CVR holders pursuant to the CVR Agreement resulting from the Asset Acquisition. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Contract Balances from Customer Contract </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,271</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had no contract assets during the years ended December&#160;31, 2023 and 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971797440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pegzilarginase to Immedica<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Pegzilarginase to Immedica</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">&#160;</div><div style="font-weight:bold;display:inline;">13. Sale of Pegzilarginase to Immedica </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was zero as it was internally developed. Accordingly the Company recognized a $16.4&#160;million gain within Gain on sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which is comprised of $15.0&#160;million in upfront cash proceeds and the reimbursement of $1.8&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> manufacturing costs that was contingent upon a favorable opinion being received by the Committee for Medicinal Products for Human Use, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities totaling $0.4&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. Accordingly, the Company will recognize any future milestone payments once the contingency is resolved and payment is contractually required. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to CVR holders pursuant to the CVR Agreement resulting from the Asset Acquisition. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622969896064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Novation of Manufacturing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Novation of Manufacturing Agreements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Novation of Manufacturing Agreements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#8220;Novation Agreement&#8221;), by and between the Company, Paragon and WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;), the Company novated (i)&#160;a Biologics Master Services Agreement (the &#8220;WuXi Biologics MSA&#8221;) and (ii)&#160;a Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;). </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Biologics Master Services Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to the Company by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, the Company is obligated to pay WuXi Biologics a service fee and all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> obligations in the amount specified in each work order associated with the agreement for the provision of services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. The Company can terminate the WuXi Biologics MSA or any work order at any time upon 30 days&#8217; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six months prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, no termination or cancellation fees shall be paid by the Company and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for 30 days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90 days. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cell Line License Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to the Company by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, the Company received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable license to certain of WuXi Biologics&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the license, the Company agreed to pay WuXi Biologics a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> license fee of $0.2&#160;million. Additionally, if the Company manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics of less than <div style="-sec-ix-hidden:hidden103884640;display:inline;">one</div> percent of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by the Company upon six months prior written notice and our payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii)&#160;by WuXi Biologics for a material breach by the Company that remains uncured for 60 days after written notice, (iii)&#160;by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968522656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Stock-Based Compensation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2015 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, the Company adopted the 2015 Equity Incentive Plan (&#8220;2015 Plan&#8221;), administered by the board of directors, and provides for the Company to sell or issue share of Common Stock or restricted Common Stock, or to grant incentive stock options or nonqualified stock options for the purchase of Common Stock, to employees, members of the board of directors and consultants of the Company. Under the terms of the 2015 Plan, the exercise prices, vesting and other restrictions may be determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant, the term of stock options may not be greater than ten years for all grants, and for grantees holding more than 10% of the total combined voting power of all classes of stock, the term may not be greater than five years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted options under the 2015 Plan until April 2016 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, a total of 3,029 shares of Common Stock are subject to options outstanding under the 2015 Plan and will become available under the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) to the extent the options are forfeited or lapse unexercised. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Plan became effective in April 2016 and serves as the successor to the 2015 Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan provides for an initial reserve of 44,000 shares of Common Stock, plus 20,395 shares of Common Stock remaining under the 2015 Plan, and any share awards that subsequently are forfeited or lapse unexercised under the 2015 Plan. The shares reserved exclude shares of Common Stock reserved for issuance under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the 2016 Plan was amended to increase the number of shares of Common Stock reserved for issuance thereunder by 70,384 shares, extend the term of the 2016 Plan through August&#160;7, 2028, and provide for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>the remaining term of the plan equal to (a) 4.0% of the number of issued and outstanding shares of Common Stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board each year (the &#8220;Evergreen Provision&#8221;). As a result of the operation of each of these provisions, on January&#160;1, 2023, 2022, and 2021, an additional 104,561, 78,968, and 76,735 shares, respectively, became available for issuance under the 2016 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the 2016 Plan was amended to (i)&#160;increase the number of shares of Common Stock reserved for issuance thereunder by 4,481,152 shares, (ii)&#160;revise the annual limit on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director compensation from 4,000 shares to (a) $750,000 in total value or (b) $1,000,000 in the year of the director&#8217;s initial service as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director or in any year a director serves as chairman of the Board of Directors, in either case, applicable to fees paid in both cash and equity, (iii)&#160;remove the fixed termination date of the 2016 Plan and, (iv)&#160;revise the Evergreen Provision from 4% to 5% of issued and outstanding shares of Common Stock on December&#160;31 of the preceding calendar year and to include shares issuable upon the exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants and the conversion of outstanding shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> convertible preferred stock in the calculation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the total number of shares reserved for issuance under the 2016 Plan was 5,019,177, of which 3,294,962 shares were subject to outstanding option awards and restricted unit awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Equity Inducement Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the board of directors approved and adopted the 2018 Equity Inducement Plan (&#8220;2018 Plan&#8221;), which became effective on the same date. The board of directors approved an initial reserve of 44,000 shares of Common Stock to be used exclusively for individuals who were not previously employees or directors, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employment,</div> as an inducement material to the individual entering into employment with the Company. Nonqualified stock options or restricted stock units may be granted under the 2018 Plan at the discretion of the Compensation Committee or the board of directors. The Company did not seek stockholder approval of the 2018 Plan pursuant to Nasdaq Rule 5635(c)(4). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2023, the 2018 Plan was amended to increase the number of shares of Common Stock reserved for issuance by 6,000,000. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions (&#8220;service-based&#8221; awards), performance conditions (&#8220;performance-based&#8221; awards), and market conditions (&#8220;market-based&#8221; awards). Service-based awards granted under the 2018 Plan, 2016 Plan, and 2015 Plan generally vest over four years and expire after ten years, although awards have been granted with vesting terms less than four years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted 153,865 service-based restricted stock units (&#8220;RSUs&#8221;) during the year ended December&#160;31, 2023 to certain employees under the 2018 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the total number of shares reserved for issuance under the 2018 Plan was 6,044,000, of which 5,350,595 shares were subject to outstanding awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Spyre 2023 Equity Incentive Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#8220;Spyre Equity Plan&#8221;) and its outstanding and unexercised stock options, which were converted to options to purchase 2,734 shares of Common Stock. The acquisition-date fair value of these grants will be recognized as an expense on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-rata</div> basis over the vesting period. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Parapyre Option Obligation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of warrants for Parapyre to purchase 1% of the then outstanding shares of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre&#8217;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of warrants is based on the outstanding shares of the Company&#8217;s Common Stock, (ii)&#160;establishing the grant date as the last business day of 2023 and 2024, and (iii)&#160;defining the term of the warrants granted as ten years. The Company determined that the 2023 and 2024 grants are two separate grants, as there would be no obligation for the 2024 grant had the Company exercised or terminated all of the options under the Paragon Agreement prior to December&#160;31, 2023. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, a liability related to the Parapyre Option Obligation was recorded pursuant to the amended Paragon Agreement during 2023 interim periods. The Company determined that the grant date of the award was December&#160;31, 2023, as all terms of the award, including number of shares and exercise price, were known by all parties. Accordingly, the Company measured the grant-date fair value of the warrants granted at approximately $11.5&#160;million as an equity-classified award, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition on June&#160;22, 2023. For the year ended December&#160;31, 2023, $11.4&#160;million was recognized as stock compensation expense related to the Parapyre Option Obligation. There was no similar expense for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the unamortized expense related to the Parapyre Option Obligation was nil. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option activity for the year ended December&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Under</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">405,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,776,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(46,246</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(637,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,497,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options vested and expected to vest as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,497,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options exercisable as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,065,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s Common Stock as of the reporting date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2023, 2022, and 2021, the weighted-average grant date fair value of options granted was $9.67, $1.80, and $4.96, per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2023, and 2021 was $0.4&#160;million and $0.7&#160;million, respectively. No options were exercised in the year ended December&#160;31, 2022. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were 477,000 stock options issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2023. There were no stock options issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2022 and 2021. For the years ended December&#160;31, 2023, 2022 and 2021, no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock options vested in the period. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2016 Employee Stock Purchase Plan </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;) became effective in April 2016. A total of 6,600 shares of Common Stock <div style="letter-spacing: 0px; top: 0px;;display:inline;">were </div>reserved for issuance under the 2016 ESPP. Eligible employees may purchase shares of Common Stock under the 2016 ESPP at 85% of the lower of the fair market value of the Common Stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year. The 2016 ESPP will terminate ten years from the first purchase date under the plan, unless terminated earlier by the board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the 2016 ESPP was amended to provide for an automatic annual increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the year equal to (a) 1.0% of the number of issued and outstanding shares of Common Stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board of directors each year. As a result of the operation of this provision, on January&#160;1, 2023, 2022 and 2021, an additional 26,140, 19,742, and 19,184 shares, respectively, became available for issuance under the 2016 ESPP. As of December&#160;31, 2023, the reserve remaining and available for future issuance under the 2016 ESPP was 72,404 shares. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023, the 2016 ESPP was amended to increase the maximum shares purchased during any one period from 80 shares to 400 shares or a lesser amount determined by the board of directors. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, stock-based compensation expense related to the 2016 ESPP plan was di minimis. For the years ended 2022 and 2021, stock-based compensation expense related to the 2016 ESPP plan was $0.1&#160;million and $0.2&#160;million, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Common Stock Units </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2020, the Company granted 9,128 restricted stock units to certain employees, with vesting terms subject to regulatory, commercial, and clinical milestones, in addition to a service condition. As of December&#160;31, 2023 none of these restricted stock units had vested and all restricted stock units were forfeited since the performance milestones were not met within the required time frame. No stock-based compensation expense was recognized on these awards. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company granted 153,865 service-based restricted stock units during the year ended December&#160;31, 2023. There were no restricted stock units granted during the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average&#160;Grant</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,865</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,865</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no restricted stock units granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> during the years ended December&#160;31, 2023, 2022, and 2021. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No related tax benefits were recognized for the years ended December&#160;31, 2023, 2022, and 2021 (see Note&#160;18). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards contain both performance and service-based vesting conditions. No expense was recognized for the unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> awards with only a performance condition for the years ended December&#160;31, 2023, 2022, and 2021. The performance-based vesting conditions represent specific performance targets. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable of achievement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had an aggregate of $64.4&#160;million of unrecognized stock-based compensation expense for options outstanding, which is expected to be recognized over a weighted average period of 3.5 years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#8217;s stock-based awards. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Volatility </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Company was privately held through April 2016 and transitioned from a clinical stage company to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage company in 2023, it alone does not have the relevant company-specific historical data to support its expected volatility. As such, the Company has used an average of expected volatilities based on the volatilities of a representative group of publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. Subsequent to the Company&#8217;s initial public offering, it began to consider the Company&#8217;s own historic volatility. However, due to the transition from a clinical stage company to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> stage company, the Company still uses peer company data to assist in this analysis. For purposes of identifying comparable companies, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company intends to consistently apply this process using the same or </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>similar comparable entities until a sufficient amount of historical information regarding the volatility of the Company&#8217;s own share price post transition becomes available. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has never paid dividends on its Common Stock and has no plans to pay dividends on its Common Stock. Therefore, the Company used an expected dividend yield of zero. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Valuation of Stock Options and 2016 ESPP </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the stock options granted under the the Company&#8217;s equity incentive plans, as well as the shares available for purchase under the 2016 ESPP were determined using the Black-Scholes option-pricing model. The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Options Granted</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.37</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2016 ESPP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.08</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622972448176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">16. Defined Contribution Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. During the years ended December&#160;31, 2023, 2022, 2021, the Company provided $0.2&#160;million, $0.6&#160;million, and $0.6&#160;million, respectively, in contributions to the plan. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622972422448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">17. Restructuring Charges </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Severance and Stock Compensation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#8217;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#8217;s existing headcount by June&#160;30, 2023. The Company recognized restructuring expenses consisting of cash severance payments and other employee-related costs of $6.4&#160;million during the year ended December&#160;31, 2023. Cash payments for employee related restructuring charges of $5.3&#160;million were paid as of December&#160;31, 2023. In addition, the Company recognized $1.0&#160;million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> stock-based compensation </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">expense related to the accelerated vesting of stock-based awards for certain employees. The Company recorded these restructuring charges based on each employee&#8217;s role to the respective research and development and general and administrative operating expense categories on its consolidated statements of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:53%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beginning&#160;Balance<br/> December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charges</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ending&#160;Balance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Severance liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,325</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sale of Assets </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $0.5&#160;million. After recording the disposal of all the Company&#8217;s property and equipment net of proceeds, the Company recorded a $0.7&#160;million and $0.2&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> Asset and Leasehold Improvement Impairment </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&#160;30, 2023, the Company abandoned its leased office space in Austin, Texas. As a result, the Company recognized an impairment loss of $0.9&#160;million related to the operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and $1.7&#160;million related to leasehold improvements. On August&#160;7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $2.0&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All charges related to the restructuring activities were recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. A summary of the charges related to the restructuring activities is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance<br/> Related<br/> Expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/> Compensation<br/> Expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss on<br/> Disposal&#160;of<br/> Long&#160;Lived<br/> Assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Asset<br/> Impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Restructuring<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971661136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">18. Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(338,942</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(338,816</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83,951</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, the Company recognized no provision or benefit from income taxes. For both the years ended December&#160;31, 2022 and 2021, the Company recognized an income tax expense of $0.1&#160;million, related to foreign subsidiaries income tax expense and the Texas margins tax. The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax provision derived by applying the federal statutory rate to income before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71,151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,789</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on forward contract valuation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,541</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired IPR&amp;D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on CVR revaluation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(640</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of tax rate on foreign jurisdiction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in the valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the deferred tax assets and liabilities consist of the following (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized 174 R&amp;D costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125,491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(125,491</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(107,652</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $17.8&#160;million, $20.6&#160;million, and $16.9&#160;million during the years ended December&#160;31, 2023, 2022, and 2021, respectively, primarily due to continuing loss from operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $354.5&#160;million and $328.2&#160;million, respectively. For both the years ended December&#160;31, 2023 and 2022, the Company had U.S. tax credit carryforwards and state tax credit carryforwards of $21.9&#160;million and $1.6&#160;million, respectively. Of the net operating loss and tax credit carryforwards $58.4&#160;million and $21.9&#160;million, respectively, will expire in 2033, if not utilized. Any remaining net operating loss will carry forward indefinitely and can be </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">utilized to offset up to 80% of the taxable income in any tax year. The net operating loss and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or tax credits are utilized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. If the Company has experienced an ownership change at any time since its formation, utilization of the NOL or research and development credit carryforwards would be subject to an annual limitation under Section&#160;382 or 383 of the Internal Revenue Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> rate, and then could be subject to additional adjustments, as required. Additionally, the separate return limitation year (&#8220;SRLY&#8221;) rules may apply to losses of the Company&#8217;s eight wholly owned U.S. subsidiary corporations. The SRLY rules limit the consolidated group&#8217;s use of a subsidiary corporation&#8217;s net operating losses to the amount of income generated by the subsidiary corporation after it becomes a member of the group. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months. Due to the existence of the valuation allowance, future changes in the Company&#8217;s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2019 and subsequent years. However, due to NOL and tax attribute carryovers, the taxing authorities have the ability to adjust the NOLs and other tax attributes related to closed years. As of December&#160;31, 2023 and 2022, there were no amounts recorded for uncertain tax positions. As of December&#160;31, 2023, undistributed earnings of the Company&#8217;s incorporated foreign subsidiaries are immaterial. Under the Global Intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Low-Taxed</div> Income (&#8220;GILTI&#8221;) provisions of the 2017 Tax Cuts and Jobs Act, U.S. income taxes have been incurred on the undistributed earnings of the foreign subsidiaries and therefore, the tax impact upon distribution is limited to state income and withholding taxes and is not material. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971948496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">19. Net Loss Per Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company computes net loss attributable per common stockholder using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. The Company considers convertible preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for Common Stock and participating security considering a participating security&#8217;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock and Series B Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock and the Series B Preferred Stock were excluded from the calculation of basic net loss per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding during the period, without consideration of potential dilutive securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622969800144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Subsequent Events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s management has evaluated subsequent events up to October&#160;6, 2023, the date the Statement of Assets Acquired and Liabilities Assumed from Spyre, Inc. was available to be issued. There have been no subsequent events that require recognition or disclosure in this financial statement except for the following described below. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;7, 2023, the Company issued 517,809 shares of common stock and 364,887 shares of Series&#160;A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2023, the Company filed a preliminary proxy statement with the SEC to solicit approval of the conversion of the Series A Preferred Stock into shares of Common Stock in connection with the Asset acquisition, among other matters, at a special meeting of stockholders. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2023, the Company&#8217;s Board of Directors approved a reverse stock split of the Company&#8217;s common stock, par value $0.0001 per share, at a ratio of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-25</div></div> and a reduction in the total number of authorized shares of Common Stock from 500,000,000 shares to 20,000,000 shares. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#8217;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted is ten years. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement on a go forward basis. The Company determined that these amendments would not have materially impacted the liability as of June&#160;22, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968359888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of acquiring Spyre, and based on the criteria in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> of the Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#8217;s full financial statements are not material to the Company&#8217;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-05</div> and Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#8217;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#8217;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#8217;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div>  <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#8217;s option to exclusively license IPR&amp;D. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#8217;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#8217;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#8217;s future success. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2023, the Board of Directors approved a restructuring of the Company&#8217;s workforce pursuant to which the Company&#8217;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#8217;s clinical programs. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#8217; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </div> <span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#8217;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of the Company&#8217;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. </div> <span></span>
</td>
<td class="text"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#8217;s financial statements relate to the valuation of consideration transferred in acquiring <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research&#160;&amp; development (&#8220;IPR&amp;D&#8221;); the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Merger</div> Spyre was comprised of shares of the Company&#8217;s Common Stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the Series A PIPE securities, <div style="letter-spacing: 0px; top: 0px;;display:inline;">which</div> was a financing event involving a group of accredited investors. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;22</div>, 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">023,</div> Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#8217;s insured limit were $2.8&#160;million. </div> <span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All investments have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any unrealized losses from declines in fair value below the amortized cost basis as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consisted of money market accounts held by financial institutions as collateral for the Company&#8217;s obligations under a credit agreement and a facility lease for the Company&#8217;s corporate headquarters in Austin, Texas. The lease was terminated in August 2023 and the cash was subsequently unrestricted. Remaining restricted cash balances relate to the Company&#8217;s operations in the United Kingdom. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company&#8217;s two U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000 per depositor. As of December&#160;31, 2023 and 2022, balances at the Company&#8217;s U.S. banking institutions exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shorter of remaining lease term or estimated useful life</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. The Company recognized a $2.6&#160;million impairment loss for the year ended December&#160;31, 2023 related to its leased office space in Austin, Texas (see Note 17 for additional information). There were no impairments of long-lived assets for the years ended December&#160;31, 2022 and 2021. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock', window );">Accrued Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Research and Development Costs </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>development expenses, with a substantial portion of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> research and development activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for expenses resulting from obligations under the Paragon Agreement and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. Historically, the Company has not experienced any material deviations between accrued and actual research and development expenses. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Company&#8217;s restructuring, as described in Note 17, the Company had lease agreements with lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. As allowed under Topic 842, the Company elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for any leases involving real estate and office equipment classes of assets and, as a result, accounted for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. The Company also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses fair value measurements to record fair value adjustments to certain financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The three levels of inputs that may be used to measure fair value are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto">
<tr>
<td style="width:9%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.</td></tr></table></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments carried at fair value include cash equivalents and marketable securities. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License revenue </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="-sec-ix-redline:true;;display:inline;"> </div>distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s contracts may be modified for changes in the customer&#8217;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">an adjustment to revenue on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis. The cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaborative arrangements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#8220;Topic 808&#8221;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#8217;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the cost of stock-based awards granted to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#8220;RSUs&#8221;) are based on the fair value of the Company&#8217;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_TemporaryEquityPolicyPolicyTextBlock', window );">Convertible Preferred Stock Issued through PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Preferred Stock Issued through PIPE </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company classified the Series B Preferred Stock outside of stockholders&#8217; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock on the last trading day prior to the holder&#8217;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#8217;s control. Additionally, the Company determined the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock', window );">Contingent Milestone Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">&#160;</div><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Milestone Proceeds </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes contingent milestone proceeds associated from the sale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development assets in earnings once the achievement of the milestone becomes probable and payment to the Company is contractually required. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisitions </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-acquisition</div> direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;D asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;D asset with no alternative future use is charged to expense at the acquisition date. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Contingent Value Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent Value Rights </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#8217;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2023 and 2022, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2023, 2022, or 2021. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is the change in stockholders&#8217; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#8217;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#8217;s functional currency and the reporting currency. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company computes net loss attributable per common stockholder using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. The Company considers convertible preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for Common Stock and participating security considering a participating security&#8217;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock and Series B Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock and the Series B Preferred Stock were excluded from the calculation of basic net loss per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding during the period, without consideration of potential dilutive securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement/Recently Issued Accounting Pronouncement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company early adopted the Financial Accounting Standards Board&#8217;s Accounting Standards Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the cash conversion and beneficial conversion feature models in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20</div> that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted earnings-per-share for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> requires the if-converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> to all Series A Preferred Stock and Series B Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A Preferred Stock and Series B Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-07,</div> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 &#8211; Segment Reporting. This update is effective beginning with the Company&#8217;s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2023-09,</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. This ASU will have no impact on the Company&#8217;s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income <div style="letter-spacing: 0px; top: 0px;;display:inline;">tax</div> disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-Process Research And Development Assets, Contingent Consideration, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971688768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Liabilities</div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622969880080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Useful Lives of Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The useful lives of the property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Laboratory equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture and office equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Shorter of remaining lease term or estimated useful life</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962652000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">The following tables sets forth the fair value of the Company&#8217;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair <div style="letter-spacing: 0px; top: 0px;;display:inline;">value</div> hierarchy (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:58%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">183,491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">336,953</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CVR liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financial Assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;31,603</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;46,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Derivative Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the forward contract liability for the periods presented (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Forward&#160;Contract<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of June&#160;22, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series A Preferred Stock on July&#160;7, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(189.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the CVR liability for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CVR&#160;Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at CVR issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in the fair value of the CVR liability since issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,786</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Significant Inputs used to Estimate the Fair Value of Derivative Liabilities</a></td>
<td class="text">The significant inputs used to estimate the fair value of the CVR liability were as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated cash flow dates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2/28/24&#8201;-&#8201;06/22/26</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated probability of success</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">39% - 100%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Estimated reimbursement rate compared to reimbursement target</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">81% - 100%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-adjusted discount rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5.91% - 6.32%</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140623064198080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the estimated fair value of the Company&#8217;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,648</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,955</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,563</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">186,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79,186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;&#8199;&#8199;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;20,877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8199;20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Available-for-Sale Securities in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2023 and 2022, aggregated by major security type and length of time in a continuous unrealized loss position: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government treasury securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:46%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12&#160;Months&#160;or&#160;Longer</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. government agency securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Marketable Securities at Estimated Fair Value</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in one year or less</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115,784</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due in 1 &#8211; 2 years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970954272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Net</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Laboratory equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,144</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971340304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970655920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Expenses related to Related Party which were Settled in Cash</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of expenses related to the Paragon Agreement recognized within research and development expenses, which were ultimately settled in cash (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock', window );">Related Party Accounts Payable</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is the summary of Related party accounts payable and other current liabilities (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reimbursable costs under the Paragon Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party accounts payable and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of balances due to affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622967796208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Asset Acquisition Cost</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by the Company</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970625808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s recognition of its operating and finance leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:31%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td style="width:52%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="-sec-ix-hidden:hidden103884638;display:inline;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">597</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total leased assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="-sec-ix-hidden:hidden103884635;display:inline;">Accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Weighted-Average Remaining Lease Term/Discount Rates and Lease Cost</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#8217;s operating and finance leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finance leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the lease costs pertaining to the Company&#8217;s operating leases (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">991</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968646864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Pre-funded Warrants for Common Stock Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase Common Stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issue Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Warrants<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">May 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">None</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968565776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Contract Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#8217;s contract liabilities for the periods presented (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Contract liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,271</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970204352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Employee and Non-Employee Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option activity for the year ended December&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issuable</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Under</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">405,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,776,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(46,246</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(637,686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Outstanding as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,497,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options vested and expected to vest as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,497,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Options exercisable as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,065,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Employee Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average&#160;Grant</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,865</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Unvested restricted stock units as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">153,865</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recognized from the Company&#8217;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employees</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used in Calculating Fair Value of Awards</a></td>
<td class="text">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Options Granted</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.37</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.93</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">2016 ESPP</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.08</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971616336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Changes in Accrued Restructuring Balance</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in the Company&#8217;s accrued restructuring balance (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:53%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beginning&#160;Balance<br/> December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charges</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ending&#160;Balance</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Severance liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,325</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to the Restructuring Activities</a></td>
<td class="text">A summary of the charges related to the restructuring activities is as follows (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Severance<br/> Related<br/> Expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/> Compensation<br/> Expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss on<br/> Disposal&#160;of<br/> Long&#160;Lived<br/> Assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Asset<br/> Impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Restructuring<br/> Costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968431504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">(Loss) Income Before Income Tax Expense by Jurisdiction</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:63%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(338,942</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(84,113</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,940</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(338,816</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83,951</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(65,660</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Effective Income Tax Rate Reconciliation</a></td>
<td class="text">The difference between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax provision derived by applying the federal statutory rate to income before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71,151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,789</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on forward contract valuation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,541</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired IPR&amp;D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on CVR revaluation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,815</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(640</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of tax rate on foreign jurisdiction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in the valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax (benefit) expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(136</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the deferred tax assets and liabilities consist of the following (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforward</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized 174 R&amp;D costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">566</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125,491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciable assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(676</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(125,491</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(107,652</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970624416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-dilutive</div> for the periods presented: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Options to purchase Common Stock</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,583,226</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8199;&#8201;346,331</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8199;&#8201;264,858</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Unvested restricted stock units</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,240</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,983</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7,975</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Outstanding Parapyre Warrants</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,625</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#8194;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="width: 2%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Weighted average Common Shares</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,201,954</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,307,668</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,956,933</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">695,111</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,063,563</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">672,851</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;">Total basic and diluted weighted average shares</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,897,065</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3,371,231</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="-sec-ix-redline:true;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,629,784</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962472560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Asset Acquisition Cost</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition costs are shown on the following table (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by Aeglea</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s allocation of the purchase price to net assets acquired is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Asset Acquisition Costs are shown on the following table (in millions): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Consideration transferred in Series A Preferred Stock and Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs incurred by the Company</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The allocation of the purchase price to net assets acquired is as a follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:89%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;22,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cost to acquire asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970670848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;June&#160;22,<br/>2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued option cost payable to Paragon</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,987</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contracted research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional and consulting fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">946</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963615840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">106 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,555<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ProceedsFromRaisingCapital', window );">Proceeds from raising capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 896,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 764,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764,414<span></span>
</td>
<td class="nump">$ 425,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_FixedExchangeRatio', window );">Fixed exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5494488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionStockholderPaymentPeriod', window );">Asset acquisition, stockholder payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember', window );">Spyre 2023 Equity Incentive Plan | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares transferred as equity interest in asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series B non-voting convertible preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares transferred as equity interest in asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CompanyAndBasisOfPresentationLineItems', window );"><strong>Company and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionStockholderPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Stockholder Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionStockholderPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CompanyAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CompanyAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_FixedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_FixedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OutstandingAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OutstandingAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ProceedsFromRaisingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Raising Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ProceedsFromRaisingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968427872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long lived assets</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | U.S. Banking Institution</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971245312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_SoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962059088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 336,953<span></span>
</td>
<td class="nump">$ 46,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">42,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">32,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">104,141<span></span>
</td>
<td class="nump">23,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">16,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">33,064<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">42,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">150,648<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">183,491<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">32,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">150,648<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">153,462<span></span>
</td>
<td class="nump">31,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">104,141<span></span>
</td>
<td class="nump">23,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">16,257<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">33,064<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">42,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">42,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622961897264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of Series A non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contract Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,986<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of Series A non-voting convertible preferred stock</a></td>
<td class="nump">$ 189,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionStockholderPaymentPeriod', window );">Asset acquisition, stockholder payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionCashPaymentThresholdPeriod', window );">Asset acquisition, cash payment, threshold period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares transferred as equity interest in asset acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionCashPaymentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash Payment, Threshold Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionCashPaymentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionStockholderPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Stockholder Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionStockholderPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968750112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Forward Contract Liability (Details) - Forward Contracts<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 106.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">83.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Issuance of Series A Preferred Stock on July 7, 2023</a></td>
<td class="num">(189.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971273152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details) - Level 3<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Risk-adjusted discount rates | CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">6.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | CVR liability | Estimated probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | CVR liability | Estimated reimbursement rate compared to reimbursement target</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Risk-adjusted discount rates | CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | CVR liability | Estimated probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | CVR liability | Estimated reimbursement rate compared to reimbursement target</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=syre_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=syre_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=syre_MeasurementInputReimbursementRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=syre_MeasurementInputReimbursementRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970581984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in CVR Liability (Details) - CVR liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value at CVR issuance</a></td>
<td class="nump">29,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in the fair value of the CVR liability since issuance</a></td>
<td class="nump">18,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(5,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 42,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=syre_ContingentValueRightLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968183024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">$ 186,563<span></span>
</td>
<td class="nump">$ 26,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">186,569<span></span>
</td>
<td class="nump">26,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">150,101<span></span>
</td>
<td class="nump">20,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">150,384<span></span>
</td>
<td class="nump">20,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">150,648<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">150,648<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">24,950<span></span>
</td>
<td class="nump">7,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">24,955<span></span>
</td>
<td class="nump">7,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">79,124<span></span>
</td>
<td class="nump">16,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">79,186<span></span>
</td>
<td class="nump">16,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">32,984<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">33,064<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">10,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">10,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">21,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">21,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,147<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 16,257<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CashEquivalentsUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CashEquivalentsUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962567168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">$ 14,738<span></span>
</td>
<td class="nump">$ 25,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">14,738<span></span>
</td>
<td class="nump">25,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">9,907<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">9,907<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">4,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="nump">4,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622961972688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag', window );">Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag</a></td>
<td class="text">Accrued interest receivable on available-for-sale debt securities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gains or losses on marketable securities</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains or losses on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable on available-for-sale debt securities</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Debt securities, available-for-sale, allowance for credit loss, excluding accrued interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-3B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971642960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 115,784<span></span>
</td>
<td class="nump">$ 20,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in 1 - 2 years</a></td>
<td class="nump">34,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total marketable securities</a></td>
<td class="nump">$ 150,384<span></span>
</td>
<td class="nump">$ 20,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968159392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,144)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_SoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=syre_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962507632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">$ 1,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968395360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 4,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedContractedResearchAndDevelopmentCosts', window );">Accrued contracted research and development costs</a></td>
<td class="nump">7,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting fees</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">$ 917<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 13,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedContractedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contracted research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedContractedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963765568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 22, 2023 </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($) </div>
<div>BOARDSEAT</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>BOARDSEAT </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyTransactionNumberOfBoardSeats', window );">Number of board seats held by related party | BOARDSEAT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,675<span></span>
</td>
<td class="nump">$ 7,111<span></span>
</td>
<td class="nump">$ 8,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,584<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,776,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember', window );">Paragon Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember', window );">Paragon Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ResearchInitiationFees', window );">Research initiation fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ReimbursableResearchCosts', window );">Reimbursable research costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_StockCompensationAndResearchAndDevelopmentExpenseMember', window );">Stock Compensation And Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember', window );">Reimbursable Costs Under Paragon Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_MilestonePaymentsMember', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_AppointOfBoardMembersMember', window );">Appoint Of Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyTransactionNumberOfBoardSeats', window );">Number of board seats held by related party | BOARDSEAT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_SPY002LicenseAgreementMember', window );">SPY002 License Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_NominationFee', window );">Nomination fee</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PaymentOfMilestone', window );">Milestone payments</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_SaleOfStockDecember2023PIPEMember', window );">Sale Of Stock, December 2023 PIPE | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember', window );">Consulting Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember', window );">Consulting Agreement | Related Party | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=syre_ParagonTherapeuticsIncMember', window );">Paragon Therapeutics Inc | Ownership Interest | Maximum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=syre_ParagonTherapeuticsIncMember', window );">Paragon Therapeutics Inc | SPY002 License Agreement | Maximum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AmountToBePaidUnderAgreement', window );">Contingent obligation based on milestones</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=syre_FairmountFundsManagementLlcMember', window );">Fairmount Funds Management LLC | Ownership Interest | Minimum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty', window );">Percentage of ownership held in third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=syre_ParagonAndParapyreHoldingLlcMember', window );">Paragon and Parapyre Holding LLC | Ownership Interest | Maximum | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of ownership by noncontrolling owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AmountToBePaidUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AmountToBePaidUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minority interest ownership percentage by noncontrolling owners held in third party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_NominationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nomination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_NominationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PaymentOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PaymentOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ReimbursableResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ReimbursableResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses incurred prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses unpaid prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyTransactionNumberOfBoardSeats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Number Of Board Seats</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyTransactionNumberOfBoardSeats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ResearchInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research initiation fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ResearchInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_StockCompensationAndResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_StockCompensationAndResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_AppointOfBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_AppointOfBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_SPY002LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_SPY002LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_SaleOfStockDecember2023PIPEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_SaleOfStockDecember2023PIPEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syre_ParagonTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syre_ParagonTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_OwnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_OwnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syre_FairmountFundsManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syre_FairmountFundsManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syre_ParagonAndParapyreHoldingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syre_ParagonAndParapyreHoldingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970204352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember', window );">Reimbursable Costs Under Paragon Agreement | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyTransactionReimbursableCosts', window );">Reimbursable costs</a></td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyTransactionReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction, reimbursable costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyTransactionReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622967762224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Related Party Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 16,584<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">16,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Reimbursable Costs Under Paragon Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 16,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ReimbursableCostsUnderParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971548000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Asset Acquisition - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Asset acquisition, contingent consideration, liability, current</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">113,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis', window );">Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis</a></td>
<td class="nump">14,595,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares transferred as equity interest in asset acquisition (in shares)</a></td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="nump">$ 291.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares transferred as equity interest in asset acquisition (in shares)</a></td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="nump">$ 7.277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember', window );">Spyre 2023 Equity Incentive Plan | Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares)</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OutstandingAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OutstandingAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971316528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition - Asset Acquisition Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Consideration transferred in Series A Preferred Stock and Common Stock</a></td>
<td class="nump">109,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs incurred by the Company</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">130,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssumedLiabilities', window );">Assumed liabilities</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622967691552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paragon Agreement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=syre_ParagonTherapeuticsIncMember', window );">Paragon Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LicenseAgreementMilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember', window );">Paragon Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=syre_StockCompensationAndResearchAndDevelopmentExpenseMember', window );">Stock Compensation And Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Paragon Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ResearchInitiationFees', window );">Research initiation fees</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ReimbursableResearchCosts', window );">Reimbursable research costs</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash', window );">Nonrefundable research initiation fee for one program paid in cash</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable research initiation fee for one program paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ReimbursableResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ReimbursableResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses incurred prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses unpaid prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ResearchInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research initiation fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ResearchInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=syre_ParagonTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=syre_ParagonTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_StockCompensationAndResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_StockCompensationAndResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963527872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OperatingLeaseTerminationFeeAmount', window );">Termination fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OperatingLeaseTerminationFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Termination Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OperatingLeaseTerminationFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962029600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating and Financing Leases Presented in Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LeaseAssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total leased assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LeaseLiabilityCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LeaseLiabilityNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,004<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OperatingAndFinanceLeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LeaseLiabilityCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LeaseLiabilityCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LeaseLiabilityNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LeaseLiabilityNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OperatingAndFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and Finance lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OperatingAndFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and financing lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970706832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Lease term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Weighted Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Weighted Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968892640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">$ 991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622959379920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 08, 2023</div></th>
<th class="th">
<div>Jul. 07, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>VOTE </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>VOTE </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>VOTE </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_SharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,000,000<span></span>
</td>
<td class="nump">410,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_NumberOfCommonStockVotingRightsHeldPerShare', window );">Number of votes for common stock holders | VOTE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights', window );">Offering price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.9975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,555<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PlacementAgentFeesAndOfferingCosts', window );">Placement agent fees and offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised', window );">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice', window );">Maximum ownership percentage of common stock shares for outstanding warrants to be exercised upon written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders', window );">Ownership percentage for outstanding warrants to purchase shares of common stock to be exercised to certain holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice', window );">Revised ownership percentage, period to take effect after notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,555<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreWarrantsMember', window );">Parapyre Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,407<span></span>
</td>
<td class="nump">684,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,341<span></span>
</td>
<td class="nump">1,086,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,037<span></span>
</td>
<td class="nump">437,037<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PreferredStockRemainsIssuedAndOutstandingPercentage', window );">Preferred stock issued and outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series B non-voting convertible preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Preferred stock, redemption value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,100<span></span>
</td>
<td class="nump">$ 129,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock, redemption per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="nump">$ 21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_BeneficiallyHoldersOwnedPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_BeneficiallyHoldersOwnedPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_BeneficiallyHoldersOwnedPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_BeneficiallyHoldersOwnedPercentage', window );">Beneficially holders owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Conversion Of Series A Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,972,080<span></span>
</td>
<td class="nump">25,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issued as part of consideration transferred in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock | Series A Non Voting Convertible Preferred Stock | Conversion Of Series A Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649,302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate purchase price for stock sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,100<span></span>
</td>
<td class="nump">$ 197,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement | $</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement | $</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_BeneficiallyHoldersOwnedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficially holders owned percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_BeneficiallyHoldersOwnedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right offering price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum ownership percentage for outstanding warrants to purchase shares of common stock to be exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised Upon Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_NumberOfCommonStockVotingRightsHeldPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock voting rights held per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_NumberOfCommonStockVotingRightsHeldPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PlacementAgentFeesAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PlacementAgentFeesAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PreferredStockRemainsIssuedAndOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock remains issued and outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PreferredStockRemainsIssuedAndOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963501248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syre_PreFundedMay2022WarrantsMember', window );">May 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syre_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syre_PreFundedMay2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syre_PreFundedMay2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syre_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syre_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622957561936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreement - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Mar. 21, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">$ 18,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,449<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Carrying value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PrepaidExpenseValueOfExpectedRecoveries', window );">Contingent reimbursement of pre-paid manufacturing costs</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet', window );">Derecognition of nonfinancial assets and liabilities</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syre_ImmedicaPharmaABMember', window );">Immedica Pharma AB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReimbursementFromLimitedPartnershipInvestment', window );">Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_NonRefundablePaymentReceived', window );">Non refundable payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PercentageOfPaymentForCostIncurredInPIPTrial', window );">Percentage of payment for cost incurred in trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_CostsIncurredInPerformingTheTrial', window );">Maximum amount of costs to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AdditionalUpfrontPaymentAbilityToReceived', window );">Additional upfront payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_MilestonePaymentsExchangeRate', window );">Milestone payments exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Estimated amount incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AllocationPriceTotal', window );">Allocation for stand-alone selling prices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syre_ImmedicaPharmaABMember', window );">Immedica Pharma AB | PEACE Trial and BLA Package</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AllocatedAmountOfTransactionPrice', window );">Allocated amount of modified transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syre_ImmedicaPharmaABMember', window );">Immedica Pharma AB | PIP Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AllocatedAmountOfTransactionPrice', window );">Allocated amount of modified transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syre_ImmedicaPharmaABMember', window );">Immedica Pharma AB | License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AdditionalUpfrontPaymentAbilityToReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional upfront payment ability to received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AdditionalUpfrontPaymentAbilityToReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AllocatedAmountOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocated amount of transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AllocatedAmountOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AllocationPriceTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation price total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AllocationPriceTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_CostsIncurredInPerformingTheTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred in performing the pip trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_CostsIncurredInPerformingTheTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Derecognition Of Nonfinancial Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_MilestonePaymentsExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_MilestonePaymentsExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_NonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_NonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PercentageOfPaymentForCostIncurredInPIPTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of payment for cost incurred in pip trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PercentageOfPaymentForCostIncurredInPIPTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PrepaidExpenseValueOfExpectedRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Value Of Expected Recoveries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PrepaidExpenseValueOfExpectedRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReimbursementFromLimitedPartnershipInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReimbursementFromLimitedPartnershipInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=syre_GlobalRightsToPegzilarginaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=syre_GlobalRightsToPegzilarginaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syre_ImmedicaPharmaABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syre_ImmedicaPharmaABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=syre_PeaceTrialAndBLAPackageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=syre_PeaceTrialAndBLAPackageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=syre_PIPTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=syre_PIPTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=syre_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=syre_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622972434640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic License Agreement - Changes in Contract Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Deductions</a></td>
<td class="num">(3,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963670352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pegzilarginase to Immedica (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,449<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Carrying value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on sale of in-process research and development asset</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PrepaidExpenseValueOfExpectedRecoveries', window );">Contingent reimbursement of pre-paid manufacturing costs</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet', window );">Derecognition of nonfinancial assets and liabilities</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Derecognition Of Nonfinancial Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PrepaidExpenseValueOfExpectedRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Value Of Expected Recoveries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PrepaidExpenseValueOfExpectedRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=syre_GlobalRightsToPegzilarginaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=syre_GlobalRightsToPegzilarginaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970790816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Novation of Manufacturing Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod', window );">Right to terminate agreement or work order, prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod', window );">Right to terminate work order, reasonable cause, prior written notice period</a></td>
<td class="text">30 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable', window );">Right to terminate work order by counterparty, reasonable cause, termination amount payable</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod', window );">Right to terminate work order, material breach, uncured period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod', window );">Right to terminate work order, unusual or infrequent cause, period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentNonRefundableLicenseFeeAmount', window );">Non-refundable license fee amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRoyaltyPercentage', window );">Royalty percentage (less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod', window );">Right to terminate agreement, prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod', window );">Right to terminate agreement by counterparty, material breach, uncured period</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod', window );">Right to terminate agreement by counterparty, payments not received, period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentNonRefundableLicenseFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Non-Refundable License Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentNonRefundableLicenseFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Agreement, Prior Written Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OtherCommitmentRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Commitment, Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OtherCommitmentRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622960949408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 09, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,497,395<span></span>
</td>
<td class="nump">405,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,675,000<span></span>
</td>
<td class="nump">$ 7,111,000<span></span>
</td>
<td class="nump">$ 8,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefits recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding', window );">Percentage of annual grant of common stock outstanding for warrants</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ClassOfWarrantOrRightGrantDateFairValue', window );">Warrant grant date fair value</a></td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Liability assumed in asset acquisition related to warrants</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ClassOfWarrantOrRightUnamortizedExpense', window );">Warrant unamortized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.67<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense for options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Non- Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock option issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock option vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, granted to employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Expense recognized for unvested employee and non-employee awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_GranteesWithMoreThanFiveYearsVestingTermPercent', window );">Grantees with more than five years vesting term, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_MaximumVestingTermForMoreThanTenPercentGrantees', window );">Maximum vesting term for more than ten percent grantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Shares subject to options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Awards granted, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Initial reserves of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares', window );">Annual percentage of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant', window );">Additional common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,561<span></span>
</td>
<td class="nump">78,968<span></span>
</td>
<td class="nump">76,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,481,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares', window );">Annual limit for non-employee director compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount', window );">Annual limit for non-employee director compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount', window );">Non-employee director compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,019,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,294,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, granted to employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Equity instruments other than options, vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndEighteenEquityInducementPlanMember', window );">2018 Equity Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Initial reserves of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding option awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,350,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember', window );">2018 Plan, 2016 Plan and 2015 Plan | Service Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Awards granted, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Awards granted, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant', window );">Additional common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,140<span></span>
</td>
<td class="nump">19,742<span></span>
</td>
<td class="nump">19,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of discount through payroll deductions to eligible employees to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee', window );">Maximum purchase value per employee under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease', window );">Additional annual percentage increase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan', window );">Maximum shares purchased under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual percentage of additional shares which equals to the issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Annual Grant, Percentage Of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ClassOfWarrantOrRightGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ClassOfWarrantOrRightGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ClassOfWarrantOrRightUnamortizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Unamortized Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ClassOfWarrantOrRightUnamortizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_GranteesWithMoreThanFiveYearsVestingTermPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grantees with more than five years vesting term, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_GranteesWithMoreThanFiveYearsVestingTermPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares purchased under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_MaximumVestingTermForMoreThanTenPercentGrantees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum vesting term for more than ten percent grantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_MaximumVestingTermForMoreThanTenPercentGrantees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award additional annual percentage increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, additional number of shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum annual fair market value per employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Plan Modification, Annual Limit For Non-Employee Director Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Plan Modification, Non-Employee Director Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Plan Terms, Annual Limit For Non-Employee Director Compensation, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syre_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syre_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syre_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndEighteenEquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndEighteenEquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=syre_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=syre_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971549840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Employee and Non-Employee Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Issuable Under Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">405,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">8,776,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(46,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(637,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">8,497,395<span></span>
</td>
<td class="nump">405,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (in shares)</a></td>
<td class="nump">8,497,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">1,065,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 113.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">9.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">12.13<span></span>
</td>
<td class="nump">$ 113.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (in dollars per share)</a></td>
<td class="nump">12.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 24.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 98,928<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest</a></td>
<td class="nump">98,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 13,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963528016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Employee Restricted Stock Activity (Details) - Restricted Common Stock - Employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested (in shares) | shares</a></td>
<td class="nump">5,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">153,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(5,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested (in shares) | shares</a></td>
<td class="nump">153,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 203.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">18.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">203.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syre_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syre_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963617056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - 2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14,237<span></span>
</td>
<td class="nump">$ 7,111<span></span>
</td>
<td class="nump">$ 8,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">Non- Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,437<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">Research and development | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">Research and development | Non- Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,328<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">General and administrative | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,327<span></span>
</td>
<td class="nump">4,520<span></span>
</td>
<td class="nump">5,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember', window );">General and administrative | Non- Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syre_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syre_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syre_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syre_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622962047232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">4.37%<span></span>
</td>
<td class="nump">2.93%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">181.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970648960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, contribution amount</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968261920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Cash severance payments and other employee-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments for employee related restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Non-cash stock-based compensation expense related to accelerated vesting of stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Total consideration from disposal of long lived assets</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease asset impairment</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment on leasehold improvements</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OperatingLeaseTerminationFeeAmount', window );">Termination fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OperatingLeaseTerminationFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Termination Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OperatingLeaseTerminationFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970664544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Changes in Accrued Restructuring Balance (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">$ (5,300)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=syre_SeveranceLiabilityMember', window );">Severance Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">6,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(5,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance December 31, 2023</a></td>
<td class="nump">$ 1,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=syre_SeveranceLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=syre_SeveranceLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622959360912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Charges Related to the Restructuring Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=syre_RestructuringActivitiesMember', window );">Restructuring Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=syre_RestructuringActivitiesMember', window );">Restructuring Activities | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=syre_RestructuringActivitiesMember', window );">Restructuring Activities | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Total Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=syre_RestructuringActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=syre_RestructuringActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622960085552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - (Loss) Income Before Income Tax Expense by Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (338,942)<span></span>
</td>
<td class="num">$ (84,113)<span></span>
</td>
<td class="num">$ (65,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (338,816)<span></span>
</td>
<td class="num">$ (83,951)<span></span>
</td>
<td class="num">$ (65,660)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963498528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>SUBSIDARY</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision or benefit from income taxes</a></td>
<td class="num">$ (26,000)<span></span>
</td>
<td class="num">$ (136,000)<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation primarily due to operation losses</a></td>
<td class="nump">17,800,000<span></span>
</td>
<td class="nump">20,600,000<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">354,500,000<span></span>
</td>
<td class="nump">328,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized', window );">Net operating loss carryforwards, set to expire if not utilized</a></td>
<td class="nump">58,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized', window );">Tax credit carryforwards, set to expire if not utilized</a></td>
<td class="nump">$ 21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_NumberOfDomesticSubsidiaries', window );">Number of domestic subsidiaries | SUBSIDARY</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision or benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_NumberOfDomesticSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Domestic Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_NumberOfDomesticSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Set To Expire If Not Utilized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforwards, Set To Expire If Not Utilized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971555328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax provision derived by applying the federal statutory rate to income before income taxes</a></td>
<td class="num">$ (71,151)<span></span>
</td>
<td class="num">$ (17,630)<span></span>
</td>
<td class="num">$ (13,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount', window );">Loss on forward contract valuation</a></td>
<td class="nump">17,541<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquired IPR&amp;D</a></td>
<td class="nump">27,340<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount', window );">Loss on CVR revaluation</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Other permanent differences</a></td>
<td class="nump">4,472<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Effect of tax rate on foreign jurisdiction</a></td>
<td class="num">(53)<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in the valuation allowance</a></td>
<td class="nump">17,839<span></span>
</td>
<td class="nump">20,609<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IncomeTaxReconciliationTaxCostCredit', window );">Tax credits</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3,559)<span></span>
</td>
<td class="num">(3,815)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_IncomeTaxReconciliationTaxCostCredit', window );">Tax credits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (640)<span></span>
</td>
<td class="num">$ (152)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Contingent Value Added Liability, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Forward Contract Liability, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_IncomeTaxReconciliationTaxCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation tax cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_IncomeTaxReconciliationTaxCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622968074816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 74,454<span></span>
</td>
<td class="nump">$ 68,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized 174 R&amp;D costs</a></td>
<td class="nump">22,532<span></span>
</td>
<td class="nump">11,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expense</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">125,491<span></span>
</td>
<td class="nump">108,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciable assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(676)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(676)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(125,491)<span></span>
</td>
<td class="num">(107,652)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">21,914<span></span>
</td>
<td class="nump">21,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="nump">$ 1,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622970592656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,583,226<span></span>
</td>
<td class="nump">346,331<span></span>
</td>
<td class="nump">264,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
<td class="nump">7,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=syre_ParapyreWarrantsMember', window );">Outstanding Parapyre Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=syre_ParapyreWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=syre_ParapyreWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622961976432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares (in shares)</a></td>
<td class="nump">6,201,954<span></span>
</td>
<td class="nump">2,307,668<span></span>
</td>
<td class="nump">1,956,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Weighted average pre-funded warrants (in shares)</a></td>
<td class="nump">695,111<span></span>
</td>
<td class="nump">1,063,563<span></span>
</td>
<td class="nump">672,851<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total basic weighed average shares (in shares)</a></td>
<td class="nump">6,897,065<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total diluted weighed average shares (in shares)</a></td>
<td class="nump">6,897,065<span></span>
</td>
<td class="nump">3,371,231<span></span>
</td>
<td class="nump">2,629,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622964243136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Consideration transferred in Series A Preferred Stock and common stock</a></td>
<td class="nump">109,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs incurred by Aeglea</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">130,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="num">(20,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="nump">$ 113,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622963770336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 08, 2023</div></th>
<th class="th">
<div>Jun. 26, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>employee</div>
</th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employee workforce, termination percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_NumberOfEmployeesRetained', window );">Number of employees retained | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds received in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,893<span></span>
</td>
<td class="nump">$ 34,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember', window );">U.S. Banking Institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds received in private placement</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember', window );">Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock', window );">Percentage of annual equity grant of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non Voting Convertible Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares sold in private placement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds received in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_PlacementAgentAndOtherOfferingExpenses', window );">Placement agent and other offering expenses in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_AssetAcquisitionMember', window );">Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_FixedExchangeRatio', window );">Fixed exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5494488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_AssetAcquisitionMember', window );">Asset Acquisition | Spyre 2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_AssetAcquisitionMember', window );">Asset Acquisition | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_AssetAcquisitionMember', window );">Asset Acquisition | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_FixedExchangeRatio', window );">Fixed exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5494488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis', window );">Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,595,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet', window );">Asset Acquisition, net liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Spyre 2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OutstandingAndUnexercisedStockOptions', window );">Number of outstanding and unexercised stock options to purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in process research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition assets acquired and liabilities assumed net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_FixedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_FixedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_NumberOfEmployeesRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees retained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_NumberOfEmployeesRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_OutstandingAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_OutstandingAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual equity grant of options to purchase outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_PlacementAgentAndOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent and other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_PlacementAgentAndOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=syre_USBankingInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622971512368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedOptionCostPayable', window );">Accrued option cost payable to Paragon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting fees</a></td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProgramRightsObligations', window );">Fair value of assumed Parapyre Option Obligation (Note&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedOptionCostPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued option cost payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedOptionCostPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProgramRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProgramRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622961969952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities - Additional Information (Details) - Paragon Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition', window );">Related party expenses incurred prior to asset acquisition</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ResearchInitiationFees', window );">Research initiation fees</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_ReimbursableResearchCosts', window );">Reimbursable research costs</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition', window );">Related party expenses unpaid prior to asset acquisition</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ReimbursableResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursable research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ReimbursableResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses incurred prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses unpaid prior to asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_ResearchInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research initiation fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_ResearchInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=syre_ParagonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140622959230928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>Sep. 08, 2023</div></th>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember', window );">Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Parapyre Option Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reduction in the total number of authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reduction in the total number of authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Spyre Therapeutics, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Spyre Therapeutics, Inc. | Series A Non Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Number of shares transferred as equity interest in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syre_ParapyreOptionObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>119
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M_*;509?M7IT7WC/C5A1)^ I"W;-SJ!"R.H*K&EKDY;'7L]!:I.5EQ%G(I>D
MSU="Z'W#O* ^")W\ U!+ P04    " #KB6589</@.T<'   &(P  &    'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;+U:;7/:.!#^*QJN<]?.D&!)?J--F$F
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M6#<9S4[VEV89:AM"MXY2-_'#AJF'BLF@E3UZD]O)Q;6%R$KWVJ()/0V=;A=
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MD+IE\RB7[?"*SVF>_"O9D<EE.!!-_.)1<,KKX53A6/\4M<7Z94M2'#FF+Y\
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M"G %OGQ:@)<O_@ O0%J SQNV$Z1(Q,U$JC%HIDE<76]^N![JN1Y$X ,KY$:
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MS?3;_=.4GA(4&)!N*NNP=QDX_L!>[\;LI5;0"[J7^UJ3!JVNTWG6VHN 7T?
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M<0XUFK3CU' H.<*AP:M4) .3BKP2[YZ#>,>L7-R/4M3+Z%=0'; -YDQ<=6<
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M08_L>N=K7]S&9%R+_4*PYP12&R!R%"7*HBF[Y(KW2=/.^=85L VL)S $[R!
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M;.U:VY(;MQ%]UU>@UK)+JN)R>=%J5]>JE60[2N)X2RLGJ4KE 9P!25@S@S&
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MF^9P%KH3Y6E(G0U0!ZM2%5*M9]Q^M;/'^U0?RYS*>,12ANX_$=]DO:Z)\Z:
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M0E5$J5UL-P -AQ1+M6"8_Q?:%EWMF 7%DI0J&*P1"C^Y*EQR\.QSR4.[3X3
MU,^Z& ^\(_I%QG<?Z:EAR<P>.&*\+$I4*3B+:6S>D0R)[2I<\"8!0Z-0:LJ
M.>]&]N3BXM=T<=R;?2S^HK:9%_;-E<IS#_\],!]E9<>@$BA?:-O"B#KVF&%"
MW\HM.P'/AX%9L$ 85\7SBKLN"V(2N^\N81A ]PULC+N#:Z6]H<!P0T^I"AW
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M^<^UDE":7L#SI4%_&#_0#^WZGTF^_@]02P,$%     @ ZXEE6%:+&>7R'0
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M.1''!)P4O4Y,6=XCF@D:+ (0/=D?/FF3^4T-S6=RDMK2&<Z"XKSC(CB/E=@
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MP5'F: *>SS6.\_4-;=!^B;K^/U!+ P04    " #KB658<_2/9GX&  !T%
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ME5"%4XZZPJ4I,2V";>)D-K4!<U[\Y%0CQP(X+ZT-ZP5?L!G5+_\!4$L#!!0
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M+7&^@[(&^%Y(:8X'ZZ#[QUC]!5!+ P04    " #KB658RFF>0@@#  !Y!@
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M:Q96NIQ-Y<HA'=9MXQD@'W =(4);V],.:^=/L@&0M.9L!V7@ ==?MSK=6Y"
MURIH3JW%>1FA142[G*T'!B'L@+U+B8XZ7I8)%C\0=R][I#A#Z&<Y.9PHQ3_H
M@;28"*WD0FEF!S>8G--C%\QPN=#4XIA#K2-9?+U@(@0E.;,1;N1X+S.M046O
M<JHDZ6MV*>:^(J=L+I@6*SAYK65V?W*;%58#A=+F<!E@D0\*39&V^4Z);CQ(
M[$YL'XAY(<T*NY5Y9OD+_@%\SHQU7%+2)W*?)*# =TPG7G;%C -^0!LD2B@F
M/&>$;<7D%/3(:RE5G+'FA,I*VPWA"@3E)(/@*/#^F'2^+&[G@R/D/)2>/4'A
ME8SX#4[^1FY%[G_]NNN[^(U9";96J"C.TBNT;:<R0X'ZG=%*DQ1K0,W+&D]=
M4K,LLS77TXIEJK*,9HT>[L3L=B[.1V>);953/.$ASZFN=TB_QJ>0[Z-I1UKR
M3"8>;#3I>(+J2)+%WLFDY!+=(&.A401>JUC;LD@KYA!7N;.Z+Q;OA::5S#8@
M=;D@][1N.ZF\;N7G2R<_/,,&&<]L[+6;#Q?W([VR%(@U*,3&F:WW@"=1 ?L\
M&659$@TFW<C&#M^JLC@V7L-"*0PFV7FA:(E:("=CM-^72Y61&XA_TF/83]\N
MM@7ACGM&+7UA:YVSYF%HC4%*%ME._I_DL?ER,AZ=G)V=G,T$?\YWB7>WYP5J
MB4+3(@\/1V3'V3L+6Y8U:R%TM!]C5_[@X)HS$=,#<ODDVW$>,,F2W2H'[BDT
M;CJNX!T3YJEIWK*NQ*SN=%=((;[-V.,E.08Y+DLT?^I-(G3J)<U!6\.<[UT9
MF^5Y#!=%6TF5GX W^X":3-=Y6Y01(^>889$I)<;WQ)^8S YD'C<B^+N @D2)
M%GQWF_!L.YSVH[#N]17NCPU@AW*]<A8&XDE^JV6IO67$:# ,L4:YBZ")@:*P
MO%2QH\6-*<6-WG-#>43 'G* PS78#JD67V]^O)5E]?G+8 ^<IY*U;^A@<\2^
M\Z3!QQ_E@H^NKYARFC//=$PMI!V . Q(6&5=6%JM+$.B,)5AY.,I+^#).!9S
MI&;&OV@7Z;T%[+M7)21-&K*U9]CSW,5A3"U!N)1J5A;ER\A(Y9P*$<2%7:,3
MYPK=#L'&<:2+L3MD'S>IO3T*7J4JXJZ&N0^A< 'ZMIW&VUVPW(SAL=*8"G$3
M,=4NC59.^7L>?9=*8W[[:CB28]U&Y5')[8*55O"ECG</W#ELAO")]15_R@6/
M9OQ<CUK+H K0T&W7SF05D0 LV)?7&><(8W)5IR[RJD'_SYF561][:</S5(O1
M#//JY_%X.IC@25OK[2/ TV+O2N0)H0\KJY7S=C:#?.7IHN>2:E9-/YSVS\\_
MOD*IQ+OQ:?_LKV?]T_/1SO(]:8H/IW#S!.<\D.-S[HZJ^!Q(^,2!PJY-^Q@!
M:FB[C@42\_$.V#=X^/>?WK1CT)OY7FRH-.,;5['AV0"87'ON_BS&X]%@].:.
M#<B4WRQZIDQ6QYW-(T:;523HS9T-4A_D,N61+<8UG%G$DLE63R/[VP<RC#59
M?$0S44 .Q"^J3 +#[X0]ZY:8DX;??.)TA!/GTA=;&U-$-6L>-7=&>/%N@GC%
M^]?$<.Q9?;CSMJ?DMLLOP5BK,<JE%S_=U>X]VRR^7AINEZ>7=-^D6RD\M&I:
M8NMH\/&LE\:V]D>P57QWM+ AV#)^+4@BZ;P ]Y?6AO8'']"]?;SZ U!+ P04
M    " #KB65844D-=$L$   D"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6RM5FUOVS80_BL'->@G1[9EITM3VX"3;EB+!362=L,P[ ,MG2PNE*B2
M5!S_^]Y1+Y$;VWO!OM@D=??<<Z_D;*O-@\T0'3SEJK#S('.NO!H.;9QA+FRH
M2RSH2ZI-+AQMS69H2X,B\4JY&D:CT9MA+F01+&;^;&46,UTY)0M<&;!5G@NS
MNT:EM_-@'+0'=W*3.3X8+F:EV. ]NB_ERM!NV*$D,L?"2EV P70>+,=7UU.6
M]P*_2MS:WAK8D[76#[SYD,R#$1-"A;%C!$%_CWB#2C$0T?C:8 :=25;LKUOT
MG[SOY,M:6+S1ZC>9N&P>7 :08"HJY>[T]F=L_+E@O%@KZW]A6\M.2#BNK--Y
MHTP,<EG4_^*IB4-/X7)T1"%J%"+/NS;D6;X73BQF1F_!L#2A\<*[ZK6)G"PX
M*??.T%=)>FZQ$D9L*#K+C4&D8+O9T!$L?QS&#<1U#1$=@1A'<*L+EUGXL4@P
MV0<8$I^.5-22NHY.(K['.(3)> #1*)J<P)MT3DX\WN0(WATJX3 !<M;MX+,1
MA16^*"S\L5Q;9VCWYR'':]CI85CNERM;BACG 36$1?.(P>+UJ_&;T;L3I*<=
MZ>DI]'^6F9,0APF^#>$%-'PHX%;L?+P'L#)X?HMF@^;(DMKWX;PJ^T=+"X*:
MU%(S@$[!94A'EH;*,OY:22LYV@-_?*/S4A0[$)8& 26%SPSW#B$4">BUDAM1
M)X> >B9*HS=&Y.?KW3D[(TR< 76F!]C1%I#+#ZAX,%^3?%M ^V9SD2"48L=N
M6W#:"8K:!LXF;\,+:C"E>%8XW<8HA$\%?*S4#L91#>=9=D;&TT-&\ E-+&WC
MW:>R'D"/0BJQ5@@5$:UYO\S$5KJ, UG2V&(>+'6_^GTT&GO#?AE!%X F*';0
MZM",4[N!E\4G/F G*32.+,IB'_ 7&=-XQ9YU5NL$HI<"%([*_$\.39X=FG9^
MD"1?)98@NR"&E&9%MP?GB;7I0UQY!E0@*"@*3<6==.N82_N9VU(%P!K;,N0,
M:BZ7SC$J>SHYBZ)PU)5+57+-$ IQD?A8VR1.[+-,94S7!&5%E[4Y@YN*YI$V
M.\\KIOJ3L5",AC3O"[20-F6=2F,=QR:I*'AUE+W#XIG]?MY=)EQ+P])52[(-
M"W+EV4((7YCS?XODJ0+YO@^Z"NS'4,#9N-=M*:+WN-!TP8F6CNA'#6(R+!-*
M")4V#8JR5!0S*KU!Q^B S>_SF(L'RA&DE2$%\QR.=AZ0V=>O+J/1^-U9U./7
MI;=.1Z(M5Z*GF%6Y*$C=25:7[-HJHT<"C,$9*50(]]7ZKU[E[T6\-QQ.= E%
MIFF2 UW_;SRWDCRB.=E-/^\8QR\]WE^JR7!7<?805Q+XFY$4PJ$[<=A[N>0\
MYOE]9B'65>'J1TQWVCT!E_7+YUF\?C_>"K/AP:$P)=51^,-%4-\K[<;ITK^#
MUMK1J\HO,WK&HF$!^IYJ[=H-&^@>QHMO4$L#!!0    ( .N)95BL;IX=2P8
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M)0O7*$^H"02>W*! \5Q5"!K6S\+^&%TSR]P ,,R(&(5O-R"0RCAETNR56$7
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M>#BZ:!EA%UI5<U>Q6MYA%2MSX!EXA"L SN;XO*13>)I"LJ3:EZ@*X].2RJV
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M:R61ZW0#KB^-:>,/6B!]M/GR?U!+ P04    " #KB65872?0\1,$   ["0
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MP1L:Q+X;U=TF6I?'X])&&K9YV=#7#7I6H/.5M7&_X0OZ[Z7Y/U!+ P04
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M22R=:X*\%HNW\*=A8,O!CY<"%EA62,.V(])0M&DLFK?TX^9P,O;FTPGKF&$
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MHQOO4@X+[U?;(D5$2 )<XF!!?_Z9"..I.+XTTN$WMK5"RDO\2PJ?W6!?X("
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MUZS_[BP!UTZW5B!;QXFRM,3S*6XK_B&@"P9\OK*6]D((T/UB9G\ 4$L#!!0
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MZU#O(>!P+,)(^(9BVFO,/\XMSH@)J:R&GC[*LD(94,TE?TR9H9%NK'0% WQ
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M>I-]:"I=:&6RA_:O1R]/.I@:!S@I9)H+GF8Y,LW9,GO?U-W69#_6I2KC 4X
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MAB&$#,EFK5O3(2%5!]SQ/#-%JQ2<305? SR.6!U(R4TC&LYUFR$&',%LV@;
ML&OGK2LS;0COL$FX825R I@69H?MBO:. 0;(89Q^CX-:K!T_9A;9._B]F1WA
M2IL$DNIC;-  @.P9',:65FK7GMMQ6B5+R&FO$IMD*6&;APNN][UL/IQ7)!QE
MF."V.?!%XJ<K72'O@5$!_X 6/'OX%IS7K2ZVH SBAH\0I-_S1:3%_-*7&^)T
M(>S">''+X:F(0]ZT]8BV@'ST)+7%S[HS$)^8P0$DP%K8/.'0N%Z36G!B_S*@
MIBWQ8_PU"=<,-^Z?3+\SEH^.G35[ A;PJ[["T@V+%]@*, U4]N[#QS_FN_WW
M;V(T[51N0#XP#;6J:&"/?U/F& E"5\#OB21+!7@D5@NL(H41,U 3&MYZRV9I
M/VCYE@XU[Y=!)C@/L?]I0/TX_4;5BG&$WP+MEWW1 ?P@;GI9C'TT+[9:H2B#
MI]:Z(_R!K=8RE(0-@$?CPPA1#S12*%YL\@TP(V!G8<26N22/3@H"BT[W36%9
MJ0%K(R>QC#*%I)VN>U(Y4 D#_@!?EZ5F2BKA[:K9$YF2+0;?*T!3 1('SE5%
MJZN1O.4S'BL8C'44V(*=:@N@0?U;= :'(MPB#<XS2"62+;0R.<Y =_ZX6^!@
M,C@L@"""7?258,JL;/L-CHBKY@EHBX"_Y.T7./5E3'V:#LTO8'@2;61UOUNQ
MZM=J\\5X6=:(<*OT&KF)5KA'!8U"N&'B(22L^H[VO8)W.R+1F8Q&2A<3+3$E
M5!>,6?< MC8%JH&'"/L3"#U&'DR2:T.2SB.KR/= /U6\I_ Z0JY(@T*$&:?H
MP.,X$HS>B3'.<^U!5>O0F(2OMW53-9M#@%640FK?$=W>>K,70U4?7C,JT"/6
M0'M-ZV!SV.MAFA;)F:F2]#.[Y=$1&@%%%%+!/M'^.:RO(GN1A>SK)F]+?/\-
M$*) 8152 KEK83$]V24CLZ"+ \@3P-CWK>F1B$FN(J>9?AZU6&#&1+F@QM#$
M7_6.-<#GC_\%-EIUHL;'/YZ=9FJWKYJ#(O0Z,J@.L6Z8UW6#6$0&C[;33G;!
ML/*IX8^FWC1D\0(74]G9R=*?_J[%@X9TH39 $U<@WO$9U#]800$A[^BL@NV@
MM[;-KBD.R"< ;?DB>]M457/-BAFP3?0*"2:','F*"-A\C=J[,,1X<>HK8 "%
MF2$AMM$%2$(8L29[!WE,MQ6[BY>QRP&!^C<R)]#^8'."Q65PL#.PNHQ&5IR6
M-@#F"2H'<):OD!\2D8T0A\,E[-ZFS7>P6S_7V5]Z4$BLWV.P8U9"XY>U0N;"
M>A5:4+1I)(J'F][809^F!D4F4"F280"(OD+=;%^!F6YWCZPK4O+';#7:' ,(
M([UELVG5AC2\=?9L>3;[[LGR-F.L1:=RK\.)*8CN "H^QS&=_V%Y=KHXS8 U
M5Z3KLQPH\<QTQZ?B#V?+Q3/WL%\@V,KXKZ.N9@U0X>M 0:BQB%@$!;LMB9\0
MY: ;8'GZ9/[=Z8QT$;*L*V;J5G+UI$.#;@$_(,9!^;HE&HK<;#/4<F3I>R6O
M9C TGKUF1)\;-Z:!FX!24[1ZQ0I=T[?9!3!0$JV\5V\4REJ6+>P8 "S(5&,#
MLQPE>-%FW.VMWHRB3Z:Q5C6I=B"<5*2B9F73KV"I*[ 'Z/'04F -1;'9QZR(
M---6/ ZX+43%^(NH!# DC-W)[H(8V"D3$3RI%Q-#P\-@CFVV(FXB@1N8N0:^
M-.O<R<?P+%J!K8D%.E\0D!# V.*9 VD0F>V++.7UNX=#+>U/^R0^G*8BL5NF
MD&786ENAB03C[7,QIN ]C";@GA#ML])+M@4)?.0<WCD*% OC D=QJ_Y<DP)T
MV9%R]Q#9W_+T^\^+RT7VK^?G'^CSV?>/F$37I)^*N^>M S+POL(X=0F"V8A\
MM@.^/;]\[<>J2ZO)BSN/WC<IUPX*NFM@]["@YAIG1^K4I<Z1Y(&7 K60,!)2
M V6Y0D8@*DGHWO#X4ZCVU=9Z\I@G,WS")?O$N62?3+ID/S/U_ @2!OF;27EC
M)T<8\<8.QR7"86)P9R!).@DZ<3ML.:()?9-PO'?Y%^!H;BKR..)YW8>&'K#C
MHI.CN&]:HK:=V\O@/$;G3YP(PMF(6::@IG/*:F22?:!"7C5DF2ZR]QYXM"D-
M$8X''Y"SU: ZM"3247JT;!^0;*F!4;>Z 9G 8H95YKG9JP)9L-B]E;K*+=<*
ML1#@;06DI5"#89L7^),!.8\*"3NHR<K5;='O#*GBHA=9-0JPP=HG;A7]0K8?
MB1W8#SQ@UJEBA"G3B'G;$I-UXL9:S0':V5#!O>Z<TU0VBVRIT"SVTO4<5.B\
M<@"RM5IJ%,.A\0>GDS2<;MN8@&H6V5_5(=B%(;JLCNBXT8"8DZ9!BE38[F#?
M0='V:$2SL$.7 E@V^8$V 7[W7EO& /M,9;Y(9V7NP?)TX7AT\F=RPK@HB/.B
MR+FKQ4QS6NW ,\41##0ID(F!&:K*4:44Q!8Z8+U>=ZRS[)T28$0)")UI:=5$
MR")8TI&GFE8NVJU7>=PHNF._5 \OUYW35;TG(.#%SJO(OE TJN?(UD4!\N]P
M9$#75TUUQ6:(\\7"EPK/\XALOAN#_I_$2"W_= S5A:IN4A!8K,[%R<N1KGFS
MGO>P6M WYN]5NX&-(]Q/2+FG3LH]G43B!>G!,"?]\2.L'8@! 4F)N\FA1L3=
MZ 3HE8 =$ELL0Z,I10/WF'-\RD^)TV#(?[L%/),/%9XNA2YY0X@^0.1L-/IY
M8/O!K"8)2*>N52K;<50>V'N%6R8\U,M&9V6Q/"%57GFH%@QG\ W#9HBEP^#
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MXQ-B^-(A071P/87ID:>8:'_\/#R2SW#> ^_@,U"WH#CC R*VD$<>LK)OI;0
MM9HKS%YR6OZ0H[E]G05<"@/7!*]SJ$6,+^2NPN,HQ, JCC"217;A-;-N<,)(
M)9,8@ZX=HW'*W(C#UR).,@[L:YC6Y$.E"9YMTRA"0^7/+O%CF&0[YOUP4,+Z
MM:U44-TU1H)L@@&Q;)<=,8FR&WP$OLCU;+*0]!69,&GMX)N6L]X*C'11H:'J
MACHJHZ%"'3:IL(RSQK0T,O0_QA%JK(\<(8<HG?LX7U+TP^'FEG;6@625;[E"
M8LZ?$G]-[9FOSCV;+L]]BZKUWVV6A/?*O_->TN2&WB.Y<&)#[S':+0"/2*"G
M8*2//8KQ%/ 59,_A$P/&<YSJ97?(?X,,OJT.486=/9@2B ,KK=/H)!9/,))$
M  N%UA?9/\"\/!)N8]"O;?GB<2Z;JVNS"5]6!H51=!%8UGF-+'R'OAZ2BBB^
M,?-,P <$'!4@2/F=7;2XP%Q&3H[&#5-V(C?M&"D\&IXY-+(IB]F)=UOS:-=X
M\!)+UVA@U>QUG;E<H2B0(3Y3=,MR0%DD&PI_GQ0LN:)&<D4)OP'NO;YG*+[I
M?MAJ8.K 9P]AV1BF453(<PVG!;&89<\O%I>BM]_EU0TPUZR0V+E:SCKU<GBG
MK_TO,RO")+D'F)M4:E-N#]4E<%I5SUE%P:!!Z262V?#)<!K[+&T)4Q]9$8%E
M?IX,L@0!HDYM0,Z)YP_I05SC211J6WS7[Z7\#JP%K+TD9#I<\NIUK# >I[@'
MYX7W.;TQEB@/>%AZ<>;+NQ%K&#H+"::S%]G/0X1Y^ORU;SJJX-/L$Y(>)7($
M^!1S@235Q_%Y#D@=(V\RT3(QD1@75-\IX,A<8R#@A+8X+3D=:[DT;(@>"K7Y
MZ:GD@"JG@+>T#7E-V2<5/"3G')A;SO-&9:;LEJHJ<6F&7N\1##Q^0;Q_6*69
MHE@A!I](R<YW7X#FRW,(/,Y;O2.GTC?QJ;B2=(6$'+B'?$++6"+N8B1BCFXS
M/63H+GM]&#,*"NX&$5E;BS'P&7)DA/^V6:JL6;*6&>5-^Y*9$!;?[,)&"+BH
MUZ!G.PHK3RDT/K?];#IW\B,G"I.[=,,UT4D%YAX)[A,*S#U&2P":?79M0CXU
M8/5G3T^?SC*)V]KGR8"Z$(O0^F*H%1 8X1+8=<%>-XR-^,X" 1&42DMZ-;-W
MBCG*B'"(4>LQ87L+V.8=90%O&O+3>)?,C/A:;7VX(IG6V)7)6;)ABK+UAPM
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MR<,CHS>OM%%BI$OVLDFAXN?%$7#3*"/29I2#-=^TV&"$:81_L%E1'*(9N9.
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M8/9#U^QQ2$S5[)H=_8D7PZ@6'X#?UTW3V0\X 1;E$WBO_A-02P,$%     @
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M0B1OP/>5,>XH^.D<=VOV%U!+ P04    " #KB6584FRDBYT"  #$!0  &0
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M?;,L9,RB"PERGA/Q;A,*=(-[^@]02P,$%     @ ZXEE6%Z^3(]5!0  ] X
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M*Y33.:CZ_2%42EF_L>J.%J5]U\R$AE>2_5W"LY1*(P#S<R'TIF,6:!^ZX_\
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M3F.&GEB8B4A%3*+S9[TB+T8]!0=K]EY8''*;'T).'(()>N"I6DITG\[8[%!
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M$SUR&>F6K>[2:3ZMYM+9W3G2W KT0"$)"M64_6\,U'A>@FZ[UF4WX@+T3!?
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MVAG@>::470G.P?IO-/P+4$L#!!0    ( .N)95B^C^R?/0,  "4(   9
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M7E!6 ?\OI31;P3IHIGGT%U!+ P04    " #KB6586LB-570#  !>"0  &0
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MT0(]!$FV1;'8"UH:V40E4B6IN-FGWR$ERX[K:'MA2A0Y/[\9SIB<;(7\H38
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MI2:]KZ,(3*/VQG&Z"@I;:D=Z#69)#R0:'T#[*ZW=UO$%NB<W^PM02P,$%
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M1@OF2AHE>,KJ2I$I+#0:RD&M4"NXX9+)A#,!]Z3T^3'P:[8TE+_$_MZ7HII
M;S\!UVPC4[($IT'I[M)/&,0GQYU!>WP@O%X37N\0>CS/F<S0 )<N-L^1'I@M
MN>"6H]E']R#@?KH/.<)*"6IL+C.PKEJ@K!-G(-E1L&0W5T7)Y,O)\474&8[I
M>$M+[&@1F/;&)6JN4K,%PQ1./8RJ##V..1L=_42FZ^("*@TLEJBWY1&]U<S2
ME+M7-*1.JV0K[BR.YGNHC(ZN<85:$[[&)Y05P@>(6H/+ :W]89^^I]U6-.S
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M6>,2K05JBVNI :<<]WIQCMN >*5L+2:X)/U^8IEHI'M;-KOYRNVZS)3<*]K
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M.# 816\8T*T!];Q;1Y[E!V;9;*+5AFAW&M'<CP_56R,Y+ITHCU;C+D<[.WL
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M;]^VN<'?'9!F HZOA-!=QP38_4#-_P=02P,$%     @ ZXEE6&SLX/J] P
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MU7FN @  X 8  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULO57;;MI
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M^QIX.@#XJ <?>8/;I0/?I@.60.K=E/"&W*\])D] E?90CGO*L5?ILE&"8:/
M(<G"9#CXR;QZ[XSII*>=#)<,DP' #WOPPP&3P:_]=C(<]91'7J5S6=4-@O+3
M>#7>&<?CGO!XN 0X'@ \CIY+231@"KPAGKZ9 _%.S8N]6@M98$L5O(KA-7UO
M#)_K59P,=_WQ$&4L?JYCL;?:_._]^\4]]Q_NM#^VE?Q)U9H)33@41BHZ.#1_
MZ&K3G6TF*&O7$2TEFO[*#4O3T8*R&\S[0DK<3FR3U??(V3]02P,$%     @
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ML 2;[40^W".;_AS@# >/3[HN9PYI=$*EIIL%9G%,HI.NK7_-U*2Q[V\,!'$
M01R3Q(2?'@#B^KTG=0Q&<8!1G.$ABD,:HE"IZ8:!9ARJ$,7I#E'P8YWJI;87
MUR1OX8;A'R[6>QK'P!0',,49'J\XI/$*E9IN&&C'H8I7G&9VTKHQL*4=LC'0
M 5YQ3'*6M@76* 7$U7O/VA@HXP#*.,.3%X<T>:%2T[?5 Q%)JN1%-F.5MBV"
M+<UL+H[</$B &6D2P'"S,!#7ZKWO?PS^D< _<OB6%DF*.%1JNF% '$FUI44V
MLYBV38!MS8YN I1 )M(D9^$FF2"NU'M^QJ 8"10C\8BEZR9*DG(+E9INMO:]
M(Y-XI>,F2C83DT/RQ ]SJ@V@$6F4O1AG@KA<[SD<(Y"1 #AR>" C22F&2DTW
M#!0CJ0(9V0Q:&I6+-=&_S ;4X>+4L2O'MJ_F7N$]>W^-;8P(Q@5J<:W!E>>2
MP@J5FFX88,7%PQKSRJN$L,I#F^@#!+AP\?RDZ^+EDF8G5&JZ62 4UR0[Z;AX
MN<W8I&TO.WZH4ZT =+@FT8DX/07$]7M/[!A4X@*5N,/3%)<T3:%2TPW7OOY,
ME::XW9M5\&.=Z@5PQ#7)6X1A"HB+]9[&,<#$!3!QA\<K+FF\0J6F?Y$=0,>C
MBE>\[HTM:!-]@$ HGDFNTK:N&H5_N'K?R:)2T\\%P(LW/&GQ2),6*C7=,,"0
M1Y6T>-V[7O!CG>H%6,<S26.$64"(:_6>Q3'0R ,T\H9O>?%(Z8=*33<,].-1
M;7GQNH,9M(D^0* 5SR1M$2;)(*[4>V)&>6Q+[;DM>-#2=7/ED;(,E9IN%EC&
M,PE9.FZNO&9XTG9SA1_JU$?4 *7,C>(8XW00E^O]Q)HQ,IHY$-!\>$8S)\4<
M*C7=,&#.G"JCJ80<9/E$F^P&.*T]I[!X2.07/WD(HI2%ZC[O,SLK[J63W7,7
M=V^R>%,^NO NSK)X7;Y\5/Y*)46#_.?W<9R]OBF>AKA_^N7B?U!+ P04
M" #KB658L#*TAT<&  #N-@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6S-FUUOVS84AO\*H15#"Z2Q)7\F2PPDUD<S-$40M]G%L M&IBVBDNB2E-T
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MXM-4B83B&,4[LU"RG86P1 L]::WUI-4F"R/]6%E PEQ(F <)\P?/--9MRBL
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M9,V-"CFE^2%[: 6DT6D0=70\.D+KSH'26!H\O^^@H$Z/9NP(K<M8:3:%-7M
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MKV^%*'Y]*0_G-H>QE_\#4$L#!!0    ( .N)95@]WP8$@P4  $HE   9
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M[0BM'+&17 PO0IM6=76%66GG;38U2U!L!!+# MFTHD\+)&A29F?D$</R6"M
MN,$ZT693ER\CB1B6Q,?KZ35:\BT32<P2A90N:+D1OY$L=N>L?$'4LVO:$5HY
M!T:$\> 247*JOZ[0RKMO1G\)O-IMNO_F54HMZ)/C@H2?]=I8C, 26& ;3G52
ME<[CJ0X_Z+6!&!4FL HWTCE2%5C;D+S)YN[![BZY7 \)J/KG3BA7:.6(30=
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M.:=\=-FTEA.KYD7?-U&6NLAB.*-&'[5;0-^G2MG5Q 6H_W7H?0-02P,$%
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M]"N];R*#9@!=^@.E>: T'Y06@-)"*%K?-;N51]-^Q<$(<EEN#DKS0&D^*"T
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M)YM?:%IY\S3.Z_^++\US1R=BOLF+=-4L7*[!*DJV_X9?FQ?BR0*F^<P"9K.
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M8_M/#V[K\6"3E/CLQ75T#F%,E1'7']Y^M#[9;W_I*PH]^"Y\%..77SKO@+_
M/M.NUO.OFG^X:VI6+SB<,?H9I7['N[X>U^YX:%^+WW\NGRK\0J[R__:L[_76
MG?2[U=OUZWP=SN6;D_+].)?99WER]<]_&+/1O_JZ@\0L$K-)S"$QE\0\$O-)
M+( PI3LFN^Z8Z/2K]YO5G<Q$>B_NTC!;B%R6LTRQE/%"W#V6T[YM[ZSKWOE+
MNPV[U@XTM%U(S"(QF\2<+3:KL6H"__G*O#S]_+0'R.$\$O-)+( PI0>FNQZ8
M:GO@4Y'._Q#S=%7N:N5A_=8@OU:W95^9:ZVA94YB%HG9).:0F$MBWA:;/FW
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M#J:B@WJHYJ-:0&EJ3[3YM$F>T*O'!E<]&E2CFHUJ#JJYJ.8UFO(N94PZ'[5
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M.#-%WFC.;Q1/LE[MG"O%H^QR30E\ NL)\'S)N=K>Z/9OV>Z?_ =02P,$%
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MIJ&S""0FF7B+WB!"T2W),F6I&+M2/4]'N4G-GE7LX C;#] MHW(E4$Q32-L
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MC<ZG4 VISHD5HDZNCB_-DUJ?+RWW)4ZF3=V?_#@)T']E@D3>?._*@49=4<U
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MB+YCCNCK?;</]QO/3:L%:( ?2G.A- ]*\Z&T $H+4315A&T>P)G\!)X:-'\
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M-#J[I*32[6C7+JRJ_3BU4):&,_]:TCB,VAV@[X52=K=P!KH!._T!4$L#!!0
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M^2'>V<7ABM;L4$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5_/YQ/5'N] ?#@PE
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M+P/Q[!0_NY%LD1Z$OS$I691>SH'ZP),.ZOLI8W)SDPQ0_)8R_@]02P,$%
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M[P@HZX#K*RG-?F(#="]3]A=02P,$%     @ ZXEE6($XO&+]!0  ;#(  !D
M  !X;"]W;W)K<VAE971S+W-H965T.#<N>&ULM9M;<YLX%(#_BL;;V6EGFACP
M/9MXIC'7G;;32=K=AYU]4$&VF0)B)=E.__U*0##86+';TY<$9,XG&3Y=X)C;
M'67?^)H0@9[2).-WO;40^4V_S\,U23&_ICG)Y"=+RE(LY"Y;]7G."(Z*H#3I
M6X8Q[J<XSGKSVZ+L$YO?THU(XHQ\8HAOTA2S[_<DH;N[GME[+GB(5VNA"OKS
MVQROR",17_)/3.[U:TH4IR3C,<T0(\N[WCOS)C"G*J XXJ^8['AC&ZFO\I72
M;VHGB.YZAFH124@H% ++?UNR($FB2+(=_U707EVG"FQN/]/=XLO++_,5<[*@
MR=]Q)-9WO6D/162)-XEXH#N?5%]HI'@A37CQ%^VJ8XT>"C=<T+0*EBU(XZS\
MCY^J$]$(,(<G JPJP#H,&)T(&%0!@W,#AE7 \-PFC:J T6' ^$3 N H8GUO#
MI J8G!LPK0*FYP;,JH!9H4-Y_8J+;V.!Y[>,[A!31TN:VB@,*J+E-8\S)?NC
M8/+36,:)^0/A@FU"L6%QMD*+-68KPM$5^H@9P\I#]-HF L<)?R-+OSS:Z/6K
M-^@5BC/T>4TW'&<1O^T+V1+%ZX=5K8NR5NM$K2;Z0#.QYLC)(A)UQ-OZ^,%+
M\>X+]5L:0%^>POH\6L_G\=[2$O_<9-=H8+Q%EF$-NDZ(/OQ=SK3A]L_5[OQ<
MN*L/MTDHP\V3X=[YX59'N']^N-D1'KQPYC>K4XUOB3"H.]2@X W.ZU"4"R3[
M")+%A,G>],][>3P*!$GYOQV-O2_APVZXFOEN>(Y#<M>34UM![,U__\T<&W]T
M.0<)LR%A#B3,A81YD# ?$A8 P5I6#VNKASKZW$GSA'XGI%BZR"562-XB09B<
MD'"Q9LF)+,J$7!YU2:UE7RIU"9L5,+64V\Z-ZZGLN=NFK.<<Y$ VRX6$>9 P
M'Q(6 ,%:$HYJ"4=:"1>8KQ$G6\)P%A*4X^]RU2UX,;Y2L28,D4K3*T82+$B$
M0CG^=JU/[K4U7:HD),R&A#F0,+>$C1J=:CPTC':G\B!K]"%A 1"LI>ZX5G?\
MLKJUL'( K55%SZJRUL(A+%?B7>IJ:[I474B8#0ES(&%N"1LWU!T-CM2%K-&'
MA 5 L):ZDUK=B5;=CS2["HN15]#PVY5ZLJ#&U30G&2\G?_*DMO<F"XIP&))$
MCM-J=RO%5DK390N!=YAUWCO>:]MSJ>"0,!L2YD#"W,F1X*9Q)#ADC3XD+ ""
MM02?UH)/M8)_I@(GTNB,QY%25BF]9#1%4<QSRN5GTMR$2H.3>*O$Y9QT+RJF
M1Q/DZ/ :++1MN=3',RITSCC&A6R4!PGS(6$!$*QEV:RV;*:U[#WE'$FS#J6Z
M>DDJ+?;2T1 29D/"'$B8.SMR?F:.#@;#XV,.>H7_XA$!4*-;0IG&_M&MH5>*
MR(FT- ?%:8YCII:770Y5H.;T,#L:F?2U72H'*,T!I;F@- ^4YH/2 BA:V]!&
M<L'4&AK45JJA+U&^KFD2*5L9W9+B;JC35_.HZYF38V&UE5\L+"3- :6YH#0/
ME.:#T@(H6EM8:R^LI5\+-IYI+N7-.4[IYL20J@5=.B^#TFQ0F@-*<T%I'BC-
M!Z4%%:TYB%G->[*VHOO\DJE]T*\23 2S<%T\]HS(EB0T/SGO@Z:30&DV*,T!
MI;F@- ^4YH/2 BA:6^9]6LD<_LILJ0F:60*EV: T!Y3F@M(\4)H/2@N@:&V_
M]QDK4Y^R^N&[?CWW8K-!,U2@-*>B->]-CY;Z+FB5'BC-!Z4%4+2VL/L\E:E/
M5'DD(TQZJD9A',FU<"P'Z.*'8)V6@N:B0&DV*,T!I;F@- ^4YH/2 BA:6^=]
M[LJ<_-+U!6@J"I1F@](<4)H+2O- :3XH+8"BM?W>IZY,?>[JQ]<7D(F5!2C-
M!J4YYG$"S#I>7X!FP$!I/B@M@**5PO8;OSQ/"5L5KRUP%*JG9N5O9NO2^M6(
M=\4+ 0?EMGGCF!WEKGGCER\^[/'E>Q@?,%O%&4<)6<JJC.N)O,*L?+6AW!$T
M+W[W_I4*0=-B<TUP1)@Z0'Z^I%0\[Z@*ZA=,YO\#4$L#!!0    ( .N)95A%
M(4U4Q0(  "D(   9    >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;+56;4_;
M,!#^*U:&)I &>6O3PM)(E X-":2*CNW#M ]N<FTL'#NSG1;^_6PG#44-T83$
ME\8O=\_SW-F^:[SEXE'F  H]%93)B9,K55ZXKDQS*+ \XR4PO;/BHL!*3\7:
ME:4 G%FG@KJ!YT5N@0ESDMBNS442\TI1PF ND*R* HOG*5"^G3B^LUNX)^M<
MF04WB4N\A@6HAW(N],QM43)2 ).$,R1@-7$N_8NI[QD':_&3P%;NC9$)9<GY
MHYG<9!/',XJ 0JH,!-:?#5P!I09)Z_C;@#HMIW'<'^_0KVWP.I@EEG#%Z2^2
MJ7SBC!V4P0I75-WS[7=H AH:O)13:7_1MK'U')164O&B<=8*"L+J+WYJ$K'G
M$ 1O. 2-0V!UUT16Y0PKG,2";Y$PUAK-#&RHUEN+(\R<RD()O4NTGTKN02I1
MI:H2A*W158[%&B0Z-2-F1H2ARS05%63HM>D44\Q20,<S4)A0>8*.C/&/G%<2
MLTS&KM+R#(F;-E*FM93@#2E^@.XX4[E$WU@&V6L 5\?5!A?L@IL&O8@S2,]0
MZ']!@1>$Z&$Q0\=')SVX89NTT.*&_Y<T+A72(9L$@=@ ^GVK[=&-@D+^Z4I#
M#3[H!C?/\$*6.(6)H]^91722SY_\R/O:(WW02A_TH2=S_*S?E.H\GMIS:#W-
M:]XDI\/0\V)WTT$X; F'O80+V("P-^66X"6A1#UW<?>"O#,G42LQ^LCCC#Y
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MR-XF.@CXJTDU)E@T$EB'R&E#Y/1=E/1T3/;'!(M& NNP/VO8G[V'DIZ]JL'
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MF&M"K!_.S%IC9?;%)N5$+9)8[\NV$]TTV^YY^N>F()T'O7VI14XC0L(H$L9
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M#_+I2AS4@(;2PHIVK%TS@HY*H32&HFUDT][Y,G[Q:PZON;R/,T42<6?PWL7
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ZXEE6*;;*[80!P  VT$   \
M  !X;"]W;W)K8F]O:RYX;6S%G%U/&SD4AO_**%=46C9D/C-5J42![B)1B@CJ
M7J[,Q$DLYB.U9T+;7[_VA-#CD+S:FT.N2&;R\<1C^SG'/L.'IT8_/C3-8_"C
M*FMS.EBT[?+]<&B*A:R$^;-9RMJ>F36Z$JU]JN=#L]123,U"RK8JA^')23JL
MA*H''S]L/NM6#^F3II5%JYK:'G0'OBGY9'Z?=T^#E3+J096J_7DZZ!^7<A!4
MJE:5^B6GIX.306 6S=/?C5:_FKH5Y:3035F>#D;K$]^D;E7QZO#$0=Z+!],?
M:<7#G; @IX/TQ'[@3&G3]J_H/U]8QI6T+UX_Z]KFLRI;J2]$*__23;=4]=Q]
MC/T50_(S^G;8_%TWXGO]?YJQF<U4(2^:HJMDW:[;4<O2 =9FH99F$-2BDJ>#
M\V8EM?L]]@NNINO?UEHHTE+ZO;(G]-6TQ^-$J4U3JJG]]FGP292B+F30-Z$A
M@"$ # \&&!S="@(9 <CH#2$G#L*]P03-+/BZ]"YU#"#C T+^&Q+(!$ F!X,\
M;ZHE@4P!9'HXR(6H"60&(+/#00JS()!C #GFA7SA<EAGQKA1?59\[Y2VT%Y+
MY@ RYX6\7\B^\XGZIV5RLY!1?3O>:FDDA1R=H)G\A!?S0II"JZ4[[N!:2_VI
M,ZJ6QCALB@F%PVR<25=50O]TB!,UKY5]F[#7_ZPHFJYN%<5$VADQ>^>S4#KX
M)LI.!E^D,)U>#Q^*AX0SXC:.'<+!I1TH*U'VP]IUS"]"/TH;$SF2WYA(.2-F
MY]A0T?JO78\;A[MT;_@CN)$M143"&3$;QW8\W?6SS33X:@>-#LX[K=V4=*W$
M@]<?D7)&S,[98/90-JQ6TNN+2#0C9M/<N8,6[5:X*WVO16U$GQYXA,@R(V;-
M]&99B\4H=Y:"(;.,F-5BFTS,[7Q]-M>RGV!HT(UD$C++Y-K.>5X/"Y$S0OXL
M9>7R0?NM3KHSJ74?U#3%XY;:0IBJ,#MCTFK[S7-5V%%:R-K(W]?5:THDCI!9
M'!/KBSYVD?-?JA1ZKFI[I8.V":ZJ2GI-B<01,HOCIEF)323S1=3=S,XHG;8)
M^[I)*2:21\@LC[X+'MN T'9'%R+:BRZVYI<062-DML:%G-D T+'5K58/7=^D
MMZ4768?('2&[.TRKN\VUM=F3GOO3#M)&R*R-J[IH*AG<BQ\^$S)&R&P,&SD%
MUXT-Z6]MI#*Q[47'0H24$3$K8](]&/F]<Y'3Y6IKRHN0/:)#9AS>PD>$[!$Q
MVP/F;SXF7.KB%@ALS8AB(H%$S +9G;\%1_<N/3+O*"822,2]WH7R./^B(X]$
MS!X!>9QK4HJ);!(QVP3F<GYK(J]$S%[9GS#U_9-B(M5$S*IYE37M&CTQ4D[\
M)EG*3BPDG/B0Z8K7#6,DG/APZ<K6H(Z1<&)NX>R)L9\O.\6$NRO,PMD9R>[L
MFL@W,;-O:$B[$PY9)F:VS.O8=B<B,DS,;!@<I-'H)T:&B;D7O%ZO%NYL2J27
M^)#;*OY^)'),PI[6H'@WIIC(.<E!DYR$8B+G)(?95@F.@\^J]I8E$N2<A-DY
M^S%OA-94C0ER3G*0),=ANGWH.<6$>_K,TMF/V7=5BHGTDS#K![:F/R$A!27<
M&_LP9:0*2I""$F8%84QOWD062I@MA#'IO)DB"Z7,%L*8*<5$%DJ9+836">QH
MIYC(0BFSA3#F#<5$%DJ9+827,^A(3Y&%4O;,9^]RAO,EQ4062IDM!#$O?U!,
M6%O&;"&(>4?3W119*.5>:GNU./0<&[F:V^"(8B(+I6^]\V\QR3&*B2R4OG4=
M0'!T86=V57KI6H8,E+W-6IMWE7<Q(OUDS/IY8715M_9T/>_GSCZU*)17F(GT
MDS'KYP7S'ZGF"SO8C\]6EG<N[?BN!.V4&=)/QJR?%\S^@<W5S9YNB>23\5<U
M@[56ZL@,R2?CKVL&F#0:SI!\,F;YH"5A/S#*8&DSLWPPYCG%1/+)N*N;4:V-
MEU!F2#X9=TD!JK7Q,,=(0&/NA;A]^P!K)5%,Y* Q]T+<?LS+:EE23.2@,?OF
M#\#T+SIRT/A0FS_'_>1),9&%QLP6 IC.\10366C,;*&]Y6!KKU-,9*$Q>PJT
M:ROM)?*DF,A"XT/4KFW67KV*L3&\Q8:]VF OYE:QW1A9:,QL(6]G\C@X<AN!
M[X+GHY]HWILC"^7,%MK"W$Z&*":R4,YLH2W,R]E,]G?#/C<HQ406RIDMM(7I
MILZFWMRF=N%A(@OES!;:L3%-DS>*B2R4<Q=-[\*\DT5CD]]2T>D]1Q;*V2V$
M]M!I+I0C"^7LM=,(D^X,Y,A"^1O5O-&M_N/@9>F88B(+Y0>H2+"8TVF_*N=A
MPEL]F2WTJHB90I8!P1R=X)L]>P\-^Y>;CQ^FZ\CKQGZ)L<<+41:W.G!_^L\*
MX\3=AS3KRO+<'OM:7S=BNOG?!)O_J_#Q/U!+ P04    " #KB658PRL?/=8"
M  #'.@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=N];N) &$;A
M6T&^@-CS/[,*J;9)N\H-6,1 %,#(]FJ3NU]$"GBM+;:)?"HT1OXXU2-DSSS^
MZ@[M]-:?QOW;>5Q]' ^G<5WMI^G\HZ['S;X[MN-#?^Y.EV^V_7!LI\MRV-7G
M=O/>[KK:-DVLA_L9U=/C_<S5R^>Y^Y^)_7;[MNE^]IO?Q^XT_6-P_:<?WL=]
MUTW5ZJ4==MVTKNJ/P^WR6%\_S,-E<K5Z?EU7P_.KJ>JE@ZP$V>6#G 2YY8.\
M!/GE@X($A>6#H@3%Y8.2!*7E@[($Y>6#B@25Y8-,HS(V@*09U@"MC7)M %X;
M!=L Q#9*M@&8;11M U#;*-L&X+91N U ;J-T&X#=1O$V +VMZFT!>EO5VP+T
MMK,_VP"]K>IM 7I;U=L"]+:JMP7H;55O"]#;JMX6H+=5O2U ;ZMZ6X#>3O5V
M +V=ZNT >CO5VP'T=K.')0"]G>KM 'H[U=L!]':JMP/H[51O!]#;J=X.H+=3
MO1U ;Z]Z>X#>7O7V +V]ZNT!>GO5VP/T]K.'W0"]O>KM 7I[U=L#]/:JMP?H
M[55O#]#;J]X>H'=0O0- [Z!Z!X#>0?4. +V#ZAT >@?5.P#T#K.7E0"]@^H=
M 'H'U3L ] ZJ=P#H'53O - [JMX1H'=4O2- [ZAZ1X#>4?6. +VCZAT!>D?5
M.P+TCK/-)@"]H^H= 7I'U3L"](ZJ=P3HG53O!- [J=X)H'=2O1- [Z1Z)X#>
M2?5. +V3ZIT >B?5.P'T3K/-@@"]D^J= 'HGU3L!],ZJ=P;HG57O#- [J]X9
MH'=6O3- [ZQZ9X#>6?7. +VSZIT!>F?5.P/TSK/-W@"]L^J= 7H7U;L ]"ZJ
M=P'H753O M"[J-X%H'=1O0M [Z)Z%X#>1?4N +V+ZET >A?5NP#T+K/#.@"]
M33,_KO.=?H_3YZ$;;T5?ZUG =VH]7>[M;K]_77Y=G!T1:JY U_<9X]-?4$L#
M!!0    ( .N)95B%GR=*6 (  ,,X   3    6T-O;G1E;G1?5'EP97-=+GAM
M;,W;RV[;,!"%X5<QM TL621%4D6<3=MMFT5?0)7H6+!N$)G4>?O2R@5HD1H-
M7*#_QH)-<LZ( WP[7W][G)Q?'?MN\-MD'\+T(<M\O7=]Y=-Q<D-<V8US7X7X
M=;[+IJH^5'<N$YN-SNIQ"&X(ZW"JD=Q<?W*[ZKX+J\_'^+-OQV&;S*[SR>KC
MT\93UC:IIJEKZRK$]>QA:'Y+63\GI/'DLL?OV\E?Q0U)]F;":>7/ <_GOCZX
M>6X;M[JMYO"EZN.N[-AE/CQVSJ?G2[S1X[C;M;5KQOJ^CT=2/\VN:OS>N=!W
MZ5/1J_/)(=ZP>_K,+\Y?RIP+C#MOYW'R<6*S>W_<RTA.I]=3+.3FT)Y_Q=?$
M6/KB]W.G:3>N^<OL>+T_QOFPS,-GR^/R._YUQJ_UW]F'@/0A(7TH2!\%I \-
MZ<- ^K"0/DI('_F&T@A%U)Q":DXQ-:>@FE-4S2FLYA17<PJL.45609%54&05
M%%D%159!D5509!44605%5D&155!DE119)45629%54F25%%DE159)D5529)44
M625%5D6155%D5119%45619%54615%%D5159%D5519"THLA8460N*K 5%UH(B
M:T&1M:#(6E!D+2BR%A19-45639%54V35%%DU159-D5539-44635%5DV1U5!D
M-119#4560Y'54&0U%%D-159#D=509#4462U%5DN1U5)DM119+4562Y'54F2U
M%%DM159+D;6DR%I29"TILI8464N*K"5%UI(B:TF1M:3(6E)DS3?_D];OXWCX
MQ_'+,^VK=GC)SY;_+M[\!%!+ 0(4 Q0    ( .N)95@'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MZXEE6%"W6M'O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ ZXEE6)E<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #KB658)%>V
M/)X$   4%0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ ZXEE6&7#X#M'!P  !B,  !@
M ("!X@P  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .N)
M95@%;O9_Y@,  )83   8              " @5\4  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " #KB658@VDD<\D&   H(@  &
M        @(%[&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ ZXEE6'N)_<$& P  ]0@  !@              ("!>A\  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .N)95@Z1UY$. ,  &P*   8
M              " @;8B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " #KB658U.%#.CT1  ![\@  &               @($D)@  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ZXEE6((_*^HI"P
MWSD  !@              ("!ES<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( .N)95@@GDV#F0(  ,H'   8              " @?9"
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #KB658)](]
MDN@(  #\%0  &0              @('%10  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( .N)95C.Q2UV@ X  #(I   9
M  " @>1.  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MZXEE6%:+&>7R'0  X5T  !D              ("!FUT  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " #KB658; /#D(,)  "5&@  &0
M            @('$>P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( .N)95AS](]F?@8  '04   9              " @7Z%  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ZXEE6$SJS-@<!0
MM@L  !D              ("!,XP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " #KB658$V-V++("   ]!@  &0              @(&&
MD0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .N)95C*
M:9Y"" ,  'D&   9              " @6^4  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ ZXEE6$G)^4M4"   8A<  !D
M     ("!KI<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M" #KB658$]0./O$'  ")%   &0              @($YH   >&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .N)95A120UT2P0  "0+   9
M              " @6&H  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L!
M A0#%     @ ZXEE6*QNGAU+!@  >0\  !D              ("!XZP  'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #KB658OW5I1T4+
M  "E)   &0              @(%ELP  >&PO=V]R:W-H965T<R]S:&5E=#(R
M+GAM;%!+ 0(4 Q0    ( .N)95BCUYU4T@X  , I   9              "
M@>&^  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ZXEE
M6%TGT/$3!   .PD  !D              ("!ZLT  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " #KB658)5_OFFL&  "J$0  &0
M        @($TT@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( .N)95A%"XHXU!$  ',Y   9              " @=;8  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ZXEE6(:C?PKD @  ;@8
M !D              ("!X>H  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " #KB658^*@IR((&  !2#P  &0              @('\[0
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .N)95C=S#R7
M!PD  -T6   9              " @;7T  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ ZXEE6 U5JPQ_ @  G04  !D
M ("!\_T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #K
MB658E1-E7N0$  #H"@  &0              @(&I  $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .N)95@N*!A"OB8  .6,   9
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M970S-BYX;6Q02P$"% ,4    " #KB658,J];!>@"  "9!@  &0
M    @($V/0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M .N)95B^C^R?/0,  "4(   9              " @55  0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ ZXEE6',D7Z\$ P  V0<  !D
M             ("!R4,! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " #KB6586LB-570#  !>"0  &0              @($$1P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( .N)95BL^X?QS ,
M ,()   9              " @:]* 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ ZXEE6*.U"3*0 @  ?@4  !D              ("!
MLDX! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #KB658
M[7_(Y<D"   .!@  &0              @(%Y40$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( .N)95CN8%53B04  -$.   9
M      " @7E4 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ ZXEE6$Z9[<M3 P  E@<  !D              ("!.5H! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #KB658-P.K<5X%  !,#0
M&0              @('#70$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( .N)95AL[.#ZO0,  *8(   9              " @5AC 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ ZXEE6%&=+?>6
M P  H@D  !D              ("!3&<! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " #KB658"N>3GCP#  #_!P  &0
M@($9:P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .N)
M95@S+]1."@T  *>W   9              " @8QN 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ ZXEE6 ]FU7FN @  X 8  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( .N)95@8NV(9BP,  $H1   9
M  " @0"4 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
MZXEE6./8<_/? @  -@<  !D              ("!PI<! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " #KB658ZC-@6J@&  "8+0  &0
M            @('8F@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( .N)95@]WP8$@P4  $HE   9              " @;>A 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ ZXEE6-5D:1JD P
M1@P  !D              ("!<:<! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " #KB658Y.S\-I("  "T!@  &0              @(%,
MJP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .N)95@N
M-F[_M@,  -T3   9              " @16N 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ ZXEE6)'8E4WF!   W"(  !D
M     ("! K(! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .N)95@M\54ETP0  /H7   9              "
M@3?/ 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ ZXEE
M6"&6MP$Q!   '!8  !D              ("!0=0! 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    " #KB658U=CVP-@$  !('0  &0
M        @(&IV $ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( .N)95B:+J7P_P,  .(6   9              " @;C= 0!X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ ZXEE6!OLV6Y? P  W@P
M !D              ("![N$! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q0
M2P$"% ,4    " #KB658):G N9("  !)"   &0              @(&$Y0$
M>&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( .N)95@_TCR$
MJ@(  /D'   9              " @4WH 0!X;"]W;W)K<VAE971S+W-H965T
M-S0N>&UL4$L! A0#%     @ ZXEE6#Q)#]Z/%0  JEX! !D
M ("!+NL! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #K
MB658%,"9; L#   2#   &0              @('T  ( >&PO=V]R:W-H965T
M<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( .N)95CLF>J0]@D  !YD   9
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M970X,2YX;6Q02P$"% ,4    " #KB658O!54X?\$  !7&0  &0
M    @(%J,P( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    (
M .N)95C0QE2<&@,  *8*   9              " @: X @!X;"]W;W)K<VAE
M971S+W-H965T.#,N>&UL4$L! A0#%     @ ZXEE6#2,+NMN!   \AH  !D
M             ("!\3L" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"
M% ,4    " #KB658 +8TA3($  !^$P  &0              @(&60 ( >&PO
M=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( .N)95A=+:L(<P(
M *4&   9              " @?]$ @!X;"]W;W)K<VAE971S+W-H965T.#8N
M>&UL4$L! A0#%     @ ZXEE6($XO&+]!0  ;#(  !D              ("!
MJ4<" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " #KB658
M12%-5,4"   I"   &0              @('=30( >&PO=V]R:W-H965T<R]S
M:&5E=#@X+GAM;%!+ 0(4 Q0    ( .N)95@TD$_)> 8  *\]   9
M      " @=E0 @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%
M  @ ZXEE6&"TJE[= @  0P@  !D              ("!B%<" 'AL+W=O<FMS
M:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    " #KB658/W<7&X$$  !=&
M&0              @(&<6@( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+
M 0(4 Q0    ( .N)95@)"A71A 0  "83   9              " @51? @!X
M;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ ZXEE6"6>!S$U
M!   *A(  !D              ("!#V0" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,RYX;6Q02P$"% ,4    " #KB658TG<67J\#   T$   &0
M@(%[: ( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( .N)
M95CK,25(#P,  (D)   9              " @6%L @!X;"]W;W)K<VAE971S
M+W-H965T.34N>&UL4$L! A0#%     @ ZXEE6!E(?]%<!   6Q8  !D
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M=#$P,"YX;6Q02P$"% ,4    " #KB658+W Y;&4#  "X%@  #0
M    @ &6D0( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .N)95B7BKL<P
M !,"   +              "  2:5 @!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M .N)95BFVRNV$ <  -M!   /              "  0^6 @!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #KB658PRL?/=8"  #'.@  &@
M@ %,G0( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #K
MB658A9\G2E@"  ##.   $P              @ %:H ( 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     ; !L *P=  #CH@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>359</ContextCount>
  <ElementCount>473</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Statement - Statement of Assets Acquired and Liabilities Assumed</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed</Role>
      <ShortName>Statement of Assets Acquired and Liabilities Assumed</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/TheCompanyAndBasisOfPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Description of the Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisition</Role>
      <ShortName>Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Paragon Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ParagonAgreement</Role>
      <ShortName>Paragon Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Strategic License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreements</Role>
      <ShortName>Strategic License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Sale of Pegzilarginase to Immedica</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SaleOfPegzilarginaseToImmedica</Role>
      <ShortName>Sale of Pegzilarginase to Immedica</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Novation of Manufacturing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NovationOfManufacturingAgreements</Role>
      <ShortName>Novation of Manufacturing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/FairValueMeasurements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/CashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/AccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/RelatedPartyTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Asset Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisitionTables</Role>
      <ShortName>Asset Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/AssetAcquisition</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Strategic License Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreementTables</Role>
      <ShortName>Strategic License Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/StrategicLicenseAgreements</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/StockBasedCompensation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Restructuring Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesTables</Role>
      <ShortName>Restructuring Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/RestructuringCharges</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/NetLossPerShare</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.spy.com/role/AccruedLiabilities</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/TheCompanyAndBasisOfPresentation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Fair Value Measurements - Changes in Forward Contract Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Forward Contract Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Fair Value Measurements - Changes in CVR Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Changes in CVR Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Property and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails</Role>
      <ShortName>Property and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails</Role>
      <ShortName>Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Related Party Transactions - Related Party Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails</Role>
      <ShortName>Related Party Transactions - Related Party Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Asset Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisitionNarrativeDetails</Role>
      <ShortName>Asset Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Asset Acquisition - Asset Acquisition Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails</Role>
      <ShortName>Asset Acquisition - Asset Acquisition Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Paragon Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ParagonAgreementDetails</Role>
      <ShortName>Paragon Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/ParagonAgreement</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Leases - Operating and Financing Leases Presented in Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails</Role>
      <ShortName>Leases - Operating and Financing Leases Presented in Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Leases - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>Leases - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Strategic License Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails</Role>
      <ShortName>Strategic License Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Strategic License Agreement - Changes in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails</Role>
      <ShortName>Strategic License Agreement - Changes in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Sale of Pegzilarginase to Immedica (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails</Role>
      <ShortName>Sale of Pegzilarginase to Immedica (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/SaleOfPegzilarginaseToImmedica</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Novation of Manufacturing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NovationOfManufacturingAgreementsDetails</Role>
      <ShortName>Novation of Manufacturing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/NovationOfManufacturingAgreements</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Stock-Based Compensation - Employee and Non-Employee Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Employee and Non-Employee Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Stock-Based Compensation - Employee Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Employee Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DefinedContributionPlanDetails</Role>
      <ShortName>Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/DefinedContributionPlan</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Restructuring Charges - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesNarrativeDetails</Role>
      <ShortName>Restructuring Charges - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Restructuring Charges - Changes in Accrued Restructuring Balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails</Role>
      <ShortName>Restructuring Charges - Changes in Accrued Restructuring Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Restructuring Charges - Charges Related to the Restructuring Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails</Role>
      <ShortName>Restructuring Charges - Charges Related to the Restructuring Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Income Taxes - (Loss) Income Before Income Tax Expense by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails</Role>
      <ShortName>Income Taxes - (Loss) Income Before Income Tax Expense by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.spy.com/role/IncomeTaxesTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Accrued Liabilities - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Accrued Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Accrued Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d518298dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="d518298dposam.htm">d518298dposam.htm</File>
    <File>syre-20231231.xsd</File>
    <File>syre-20231231_cal.xml</File>
    <File>syre-20231231_def.xml</File>
    <File>syre-20231231_lab.xml</File>
    <File>syre-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g518298g08m07.jpg</File>
    <File>g518298g40p53.jpg</File>
    <File>g518298g61v60.jpg</File>
    <File>g518298g68p81.jpg</File>
    <File>g518298g81i79.jpg</File>
    <File>g518298g82k34.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1087">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d518298dposam.htm": {
   "nsprefix": "syre",
   "nsuri": "http://www.spy.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "d518298dposam.htm"
     ]
    },
    "schema": {
     "local": [
      "syre-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "syre-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "syre-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "syre-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syre-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 367,
   "keyCustom": 106,
   "axisStandard": 36,
   "axisCustom": 0,
   "memberStandard": 39,
   "memberCustom": 47,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2023": 3,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://www.spy.com/20231231": 2
   },
   "contextCount": 359,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 755,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1087,
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://www.spy.com/role/Cover",
     "longName": "1001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.spy.com/role/ConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:NontradeReceivablesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
     "longName": "1004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical",
     "longName": "1005 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "longName": "1006 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
     "longName": "1007 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "1008 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed",
     "longName": "1009 - Statement - Statement of Assets Acquired and Liabilities Assumed",
     "shortName": "Statement of Assets Acquired and Liabilities Assumed",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.spy.com/role/TheCompanyAndBasisOfPresentation",
     "longName": "1010 - Disclosure - The Company and Basis of Presentation",
     "shortName": "The Company and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies",
     "longName": "1011 - Disclosure - Description of the Business and Summary of Significant Accounting Policies",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1012 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.spy.com/role/FairValueMeasurements",
     "longName": "1013 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecurities",
     "longName": "1014 - Disclosure - Cash Equivalents and Marketable Securities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNet",
     "longName": "1015 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.spy.com/role/AccruedAndOtherCurrentLiabilities",
     "longName": "1016 - Disclosure - Accrued and Other Current Liabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:AccruedAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:AccruedAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.spy.com/role/AccruedLiabilities",
     "longName": "1017 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "syre:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "syre:AccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.spy.com/role/RelatedPartyTransactions",
     "longName": "1018 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.spy.com/role/AssetAcquisition",
     "longName": "1019 - Disclosure - Asset Acquisition",
     "shortName": "Asset Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.spy.com/role/ParagonAgreement",
     "longName": "1020 - Disclosure - Paragon Agreement",
     "shortName": "Paragon Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:OptionAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:OptionAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.spy.com/role/Leases",
     "longName": "1021 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquity",
     "longName": "1022 - Disclosure - Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreements",
     "longName": "1023 - Disclosure - Strategic License Agreements",
     "shortName": "Strategic License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.spy.com/role/SaleOfPegzilarginaseToImmedica",
     "longName": "1024 - Disclosure - Sale of Pegzilarginase to Immedica",
     "shortName": "Sale of Pegzilarginase to Immedica",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.spy.com/role/NovationOfManufacturingAgreements",
     "longName": "1025 - Disclosure - Novation of Manufacturing Agreements",
     "shortName": "Novation of Manufacturing Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.spy.com/role/StockBasedCompensation",
     "longName": "1026 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.spy.com/role/DefinedContributionPlan",
     "longName": "1027 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.spy.com/role/RestructuringCharges",
     "longName": "1028 - Disclosure - Restructuring Charges",
     "shortName": "Restructuring Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.spy.com/role/IncomeTaxes",
     "longName": "1029 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.spy.com/role/NetLossPerShare",
     "longName": "1030 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.spy.com/role/SubsequentEvents",
     "longName": "1031 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1032 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1033 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "syre:AccruedLiabilitiesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "syre:AccruedLiabilitiesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "1034 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.spy.com/role/FairValueMeasurementTables",
     "longName": "1035 - Disclosure - Fair Value Measurement (Tables)",
     "shortName": "Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables",
     "longName": "1036 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNetTables",
     "longName": "1037 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables",
     "longName": "1038 - Disclosure - Accrued and Other Current Liabilities (Tables)",
     "shortName": "Accrued and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "syre:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsTables",
     "longName": "1039 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.spy.com/role/AssetAcquisitionTables",
     "longName": "1040 - Disclosure - Asset Acquisition (Tables)",
     "shortName": "Asset Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.spy.com/role/LeasesTables",
     "longName": "1041 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityTables",
     "longName": "1042 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreementTables",
     "longName": "1043 - Disclosure - Strategic License Agreement (Tables)",
     "shortName": "Strategic License Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.spy.com/role/StockBasedCompensationTables",
     "longName": "1044 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.spy.com/role/RestructuringChargesTables",
     "longName": "1045 - Disclosure - Restructuring Charges (Tables)",
     "shortName": "Restructuring Charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.spy.com/role/IncomeTaxesTables",
     "longName": "1046 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.spy.com/role/NetLossPerShareTables",
     "longName": "1047 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "1048 - Disclosure - Description of the Business and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.spy.com/role/AccruedLiabilitiesTables",
     "longName": "1049 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "syre:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails",
     "longName": "1050 - Disclosure - The Company and Basis of Presentation (Details)",
     "shortName": "The Company and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P03_10_2015To12_31_2023",
      "name": "syre:ProceedsFromRaisingCapital",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "1051 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "1052 - Disclosure - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "syre:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "syre:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "1053 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "1054 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails",
     "longName": "1055 - Disclosure - Fair Value Measurements - Changes in Forward Contract Liability (Details)",
     "shortName": "Fair Value Measurements - Changes in Forward Contract Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
     "longName": "1056 - Disclosure - Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)",
     "shortName": "Fair Value Measurements - Significant Inputs used to Estimate the Fair Value of Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
     "longName": "1057 - Disclosure - Fair Value Measurements - Changes in CVR Liability (Details)",
     "shortName": "Fair Value Measurements - Changes in CVR Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
     "longName": "1058 - Disclosure - Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
     "longName": "1059 - Disclosure - Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
     "longName": "1060 - Disclosure - Cash Equivalents and Marketable Securities - Narrative (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails",
     "longName": "1061 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)",
     "shortName": "Cash Equivalents and Marketable Securities - Contractual Maturities of Marketable Securities at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "1062 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
     "longName": "1063 - Disclosure - Property and Equipment, Net - Narrative (Details)",
     "shortName": "Property and Equipment, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_01_2023To06_30_2023",
      "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "1064 - Disclosure - Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "syre:AccruedAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "syre:AccruedAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
     "longName": "1065 - Disclosure - Related Party Transactions - Narrative (Details)",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "syre:RelatedPartyTransactionNumberOfBoardSeats",
      "unitRef": "Unit_BOARDSEAT",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "syre:RelatedPartyTransactionNumberOfBoardSeats",
      "unitRef": "Unit_BOARDSEAT",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
     "longName": "1066 - Disclosure - Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)",
     "shortName": "Related Party Transactions - Expenses related to Related Party which were Settled in Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "syre:RelatedPartyTransactionReimbursableCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "syre:RelatedPartyTransactionReimbursableCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails",
     "longName": "1067 - Disclosure - Related Party Transactions - Related Party Accounts Payable (Details)",
     "shortName": "Related Party Transactions - Related Party Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
     "longName": "1068 - Disclosure - Asset Acquisition - Narrative (Details)",
     "shortName": "Asset Acquisition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
     "longName": "1069 - Disclosure - Asset Acquisition - Asset Acquisition Cost (Details)",
     "shortName": "Asset Acquisition - Asset Acquisition Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:AcquiredInProcessResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis",
      "name": "syre:AssumedLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.spy.com/role/ParagonAgreementDetails",
     "longName": "1070 - Disclosure - Paragon Agreement (Details)",
     "shortName": "Paragon Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis",
      "name": "syre:LicenseAgreementMilestonePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis",
      "name": "syre:LicenseAgreementMilestonePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.spy.com/role/LeasesNarrativeDetails",
     "longName": "1071 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "PAsOn04_30_2019",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn04_30_2019",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails",
     "longName": "1072 - Disclosure - Leases - Operating and Financing Leases Presented in Balance Sheet (Details)",
     "shortName": "Leases - Operating and Financing Leases Presented in Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "syre:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails",
     "longName": "1073 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)",
     "shortName": "Leases - Weighted-Average Remaining Lease Term and Discount Rates for Operating and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.spy.com/role/LeasesLeaseCostDetails",
     "longName": "1074 - Disclosure - Leases - Lease Cost (Details)",
     "shortName": "Leases - Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
     "longName": "1075 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Narrative (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "syre:SharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DividendsCommonStock",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
     "longName": "1076 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Pre-funded Warrants for Common Stock Issued and Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "PAsOn05_31_2022",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_PreFundedMay2022WarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails",
     "longName": "1077 - Disclosure - Strategic License Agreement - Narrative (Details)",
     "shortName": "Strategic License Agreement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetNet",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails",
     "longName": "1078 - Disclosure - Strategic License Agreement - Changes in Contract Liabilities (Details)",
     "shortName": "Strategic License Agreement - Changes in Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:ContractWithCustomerLiabilityAdditions",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
     "longName": "1079 - Disclosure - Sale of Pegzilarginase to Immedica (Details)",
     "shortName": "Sale of Pegzilarginase to Immedica (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R80": {
     "role": "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails",
     "longName": "1080 - Disclosure - Novation of Manufacturing Agreements (Details)",
     "shortName": "Novation of Manufacturing Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "syre:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "syre:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "1081 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails",
     "longName": "1082 - Disclosure - Stock-Based Compensation - Employee and Non-Employee Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Employee and Non-Employee Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
     "longName": "1083 - Disclosure - Stock-Based Compensation - Employee Restricted Stock Activity (Details)",
     "shortName": "Stock-Based Compensation - Employee Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "1084 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails",
     "longName": "1085 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)",
     "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Used in Calculating Fair Value of Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.spy.com/role/DefinedContributionPlanDetails",
     "longName": "1086 - Disclosure - Defined Contribution Plan (Details)",
     "shortName": "Defined Contribution Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
     "longName": "1087 - Disclosure - Restructuring Charges - Narrative (Details)",
     "shortName": "Restructuring Charges - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
     "longName": "1088 - Disclosure - Restructuring Charges - Changes in Accrued Restructuring Balance (Details)",
     "shortName": "Restructuring Charges - Changes in Accrued Restructuring Balance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
     "longName": "1089 - Disclosure - Restructuring Charges - Charges Related to the Restructuring Activities (Details)",
     "shortName": "Restructuring Charges - Charges Related to the Restructuring Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails",
     "longName": "1090 - Disclosure - Income Taxes - (Loss) Income Before Income Tax Expense by Jurisdiction (Details)",
     "shortName": "Income Taxes - (Loss) Income Before Income Tax Expense by Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.spy.com/role/IncomeTaxesNarrativeDetails",
     "longName": "1091 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "1092 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "1093 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "1094 - Disclosure - Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "1095 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
     "longName": "1096 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies - Summary of Asset Acquisition Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "syre:AcquiredInProcessResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "1097 - Disclosure - Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Description of the Business and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "P09_08_2023To09_08_2023",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_01_2023To04_30_2023",
      "name": "syre:NumberOfEmployeesRetained",
      "unitRef": "Unit_employee",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "1098 - Disclosure - Accrued Liabilities - Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued Liabilities - Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "syre:AccruedOptionCostPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "syre:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_22_2023",
      "name": "syre:AccruedOptionCostPayable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "syre:AccruedLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
     "longName": "1099 - Disclosure - Accrued Liabilities - Additional Information (Details)",
     "shortName": "Accrued Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis",
      "name": "syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R100": {
     "role": "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1100 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d518298dposam.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Related party accounts payable and other current liabilities",
        "verboseLabel": "Related party accounts payable and other current liabilities",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net (accretion of discount) amortization of premium on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "syre_AccruedAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued And Other Current Liabilities [Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities",
        "documentation": "The entire disclosure for accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AccruedContractedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedContractedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Contracted Research And Development Costs",
        "terseLabel": "Accrued contracted research and development costs",
        "documentation": "Accrued contracted research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "negatedLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "totalLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "syre_AccruedLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedLiabilitiesLineItems",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Line Items]",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AccruedLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Policy Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AccruedLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedLiabilitiesTable",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Table]",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedLiabilitiesTextBlock",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "Accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AccruedOptionCostPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedOptionCostPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Option Cost Payable",
        "terseLabel": "Accrued option cost payable to Paragon",
        "documentation": "Accrued option cost payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and consulting fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "syre_AccruedResearchAndDevelopmentExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensePolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Expense [Policy Text Block]",
        "terseLabel": "Accrued Research and Development Costs",
        "documentation": "Accrued research and development expense policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r737"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r203",
      "r607"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r127",
      "r209",
      "r603",
      "r626",
      "r627"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16",
      "r40",
      "r488",
      "r491",
      "r533",
      "r622",
      "r623",
      "r796",
      "r797",
      "r798",
      "r806",
      "r807",
      "r808"
     ]
    },
    "syre_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired In Process Research And Development",
        "terseLabel": "Acquired in-process research and development",
        "documentation": "Acquired in process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r641",
      "r806",
      "r807",
      "r808",
      "r870",
      "r892"
     ]
    },
    "syre_AdditionalUpfrontPaymentAbilityToReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AdditionalUpfrontPaymentAbilityToReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Upfront Payment Ability To Received",
        "terseLabel": "Additional upfront payment to be received",
        "documentation": "Additional upfront payment ability to received."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Issuance of Parapyre Option Obligation warrants",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "syre_AllocatedAmountOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AllocatedAmountOfTransactionPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Amount Of Transaction Price",
        "terseLabel": "Allocated amount of modified transaction price",
        "documentation": "Allocated amount of transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r451"
     ]
    },
    "syre_AllocationPriceTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AllocationPriceTotal",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocation Price Total",
        "terseLabel": "Allocation for stand-alone selling prices",
        "documentation": "Allocation price total."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AmountToBePaidUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AmountToBePaidUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount To Be Paid Under Agreement",
        "terseLabel": "Contingent obligation based on milestones",
        "documentation": "Amount to be paid under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Percentage Of Additional Shares Which Equals To Issued And Outstanding Shares",
        "terseLabel": "Annual percentage of additional shares",
        "documentation": "Annual percentage of additional shares which equals to the issued and outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "syre_AppointOfBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AppointOfBoardMembersMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Appoint Of Board Members [Member]",
        "terseLabel": "Appoint Of Board Members",
        "documentation": "Appoint Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "syre_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition Assets Acquired and Liabilities Assumed Net",
        "terseLabel": "Asset Acquisition, net liabilities assumed",
        "documentation": "Asset acquisition assets acquired and liabilities assumed net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "syre_AssetAcquisitionCashPaymentThresholdPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssetAcquisitionCashPaymentThresholdPeriod",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Cash Payment, Threshold Period",
        "terseLabel": "Asset acquisition, cash payment, threshold period",
        "documentation": "Asset Acquisition, Cash Payment, Threshold Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Cost to acquire asset",
        "totalLabel": "Cost to acquire asset",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Liability assumed in asset acquisition related to warrants",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "verboseLabel": "Consideration transferred in Series A Preferred Stock and Common Stock",
        "terseLabel": "Consideration transferred in Series A Preferred Stock and common stock",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868"
     ]
    },
    "syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable, Shares",
        "verboseLabel": "Shares transferred as equity interest in asset acquisition (in shares)",
        "terseLabel": "Number of shares transferred as equity interest in asset acquisition",
        "documentation": "Asset acquisition consideration transferred equity interest issued and issuable, shares."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable Shares Of Common Stock On An As-converted Basis",
        "definitionGuidance": "Asset acquisition consideration transferred issuable shares of common stock on an as-converted basis",
        "documentation": "Asset acquisition consideration transferred equity interest issued and issuable shares of common stock on an as-converted basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs incurred by the Company",
        "verboseLabel": "Transaction costs incurred by Aeglea",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r866",
      "r867",
      "r868"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "terseLabel": "Asset acquisition, contingent consideration, liability, current",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "syre_AssetAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssetAcquisitionMember",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Member]",
        "terseLabel": "Asset Acquisition",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "syre_AssetAcquisitionStockholderPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssetAcquisitionStockholderPaymentPeriod",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Stockholder Payment Period",
        "terseLabel": "Asset acquisition, stockholder payment period",
        "documentation": "Asset Acquisition, Stockholder Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionTables",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Asset Acquisition Cost",
        "verboseLabel": "Summary of Asset Acquisition Cost",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Asset Acquisition",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "terseLabel": "Lease ROU asset and leasehold improvement impairment loss",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r205",
      "r231",
      "r271",
      "r278",
      "r282",
      "r321",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r483",
      "r485",
      "r507",
      "r597",
      "r678",
      "r765",
      "r778",
      "r826",
      "r827",
      "r879"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "syre_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information",
        "documentation": "Assets And Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r210",
      "r231",
      "r321",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r483",
      "r485",
      "r507",
      "r765",
      "r826",
      "r827",
      "r879"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Carrying value of assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r107",
      "r113",
      "r147",
      "r197",
      "r198"
     ]
    },
    "syre_AssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "AssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumed Liabilities",
        "negatedLabel": "Assumed liabilities",
        "documentation": "Assumed liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r329",
      "r596"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due in 1 - 2 years",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r594"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r593"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturitiesOfMarketableSecuritiesAtEstimatedFairValueDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Estimated Fair Value",
        "totalLabel": "Total marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r329"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "syre_BeneficiallyHoldersOwnedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "BeneficiallyHoldersOwnedPercentage",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beneficially Holders Owned Percentage",
        "terseLabel": "Beneficially holders owned percentage",
        "documentation": "Beneficially holders owned percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "ASSETS ACQUIRED"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accrued liabilities",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "LIABILITIES ASSUMED"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net liabilities assumed",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r599",
      "r652",
      "r673",
      "r765",
      "r778",
      "r792"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Acquired from Acquisition",
        "definitionGuidance": "Cash assumed from asset acquisition of Spyre",
        "verboseLabel": "Cash acquired",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r201",
      "r736"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r170"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r138",
      "r228"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]",
        "terseLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r138"
     ]
    },
    "syre_CashEquivalentsAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Marketable Securities [Line Items]",
        "terseLabel": "Cash Equivalents And Marketable Securities [Line Items]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_CashEquivalentsAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Marketable Securities [Table]",
        "terseLabel": "Cash Equivalents And Marketable Securities [Table]",
        "documentation": "Cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Amortized Cost",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r889"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "syre_CashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents Unrealized Gains",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Cash equivalents unrealized gains."
       }
      }
     },
     "auth_ref": []
    },
    "syre_CashEquivalentsUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CashEquivalentsUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents Unrealized Losses",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Cash equivalents unrealized losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ChangeInContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Change In Contract With Customer, Liability [Roll Forward]",
        "documentation": "Change In Contract With Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r206",
      "r207",
      "r208",
      "r231",
      "r255",
      "r259",
      "r261",
      "r263",
      "r269",
      "r270",
      "r321",
      "r357",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r371",
      "r372",
      "r376",
      "r379",
      "r386",
      "r507",
      "r632",
      "r633",
      "r634",
      "r635",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r653",
      "r665",
      "r687",
      "r709",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r782",
      "r803",
      "r809"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r269",
      "r371",
      "r372",
      "r374",
      "r376",
      "r379",
      "r384",
      "r386",
      "r632",
      "r633",
      "r634",
      "r635",
      "r751",
      "r782",
      "r803"
     ]
    },
    "syre_ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right, Annual Grant, Percentage Of Common Stock Outstanding",
        "terseLabel": "Percentage of annual grant of common stock outstanding for warrants",
        "documentation": "Class Of Warrant Or Right, Annual Grant, Percentage Of Common Stock Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per warrant (in dollars per share)",
        "verboseLabel": "Exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "syre_ClassOfWarrantOrRightGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ClassOfWarrantOrRightGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right, Grant Date Fair Value",
        "terseLabel": "Warrant grant date fair value",
        "documentation": "Class Of Warrant Or Right, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "syre_ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Offering Price Of Warrants Or Rights",
        "terseLabel": "Offering price of warrant (in dollars per share)",
        "documentation": "Class of warrant or right offering price of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of warrants outstanding (in shares)",
        "presentationGuidance": "Number of shares sold in private placement",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice",
        "terseLabel": "Revised ownership percentage, period to take effect after notice",
        "documentation": "Class Of Warrant Or Right, Revised Ownership Percentage, Period To Take Effect After Notice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "syre_ClassOfWarrantOrRightUnamortizedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ClassOfWarrantOrRightUnamortizedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right, Unamortized Expense",
        "terseLabel": "Warrant unamortized expense",
        "documentation": "Class Of Warrant Or Right, Unamortized Expense"
       }
      }
     },
     "auth_ref": []
    },
    "syre_CollaborativeArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CollaborativeArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Abstract]",
        "documentation": "Collaborative Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Strategic License Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r185",
      "r194"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r772",
      "r773",
      "r774",
      "r775"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r102",
      "r598",
      "r664"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Novation of Manufacturing Agreements",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769",
      "r770",
      "r772",
      "r773",
      "r774",
      "r775",
      "r806",
      "r807",
      "r870",
      "r891",
      "r892"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r665"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r121",
      "r665",
      "r684",
      "r892",
      "r893"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 400,000,000 and 20,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 36,057,109 shares and 2,614,014 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r601",
      "r765"
     ]
    },
    "syre_CompanyAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CompanyAndBasisOfPresentationLineItems",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company and Basis of Presentation [Line Items]",
        "terseLabel": "Company and Basis of Presentation [Line Items]",
        "documentation": "Company and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "syre_CompanyAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CompanyAndBasisOfPresentationTable",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company and Basis of Presentation [Table]",
        "terseLabel": "Company and Basis of Presentation [Table]",
        "documentation": "Company and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.spy.com/role/DefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r215",
      "r217",
      "r222",
      "r590",
      "r612"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r187"
     ]
    },
    "syre_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement",
        "documentation": "Consulting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ContingentValueRightDistributionToCommonStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ContingentValueRightDistributionToCommonStockholders",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Value Right Distribution To Common Stockholders",
        "terseLabel": "CVR distribution to common stockholders",
        "documentation": "Contingent value right distribution to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ContingentValueRightLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ContingentValueRightLiabilityMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Value Right Liability [Member]",
        "terseLabel": "CVR liability",
        "documentation": "Contingent Value Right Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Contract Liabilities",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r391",
      "r394"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r394"
     ]
    },
    "syre_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer, Liability, Additions",
        "terseLabel": "Additions",
        "documentation": "Contract With Customer, Liability, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue",
        "terseLabel": "Deferred revenue, current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r394"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementChangesInContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "terseLabel": "Deductions",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r394"
     ]
    },
    "syre_ConversionOfPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ConversionOfPreFundedWarrantsMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Pre-Funded Warrants [Member]",
        "terseLabel": "Conversion Of Pre-Funded Warrants",
        "documentation": "Conversion Of Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ConversionOfSeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ConversionOfSeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Series A Non-Voting Convertible Preferred Stock [Member]",
        "definitionGuidance": "Conversion Of Series A Non-Voting Convertible Preferred Stock",
        "documentation": "Conversion Of Series A Non-Voting Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of Series A non-voting convertible preferred stock into common stock",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Description [Axis]",
        "terseLabel": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Name [Domain]",
        "terseLabel": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "syre_CostsIncurredInPerformingTheTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "CostsIncurredInPerformingTheTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs Incurred In Performing The Trial",
        "terseLabel": "Maximum amount of costs to reimburse",
        "documentation": "Costs incurred in performing the pip trial."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r366",
      "r374",
      "r540",
      "r738",
      "r740"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued interest receivable on available-for-sale debt securities",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r329",
      "r330",
      "r331"
     ]
    },
    "syre_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag",
        "terseLabel": "Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag",
        "documentation": "Debt Securities, Available-For-Sale, Accrued Interest, After Allowance For Credit Loss, Statement Of Financial Position, Extensible List, Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "terseLabel": "Debt securities, available-for-sale, allowance for credit loss, excluding accrued interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r335",
      "r748"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 Months or Longer",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r335"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r335",
      "r748"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r335"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains or losses on marketable securities",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains or losses on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r814"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total, fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r333",
      "r748"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r334"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Available-for-Sale Securities in an Unrealized Loss Position",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r748",
      "r820"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r172",
      "r467"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "verboseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized 174 R&amp;D costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r864"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciable assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r864"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, contribution amount",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r274"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r656",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r721",
      "r722",
      "r723",
      "r724",
      "r768",
      "r770"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r654",
      "r656",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r721",
      "r722",
      "r723",
      "r724",
      "r740",
      "r768",
      "r770"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Current",
        "terseLabel": "CVR liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Non-current CVR liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Contingent Value Rights",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r88",
      "r89",
      "r90",
      "r95",
      "r238"
     ]
    },
    "syre_DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of the Business and Summary of Significant Accounting Policies [Abstract]",
        "documentation": "Description of the business and summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "syre_DevelopmentFeeAndRoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "DevelopmentFeeAndRoyaltyMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Fee And Royalty [Member]",
        "terseLabel": "Development fee and royalty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r408",
      "r439",
      "r440",
      "r442",
      "r760"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r24"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Total consideration from disposal of long lived assets",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "syre_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "terseLabel": "Contingent consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "syre_DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Not Discontinued Operation, Derecognition Of Nonfinancial Assets And Liabilities, Net",
        "terseLabel": "Derecognition of nonfinancial assets and liabilities",
        "documentation": "Disposal Group, Not Discontinued Operation, Derecognition Of Nonfinancial Assets And Liabilities, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 8.0
      },
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of in-process research and development asset",
        "terseLabel": "Gain on sale of in-process research and development asset",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r801",
      "r821"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedica"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Sale of Pegzilarginase to Immedica",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r144"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758"
     ]
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Common stock dividends declared",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r155"
     ]
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "U.S",
        "terseLabel": "Federal tax credits",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r253",
      "r255",
      "r261",
      "r262",
      "r263",
      "r267",
      "r496",
      "r497",
      "r591",
      "r613",
      "r744"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r255",
      "r261",
      "r262",
      "r263",
      "r267",
      "r496",
      "r497",
      "r591",
      "r613",
      "r744"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r264",
      "r265",
      "r266"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "syre_EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Contingent Value Added Liability, Amount",
        "terseLabel": "Loss on CVR revaluation",
        "documentation": "Effective Income Tax Rate Reconciliation, Contingent Value Added Liability, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "syre_EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Forward Contract Liability, Amount",
        "terseLabel": "Loss on forward contract valuation",
        "documentation": "Effective Income Tax Rate Reconciliation, Forward Contract Liability, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Expense recognized for unvested employee and non-employee awards",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which unrecognized compensation is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense for options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefits recognized",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "syre_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "terseLabel": "Employees",
        "documentation": "Employees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r196",
      "r219",
      "r220",
      "r221",
      "r239",
      "r240",
      "r241",
      "r243",
      "r249",
      "r251",
      "r268",
      "r322",
      "r323",
      "r388",
      "r443",
      "r444",
      "r445",
      "r473",
      "r474",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r495",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r533",
      "r622",
      "r623",
      "r624",
      "r641",
      "r709"
     ]
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]",
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]",
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r505"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r505"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Significant Inputs used to Estimate the Fair Value of Derivative Liabilities",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r500",
      "r548",
      "r549",
      "r550",
      "r749",
      "r750",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r169"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r502",
      "r503",
      "r506"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r396",
      "r401",
      "r500",
      "r548",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r396",
      "r401",
      "r500",
      "r549",
      "r749",
      "r750",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r500",
      "r550",
      "r749",
      "r750",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r98"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in Derivative Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r98"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value",
        "negatedLabel": "Changes in the fair value of the CVR liability since issuance",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Fair value at CVR issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Issuance of Series A Preferred Stock on July 7, 2023",
        "negatedLabel": "Payments",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsChangesInCvrLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r548",
      "r549",
      "r550",
      "r749",
      "r750",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r506"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r26"
     ]
    },
    "syre_FairmountFundsManagementLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "FairmountFundsManagementLlcMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fairmount Funds Management LLC [Member]",
        "terseLabel": "Fairmount Funds Management LLC",
        "documentation": "Fairmount Funds Management LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "verboseLabel": "Finance",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance lease obligation",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r530"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "verboseLabel": "Finance",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r764"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r764"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r332",
      "r336",
      "r337",
      "r369",
      "r384",
      "r493",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r611",
      "r748",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities measured at fair value",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_FixedExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "FixedExchangeRatio",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Exchange Ratio",
        "verboseLabel": "Fixed exchange ratio",
        "terseLabel": "Fixed exchange ratio",
        "documentation": "Fixed exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign subsidiaries",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForwardContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForwardContractsMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsChangesInForwardContractLiabilityDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contract Liability",
        "verboseLabel": "Forward Contracts",
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and office equipment",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Change in fair value of forward contract liability",
        "negatedTerseLabel": "Change in fair value of derivative liability",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of long-lived assets",
        "negatedLabel": "Loss on disposal of long-lived assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r689"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "syre_GlobalRightsToPegzilarginaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "GlobalRightsToPegzilarginaseMember",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Global Rights To Pegzilarginase [Member]",
        "terseLabel": "Global Rights To Pegzilarginase",
        "documentation": "Global Rights To Pegzilarginase"
       }
      }
     },
     "auth_ref": []
    },
    "syre_GranteesWithMoreThanFiveYearsVestingTermPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "GranteesWithMoreThanFiveYearsVestingTermPercent",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantees With More Than Five Years Vesting Term Percent",
        "terseLabel": "Grantees with more than five years vesting term, percent",
        "documentation": "Grantees with more than five years vesting term, percent."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ImmedicaPharmaABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ImmedicaPharmaABMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immedica Pharma A B [Member]",
        "terseLabel": "Immedica Pharma AB",
        "documentation": "Immedica Pharma AB"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Leasehold",
        "terseLabel": "Impairment on leasehold improvements",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairments of long lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r146"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r149"
     ]
    },
    "syre_InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In-Process Research And Development Assets, Contingent Consideration, Policy [Policy Text Block]",
        "terseLabel": "Contingent Milestone Proceeds",
        "documentation": "In-Process Research And Development Assets, Contingent Consideration, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r477"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r128",
      "r174",
      "r271",
      "r277",
      "r281",
      "r283",
      "r592",
      "r609",
      "r746"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesLossIncomeBeforeIncomeTaxExpenseByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r477"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r24",
      "r28",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r114",
      "r115",
      "r116",
      "r148"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r344",
      "r694"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r694"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r82",
      "r165",
      "r166"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r455",
      "r462",
      "r464",
      "r471",
      "r475",
      "r478",
      "r479",
      "r480",
      "r637"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 13.0
      },
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)",
        "verboseLabel": "Provision or benefit from income taxes",
        "totalLabel": "Income tax (benefit) expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r193",
      "r250",
      "r251",
      "r275",
      "r460",
      "r476",
      "r614"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r458",
      "r459",
      "r464",
      "r465",
      "r470",
      "r472",
      "r631"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in the valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "verboseLabel": "Other permanent differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r461"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax provision derived by applying the federal statutory rate to income before income taxes",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "terseLabel": "Acquired IPR&amp;D",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Effect of tax rate on foreign jurisdiction",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "syre_IncomeTaxReconciliationTaxCostCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "IncomeTaxReconciliationTaxCostCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Tax Cost Credit",
        "terseLabel": "Tax credits",
        "documentation": "Income tax reconciliation tax cost (credit)."
       }
      }
     },
     "auth_ref": []
    },
    "syre_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]",
        "documentation": "Income taxes line items."
       }
      }
     },
     "auth_ref": []
    },
    "syre_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Development receivables",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r800"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r800"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accounts Payable",
        "terseLabel": "Related party payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Series B Non-Voting Convertible Preferred Stock",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "syre_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Increase in common stock reserved for issuance (in shares)",
        "documentation": "Increase in common stock capital shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Weighted average pre-funded warrants (in shares)",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r263"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Net",
        "terseLabel": "Interest income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Marketable Securities at Estimated Fair Value",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "syre_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "syre_LeaseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LeaseAssetsAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Assets [Abstract]",
        "terseLabel": "Assets",
        "documentation": "Lease, Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r764"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Weighted-Average Remaining Lease Term/Discount Rates and Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "syre_LeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LeaseLiabilityAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability [Abstract]",
        "terseLabel": "Leases",
        "documentation": "Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LeaseLiabilityCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LeaseLiabilityCurrentAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability, Current [Abstract]",
        "terseLabel": "Current",
        "documentation": "Lease Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LeaseLiabilityNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LeaseLiabilityNoncurrentAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability, Noncurrent [Abstract]",
        "terseLabel": "Non-current",
        "documentation": "Lease Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LeaseWeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Discount rate",
        "documentation": "Lease, Weighted Average Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Lease term (years)",
        "documentation": "Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LeasedAssetsObtainedInExchangeForLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LeasedAssetsObtainedInExchangeForLeaseObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leased Assets Obtained In Exchange For Lease Obligations",
        "terseLabel": "Leased assets obtained in exchange for lease obligations",
        "documentation": "Leased assets obtained in exchange for lease obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.spy.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r231",
      "r321",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r484",
      "r485",
      "r486",
      "r507",
      "r663",
      "r745",
      "r778",
      "r826",
      "r879",
      "r880"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r173",
      "r605",
      "r765",
      "r804",
      "r819",
      "r873"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r200",
      "r231",
      "r321",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r484",
      "r485",
      "r486",
      "r507",
      "r765",
      "r826",
      "r879",
      "r880"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities",
        "verboseLabel": "Fair value of liability",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LicenseAgreementMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LicenseAgreementMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement, Milestone Payments",
        "terseLabel": "Milestone payments",
        "documentation": "License Agreement, Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "syre_LicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "LicenseAgreementsMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Member]",
        "terseLabel": "License Agreements",
        "documentation": "License agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "terseLabel": "License",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.spy.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r404",
      "r575",
      "r621",
      "r655",
      "r656",
      "r717",
      "r718",
      "r719",
      "r720",
      "r725",
      "r732",
      "r733",
      "r747",
      "r751",
      "r759",
      "r767",
      "r828",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "syre_MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Number of Shares Purchased Under Employee Stock Purchase Plan",
        "terseLabel": "Maximum shares purchased under employee stock purchase plan (in shares)",
        "documentation": "Maximum number of shares purchased under employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised",
        "terseLabel": "Maximum ownership percentage of common stock shares for outstanding warrants to be exercised",
        "documentation": "Maximum ownership percentage for outstanding warrants to purchase shares of common stock to be exercised."
       }
      }
     },
     "auth_ref": []
    },
    "syre_MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised Upon Written Notice",
        "terseLabel": "Maximum ownership percentage of common stock shares for outstanding warrants to be exercised upon written notice",
        "documentation": "Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised Upon Written Notice"
       }
      }
     },
     "auth_ref": []
    },
    "syre_MaximumVestingTermForMoreThanTenPercentGrantees": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MaximumVestingTermForMoreThanTenPercentGrantees",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Vesting Term For More Than Ten Percent Grantees",
        "terseLabel": "Maximum vesting term for more than ten percent grantees",
        "documentation": "Maximum vesting term for more than ten percent grantees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Risk-adjusted discount rates",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "syre_MeasurementInputProbabilityOfSuccessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Probability Of Success [Member]",
        "terseLabel": "Estimated probability of success",
        "documentation": "Measurement Input, Probability Of Success"
       }
      }
     },
     "auth_ref": []
    },
    "syre_MeasurementInputReimbursementRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MeasurementInputReimbursementRateMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Reimbursement Rate [Member]",
        "terseLabel": "Estimated reimbursement rate compared to reimbursement target",
        "documentation": "Measurement Input, Reimbursement Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "syre_MilestonePaymentsExchangeRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MilestonePaymentsExchangeRate",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments Exchange Rate",
        "terseLabel": "Milestone payments exchange rate",
        "documentation": "Milestone payments exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "syre_MilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MilestonePaymentsMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone Payments",
        "documentation": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r404",
      "r575",
      "r621",
      "r655",
      "r656",
      "r717",
      "r718",
      "r719",
      "r720",
      "r725",
      "r732",
      "r733",
      "r747",
      "r751",
      "r759",
      "r767",
      "r828",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "terseLabel": "Percentage of ownership by noncontrolling owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "syre_MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minority Interest Ownership Percentage By Noncontrolling Owners Held In Third Party",
        "terseLabel": "Percentage of ownership held in third party",
        "documentation": "Minority interest ownership percentage by noncontrolling owners held in third party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r140",
      "r175",
      "r198",
      "r214",
      "r216",
      "r221",
      "r231",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r260",
      "r271",
      "r277",
      "r281",
      "r283",
      "r321",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r497",
      "r507",
      "r610",
      "r686",
      "r707",
      "r708",
      "r746",
      "r776",
      "r826"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncement/Recently Issued Accounting Pronouncement",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "syre_NominationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "NominationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nomination Fee",
        "terseLabel": "Nomination fee",
        "documentation": "Nomination fee."
       }
      }
     },
     "auth_ref": []
    },
    "syre_NonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "NonEmployeesMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employees [Member]",
        "terseLabel": "Non- Employees",
        "documentation": "Non-employees."
       }
      }
     },
     "auth_ref": []
    },
    "syre_NonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "NonRefundablePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Refundable Payment Received",
        "terseLabel": "Non refundable payment received",
        "documentation": "Non refundable payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "auth_ref": []
    },
    "syre_NonrefundableResearchInitiationFeeForOneProgramPaidInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "NonrefundableResearchInitiationFeeForOneProgramPaidInCash",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable Research Initiation Fee For One Program Paid In Cash",
        "terseLabel": "Nonrefundable research initiation fee for one program paid in cash",
        "documentation": "Nonrefundable research initiation fee for one program paid in cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Development receivables",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Employee Restricted Stock Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "syre_NumberOfCommonStockVotingRightsHeldPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "NumberOfCommonStockVotingRightsHeldPerShare",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Common Stock Voting Rights Held Per Share",
        "terseLabel": "Number of votes for common stock holders",
        "documentation": "Number of common stock voting rights held per share."
       }
      }
     },
     "auth_ref": []
    },
    "syre_NumberOfDomesticSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "NumberOfDomesticSubsidiaries",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Domestic Subsidiaries",
        "terseLabel": "Number of domestic subsidiaries",
        "documentation": "Number Of Domestic Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "syre_NumberOfEmployeesRetained": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "NumberOfEmployeesRetained",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Employees Retained",
        "terseLabel": "Number of employees retained",
        "documentation": "Number of employees retained."
       }
      }
     },
     "auth_ref": []
    },
    "syre_OperatingAndFinanceLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OperatingAndFinanceLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating And Finance Lease Liabilities",
        "totalLabel": "Total lease liabilities",
        "documentation": "Operating and Finance lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "syre_OperatingAndFinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating And Finance Lease Right Of Use Asset",
        "totalLabel": "Total leased assets",
        "documentation": "Operating and financing lease right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r277",
      "r281",
      "r283",
      "r746"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r764"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Lease asset impairment",
        "verboseLabel": "Lease Asset Impairment",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities",
        "verboseLabel": "Operating",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r530"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/LeasesOperatingAndFinancingLeasesPresentedInBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of operating lease assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "syre_OperatingLeaseTerminationFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OperatingLeaseTerminationFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Termination Fee Amount",
        "terseLabel": "Termination fee amount",
        "documentation": "Operating Lease, Termination Fee Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r764"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.spy.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRatesForOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r764"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "syre_OperatingLossCarryforwardsSetToExpireIfNotUtilized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OperatingLossCarryforwardsSetToExpireIfNotUtilized",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Set To Expire If Not Utilized",
        "terseLabel": "Net operating loss carryforwards, set to expire if not utilized",
        "documentation": "Operating Loss Carryforwards, Set To Expire If Not Utilized"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OptionAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OptionAgreementTextBlock",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreement [Text Block]",
        "terseLabel": "Paragon Agreement",
        "documentation": "Option agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of the Business and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r141",
      "r142",
      "r168"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "The Company and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r168",
      "r628",
      "r629"
     ]
    },
    "syre_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "syre_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "syre_OtherCommitmentNonRefundableLicenseFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentNonRefundableLicenseFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Non-Refundable License Fee Amount",
        "terseLabel": "Non-refundable license fee amount",
        "documentation": "Other Commitment, Non-Refundable License Fee Amount"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period",
        "terseLabel": "Right to terminate agreement by counterparty, material breach, uncured period",
        "documentation": "Other Commitment, Right To Terminate Agreement By Counterparty, Material Breach, Uncured Period"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period",
        "terseLabel": "Right to terminate agreement by counterparty, payments not received, period",
        "documentation": "Other Commitment, Right To Terminate Agreement By Counterparty, Payments Not Received, Period"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period",
        "terseLabel": "Right to terminate agreement or work order, prior written notice period",
        "documentation": "Other Commitment, Right To Terminate Agreement Or Work Order, Prior Written Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Agreement, Prior Written Notice Period",
        "terseLabel": "Right to terminate agreement, prior written notice period",
        "documentation": "Other Commitment, Right To Terminate Agreement, Prior Written Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable",
        "terseLabel": "Right to terminate work order by counterparty, reasonable cause, termination amount payable",
        "documentation": "Other Commitment, Right To Terminate Work Order By Counterparty, Reasonable Cause, Termination Amount Payable"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period",
        "terseLabel": "Right to terminate work order, material breach, uncured period",
        "documentation": "Other Commitment, Right To Terminate Work Order, Material Breach, Uncured Period"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period",
        "terseLabel": "Right to terminate work order, reasonable cause, prior written notice period",
        "documentation": "Other Commitment, Right To Terminate Work Order, Reasonable Cause, Prior Written Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period",
        "terseLabel": "Right to terminate work order, unusual or infrequent cause, period",
        "documentation": "Other Commitment, Right To Terminate Work Order, Unusual Or Infrequent Cause, Period"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OtherCommitmentRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OtherCommitmentRoyaltyPercentage",
     "presentation": [
      "http://www.spy.com/role/NovationOfManufacturingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, Royalty Percentage",
        "terseLabel": "Royalty percentage (less than)",
        "documentation": "Other Commitment, Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r127",
      "r508",
      "r509",
      "r511"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r320"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "syre_OutstandingAndUnexercisedStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OutstandingAndUnexercisedStockOptions",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding and Unexercised Stock Options",
        "terseLabel": "Number of outstanding and unexercised stock options to purchase (in shares)",
        "documentation": "Outstanding and unexercised stock options."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OwnershipInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OwnershipInterestMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Interest [Member]",
        "terseLabel": "Ownership Interest",
        "documentation": "Ownership Interest"
       }
      }
     },
     "auth_ref": []
    },
    "syre_OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders",
        "terseLabel": "Ownership percentage for outstanding warrants to purchase shares of common stock to be exercised to certain holders",
        "documentation": "Ownership percentage for outstanding warrants To purchase shares of common stock to be exercised to certain holders."
       }
      }
     },
     "auth_ref": []
    },
    "syre_PIPTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PIPTrialMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P I P Trial [Member]",
        "terseLabel": "PIP Trial",
        "documentation": "PIP trial."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParagonAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ParagonAgreementMember",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paragon Agreement [Member]",
        "terseLabel": "Paragon Agreement",
        "documentation": "Paragon agreement."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParagonAndParapyreHoldingLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ParagonAndParapyreHoldingLlcMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paragon and Parapyre Holding LLC [Member]",
        "verboseLabel": "Paragon and Parapyre Holding LLC"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParagonTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ParagonTherapeuticsIncMember",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paragon Therapeutics Inc [Member]",
        "terseLabel": "Paragon Therapeutics Inc",
        "documentation": "Paragon therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParapyreOptionObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ParapyreOptionObligationMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parapyre Option Obligation [Member]",
        "terseLabel": "Parapyre Option Obligation",
        "documentation": "Parapyre Option Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ParapyreWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ParapyreWarrantsMember",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parapyre Warrants [Member]",
        "terseLabel": "Parapyre Warrants",
        "verboseLabel": "Outstanding Parapyre Warrants",
        "documentation": "Parapyre Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "syre_PaymentOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PaymentOfMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Milestone",
        "terseLabel": "Milestone payments",
        "documentation": "Payment of milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForDerivativeInstrumentFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Derivative Instrument, Financing Activities",
        "negatedTerseLabel": "Payment of contingent value rights liability",
        "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r741"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Cash payments for employee related restructuring charges",
        "negatedLabel": "Payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r799"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r224",
      "r287"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "syre_PeaceTrialAndBLAPackageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PeaceTrialAndBLAPackageMember",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peace Trial And B L A Package [Member]",
        "terseLabel": "PEACE Trial and BLA Package",
        "documentation": "Peace Trial And BLA Package Member."
       }
      }
     },
     "auth_ref": []
    },
    "syre_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Annual Equity Grant Of Options To Purchase Outstanding Shares Of Common Stock",
        "terseLabel": "Percentage of annual equity grant of options",
        "documentation": "Percentage of annual equity grant of options to purchase outstanding shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "syre_PercentageOfPaymentForCostIncurredInPIPTrial": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PercentageOfPaymentForCostIncurredInPIPTrial",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Payment For Cost Incurred In P I P Trial",
        "terseLabel": "Percentage of payment for cost incurred in trial",
        "documentation": "Percentage of payment for cost incurred in pip trial."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "syre_PlacementAgentAndOtherOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PlacementAgentAndOtherOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent And Other Offering Expenses",
        "terseLabel": "Placement agent and other offering expenses in private placement",
        "documentation": "Placement agent and other offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "syre_PlacementAgentFeesAndOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PlacementAgentFeesAndOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Fees And Offering Costs",
        "terseLabel": "Placement agent fees and offering costs",
        "documentation": "Placement agent fees and offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "syre_PreFundedMay2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PreFundedMay2022WarrantsMember",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded, May 2022 Warrants [Member]",
        "terseLabel": "May 2022",
        "documentation": "Pre Funded, May 2022 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "syre_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityPreFundedWarrantsForCommonStockIssuedAndOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion basis",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "syre_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock [Member]",
        "presentationGuidance": "Preferred Stock",
        "documentation": "Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Series A Non-Voting Convertible Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r769",
      "r772",
      "r773",
      "r774",
      "r775",
      "r891",
      "r892"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r371"
     ]
    },
    "us-gaap_PreferredStockRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Redemption Amount",
        "terseLabel": "Preferred stock, redemption value",
        "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r69"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Preferred stock, redemption per share (in dollars per share)",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r73"
     ]
    },
    "syre_PreferredStockRemainsIssuedAndOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PreferredStockRemainsIssuedAndOutstandingPercentage",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Remains Issued and Outstanding Percentage.",
        "terseLabel": "Preferred stock issued and outstanding percentage",
        "documentation": "Preferred stock remains issued and outstanding percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r665"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r371"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r665",
      "r684",
      "r892",
      "r893"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r600",
      "r765"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "syre_PrepaidExpenseValueOfExpectedRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "PrepaidExpenseValueOfExpectedRecoveries",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Value Of Expected Recoveries",
        "terseLabel": "Contingent reimbursement of pre-paid manufacturing costs",
        "documentation": "Prepaid Expense, Value Of Expected Recoveries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock in connection with private placement, net of placement and other offering costs",
        "terseLabel": "Net proceeds from sale of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "syre_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs",
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants in public offering net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series A non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "definitionGuidance": "Proceeds from issuance of Series B non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs",
        "verboseLabel": "Proceeds from issuance of private placement",
        "terseLabel": "Gross proceeds received in private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from employee stock plan purchases and stock option exercises",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r23"
     ]
    },
    "syre_ProceedsFromRaisingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ProceedsFromRaisingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Raising Capital",
        "terseLabel": "Proceeds from raising capital",
        "documentation": "Proceeds From Raising Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r812"
     ]
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/SaleOfPegzilarginaseToImmedicaDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Proceeds from sale of in-process research &amp; development asset",
        "verboseLabel": "Proceeds from sale of intangible assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property plant and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r577",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r735",
      "r753",
      "r766",
      "r784",
      "r824",
      "r825",
      "r830",
      "r890"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r577",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r735",
      "r753",
      "r766",
      "r784",
      "r824",
      "r825",
      "r830",
      "r890"
     ]
    },
    "us-gaap_ProgramRightsObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProgramRightsObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Program Rights Obligations",
        "terseLabel": "Fair value of assumed Parapyre Option Obligation (Note\u00a03)",
        "documentation": "Total amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r188",
      "r191",
      "r192"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r202",
      "r608"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r595",
      "r608",
      "r765"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r188",
      "r191",
      "r606"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives of the property and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesNarrativeDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r395",
      "r404",
      "r434",
      "r435",
      "r436",
      "r551",
      "r575",
      "r621",
      "r655",
      "r656",
      "r717",
      "r718",
      "r719",
      "r720",
      "r725",
      "r732",
      "r733",
      "r747",
      "r751",
      "r759",
      "r767",
      "r770",
      "r822",
      "r828",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/LeasesNarrativeDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r395",
      "r404",
      "r434",
      "r435",
      "r436",
      "r551",
      "r575",
      "r621",
      "r655",
      "r656",
      "r717",
      "r718",
      "r719",
      "r720",
      "r725",
      "r732",
      "r733",
      "r747",
      "r751",
      "r759",
      "r767",
      "r770",
      "r822",
      "r828",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "syre_ReimbursableCostsUnderParagonAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ReimbursableCostsUnderParagonAgreementMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursable Costs Under Paragon Agreement [Member]",
        "terseLabel": "Reimbursable Costs Under Paragon Agreement",
        "documentation": "Reimbursable costs under paragon agreement."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ReimbursableResearchCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ReimbursableResearchCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursable Research Costs",
        "terseLabel": "Reimbursable research costs",
        "documentation": "Reimbursable research costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReimbursementFromLimitedPartnershipInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReimbursementFromLimitedPartnershipInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement from Limited Partnership Investment",
        "terseLabel": "Reimbursement",
        "documentation": "A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r537",
      "r538",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r683",
      "r685",
      "r716"
     ]
    },
    "syre_RelatedPartyExpensesIncurredPriorToAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "RelatedPartyExpensesIncurredPriorToAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Expenses Incurred Prior To Asset Acquisition",
        "terseLabel": "Related party expenses incurred prior to asset acquisition",
        "documentation": "Related party expenses incurred prior to asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "syre_RelatedPartyExpensesUnpaidPriorToAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "RelatedPartyExpensesUnpaidPriorToAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Expenses Unpaid Prior To Asset Acquisition",
        "terseLabel": "Related party expenses unpaid prior to asset acquisition",
        "documentation": "Related party expenses unpaid prior to asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r537",
      "r538",
      "r539",
      "r540",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r683",
      "r685",
      "r716"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transaction amount",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r537"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r878"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r694"
     ]
    },
    "syre_RelatedPartyTransactionNumberOfBoardSeats": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "RelatedPartyTransactionNumberOfBoardSeats",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Number Of Board Seats",
        "terseLabel": "Number of board seats held by related party",
        "documentation": "Related Party Transaction, Number Of Board Seats"
       }
      }
     },
     "auth_ref": []
    },
    "syre_RelatedPartyTransactionReimbursableCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "RelatedPartyTransactionReimbursableCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Reimbursable Costs",
        "terseLabel": "Reimbursable costs",
        "documentation": "Related party transaction, reimbursable costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r537",
      "r538",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r683",
      "r685",
      "r716",
      "r878"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r538",
      "r541",
      "r638",
      "r639",
      "r640",
      "r692",
      "r693",
      "r694",
      "r713",
      "r715"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r366",
      "r374",
      "r540",
      "r739",
      "r740"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r861"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Estimated amount incurred",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r861"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r861"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "syre_ResearchInitiationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ResearchInitiationFees",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/AccruedLiabilitiesAdditionalInformationDetails",
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Initiation Fees",
        "terseLabel": "Research initiation fees",
        "documentation": "Research initiation fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r793",
      "r802"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Common Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs)",
        "terseLabel": "Unvested restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "syre_RestructuringActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "RestructuringActivitiesMember",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Activities",
        "terseLabel": "Restructuring Activities",
        "documentation": "Restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/RestructuringCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r343",
      "r346",
      "r352"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Employee workforce, termination percentage",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r347",
      "r349",
      "r823"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r349",
      "r350"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs",
        "totalLabel": "Total Restructuring Costs",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "periodStartLabel": "Beginning Balance December 31, 2022",
        "periodEndLabel": "Ending Balance December 31, 2023",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r348"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r155",
      "r604",
      "r625",
      "r627",
      "r636",
      "r666",
      "r765"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r239",
      "r240",
      "r241",
      "r243",
      "r249",
      "r251",
      "r322",
      "r323",
      "r443",
      "r444",
      "r445",
      "r473",
      "r474",
      "r487",
      "r489",
      "r490",
      "r492",
      "r495",
      "r622",
      "r624",
      "r641",
      "r892"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r276",
      "r279",
      "r280",
      "r284",
      "r285",
      "r286",
      "r392",
      "r393",
      "r577"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r734",
      "r742"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "syre_SPY002LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SPY002LicenseAgreementMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPY002 License Agreement [Member]",
        "terseLabel": "SPY002 License Agreement",
        "documentation": "SPY002 License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate purchase price for stock sold",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "syre_SaleOfStockDecember2023PIPEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SaleOfStockDecember2023PIPEMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock, December 2023 PIPE [Member]",
        "terseLabel": "Sale Of Stock, December 2023 PIPE",
        "documentation": "Sale Of Stock, December 2023 PIPE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/AccruedAndOtherCurrentLiabilitiesTables",
      "http://www.spy.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities",
        "verboseLabel": "Accrued and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareWeightedAverageEquityInstrumentsExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Weighted-Average Equity Instruments Excluded from Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "syre_ScheduleOfBalancesDueToAffiliatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ScheduleOfBalancesDueToAffiliatesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances Due To Affiliates [Table Text Block]",
        "terseLabel": "Related Party Accounts Payable",
        "documentation": "Schedule of balances due to affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.spy.com/role/StatementOfAssetsAcquiredAndLiabilitiesAssumed"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r481"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Estimated Fair Value of Cash Equivalents and Marketable Securities and the Gross Unrealized Gains and Losses",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "syre_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]",
        "terseLabel": "Useful Lives of Property and Equipment",
        "documentation": "Schedule of estimated useful lives of property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "(Loss) Income Before Income Tax Expense by Jurisdiction",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetNarrativeDetails",
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsExpensesRelatedToRelatedPartyWhichWereSettledInCashDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsRelatedPartyAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r690",
      "r691",
      "r694"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Expenses related to Related Party which were Settled in Cash",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r861"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to the Restructuring Activities",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Changes in Accrued Restructuring Balance",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Employee and Non-Employee Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions Used in Calculating Fair Value of Awards",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70",
      "r71",
      "r72",
      "r74",
      "r153",
      "r154",
      "r155",
      "r206",
      "r207",
      "r208",
      "r269",
      "r371",
      "r372",
      "r374",
      "r376",
      "r379",
      "r384",
      "r386",
      "r632",
      "r633",
      "r634",
      "r635",
      "r751",
      "r782",
      "r803"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Pre-funded Warrants for Common Stock Issued and Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Letter of credit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "syre_SeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Non Voting Convertible Preferred Stock [Member]",
        "verboseLabel": "Series A Non Voting Convertible Preferred Stock",
        "presentationGuidance": "Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock",
        "documentation": "Series A non voting convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "syre_SeriesBNonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SeriesBNonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Non Voting Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Non-Voting Convertible Preferred Stock",
        "documentation": "Series B Non Voting Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ServiceBasedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ServiceBasedAwardsMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Based Awards [Member]",
        "terseLabel": "Service Based Awards",
        "documentation": "Service-based awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails",
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Cash severance payments and other employee-related costs",
        "verboseLabel": "Severance Related Expenses",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "syre_SeveranceLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SeveranceLiabilityMember",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Liability [Member]",
        "terseLabel": "Severance Liability",
        "documentation": "Severance liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Non-cash stock-based compensation expense related to accelerated vesting of stock-based awards",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Annual Percentage Increase",
        "terseLabel": "Additional annual percentage increase of common stock",
        "documentation": "Share based compensation arrangement by share based payment award additional annual percentage increase."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Number Of Shares Available For Grant",
        "terseLabel": "Additional common stock available for issuance (in shares)",
        "documentation": "Share-based compensation arrangement by share-based payment award, additional number of shares available for grant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Awards granted, vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Percentage of fair market value of common stock",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Shares, granted to employees (in shares)",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Unvested (in shares)",
        "periodEndLabel": "Unvested (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Unvested (in dollars per share)",
        "periodEndLabel": "Unvested (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Equity instruments other than options, vested (in shares)",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share))",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividend yield",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Annual Fair Market Value Per Employee",
        "terseLabel": "Maximum purchase value per employee under employee stock purchase plan",
        "documentation": "Share based compensation arrangement by share based payment award maximum annual fair market value per employee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of discount through payroll deductions to eligible employees to purchase common stock",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments",
        "terseLabel": "Number of monthly installments",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Monthly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Initial reserves of common stock (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for issuance (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Outstanding option awards (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease)",
        "terseLabel": "Shares subject to options outstanding (in shares)",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Issuable Under Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Stock option issued (in shares)",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r412",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r446",
      "r447",
      "r448",
      "r449"
     ]
    },
    "syre_ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Plan Modification, Annual Limit For Non-Employee Director Compensation, Amount",
        "terseLabel": "Annual limit for non-employee director compensation",
        "documentation": "Share-Based Payment Arrangement, Plan Modification, Annual Limit For Non-Employee Director Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Plan Modification, Non-Employee Director Compensation, Amount",
        "terseLabel": "Non-employee director compensation",
        "documentation": "Share-Based Payment Arrangement, Plan Modification, Non-Employee Director Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "syre_ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Plan Terms, Annual Limit For Non-Employee Director Compensation, Number Of Shares",
        "terseLabel": "Annual limit for non-employee director compensation (in shares)",
        "documentation": "Share-Based Payment Arrangement, Plan Terms, Annual Limit For Non-Employee Director Compensation, Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "definitionGuidance": "Awards granted, expiration period",
        "verboseLabel": "Share-based payment award, term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Stock option vested (in shares)",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of market value of common stock",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "syre_SharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Authorized",
        "terseLabel": "Shares authorized (in shares)",
        "documentation": "Shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r229"
     ]
    },
    "syre_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SoftwareMember",
     "presentation": [
      "http://www.spy.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software [Member]",
        "terseLabel": "Software",
        "documentation": "Software"
       }
      }
     },
     "auth_ref": []
    },
    "syre_Spyre2023EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "Spyre2023EquityIncentivePlanMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spyre 2023 Equity Incentive Plan [Member]",
        "terseLabel": "Spyre 2023 Equity Incentive Plan",
        "documentation": "Spyre 2023 equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_SpyreTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "SpyreTherapeuticsIncMember",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionAssetAcquisitionCostDetails",
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfAssetAcquisitionCostDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spyre Therapeutics, Inc. [Member]",
        "terseLabel": "Spyre Therapeutics, Inc.",
        "documentation": "Spyre Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.spy.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "verboseLabel": "State",
        "terseLabel": "State tax credits",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.spy.com/role/AssetAcquisitionNarrativeDetails",
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r206",
      "r207",
      "r208",
      "r231",
      "r255",
      "r259",
      "r261",
      "r263",
      "r269",
      "r270",
      "r321",
      "r357",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r371",
      "r372",
      "r376",
      "r379",
      "r386",
      "r507",
      "r632",
      "r633",
      "r634",
      "r635",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r653",
      "r665",
      "r687",
      "r709",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r782",
      "r803",
      "r809"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r38",
      "r196",
      "r219",
      "r220",
      "r221",
      "r239",
      "r240",
      "r241",
      "r243",
      "r249",
      "r251",
      "r268",
      "r322",
      "r323",
      "r388",
      "r443",
      "r444",
      "r445",
      "r473",
      "r474",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r495",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r533",
      "r622",
      "r623",
      "r624",
      "r641",
      "r709"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r268",
      "r577",
      "r630",
      "r653",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r688",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r771"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/ConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r268",
      "r577",
      "r630",
      "r653",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r688",
      "r689",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r771"
     ]
    },
    "syre_StockCompensationAndResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "StockCompensationAndResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.spy.com/role/ParagonAgreementDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation And Research And Development Expense [Member]",
        "terseLabel": "Stock Compensation And Research And Development Expense",
        "documentation": "Stock Compensation And Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Settlement of forward contract liability and issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)",
        "verboseLabel": "Issued as part of consideration transferred in acquisition (in shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r155"
     ]
    },
    "syre_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Common Stock And Pre Funded Warrants Registered Direct Offering",
        "verboseLabel": "Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)",
        "documentation": "Stock Issued During Period Shares Common Stock And Pre Funded Warrants Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Issuance of common stock upon conversion (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r37",
      "r70",
      "r155",
      "r368"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock in connection with employee stock purchase plan (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r120",
      "r121",
      "r155"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)",
        "verboseLabel": "Issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r120",
      "r121",
      "r155",
      "r632",
      "r709",
      "r727"
     ]
    },
    "syre_StockIssuedDuringPeriodSharesNewIssuesOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOne",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues, One",
        "terseLabel": "Issuance of common stock in connection with private placement, net of financing costs (in shares)",
        "documentation": "Stock Issued During Period, Shares, New Issues, One"
       }
      }
     },
     "auth_ref": []
    },
    "syre_StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)",
        "documentation": "Stock Issued During Period, Shares, Options Exercised And Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Issuance of common stock in connection with the asset acquisition of Spyre (in shares)",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Reduction in the total number of authorized shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeAndNonEmployeeStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r120",
      "r121",
      "r155",
      "r418"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract",
        "verboseLabel": "Issuance of Series A non-voting convertible preferred stock",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r38",
      "r155"
     ]
    },
    "syre_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering",
        "verboseLabel": "Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs",
        "documentation": "Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r38",
      "r155"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock in connection with employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r120",
      "r121",
      "r155"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series A non-voting convertible preferred stock in connection with private placement, net of financing costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r120",
      "r121",
      "r155",
      "r641",
      "r709",
      "r727",
      "r777"
     ]
    },
    "syre_StockIssuedDuringPeriodValueNewIssuesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesOne",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues, One",
        "terseLabel": "Issuance of common stock in connection with private placement, net of financing costs",
        "documentation": "Stock Issued During Period, Value, New Issues, One"
       }
      }
     },
     "auth_ref": []
    },
    "syre_StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options and employee stock purchase plan",
        "documentation": "Stock Issued During Period, Value, Options Exercised And Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Issuance of common stock in connection with the asset acquisition of Spyre",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r120",
      "r121",
      "r155"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r124",
      "r125",
      "r143",
      "r667",
      "r684",
      "r710",
      "r711",
      "r765",
      "r778",
      "r804",
      "r819",
      "r873",
      "r892"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Convertible Preferred Stock and Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r230",
      "r370",
      "r372",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r388",
      "r494",
      "r712",
      "r714",
      "r731"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Stockholders' equity, reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r543"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "verboseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r543"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r543"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r543"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.spy.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r543"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.spy.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r544"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "syre_TaxCreditCarryforwardsSetToExpireIfNotUtilized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TaxCreditCarryforwardsSetToExpireIfNotUtilized",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforwards, Set To Expire If Not Utilized",
        "terseLabel": "Tax credit carryforwards, set to expire if not utilized",
        "documentation": "Tax Credit Carryforwards, Set To Expire If Not Utilized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.spy.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheets",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 150,000 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r450",
      "r602"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/TheCompanyAndBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Series B non-voting convertible preferred stock, par value (in dollars per share)",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r65"
     ]
    },
    "syre_TemporaryEquityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TemporaryEquityPolicyPolicyTextBlock",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Policy [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock Issued through PIPE",
        "documentation": "Temporary Equity, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Series B non-voting convertible preferred stock, authorized (in shares)",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Series B non-voting convertible preferred stock, issued (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity",
      "http://www.spy.com/role/ConvertiblePreferredStockAndStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Series B non-voting convertible preferred stock, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "syre_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance (up to)",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r877"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationEmployeeRestrictedStockActivityDetails",
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails",
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.spy.com/role/FairValueMeasurementsSignificantInputsUsedToEstimateTheFairValueOfDerivativeLiabilityDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r369",
      "r384",
      "r493",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r611",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "syre_TwoThousandAndEighteenEquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TwoThousandAndEighteenEquityInducementPlanMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Eighteen Equity Inducement Plan [Member]",
        "terseLabel": "2018 Equity Inducement Plan",
        "documentation": "2018 equity inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Fifteen And Two Thousand And Sixteen Equity Incentive Plan And Two Thousand And Eighteen Equity Inducement Plan [Member]",
        "terseLabel": "2018 Plan, 2016 Plan and 2015 Plan",
        "documentation": "Two thousand and fifteen and two thousand and sixteen equity incentive plan and two thousand and eighteen equity inducement plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandAndFifteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TwoThousandAndFifteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 Equity Incentive Plan",
        "documentation": "Two thousand and fifteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandAndSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TwoThousandAndSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.spy.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedInCalculatingFairValueOfAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2016 Employee Stock Purchase Plan",
        "documentation": "Two thousand and sixteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandAndSixteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TwoThousandAndSixteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Sixteen Equity Incentive Plan [Member]",
        "terseLabel": "2016 Equity Incentive Plan",
        "documentation": "Two thousand and sixteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "syre_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Eighteen Equity Inducement Plan And Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Equity Inducement Plan and 2016 Employee Stock Purchase Plan",
        "documentation": "Two thousand eighteen equity inducement plan and two thousand sixteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.spy.com/role/RestructuringChargesChangesInAccruedRestructuringBalanceDetails",
      "http://www.spy.com/role/RestructuringChargesChargesRelatedToTheRestructuringActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r349",
      "r350"
     ]
    },
    "syre_USBankingInstitutionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "USBankingInstitutionMember",
     "presentation": [
      "http://www.spy.com/role/DescriptionOfTheBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Banking Institution [Member]",
        "terseLabel": "U.S. Banking Institution",
        "documentation": "U.S. Banking Institution [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies Debt Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r887"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government agency securities",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesAvailableForSaleSecuritiesInAnUnrealizedLossPositionDetails",
      "http://www.spy.com/role/CashEquivalentsAndMarketableSecuritiesEstimatedFairValueOfCashEquivalentsAndMarketableSecuritiesAndTheGrossUnrealizedGainsAndLossesDetails",
      "http://www.spy.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government treasury securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r754",
      "r756",
      "r887"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r463"
     ]
    },
    "syre_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.spy.com/20231231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/StrategicLicenseAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment",
        "documentation": "Upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.spy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r184",
      "r186",
      "r189",
      "r190"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.spy.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation primarily due to operation losses",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.spy.com/role/LeasesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r764"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.spy.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.spy.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "totalLabel": "Total diluted weighed average shares (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r263"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Weighted average common shares (in shares)",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.spy.com/role/ConsolidatedStatementsOfOperations",
      "http://www.spy.com/role/NetLossPerShareReconciliationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "totalLabel": "Total basic weighed average shares (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r263"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-23"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0001193125-24-059407-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-059407-xbrl.zip
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MYHD^8YS'U"K2H? 0\W!$7A E(0<LY5Z.\2$OP0HPQ:.N.E<]L9*9^^DU1%L
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MXH;AO6KR7L/PWEKRWH)X)O,H*F<_K&^$K22E@W$=F6F5X/ML JTXKC71U:K
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MJX_'/M&=B/3J4FJ:^II9#I@18_PC)&>SZR=! H]B$=PW2L(HP3/U<-]M J"
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MT5#3-9AW_N1]F7RJA+.X0J:(H@T@7#X\71C@(=\126M'NWN?=O_U]V:S]>F
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ME) FN$_/K4R'V;YIYW(K17MI3 ')+5=N:E&"WF[N2/$@6K62YRHNXGO 4/R
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M'=2B3;Y29C9B6X?0I9[KT8\(UTCUI%-5(46.9&"+<K2V;#*D'H"%A>A.FT:
M'8%S=]>TDX P)T?60A%-R42&[TC6/XA4S\!^&#S$@W03C+(RQ7164[0%4D_
MYG4N[C/I5( 2,HD3L^?Q""MS?4$4$(1@$3K;7H!-BP$KV=E$U2ISR!Q>M ^+
M,YSX1'E(DA D7@2 I*(*\'/'^K,@RTXKJ8RKE4(QAQCJ?Y=TL64]'NS$?A%T
M,D!V:9RFRU+9JJ@O'A'Z-M-D,'?L/"7OB2*OZ/S-1KA]P^5D=1=VT<N&TS+&
MM#&FIXQI/3=<:U:9GDJGVE#]0/9;1\T3CYP_B'/^B:^NEWUL,I75EM@D]L)&
M[]PI,YT-T#8$:*)/,MI3U,U6=+/#?4X5!5 E?ZD_*1X'$'L";@7BMB[5_NNY
MA!>#IPW'$_9A1+TSGFBZJY?4<+'&/[5$IK*!H(-Z08159%6W1#3<P'0FP/02
M[#)H<+7AN")YD]\/Q?Y&"9=R8U.(P[V-:H[*'B*Z_DC-V(4,PP=0<9[I+9+*
M@9#N[;A>HLJ'378A$T_AZ)VQQ5LRK;X4L>^IN5))6S>R ^SK7=-;  OE-1@.
M,9@$:__?PJ*71G,UC/H$HX*-)^O)Q&Y6WB\K44,\2EI'UM(62_^S<=J-7=X-
MG F*13]DPW)F,JC: %2)VH$""9:L:CL*N>VY/HX+W1E]$71T)@0:HJK'7/36
MY[X+L&T6>4\<$(YC@Z^-QI>LD(<]T6/47YGP:HXX'4=,VPLEMDW=8F2MY9L_
MZ_6&Z#2)OS:-L#)@RG15DCJ4?3-P^;UPX0) _B-J>.JRJ!\P+VWN1#[5'J"(
M1WIK%X(9-MNP8X.N3497VP?)A)UA8-]R48E'*&%'BP3CZ @\4JU<T28)*]E@
M+"<(QSKD:F08>>.:=MJ>HAD&6YN,K;R5+;>[7D+*4U>57F;6R!T!]GS10DKZ
M!6T\7^Y0 R/15#0U)$753P.L30;6-;E-$L>5ON,8PY51'FQ8!MSEXJ2!<MMH
MTDMOJ"K+Y$P ST!LDR%V41#_RB28E_<M>!26Q6P QV5]/XBP]#TYGZED?%8/
MOP!F-14'%X6;T%-&/D@WI&P(7?*-@IB3-6&@N<G05$$VU<P'U?C0I922S"NA
MVD_8F@<6/],!2J42LW =B$3*=R'<PK^NS/?0I*;M<192JG6@]1JC@DF^#GXK
MQI8Y!J:;#--V%@0A(Q1E7%=KGX;A#X)8X;:LA&>!0HBP%4&\HF^[7*8X]:04
MQ=RDA!JA 2]T7=G/3-YI,+K1&)46"LC.(,$T3$J!<^W$HQZLW \#46YPQ$(1
MA=:J[TL(IDYCH80:/&TRGFXP910[&V-B:*C2\N%]:-^J%'N04TP$L1!&$_B1
M?2.HXQ6(+,J*I1M K@4X&G;/7,]DQFPZTJY+)1 A").M,)"EI<0P1YQQ$>V<
M*6(%1)!MH(S<VF@T3<089-(*6J*@*I$,RC+R$#FI)0J&L.;7,TX4 ZL2(:7T
M[=35H>)8A3ZY4'=[2( 9*&TRE$YD+W-9RC[-WA#=U3"]AXM( 27-403*A,\-
M<,2AMO/3MB9WZ,1QIH1/JD_4@MJG?8S%H".A4P%+'KNRC/$WG[QNU!J[FDF9
M7S ;TZ=<@%LA74WFI>&;9_(-\HQT((]8*#+G01&$"PJW;.K[0#GWU'B7^_UX
M,!;!.7CS-I[@2X;**?U0F'XMO8$R=[/+12J=/--'W^']!2_/0BU& 34@?CK/
M?\AYK/S0XCPE]1 ?\"'611C7X!X_P:.EHCNIX (_#@-O4OTPZ-ID=%T7QR>$
M)3V1M!X%@4^UB9BO'6ERL-:(J$02)NHD7)CNV>D9>Y)U'OD4^]GFCBU&(KJ,
M--^0TQEK=:[$]6.  A>GO&&8(UBNL0'L)@/V[)ZKD[VJ153!=EI+S]A1(DWW
M/Q)4\#0.-,#<4U\<%M9NUAH"&XQM,L925Z+-\]$T,K8&G'GQP!8Z8M^-9%V0
M$$OK#+%//':7-@C:: 1=YXX]BNI\6'VRKRJ,B#(N;NAL4UQ6VAR:I-)0IHDH
MCST89&TTLOY(LU"RI#ZJK9:YIT'=2M6V>ZIZ!&:MY8ASYHG?@^47QC!^H^V!
M>MV=#)OHFX19LSZ7FIT[["9A)$JRCP(/4U0-)@TFE<$04O* 9WDNZ[H>EBT-
ME#<;/2A@LF*:G[!7[]U X0ZLTF\[G1V1&26=-'&(!9@T=*YS4=-&W93[,^7^
MGEGNSXC7#1"OYU(<9FX3X:!QA]037E;:H&U>.?DP)9_*$I+?163->/ ;)<J0
M:T66,C(;]R8C"T].8C#1DS6N !0NW.UP3+J2&_-/?*>_ WM[%.-^C"6*LV]_
M5F$0ZHF2.:H'<#6?JBZ@V3'B196,/*+I=J'['6^DW]%$'PUS/=<'H%3@+#2(
M^BU8:K&2P^A"]V5WYC3G V0YI[-8M-]'V(<93[Q3^HB1V)L,*CW+,1=3II"S
MZZL_?8ZA; U",J)BHGX&1;H32?,X"DF$-?PQ9"S\.[;'W&&D\AE4";F>Z]%9
M^('\WH#)@$E'DD)-SWH( [^/:=4#E_(0X",N.^41JM+OY7$W,%]ZKB/RLO5N
M$@9AFXRPZTD]*:]9Y=0I/4<;Y!O8R(R.:G;5D:1(DW4FG&*@I:"E8"1ZUZ0M
M&+#[+!5CE*?B8GFZ_,G^B7[@;U-A!1</FZ<]%$66BV8(9RE<!HF;C,2)\TMB
M%^Q1] 33H,)12!E_'K^GWK-:?$Z*1@,? Q]YQ+9 &8/-S\.49M6/"YO=^-AX
M9.".*$+WX'/Y1\_DWAF,%1X-%QLE"*-AIF#YS($]C&K;YU6Q7 Y"$(D<4I-\
M;/"44[X +@,_\(+^V/)<F_N82DQI=O<L=(,D$CN=I;*DIMT6L"W*&C_DZ*IL
M3 '^=$79(1\;?L&<;N2<3%S!<,W+%47E]05YZWD,B*7E' J.H@,@Q=F'*5^I
M+A$AAHF-OV6S$7:72TS-4&&I7C3\D=N)VL_S5>>SBI9%-3VRZ@PA)MPGL2QP
M16D+LIN?D\0FHW##$5B4Y9I08YO,[,V?<).'G%6YRJ++L#G-C%)9;EI1;9;#
M^3W5B#/I.K>^LAB&']7@%Y^12?=%],E$OKNF*'*A#G*L^OT8E<.PXPMJS&55
M.B<Y9ZB B-N#;-HJ;;T@[#-?]DXR4MW *&L#$=.>+U+#2(4=@/0#3>,O4 /<
M'M9Q!;Q%@>]S4RYXHX$SF4I%)ZNX[.),N;'PQA]<9$KE? -IH*6; $E]V#)%
MBVK<*-.4*J-O&H"%%H]B=TBGWV'C$G@"I&'1_<1'X*F3*3:+8OT:N=ME_E!L
MCX[P5*'JM,NB2H_%.T1A'A@M ^DGBJAC">H8^X,;+&X\%O4DF?PY46'!]/$\
M'NI=V+A25'I*CUFY0Q&NL6!S=>]=(]TV'5&9-8WI,-1LJSNV(@YR2I[/$^5Y
M8;WM@;2B)Y%$;=YD$BE>;1"UR8B:4,@H>P\^\FG+I&/O8 IB VOAZ8-M\X&%
MCO0+JC*(!+&8/9(AX'8357BFF_:%,"#;9)!-5O3%9*JQ"%Z,0O>>V4(G(]F5
M"K,Y3@L;]&PX>KA_[X8!G:3$4D&BU 9A*6(]'HLR&Y-UK R:#)HF4@]4.7J]
M#%#^G"/N;C+MV.#'X">51EJ3-,"4SWNN<"GDW 5!5IJ/V7\EKDBA2H-<48Q^
M@[YKH\N 4DL,Q@S&ILP\A!C"#BO8 \)ZK@]0$<=KHMB-D]F;VWMG39T$PV'@
M6YTXL'^8J*7AAU?(7'D .T(H#0!Q/,QU4$4^L0,?=W0M4;6# <_(.K9N0M[C
M84A5T^$!1M)N,K)0,J$;@_H2Q2177=\.PI',OJM9IR#&'JA$)'O(>3U4IA-&
MS6TO<3B5TMV.V0^.Y5UPQ[\7%7$-Q S$RB%&H.J.R5)%3"&V^",@BJK;]H(P
M&1HL&2RIC= )1.>0M&RW-6)C41D>F][>XW$SAS)Y2%\,0AYQ+CHF4/,C Z!-
M!M"Y:( 5,4]$QZ,!;&T16A?\T8W(V:^I59$\/RN;V)*IBNJ[J% &FIA#"<,&
M4P93"E.XF;E1E) 7@ZI$_)6HG N'=V.)* !=XF&)$HMEG9D=L&UI1Y3121V)
M!F*;##'1W +4)MCQO+R$"AX 0[G>HB,>8CE3S*N0ME\TT]![0\_(%^[S$&:
M'A+K'(R'(#0IW(87GMU#3B:LB7U8@CSG8!NPR!K AAZ$.%8/?8G<M^ZI2+,G
M$MK0H^*$P2A5%8UZN/'8^@-3T6R4F)H\M0-,DV11%-@N>70I]"K"L*@PBCA^
MTO5<6S1H\S%XC^F6HB2]J8MBP$4U:BT/J\Z"N&*@[8VC..M'0(U3R<A@RJ:@
MHH@3%@>F4(8,:8>B+!F"M"H[0ZO2W4#0B:;BZ$RA\BNH::KBRFM=AKYARM#+
M,O3+6_=)%:^ $);KP!P?]QJ'S:/#[WM;GV\O.O^VSMLG=]>WG4GE3R='\^V"
M<^=I+/$D\(4]1JQS(GJOP^5:?\+R(>\O9<2Y EWB4?C[1^H*;].F10W"5%'+
MD+DH2#*[4G:0KPGCE#J.H4,_.Y#J!%846 \#4)'P(=S)NHY-=&M$P>'Z"7P
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MADQU89:G;.B1J"IN@-*JN;)6E\&))@8:1>\V_]C]$C@1J7EY7#2U:7:<%L[
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M56PJH\,H@TZT RT_\I6(O"3]I;E=:R]80J,8[$A19:A\!^ (VT:5Q)09<C!
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M]6+I(=_-/G =NS^F/_8M(&,'R.^^MZEWH#=GA77=?_>]6^*[^BV7GJ)&M%L
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M!;*9)3@E^)(>;QPXW.+*_VJD^;C#NTCLJ7'C1K3V*0-&P2GF8Z^=K^K%-3E
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M%5G8Q^@Q6BH9N4]?$E%FVS:!\3-4&EI52\K$P]VC<%*(&O$9$99SLUB^.K-
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MT\'C',\^A/IZ\F[EAWG 8SRBW[O( 9]>@!;W^^(W"M@GVF';5!:1/Y/O3S!
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MU -)5/K.J#8SG.;,N-*<_PP>?0OG: Y[R_Q%7W ?@]/'QXR6W>MU?>N:V<*
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M:^'T]_\R^;Q4\B_X90TK\";Q,>]#"= ?_!X(^&BLD>SPJ62", HPXI-SK%[
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MATZ:/F,[<<4G'.1$(O/ZOZ #2>-OY590FUKVA_?[:(C%5]-&S/35M\W1M1/
MF/#A9W5HVD;-$(76Q,/79<WU-*7ZW'><2+1X9TDDDH02X,#JRZ.">Z*,RL#G
M5$3,7"U^=/#CG.SB\C[:TDIU:LPMW#:_S!FBB,OAVJM#/X(T=*\B3F;2I!KE
M%B>V+!<K73N&R3**6B;DQ!;.[)90)Q%*J1UC=?+H&A,<T<-R3BZ9/M3HKH94
M(XYR;<:)A!<KD,E0OPRG2OCXQWV_>OOQG>27V<1&1U!<_7MZ<+:VC:?+IN31
MX-@>8P'R)(/MIWZA)(1\X_+O$D77HIERA[X7?9VPVE(X&*/-&8+&5D2[\O5W
M_5L%9#C92,&BR=/*;[P!<1UAY$,RZ=:(YSX2<201;QOVY!C%8RSI%4XA?<GB
MP8MO6(.SCC24*?_D*."6R,O/#IPL.RWOWXZS+)B*]4Q[ED,2O Q#J/?#H7$7
M-"D"&2EFVK!8Z-!LL,L]P;=1?@%.-6Q6+@1!2L"%,7L.@'1'78/E-,:\?1;B
M"W(QN4@P=:Q]+^"W^.JVQ$NNZ -'.Z(*A;?%D#JM(O&=P,]JYME&&G#Q@ X
MM?,Z5%I#>K&9!R>MM_$ MDY>1.2G"E/XSP,)[-(!\%H FS4@FZX.Z;RFQ#%8
M06Q'0A[\%%?EA3Q[I'L-RMD6.FS,Z_L0CC-DIV.<E'@H<4<)FAFT )7PL?Q8
M]-BW1RC.TN!^?"-K+*P9KZL@1J"H/B<IPHT@V /;[TDQ@N8-"T;"/[,/LE)
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M93==G?V0+,Y[9ENB#9/==CJXWZ-EL)U9L9T52F13\YEO5M&MO*Y%Z:Q<"GZ
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M[&ANQ>$V2 -R:U;-H;DUE99J77@(22+O,7Z.H^UI]=Z%AIYG#[48H1S*.)<
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MO!O4JI);LY[ERD'#\ %A@/"'\&_=6EOJP3'DC>TJ51>!_>G]R>G;X]\_O8W
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M(ALEQI9B+E]BD"D_=S#VR(6F?X,]PB ESEG@Q0P*)#1.)"D7(XM.18P]<-G
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M,(;B+7*KP7H$F?J<VCE,6N2^X@7*T2AA7)W.YH+@NJ4,/ZE7F9J@X/8%0Y%
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M0@$[(NH"5B^\&/OZE<\<4*V%0.!(&2QV6A)+\.5;L\>FJMM<M7C?X"$U2Q^
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M?I7%;=M0DT58L(DVK;!"<F3_LZ-B,7V7MX4W24LX22E<OCXCGA?Y%B4[P'X
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MBXB*$I"SME0\Z3+(JHYGZ*@@P,Q(,HK3(?U 3KA5K)&'U*X;MMUU=<4D.0\
MI&SI*]?\U<+N5A&$+M/#<<U1GLP8!H) RD?$4D]QRBQWCC:_!M<$D1.9I]Z1
M0)@E;W5Z111.@F$K:.*EZ"C#<+]$!9:&GJ__(R,$OG#P?;I0G"D(9L")5%XA
MU!-@\U?B#_L"0%_/A/NI%054R(+&;1# #@U+^)MR$B((ID,_0Q#*H7 ?^=_*
M[: D8VVK[RMB-+>#%+S,H%+KA'':A_5*,P5^>02>!KP276&QB]0VTRGE+1B)
MVS.O#ZA!)]:[KN^*@_THIN>Z850IAT4ZX1E,I(M)S^<:6PA\*6TVU J(=_1
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M0U\"SKZ]7I"O'9[IEZ(D(FR&FU,K1, '<:8:]2.,  _P,PH06P0<@"HK\,Y
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MEQ M)=P&4U=U?I6$Z\IPR^_+_QAK(X!,1&NM9UC!AE>P?@/# )3*UL) *>C
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M-3[8X@I6EX'[<MCTC52:?TXQ+R_+V@*XDOHM3]'B[&Q&M25#+\%<!1PFD]#
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MH]'W=45/W#^>:O>H>VNJ;3KSG7>FTSWS)UI6=M3W;.KQH1@X<^Y*R_68$*'
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M(O%J'A6>6K0+$XFC$"*ER^?V;TOO=J!UQ E16^* +\5,@+?BKB'3ZE#/LP\
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M5UCM4S;1RP14QRBK:!1WSX&/-TG NDQ3&'=T#CXBWHU@HJ$5R'J';/N(",3
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M8O#R 654,(V+PI\E) DN#5"PVM#GS].S_V136C;<"_B2!OI)L.'"Q?'R(JI
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MBN*F+O0WA"G@7WWWTX;M^^H([8M/,."<0NM7"+!B)!I$L:J[,:-ZGI83#JO
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M'_'9N?Q,7>H/$'R]8:DURO+*.@_?"]IBG"[Q>%4-&HWT#33\P!2OBJR!/TQ
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M8Q [CTYAA0?1AP:D>(6?:"8I/!M,.?]T_&?T8I&6K-?^)Z[C<A#]H[F,4UB
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M;U1E=+?7X:MJSG;%5G_L\J#=:NZ*K7;%5E]EF%QGG=$=78/[CX\'3Q]^%27
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MQ<_=>A)!?#&,(84-EBC7UZD9/J5E5:M!(:>()AK[45O]C8<7#08>1L6"+J.
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M!F#LU9*-<(Z9;+FXW>ODSVXX.AZY5&"X1:W /4HP(V@3B.(.H1\YD,DQ"'%
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MD7\Z8998U%(P5E!QV'O*Q95%BVB7.H&,L1J@RT63@[#@=2,'!DQ0)T(:P]"
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M+*6:7>$8F6_8<@(/%,WE1/Y*%9CM;RAH.:FN5/Q-9\3UGD/F!-BOD0^M>\/
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MH+NE87# :.,]AS.5Q(3NAR^?]B4_*DG=7%;/B/SU2?E"-C(HL-8[?L9E=T,
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M*U@$SN[3O,E/<6NOS+>R!_Z\+NOB/=O.@5T-CGQ5"SI2(J"\KN2X]HD?W9O
M,EX1O=U?%J#NH3PGE:@^E,Z'G5?X9DGK9?*7(G(9.GPXT@X*^0;WFP/]#<41
M N^<K\"QBA)/<L>U.1A8R!NEX22>[+03J.\P\ZJW)B$!\0+& 5U:(,!$ XO4
MO9>\1@YK2+)3Z(5;1'HJT!,$QB58D.@7,%\WMU,HK-* @_X8T@UO_Z@7MJ5!
MG?A]M$3Y9 C\MYW]?;L+5K7>=*OS2$Y9JS3)>5LVL,TYQ94,6JR0B8Y';?MG
M.S6\D42[HDR7<4P#X[Q69,/7YX2^A2@*_E<QT1C*X54QAY-96MZX'RQ3B4))
M.+M_P;E-&2V,I*0$#R66!L&X'4HC&QREOIH-]/\)ZN"I#2PYYQ!-8P&WPY/S
M$+EV-9PDE00KK2ML-9\47YO*0E)\A01$QHS=L:J:YJ3;T)QPLM)*7-+P;^EQ
MEI%'7+94146^)@Z("Z<4A<5_E<H?^ [^#>NHB(F5_YB5<%>O\M7@7W<6Q>0:
M;-E&KS7R=&-ZJ6J6&,Z.<975-;[^JE@*&A.9.OD(X*K##SCGN:!8K'8GL+P6
MBP6E7=%4P?,-IPNC&'!OGN5P+4HA'OTG'%&P^7C?]BFG]RA-#M$UK^H2/.@1
M"+8%-A-_AB[C_L$//X9S[C[6&0,<L%DN7(A$?^VJE41#O $S,UPDA,2AY1\U
ML G>[1VOX/T+A=\E*(12;CB,K[%C$AU"7>L"[YB4,69O7@UB]S5T,1(RZ72=
M!4YX)HXA9:1J?$$</X&N"7[*Y8'0NU13@ ,GI#)76H+ (%!44JVDQ"D5R<U_
M-'_"'*H-M0!%.&NUE!@3IS.FV"_(0D>QK8>F3"6MCLF>K3@,RX,-IC@50;@6
M/(JH1/!"/A!5LK+$B/"ZGXY(V4-)@YG&]--<C%"S<^D>-LD6X*/#/X2UK<,"
M$@:\@[X#G-%!-T$C;R8"\:5>/#ML+GV%C!I!M;;8-I3)/J,L3>I82RK"M6(*
M>&.C/DX.-Q07I/">UM[=H=BNK,J=L/^I1G F13.K:@XA>:>-.@T48"[R'Y1=
MNB7,JZPGC+'E+4''(D,TB:OL0)E=N(:HXQ8UZ%RY6*BXL'4TC_$I_/QIR"-$
M])ZB,3[F .TYV/?U]BK\?FW!B*+.%2MJRRX").V*GD9.L,04X5B(,0I;"W*^
MT+;7X"^FU"B\P7-$6SIEWG$**?)S&YTCUA&0NX!'(>AS[ZCP-=E1#>\^19B'
M'K@*E;%,J9][&RK3]B_C3Q'*^I+(B.,6#"Q5^4,\KL@*6<HV\L=H 7LCH)#Z
M(H^"R\.CVK#>M,"8_I]7#4%@Q6A?!?;MSI*%:,+06FNO=4WX=,2T6(3^-](,
M!ES&DLR"J.<M^61DCRBJ1_+.9D*&-U_DXZL2[5B.Y1_#VE0+P18<JO$DWPLI
MUXOCPY=J!*;.;L$6*<I<HZYBW.V@$>9Q-AITNU([CORTH8WWTA&73,QT.0,J
MPXFP!!$J_&M$;LDY\!\DJ#(,#/0-J6/7K_$]U;AI$*M;I>12ZJ$LREMN^H .
M3S]'%;A%4ZBC4=,Z2@-16,R.%_V; AC=?*Y2>VM C4QL=*4YUJ3B'8O4I.<
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MQ6%#@WFJQ[OQC=]UWY9JMT6R1]BHQ8!]D2FS&UQYE&&\)-O!]/18=4@+Y!_
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M3AYFJ"Y*^P5(8AWU"*.UW[-"0%,S7<0 B'BGL_$[(I9'I%/%B0_LYE)/B )
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M4>QR,U*6^Y<&_5_?PK3IY\M4$TH5Z=)_/K.JX<Q.W8.7J-)'H,56-EF]T*Y
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MZFV0V"V[S+EW"C@!.\5BT4H&X'V!_!_ZT(=,\#PP<M=1:,/XT3E=YRO?"2W
M6S17S(0@J,7V'DM6X<99LTK0X:5#(U-<KY+-^@JI56!-3OV5(<IA#<(5QC1,
MW&.A7USGCIZ,(B-M^+ SG\^EA7N,%1-AIUSZ)H5RV<HJ'#MF/+%/29%9,5\[
MD[Z7X+S3H+:)61D< !M6&)%*8"DR-:TR"YREG$^D!!]Q&S$7,(5=0Z$9:\98
MW+%_(#DA?$$AM3;=IRDQ_(#N8YI.:KU')YF.ME"'^%JU^,V+:F+4) VWT%)%
MR8&88)BAJW>G)4(3FBKE[#9H:E>\4_;J@DRW*@&9.W//:'0W-3M=*?O&>;&4
M=6,M (^+ /<82X-!B.87AIGQO!J_0]K()57^YJ77!=<U1B?)FJ_JCH5O<)X0
ME>MDN!F5$CC)0[ N:]XY$!I,#S:#[2'JL# /%&8A^,<N2L:=203 DVI#CZYF
MA,%90X>IL#J/Q^"6U:(9=+?!@W._=SNRP, *3D]XQ/QH"13U89POE0B/!1BO
M7E^.T6@40L)KQK'N[%]4+N,EA\J4-.[);3%1:K6!7R<#F&T"(X\/T@[.Y%*(
M]>AA-G*T+%U+ _+K^%3"P/:?R(DJIIV=-/NF:;'$GHAN_P7^52#PN665[0Y3
M-LX<R#Z2*:Y ]7M*,1@86<%.0V-J4R*\1C9(63OA38TRUY)L-- 4G9N2LY$!
M3<0VF6]"@;]IY[!6Y%P8\@.G3*>#Y8 F(K[_@1>1PT+N7MHFR  ^OVE]% 6&
M/J]Q'0(CI/6GE 5WR%R'-AB#B6C8@D%5+4DO-&U!@:[$4_;S^YGRR 21$ARD
M,V[:FP6ZW(^UQL_)R+^39?(51]F??(NR;P$=/V2ZIM1I;RI)W-B^N;--^E3P
M#C<=^&Q3I%@ A9$EJU$L,L"*!<C'K,P)'!D-4,'(U(4:<Z4=,-93G)Q!'H;&
M1N&='H9KH!2%Y ;]U4PGBWFY&(@DS =>PQX)8MB,THPBSYUU$$L@?"@@S:R7
ME15MT4?)'G-$=)R(1^RO#1#TQX-%2P6@\MTX=O-P.QS"FPX =^5I7'DRU6,C
M52GQ[(UY"KW*I"%SR!$_,&B[PW"+D2@\2+WHA3]F; L(-J[[!E3:Z+-*%_*)
M+Y R "+W<>F\1)Q9L12B0$?V/BOFF5J4F[)%^%K479J_+<J/UEY:T]%=GG44
M3^H,/!44 -%SC//HLJ3">(NVHR*)K 55%U'J&?2"4\2 P4TC*P(4V>Y0M'6I
M@FWDGOC18>2"2]VEO=]\G7CV/06]P_$*3<-6R-:)E/!YTROB)4^G:WR2]6A&
M.Y]!1G*$BLA-2U[V3HE2%(:ZV3K7*CZ<(C>:K59,06FX<00"4 +%2V9A!2R:
M94M=T'"7>M7_F7X /:IJWK*/DB/@OF@6XN:NF5*4@2F7<AKJKE7+_9.EEA7F
MKVB#34'#SV^FGN&RG03\!'86VY)5.B(,Y37'["E3&<A,!H>E(<,S%S&<4..1
M2^LK@M]S<!!!HEH%MI;@LJO$I624#^)^$@)]I'YSVG:*DG*,+$;7&-R+A>H>
M:F& UZ$:<Y6/01%%9NTF,%;KBXX5[W1^. 8BF$3%)P[D(<B%E,NOD5R,JN"J
M^7C!)0*4<B=&L7S$'@Q#Z-=VD(W.]JXLC3BT^+Y^NG?@^J9B7<A3T$//M55A
M%Y4CVX!(79EZU/H[4RHNPMM7TX$)<@F:J!QI=[DV!JC82= V\GPSN8'<:H>.
M!E+9HV:M:FXN&5Z)W<"H1P?YY#W$$7R!)\7[KX&,.:P86EXZP&Q\I;57&VCF
MNT2XQCT2\7G%C2_E"& \C$'4H<.<IF!1NM!9XT0!J;[YVAMA(7>(-H<E:D-0
M+#6A2 )]51F*'^2<%.-\?H$%1_,W-?E.N6IO2T[TJ#$HA095P:2P(",U0:2Z
M0;A]"H5O<O=[(7&*;'@JRO#JF70+G/\ A0D,&O"7.+!I=TT..7R6CBMBR\?V
M($G0CSI)+"2RT!V6^D<7\CL^3"26>I,0X.9M0G,K42M,^H,HP\[:$>==]TZE
MQH2GDI/.'5XG%R?%Y>,*!4F;=H A.!7YBTDY HJH8D;3&?%_&?RM1 &Z@%V^
M:GP97GB'K ,7BFX!N!V39N%8KJKYA.DVS"R#G<(L&4^OI[0H!,]8*-5VE5"/
ML* D;*GC>U1+GO)(JX9K@JRAA^_C$U574^'>I9;RP%E@\@KI(H;T**'*,)]S
M0YH5I6,;K722;%AJ73]JJ7 .F1CJ)S34M6FH$1/7T6B+)<1S@P):Z\Y;G:)K
M95)(OBNFZW#!Y'8K-)58W-D)-BB(F9P<REF[L#^S%^&>N^8^A/"J#)TMB+D'
M0N/*R<\!%^@AI1PBE)WFOV5$;/[XFD=UMEQI--=01W,8<X:5P_ D:+9!"*8$
M77Q]A@NYI2HAY"=I[=25)2Z.A;9*AHE&D!8KG\383T8EI(&/-N,VG7"PL6I5
MH6"=!Z#>/@R?(-?!4"K!#X;-I@&FS#S3[4.;)JB!-&72UPT;PJEV/JQ6A55
M@?R?3!GY"L4TEDV!:,'UZ*Y RE<EX]X_%;F@'4 4*T9:I[SL$ GRXJR4 .'M
M+S21@$;L+3B.\JM&37__+9Y[__%<H;[GH,@5,5D'SOQ4#SZ)PNC&]VY[)#Y4
MQ!K"342DLQ;R<N*Z7J"T,0U*:4KY(BZ-WKU ]Y%(+>*>%L#)VZPIL/W=%TX_
MJY'%-;D(-9IL^IH;K#)*:P%1"HTIBHK5P:FKS72CW_34-"R8**2 S286-UKR
M6'<P-5I7<[@J>LG4FU#6M:.1<UERW9;T!!.O<[392,;:@*@2,4**W[9'FV;Y
M^5V9D<*D+@0F-5"EM%UX_]LAJ)"W M$.[070!,&!9/5UOL.13H2+R+8XYIC+
M]2:WN,-@'A6D$=@'O2IZ.7HA-9**(V9+$H)K-]B&50\9H;T_<X:"K%(X([!F
M.3'SA&^'NDY\//RB9\N&RC^!T99Y1-0!"UHL=<*<$!&&067VSR5NR%QA%#K@
M=J@UI48KY,S("7TV*XGQL+8(E,'8R.L1U!JU)%UF5(6H^&8P"/CQ/.S=Y+2M
MFS8K+45 'D6 WPN.P8KFL. I/IZ%:Y1R.+HPT=.!(%%WNO)?;2F<>%:<B]GY
M87@.[:O#,>"BP1MXS89 21Q'I\Z_41EG>! >C_ GB[L'M[);HLB]Z!Q7XS&A
M#I@2@>+10T0POK#1,TJX>0E<CP*;FRJOZ>)T:]^B0/T8G&<884YT-S+-$3@U
MY#=1IL9-5YO]=&K>TJ&B:0K*,7-_J&'&S(! OYU[Z9N?6I4;-KV>W!K*_M1-
MEG3]0^KG#(%.W_SG+]]_WHIF/78(LD-/0?+=H095X2\C/=';4;+GTCJ7;;,
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MVH:\WM#DK<N_$U>9N\-3$326FNVX:(^@@*6OXRK"XW\<H$&;OMAKM'$!3<S
M:A,!YANN).X1#OL$0Q=XQ EV\WRU"O=,NH>KEO*>*@QG5E63SN.6F-(L$$5
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MD(*!HJT-X6\*W74N:5] NN(/(T'2V^M);*A*VFBIE%L-([$%T:1U3G*G>>$
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M"**(;B6W2 R?$CXZ"O"1]*+H!P8&J5\@ZL=CQ*O23PD!+S368#U'TQ"K)>U
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ML:Z6\7=>U-DZ>?WZU%?/PJ;!NN;4S$$!Q93)[1!]!J$@PXI1>6D"_YVK/>%
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MRI95N8.?5LQBE(*DQO)DIJ2*ZKRD8M)E5I#QXO.K-^;5B#(@Y-;@@""5CS5
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M8LE6-,Q].!0WW4CWQ&-GH\A'&26\4%(!2Y>!VI@312 H[3'(%< C._O"?.K
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MQ\O:]!]@ P8VLD_%I<,< #84<KA3]# "20:JZ (H[3F:#-%-O1!-]AP IWX
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M+>&%TE2Q"Q!SS)F!DN4 DW&%;C6)7?C7+?79(DB,?>;Y48*C8IE3/'W\>>J
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M?F VNQQ-^3B&XS%;7]X.L=F.*#>>5JENJUKAFFI:H<8H167E"E'L0)9"U[[
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ML*MUF+^,;P,>1;:1(09A"6R" AZ#\B"&<BA/PKA&^^= ^^W'^V.57YS'[6^
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ML)!59.$_YJ"]D97M&$!JM78]//8W.PCNV54<1"ZG-N1[PD9-LV58S7Y-*1\
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MCLY^'%#<SFJ@OTPC&_%V& 5/Z#/7QTO,,%]P5K]\QC?E85/,IQ@RX+3%B*J
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MDBD;<MJV7GX\B=1Y/"(AY,^2O&A\ '.2Q2ZH7$X)!\'D"M*!5%++V428F9S
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M,N6E!:1P4MC" I4I7'67I679B ASM/F*Y+%I6W"!J!S9'-N!.=H/$9F ]1:
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M_?_C')M&.^IB;TAR( W4ZE&[D_R,'RKY,7WW3:C,1W=DX=U,[=E#+OY'X Z
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M "Q:X]7W;!]<C;/0@S]OF6>[%FBLF^'#B@O_\A@/ U8BF(IJS^DZ9L86Z:%
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M +[LG+*7HVX#7I<<2/NF&4?M3O(S?JCDQ_3=-\$*C^[(PKN9VK.'(;E_!.X
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MN;!1/^@HF[X?OH"O//3<EV@CU>#OT/;M:#KK_7CB[4R^:[&AC1#IX^T]9ET
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M)/C[2H(?R_W_RG#[JH!T.,'=Z^# FEJG4Y5I[ VKN8KK_K[:]U>(W:^4WMO
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M/ ! O(6  ^ 5""4/+_LCW-N:94^!>>"4,@LL% !R  "<TD- 9@:(R:O0>Y<
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MA'VK"O9&>@7[H'[0"G8D!T9$X^UV!7D;E>)=)V]PQ*-E^$ .H:%I>^1/93'
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M*M]HGG)E/JU.%#!&+]R)*5*WRD73]1U9,\%H^V@Y4<\ZR<-BS)<;EHR<,?9
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M&[-L%SL(Q5)5:O2A[0L^T\BZLP/X=^40N.7  5C9?K23Y+EP*8>4;LL#6/D
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MVEG1_+LGSY*RRVW.U(Q#/0/?Y-%(X%O0L#SMH;DCY?RM/7VTE\&)"2.]]BK
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M./S^*AP<?G\5#@Z_OQ6_\F]J1% U 6 =ZHK<1+_47]]]<*,LK8I+WR@P=0)
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M61[&[!K1&".\)O+!)EG7-QD1:=O9+IR922@V(Q7BHVL0Z@!LMA2P6?LPV/
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M@+P+)C&-D:I3QR/\7SBD,W'K"EN+ ZEV ^X6Y8014D625760G%V?6_UZARQ
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MNLOUKK*[9I4*W>6*5EE_:Q\+W:M;@ZYINMK=?QYNVKQ@O&DZ&TS3^> .84&
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MN-2V1D!AG^;"L\ @QH5#=W31NBZG7H@^+F=??A T9'TERJ[%_B9<A87V-XV
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M>26"T:HE@K,H$/D#^8Z;R^3@!X.-YN!_>3&*= N'F\G)IP^W57BX)4GYP6!
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M\(?X;,$ BPB\F*8])4[:S+N?6!]_CL1LS@,;?/RV?G29  @(IQ,+$1^P,CK
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M)3*#P>OEX($H8H$8[E).6M6'+7FAIG#G:2#)A!%, T$^/XIYFOW(>\9J?'6
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M;ASM[Z%#Z#"H+8E*C)T#",E' %QU[KE@BS 2UT#!Z)\&H **Z$1OH&X9'D.
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MHEGA.0@N^<NV>=MQ55YN;/ZKZW!YN@0QX7%'LPI.AXJKL"+H TBVOPHVGF(
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MW8C9] J'./I-T#5[G7HGP^N,L(93L1%P ,S049!I[8PAI!.70T!SP\ /@%8
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M![B<6BJ&H '&6=BYD9HZ(QI:<Z#'NG8G_\ I:S-]P4>4(6P8'RN$W:'$D*,
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M>X'1J[*D?&0M,=V81D^*=#O/M:.)WK&[ S^"Y@$WH/9E@OIDNW.R=_#O1^;
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M1P.MRU54H3*A!DF8XDZ9$:3LP]G!EJ1^*^$CU%LP$BCQ6 "1\E)"!_/H.>0
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MH]O:/>_]JSTP[\DRF*:;?X9^,*-QDZ#)6#:M!K7&$/1& UX">Q&^#UQ)GA8
M*JW2I8->'XN  QADR[XFE$G8Z,YF 7F;_" T%P@9]/&@$)HRK"D&@&KNL\,\
M?VK--8/,;KK?-8R0_$*P47DM_H._/C&03<S19J$=6'.DD:4G^)IOH>LGRX'$
M132WFIGT:?&5_@0MD)^PZP>X4->P=%S^LP7&@Q\:4[D1;CW3X$\=#WRJ!V)U
M,WV!@A/GF^%+  /HOO0*+7[&DS (/5;7;B9+QH9//58]B\%&S$PPP3L)9^$H
MQ'X1$Z+]U01")-QM8-(B1#TQHH&V8<9#&K)Q^]D-;1-WI2"XC@3CH%O0MF96
MP%\2 O)X@.I$]<*H&K3PA>U!6RXA11H?79.!<C.U8#V6#\N!WV>6PQUV$\N#
MLQ GO9!>#O3S,?G Y1/VL=>BQD^$0T=<F((@/!^_U^=SVS*('=BN\WB)[Z]I
M"2ZI!%4T$571-IVM!_1ZR7ZRV5S$0S6@9Q9AD@-8EP'F&(\4S@$WH6OUWR%H
M@JCQ11>AEDC\A,UU?#I<!.CEJ&=$3$5Z.![NO_PK<G%XH0UXB0B, "%B15;#
M_#Q KU# OX9H:MU.I%'Z$(Y]R[1T;]-\T8?O'QYN/HWN_Z4JW8U(YVXD=.Y+
MGQFH=S^[@+;,2:C<?5"Y2=RF=&Y /1<@1^@A3'Q?+G<!:_7F;N3J0C:'0!/
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M#PB$92$Q_-$82"$1?4XP_&X#>.HEX--E*TJO%:]/:MPJI8OW:O3.&(FO?^*
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M!:Z'EH6FAZ:%5<<3.;Q B]HO^U0RSMDNSV/WL,C=Y?7-(#8Y)U)N52I1$QV
M1VC&P/N;301RR="I"^A\#CU4!WDYK[+CS)T:!#X!,+J#:H=]D4<",@<X+&@)
MV!<**WL7R:I;T#.?J5L;@+*N_8_[C+VI:W &AHY*H'I08^S7]<1$]ZUD;3@6
M@F>OC[IINP%0)-&#+=O;I=J"84VQ;'2'A_8L]6_8A6W-Z*QYY3<\P7)@(5CA
MG:R_1C PZEM$S<4F<>,_0/+X#P$MOD!>AUTZC>*6]HI-DM0$!:TD%US<.K+(
M:1>FV@6RMIW*YSG%^4P>^+,.!H8GCZ@6G4K4YB'!%/#QNKR'$,X*!*[S[3C1
MCDJ8XB68^%C*(]IH*C]K&867\K5B=3ME,<+WZ>$:==R)8U[JMNNP%12UU$QR
M.1],6(P!;S\/]#_7\6OX\&11ISS4]&%;&<_F!FQ G<RI32:\ @B0FE[. 06I
M'7 DF*.>B]&#YJYLBL!%I<_[<PC%WZ?F= :&?">4JQ:CR[$UF+-X%[GH[#Q
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M<BMI^JT]>@2;@C[62FQSEJUH>4Z'MHM>;6O_G/[]2C?M0Q_-C.DXG=6/@K&
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M\I*Z7LYD&&M)!\0<-3/&5,QS0R6#<5/%(X?2SX5R"#$1PD6 =DZ<,<D]2 F
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M1/KO0#$.6V@?+.P:;QF^RD6I*>!\CL\2L>K$D,5L))N*<9^$#:+<A1QLU-!
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M7]SZ/W7W-.+_[.[/_OZ+NZ>U)>218" *@31 (*#_SN-_K?9/%L *I[NT )^
M$#>? +> F &_J(0@'R>?\.GQ-PL_JOV+ 4V$+<3.ZQ\,"/-)\ G_;N.WFO]J
MXS3G;($HX'_*RN]U_R_T@*;F?]P',!CO/VFZHA3=4?^QINO9JRA>/; KP@T)
M BNZ@^$HEG\VI0?^-WG[SZ9.J[/\:VIH:DHH($!NL%,0505I-S>(K80LGYB0
MN(BB"+>H@J(<MY"XD BWG*"\(#>_*+^0*!\_GYR\J.QYC/^J^S>[JG!7%!!^
M]GY4^I3! SDU+2PLKR2O)"LG**@@HJC(SR\K)R G)BJL(,2O)"0L(,?_T^QO
MJG\S^^/-*1#ZWW'['VS\#4<%XGHZ%KRD_Q+Y\T31![O\E?M3 (6<)XXS$.EZ
M_LY6BOEGZ)G_IG"F<YX,$D#0>2JZ MW!MC=Y_\+[]TJ0?PBNX/\NN']3_??V
M/1S \'\98D+BIZ/LYQ#[K=:_-W(VRW@ D6!9^],82_^X0_SYNZJ\O@CC=6,(
MW!;AX7KCI\6_JOQ[TR '(-P>;"O-^U/Q)^-O'</[HV?^/]EC0O]W>^POD^)%
MC\&E00CXV<\&_X5>.\4!GC[J@)&NTG9(!(P1Z.P,A8" 9UJ\[G#;/^9<YU\A
M0B$8(3"@/9@7[.QJ]Q/E-R/_#QMK"T9"_BL)^IN7O^+$^/^W1O_WQ^3_]A9U
M,2;_ROWK[?#G+?;OM\^?CQL_TE+I++'^<_U\\_Q)Y_]T OT7U7^R;/M_]"CQ
M-]U_,HWX;SVM_%L;?X_W;V']'W_<M07]>LQT=D-"SU=AMB!>,!1\YH[KZ:,F
M_U_7'+8@"="/M<1_[?%)^F__<.J_DGC_B'KFBQT""0.BI'^?H_[D_D\'Z]>T
M^&^6E#_%?U^I_1))G/\B?;H. DL+W>3])_9_Z/0/[NDZ^G0)S_MK#?]/T\#_
M/%V 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R
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M 5D15)>\YT"#&$0*^>'&>,N5+T<Q72YKKYV*&(@0B%G1)7OGR=GRS#D-J2#
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MO,X$+&Z"BJEJV+ZA?G1!DEM,W"<6:ZHF3E/_3N;=W1&Q>*C%"D-AP\WIV5=
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M=T?>.338"*)12? D\'()>B*7F!GBK%0KHDPV:*.-']N!(?;+KW_TRRHPP1M
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M%S?*=%O;8.ZL'-UM==5E6U!^"R.@[+;C"1K')@YP<)*<5%*G#X_P#EP92M/
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MD7T(P#^GE# !8HQ_X>5"?%9$V@R6Q0G <*:OTG@KPH*:U-6W[7D L%A.31A
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M7X3$#Q]J'Y[M4G1]J5X9.BLH<5O2Q*,[[E\ :F(['\PVZM-8:#;^=.P8W#_
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M_3@VU59YFTW:&"B4$_RNOL0DQ[>U]2N+)/6>W6#X_3K45UK<&,&6'1G_Y&M
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M."E3\>Y7*6?]9,ZS;:%<KG_@1/"M>@BSEV?B XF8==.W.#1TISG.R/%6 .:
M*W2<7"LUUW1\2&"24[K78ZIOQ>3"TK!K.RY9/'H&Y,O0>6C04=<]S^WF3-<-
MC=Z92,R\&1#?9&-J,Z0+7U&I%XLY'_"0/N7@O1YR*O]_;EC\SRT+98D@@_JW
MBVX?70P/C@?THI"HGI3BZF_O3#JD3AOO09^"U]C0SKD4ZT_KFQTT)D,K%%3F
MG47_(F VB0^2:?&3LCW>#E;@X@V?G-S1_&AQ^8\1K>/S;H;\8TC^YB='S$(6
M?49[K_MX\:CP@?>4O$0BAQJK02YNWS!8G_9"4PO2 WRHXC4]2!V/MRT82$^M
M;8K*WT;@"7]D7[H?>:D"CV(E^B7U)ZQD(E^$7B.F-CVW45&=-LD? [S_D ?8
M!@/>D^Z)5WXA3NR>@*X63N'+:*ZLR#BO[^CL0:*0H%8DX5=OJ2-^#M@%)?>(
M+M=4[R1__I'T3>I"9 Y7?,SL1E6M.B-CER>]O,D.H,;3F"?5*Q$3A)>G?E-M
M])8UVK2;7I?/^3EG!/7^"^[IV:-E!96NSG]9,JFG.L>@>".Q19*D :['Z9L[
MQVAO%X[88,9>OJ8*;]<FH5LV*NI!%O-V5YXT1[;VS*0P @_-2+0=TP)"?*E-
M1J\@*_'*<IIN74;;_2O=5;K>$09Z:U9<M?Z18[)+1%:I*>"045K%S*7WMS*
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MI_NSO.,IOEK7E:E_B&KK0UY(SW"RB ><#G)(W08XN]O_Q:Z$*L.#*H7 1HZ
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M9?I_^'KKH#BBYFUTD6#!0H"PL/@"08,'#^[N;HLM[N[!6=QA@1#<W18+P2%
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MO&)&?:\-C'3D&SM"FO/RT>SH:)>O;IT>JW$6D[7%_@)& FPWGG,R/X>IM3C
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M=V^\LH%'Q>;D4?M^>5VU!;CZL/AV),3>,VUIP?':G4E\4BE Z5Y(L<Y126O
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MKWQGB]EF0+54^T=T_3''W)5&T\M)*4AC'P1FXCB/5!@'<\TB\4O4B/3HXN7
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M39LN:K@K)"\Z+2E0VQU!#U_'8G$.),N&YHVT79/!G$-G<,)KO14=G6]9BWT
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MR9F>A/X)A'+KQ_7N;I5!G'3"A,:M];AZH9')/^YW^-_5RS^H?P%02P,$%
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M>/[XB?E?HO[#_*]A1,.=_J4#1Y9_A<'\X/\".[)\ARG_@5,\''YY8Q02BH'
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MIARV='03;8*AY#A.<=O/A0LL5L9USMP^3\^./_(F2(ZZBM_LO&->@JT3 S)
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MH'LV][!D7HK+F6+UDT@79[(49^Q+'QU:P2\32>GL/+$*NTZ9<4%?GTN;[+]
M;@85.][92.&8S-*^GTZ+,T(Y.O1EY+3<,_'UR;K:!;$&.TR,6BUU1#:][_7J
MI6J+AV":IC!G7E?.V.[TYM4(."%5FW_;W-N+'<R_D&])S['?;_M>X\7*'M;'
MM^<YIT1MHV.QN6##%,2DJ8R^^?K$*:@I_[7QW!PCDGM* G+5L?-WJ?)Y:)(X
M#+J;RP\:Q\*G'S)F&0S39TLRR>@(Q=5.  N$<4EV4MF1?"RFW-:OPR_JRK9Q
MB)&H7.@7&(Q]F?&N#>M+-AYDP[IF-R*VR7T'48 SS*CU6QN*(:V1VM802,3>
ML+0/5&$Q66Y"6:#O252_LO)U6KV#(2ZM]%.96E6SYP%S<U54(9+!7XTD/#\'
MTB$F-W-R"?:[JMB9MZ^*JO#R10L,WD[:5W!MM&!Z=#4^\O7,>E8%2\%Z0JI
M2UM4Q:7S%O,WLR!;S3S&].]LR BF6D,$XH+S>WAMC*?,9X9G:A#10+Z5U:&G
M6M9Q/ DDJ@,!X+L5_50!S[J&Q['F7DPEU^<CXK,%![]6W+O'5-XWCM3MXL(N
MO,&>"G5G$EN0G:D'IFW&528.?:01?//,=#;;'FO0!]+L=I]E7@ZOUS,2C&B9
MZG20[X:;\CV0>B5HF_6<F3<#HJ>*!S/?E5$TZ%[X<'7)_(( B[>5E961G3=-
M +JFT\Q0&[TG6VN!Z6.6LI;A+V&ZE0WBNA[I>+9U@E:I,[W?=41J=I+"\@RL
MTRRVTS=8M@HM&6PLAN=$*'*3(RI$EF1Y^$IOC"-K+30TUFF#V3W+VNIE45'@
MRY%&IZ@G[3;ZJ)U**@L6>V;/]]W,D>^[8A3%Y2LSB6,N<:8-8&A?YTD+U@Q=
MEMR\Y52Z";K1)S%6F9XD,%7LP;\ZA9/W2R*CZ&;R++&JMPB/?9$U"[&]L,,_
M0C']8/HY@\UF5*'3%/R9MI'F;;_SZ(3$R"F7.9^#E^^1LU570@JIHAAX:B==
M!UG>ETZ]B;D_%7%PWSKJ8E7-I8QN_7';]35.]40#;QN:=)KD$I7D.UP?_%>)
M>_(O"W=NIB)<.T5'>K-U>[,'I(M8]#]V.@6(KN2,*1?Q+67P+:0,):=:&G/%
MW8W+T#I@78O07BZHD)UY=ZO<=)27G2XHP/'L\YOQ1336JZ%$/3,VNKKTW \Q
MX\[E8^%4-)E155&5N[H%+>TO-JB<T[E+R[A8^]GL@^LA?D$J(I G J>M]Z[)
M!&HZ/F:9O4^>)9)XMJK,I_V3B.N#"C<'*<LDX805V56;+"!PD'QO:Q!'DFRC
MGF#$[52N8*'D:*!ZCD3X-J:\P>L>1;31..:L>U "NJ-N="\T.H1!H58D1FS.
M<.Z9KNK![7$U>ERXNDZCZSBP>C358.O9W@;_")-V7SMW">$23Z+R&S=]_8%B
M(<1R:C@WS HT4Y#S(3!"[O(%@73$Y;DMI*NI4OQ(T@9D*(AC*R\I"M5N::*Q
M96#(#X[QMQH-/[T0WY1BTT7H*^Z1BOE@SQ3>8:@!]:"\)B/9P<^F^[PZS4CK
M=ER#Y_HG9UI5:B7>]B=T%D-336>=M"_YF/3PY4QR356/DGDAI8WU% ?[*:1)
M)0=3$QFK%"^=7J#1/U6I<P%0G*/[.,9?,<-K^4O.=G##3L^!W5;<SEM+^S#-
M01='$\FM.,Y\F&0T3CYRIUB /[+?U;B/J3YEHBFLJKEAV^#@5JD;^DH?@ZJ
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MJD4WM=.\P]'G\4\S4P&<P)C&F+I5Q**)YL$GR^26_8NP<==M>=NE+XF"@V[
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M/P8A:<D_I3'P;V/C]\S;8?Q=RS;3;RI(7XW_M=O^G6N\E[\UCXZ2O^<]___
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M[W54Y"T)G7V^O\^!3K'L\UGZM=90HL:ULS#>0-E^/H'3Q]Y25Q5NTW_%0\%
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MJ<MXRQ08S\2SC*"DS-P5I?S;"J$].-O AB)&1;-R"U?#/QZ"2AS/*<?MKI)
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MQLP;AG:'$'WDN^P2H@WHVOWR+ 1W0&3Z+MOS23K4G.D7<>>RJ'(>7$,[81)
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MRTUM"::\-SJ0YT'<XF.K-1='FNR/DE\",DLL3L*N2WR-0VUW-,'?7$+IY6K
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M  :>:I8N?VN8<\YEO<I^:WGD3-J%YB>=4N\4!@[.7-KE; D3.)?H4EUS!I2
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MW8>M?=C^^JU/=5=W]3GG^TY5=YA86<M<<VUA(6'O$+C$![6QJ@2=6S>)+[>
M41@^D<6W.];W8;<:$O3 I7(.6E1*U1?U=CT]*^:D5[6^8G3AB=&RJGA2*V90
MP$H8DHK]A37Z)3%&F<8=N3>:"[+.[$B\K3CE ,_OM/W.9HUSH]CQ(X/WMZDP
M4OF>R@E\>%?7RMN0JG5VRD"DY'YR]"TGQV5[I6N<,4Z %BF#L<IGG>P$X^7G
MY\=>#3V93,$9LWOK637.IW.BZ+44O->XE.(03DS\%*TJ.KV@A=^ZB936=)W6
M)\.KLW4)'@$AA&$69D39N:]RY[J)PS]( WNO>X*/-H:SY@6L4R;Y_,+J%(:?
MZ&M=0<XQUQLG;FVH[(;ZAZ=)[#PH-1H9$)WL\%JT[YZ!T;)6 P'T@(IZ_N<8
MXXI8 Z.1@PC<OK7#"Z-@&1U]BR3=VB3C^;=552F+$$U,A+)UZ7);6PI:&?]*
M9_;_=([TQ;G#/ 6-J-GU+2]<V'>B2C7H 65V!*@%Z'3U"@8>:>\*;;SA:?E7
MJ!-974B$4R9I"+B8KR.B#.OWE@P!W?F?-<3PE-4GCBG5$**%Z\9OE.^T@7DQ
MV2Q_/C(+B2S+"R==70_TV?/+IUO:FN87H^A]V(NBDM//AMJ7]RWM0S-N]1)E
MQVM08)4:*8^0]9BGX-,S)'=@'?QMPAD^"1RMY][L':&"80,OJ7?2/,SY%2RN
MF78TNF:#M9,@1.*ZA;_F,V05&A+PO;Y.9-8:^TAO$I+Y84OH!Y_1?++5_,-M
M[9Q9^W1B5Q_\M*7O.MSWN_Q$Y]&UN=&=3E-_9,L@C'Z(XYL H^VICN>BZ=T
MFVJ#B=52:QE,J\_[[!T&^0A^D+?MV,L%7+_3=']"#\P(2999ZW7K!6>.C%O(
M_L]F<1^191_-NY$&6@\(.HL/U1O[-QHD3AT'D9#<@!!4[M ^<2"+\G?4<89E
M67F!0S=5/JH]WY/V!G65QQ707'6)KN(EI>PX=M+"$F@<U-RA@^."!_40%QT+
MZ/#= CJEDB6$O'R<#XEV[PZ@X_8^7?,<[66VYS1=145W9?\##!O;\Q2M80>Z
M#44TYS]4*<- ^#"0T$C3]1DQ8S34I?.=53&U37HI=N9XO?B90>EX"_KUT<I5
MXM'&H>[0]BO%^ZOUU02EC*%I8P5=30;1&KYA%"JVU=83) D$B-3]'K\$DM-^
M Q]'!=LHEQ<#CGJ DC3@;IN9&@+?&4^]EQ'U<6-U#G1[.&/./WZV>)"'47Q8
MW$\,/E>2U2AJ5V!K9]2.U;LER +WBS]%)#^Q5F9B>DNRN\+'BDG@Q(] !"=[
MLKH\I,[,]7VYKJ8O,@D[>)7!E9#L,=8,CNWFAM>=B&SNS#G/W9]9 X$,%FS$
M!!X'8S07$I(".\'$AZ2H@L";:>II$ICKW1^[)2NKUY7-\0D+.%A_^UDNLEQJ
MA/<=>U+Y=\OLB9/<CG^:)/">HA#8B2XECR[#>#2"27.Q"=+K,RI(AT?%:]WG
MD@P+FS0@A#=Z[>V+<Z/UGB606)]8D"[58MKB0)%U/Q;OZQ!8#&\IXN_S.0+^
MNG-7N9XT5@)>*9Q/5_\1UG  ?.<'\7F/W14V\?SJ_3V4$5!9T4[G2I&;JFC)
M>/LHE^&!R[+"O7_X4P[-5KC;;-V:Y;"9&M7-.)R/S6S/*3A&?%#(:"*Z"/$D
M4;.($_MRD#/:W1UGJ[3TM(Q2JV(L9-R@Z= ^JLX5PI(4-2OU2>D2TEXGC-Z;
MOHR.37:?OEQ'T4/I;WTM<C-"O3$"'^_O20M]U:E%L$\YLN;N;Q;:[^B[I8=W
M<9&^XF.P:^[];?5-2O$#6IF+7.2LZM)@VT*C:<32G-A4/.BJUUDM-[W*\ ^
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M80$'O&;-5\H7B(N*AD/YHV1)DFRZ!!EOW1BK1QL*/6H0/3YWP@=6;/Z1OI0
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M" -TAMH38D5101]V!#VA'P0R;=X1T.7 T-[O[<4-[L4)]*\CDOK7*_R(L/>
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M$;/P^6&O0VUN153()DGN*,9<<*?!UHF#T.G4,ZJ&%"BPS?PC)SZ>_^[^W<4
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M6-?XZ5DU7I>]L8C[^4E[HS [EQ]Z:-=/EIC520_$CA&/LW_;U9RI=@_9V]Y
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MOYEQ*3ELCNG:%RTV_ _/LW 09^/R3<0YJBM([O%2_Q4)_.(X\6G,C^;YXMP
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M7ZS&NSH&?\]'155T.:1<>\F)X8"1@+@^3B9^VYY"H[>Z/:F*2G_!*=7F5W(
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M^7A&L_'32J2^"N@+CVBIKJ2[7?6[7UN@-E_WU6..>TW/,IDB;0-DP)>8O)2
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M7,>73IG\?.DA>.L)0 L  ,H!_[4)@>XM\]\K&^N73+(_+>NR*_7:> PUO-(
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MNZP58[%XE; !8(SL%NK>WH^@M[]CB.1IF$B[FO=R"N^%#YBR66:Y4F)6$WJ
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M5\?"D[W-B2*#]R=:V]8DO$P%)6&_PKYW^?P88<?VZ:HN@Y5EXHT9&Z]P(?+
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M;J?U.Z[64*U2'CY[, )P]AOCG4ZHBQIR*W.M(6Q"?J83Y%Z7,1-"M]V'@ "
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MV='!5*#!7%'NDQC_VM82)&C4G YJML2VDF@H=2^,,]MJ:FI1E_)1L:*/OO1
MB+7,7J<!!0G(?2@I>0$P;/.D5E(H5A9_%RD^S2M085N0Y.;>V.2=ABC::._.
M'&NS!I%-H IB492,].$12VSV<;7]CF$Z&SGL_7XJT8V4N+A1D%_ ?$%I9O!
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MGHDXCFLEX<;E$'<L;?%K+D;#,K\3O@V;V&Y]G.(/W*@Z>\')&\+ZJQ= ZI^
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M"/&NA;_UQ^:E34,15SBM+C\41[=.M,VF(-/:Z@^BF@0UEA"FPFIN\"D ?/1
M+CEW;'E@'6\65;3WLR."S"=!OT'(]<&?3FU]YK3ZL"2;#S@3-.T>%]W_Z]#\
M/?XA"XKJY\_9[.';*J]?85D=?CC(V(9'6Y:@RQIN*IBB$B1D? Z\&.>!>3@K
M)$)1+<T)ENWVW=^;+QHT>;N,-9=ZI;D,?1[<R7L!+$8+JLCTJ&.%.DT $X8N
MQHZ9&]I'F6ODA1*&!K;B%Q+D!2&<N"!@@HN'"]:'_\^)M:^/)LPJD 1M7X>L
MD0D73W<4NEAERBK6HK6QV)^$EY63=K'1B>P>_Q2>(TV,,5LU.]N58E)+\4%
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M) 11]1J7<Q>%3Q.Q\<-7,_16*S.JUG.BX71U+Q<Z'>)Z>>$V0Z639>\LS9
M-NJ('R6CEG;]0CYS)2,D[J+6'#-9%:1/)4Z-HU*D_7DY]AP4J0.',<B:3B=<
M8@D!0R?/@06:XF9^7$(L,Q</7L*33]5+%1NB;-F>'BKXJ21H5'E9!C7>["WK
M9;=$C5S9H(-HNDK)LXT=K8D9YU-I0RZHVIK;O=GAO.<_QX!/+4A,RRH$KSW:
M)U8;O]"*Y]TR&U.@SX_L2[X)-QXNY159/?:M.3K4E#%#EG/4[\X38T9&XRCH
M]LJ&+PI5=<,Q,[X([%MN&"5^)'Z@!!?1MIBG)3Z89>B8.+]>PE.2W?1XAROG
M)U0]U#S')W<*B.%/+\C<57!=_;0VO9OXE$0):V@GXR)/L_0X=A#Y[WN9BUD_
MV\!^2_4X&07SHP%@<!U=9_5'V3KN#IW098V3U.U-57=,'*%7%:8$^BB\N3C*
M[*N#1'P&K!(_ETF"[B+\\ T846 (Q;8<;UZ)+0N89THM-H33>Y>I?JT\UDQV
MQ,A2*9D^*\KK<8%3H.CAVBD2PF/;K&\2<E65UKL]'(R) *UPV:D\V;T39'+Q
MG 6'$:(?+30-'3WHUZ(46%8@SX22C RP[%PB9"(FVL9%??FF9'W\5OJ*E[C*
M"MR/(ZV3P!H*DH92===<.0D^X$(AT1CVO^%%T?9W>;\)>Y?W ;T:'GYKI"<%
M5T*O'ZFEA2W'YO<DD'[HE=<O$:_(&A2E@([K?\RK^[O-$:_9@7.Z-Z;:5^UK
M7R5X[I;LZL4$O6Q!-%C.U[H2%%@I(F0G0K1*+T6G8JG3]QF&4ZK'[G5(?2R=
M) O[X%MF6=I.SLNJTF@ 7MY<LI)Q"YLEQF"VBE47)CV&O>OKVGH"XDA3;>LK
M665GVL*&4M/S>>N:/7328])U,"5KZ?A.0V)WA??V-/DWH(7 :V;D:0Q69=%Y
M\3ETGMQ\0;^O-V*MPI,4GG;C6&]9)X/@8^"$3C:!Q"4^0,1B^&!.T.]O&W:[
MO[26:E#JU8Y%8!-WQ6C#QI>8$;UAI-GG?LME8,N*KO1&#ES+[W;'8,-OGEDN
MPS7S/<KA[MFBHZ:NQ@SV.)X:+'<Q+#3''-B8Q+R9&;$*4_$;,!HF70Y8E4=:
M+H7IX"#I*U1]B6H^\WTG>8Y$-0WW@+W<D-G)[TO=8  Z\(D2"R6NZ-(G7=F_
M6"73-(SV3Y),([2X?9'$T6ZU6XR3 T85A*0W4]0O^/2,]V_$FTI$44\<Z,02
MFWYGK,ZYD.L]S28MJ_'_HKWVPG5A&U&JLY3$)Z^8FDQFB1[;PDW%P^D4H9SN
M@!$#5,Q /S4D1Z97VHP5#>"<S*GKG3UIT3?4>&]G$C?^\S\W/-_67[S>^0Z]
M/KXJ__-4(9>@A\M.\BP'/+WSHL1P=65#,7F3 +,-B "'QTI'B4!6QSCEE$NU
M*.SRAWU44:ZG#W6&_?S#>X9]R*)ZPGDH>MR)J" 9OI7&#0E/'@[W)X?M[N+F
M%,$+<1Z\;,U*W<X3U#Y8,+*!DDV+R4 "I-ZZB4?L\X7)Z-#FJ* %C*0)5A<'
M*4$CL4=]VVRMO&#R?6YC*CRMN1S-(R*:6K?/DAY%G1TO;. $OJR0+W;NV/+)
M#4I=62I&AB;^P]:8L$,IBV%+3E1GF$^WFY2,2VG&_K6C'JOZ0<9W';##K 2G
M$U;<R%HTN/U,[1ZKW>E;K4:"3 ;09V/"<2Z%:_B4O4\_ T7+9(,3)@N@5.Z:
M-6'Q[^G0OXZJO^:\T>)JK(S=:1V++NM9VL@;*,#:?66-2+<:&\'7DMC5$*?=
M^BCURNTNF"E!CAA!$=/<! V+BLK/"=02#4,BF,O'[>U5Z?[>]@G):'(&4UF]
M5),]L1H8!U=Y^NPC?0]?,\A^;\X4^\UBN&R[I(!&@+T,#H*HU'F;(0^.^_8.
M)9R2F'70TPAW:M>QX]28#HE]^#S@;0-4(8I)$2'L6TDUC#$?3<K$X?01Z35L
MD3KG4*,5>'K TX1V69]C7P4F7IR^Q M,;)4'%D=UK+*^*%NS+NNPACX[E"W/
MB/(N&9SGMVZ)*[DM$4UZK(DKN0^Z%G;&F3,.=H:O$9,OTM:^4ZFX&BIK9!Z5
M).C6TT+-"B&KMG2S?[&V<FA&)+GD8_](F#Y\S/#5%@1Z_ 12C_K9GAS-YA.B
M( LJ_!/+6Q/OGKIWA04+8UCK^$&:*N-NXET/E=6^-<YHBF?/53PZMJAIV*:.
M%/395%'#4RO;J$V&H1G,),LV9\,7@WP&N,]I5)WAKL44.W>_ 85'E$-Q8WZ(
M'G<_Q=U( Y6??"H6=6]_)"K__$MS*D'B#L?$KZ]2_Z9UA(O/ R*27DTLQ?-4
M:;&2SN955A!X_DV!5>=@-L_'[RJ==Y9J4J(JQ_O1G.=A<M-GU\XRZV3_KH5)
MPO>^4TFL)7(.(S_?T9;,3QY"ER+_/<0/H.R3.(+F2ZFMTB/VIM1'NZ8C7?_*
MP=;'TH)7A-*ER:%\L0AO:,H<$"(YPO#@OWY\\[<]H9R#W$:KVX<I[RZT".M3
M@R.6W\KMGN4EJ)(LFI!2&'9F7$S/WSJ^1;KX('W^8=T9?DW,ZHZP;L&MMT_E
M@V,/T>C8T993IZ2MTG9#P0!*$!2&+WA4<<DC3JXN[QO-4KN 7E^J@$N3B(V7
M[4[00O%Y0J(M;[#VP'[R-]YD:3T\]('4,*)AY^^\,LJ?#7-R/JJ<QQH1X*:I
MNS D9=>@TGT7%%$ ?E4+TO^LE/.QQG D3,8VZG.I3&M6-]<[ D-ID,A'U(NB
M,FD2KOVX+Z/I.S2\AA82LWI4)G?^Z%ZZ\..5-#.XRL6AVGX9*0C1Q#H7T1T;
MAKQ<E2Y5>(-MONT,:V\SWT%RD?ZY3=WKT,MO@,K&(-?A/Q-Z$K\!>-F2;1^E
M?1F88I_X,B+".3TQI/VA2V_+ FV*1V00:8\&-39&0,PA0[P@5G/-O X0$)+.
MOT2VZ39OS7YC2!::E6.)^P)+*2?-0OF)U22KT F0NLL2_R*(J[SY&P!:5,L+
MO\!I2,Y,P2(+IUT/^*02VOW4HLQWNJ1?424*K?"IZBC#0 GH#+Q/G(!-Y+#P
MJEM[/&^LSN3_#)N0YP@]:7.YTES8<L??\F_@TYIX"5\K+_RA59X']T,S1<[L
M8P4-P8>_G& !F%PIDWM=<8;K&9ZF[[DAK.,#UR +8.I4BJO?#=J_&,'X;Z3(
MZS#EV;':/Z-0JJB[ 1H_[[3&GN+B4-_T3 R"MBE@M&K&-A#CGM9J\YR$IW.W
M4MMY>"='=7JZ+I73J?%='WTJO]B?Z<-U.4OP>GCIV71Q\4IROR@^ S!^L!5O
MV>EX_73/-2_SM68%:)8.9U=FTG;@R&T_,^NM09?>MLE>1BH D]A<S)> '=A4
M2S ZJ3Y$+&)Q?Q3[!K+9M-3RG-J,7IJOQN&OAZJ^>"QV+72AB(B-+1 \E,>]
M[*JQ,]N7P]!9"62"@/0_U///:-"9-_LF!@TJLO\UB#04D']'IS!2H?7R\71S
M^A&8G#<J2;B:4W=#P<M&DMJ,.#**^"Q\_3 +,RSN%W2#25HA&?/6L&2A#]2N
M;[@\40O$YR"P\Z.2K(&+P$)B9I4(5EQ+)&(UOF1I-A9P18PNFHE%5%(%-<G9
MIX Z+8[I8YB."G).([@:19 ":^&F$W=>@___ 9!_ELK_1T-S474D:ED(,D/'
M6!WTJ22&L;3.4U538TOH*,?ZN&[M1\\SV)!WT&--8)"[0)JK*L.40(/0PA2V
M*G@$6 B V4O=QF)@EO$VI(TG 0'-%79EV2\NI(IH*EC'QZ6J*NBB ;#*LFM$
MVZ#NE<7A+&FI^"(2)?'F>'XBV<\8JM8X0>G1<8:;M83:.R=Y$=\(F_PJ\YTS
MV6XGV]:$_ 5%\Z/>_O QRO?>:6C06SZWU#$'296*NBW06")/#!%Z?&C,V/9D
MW$T1\5E2G%ZV$L+;EW?V"1_%"M2<ZZ:3TW>WJ#&RGU*=6]=/@.-B</9W5%P#
M^0K2,"F8PCVFK9^Z#E_]+9+]P=E:(0N*A-25JG6>/__O^>HF+Q!'3 O':;)6
M@'.8],-AJ=*F0M;B;95_6/Z(M8SE 6*)01(G+X%/HQ=)T&/097TN/1T?MXJG
M?C'WJ<\)V)&GM1IM590,PC+R1*Y\]BM# Q5 C/QV=%TD4M)(-B&M.AP]\^*;
ME(R17K=#\X$@JU*@HW%\XM&P-"'7?M!9V7;?1</@9\UUA?-TS&^C6,0HZA96
MA\YQF[RRG99*.O9Y+0[[G6[8AOC-FOAJ*O9N"W'Q^4/I<9&S]=$94$6U<^VD
M$-.X:6?W[[#\](UU;["(<U>&)6O0YS^ 3"S&@Q3.\L(<&F0H@</.<J6CB4K]
MQ)K^:F=+%N5:=/AY)[Y"+/8D++#P3XE)'!BX<,*GBR]P6H/)]\A)\+0Y@OC!
MD[M\M+@F5L5M.\=EZ\ W>S6$;]O"LX9W5X1COQ"*^_J11]S/E2Z4ZWZ'>^YF
M\'V3VB>LS/P42)-LO]B9WA%4(#^TZ!0.RZ.H5H^\W9&X:=TQH0Z.:%L9?*.4
M?+@[=++[:])?]BKUOT_W%8I\[!!,]J!VJ%%KT=:)5UC36>3]#2#E>!+&,#W?
M*Y,DJ=&K9;<ZCQG7%7'I+3$=6FP7:&J^MR[,^D2.D6=?U,GKNN57*"MQ=J&[
M7&,4[L/%/"*,$ UL[*-':@NW2/G23(54F+LIL>?"MYHO=0&$&-BW^%3NAM.%
M7K2$*G<WVDG#)Y4V)N)SRS7YJN UO[N4%I#GBMI-.?'YF@Z-U#\R<QPB[>R<
MK6!I/A]Z=S3!FZ>S*HM@RZ$[&'HWDU"G(1RYUMXORF,??EW>.Z?Q(K2;N/+,
ML$&ZV3\$\35,--MM2[2\^SBSW3I)V]2:\$/$>2JOOU-/R)--(V*=_WNMJ0YM
MMXX"B[Y.?I).'9U&YG1NZWS4<-0Y*0L7+6ZQCRL2I_._N-?_Y997L >L1*.L
M=\WO$]]>DSFTN>M"8D&._==F#BCO]=EB3=]N:N1$!"<1,C6R=+B^L1,%!4YL
M*>BTN1E8!87!B+(/FKVR6DOWWQE^B]#C)!86#%I.3QZM'&]F12\Q1-D5K' !
MR$\L-J@.RVS+&D% <#7J'L,[\CG1ENA.>5<*T"?(_7- S8N79@9R0$R3"M>T
M1R.X.R2'%((?BQ8)6YLW'MM_^@<%JW<OW3<C$V47(SNB[:S09B-*8<X"6\$'
M]./O2#.H=I+$Y8_^,HZ1TVW]QR+)_R<5.M572=]H0]/HPQS3X9!2R5)615]E
M8YOOJ:3$-^B^I70W^><!R?=8$OS+)4M@#YN(P!@U21(>%IDV!%D,F;87J9=8
MK8F6I9A+B,/,G4Y75X%Y]&M(30DL,E4(#%)>*,\'R( OK>47DMY8OI8N"VVB
M+8MX;/O\.)VE[ACO:U(__-M!_RP%5K 06'#2'73? 28YCA<UP%+YAI^O DUA
MW)596&C7N*>IY[87"K4TE?"5^(7,N^#U!!=\<57P<AWJL."8BIE:;S,177H2
M7U=H5V1=DAECR'GM/4=R<HUY[R!J^R(-1=I8OUM)9)O"*\]_]?L-^'M'RWS6
M!#E8*NRTC _&;@%BY#V&Z5RZLXIRB;;Q=W/LY)T?[7$D61U[<@[=^98^:JWN
M3DT)[!+?).^4E6H^7J9((3/WF#N<DO3@GS4E WR$^-"/7F\DLN%;=3<^G..<
M85XM;#E(@@6;71)^@'T_G<PL\67HVF;(TQ:6_ 9$KNT^"8[7?U/NJ0CSD!+1
M0*#^,'&VYA'>L$OH<O/:IIX1BS@CJYL90&+$.GYQ5DP.;8YG0?5%)U$,S38S
MS-K9?LA)BD UY52OH6P]_OF:>'GXUB9]F&S.G=VT?BP]SJ(Q^$! \4FH540&
MT[2O1_G7FK^;B@9:%^7Y.JZ\QMP"0PQ;&<\2R:X!EZOY(=$:\9(=6&!2I"GN
M+X>RPB_$@P'9@X%R7H,BD,/#_43QMV_%W]9G;NT?/CQZ_P8@$8V:_H>ZZS]6
ME_P-Y5.O-V]=G;Z@2_NQ<"5YQU#'<V:/@3_UM)GQULZ7%#,Y2Q7=MI M+R;H
M[NEM42Y3'F.L=V"YDB@F="V@4T<T5]/ ^6&B]CE!X>%9K-Z0QP9KFL1W%F>H
M:\!;G,=I]Z")<E#F(\5O@.BU4P"9_^'.8=NE'UE;G<L_S]_^S9DJP%SI20,)
M6[P:\76E"[ZYKPN7^ @N<1!^0YAZVR[P> DJ2)#=X=31C8F[8;K@;FZ_O]&'
M;1R(+@W]=/PLF(?1;!=P9K9]94+.IEY;/":S[RJ'5FPJ15MG3 /D553K;O+,
M&I:'HR2%)NH9!IR!Z:^&WB[(6$G64ID1#^\/PLBC0PQA:X>1P4(?D:)=B2,U
ME3HHVKZM)4 3N%0XJRFX+:1(6_T1ZDKBB*2B)2O%NB1I32,P1(:=AT7DBF,X
M8R9SQB*SE'XUG>.\432ON8K;M3N/]YAL&UP#$T]V'(KEV;=FSA&OC8GE68HK
M'HZ)?0S,"+C@3"<FOHBTVH=RC!I(L'=UI8VPJE[2WR];0$&K:DSLB0L9+ZF>
M"^@9.M.X2_#00L^/_=_?TB=_3U)X='%MS$F*^S:E/<M8%.?_9>FG?Y<%OX57
M[PS!G8I!@.8IYN@I?[O/!A$TW5+)'7K2^4GB1@19%[IS9=*[4]][47&]BWR:
M9E0QG&)R3Z1Y0QB-(VT R18/FORIWOO\:>TT'A+_1QL.\BT)G2<>ILC>3K8/
M_N7B1^_\-P5)=_GWGP#4J74?/(X;5&70VNQZR=K]=F!J";VJT'-W[5UV5BN+
M&^UG!E?W-:$S(O:)V@6LR]FVO:(1VNXAQ/1F\;XEYM'$HT77PODA2=7#^U%D
MC^/=_H)\_,>VWU.(2KL=6@3V(0RE1DQLBDG U+'>VQTYI]F1WC.)B=[=N%I*
M#+0&\HM"*TOPUWQD*5GOCC3&;+M/.YTZ5Y<3=_$A-I)0/% _1!B=_:R(2%*$
M7Z>/V:HZGFQ'T=MSQ.'^RP?,ZF59HP%<W:UN*)Y'8ZDM!T/C$@@O: JIE%NQ
MN[BE3'W,\^=3XF] *8/TUA'>M<JGIH9B'VC3)]-Y6@U=F@S#C,:S2$M(1G/W
M%!F_;,>'^:3A09EB&H*X_MYF,9\>O^*_Q[LLI61*09;@]V#.)I2A!$KX7Q(W
M,0+)W(]J]3,KT!_)OCCBA*D0CPT"?-74;35J^!7A/LR<;I",\\&@*E8D434
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MWU'> /ET]D_S>9F 7(-BQ!:@-L58)F4PLWEJ;N+G,WJP50U?@;RM5?L65(U
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MYP^VD;U14/8UM#\!NEGFR9?[";GCNH!CBFM/[@A(LI16D0=![-EN$X (ZT\
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M=:VC"Z=7+UE]9Y+E!1L@7L#_QJ-?$.^!MT['Y8Q8SP6,-P0U7_)'PO_%Z -
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M$SHU)H]6R0E2F_1BO5=PS3IP]<"FQ=&>>T)'USV6(L*)HRI@/_B7F2MRVN#
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M45 1T/+R_YQD_O^3@E?P_P!02P,$%     @ [(EE6!E?[(7>00$ #Y4! !$
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M,^@T&'LM!K1?A0>C50RIP0CQ-QRXIPG@<4H\&3])(I<6HF8LB82N_4KAWV?
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M$ERP3$/I7$MSD6.\OY !@W9.PKG[9'QR'DUH5%=QJ^:USFT1^JPS^,M"LCE
MK/2"E\F&-8D_VG!B-F.AVZJ5O@,B-D,;;XW4T1Q%$]B,3^A%6\>K.[\J:*ZE
MN\F[I4\8^9S;^UX7E=-PY[Q&MF)JDD6#)>8+P@-DKV<:325Z)!=JI5F#&V?3
MK2ZX-&D4'?&!)[I?1B.BCR?UI7\__]QQF]N4^B YCNK+0LT72_M0X8'@3OUJ
M#$"X7L=A2> EW=Y64$N.#?*@&)&WPFT9[8%?3^-M0M&-+N5NBN/Q5/D P6+9
M[^\L3C3>16GS_/Q87,FHIK%)'GWCQTXVNXVDO=MS0;0N>!U1VM)(O<9976@4
M4=[555\Y@[]2/JYCK:/%7_.V'E8;X$:F!KXT>3V*CF+@%=0T:=P[E"T&\[.9
MAR\63M0C^GEA42TFGP\6-(D/E2;&O:_H6:[LZ#'G-CRSG^ 7I!A0!?5?OVZ]
MM'S9 &@P@'75PX[1[0U40Z21=0&:OK1[PV93-O8;IF: 1>2%:(KA%!<*&(EB
MH=9& Q;E=?UFRD3NN160NKR[XR#7)4;^-4&.!6-K_I(E-<FG8',5+2*NL!&I
M.W<3^2,>"BL\Y\;'PTH@(*GUZI5<HD24Y/E:N&HYNY745R&R+5QT,W:CY0%B
M*ZH'1<4"@[V-OFK&_EAV2KRD#&^[;?)Z,@945H>SUECS0!I5%/HED]YDB.O=
M/F\GA"BV@>5U4A!-B8]YI2:EDGS;P$4R1@F9B,K"1J>WR4:+V7/9BO&-%!_P
M@:&>>NYBK*1WF:@[26;CZA[/V10B),I$=F6OQ'I[/YP#94BHH00#PK6_YA=V
ML;H*HYJ[ZI?MAVGX(K$AJ.2R[8IC[IWYS"?-V<O@TG)1E3VCP+=W=\&67VRG
M4S[NTQT^-)_0^70A6U9-JC"*W>? 2(TK'*:&/; M"]DDXNO>8S=/HZH1!J4J
M-3YWH_.9]^_GHN.B'DQ\* %L"%OC&]* I&A:6PM0*+O;U]TT$6"67I9O,G_1
MDB"N=V?\LFLK5I.47=)W +DF1U/)H*G(U)J)U1SEQ?5D[Q<7>(2HDQ(&A>MY
MHLI"S'U\PB4Z(=BE&K6I6%J?4''J.#+&ZE&\UH]R%_M:NITZXN8MT3KO9ZL&
MF&#JW'04XR0M=Y90(5DDQ=^&W[OJ,R4NS<]W<<86NXK5#2,V#=4;ZQO:@]:$
M4RPC2 9;BK&>Q)IO<-,Y$H\RL^A[5L[5%RL_ZN^%E'F 6F99.8$FI6:NN,FY
M"N'Q]\%LH[B]VY]5'NYH"\-B<DU<Y-58K<4GV/9O@CR=M2,<6U@LU8V:+PZP
MQDZER]!VZR>YE6$)&AUB])<&7)B;_ !WFDE)$>[+WY&M2TY7Z;D)Z=Z1G*&5
M',=]30TT!X=T@T!N_8/;;5;I[592!>I:U (AS5^FJ%S35/G\LQ@6GW""E!B"
M4V7?I+ 5LBR9.N3/I:P1F-(W<1=4+9.-+(E9IW/IBYCBOQMYHH>/ !).;XI*
M47KM?6.FIZK!%4C"N_P(A0TM^)H5O7#38F.QQX\TVO_V1#D4.-XIF.TXF>X>
M#Y2"CS"DVJMO+8?V]CGJT4FN&DYC+!W)/R4WQ4N:_? Z6SGF;E8*,'%GHPJ7
M<(#NR$1B1V@'X4,WWJZ!>T$O+=1ZS9#L:4;1TF?58[2Q9HH)K?!E5[9JO[P[
M^1<M>96/H(8#[*[P/.9UB1<2R_%32 +D0F 5>:)>LJ6?\8<G0Q*U!<OZ]5"0
M"'_)#1DC*K\.WL U%O^UBR!'NGEK*R\4F7*76?F*$\R(PXQYQ3EY:$]!/O9^
M&'99(4A<&=Y#O.VWRS"F^T1!OR2R5HHHC?%2#82XWUJJ-#73O?.J,7]GD.(B
M;_6FT>>.X!OQ#@M["X9-K33.)=L\0%/?HYGPKLDE :ZJL1FS+)DL.1.0+3$*
MB]Q;-)=,-1 BQNR_!&-><D9^UE'*FP_2"@RE8Y9(3P DN2O1J>5G2CRH5D@%
M6WI,0\+D<_*29#U64BE@B#QC$YVVNI@&]&7/ZHM5*;9BR8#G2?J-:#SI>6$9
MML8EJ7&I^_I%UN;.#632=>ET4X7P>'Y137;G[&C7(=Z''N1?I)>">5B8IZ+*
MVW8NB.;I-$%\E@6'@EQMLBM5[W-%N6.42DV%C]S3,5)WJ"*0NY98R!M\7>P[
MH 97/9PUG&-B4Y0ND5AY^ O3OB72]QXJ6)$P!J3X)+@/P%#G]NRX; TGRS50
M*Q+Y+;LU>7DS/RK0/\"WU[7%?)U@K0L1H?':W#>>0C*E"]3?8>D7O0YZO^&6
MK$FC5*PX-,5O$I71%/^DEZ-3=F2:,XB/JL-RGA9HV<U5,,L4QP\F8L@+"$_0
M_MB@9$?2IW4_PT54QIP]]@C3Y^-8*RJ9-S/,V)VJ7IT]AMS:\GIU^:UO[[:/
M8=,I'_27S"QUB85\7BR]0EKK6MD)I^-/73-)MVJR^ACF$ 4T$66"&N^_,3JH
M-HK:E(V'I:2UJ$,^>A,.@E*/)"LKN!B<]]"O"N;-I\.S[AHHO*$6H#LN.W9<
MXWY8:E!P-4<UG$"\Y6Z<L_D4Q;P6-('LY<;BQQ8J/L'75^]VA@"N+B-,WNZ]
M,AG/1N_JH9?IV!NV=[LC\S#7++5OOE>M V,%OAF.S;<J[S: )5T(36+M+/H.
MN/1JK;U H51;U_2 IEJ\:'V(4[NE,JBB0]4H8Z,%JWG3V5]V[H!"E-.X*SD_
MX'TL-!"_#Q1?9CP8)NK$*!<KL^IPBTI\.*HEDG\L!QK$W;X3G,M/FWA'&KCE
M>W3SAF!%KM9GHIM;IEK<#I:?\N\C71D#/_=G2TX/QQPJ>0;CN)6S%V,#C.Z'
MY1VP-%UAV&A9E-#I- HI+ ^(B$M)P^<1BGV<*Y,5E7:3GII>UCO)8>H=:Q 5
M-"6"GLPSW:E,=<(:;I(\E=-H1A?F@[_(#$ 9SUSV%.Y2N)Y:@?,=H$LBIC\N
M_M;7K6B@6*E@A)\F9VW)[;'3?"<"IW9BZ2JYQC3]NCEX_@87<9J<ZW6>P(-'
M+8YZ<:F%&P1))M"&V5WK5;KY87XBC=8/^)V;:FN5EV(@P(QZS_>="X.54?1Y
M:U3;6++(B ;S0*%"S9;>E]7$.Z5+\7<_PBZ&-'@OU=;K 'KYQA>_9EYG7Q1'
MS,^+MK=XX]Q+H9W08=GV14FX*K%9IN9G+8'?P//XE'?9J4P5P9J]7\O<7V/?
MS6^F\6E 4?::\L?3>H#-'PV;O%CC-=</Q50S"YA95^^S;:'F8J/$K1$E*V[%
M:@X(R5>/I+@N-6XBE\NDI$G/'INR/"!Z=0U'874S=^E.=L1SV\RH7:TC=\;K
M=2':R43[LEN&E1,D;5,39B-,,_-<^W9,U?? [AJD&1T^5P%4N#6$TV^WS$FO
M1K5W:$GPTGM(KF?ZWXR-#O*U47N/F74T<X%  +NN*%%P2Y?R K#I 3U-Y:M%
M#+-R8/\.O7U!)<DJG97,:UNT^@1'8H]MN,]4!T8_CL9B6_^>FMSHG1H_Y':M
MZX)KV[%"2-%.,JVH3:"1%.U,9/ZUY+>M)%A *5J1-/Q;9*_+//DNEGFX;T(_
M@GG43<GT1:;=<I32-S+YV:?V5;+8GK\ )B25?Y-0KS/0JDO3&V%2E:\*56OQ
MQ3-R6+F8Y\>H3?"*K_AF8K(-/(>>3C2D-FCP32;NE:Y>;8O&SW)ARTN<8:J-
MK<DK%3')C_R.JLR9DR3'U&0OZXM9B_C/&2P%$S1@?:X6A89GL7R<5VA\,7\0
MF6#1^4BG:KGHZ22H,1O.X?[ *:Y$NRU</1GG(DA6;;&4MIS1@CS<^(OK$QE%
MG1PMMJSL?*LAMC(U#3%^)24N(18'0LPXG=F54.*;XYZ ]6B\N8I\KYNX#TB+
M"X>0S:$5B3X$+:'(W9;[TB[Z@58-DF_Z*GL=(OI#)S7C\F+[>V$E[LF%<H;#
M)I8D\"X5A0N!G*,?2"ZK^SY-8[]H&-="O\YA"\E/5="8\C'.N&>@_5P:9]2G
M%(@:Z-A.'E4--.:/\Z"V6+I7'=F)REF@L\T?[(^)(6,B4V)B6%U\E[]'VW;%
M#OOH[="DTZM"ND5R JV%:!K:2\=F(^[CW%RXG!HR)!9UR1^Z8%Y687?[4H\"
M'J#XI:R(QVBD'.K\U?3S'+;[])-V5>$BR3VLDP';ZH55V+%)2?9YD**\VC0B
MZA?R.DL5Z>@A42W>:LOY1=VDY9)Q1:;4(.BEUD%(R48":!%-]?DBT=X!SW+@
M5_M5SK'U\>9>B"3:HXGAD=9LIW24^CWQ2#"P0:3&.M2OWB^<)9O::ZE^[? 6
M=7)R>.'E<-;<H_4KB>K^ZIYHI.M=DZO9D^F\H/WK;,8,Z:(]O%6YE#)!CLRI
M Q5Z[LQ@[8E](?NPP#HH4>E" <&L"5>4\G5^^:5\=7X__<8L,3.D$,AY2</9
MT=\GI7 AH'JAL%[)+Q(_;.M:2^-\61_A9;58$V5/##T_"1HS*><'7GF"P :=
M1P*!$94;I2I$K<8I  OAT.)VV<()REKS#;ZZ(:8O$]O&;+G]W]PR2^%$SAQT
MTI$:8A<E=,L'"LR>>GN1#KB]( MR>;;C93W_6:7YH[(S>; ?S+.,8#!Y "O$
M^N*5G%IY%YWL8$KG_)&";5<$F%]>"?S((F.[SJO LD=B/X/.3K2*J.Z^V0%)
M# 6O84_+<90 [H1]?\S%*_II")PLE("5(T.FB<J=8@<9?E\<XQ*JZV\XO*@N
MC=_=,-)SYOB8+//65SE]-*C-_UWQ](XTVP?"U-!Q=3K1-%9B&T53>&^>7)H<
M#@@/0#PY\VUX*]Q42X"=O)?]6?F!?9,@>GLFH"#BN!6]7"KH5K[$FMH'' RJ
M3\ B\Y+:<EN;\MFIPY!KTQQ%K+#;]-_;C[6) Q.7^:_A'RHHV_BXL/%T/T^W
MOJ)+U;DS>C$IM],=ER)WZV5#5?(;06;1\+D7(@ B6J<C-- 8T!">Q+=&AKN6
MV^ZU&>"8(R%8$'5L+>L*GY9B@);5KT8OZBH\%+Q?$(R/VD#C)\_ JKEMXX&N
M7W1$@C7\(E:+%KRGB[Z6-3N/W;Y4A\Y4?RV$\F*-L0/=FAS#QT60"F@;'NJA
MH$1"//B]-"[:(<G7EB-;ZZB7F[5'>Q+X8-X&>7SQ7^[B=\);1'4(,*(!'<]G
M0)=J=/*:)I C((F@]4E&39&\GM7(N,(2[7QN\SRUT((HLQI^E[VQ;!-;#.G!
MV):K^Q?U<H'"8=I0VX'I*5O>9Q>H\KX#*J2^,$C5Z'")A^:;2=A;JDAY1J.E
MT,9O>6A&&16<4H.YO,K,:@CHK24[:'N\E[']W4)NMW0ZL"?>4:(;=<V\3P]$
M[9J*[-37+#A9N/5F%P6/\T?S!Z3L]?/G@.(1+5:U6K3-9!]S5U:#.R4?4435
M'(\T?1,J4#=W?#Y _(V>GJ>DLJ?_2?O &[K.O;QHO^(/%'4?W%:TJ_TOX=F"
M:(P_^W,7MAOHKU#X=/F-<YI@7E]RW\(Q9V1C%^Z 8$PEZ;8V*7KB<2B]/[X^
M)YAS7)_B7+)")&>Y$%[=8E_."'Q0R35C0DT)RHXJ8Z.7].!A&V $=.&JWEVF
M>#;MFJ^]#UKP:Z9DW\#WDX7P\=ZCG&4XD,LW+/=!R*6@6K(8K,MTU\)BQ^_1
M>KV"0FS2,KA%)1TNF(Y/Z[PLNZB)CKJ.!^@?+FKE8:W.2U"4)DI$*[[=?^9+
MXESH0N)KES>W[)2NDU?NC;CIY\XQ52?7)BM6S>= UM\[EX<67692CUEF[>5=
MO_1X,5!*B,F,06)',^^%(5YO6PLP]F:>JOX'0(:AWN@WB8T)_TWL@ZR<0:NR
MW(LQ]FVNF7TP/?-K#S0S.<UR:;4*U+JJ[IF_D6/'X341]"7KX/[&3^;*?N1=
MK.:*T]U0[_GTLNR[9^97A?WC]VCG;J#9^*C$$BP6/)E%@XTJQ&SN-!A17PO#
MX'X/B/"T)=]^=<!TB(NQ9[M^AXQLA@_@*=V'.I3_#GB\\F'F:9B2K;JT?<N]
M#1'LD&#I$\VW]PQ&4]4V!H+,,GMWAQ/I4J=C33R/E#76?8C3):\%\S;"]\<C
MI=R#H<PZU8/D;'@(.JQKJ'YZ]@1YW83#(A9A7AT,.JYGS 2?2\T.FS\;CI!I
MVQ[B*O7"R]>!SU(CD$]Y>TU?9$,94:H$K 1V%7-K6ZSWTZH/&(I:(2%JR4ZK
M/H-, _S9)/;S+PY&8I)'2_9:- ?HT&SE77R].SOK3#$A81AA^.OE>;L!R>'\
M;YT3/UY N!\U$([UB2,ZGF\"HXS]-JPR[W0MV=(%=I"3RW19DOF:AI;B)#)+
MQ-UU!4-F]VHR4HO3\#\C<B[7J9GS5TDE3QP51?/E<!ZXB/9P\??J(PV-WWJ3
MVGA76B^&+UL=+ ,Y3 DO7FWNOXMCD)=)EDLO_;XBYWV#0=F,*=\-J:41.P20
MPG*!T>\ V6^S//B".UF,R7"AB[^8"<6;@)8>U>'C!H/F(,@09TG)+Q8C0UJ'
M<R(Y;M5E"!\204%N'K!8?UT<:)+8P,G"134,1!4;B7^'+%XO3D?QSMZS&<.F
M(9H!;$?FHXD![/7E@8W$ ?FG,B5/IRP^]ZU*/CPH5 ]720PHQ9MX/FEIHJ[$
MUZ38[G O\Q5'I89^$$''_HPC2H9@HVOQ?FR>R *#"4_Q1!'NT,[#47XO9.9>
M!C7_$%?"Y>A%^[@-\/VZF'JQ9(V:_J=&Q1=Y&^D%]F_+=51E782@AI)PXE[G
M O8_>-4>Y@>^G36]]6K_@L4#K?IJ\V6^[DGOP$^/LN-6$+?FZJOKFQ2ML4#*
MY@G7%#%KR!H[J=._==9C"SIF)M^ZHUA5E1J%<I$Y-GJ3%YW5U OA<7H9D=W/
M%?>H3[;I">@I*H;1;[I8CFU3&UL_X!/'>_G]R3L>J-3@O(NY,JJOQZ(!= EI
MBEH4>%LC)ZM:\\,,V [7M^FU\34N)]LWV/7)CCI1(&@\_]A<B2H19=(!$61:
M7R[FZ"KT<7GB"_?4KX$9:<DF4A<LM_!$WI3J]LW$&RG;ON__W!7P9B/6^LH3
MV@"G5P:;$>0<4U)*?J&M348B?)4Q;QJ<OEU<J#_HE.['<_?9&HISL7SOJ&?I
M')FG%H"38_[4/K=+><C-2ZI6BWDMOSZM\N/ 1H")//G=^DMX^ %?W'*"_7H8
M#'(ZT&ES>VM[V2]I(C['&C!3;XQ\^CQ+9U8J[BJ3;[>:*6P'7"7CSW7&'BTA
M'%I>OOR(!Z6E\=B?W W8G 0^*,*N1C>Q)%S ODW6YC6S9.PO:V6U@Q"+?'60
M9_:\1KU"2$)>_EUI2]H:^4=X:S+\,@P"<LO;QX@<CE8*FOLF475MOGBFU9M<
M2-(<=(!QK7U<1R#$N=B;RX%Q^CF'P"-;WFN;#D;TIGN[Y%7XEY&JH]O4I.@;
M+NDO7G@3L8OPZH5U8.\MQ'8+;K&:NE_WZI7GBRYR;<XJ=29)>E<UX(%WIRC:
MS9F2W!5VY+,Q1*7%!POJ9\Q$$Q"3NE+>C)84/S89X]T9B5UB6!Y]/6IS^5-9
M)VY4&D?0^B-1/8F5WM#@$AT+^K)F0\HI![*W%XA;0J<#O&?TP7N6+:&SU&DW
M1$/-V((EF4HV2(8I@[,/I=>S/CS>.<@F^\AWL\ZX=LN<FDRG3QWKZ(:NX-(K
M)B!FT9XA/-ONG@G%Q>R;%0LO]1O'/=C ^3MZ_:8+777@E/75?/O@FNU;A"]D
M!RB=P6#(T>7R"-4\1LV\3WJL0=Y3."FBZ=/F)@Z9,F\8?=9,62.7,HL-2!'H
M"\PA;$W3QZ.YKK<E\XF+!%^DOS 'HL43U&?:]X=$1:OA:*T#U H*K::,F&6W
MHY3XN#->8_:&KG'^?5@)/LBQX?7N-45SQ^ A_B=/61D3S-7GQU%9VC+Y]ZKE
MDCSO/L2:+E3KQ\QV<I$JZ;G;Q-^_T:K!.4-0 R]E):K3T*-EWF:!,,W8KU0$
M%$ROOF)[K()8%UBKK53AC8X.=(:5MTKX+1FHUB>-77<R-AP@F7\:_SIKBJ6"
M=B%T@==^MZ84!*I?<JV*AX<(5TS3F9>,O1>!K)74C8W8.WBW&E!<"YY<8^)4
MN,C&3VE.12FB+;I#2R'02&_H'BS\,IL^N'\<JQ&PGLQ\X$EJ"4C,F"^TWO$U
M"3!.NF.)O_>NU)(QC=S>->U X!7'8XK(+R*\*NN#8ICM3\ DHUI&B=:]&<!2
MB2!EWEWE%PT>Y2NL\:R92Z-"C.#"[O:0LOLM30M#'Z[@W8U*3'!DM-"'\HU0
MP%EB7.S1;%F1@@<</HX.P&0NPA*=MTTU=4;0#.RL3Y=D-ZV\P_67ZC92: <A
MDV5U1$0OU%F5+C.4LJ\<&,<0C[XDHB;LBLU#&"6F%H+%MOQ\CW8PKR9F/3;+
MIXT=U;&S&6@=-.C.;.\;: MM$PED-:\:X+QZ84>(J=1$F"JBD R?,]UYK4$L
MU'BQ@T4OUXD%!LS>8*+F"I;9HN_8I#5]3RQ"Q][&C"O>%@G48 VM=7)GF=B(
M2)(#-L0=>#&&$;?,)BY0W*2>GA:I60 ?@Q1[*OFL5]0TS*)6.!5+IA;ZI;F;
MA\WJ(6M/6J0+AI^OT8EHW],DH:<K\N_SV"'-B7+-<MXR(A[N%=5T!%9H@$=Q
M?6GLX8&96^W^S<F/BEUV76FRX8YQ/>ZA]4:XAH%(#T%2Q47?18J-*BY^+U0/
M2"5*DN>U?Y%']\?%LCWD0A(NE'6$B]S7Y+$U!YRZ0)I&8&'$/2^TWD59@P>W
M5T=97B(Q+@XY+=+BX.P@Z*[%)U=O5(Q-_#P'?R98Y DW5E-?OG>XN3>#M<!>
M0'3TW=;J2:HD99SI!S#8_G4<S9"++:+$GDI;\B6' 8*#QDC'\$:PGM5,\6+2
M)'T0*>ZF8U%+]LA@Y!7:R!L-QJ:OV+5H.[H;J&\B'#3Z"Q+O;2Q9,6&:W<DV
M(A.F]M<3QGO=H)#WX+ZQ3?[T%+;]9WR!YW7S[(:I;G7D)=V%?-\R%OLOW'@-
M+\2BC.U<P E#A=R+K5X_?&0#BH@)I$8,I[^.OC5"WV"G:F+3OG9<QG3\_IXE
ML,SE;1G06'M;EX53['VR9X'#\8<NLD@J%D&0O4''T/ =A15RE><0/N(OH389
M%;+I?EGTWC0\K),#<SB5*)V*P9G/'$Y?U(Z"HUM(.OKU,%B.VKL825 1FM0]
MR7<R+;RC1Z2'Z;=\]RA\+?HGT)*6$-6'->UYS@Z/'/-M!JN Z'A,\K6(QKL?
MX65S:2T+'MAAU\EJ\TII7\\DJQ'F*UD)4BL?HS*S7+%W;?(-'R\L5B_-7>=)
M8O67+]6IE91$B\%LK_GT.6#,@XAX['KFKGE4O=^K-DF"I?;-#-ZP]HTE2L//
M)--ZJLC\2 +L;*:Y8S'I7:*#8TK^5 #U1IO?-6^UHYB-R[,ZO-O:*C9/+LP@
MCXD4LWZ3*>8YF; <\<TI:]F:(H,I-YRC66QGNFZOS^JA@FKS\Y]UGI(ME'=0
M1&BEA@&(-LWO4U=,5'6G&R(7@V)R@,_ZWGTQB;XS./:HXQXOQL5\@]!#H!OI
M@C]*H]U3"4TUPOT..RS!;V,@#_+>2DMB\!XJLU3'W9*]=4_)\3E8T%_!RN=M
M":U%;^%MF("0>ZN3P='Q5T/;ZY]C54,0G,HA3?T&-\)6D,23GG2W[5WJZZ\V
M5Z][IUH^YZ_SQW\OIC\5%_=H$6B86M-K!)YLN5].4/NN1./*/4UT)@:SS+5H
M@4DXU?S\3(.]$IM<BD-\H,C^*H1=^$I?[<5<UOBBK;BJ79T"GWI_":PU\R''
MRW 5)OW+A]M'69T.,_SDUUYYN%P6=]9ZK<%OEFAX<[FGWBH4]*#W:"\M9F.[
MWNEJ4E-1WB&,*B">=?FAP!3,G&Z72(:F@*I;D4D"&8VFPU#F-0S7,XXMB+.#
M9R<[;0A1$GOZE(2$H()QA?W>4S^I:6NJ;*M_7)?2U5R7:JW&S@VOB630\X03
MD':_16WVCQBJ7MM/)GW#@0+#380U5\0L[A0,##[@?%*2_KZDI9C6TZO;MOSN
MFY<7HR.OED37FN>][R\?WQ_OB,+116BQ/XPXF"T;S<7"6&'L?XYJ! CKX W6
M+[H<)TW%6-SLWA7(\TTQ+26/-2K[@";@2H0'H8?QL!.$)8.6BP5&Z[-]'@U-
MP4QABJU,DR,^MY3RW+[58)8.!-3%\<X1OQ]ZR3,[LWN_+IC^;G"^<4?2MKZ<
M5+[GV)/]J=2M+"X-L",%*)ZA@6LQ@=HNC-&K-DD^'!@T H:6[/C0ZB];V@RG
MD/5Y4[>6;<[C/Q( 5C6I+K40<=2.7[TC;;BAR-:9M"IY.V,B3!>X4C7Y='5-
M1RI2/\S6U0*9*'?9Q4N2>S/+1&",-$MUI"\GT=RL<$B(Z2M5(GM85,)#/4M=
M^8=V6**OY#)X&8$B4!;1!,FJ052_?$2I!:BMY"5H8SM%>=$Z@S/5S^ESAFYB
M3YT]O?HB&OT\ANF#!/;8:YM)/G.:&>^4(>D=./=;ND%#YJF1%'6SJ,=[[8FT
M!H^*99C;]IVB:_-<QC0&GFB9YZS(AWMZ6E=WO#9!2FY.<OJY/52=6R6(0>\;
MC$)]? ;FF2 BRB4+Z@,*RFVDQ3/-4]_N.[N@(P0I^DSJVYMCV2FL)6L"9GS;
ML6"XDQH'_"V$D?A 6PK>!QS[WP%.)IH"O:4J [/MV5S..J3R9;E?BD+C9.L
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ME8C1ZV+(Y;"H\5QRJ*HJKIW\,.,.5-ZO-YNG!QA;CXF5E14";E.A<BGD]SX
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M^-(E4'%'O'*H;+>#:)G>^?DND&?&AL\Y+%A@@07^8B>P )ZKT6'PL.'7Y>$
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MY/O(1TB[KUY/;+Z3N_X;9,>7[-V9W;^CE_P'OH3O-<C_Y3=@X@_PJ8=7[]^
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M*!C@L#$DAJ"@CI2TY?ZI\?]7JZ6Y0IV^VVPYM[W*K.2;] 8V:)$O:8/J%*.
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M<I.#IVT?@#B"RCDF9HZZUR44U\(W@RRU.S! $CL^%&2E;2H(0S!&0$C0/R.
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M2&:8T71L"N9;"C5UPC[$1SF,&X/#GRP,4@Y5N2JUQ[D34C%V)&1%/G(G%<H
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ML@"^ ;(-S&V_%HPP=H4B,M>8G$DC @ ^UNX)+;YMT&@1Q]6?7)_;.J)/3$;
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M634PCN[O)[ M_N1Y-O1C@3)!Y:/TDFT)%E"*=;@WERKUV@DLIXYG;GGPQ*\
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M:@FM8>QJ2E,)SO)8^71XU%PI"G$IV=#D8C6L0 $ ELM*G31R;1FD6@TP, !
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ME##7HIM>NR+!_$M&];XO;UY719J;OU=8_H\BU/]1DII)^)%<5%6/*ASC_V4
M@?WVW@MS%VZ6 DIRIA8$G;V'_K@?"?Q'1"8MQT;C%2EN":W64V[2\ZK.$)_(
M>V*4?66*E)\%3EG>S*%10P2$WUK;&]2I;Z93U.X<*A+CK#KX()P$S?FA?G)6
MM=9_?/_T]2N\Q7"#U&$.DK*_P_R!]\6J"88+N9H7H20= ""5X_,<T]YU O-O
MMW>?UJ3*P9P.K&PIDZL)&<<WAI60YL%#2T[XZ5C ZJK5TI?B);,Z9K,$JXX>
MPD.:H\WQ)8,A^>:$N-8*]JJ[:DWK5\BD_2+K"D\YI..A<L,1ZNBK2;'OX'6
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M-4Y($/I]#@M/GU9Q0J=<?\S"ETWPC#R[//4PSKB3Y!"UW':\J<R(46]CI,(
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MX\ ==2#9Y0MB>E,B,?DI#L*\_&<:BTV:XTIIX?;Y0TVP:#,H0HZ24AIEOD0
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M"<9N8]FG.#ISB'2KT$IX;1W8KH2YAIV2\_9.0;K2J\'B@I<@NMLK#WZ3#=Q
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M"&M.3O%R5S]P<W.@UQ_UA(LU-#1,E=[\Z?\^)XWCM\B2P4?XHU>7$/6[Y
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M)X>&Z])NW)@%M-TV/A.7O,RPOS,2VR"@_&#B'#>VZ4CG?&?+Q ,QB9U0(6G
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M%%&+'%G-6O2I:8OY9RLGO:POY>)8(IO\$U[9W.ZH+:75YY7KH\U]"DR- 6+
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MC_%*'^@SYO1I#G\D)M"R+3.,TV@+:()F0<_RW=2+/B26BFYU4861'7EY#YZ
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M,P.:OZUO9/29!10E<82A D3?Q1]=LO\TC,A=SR/C&!^D<(]]\7_)'/K]L-,
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M]@S=Q$::HDC1R@M^YP:21ZQY[/:OP_.(,9H^4?WWA.SYA*-B^56\SUZ)D:5
M\I>W^C_^BH(<0$-#II%N>(XN IW\@U%$_=Z#Z'+EH!&UM0FZOFT=R-E[/A\8
MV[)B&F_((P-3>C5+5)@U,37#/79[&G=2^Q,**7! JBP_A]U-E=:OB\[N_K]I
M(#D*70%[E,9_9+5,K'K_N=S8Z?G1G5S[Q3'G] YD\,P:H\:P?FW+(O^MDE/#
M@AJ\WX)*D_[1O7W=;&T^7^V@Z<&+<:$$<N9=PWP\$K^ZY*3FRE9DE'Y":/]<
M,3>NN62KQ*-@%L5Y8]WX+*A%'4N]A75IGD3#81A6VVD:E0.Q-2-#F*JG>_"J
MTJMBXUN[U:,'S11[/8_M 3G\*9\GH%MY"UN>CQ=>M/)UU1=D-9,\8D!9YB1K
M@ONLDD)=4Z95P:HC:DZK'WT&P2$-<JV=7/;&%5IX_=ITJ:W/4+^FO6AOI_HQ
MW$=^D)9)\L0EX,RC)),)G%O53V4*GL:=XIR4DY>0V3[@7[SBJ2. YA)M&-#G
M;IF2Y,>(0:,G49^&2.+%9>$!6$F0(FQ@VNQ':]7,?PQ$[AJ],YI-D0]BTGR8
MJ&35< W_4$YG>5>0(*(PH3B-H)ZQ_:,*7_Z'+0,#^^[I1CO5^#E$!)GU?7AW
M<QF:X+$420FCLMT/'S^=D<-<I5 Q(MRV":>,H)D,E6FV%F1DZBK?$/-2W/43
M%9?'U5Q'-SY[/[/L.@V5>S/6O*I+=Z*5<VW?!=&)<HN4.,7^Y. )\?A569,*
MORZ;E>I_-<6 ^MK&A:?RBX7/GO2 )V8?$_.*Z4K4NQ1A<^& #L&B4S;%4>%?
MP"^-Y'75[ E=N\D;N8VNI11.>]WI>?79",KUUC:8BZWN[NZ>3M.]\[LW/[+?
MEX>Z?=$MQEU6MJ_@,^IMUM!"H+0YKZT@;G+RH+(=YN8R9LJVO<5(1M!U/.@[
M!"&D0 G\6*M3<,#[MN2XS&U%O'6O,>1Q#NTMAV58_N0'- 36_ 44;=%:%=/=
M#:2X>Z=#&%Y+BE;^0"40S)43[,:4\HR[5IFJY3;O9[/0-308%!2<.T[5DP]^
M[L3<&(IP#PV:8])LD"5W9Z1C.D[-\%FVPY8ZCV/+/;[Y>*\ ,-YV2B1YJ&X<
ML@J(SH-V=:Y$HX"A!3)HS9VZKR07)M@E5B7=AD3R54<K'+%.;H=7:.M*DSM[
M&T2?^M]YJ]3X-8CG@M*!"Z^^#GQ:77RX[0<7X4T^6HZ3J)2&^D=?VEPG5\_+
M%H\OFJC?0FVCAI=/*\XMTW%N5-,^VP^76OH$,2M'XDVV1V&2LE<$DV-S"!U(
M7>R7<[;Q(,N!^7!?%N]6W"FK(3];*SAM</=<+^S6)X8GQ5L=$1(M$B1HI".E
M[\HVD6X%((XJ[6!@N)"AH9[6,6UEEQUDL_*[0$+9EOWC1F@4OMW#KN;\L'*%
MV/%;%D,;O+K^@E;#][T1AC%%0>J^J8*:T#<!DCCE6BK>C^4VT&J33)7WU?W+
M:P7:2G^^=M>Y1T3'\-R\+*ASZ5!Z+Z7:SE[&[JI3Y\%]/VS=6HN<4Z]*V#AD
MC2N?>^K66>,P(Q.;0%4IHU:>4HGT0I\+EK\;^O?(_4C:J4&IA[?%MYE#PC\9
M^<[JU7T'/OPH-W(_&;T"ANN_][<1?7'.\$J**[N/@M;-_M+VU*$(&U"ZF8;'
MA[TW&$05U<Z1:MZ_NUF[" W,>_;Q>WNL3KAA&/_ZF:,Q>RSAYO#C!^$![9:=
M5C*/UQLY!5C19#TS5!6_+)G]TGIQZ<4-GB:E8+0I6E%^S+64\#GQS"LDY=^G
M,@SU%,EV3^ID=RK1]XQB7$.WLKLLMKS%@<82GUIVC)TW,[AXD&:852G9,LV@
MX=E0:R^1GGXT5P0=,3HPHB%3K_S6/1R>V?BE;GI[X?/1'3=,DK2=%BDF2<G!
MJ$6UV4" =%A]A#)R[> C+&[_%9/-N%LK8:WYJ-''CNB(<7DMAWW#^5'>^+B\
MOF9'7C.3*/OBV35:[H%EYOFC]:V2/V"KYF$3U)KY[DUSA)S*(*A2V;B1<FN*
MN)S%L\7</?:J'CS&_GI>LAJ&$NT#"]?EO(E;EUPK92KECU3;T\"?&:\8O?>8
M_"XHF.M_5[O0G,+^7RQF_]MJAF3@3M7B8VR&9"XSO>H/W C])==;I<\J(5HK
M='(<0RLMY8^8E0YZPI_(0;),J(%%HSC=!TEOGN%E!2C(+BNL>R1?SEAS4^:W
M2CFQMM5$>K5VEVMJ](*UG$AO9;1LOA(TO<PN#7@^JJ"><V_G"K>LVM?JRM1T
MRDES141I&%":'ZI;+!RO/K[5^=7KK'%MM9AOQ"9L2(3=0:NV?L7>ZZS7^-FT
M5L',X1/U-9N^#:Y6(2"OS5\PNCAQUF+UYBZ<I9JTL[$I,^ >%<CM44!-,[/U
M]F&0LM(F<-2_B[Q%A;G\^\-\4Q'4N7B)!QM&W>?@2D-'K\E3TA,)KC.T36QY
M+1$H$Q4I9N'!@T:=\B9-1>:_RXNI[>_&::!K4,\-_W< 5.4P=%G5M>;"BLF!
M ",9VU*1&+U2PN_X4K4[V-H0C6\3PYRC[93P=!'YETYH<*\$*JER+^'.29<L
MQ&FP>0L%N@6SXT;..5Q"ME WZ&MM$YHNWL-*R:UF$Y=MG!&JTA3];FOU GTZ
M]2X>0ANM0C7#PD(3;?="?F5'$K#&>H"K<^C!12Q0:@]/2]Q7M;82%<(&,ZW1
MY+(*-6933K7V@BK%F$VF=0UG#W7*:A:9]+:= XQ)7J/+J'K\-O,_E,&^9/TI
M"J"MDM6S1,UTQ*E>XY-S"5;>#3J+"J;X2KAFT?K\E:5FO15O#4D9.2C)>AT1
MJ],09$*SC&%R"QOT"'^98A%^Q\W'?Y3C^&>9*JIE[I=>ETK^IE5'^."5-BC:
M(TRS4G)<_[R.TX*=(GU*NK6NJW)"FOTGV )UO05$$0#2;A;PG;+OG;;$XPM-
MDF@H71#XP([:\A%K#E1+&*ZSO6OF;ID^(@.9KXZE"!YKIL<VR9B<[:?RR:O8
M!3.'LF*<F<$I7TR8U$E@;VXVPEGA2J/IL:D6(\&=_@[=:J8UZ9;*6V;%,1A)
MH4_2'+S#^THD-(K<MW$>N9;A1?W25>+%.PG^+'+]ZI1%95(E2X'[(@MGKTI"
MVL.::VB0D@SIZM^U[2(C0P,["S*,.=U@5)68F91IK0\URW*22H\H"JJ\XN)Q
M765*"6IP8%@^N"39[H&FP;+?5'$#BL5^=YQLF(:RRF6YJ1:;O'P(37BBH30U
M'+R&2B:@>/PRH7RX=\K*E&UTKLZ>$#=]Y3];M.$;0<GX&5,#9]43;[DO-=JC
M[IFS8]"3=E\-&O5CVK <P7-W37?2)".5G;Y4^Q&_ 4[,K!E:H;31<6HT#LJ7
M[U^NNX^RX=*/W2*'4*F0:-<G_4 DNI4<'9*\M6:^TR\J72D1["':=.<0N-CQ
MPVWT4@F)SQ/9K+#?-)&GRM81-L03K4_WC6%;A)FLIAR>C7=VCL$63L*VB1'5
M%U*'-S.N&$T.^.6</C*#+;3=$BZK]C] V3L@?$=62ZI$;J-(G _-&>$/8+=P
M],^SV!^QG'AT*,!Q=_*PWY5-!B8)C+SRKC@WT5^ (A+1SF@QV@&^VNN'OV&U
MVW\:09R@!HJV=Q[^'/"]>ONC[WJ@J[8FJU&C$<)#SPMTW!H@[[20C0 (WP,$
M _!5JVG7Z$[D.6NJ.7"27X?EQMB#5<Z=Y-IBK>L)VORVV<>AAS+RVB,+*I/G
M6&DJG.)'H'$!&C"!.RO?XKS*H]/ 6=9:L_/R9ND9%@KCMQSS:+IX U_I6+T"
M]3AY(S+,XPAJYN:%'7E1531@9274>*#4-$MQK!,Y86P8;1TB= E_\0TO+9FE
M%_,>1GXF+1R>@]<F)V2GB2!VIV[AA;V=5B,$E*)0^[= =!"A2!';O1U["1*X
M + 'PGR/:-M_7FZ_#7+OJ>0X/CP]UA@YQ=6]>SP"KR\WGA >@24I''=5/S^,
M+@CC;J]W7MN =0YDJV(IDE(K*Y!3=46M.&&,KW)%FU\=LEPDU)X-;$)C54O^
ME=8SWE+,^*(_/+&PNQ**GTN!J;[>QRW^[1V=)?NE61O5@F]_F,/K;C9A_+)_
M?WN-"+]&HW5\F'F:]G@ (N7I#@&VSKF/OZA82DMWJ 3#T77;)HW4)H \*71^
MV1:$Z@P4%2ZHW$:0BU5(6I4=#,%(.P>5U.P[A;?^!<3]_@M8%-*GR:VMG:]6
M5=PGU>%.3/58%^0!TW:X/9\=V(]E@80U=29*Z1"5[8,HJ,L*QK,CBS+$^TV2
M.X-R@;5,IQH29!(+)U3P5/Y&Z$RSGI  )C_A7GN!D!+JF]Y3E;[7GM:/IKZ#
M9%LUDYIWB#E#Z 2GN,9\L0@;7[Q;% X*@AE,GCM3+L^_YSC=5J;9%*Q]^F8F
M+4;-$OC.\NRH(865#( FJ//9:GN\(-N)LQ=X AHQHQEQ(676P895%.FJD?^,
MU,33LI(JI@U),B-+]?,4"BR:XHJH,A]Q\TQ 2&PA#2HODIH-Y+]A%2V#O/D)
MZG<<WU7>J(G_!?!X!P2$*Z,YHGJ@'^_$E?8X/1X(NY0(R6NQDF>:D(H&((1_
M(GF Q/)YPQ/Z<E^1"NZ3TF9^(R44EH<>\TX6_I<!>S/V?+])@;TP'G_FTR]_
MU]191R"@2=\21B"D>T)A_,-Q/# Y#V@$^/0;7_G.$+8 >H3B./#L2D#_XRTK
MX140X/ ) " FV9#U]?5U/ 0?GB9 G9U>$3J0DO(C  (0G&>@=W+$8M_^9>*>
M,AS_S,[+N^/OFG=:J__6F?B?VGE,8<$#5-M&/Y)]6[!R5F6BX]15=X)P4IXI
M<TRX\OWBU0FG\])"06HD2;QF_> 1!\[5B5,";DR" 5\'#U,^_Y!%038PVX..
MN\- %U5Q,V8M%5BSWM+D5S'_NR#NQO<GG_V]4__C=UKGU.#V.@Y_[9 AF\X1
MI+Z6<%O66,KC8H33*$38_$5U/R#P[N&/>1VG 3)/^90^+T>M\]/^%"Q',T/+
M)>VA67+_@I(3#TO)NG.WZ-@2X@M#M!.?)O;&PKA$8KVT+P4#FHFEU0G:<%#@
MHL@OWHK,^W#'+/4IS>P;Z2VX53:.+U^.:#](?^W*B>FU15/<'@FVFM)]*\&\
MZOT+@*O=N2D.PMQ2;1KX'"W>:$.0BBEO9D9*48@J02!@73:R,C*3*]1SK-N8
M],;@-*S9J&O.R)=4MHZ29>TM'+Q)46.!E)(JJFEC^4RJ13ZBM.N)BSQHYXU5
M&@^B2+6BPOKXM+I=][M"&Y*<DNBV!Z4.>?DC9.AN#;8U0$2U36_(B!GA%EG)
M7JGO?K5*?-26]VCER4G9&CZDW0BK&!W[]28[IV-)2[MD_F!CYGL!EM4GW190
M2"YVI B(+-<AVGLCO^T^4$"Q:#J*IE)OI_G6JFO6#4UHG!TN/*3FHM#?"SG!
M6]H>4'5.,=^Q[)8JC=/),7!;L??&=@<G:391(&)-4U+<(FEJ;_33<#H+MG4K
MA<(=;;]WN(QW.:JZW4[OQYBNS6^H6L5L*[5GJ!R$- *Y;IP>X<<9ITYAM0>&
M4OK'93)48CWNA_F[>Y3B4MGB.LE9786^@"IXVUZ!S>VZ;X(.<(-G?])]^ N;
M4QY;B=R9Z&,.WZWG;++(#JZQ)T,1@:;!5M1CXA0%H,/"8A7>&_%H]64:T=^V
M8^H2F*EB G-F54@6^BMF7\>G5&\E(EN76HQ;P"5?ZC7G,UH/HQ3612<4_;45
M_4@WS'XI1L_2(LE(<A@FBRC5YF^<[^F@<OUV:U'6W:](:)R25(S4:K)5HMK:
M*8\J&J%K'^4C&,:]!O:*0C;.T@K9*DP)7CMM4*@8 !\M+%107]F\@V,27+B8
M(GHKT&9G@/Y$N6CG:MT3/NR&EXSO 5?FHRF52-K>%FD"]?(-H275AHYVV<T6
MG'CQ3&%N5EI^H@IO:7-1$IT*=\4Y79KR#>2LE06N:&DSY\?*!NR_=]O7[<(9
M#A?U[7+@-[^"U=H3DU+82S)!+R4?15\ZYVKC;\F3:"VK1:W<$LIUI/?R!/RY
MH#G[T(3G.&L,:![.8S?]@"O82,-/2)-<=7M9,#5[!7I?\5<YQ6V"M<_XL]!'
M5^^LM,F(3,<F_:E_#)Y!D3; R0\^_050M,CTZ>=C2<.0&E"1]XC=+PD9SC=/
M#*29<5U6'1ZKN+E73"TSNPUQAC=F#AW4R_:.'/+!<:9-9'QZ< @+UY54,*]3
M*>Y>W-4.#I>EUPFYN)BLC!-9EI "&AI"FKS)BA7^YTM$_W=OB*5=EA(= P"I
M\WX-<+[Z%KSI_>I\?5E,=[N59+E-%RY%KV.=@>;!<+BYOX/9\9/S$ZDLV>[E
MK1O_%@N!K5<A"F$G<J@HXU(DZ-NX1#]R4LZU@?54]D X>C3^2(*R(%#GH[O;
M-=>LBJ_'*A==TH]DUD,3Z@$>P4)>(;!R:45M!>8/E$!3@>0X1.^!0FY8H8).
M]=BJV:;9_-?1,%H1DTKSUPM';)EYE5*1!H9O%?XS*\72VU]7(>ZXN<Q:-)SX
MCWZE^^HQW1.H9K6'YG53+*(XR#GG4TX;\K$X"B2(T.-**L=,29K.#2KK(/MW
MXU8,KG&U40TI^%=/QV?/%5^R3PUEUT"*[AD#H,X7@>,H\T?SVP^*[4$U)-(F
M64XX/^U&4Q;GU"*FN:^9R7ZX-47[*11ANB(U*9$7JO/ULVQV591>M,#:GI9J
M43:)&QOG:%932T^&62DS[)LYC(G8;:XR'TP^/II.>K]05X4"3_KM9H. "7O_
M7Q9)P[9S[](T(LH,V6<@59WUHE(@VLT[VI'?2U)Q^E-@K_RJM69;S*7L+CAG
M]T_P5^EZ8U>K.^^0.LEBW2'55R6'6Y/]+<IE/="^O1C+<#Z#)<QI:#U72=,X
MVH8*V2:2M>G-RT=0%9>9CZZ>6<Q66Y1O%IX$5=0?QU=6<$QP;6=9+?0K6@V!
MC5!@<:%YIK"D.3EKXCF>FNK:=XL#BJP#SA7V0NNC$;3HEY>W'F!@*=#0WW^F
M)W>XKFV2HEMG,RTB)MG ON0O(.;W]KV;3HKI8?9$M[L9.6RCE2*\D)!\4_-<
MK'G% TI?NWW?FYP;,DLA3'4,PG*5T=!.<BGT<2S\Q-X[K"F/G]"04W&C'F$8
MOZ&')LK$VHV!RKB6G'&IGB[A2L,]2D'F>%0$)<L&C-'&<$-:$95I&CBA89J[
M &MV0>'8ZAGSP;*6E3;''_+VXJ==F? ;]>'L>]JXUF>KN%N;\Z+N/XU'MB6Z
MK'1BJ_4^/A(K P4/F@-W%Y3T%)X$4.AZ)Y6TV#^KV-)75# NSU/&DE7#$!97
MU(X#1T[?PJQ%R@>>DM8Q1U)2FQ4@6O4^1QYK,&YB=3M;*_F-ZKHU)QDN'=NJ
M@I(\X E)8\EEJ"$4"/E&(P*<9J@M:KUW[8 XV"<Q_!SR<,M!M^T_KV.(F*VZ
MX6S1VMDE94^&*':%9_-J?J)[P'F.T@W>I+_;B%PM&NIH7=/#7?_V/J\R#JMH
MDEIT$5)**^A2OSC#/;+SL'']9,J_3S9ZU:E4_S9M/_: 7&,(6MI:&8K,%O/)
MH-,20YYUC)&-/9MIF% 3U<9C#JH:)%KNE5-O5AHK6](^U)=8-0@U)BTE*HV_
MN]R8F1!BXNWC7/"?>BUK,6\WHWUHI6\*K3_2WY"XJN1)I22Y9'/UQ*><J=;Q
ME4[(J<6=@S"0M</C9MHUPB/S^_CAT8HGA>"V(%3X=7?W\(XQ#Y$-X;2!AMC<
ML@,[K.[SYW\W_OPEL@GL[ZF5F3SPY.%6>);4UJ8"@*,&U2JC(=F38MC]"C3V
M*?P'LA+I3E5!%;Z^%F]:F#MVR3^0%.8OW2GM>IQ;=\A4;CZN+UTNTLQ'%'9O
M.FND<V;:<%Y;YD:X7&SEQJ3UR:N;WYQ)I&6JOEB 9PJ4Q/-X[,'@\MS:\U/#
MHHIX^5"#3AQBX69@D,3GWYR0!1]+[3S6@@!X(W'#J&"J$6/J@( (--)BT'^U
M=?R?(!N>E!^>[$I(!;*1>_@?)[4(K&(B6=6 ]UX _)F0\&M$W&/</_7%\%_^
M1/+?PQ &X-L+'[LWZMS[ZOR"$/YX*NN2]G'B[7A!M//CL)CN6$3@16YFITAP
MT[=[JR?MAQV-H7 QFA$ LA$ @*P*]0*$ZMB+?3"3/0^*B82%/0%$PKZ]WNY0
M+W?%-+.*PE[(H]YHTD[? OC<+E>+47>$ 2]PR:4R'I"BSG\RR'&DA=#Q\;*8
M9E[YD<9?^"]@05890?@"EAK^-S7\+/3E(P#M .H1A48QR'EIWB"?2-Q++($H
M)]83DN,EC#S3(^UXN2&KEI<-Y24W#ST*+^T /<,?X-B+)O#\Y[BG.SF/4O@X
M")T'%3XHW.$5S7ZOF"X?0NF$0LCL-U=YQ#BGTE&B1%!T6)AZEBQ=@4I +U;0
M0(LN7D&>_UDL6;R$.B#"2B7PA.Z7BK@:5BCY$ E5*DTD$@W85T#@DPAJ I72
MQ#S)PL)&+'MYI1Z%6X^.D73%)I: 'PL'MG;";$)T@3:&V=1R>Y%Y']SE>,'(
M\Q(W)9SR#LN@5'=R90_41IW;/Z:K^TTRZMN!$'Z+@5:37"&5,'=+G=(9C/-C
MEBRU%BEX>)17O&:55^;NJX2"$V' 8=8BNL>2 S7MUCP-M_B@!BLA5D4O ,T(
M\OQ?-RC^_X:Y#;]KK5*0C*[I.MAFA,0YJG) B<@.CH$"GXB5EG6&]4:+7H"0
MW9>+XCNUQG?D4B8M.NT.UCN[.9]]MCU4-W(\>#;HOBLLM^O>;S=)I[KBU7\!
M53=CQT*C7D0C$T ,&9'M*+G+H2Z%+I9[K:%-+G:LX%,W*V*/$?7F9K3OE&:%
MHU$:N#,4//"4P:Y;%<L<47B/)T*2TC&JX])(^3_0/YLVH[(*'_.\-8[$<Y#J
M9</8^XS>'T\(O+J]OIW3=U^5A_$U:QL5[1K(B2_U(W:^'7Q_FJ7GSRZOB.(%
M'?',$;0[F,]IM4\NF.%GG_#%B@X61+$[$TYEA]%@&+$0CSU;Q/)_0$;O\-BW
M!R;<^ )XWOGC@/X_C8ZVRY@3 J)S2XO1?\^+?7&Q]Y8G!6MM-[3F1!E)DN]G
MR(%TVSB/&!8[-*T*&/*6_2FC2LM8:#;-FP_^ FZAGWR4N(?A4_WTG\LP$WZ.
M^D0,^PMZO%QJ/A*<Q J?I\YHN.,C"*5(?X3)\HR6 E'BXX?G?66X%=IK+C]3
M;$M-\95+9?2M+ZUX,GJ&)H,^8X<%P_\%$+_!W^&].<Y@"W+_!2S[\K]&'T\7
MK714&F,K6%AFELL/MKM;95>$\)7C8E(SV33=K9)OL/@Q1@_K>O1*T"4LG=S5
M[*L>146$R55^7O,F(>[U?T1C$MDY@N-^)O2QYK?_V+M[$/1MY8;4/SS 55*P
M%7?SYD=?SF@ODF0>8%<EH2)=OF5'6>H2:G#.Q)M6$>_!)1P[G#RTXE#+-2E'
MY&VKVJ%;MH_^PNRR58D'X4%?S9C.Y-9"WY=&O#]^Z^[V$&B<AG7MV:R8?=!U
M+7^#IKHXODDZ+RK06/M%94#Q0\'+AUV3K9HYROIA\CW,:\/)5"]6>W>,39 4
M@3QXA#%9H@;PR3N +<@7JA<^D?OAOKJ4&).'>]<7>DIEZ"IPHMT71^:05SK-
M&[H%(Q4_V/PV8=($9%(%5[0:6!R[@6)H>QGC=5+E8SN?DTY!NL'+51MN^Z9B
M[9N#3KPO<=LW^OKZ*.2>P[><BQWN0@XT@!";!MX]O#YQX#'O;&G*:#(N5 M9
M(5RE'HT:>;/ A"8GV;"GJ7:H"WA/JF@F:NK0-A7@H'!-M&A:[2M/%TB?1OV1
M98D#_ 5<& Y:=,/!\3R]^%C[_/AH? *>^759WWS\;()B)DR1.491^'PUGEEU
M2'L5VXG6&V:7D'22<#]9DH7]=8K!P7F&)'MQV>1P8J#=^*!-8Q?X'GS[D<N;
M2^A_+I3[\,ZF Q'HU3VRYCX;(\!6BU7]"TAB9#<_].?\M:C*[,K!=)7<PIX)
M%BETG_RF>;/8E%(Q),.IJ--EE%ZSDZ(H' '7%^]GB);FYU]*QFQF.C[L>+PC
MY'#PO *"\^OD';C-(!V*+<HOC906>,0L:@?)9)UH&*^--;)UN)AFL9-!EQ46
MH^,HO:,4F]1[%'H%/MEJ,<^5F< $0T^:$KH?Q!E6J7M4'^,!XVHG%J"/#V<(
M;U-/"ECX[UH16XO)OS$;J[O<2*HZEOVDL->DH+UAE$%M_?R:N8"G/DN1,_+M
M&SFZ1%(<5B&%POD8OK0[D1E\=( P<-33 L^62.0R,Q?C+^ A5TCM]A88[F,$
M;A*W[TL:+]Z_HS#4)&K1TOQ)-&C8<>[7>5F@LN5XP#]&FC[>8E2$G5%O:L -
MUG7D($"*RTC9_43-%!\IHTRNJC3H;ZBDLITW"N$1"]SI(?2"X,[X"]J@QN[$
M,&IB5T$0X"?8?7%#*EEIN P41BFS75[_W*#-TB5Y(=NDV,29G"T9JUC1R6>T
M$V D8>E)D^4V$OX%'.#.# BEI?%0]< W&5\2^D/-Y);PO'WH &.4LWSKSGAM
M&6P8E##W.56>QID< ^Q'N_7MRW^$, V"D]*3 ]\^3ZX!2PYO&;6U"](U,_-I
M2%@#R%!^Q,ZCOCU>G["RQ2)"]J8$BOX"SF=R<_/OR:XOG-<K#:\+&K:*7HOH
M9CQK)R>'>"R/)*GC8.*OC>*QLX-H&<%HWZ3&!;/(^8U+R1.,T4C[SN1M$VY_
M.VI[P/C?HN42[KH3.A^>;C?JW**:"N7."'S4GV=.-6B>S@\_TN"&<SP<K XR
M 7&>SVS 2)\G0FBN@0^DDHH"A.2FMDG"O/-@\ 0W?7*_7>'TU3<L,P/$OX!5
M(::.B7.(C@?D+T#G/Y82=>H?3ZNY;%. RH[B<>%!V?5<$5$>G"3>9J#%V><^
M*:K<$%G"^HN<YI]]\U-?X=B<5 ZLC".Q@&WZ'$^ID2IB'OF15]RXEZ,C G$F
M4*,\ %1'S$;.3X1^1K['T$=*I5MFSCU((NCU,G75:U0DM,Z*.@I"H??(]-*Y
ME"57O I%/@&2?'Y7DKSKT17R^,F3HKSXKG.4F\B:4]O"(?$(\4Z"P(5].C+F
M:7ZV'4C.O]=/N'^+F]24NQI?7L[", H?N:"BO,C@'(JCBT](37_&<;(<'$^,
M ?)O6T:P1JM4Y2@GU"Z#D?E!<U4N_:QQ101X'!N4OQT\XQT3O4U;:@0_4#W*
M,'G^ D2(NO-\/SQF'.!-UZL7.H;J%NS@*_18GNI=DB_T':XB*?LHD*FQV*\U
M"[HE&C-&M5,U!JO3:\CG976)6#2^VV8]K%@OMY]\38G\3BS;UB?0Q?;P=. V
M*BMRB$CD9S'J:0JD_W-WBX>=YH7M-60=:1E?(_OR?4ESQMY\+.DD@^L@,H2L
M:8^PB0P;Q_[A9UL4E=.<FFR'\7<[K"4)D/FZH &OH!0:S!79$"[ RT^@ARPZ
MCI$&XM_7[:_G0YO2?9_W$RGOIZ3#,"@Z\SK!CD[/Z2]@+*@\]>U#)IO47K+W
MK(5"^>[@/+$0*R2D87);O#,T-)%4IC(MP/_QL^,,_$IP@&/L7\!Z#M=_Q,/=
MR]M;CVSCKVT(5ZVJ?),HBPD+-@UT6T+]8#- <\^]#G)TM=6NCX4WM)1_G"G\
M9N\Y-GT#<P LFD<\B_ZB<MXK] HUPF^Z()@K* A$\O@+>+?HR?&OS4V;N2I'
M;6RG=%N566M]V?QEJKWN:SZ%ST8GCJ&#?=GHE,(]^L>2PZ-,@OIG-XY!=[Y^
MJX(8TQ?*]NZ41K>*,9& :Q$( )65&=7/XJD#R'28)$CF&+&1G<LR["?U</]0
M:3.U,2P!&6)J2-'A)+)=%1L>$$P+-'\4/QX*F>C^[KJB34!#+@T;A: =]E'>
MOWPP_*VA)C,[,3P)$1Y.<3,;X#$MP',W,EXXZ)PMZ<']]";4LS-37"/E06%!
MG,79^N%[RU@@:9=5&R7,(9Y )J0?+/.6>$ZXNX@ZO0%EJY$% G*;J>M<! WK
M2I3O(?U&^YCU_V@5^GP)'1=^G*"$'2Z(!PW)_B $WF2>2'ECKU&M2+?J_NHX
MQ:='7SO.Q)LPCV(.B@5WCZY]==.JCI>?WLN9-5B97.:Q@CN;G!0IZ0R&(>S4
MB.K[QU? M%O@>@[+;?1;3ZG/BV,NVPQVZK:[\$\\I,Z!\>3"];=W _LE4K<K
MO$(.PRCAL8ZJ5D>L5JA4#C!45UAOI:N&Y2]Q5Q,C@T#"7WQF1(@\@\%Q0NXO
MGGZ=[F56&7S#_CWIUW]NIH7PZUBWZ?6RSVYN7-K*<7$TOZS\U%T;[ZW&*2@[
M0,C$ORY,4G#%\2=,3,5?W&V7ET86U][7LI60N>'8[X>.>PL^<OMSOVLJ\!>0
MZBS1"M_I\WCE">GQS[6^&GX=J@&]LF-[=>EE\SKCL%=:RSU'#P6[,YZUR'EC
M8TJXZ,JTDA12.T\=>*7G92'"Q:K8_\IR,#\]P)6>!EUX>W<;Z'?.I/F3G:KM
MMUUDNW_KO1<8NWMZW[P!5W9KCTP>;&NQ/&3*\-Y'%W!B,IXQ))[4158*93EY
MN$R[2NHJZ*1'9E;B_NKCT)L<:;I+-A]W(YF_V[W)Q3*].IY8F" 36F"_ ?Y+
M@*?C6+^_ 'H'Q+LWNG*%)TVO==KI0O[GCF.0^6($3YRRSRE2%MV69^4?:<H.
M[4@9_'$<\:)5:>H$XDN,FSHT_8*MU[&R^H#HC]^>_[&B=7LA)#3\GXE%=0UD
M8M/)D=@:=!-J6:^TIQN7)M$*MN)L2Y\<I&%W,%EN$K U/T)4*_CE":EP,Y]W
M9-IJ5V15>.6:Q'$:@I'XC?-)2Y"JUH$50=!#S]//E53SRI0; LD1A&Q"6ARL
MQSZR4H):X<QKX\IE+1_<93]H:A))>!JF2V&^ +_P1/Q8:]/0SXP"J9A+YSL2
MKQ/Q9&>?ZDNRCXJ,;1%?^/(=?ZMC.SY^KV?+=@CGN1>(5:K%A;2^C98'9:73
M-Q\]*?156$D4IYS$_;BUP N+[:\F2E;_\I@PFM* ##.0U-8PV.3R&W4J408<
MQ:4REDIJ><Y2LX:0].0&:7%2LN>!)[P5!N88;[B86MQ8.!RX]<WX'%@0Y;+U
MK91LW( ---W!>E'IN$\G/):A!<=TUQ:4N')B_5.,D4:+&@W%N1%Q#7UCVGE)
M#J9+IN@-'=EN:0-[:C]'Q5)$R0ECI4>HR"TFG6-9=F8U*56+ \7Z[N #HU_B
M5++?/*O6PG[KC$Y3:-I(IZN.=^5948"?ACP(<3P8KLYL1BDCVN 5:6ZL6T@7
M<'YEX46Y6Y>BX(8L9AB0C^U!;4M<YC)=/AQ8F@GT$_J\NM_RW\7"YPX0'C3R
MQ<:K4:9A+-HH%%63-[/7"'C2L :[89S4!P<TKQORFP\5CG&6I]:S'MS/=]N/
MW-AVH@3"3 %QIJ*+"@<,A#S:/KIZ>M*L/6*BD[E'R)VG'9^ :35\6D,MM'L5
M>***DKETB"ABHQRVSIB/X\@:R#P,1NY$<SJ>5)S4RQAUKNI^+-CD(>U,)5H&
M[7MXK/5/4<O,4?S,BC!1[P(\%SYU/J?["7$.S_]$'?3;JW/2=L%XSLO:&FW]
METK(6',#8Z5ME3-ZM;G-U79O@7E2+D9LO'P-+,A<(RN4P;X>>#I=G/'6R1X(
MQXFQD('#!/C/:K-S>/KBJ?XT,,WV_.?-9V;N4E6!SO5W"\@VD=Y(GRNX=!G$
MR,D32DE"2$8 D.VDJ"",Q31Q#T@)?*5Q58X/4>DW"_;$8 X>.5;!B>2. QPZ
M4A_6Q_)<]^UZH3J/^$#8;[I,N9^!YS-/KS=4KPLQQIA6358-ULS",YEEA\GO
M5I"OMQ=D-6H5(EI%Z-J75(=*&&)IH& WZWARAGEEU[*!=K)(/(_\@.M_K-A+
M[/C.RC:"]RZ-AI4SU_PO@=ENKN/"MWW.ACZRT I_<BF:AW2$%).KBY+]?JOX
MH:J/5V:Z82F3\3KZ&('<H:"2W*:F $IO^6%C.T^B53Y I#CT51#JWTF))=LB
M[O2>9THJ6LI%(/)8H'N?C^B]FUC3"J-#=97X*M5CO5]&6$1^_KQIQ7JJSN-(
M4W<*I[K$*&D*$G&(OW?FDJ;"R2.]M$5'CH1WKY*H,&<Z^>%#08B'E8VIZ!,F
M*.S[H0<!!Y,9Q5>Q;1![NM\>O^QZ+@4Y>\;N&V2VQ_(DN#KZ_CYR<(5HG]MM
M=F=F5ZY1$D,6[M*45DAEQI.;-!>(1WV_>=EY+%\NI=JV7^L>7CP#PG>C'XE*
M]QT<1^&[!4WJN3ZC<A(&B0@%#'O@$7D\/&G:1/[A;E9H+86S/I?6ED*698M+
M)OB$B;K#&Q$ZC'GD0M_/ +8:F(B5 VVCK'W[MG&?9'1RD?4Y,*MEV9B,:G :
MSH'S[CAVYS-0_@,ODC AF1@3/G?GR>BM\X//N]JU_?^D!U='_ LRXD9A195<
MSF"%8RW@K*'R1MK81WA"0%LYM#MD*HU,!6B4P')R*U@S^?D%'(Y!C$RU7"C0
MDZIT^^ZHHSPHAI3C,#2,U$F85]9@3>M2@9@B^@#6UZ-&*(!']> F3R?("?K-
M'TTD<H5&]IN#8],<8SQR\"*#FO8>'&0^2JC^C"0:.2A-ZA]?3"*^^19*(U8'
M #ANQ*5AXQ(%GQP_'!]KVVJ4$JR6%._FFUNII=(NA%-DAD4G!21E!KD43+!X
MZ&@_1M4\TO1M08<I!NY+4],%C=(+^!ES\)#5DV8\^3L'?K#ZLFBMYE<K<'UU
M+!/M5.A,+G3%LL[V+N!*,S^=!,V+5CHHE_?8/W#5WPJ3:B&V*DQ8$&M B5HE
MG5D%G@A!/1P_+ZU)LIQCD]).91;+_%"-5+</',\*^()6)EU"'(@#Q1(^10SU
MS!)>F?!-@ED ?D_[0#\UQ4S#\JG<:W!ME8&!R*W^ED4UYZ>EN\R@0@,K0\KW
M,5V&]='A"8Y36%QN?9P?"(G@$K'R?P)@Y%CKWL0DJR23 4(V*T/V'$D>Q3E&
MF?'67[F<@9 A*_9<1-HE 0 R%PL)2$#!*KA[X8B,?%X/_Y07_M*N'VH:!([P
M^1FJ <!2]IUV@,Y* J"FX!(%E8=AXHY[ED1$LW:;T#X']965'[60)-J7:A<O
M'1%G1&=2'9>3X@X2)Q>0%"O"VSJ>ZG6C8?3"]T-:J7EIQ&:;=Y&>]@OW SSU
M /S*$E+"W[()Q2=<TSWGTXE2-C$NH-@3X12@R %#$L2V$921\F(E)D6*L<F]
M8V4%YI\ @ 2Q>#\U7#AFMNS/+Y#<X915ABS<@(RL/%!OGK*\JKPT+-,WBD^1
M7L+YO0Z$#H3P4!OR:")/JN4K4=$NM,CI1ZBPZE 5!1V<YT@Q8$?EZD7L+URZ
M@#QP0$*;/"JI Y/R73FA&^10]J4*Y#1*OR7Y.3;HZ%R'K$EXC#8/5Q&).B,)
MDW W+[+WB#H=E=2(J.9%'5T ZOEE*3"%M!X/LXK=!4M.DJ[#XQFD;!*(Y)Z(
M]DW0X[I,VCEE?IJH0[TRL',QNNVM,)Y[\>J'VE.FG=J6U"YM.V>U7N2_ MF/
M2M&(L%R=T6@;[:U*&H3BDR >&8^YFR=!4%#FZ[,X6A91ILS,ZJNT;\U9^ZJ>
MJ_?Y(T67>78?'@H<@Z[BX)*'C%. Q .+4,?-C:2'YZ#!O@0;,QY0 .(F* M%
MCT[:7 R -X(?]?7*+**P1H\M_A9B"L6_D6PP ;5>DB?DL16%NYC=1AH 2E:O
M,BG8@!IB%DHCG"WA 0<)9Z8#5R!W-60Z(>P;WQ'W5XETHJ2B,X380.]JDM>+
M,EJ1+6JE+T*J+F#:[#PD7%A1UT <[5(C]Q'!7]! _>Z>87AL@VAY-4?NEN@X
M80WE<VKJ!MOXLHHPEF3U=\2T:HG/SNG'7)0\L<;,$>GBZKWWV%/<JP=J$N3I
MK#*4?0,N"]:!7X3Y^QGZR6F-U(.G%#C\A)GN0TC^ CR*T=67,B>4:[^; $45
MADL.0R)EM82#I@M_$N2-$89+RK*X.<FOD&SD@38;W8)#0K&B,XNQ)OH+@>Y[
M0^I22^<)*H[,<[]54$AW"[+Z!NI$!<KQA\6:S)-@R' +#UV:3;+(5:TURZ%4
M[T\32*CC\_#5EX:X1Q?EX24%P%(P\^*H6>((1C(PTV!$*' Z B58ECI1_+B8
M?9$' :"6#INTP>^E!MW-\U#A$!0"TT<<#H8)Q&R&"1+(HT09=U0N@^+/B1>O
M0,@N=YR%QV#^FG LJZ$T4/C$[87C0ZV:(GQ?YN"4HE:CFLTK:)+B_-,DL V@
M?JP,7=5/^O3\,E_-BJV-2)6 MC4HQ7B$,CX-P=+)I+JWUR/7/&L3#C*DKX%M
M\TFD)\?^0A*-F)Y]5RS8W?87P.'VY(WF+SJ30!TOM4"V&:0^2O$^LX5)&BG>
MW:^>1!V.F PEC_ITO%S5B(UTL>D2_7TUC-*",:TT18$<JKQ(%UCTU?)&,RAH
M&K]=NF!KPTR=S3T&M5)*IF;)+%Y%)4[Q+T#_HT>VBX9HR.3W7I;&H,QANJ8]
MN$OB=E%:UKZ!(!%L0R\"=4&N(7HS[PPH#_ .\#O;3P99 P#1WEC"@&* 3*%+
M+Y*(M#0 1I[[$Y@Z4I@/2T5:+(X^FU7).1/P'Y$+]:(U/*=BVQLPSQ&LK/07
M$(:2T2*,>%MF&(\IGV>88A:U$9>B ;UZ!*6^0AP=PR3 <B&6A#LP( Z=A.O)
M$A[RFCZP.7!%MBGN4@)?.GOYI(4>&?7I/L36 TL3_I.R^282(Y2(]E?(!&0:
M-D0#UN/\#D9I:9&45PUZX;SG?,J77<]XF2]8BH4M%$F5NBV3"SM6%/TT/EQ=
M[4MZL8)8?#%+"))8=AY #>'SP4NFD9>65I]QNY??%[R%T]&%TEF.T_OR;'6%
M%B(MHFPP0IFXQ^VXXQ>L/.-C%97 $[[CZX?G):OO7$RI%/:1$J1(5BY%Z9Y6
M$5BP[$],HR*?T&%"=PM@J!W[Q")ZCP-G_/C>WJU]!;]U YED"\CI>7T%]>1-
M?.'T#DZ,%G_"NRB3%7XM)CYE2P1@.,-_JA=&RDL'0*L=QC$I,?6G$V8[>><:
M_G3'866/>DF4:B#+"9!;Q"Z -9R@'7% ?,Y+IYE%Q>+=5:R)USY6_Q=NQJIM
M. *!FBIC.NQTH>)!E4'-XCC*:C2CZ65EZ*B.)%C*(5]PO63SQPT PU"JW35#
M2<F+,A.<-9C:0[QC-5L4:NJ'IZ>L(<IA-),&02[IO:3?8'?]E/?DH3>U9!U9
MI,%!R2 OT?((5PE.A0C:[%#Y$-8@]5Y%$PSR"#&"!!HU^3QB&.I/_TA!A$PK
M("DJ/LP5@]!C3/,J4X85KIP\ZB@.7&_ I8<.,SC6?K=T]XQQY[/$V\8RN*YN
MA+KI4]&9H!*9MU5OFHX-5R(A.9J2Y52P)7ET)B+^!>8%DY?J.9$'4"*_PP(#
MWYW",6I*)H\86+B:CJD!.P]EN2E"L7YWFBH/*XA0Z9=_B\4$+Y5P.]CYCX/N
M7ZY?[C1/D3H_1ZEGU'X!'N13+IM]2BF@"<*LVL1>\(1Y:X@7F?M*C"?!<^@R
M6>GZ-OA5AZW\%O*R+-C-4=[>S-K)&VE_-$5 6&4*?TY]*IY1T#!>4W%9J.[@
M\:M(T0(U*Z1/Q\<HX9I($D=L[TK+MNC@)7=PF4^*']7Y@"WI^)Y'*-3PNT;>
MAAP#;_9WS G&N2Q8HI0V$67S(37Z-9B_@$WQ+^I;)J (,;I##ECQCX2Z8NRT
ME979^ZJH_]&0^O^$9KG!8_O\'2B[CJ?U$X)<5=]N;T<56U) @E>?]5QFN6,H
M?Y+V=T?3=2WD;^B7EJ,;R)9_QH?'M"E)=4:DV%>3F F=$^(4WY\NGSTU:Q']
M.H[C!/\"<O\,!(-<72$XX:GML@HC=2'\ O*)#BK(K4'*M=5HNE."KHM(4U/8
M!-]/M!3!+);5AC9 PK%?UF45#YXWWWD(_7+#H5?&PXA]WCK>B58%.GPW-<VB
M.?-5AKG*Y2"(,$4'AV1DI('PZ/OC@@Q9W"_C<K^"@HWI8Q11$IT>N-=:X>8X
M2LQKZ6_M&N2ZR(-H68<.R8T[+!9F@(S\'XW9J1QB":=Q,T(+;P[,'4?C$"<&
M5=5:XYX.F!R>T:"Q"?Q]!9%*^9^V*9W:RVZYPXM.'[[(<JTR99Z@7*F1!E>U
M</M]V(OO'3 NB_0A%E8SMK]].KQ\D5*5![\<9OL^.);93K<HMXQ]7],K3O![
MR8BG163 P%U&DBD[P LIR9F,>K2/#2ZG;ME]D>7IO^F_,*<\_-GAL1=I3)K/
M=I.[]^3[WN5\K.U!=YQ;99H;_C2DS[(\2Y/^LH;H]H-6Z\NL$RC!7/OE0OZS
M' RR9H=&6EA0K#D=/B:1!%U&B3E^WJD9Q04& T5N36-*-NX '1'WR$CN=6ZL
MKU()$>:Q4"E0K ?W<L1Z8'G5G$]_D#1*:9QZFN;2^"["!?\-G^2N%=<*0:JA
MV$8G/E"E\[X?=;U354)CFT-448!J0E)0?0A&TN*V]_J]!VUFIF[0@^[,VQ1R
M./-X^^;<Y;7TO?S_U3SY_PWH_J[]+U!+ P04    " #LB658Z1XEBE>9  "A
M^@  $0   &<U,3@R.3AG-CAP.#$N:G!G[+P'6%--MS\:>N\M2#'TWD)'0'H'
MZ45 "4D(( 1(Z(K2!>F]""@=I$BO%GHO2F\J($6J"H(-]09\]?5MYW[G_WWG
M//]['P:R]YZU9JW?K#5KULQL>/)MYMLB@%)'0UL#@(6%!4C&_ "^[=#8&SJZ
M>;JA'=W<0>+"H@ 9%6U]7%P IM!H/-*6^+T*X&+&N@C 8>+29,8& #"_S-B&
M "H5. J)%@2IH"!(&!P)4A7^KH#K1((2"N\@2PQGUXUA(F=]_6R^^H0G=\);
M/>9C/E@G-1)WE!/2\X*7I[N7)Z:*=TPS1'N:V+NYN9RTT$9ZPN%(+]<?S\=W
M51?4<9WB1-;$R?>XA8J3Y[',[SKA* .(*]Q4W=+T)]AW 4.4FYN#"=S3R_V"
MO3,40R8%& )0 #?,CP, !# !P &> "^ ^XD(L?O/UC_4J+AX(G_K$:F]EY.+
MIQ/R1"6F3G326E7?2O>[-\X=M\<6^H/%U+]8?,'=T\D-B<90&4[L<O=$_C "
M8Z0]ZF?%&('6_YV#0JK^7D%Z_E[1LW=!_ZP8(#R]?U;475W4?E8P?OQ=M0KT
M"N(W1WSO(,!84T45<\,Y>8:!0# W+WLEMT7 CZ*)0OZ%IN+RUW8J*)BI&=)3
M@\/8Q1/P2U%Q@8'^CFZ,=O$\H1OZNBBYA&G>_4XF]H9#/=U0:A!/R,^H,$08
MHG]$Q?'S;W?5$R? '3S_3KTI)M#_CFX"=?E.-T1!E:Q^DBFA*#=W"T<X9G Q
MX^6$1/SP&/DQPQC3)Q4W3T\W5Q<W).(W$=(?G.,N_$(G^T$W=D(X_LH@^<'
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M E1^1O#W;AC_#-#OYJ!=G*!PM+F+WO$4P_H##MX)#_- C?D0G%2TU7[138!
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MXP'%.:D?MP<0/OG-87<Q'V',XR( 8*Z$H=<!@ "L;S/?=@"DRC W>_AE57T
M]K== /E)#0 +/);[-@\(!9 2$A(2$9(2$9%2D1"34-%1D))2T %I:.AH:(!4
MI"?EM]O?%RPR$A(R<C)*<G)*6G)R<MKC"SGM=Q&J?T7!MS8 %2&F\W=QL-@!
MV%18.%18WYYA#"7^UH5U'M-+/*R3\IL;<0!8V+AX^ 2$1,0D@--R6D[+:3DM
MI^6TG);3\G];^;:DY.;HZ>DN)R*"1 M#CC>?PE W5Q%?B+N(F+"H"$#^O*\[
M!'H%[@FRAV..0 KLKUL?LX.<8 KL%I+ZHOKNJG!')RU_%-S$W\ 4ZG\%*@MC
M/Z](+.\KY^OJ[@KWA(!\75V0:#E?!?83Y7*8YV.R"#OHI(GG%07VDRTOR%+?
M$*3JAH*#9(7%A*"BHF"0M*RP@[BD!-P!*@@"BX+%1<3$1$1EA<3 <A*B<F!I
MT&^%79$8<Y5'P1SDC-4T?L/#U!38?S/,Q\='V$=<V V%$!&3E945$06+@,%"
MF!9":#^D)\17"(GF^*[DAQXU.!J*<CIY\04ZKD,P1SA/!79V8M OY3N0^R]
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MMS]D<**&TK6@8;/.!XS1;I,::<S5=6.BF1<TY!%79:AP9-"BHH 9_GM:8(U
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M#\]G@7TC'@E97B^GH_=&Y&HM9=M[Q&.M-D?+SDOZOS>Y53%#C%-3" ;VY'&
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MB5?%IJBPA%&3*[/??7NSMV# 0@8FP\%!4$XGR_HD(#_;D6-!_DK)()E&%Y(
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M)5_'^A9LF-X7D7$9;.:X+IAE3LK$]$41>D58T1JU/KUO+B/P4:%\H]/@3(K
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MG&R*4;GD31( O<J6S(S).Y:+G\FU0"MTG&<F<)>N7,818;;B2%I_,F.:JUW
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MK*.E>'#QQP(4TG>$G'?>8R9_V.E^4=.5*D..VKPC5?MM[C>S%9)UU\F8EUY
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M] *MC!_B #QK9NF.X98J5W_?[V:B/G%;E0W<R/.+=<\R.BX=,$[R.NN>C#*
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M+Z^ XSSAAXSA6XD?*TB"WL^N%AE*TQ6KL*^ >EINK\E;N8AT.9.7;#\7YE?
M)R66&[WVCI;\C[5M4YNEC@*))]%"'CA>KX"'FYFP@B*M=I17P)H2"D1W_WS6
M+6/X613ZS.#%HW2;CVGUXW_,*E!:\"[\T8XD.!XWY*37+N@L+6CN7M"O?N#.
M=HV)W6EV?U,5=]3@X4(3>,SD<+<_?:-W0,WDAW)YS)J><!H)S?R<=Y))R)LQ
M\H=MC1?/?*7JY?.U_PCH6B#Q(01YK?OI7F/$,_&TXF3_[XQP_3:RS9J>>!JY
M//6G"*>*CCJFY:UA/NX.F7X:OIV[=>B^26SV<#AP9[K&Q.\,O+](CJQ^OGY>
M_HO/WWA@_L"3;W34X>G]'X'+%E2_ A1^L^"=21-WU.'A=9+T3ZS5]&=./6/^
M 9:WO>+1N_J??[_T'A]_!:PN2Q>8/&[>>,^\ N[OB_X:>/L?'#YZ'PY/T1RJ
MG?K\WJO8_V681G]"I0?S\<;E]L$[^T]D.CH+-CS^ Z'BS]*"+YG]'?=*- M6
MWKL?CQ=> ;U_-F#V-UK&E*J?SQ^;#1ZEEC_Q.OZ57.G^!:^'E__ 632*,VZL
MBVD](V& L[F(C8;55A-(-':KN/39:I$NOB)LGT\+*;[>E2K\V*-2CMYFF(.U
M[\ LK,"DI;M36K#.O:#W%;"Y6Q+ZEZAW(29\#*M$"'_V.?XGL?S6Y7A\VM\[
M_5>2? A!_!WDH_J0DU8[/^;?<87]FZN;9-EAYW[?/UNI^9LNS/[>2L%?O69V
M/[>%_;$LM]XEC]=_KX/G5<AO);P"MG^OVHNUM-?IT;^4]V^5/$_^V551W#7=
M;?])[_])5;-,_R!9IO^S9/^@:<CD_YY3_W=I_B-[?\/]SZGY%_;^/C4/!?ZF
MX%? ^/C-\W7:GQ3\NU%[!7AG_)TOW[L_^:)9\+K[YVQZ!9A%"A8\_"D^1T^]
MWY--_F6Z_??JA-G?^/H'+?<K+606KK4C"H[7_2'%S<[_1)CY/R&]>@5\E]>-
M?$CR+GCZW;0*7I1NLUWH?;SO\^(7?*'YKY69\<V7V=,_K]NS]Y+]OTRKO^--
M]4^(8 ]>=F/_N6[]5Q*TZF_4&-$L@._.E/YJQ>//J>)F(F#QNXBR_U=SA6;!
M.W7J8\ON<URWNUJSA_+?52+9X=_2_D]5E^VCR>/A/W#_XS]QK^1PE!?;-;0=
M(+F(9)4/7$^ W\X4;>.O[*:?'D9B2I0Y[Z=@:^?<J[L<NMEOM5!YGHP?7QP/
M#%JYTR7=^&RS9I6UZ10UJQY0@[@PJ:6E#N0P=R18/E3CJO;[,IB.AG_0A@06
M;7'GZ35=J2*XIT.6U1$P4]\,[^W6J,%>WDOE:ZS  $_R\/6@769^2=-?F[/>
M:Y!F<J-.\=6 0);"Q3S?NLJ,8[,TB%\O,K@M&ZWS(LG9&A&P@0?76HX@C^H*
M=A]K7@%:$M"HQJW%HLY#$K5AE6P;;S=A%H+X<ASM4L)(0WUI*09BK5!Z"6-_
MGEU\I<[4)DF-+F91J)&.7@G-55/@90X1R*;;,U9QS3$GZVC!KGY##J[ %V?-
M"H^*  8B(;Z#E/&7'SHEH@XE8 E3U.S+9MICLJTN FW-)\M<'$+V%4]6MAD9
M3&JGR;Y!9-Z5V*S#<\?QG33BG74CFU0X.#5;R/LI:++I]W%^5GO7T]NUM'ZW
M8D9@%LSR^4TPH#?+>1+V-),<27YXH?=\E+YJG$)9#5BG =EYV8_7.#W>KH_B
M&Z4<V(9K#QTD&QH)Q2M.)KQWW-)_WT0EZTCC&!%WJ"B$E$A(.\E4JY6;LO&R
M.PIB$LU^!]V[/-.[5:W5;8;$PC'3\_*-Q.>-BKF:H%E]HRNVT7M=>Y['0#CX
M-D/;:AY8J]J(#U3+I<[&<2)S,OWY+=JR J:YHALC=D)ZW4PK:_%GI/DH2JN$
MY,T:*;90!'K<$2><? ,A&X0"I:31RE50?3BR6=7<A4U#X04U5 G(%GSW=123
MM15\(-TY[3HG;,8$S?1(T;R]MO@1EM:1<I!1E(5":=;<^$90);,?6O=IS90V
M2BP5V:S2<F!)E37/7*K #Y_OFB.P#?.:*P*\H7#1#^[PK5D7KP!7WU1U@XD3
MPL*93>HSU>/2H4&:!-%]PF&1KI:&^I8G_]$L9Z5W^)9%H!V7CLXP6DXIL"XE
M D)M-=9R=%CO=J!6RL""98IJ9 7V9%TX@E;R>JQ,BLQ'S;;).L10^J_C!N@V
MC%<U KF#>(,$#8E,5-@V[_K&CT[GFAA*M=<%D_)%=-J4NPIBT>"$M4T_BYO$
M0RY$Z$WI-V6,J_CS[/S\47F)T<ASAJ!L0[%(<7F[MNS'-RG&&#L;OI=-!O68
MG.#A;$J)UOCCP<1GI?HA4"%OBU#;-N4:[ 5'TKO]U'%BRS7/)S2EJ-<2L2W^
ME XR?Q]L_4-#2RI_V)TBX@?[(Z*6<VUCBT\%UCYW]=(P[EJD <<<7?_^?_,U
M"XYLP9]^F3?#/68O))R>-&H,_W]X^>,O@\?=\2N@KO<4;A'/-??7)+(9O-^"
M>U)=+L*8*G1JZ("SZ0"= Y@/;I"/RK1!:_IAF&]\=O&CW*_N@HD&CU]NF!QE
MG R?#V!6@\F+NBZ]*+D5,<=.6,V<V,);V_+;4RY,GH@,+P(GZ#[%"4KJ27&I
MJ<WVC3KDM<S3GQ A/QEYO@&M<Z%UX]N'9327>9?#T5SU="U_&C_)WKQH>P5\
M>3F]\GJ),+NK_9@^?LWR<J[K]Q1%LOU[:\C=?07X4(UY:F9=([U O+51E?;]
M(YT;'@NY7R*/*9<%6W)NE?XZ2V[+!T7P_I*)Z0G:R\M[5]:[AKWC\8=OPHU-
M5]?SLN"F:/^#-]2CM_/+,\K&+R]GP>G^QUZS>V*1S*L=W=*+7\J/WN="XSOW
M^\\V0H+YE!\['@L;3UX$F#.O'*;^ZD/]10+->S79R_L>FL>K]2#S:%3P-YK5
M5\!$<*#S*R"$[K'C^<-+BC>6WV732[[@"LU3%.EO#)^,M_\ 4O(*4'X%@ 3_
M1$#W*#;1XY57\(O[BVK!^5=!OLP#H^>-FM\37@$=K \=1Q^NT[P<GCN*V\.S
M8:UI@GNW%CAK^',5?@6"QX8>'CF:;,N"=.H2VN$?#DF<B8J''FJ?3:JNGI'<
M//%=/2;.3!/H3]:ER-VKPA=QRFUCPS:Y!_OKVYFF0?S=\NU5*+U8:HFJ:3(M
M+AG6?-T=8"WP<VK]"?<8JVU*M(I*P?\+_=%IFKU#@&7X[OISMN 2[Q$ #JMU
M^,QGA,NAVDV I=^[-U<AEGVS1WV?PTJVS&,94MC@-J-]IL,?9@P>6PI;^V:;
MX4*.^IXW&,ILYH^_UGW3V4E&_%'U,W%T1B7<>*U:&3MW]$8]'_+&D#.;;?>$
M;1JKY/N?9Q@X/E;?(K?-Y@^7C3[I6Y)".Q7-;HH\E(4:1$(M^"46%S*>*- &
M,'I*:NT@FEHZ"'&S%7K4Y$#C;PDWJOM0_1K@N=XT+Y-E[S1S8D%#_/!3#2HJ
M:&'0WF??".?:[%/QX1B-T_2XV%YX?.V:/($3>0 &2OP0!NI9-ZI^/UN8:/C@
M*F&,@-TV]A",X1*CQ [_.^==!%0G?G=EW :[HY]M6BZ3YC%<GB$C)5'PAAKQ
MPH4'@^-:!I^ATBY@[M-SPI>Q756,?#^_0Y %WB YOC=>LSO\ (ONH8$]"7-M
M!)CX61#(APW*;%U%<]INER?$ZA)""\B(#>Z%GJHWT\1.S:$R7GY.XW!%G7M$
MF">+G2U;XJQ'=(PWIDA"_6+S#89(D3!>ZU,V!EB,^21Y.^5[#<Z0_ENX54KO
M5!S:O, Q1&,D@N(&A<[RM7YZ^WZ"LZ$%H_BR!!XC=Y,(]6UPJDGX\90EY*:M
MPA)R6W?LE:J:9Z5J_K?5UFV[2]D(-;-@2#N@I%C)GHTF.0-45[*!+O"<5I#K
M3;8&!Y,[9G,XDX0-B%.2SRC7A:F?ID?-,>J\L2K=)NDKU\<2[%N@FZ6(+LBC
M0^.-_:-:+=Y&DX0%N+X9_"F?,T'F),>@D>_@F6-(+2\BB6\59K\'"T5KE"!E
M? D+9E/!6MYL,?B\HW7\;2$247AI/_]7 TLX-".U[>S5\OM</"?$&I5W%1_[
M=]5ZLMCZML%K9_TDCF'AJ9.C^-1E:52ID6K&JD&'\#0V+GFWTHUH7[#4(EG?
M!KX1#O08*,#]S4F3H[F- 8% BZ&A=(PIAQUJP'7"?"[96XMCUU[*:3-^DNZ#
MYBM#;2$)"H.A0_8:(D<)_'2 HU8,2?UV"*78&(2A)(F##C;=]ZL!?@SDHU\@
M@@.S6 _<=KKP"FLV:->W^$O:G#>N*UQB @IJU)Z$8.R*! 5<B<LD>!WSK:J^
M4C1-%_]P [.04)Q!AG4#09HA@F5X6RA*V*(ED.17#.^B?OA*HWDE"4&:&;NL
M4%%:8JU,Z=[4+M-;GH_5?6\H%;HZA2,TX2J4</)9#TMK;BZUU)<;+<8(D?@5
M/R_6?^:*4]@W9?W=,*VP>A+H_USB+;]1H>Z2Q<%%CJ/Z:@B$XL8= %2HPI<(
M,'3W>)%3-?=>X%$D],Z!#=!=38==PPJ=\L,/@*6:IGJX4HU%\,+HBI0BP+4
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MZ/%WW/P7KG;N9>#(YXJ36[T']U> <_UT02&29__,@>#B^,[AAVHDG)ZPRI\
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M2.)QV-:"S$,.&)N+Z=*/+37O3;Q"-9=G+J\GB[672 %H5,G*[W^4D$&_VP$
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M4Z)TZZ5*[;[*<_%K<2'>>AH>MXW +,[KGXYHT;Y!K4GZ(QNN)_X+4$L#!!0
M   ( .R)95ANH0*\]SL  +^(   1    9S4Q.#(Y.&<X,6DW.2YJ<&?MO 54
M5-_7-SYT2R,A'4H,,)0TTBW=H S#D,,,#$,K"B)(2THCW=T@(MV@M(!%*HT(
MB@'O@/'U&[\G_K_G_S[K78N-<^\]NS[[[+//N?=<U[K',\>O 60:*NHJ  P,
M#$ \^@]PO$DMJ^N 0"'<'1"N+,+\@@!Q!75M;&P FJC9'AN2G38Y3YH ,L!?
MZ%0F>7JY_4..<=HB<D4ZPE$Z'BA7#Q2ZB7/"TW5'&=@@$+!3#74X"@J%>[C\
MO#XY*\*0)VW24UL#1^\3#05'U(G-'SZAR*M@%ZBALJDAFH4+D ?H I0 0(#0
M*>QW4UTD F%G $5YN.K8.$'0;&*T$A* 0/_9 5@ !@ H  7P +B>FA"Z_M+^
M&;T"# 7_$1NQC8<C#.4(/W6);A.<:BMJFVE^[[O4B3XF\$]]I_BM[SJN*$<$
MW!W-/7_:0U<4_&=WT-VU0?YJZ-N[:_\A0<(5_VC 47\TM&Q@[K\:5^U1GK\:
MRBXPI5\-=$;_<*T <;;_D8CO 0+T5144T2>LTVM;%A9;A(?-%<3K7\.JBH3_
MC:< ^[N> M+6T B.4F'7AZ%^+PL%F"W+/_'UW6&H4[ZN-^P*\LE/-J$G%()"
M()7 */"O^M"UUW7_61\GUS_.BJ=)@-JA_LF](;J _XEO (%]Y^LB(5?,?K')
M($B$JXD#%#VXZ/%RA-O_S-BY$X$^.B8%! J%<($AX/8_3(A_2DY"^(U/\I.O
M[VCO\+N Z*< '=LO]DGE8&U^CP$0/S2$'A;,G^?3JN(ZE9W[HP=RMW_,-9+3
MYLGD9#IMT_VYC;5WVB;X:8=Q:G7Q^[PE_#G\WU&P]D^OU0 "=G9H"0Q]Q/UA
M])V3E9SRBR-T>C0' 'YQ1$^/P#\XISX_G5ZC9]+Q/Q+6VQ/Q_[SL-!?X/S)Z
M6N:85[[_?LB4?LDP_R9C^I7#[VWZDRLL^5\]^TY1:!O54YXMP!W=0T'TGS#@
MUY3Z$_W&.[6)^@\4?M$?"P@ [@&#?0\5@&N#\(#;NO]E_D)0H)\AGQ3];P4'
M^$ME A3^J.#3,/1_%>CW[KC#'"%0=V.8ULD4P_@3#LZI#'U!@?[AG3;4E7[S
MC6>/1'BX_HF%BT ZVCO^6CV5#4Z,=$YYZ#8)V .%4(7"H4@P"FI[&KV/Z\_;
M .%WY1/.B43=Q9[E_T+_L3R0L!\WD]^2_V>.MKL]]$\<7# ,90BV_Q/O' 2*
MMH-ZH]3=U0RUM7XN9/@_V7]2)G! ('WE88[V/S-%^KWS:C_9)]FUA=J!/4Y7
M,@)/*!+U#^K&/]E_5B>RL5=$P!#(WY)+_MU 0?67X"2,JPCXR9D A7!%WZ[<
MH;\GCA"&3N3?N,0VITOBW_A$R).%[R_LT]ETZ;L=^H<IMP/X@T]^>HGQ?87"
MICIMG0PHSFF;^#2$[1\)BT#_V-"7N0# Y3XT?QQ "\ XGCG>!!#+VR)LH-<5
MM0&8QUN <Z<M@.WM$[OC.4 0@!@?'Y\ GYB @)B<B)"(G)J4F)B4FI:2DIJ2
MDI:<^)1^G/Z9,$B(B$C.D9"=.T=&=>[<.:J3PSFJ[R;D_Q4'QT\ Y/CHX".P
M,-@ F.086.08QR_0'24X[L*00T>)@W%*/]*(!<# Q,;!Q<,G("3"^*L0?7?
M^BDD V!@8V!A8F/BX.'BXV 1"Z.%Y%C8K!0@''D],"6;6X 0+E5,5I4".P>U
M?KN-L @R\)DB'F>LP<Z;78B[*$UV]1TNI3A#6^6.')38^3&C!>C[FJ#.<8_%
M/96+\;EW:Q.Z)I8^Y-5U3R[O&]MY!B?FU_=,K1Q<5C6Q]PIY4-#0.[WZD1R
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ML3Y\6?.*S\VC\.X%!497AV=A\1RHU$OFM#X**CB!I (#[L][O"X9@_BC@AM
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M]U)DF*1@ LPH )M\$QN\ BC!Q,!FN-,G[0<J^9A]"P,[G7F02 .\L&OGYVS
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M'!.X4[M.-715LCX6]B0Y($1&E\.WR=28?I9/GC("JH[ XE0N4!2+$-8G''H
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MM"1WL51LUK*^S=D(J;]87%3':P7UL.C2OHIGZ2REQG<]&R0C*PD[3*@?O/1
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M3E!])6/]7V _#'20"(2-'A3EYJQM[0 ^91, = !( .+TQP; !- #0 $H@!O
M^=SDDO,O[9]NY&$H^&\1$5B[V<-0]O!SEZ=EO'-M!4T3]1_9D#K31^?]4XW)
M_E!C;6>4/0+N>LJE/J^7,PK^LQ*GE;1&_BKHVKIJ_BY!PA5^+\!1OQ<TK&&N
MOPI:MBCW7P4E)YCBK\)I'G]W+0]VM/TM$3\"!.BJR"N<GC#.KR%,3!"$F_5U
MQ#S@)ZD@X7_CR</^KB>/A.@;P%'*K+HP%. /) ^#,/T37]<5ACKGZWC"KMNM
M[CWZP;[D#@6C$$A%*Y35KUZA8ZOC^K-7G%W_=E8X3P+4!O5/[O5/!\0_\?7
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M77@9LL,77!'6.C<U?XWOI*%V<MAM]I%;R&-#=;BIB+0!V7/&^DY-@:"W^&K
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MP."/UW;#GD-7L#=#QZB#;V\?N3F5<&8LI<24R];Q[L,TH!AQ+OH?W73+&%J
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ML+\\]:'815F(JMLH@NW*E9>:5,;V"Z5<B&JO&.&:>X#GO(GI?(/$,D,<R5P
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MM/DR^+8UB/ 3.X7QYFX_XF_QEV#<Y-^Z<8-OKG_4+_YHXS.\&BA<1\7!&5P
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MKG"NC5&#_BZT>NU/B?F"1! NV_AG[CH\"%.>/Y:,V43,>,36HU-J4"VPFY7
M%L[$^/[GERT5_6@RN53ZNZW*B5;C ;PNK>]UGZ4[DEPSJ$*=9D(\Z7):4[S+
M;+=7ZO3<#'B8B%;#%'VYS?MI,^_#U_%'M]\7XMF?NZE=UMMO"^6U:,IGE"*F
M,4UD9;)LA=I&1ZO$,"XS&W\MNA:D 8%N\&$#3Y(J\8G 0AK>SM%S+%*1@9%1
M\&AL*9>%>7.?YE65J64=BO/@(TN8/VPSH89R 1*/S%G@MY?^[.I?3;)LO="N
MWK RA!UAV >?9=-Z@U\0P8\R)^9@,26^(815,T#N.R)!4.OM*=S-/1'4B_\J
M5:</00PAH9\GT7=%0I1J/W?BHZ.-+K@:%%T_QM=?@[N*\7R3 :NO2>C:HPCO
M^N<R1W=-2%-SZU*J-V@2U6TS.$DBJ[96BN;D8(=(P-)4^:-4HK/$,/*&H "+
MD+[0FJJDW8"E'7QE/C >M":G4Q.4D/[+NSIA& B&2!RBLI2 :&4H?.J@%%DM
M%SK>@#AHQ]"N\1Y05_MCO).MFXBTTMH.#]W-RJ,7%]M,>060"?,M0=8XG3^X
M!_P^SONV6.YS6IT& IT*:C\Z($PK;2FM,FW*+XQY5IRK.*;Y&I=Y"=AGFA4,
M)]H%3S[Q"0I[C"&*C<!:MM0QK?"8<3P4YR %+56+<=A4>=']!IK$-9.!#" B
MN4VD5W:786ESK/J9]0$88U\"NS6"F"&K5;R]:;S*[ZP6NY:/CAZ[7*\V<]2D
MIZI(TE-62E0;$=\GID3!(487AQA+3>;D ;]IY!;925]Q>=NZ#Z^M^>CE!1:@
MX]/-'$X=[+C<[F:[KJGIJ!DR .+HS@PVLV]U865EJ3,4:+:KVD_;'5#?4_F(
MDOXD;!U;W$V3%>.^'M\2;!N28-C*[Q&!"^Y*+T9EPA%<XPPA<Q:5!',.[*?3
M^<CH\Z%\*)!(%0#Y4(_WC,W6(C/X4XB#1+QZDQ#C):$L/?G0&ZKR9^#9FXEB
M(EOX-[/"7?V[1'DNG^.$E\+A_&X)-??H]+#9\#HFJU4;Z'+./*1W&0;E'JHD
MNJIK:> 8PS\ZWEX48.>AZ'?X>;_^!H!:[RXJTF]@]#3Y7@>U;PH[@U&M3VZ7
M'P@DF-SUTC[^I_Q4/XE215 S07>BQ8O87R\%(JJ9IA9::1PFJ3",<)4U$W5X
MAA-MJEDN3CBG<NH.2A:)&<GF#])?+,8=C/:%;//?9V=XI40N;<Y8Z;N=JU2I
MI\9(P6L8BZJ1>KG%'J)':XEF<JJ&=_)\?)+)-Z%04@UA9MSW]EXY>2HO?9_H
MF$H3?R_B"W=V"P7UXHV*BGJ1=[)80=VVV^;X/^W>!83,AE@-?X[/ZFC%RQR
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M 6CM:'/SS6S5<:PJ4L%UU_4F6^NKIM1(KT3K2F4EJ8N4*;Z:DE9-I$-O2IA
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M]IN #& <BQKFE5:2V4WL4X,73I+X[VAVJ$T^8U734E-:>!CX5A0)^!XVJGW
MB<"1HBAME\9E0FODY(S(ZY__#?@.V<CR7.PM"QLXOYJT+$$%.&(/*1Y\[N;@
M$+"! <,ET]KR4UQ;59-E_'"KH9&KH-6HN"PI4+.<QXM-B?[1]E-#CF+^;OA^
MM%'$5KV(MV0R[T3MQ:]V?Q]/>0530@K>,IB]-Z1SBJ+IAUPD;X!U__I^(]]\
ML[[M=%NM',)>YV8&Q3W0H;E5AUT;]A:(]&W;_?M&]S7;W7;FC((62Z+,\B15
M4"%=?VOTX(TM6J2<Y'0EJ-U0"]*I2K9L+CNVT"W$/ 90JO'7F:I\]?5XH@M
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M:6Z,+G_07/(M_"9:&4X"0P>(!\37%0WOXA!R@LDF?8ACX8"Q56>.)@ &QUZ
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M*3^OC]*]1?.*9*U\(Y74,#\LP^TU[W?=$^B,X4!V=]5,>VQ59^ +_/Q:,IB
M:V1J[X.WR,J"U3#IB&@73]]S'J#_\FB3!K&?OV^2GN)5R;NG%)^^09:I<]--
MMM;4Y1]@JQ/[Y-*D%4IE/IP6'4K?C B&ZMK<[OUB=9S#4>0VCG7)N\R=E#RJ
M')F<EGL^3JKO1:R5Z ^6U^_M3%U,Y#F[:*]G#GF/N$]U@KI+5#'=NMDJ7)#&
MD1B7EH3P@V(H)K$E?O)KRAKSV/LN@5J242>3$(&@$R=YDHM)&XA@[YB>A4:/
MA3EY,J*># TBO41=1R$8D?N*>?TQ/^&'-<YS<[PTC?*^[#H/5*R-%,/(;X"
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M*3YZD 2):Z'&QV:QY!Q<SO?:QL2)*>,BD2/]V'0..D6_17T5!3@N0<QFZW6
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MN;OMY1]*K5ZJ/'!^K-6I=_GSE)Q3+$RWH=4^K\B82L>4!NZF(2LN?!X<F/B
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MRE?;S;NU&=UL^ZK(A[@/_@EA(GY%'5HKZ/%E2%[RW#0J\-P\GU(;#&CUB3A
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M$8CGOL#.=NN\42)YP_/7D+BZ=_56A8EBCC4+XQO)>%'K93$D)%!?^KXMS;W
MNGXJEN82@!% FL]6MY&[:DY > ]\L4@"=V(G8Q@OZI[&Z-FPK#ZAQ[7[D)"
M*"OY4CZE36H6DWMM%XX$'(;BK'PK(CTH%/+8"/M,FG*_T)'Z!;/7B:O.K0>I
MQ5A_3L90AA[;;AV#!5".%O3E;?PF=AP/\3)J4OB+X#6F!1H<V+%ICE<*,:66
M(_/U1'BS0.QO$,RQTGET/4F3.6;J@I[Q[[RW-^',[_!:$&N -@O_Z52=<5F'
M2C.JREY>:JG*CJF%5$!APLK/@QR#8/(AH@S=Z N<H%!F"&".#]LY(G$W,""4
M"#F:>B*D^0HRY4)RHG'>^95->&^3,B& =B*/PL3XR\.=,YE#3QK'&9:+3VU
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MOE@:JY4UC\B1'Y3D>K3GY4F-&GBL:^S%T9P/,$;GP_Z#KV@R6X\CY%2.<CY
M^"T>2\JD_<GNY/Q;*.S?N^3ZZRT<#<H:2R7 =7;7EE:*R/W2Y3^X"%$T5E86
MXM@J(V%V)R8!N"H3A."OJ\X\FN^)5>5G.)IWK>Z]1K_?344;B+TE^#?1T9#[
M1U/PM2VI$@K,CHT6?M!UX&Z?8K+&T-8ZH_;C.:^Z#;L?F<Q$%J-3T=R+2QJC
M7V:/\R9?L^;_J;AH\T=L','H\4$<OR5"()$!_5VP!-:8 7&Q#/E-[-E<PX5
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M.#+&G>)042M%0GS(F2+RL_ORD@9UDUGLCPI J>H!_D]&^ XS5IGG%+,3,H!
MM_>5TGOOXX7,!)TX!]5;7Y[('_+2/'6@(9S34/\I-)NEG4;FO035AE8UD'!6
M.654<G^1\YV(A* 4_P'QQ#*%](^QHP?WT\NCAEN,TG\@A,_C3\8<>N<!*6O+
M-7=F7, %Y )%OF4&QU2^T5UQ=5D>\*?^L86C?F>!2#MGT_J/IK!4,KB/^["C
M$B58,AT(.(U +OM7@3P%?Z+$FEN%W70,<<W<P9P.PK+-7DF=%T6.%#7-:=HX
MEE88)[T&%K17:WFL16'AE%1I!&U&'+\O 13?6!CZA ?VDMP*BZ$S*]<3YE\%
MVE/4&T!?:C!73U(*"5D&=)I$I4%53.AV>#*B\C^F6 QX=$ATF$]D&Q.^)QKM
M#W">Z1=66MIKJ'<<YY!_4J8VS-KZG662IANB1+C_Z56LOJ5Y>A^,6#G64C<5
MFD4V[TQ)!Y8ZAUVB$#%%A2$WW/@=;([%(Z?:W>G4X.0HQ<?O!1'@ZV"<)W>M
MS?J5 R=\K190)D2 W%&R-;"PNQ7@. +/;YA?R?5?K/38J#BB"94(?A@4=91+
MT+@1D? [C+XO7P2UD/.W,6&;52L73*&QBG0#*T6#PQGZ*=J1".!P/FU2F>>T
MPZ+:KS6_WZ S5N_?U,QL^$:I=L@4L<W_/J)*SV8)G:66+KXNUGWHQ\/WRLI<
M8') 354</KZ87%=G9L?9Y]6/I+,9M+((PT!X0-6J$!4@6;/-IWUKON^F\Q?B
M!KUCXB)&,AWF3DGG]JQ<WQJI<1U';Y>7$?%^O*,[E@M[!>=[Q89X ]N5 JT^
MZ!VACZ;E9$6[_N67#^K^YC[*>\4?H8U2M\KTV3H;/%6U7WK8J6F$4U'._+:,
MES2R*O+7A\]0V6Z.L"61X3,238P84#S]?6]/&B>1HF#G\#<-VEDQ^='.68#+
M*KC"Q<6NR9,$0>!NDX;S94:1=SORHG#E;J2A-(W_\C2A>/4;P%J2E),2O[FF
M)J!(0%%AO^$KF46O"T2?LNX!F9$ T9M_<_'A-VSI<BIN,B3F448=C^)AO(6#
M;GL;(R&)U>O]&LGL/N&EX67B3!='UYE\RD@'/]BV77__UNI6*<?C4%:O[;;C
M(*Y%0:*>&4+_ZC]G6PG!G8M',;<TQ#4*U&XI#*;&FIJG(O!^:O?M\>WBY, H
MZF^X5^H3P1_^U%?"%.'M'0B("*\MJQV [V7)G2^;.>BNVIR08K5&R$2':=DX
M9VL)7F*?*VPE>9^W:S<1KDRM07>=9A96[+FXDQ/;5ZNIAHE/P63Z96)&G6$Y
M BJ+'ZRG(U!&F=%ER=)[S>L#:CS3<LIJ8FT"N:[2^XWD-6Z:?M1(&O4[*VV+
M-6.+>_]H92= AD;4%/38RWER;PE+ZBSA%2"?Y>E#ZAA.OBM5QNMS&Y-'\  Y
M?& X&RWX9[:'JF *.RLEG/#R]&@8-9&3V21*03GECA659KP432N[3D38XPP[
MT9&0ABJ( '_P^GD7M;-Y=/4=IOQO\/(6E.4M&S;,O"J8):&6X2Y<&/C B*T2
M098ZL/QZDAPB-EN8E>$-GL?'CFU3P4B\@=I0\37;3D;!_HCA\+M\#*.TQT_Q
MB,[E#>"3 S*#O:FS/6YA4Y <D5PBSZU)MK>T'80^/O$+W#N\SBJY=%C4M@^P
M]?0/M-&PE.%P:0]I/H49A5J0RGH#Q%3N@K8N5S!IQHV894SBS)F@ OUG4<[@
M((';,G\??\PXA=P2M)S?<A'!K^J2LT/1UCOE#+G^_5(]YN!P64,OK:J:T;*:
MGSZU<.)]P95LGURM84R<ZXQ-SQ4R\8/:9*N9#O<X#^^>(,6FK3QH)OW^!KNN
MIUMXC]H_BGV>NK5$/2O_);O2 ]*&@9(2P[T8DRQ-U3*DH,!UTNY;GRY%^=-C
M<J+'LSV++A[8$79V2$T0P(ALH.OS4 E&U(C\X[;C J6T^+-U"_5SFX(Z6RK$
MV-/B&R?LM(%F80T.72]>D?8HZFWCOP>0XE_F8Z$)9";78_R2-"Z1:+(CT^PD
MQC'<'T$UT5^79B#^Z NUCZ6"9V^ VPJ_0*B'5Z+6W5#2N^O3TZTIC;_/*Q/5
M-;";G4;%COUSFN;LX-OI(1O;W804N_*U3 FNIIEV\+!4FT51,C[J2G:@9DQ7
MN#2GFZ,G"855NS#,-5OWI&=)-:F)Z0>HZ_-/Z_.$+-S[I[J3'25:Y#EU)AN%
MB:ZCHN]LSDO S2BL:>3-H(-,NH8R[DP,7P%HU,/#P]\OCF7"LMOPL?*VU]37
M\E$IW=O*Q+[EI]&,/QSZKJ4459[/*UE2BJ8$.(5@Y(=PRZ/"45BN(S'X)*E.
M=Q=FRGCJQ1Q'W0R*N;G5PIEQS[V'9B1'TX\+3<_2D\&+BWK] "/+ALH:.MPK
MMY$Z#,2=T:'K_"]P)E&A^FR$W3I9>[2'"SD.= [BKBI8##HLUL'64I%8:/6U
M:"139*0&G+Y#\S08'S.K-UJ4Q;"E]IG%@!2N?]0Z.2K41VIU  I18.#K]__1
MZT_E;\E<IK2\.M7[,39CUW'/M('*RGS9[(C.J#=4EZJ,Z-==H?J,=_J$:>/Q
MOHW=K2.L[?-.]>=L67PSWS&U)6K)D>V)-$%!9''+7C-WDTN%GV'9-78XT6KT
M8=P',S!X&^SK-24-4AH$]I6=0/,H0^UIV>DIY<W5DZA!+46]]$05%;9$,X?[
MP)_AJ-Z0W\(M6XJ:HGT^#X&TYNDJ'<O(:#+)/H_2V?R\J!"J\#(ATJTCJ)=W
MH7 )=SYIA[;I3KH7IF"DLQ5%JY+2Q07G5/U+Q@*,4J2])[%(21 ;N#)@VY[[
M=[02]5R>=/@42@D5.?PU%Q_HA:XB^<6>>9C+W5I'/(=%B_M2=>(#OL1=(U>H
MQK/>D/+=1@2] [+#F-'7-P#,"9)I36<KK]K<FAX'^7+_04++8)9AP0$Y6I-0
M(0F)"@ ^PM.'L/.R9N2/S26JY3JS,L7],5:-U(N+Z3[_C!UDW=*46^VXAUU+
M5_+/-!LMG V\/Y)C;N\S)>\; )SV!DCWG^VG_0T#PPL%!06!0@Y\#9 C*5BU
M9>*$MX2 V>3<SC"*W#.E!V59[$GQ7X#'&>RZ'5;G[,K:K,D#JPK"3Z(%1T)1
MM$A?K9VGU E.EY>11DI]I3'M#8Z/>E9USA-%G/2GF^O&&: <:]G$8 ;SM0U*
M.#98OKG[? B4[G86B96L);'->0/4,J+VBJ=89[W&U.D-$,OSQ41^;A# V!B1
M;(,6Y8IP&<L^LZ^H_&E.J9D9_)5D"D%*.XR^>"VC7T*Y/B";QJR7,4#P:]@;
MH&7?$H!"^(A"&"+D_>?O/O#5Z7$ 49/K;PWH@]+MM-U]1LR3.KNH[XD5NHW%
M)[:+@>!6";MDS&7-J0*9GM6,S51^;"$'+%WR:M@88N1F>J4DM/B4#9[YSO=&
MS?RQ]@VZX\Q45UN[S?9['-=\<9TV+Q33=CJE>8OG-7>5:#*:MK_8%PVG!_I&
MI:FY(%=%QB1C.I6+JS)CXZ,Z%H;UECHU&D7%N=("2<;8:$OC%WBE)M& O(R5
MZSU%^G:OK2$=%_S&610="LU$CYPTP_+C-JTQ;FU;]SI#]5<9,M9#5+2ZZSH-
MV(06*;"=7U!61V>'Z4H(O;6.;FX3TQ:#6Y^,HZU@K>!,0)Y,=VK32W?'3G6#
M7]IZ:$]W;B>[3RWUE2;-@DS.]89*[11/0H.ZR8_J@W;#U)BHGKZ4Z"6]EIKU
MU4DQML3KXEF+K-]H6B%X3T-Q!M@/]'.:@=#0&(C\X6/*+\A^;X"+R*^GD-_\
MX<^O7"J5./]XNM_P6 4OJCOLL]!]&\1(%5=;4"=79<+Y*%I:\4DT_J=#K"K&
M$+,?#,\E?!U9^&=(H0/AV%RDT:)JK08VK<Q)9!G&[6DG*G/08HQ^/7:)?/4!
M_@3^C7L%>GE!K"E>H\=[3#6%/?>[FQ5O*!5X4!(;&@V=ODIKEPH<4TK3/"F0
ML3^\HDLL+4;&.\'8U^1>=K_B@Z2-.4#.DNSJ7H620>@U+W<3;W:/#]N504FY
M:%DZ=B&Z\:B=E4$BC&$E$H=F?@;IB&K8SH.!##*89TD=E6BU)G4E!.#.*%M!
MF3'H]HG//'Y )B)H__!\+.6!YCQOC]<;YS_V1&E%L=\XK!#O-M>/&&Y=$YR,
MH?P^074GLZ+<!9]?QA2N!J/6ZB_I%O[\X.&1C;X0K\##^PJ)+@IRH+K^D]P1
M3#ZV4R91NSU=G0NTO/XV<[5?S?1S>29*R#E<>1TZ40H,"D%YZJG953J.#4B'
M"8D<O19)'G)&:^/K17EK%-K"'$Z2Y(1D'_C:G_V)3K?I7[*3.(XOR&VE>3L)
M@./N$]W?J*L[#LYO.BDLH.B3;"7*S',-C?J6+JZ.UFA"0NH'A+1_DA[0UJG,
M.3G"%Q2--A3C3R]M'QY!3D&).3@J'4O,HYEA<M\*QD41I @\7 $>[Y%1(P@B
M'N$LJ/Q* 9!^[RL=RCTKQXPM.^Q&"$&<]E(];BIF+16^]>?,G%P0;1T=TD2M
MNV_HF'Z.03IP2+/R W-ZG'"W5G,6>7+#]]C*C'>2-9E2%0O]7XQ/PM\ $X.;
M6<YF$@""KWQO /:+)^(7?NS6=NA[\&J8J5/."*Q%8RGS!?@IDQ0&K_H.1M_1
M&.57<;I?".,S:WH7GH>M9/QSFL4_=/;^32_8ZMK(,2C-&!5ORC:;DB2 NQXH
MQ*WV079 &9).4X8(A.?0>:4AM= C^5EX>/BOH9C=P#W7+[$F<Q'<'K]P\\7\
MCJ\W?UWUQ?-@YC!N4U5U!/].5I*!=H6/"#<-I06'Z.$ A(2\CX2$?.[=0;4!
M6?#YMZOYBY$]UBP\8*,EB,!C3IEN-DE%#,JQ_O=EX@VY:A*&Y*4<5B_;2%8Q
M,REI+$2VNCH9;G&3?:EDE7(R9:'KNYL[4)<AL1%=44UK8UJJQF.KH\9$Y>U:
M?L6NB:8_(]#G?9'9Y%=TG?'91@^K%=U2$<1KE$\JEC:!Q'UD.WX+H_%N"GHS
M@K\$#6_M*KY PW[J$Q+RKX,@"Y_N/CJ5.+E"(5(0!<*9/@2?OQ!9Q>7_D5RB
M1>\#?C>:C5IP94N2(!U,(0LISD^=7AKI-KFI[/#:Y'R&1$&Y=XM"@4X 9C$Y
M@,E]E/K8?XJQEH.@V7+P^I.ML_W3^T,?<>F+400J/'J%BKJ,'XO$PZO(-15/
M*AZ%*[33I;3+!"/5[NJ"FH;F*IE:!\7D-,L=*?XZ^F<5XYQ;CNY^/'%Q(J4:
MOQ82.6-$IH-KB$34*8"-:RUSXBHV]%XVG=S\DEX5!K3*KL[?-YA\N]Z5 .6V
MMYYS(55)6G>([7%:L;.2#;FMEW>7AZ=EW^+@K["NR(>03D=DY:-2'W]T5'0%
M>W:/)6-D.J/H&B8L@ VFK+W[,9^_!S=5+$GCG?':U".^ 0[14^L5T_RO.#\E
MD)#CW6PY^+82(9<QAE83!Q275-1@UG N<Y@ADW!"A*-7RN7MO1:4?%R>/A>V
M8"!Y0HNCIBW6-1]G^CR4J3@D.E-2FB;44)PWJ8D8TW1<'36I%1L*Z"9!#B_Y
M7FTA^CJ7![^)(F#@]DH) N-,WP!ABJ">D5E_XM.C=\NH&K_^AZ6SR>,DR5&:
MI5,W_6:GC#G]QN2(3O-Y)9@R>3-,ZD2U,*KT4I(09CE8%"9X8ZQ6=JQ(L")'
MZI6,0W8<;L6<AME,>=4CQ;C,DX\N>D< ^)2A2WDC6G<%0X6;:R2.S)*JBDPU
MT>4XD3H(G6840Y._W*VZBP\Y=D, *(>RGEE 8J2,R' ?)3E(SFN(5;8"6&7U
M0R/H&%^E:N%&+UF!CNP 3<;FEQIZB.47IJN>WCSXO!)^F!](RCQN#)OK1.+%
MRLQT*>=4$+03J=2(<SJLIRK <WIOH%PRM8*<C)JJ:4,';8C )W&$R'E]>'&'
M'/!8?2:%59O1XQ#=HA#O.=<OIM]9"DP8<)]3RC=;$G<3.Z;)#$5A_I3Q7359
M2(;DW29&K<8_T  +;X FS7"^@KW7U46:$UU7*7N!9@-%0_N#$7#6.UVYY5.6
M+&Q#\"4K)E>4KFI#FU9+34>%XO&7K\S$:!=!F';QN:&>^=*R'&QO@%Z_@(;"
M]H3)QY?DYI\*J6MZ?KL4/4NZW]2KJN>[2H;FQYA:5AWKF[EH,4]&S,I./2N'
M)D5 3E'+ZI^M9&#LH]P;.>>_5UKQ*3<8>)(E4^I>"Q#J>MX_EK#\*G$B>0_%
M%"<$M1*W@J,@JYZ=J<,CN>9X-BL/1\70I1Z0">.121,_P:8MKR^OC9&- C><
M7K&7(A*__VA&^;U7\MA2$F,9J^P0B^H-\*!<Z[6:BGPO>Q_-U</UNQN:X_+L
MU\R:'*QT*XDG%& 3M&3/#X4JE?.2 U=F$'1$M $)<Y7XZ?/ME[L&'\*[=21D
M0_HT!YE_L<FG]&1TE:6A]Z!8WJHV:5=PT8Q;$C1H$U.2YHC5"*QJ0JB<Z(XE
MAL%489;5&_B&J(!']O/U(FM/OS!!%3J*B$&SVQ\H>H9D*[.&0JO)B$)?9JH
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M$/6,=XH#1>>=(HICO>^=8X/X ZKLQ)(27Q_V82NKOB(K9.-K .V,;>V>3U7
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MV&:FK5E1KZ3:<?HQ_(>NG.MI[..)W"JW;YHVWWWIR9K%#E.TZS,XI25K[Q9
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MQ7*C\P6!+_!\W'E9(U9_*J=1ZY!%EM:L>V,=P!O[_?O-&MD^F8A<(N,LAJZ
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M?W^(Q8\DH''UET)]#?WXX\>/A[(TJ0J V ;03(LC77\2)@W2E7\Z5(5K*C;
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MJD-"69/XCY;(I2[H-L.>;I/\U0X_?7'G37 G]>6O=CA]PMR@"=)U _6S'=J
MN4V0QM7Q1TN$X5(TPAC7E[]JX\Q/QH]JD?7I#$^+Z\UA3XA,*YS('W'Q./ZP
M%0DUEY 4^G!KU'K_.,2P^@%]67K$)R$7JTOXNSXY:2A?UD :4I>1[X2R)L,A
MKHX_:@^&]"*).WBM>;9Y995@FA,0B+ %!= JA3V!T0K]EHA;S;])* Z18H1U
M-#@Z'IP<FRFH:BG_#E(T4$]=L4(B,-U?^L:F.MA@_NR>"C2,;[C_*T=WDO&.
MYS5=/%)QX"A-#_ K7G^:<+S\/@SI HV1 X<\!O(.U^>#$,QD4-. 9/8)M"_&
M)V/5-A*R:P>.SSR9\S>NB]8@ZHO_[(K8 *S D(4RF/"KX-'R\X&BAP&]I6QZ
MG?RPUO&S5]GQ!E0U[_@%?:(>E\DJ+^7=DCN^(EZXLMK/*B*:=TL>(@B,L;X5
MW*5!< <&.^Q3<SP[6V.+^Z>@+3CLJ42LRGHW)5[0MGNUB:GHI_K]J*(5 3-]
M9&%I[]4X":1OOW 1W:ID:U'27+QIL*]SS=J*PE8,0<CP08;MW^'A_@4+DECR
M,4\E'] Y >P,_G:4-9L)+C#0,!52V18N9/3GK21?GED'*<PP%0OC\X[.@% *
MP"]@^KKA: JR A!9Q@425-=LVPW=+3;&373<T&=9%(Q\NG>F9(GIN*?JHF/P
MY84*EP7R)"Q[ _/9AW$[9TN\L[%W5C2DMC->R1G>R:3:U6JT$\)WO5A)ZLQS
M;1^\:C39NF' %E-P'QSJ=@[69^&8HO$-G54!??663!LK5DO"NM&%DI?$;"N!
MU90T[Z"T(N@DP'A19!..B=&T8OD"XR-Z])@;+ULW%%:P^ ^,L[*D#^Z,^*Z,
M)YDP;Z+"ID>/(<%[F4/_RXLKKY%=<B$KC("<F>RK);ZU(*LKCFP?*Z8YD%MF
M0I1>YZZ$SFAMXW6H"),:TY?PS(-!7ER PKBH>^]#?:):=_EU]+&K3NE\*G&&
MH7WTR$Q":QF5>YWTC3DY_%=[E%TSZIHSH<+YIA;6]88-OP(VH8IZA7Y_+-H!
M[<T9F-/?]LV3>N1TL:#M?6ILHJ6%[9X\5Y:\#?<0T&GD7;$G?.DN?LD*[9(P
M_3S6&&G<!QLZHW@;9NDD <%%1,?\=#J5%V1@G]D_4VI2UF(JE%Q4O()5B-*]
M];H^26WLQL62^/@B'%YXDN-J'>4IP5O07^L08>C:)/PT!S3"C1[IT#B@EX %
M]&)!EA0 N'AUW^Z9Y@8".I;9%6C^2'W>O6%=;BE"6L["S(VMU.XN7U=2)TCQ
MM5)T409ADF!:VMCX;*ETK-AP]'1,\/8<2QTMW9(55E2^IBPSXI[MFAUF:IKW
M])*] !^U#^ .*<GV:1D)VJ@_*B0WW-"=,I0M+*QU4G$0^8-/8S=I*I^EE<%:
MDY#MG'1W!&3OS\[)DH7$L^]GR^/ORC$DUW*,_8JGL@MEH).A(F9_4ZD@I,7F
M4NO!:&N:01-JME$1ZB&RNKDVI:BYK!_NSXC_'4GWDY96A_ F IIWYXH\@G&,
M4;B),62U-QOPMS#"^#1\AL7?[I*20]J!X@:C6._XXSEL9:@#[%,1V41/\]Y>
M4X*7#_'+T%]&(>P_C_JD:S2]CUQT7UD58!."MN_N'66+QT@$\@LF4]IK7XW4
M;+T)/OB"$H_]3B=?H1M=G'U5JYQ5)'1V=FY$A+E.\L:3[<[&-'1WJO<8KC?/
MTR?")$&77.!#&-KU&%MGIU/X]]3S^#."Q;>,)!>1IGNP<27<T52_$DB\6ZZ6
MF"\O(07C#\!>L2"\X:&^I4PGEQ[)Q]$9-8=M%KW7T,O63NCX11C3Z4A7Q_;5
MH[(909U-2$Q$O< #6@P'"*Z)3V:R^,JSZ[2J04<+"U&_7>OCJ]L$+9A?8 ?&
M!QTM]ZX.(:V[MT]?XV826DS+Y9(S7 +..!$3!<>N4K.1@E:A4D'DA>DG>FP'
M2)GPMU#)F =K.*Q_6JFUK&Z:L+=PCL6A@?&^9+4C1NSM5[B]C"T3\A;VIWQF
M3#H$+Z@KP:"OZ79X^\6N25I-1XO.W?[CZ.@D_P">W7YM)*%E='KZ#0R\4;8I
MO,1N;]M2UYP1L1F(=$C5[,&7IPY[G)7-2&JQ14LU;<S/8!UF$PD\@6I'4]Y(
M0&>:\37SN4@=GZW#R:E YS<HJ&>K&^Z[J+%SSX,M5E7YA7I@[XSG3*"V%ZZ*
M<E\J"!WSI4."FX^*&[X HPWK7U)JY_PEA[(SP6OU8C1-% Y+YTDE>#OK5'I5
MB-="BS'I&]!WY6W1#U+($:S7=;1%,!AW<@O$BC'/^V=M];T%8;ODRH._A(5S
M=SRI7JI:4-7A3%CCEK$21#Y@<1/AAJC-OGM*\C,#;$(ZHV*'C*@@IHURHB;:
M$//.Q0NEM0E?CKNS@W&,52@\!W>*EUF4X^ALM:ZB5U;YS%K,VFO8!>>>3!)/
M/$_:DS8$OANZVXR-TH%74![M+Y&;J>EJ_'0:0I6Y734"<^,TT!D(J I6^\,%
MA=7H40MG1:*'CJ:GOA\13]'R%6^@C:8Z%&C,;R-8./"JU3IRJ(0J6VIUUU2W
M<_*@SUBA6E] L^[LV41$J]/[:)&)O;>4+*8$;W<'G!RQ<O5(4VI9MWA!KYJ$
M%M$N>==1WA=KZ8IF-1F=21(L94&GD3])VRP9=>:2BQ&@%GPFR )]$4,9\6'+
M^FU-7E=[Z&@I=Q=_)B_&CJE(V>/*26/%F*A#1J=7E_45"7LSNA1KFTN7FE&P
MW:LC=BHARUOSH^F#QF%7:%6T="JY)#6 ;>&5(&ZQ"&<@Z6O&>^M) ?^V'4+7
MY)[[5$9"=_.L6TVG_1S;C>8C0><>8L,P'5R ,4#.ME!KD=)RS.9@WU%4N-,[
MT)X[NXF@YET^HSZ=,HS'\E:_J/QQ>' P65M&W=AB-3I;AY0601H>"<!,T[E0
M1D)O0BKYR:U@F#\E3I2B2X/2+DN#K^MPQ5;$=<2$._J$5W5*CI)4'/.8C\EW
MJMX[E;%]-SQD;N[ 9%?AUMU2W"(<AKRP1;0H086J]]H-$$MG[2,H<0S@>6:2
MRLK:?-IE%UX30Q^6W/\F6!A2/SM"_\ <+NE3BW-;[59.(5$I5-5"@D?#MWI=
ML^$>;T3.%G%?W4EAS,^IP&11OV1SONY\8%GI2PMGI4=<Y6["1"EXZ(-YD?:0
M!:T&'5W9EMD<PTKY"A+/>DHD76M,-;S7;4AK$1 F1]9I%,ZYP*L46Q]XU#Q)
MRZ!L[UG?2^9N$_(V-Z%U-K]KLCHY.CG93W<JB-BB6_OMS_8=^>IQ6$74%@:K
M,9W]SCPB9F"26XZ,K$/(]H<#=N5DQ-[F@!+VC+$ ZQ*SC%R=WA+W.RR(=H?=
M9AI:=&IX*\'9[44.:8O3P>0QS8?E5' _C(,AE*=NS.^H2]E3?JO9V:%A?7(Z
M"U'P/'RD!S9J>8@QFJ8B(Z3=;ZGGU61TW.,8\)A;R^51CKF[UT*", GY&_J@
M:N'KL*!TC>=JJMMZ***2C,ZNOK)@R0/B21B 4KVO)'VPF$,1M$_MG)9Q*F59
M%:UXR+L@<R<LTU=<"U1<4$%=/E,/R8ZF-]R?QG=ERQ*WW5@ZS=L9[5TQMQ H
MD,JOE%M'&V=T:G-U+8N^3;B]?Y><_FN@=C?$S11T9EFG@J\T$KPT#@M9:AW3
MNH8USTLSHEK9/1@*K0.CU5L'4_Q+70MW^1,5MLX0:]/2E<2SZI6=L9S'V=F9
MZ'"Q@#*7W,Z)6)#3,ZLZN EYBZ,AN58-_3@YP3<6SL\C6- 65"1GYW?<\V :
M8*RRC2"WQB2U>^;""#LV""P^\E6'ELZ&KDIESQ<+%N+7S'*O36[+85Z-".HL
MQBV+5;I.QCP.,EM['<Y6YXB8BB7&L%]#$:[^9P*L^?D#[@K4:B:J'9#=XK2E
M%1&QB@1J9*Q/O'[.;2!Z=WP;B6]<?!\)O-Z+UZ8RAX&OD6>U"-X=O_X83++(
MF40:V<%\1TG ?7GIAD29B%JUNL)@+V;DM+/J=]V#76V71CI?^\Y0C]#=C<2<
MY%[UE&U.].[X]N!'042\D1CZ4T%_B]!/)6EYA>RJHG5[+JG'K>V?ME?3T>KA
M]"<80O)"J+P):O=XS8R^Q0,WSWP\YU% ?/E8HPQ9I7Y\(7$2J8 -Z[FMFY.U
M;=<OV111P*_L]WOVDD:=RK%=J/I*N6>I9QT)8-]9U9L2M6VW8RFDGTF-@\/V
MW/FZI'7%@E<E^6JB6AR@R[O*F=O+R1FVBIWZ-F<N9L*%_6[,RV+"LB^:[-RO
MWB'%'86_*XKD3>\T6>F[\6O<MI2,+BCMB#\2WP7H=IB^51X.6/*&UB6FNWO=
M91@?H(R+$*,/]0&)G036=6GIR@DJ.4MA^K%P?LWQ<2GB7\("]0]*1/ K#?!@
M'-5\/?*L+1B-Z6KSJ"4,"MB"\*0AF4KZF1>UV.#=:_%$)Y=<7$8A'A[K-Y=M
M)/W8BKS6%S3B*'V%(=ZE52H^XP9N@QW;T=>:'ZFA!FR.1^*8^GK@Q>/4CAG>
MF*B6X=YMLABM-_3\9A^/9&N+QT[[L!>69H=].A._E+6MF/P==\(B:_5,4F)&
MK4(]BB1UB]OU4F)'Y]E]+[K/S1:3L292VC1\(A^'E_1+JJ[8@F$,S0U/#, +
M)J@;8EA-JK/V3IMWWH?.--,FE/XQ^?O:.(I;:M!(Z-E%S>I"O*LNM(I9C!'8
M=6&7(;:XB^@,<:>SF: S,$^'/@9$!<R5*[#%3!$[[T%SINYG0'0P&E+^NTW^
MZJQS^[6Z7[OO09MC+DQ=@BEJXJ@VR\=<)O2M\NX"=!>,;<R]XX;L20:T6WX%
M8",-[1,%7/ %&I;N/4!@$T:*D<B[S0Q0CG^+)$WX]M@Y$6(U59&BP3T-Q_S+
MRQ(VP>'TAH</(?.*=YIWGLRN/EE=Z>UC\J*>8WL][&A*4E>L $L>QAE@M_?Z
M<!'E-D\,IZ#9?$>X'&T+O4#FYV%/- &(-V7POH'O@JQS-[*4&C*9K).ZKCHS
M9>JH$UT1V]7HK4.0CHN/X\I?+>.JZ.Q\QF?1XP+$@_!<6XLVN%*/DLX"W,6,
M^.SW>) &W&,3[=68W(*EAYY-_#/U*F?R4J>UM;$+(K=93?.YU>V^2&A WD+G
MV8:--K>1K@C=_DEQ?3,5/P@9;)"ZH:H3B7=SR;;%0*A+6W<IL;4.GMC/=Q2S
M1>5UP38&0!TWCAG[MFFJ,(@$0S?C_%#QFS3[2%5EIJ6S- OJJ6'EU<$]Q69
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M0#>;"!N6=P1#0VD4($KB/JWX(9L[!,W]D'PI=P!3RZ!8)V\MJE$I**8,@UD
M2J5 D^Q-!3*MQ3#&)#N(+I@MVV\B?;M5;,S1D/*N@*/% ,5L%D=&6!1?=02(
M(N,*%%H+,?2# *?,C#T<#*.!-\?,"S<8UPTN!H4=0<I$% 5V;48FDAE7*\K.
M"VSFTDF3<?#$*1\1&TT^>2]Z+Z$:)5=0K2J7 N(6MY P#T<HN/9(!#-&NB'0
M%9I@'^LWDY07=@1($U$4V+46Y^!]!V8B<Q3?[PDS1^ <1;Y^KJ4MY:1OJ)5(
M 5IKP8Y/:#:/B4<6J4S+3;G]&9^!]!DC^"%A(AH:C[V2N5<-6DX"7$-.!>R2
M"$ESFRH46?0:W(:+V'I,TMC5UGL-MHYUM3=@/6E33@#JM;JV\K,A>OW"B ?X
MX@@,9 @*%NO</(P6A\#:=!@Q1!#5M:.#UMIJBY,BOMV\#BJ^9:=$5K%QHX8@
M?;M50!MH(,KEA$TE6'9ZY X]H2A!2YUL1]"O7_PPX=EW^>8[^!?H9RNUJ+5J
M%AJS+GJZ-82S[#S)2MQLN[Y1&UZ_ZPI4$M9MR_MRAR@"#? #9U=@6&$LMG]G
M_*YM*4NH,(S&)/9%(@;M@+P353O0W;9,R9F&^B):=@XES6$>@BC]8(8C3!D1
MFP4R:31 EY9T \Q2,?9[3D69H&++6.0V)H$CR^Y@6-QN3*K)8MD9E2M,YS'U
MPO<D3N8?8P;?_=3'XVDW,A?OO8<C/FR,HN7KNOU'=2G:C?+.XI4>?FEX( 6?
M/,Y[!N6]IZ;,ES9)T:C"^'A-4R&.)Y"#]SXIG_JC@=*WVPTIE!EJ,;P@$<&V
MLR)B]:9.&RPKZ!969=+8=FQDHV=?;5'E5^<0<6<.7W<;$\2TDWUS$FY!:2Z7
M;2=+"I=O@'<]T2Y$*DNX$GR5L%Y^5J3;[A)&\6:=1I<^M]?9#78A:$LUZ>OM
ML [3EC$;:+S@D^79MVTE0+%?XP8<4SR-TOV?_N(3\2+JB6M_8.XHOH6Y246?
M8 I]\E5"X.\8NMHX,##%1FIWS6 :48IE*Q<JF3]'!'DAST_[]SCDH<#U>+[.
M][1?V]N]RF,QN-TU86%R1OD]<\TFZ-M*2I=/[ .-.?]@X\U4OX .X6>:KE#Z
M/WQ/X^37+_ZC%TT1O]LLO?%,YP8TS$BSG@7G=TSB)PQ&<KGX3'D0=!5.Z_.K
MX,I.XU0ATFZ+;\6B)&Z.L;HL\X&*TB^/PJS3UNFG70;%VYZ#56P0D@F:@9"E
M7D73X60'IQB[8V4TXVAMU\(5 C_#7UZY.0]1YL'V9S%A^ _Q7+>28U3<<03-
MA+0L@>;]HT?0)?0- ?<EP9$L@U)5P''P5&)9MEU!W:-O)J*H->[E"3@.IZF8
MEB7A++*=Y79=WA,LS?%:"6XS@D<'OYG8I5LJJKE"7_)FE_H@[F,73&OI)+Z@
M5;V=6^FNRWQO6INB%/L7;?*32AUT"27',:\LKVV[+8H"*'(650)=2>/HX%9*
M:MO^C*_[&?<V,=[O1L>S]D)3PD\<SL"3)'R(&L"D<:K/#J4HX#BB*K%L2Q(J
MG08J$ERM.R:CO%^[DW;<!G97@&W93"6#E9@<&M^&:TK@Z)"7BVE;&M2-E7 O
M1*-)[@J0U?T?1C,S/0''\345LSQY:M/#,W1 :=1](^0^F@A_(TE3;,",<H:3
M&5WO["Y+[EB'H.,&4%?L\NRL#1N$]A:93>$,-LM7)N6X$507V+;4KLL3 3XH
MHNJ9"$D9U_%42U:>SK7A=ION6AE--G>RC**=]LQH,#](;5]W%QU&K[;EM%4T
MS'1<W'';FI3(5\.JI"[;,NT*)66+6_R(J?A,<<FN"VTI&P<FC?U++WU6R69;
M9EZQ&HD"<3HXG1T-(P96BV'&6[H:;U+8<3!-1+0MS^_86X@)S*<X,T/EW: Z
M;"L0<1WC"J*6YP5NV+4L&F@MM*M0<1WN*K+:EB2X8*OZ^^BK-/ R2J[#7E7>
M\AS#+3=UL-0/'N,\+T83M305FKTQ1==MH:[<MJ4P5JCB!D=>Y.\X6Y,2^3I;
MJZ0N\]S'S7<A0TH3?K,T3Q\ 38<P[M/FKQ,Q[#J,*-G896C:B:[+,))7 7UK
MR8[D HS%1D4$GH^/*OB(.@)'"7113,6)IM8"=RH#-;G<Q:#L4:)J<.7+17MW
M6&4.*[@ALOW$U<;X.L1<A[R&R H;J+U#3W%BHM0:TQ7IFX2G%_C%(P3FI708
MC9.'$/LC\$YXG@.1X6#YA2>CE>$O#A\<K#I'+>2P2E'84'OA0*F@XH @_0S"
M$?"!H3U X^ W@4C/#?+ "%VYRD([(R&@Z>3R /4Z:GL-:4=AA*WM14PU@\3>
M"_"E0$ES?OW:HFS'4DDYQXV@1#H%B-]*1J/#YJ[9R [+-]*E7[<2QRZ3YBU^
M2@BF ?;3<^/,PV&3J6V.]=H::[5W!1\HP_Y^M;.F^J6E3]Y)6?8EM:DJ2Y9@
M;K_6M"+ZU9C,=66<G:^QL2>-RZY2P\$S'JV]0Z 0'X?+3"7MC#C[RY';,-=Y
M]2E8Z[,;%/![-7CFN@2X6>0@,)%U/_58T("52"OS">]']/WV[8K(A$D3@Q[B
MV2/!\J#SZLQK>@FD*@BQ#\HNH+\W82W+CJJP9AB/H"M/?+$&DFG&./_''FF[
M8!I[%'>_^=1VZ Q6=_PR<>M]/PC6)R;WT",8D7<!^_U*;%G6-85!#\2*^C"Z
MCCR^(%_;65#1<0'WFJ+M-T^;HGTK>(('/)0]("B0NK'"E,W*NH!0!7'L2Z\F
M8SH]O1S\.RD_$&I,P04@*PMEV8US)5W$,M<;O)#N/.?C0PI&&,;//)!<OVLU
M(GX$1E!)7N-<;(U%0/CR3QREB>,+(H"/N)&/HOE 2(&A#6[T5ZN5EFPT-7#*
MRTKK9OE3],5:;3F&N!3S_^HD*HU&-+PY>D/(#3[KG(6H3,D*<'7FJD+66$++
M0A&[C83V#W4[-M@:8YKL*K.6L'Q/]&GR506. K%,%LNF]P4VU[DT@-V!1\AB
MD@8S*P&GHV(7FCF;+ 51)Y=E^=<+O%?/X5R?E,L8U\SCW%JHH"AN' ?/. R!
M[PHGOJN1<1E@K6"6!0X*S.>=PBIX;I=T&<)M62Q+K5[@%SYLY?/GG0MY$GDG
M13)*+Z3%I)15X*U=A<MV4%MHRZZK-Q!L<WLP")?%R*A\_S"/;.]F/#6J.RY#
MJJ$ VQ+ RZ1,USMJ._8J"HYC+Y7)NC3OA=D(7_:H-"U+"[@,5B9">;YU70"_
MQ^MZ@$;\P_\!4$L#!!0    ( .R)95@I:?L7WWP  "0?"  5    <WER92TR
M,#(S,3(S,5]D968N>&UL[+UI<^O&TB;X?2+F/W@\GWTM4?N-]G10FZ]ZSA$5
MDH[=/1,3#(@LB6B# (U%1_3$_/>I!$@*("MK 6H#[8CWO3Z24(5\,@M56;G^
ME__Z,8]^>"=I%B;Q+S\>_NO@QQ](/$FF8?SVRX]%_OK3^8__]?_X7_^7__*_
M_?33KR0F:9"3Z0\ORQ^N;^_N?_COEX]??KB+LSR()^2'ZV12S$F<__#3#[,\
M7_S[YY^_?__^K^EK&&=)5.3T!=F_)LG\9_KWWZH7_O!X]*\#^B/]U\'I3U^#
M=#+[:7 P./[A_SX8_/O@]-^#T__GA_]W^/7_^^DG("$*XS]>@HS\0$F.LU]^
MK+WDXR6-_I6D;S\/#@Z.?EX_^&/UY+\_LK#Q]/>C];.'/__WKU^>)C,R#WX*
M5S@VHV :UKC#BXN+G\N_TD>S\-]9.?Y+,@GRDHE"NGY GX"??EH_]A/\ZJ?#
MP4]'A__ZR*8;NN@STWSSFOH$)S]7?_P1V)4F$7DDKS^4E/X[7R[(+S]FX7P1
M <+R=[.4O-+?+5-XU>#H<%"]Z'^_2NB"^/$'F.#;XUT#4+98EC*$O_V\>N[G
MKF^#]1%.865=!A&(X&E&2)Y)48".-4750Y#2-3XC>3@)HBXD;DVDD=ZGG/XO
M?(G9Z'6T@&\6OCU%6K%)C-/9A<%2,QI"<#4+XC>2W<7T ?I=Y.%+1![H'"1-
MX<%D\L<PKOX[2Z(IW0!O_BS"?-D!8>LWFN) D,UNH^1[EZ56FZ,CE9M91Z_#
M+*,?W'!"X5/.4*9\"8.7, KSD&3T;_34FDJ0K#IA1_J?9^0JF2^">$GGOPRR
MD'*'2C>C!)3+^IKD01C)\%IZIJX<+^;S(%V.7I_"MSA\I5];G \GDZ2(<ZI.
M/%!Q3RA_[H,4OLMW(@^@[<16\'S+R&L1?:'O+=F:T&TG!T;#Q[: Y:(;I_P+
M.^*_#<+TMR JR%<29$5:?:*W84S/L#"(5M] 8^VO'IP.\\W84?Q()D6:4@#E
MTI/GAMG7F^!-BZ4M.8\):C?'QVV2?@_2*=V2\S28Y&N&+CNBD)_?!+K:)W07
M+XH</IOI<W*3Y>&<[N-T3_Q<(Z_7) W?2X[K J_M]48E?_6>:I<V<\ZN&@?5
M"F![>P\B>!?]ZNEE\0\Z.=5XGN#[+C__-7.G-=;*C:2_IA+Y-4VR[%N<DB *
M_R+37P-Z)80-AOZ6*.Q;/A%KA>_#=_HR^!7]T)^"^E_NXF'\22/0]I!DH9KV
M8H$&*UQJ<3BTG;@C'I9.<4]RL)-,BXBPE0[Z@#RPSF\P@["%B*1GZDCQ(XE@
MLZ!7V7SYG 9Q1@]2N-NV(%E^*D,TWWPL2$QWJ=7?GY/Z@[_/PLGL=Y+2!9[G
M$9G2 X5^!=W1=7FI(3[4?[]2\[.'8 E?=W>\,I-WQ%6JX.4EN-I/6ZQ%\12:
M:=S^^2K)%/8MI=FZ[E%!&KS15[REA*A=(]&1'2GZ0M6]5N<8-K"['4K![-7F
M_.WX JOXZ".W13PET]^!#K@J)^E5,I\G<?GL7985I:EJ1"\C>1"#A\<4)[J0
MTMGJ!RZJMW#R)9S ?K_Y"-J8G>3GZDIU4"H]Y.TOJL2F;V%,OY?GY&X^)U-Z
MA52@6&Z>SCRF0KRD4T_!K$@Y$[3<_64G,D+O#1V:+ F=,\O3<)*O%S0]/M^5
MKL/=IC>"#2&I4H&Z(I.;W BNWTGX-J.L'-+-*'@CI:E]4:H[8%X!K2V:%%3O
MH1M*[5H]!.N3P@7>X+L[:Y)T,163O ![YM6,?N*MSF.Y:0S0NC$248TTI6=
MXYF5=[0;#*4WF$$(_]G<,IYGI/'8ZOL/50Q*FM[3$>U=3 DBS\%'JR7'':V/
MLIO75P+(R>9WCY0_CV22Q),P"A4=9VTGUH<'-J DKERCURN]B_Z!Y?QH!:O-
M_!W1W9.\-,*1](FN8;*UK58*),04I64P$;VW3Z*"JI*W:3+?;+%)3,D-HX*.
MVYI.G@N6Z.C(K6N23=)P4;V*?N2711;&) /9R'D+-T]UN_E:HL,UMX;3:4E4
M$-W%KTDZ5]PP#+^_JRVD.A+KL0K=X*I.V-D?_Y*1/POZ-=Z\E_;P;M2K3:=$
M.[PR6P?GO0;92QFA5V0_O07!XF< ]3.)\@Q^ U-F)<X2(R'3^2[M.U.4 .#9
MGV\^<JJAPL7\)J8[517R]"7,-C%P03I9D[WZ9WWF3?A@&.<_3\/YSZMG?@ZB
MZ$<IG(Q QG4<(D0PGI2PRMFZD$/_#3"3^*<I>0V**-=('&-N3:0F\R",S5"Z
MFKH3H>4</\W)_ 7B./51V9RW"XDS2DTZ*5[(3QOH&@EESMZ%W#C)AUJ_F_6$
M)5%T=89Q6'W?\1^-EQ#8!:80=5;]%J@1!>Z6,=7)I#%/!%',2<K9S3(R^==;
M\O[SE(351D;_\;E]T1_&ZSCPVBY*Z25W.9EGZXFCX(5$Y>O&HB'CPXO!T8H#
M)LE]IC,*R(-'QH<'@QUY#-,F770]K*=:+8V67^,KU3:5V+2B(N$17V24G&11
MG74__I"D4Y+^\N.A01[?4"4G7](#-@5EJ/H/4'Z(,!Q]?GQX>- K[@N0L$4Q
M<""*@:(H!A3 X5Z(8H6$+0J3.P]&T)&B*(XH@'[M20(D;%$<VQ+%%?WG*'U.
MOL<R@OA\FA)_U%\Q;.-@"^'$EA#*:/M1^I F[V&5E264Q-80"N.XO^)@@F'+
MY-263!Z2+ ^B_RM<7"53*8DT!E ()_V5!P,*6QIG!J4!W^@P)0&'__5'*)FG
MO>+X+O%L'I\;7_%7!(+5HSMZJ?KX/\F2N]BWGAT?#LY[Q74."C;[+PRR?TC)
MGP*$VRAX0]C>>&9\>-2O*P&#>N1&=F#AVELC_1F" ^5OZ.7C%.6AF=5>,T!J
MO 4C]%=VEW]/DC@G'_E-5(;Y_/)C1M[@'Y]_CY*,3'_Y,4\+@DK-VD6:K%5G
MN-H//T+,NL(?!!RX,")!CO%.*-&&</@G,X8($8_)RW6-D.N&[7=[ ]M^#M:M
MH5T,L48W)2#%4,96AN! 6&_R,MV-]>.FY=^8")J^"X,R^ 2$R,+D;7KM]H2,
MOV"2?VV<H%OR8#X+$)P9E[!%O<MZ'NT(VTW>GU=D/) T2^*81/?!'+TE,!X%
MPOMU0>.@0-AO_JK\2-["+(>H9P[[68^.#P_.>L5]' 3"?),WXXH8B&Q*%TFZ
MBE,-<G(% 1;I4FBPX(ZDJ/IXHY/ A$C*_/WZ.?BXFU)8921,&?5=< X)[AB*
MQ(S^:E8Z7#2(7$Q>O*& 5?0P2V+"%<7V8^/#PWYM6VP B"/.Y V\6@:W8432
M*\@S25*^F:GQY/APT$=? P,#PGGSM^BG>1!%:Q6.R_G&DY3J/KH5&!@0SIOW
M/M_,"20GO?V:)M_SV:HV$5<"S!$41;_T52$61"+K+_WG9@20YI@@K)1>N[7
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M2[%<A-=!3FZ#,"UK\RM]Z+O#*8Z3?8RK:L$#1)9VP[W+0O?#"3V0LE(2C39
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M^F:JE&2>G12RI!06D:\-<82@UQD,"^.S8V%86AK&0V%W>L/ PF$=<=B*B\4
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MK-)]LZ5H<, ^>%_:"E22J'@:Y(4*I@E9M9JUWZ;T_2G>T=VO0<H6CMWWPAM
MMQ>%RJ9E9X<!+)L]3W]])@5)*8GY>.Q")J$ESG* 6BMI%C3.K!)F 7R<F5A]
MSU9&;+'T,8E_2?A-4?FW/&2K3J; GJ8IW0F_8L]VYRHQO("[W>:O)>LC:YY<
M]4Q621IUDJI2.>@LYSEV=!_&H=C3.X6[(*ZE/>X.+[S.2"IHO1$F#YR]E$<
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M)_("F,YP0:YV/=Z"1 5Q:Q]ISIN_39.7<$=WYZ^?,LI\\/OR.'&]S<,7D:K
M8L]Q3&6 3FF4K<I4@>;22935D,=7\@VOB83QMZ2JC-2UH6_2S6*XF *]O]G\
M>D_>WVT^D/?7']<?+ZX__DS6%P_7OUP_7%_=8Y)^/)*[G!X/8Q#*2CWH#9\=
MW:8A4^G(WT,7X=>F.<6 '" 1ARSH0J\H3X0 6]Z4(F70^8S#\9^D!3%]XDD7
MAXCE:DBM^;$HQ$?5?6%>)!9KR6,4/HE9!B:;K$#6)8X5PCP;UF89SCP=QN89
MOG#V!"9;*6:IQX:5=8A4H+7-SP%K^D %2KZ2\>^3])**B+7PA:WCV5 I@@'<
M2#BF,D RCK)5&1;*P6"?I*2NAM3UK!9F9GO8>["95,YI>?%J>AG0\2(".E(>
MT)'A1MM,AW27L^/Q#,/=--E2NLO>LRXH@U=Y[KHJK::)JL.RD,RTL$2=GTD9
MPA% FL&[S6R?6)FWIUL4SI*LIOJ-V/=)\F>:#B32A5GFCND?/E,XMOHH"R*E
M?U!=CRTC%4]C2\<)X:V#;?1EX;V.;T]LD;,M4^&R;[#9E_^XX/C1A<0NUAQ4
M&.UR_:4E_ON6*]OL[1(77\=$-EHE+":<*DR\^O<%/-.Q^M#L/ TIR=]."O*%
MF=P*0WX+-+8*77Y+4#Q*.E=PZX7?=^!AT[HNK.Y%53>YQTX_M35Y,!G56^DR
M-;6^]HX[#QMK;*A>HELFT:G[Q-:'B>  4VRGA0,T070&M_*#W99?Q]D'J!6@
M4[_')GO&%\*DDIZ=YSNZ#V.1C.KG4[CC[2YO80_-E[DKB[!^G;3"G]232C?X
M-"986/9SFF19O41G<V@:OHC3BF'3\+VSSG79.66=WT+TQ3(-PR<VNTROV2]B
MOGO))KG]N:%X'L;ZJHA,!GD<>A]QX7;1/?]\/:AS JO68%$FSAA,UE9'!LLF
MZFR;/KF,Y;M/^M!N?EK^ '69I%9FL&WFM*V2W7HX0YR9LG:N:V:^8@8-7+-I
M1Y;/% MGK P_B,!LJV,P0579&XB%<S.\&PMW_?&7J_L'[V/A+)!L&6)@ 6.P
MBU'B"56V%. .J/&<JH&;1BG@*T=Z[?ON!Y&RN!RD&@*X2\ 1E@1LK#B4AMCG
M0(9:BHVQJ"B.?0]H@!!]EW8&V.#9\#O+L.OI<#O/,.M5S)Z]E4K,WC>GTLJP
MLM+KZ#T#6L</K2C1>P])X136+T'(]([H^R2]#YJO5U[21^-FK&M-"'%[]E9J
M@_;RI!R5"2_:>-EU1:I:S_9)>L;KQ0I5G\'@:O7+QN9#D/Y.<RY.,NU+MA@1
M>HZPU87G.6(6AYG,=1QIFK_R]7/.GUUAOST.G9 X5(+)1Y-M-E0LY5?B-9A<
MWE&L*O&&A4YF-@EX+ 3E8THZNU 9. C/0?(-8A-\)YR[ *;(AR#G7N!UL]?[
M!\L];J<:D7:OW:PV;ZSRX@*T96T<S: #Y]A-Z#E[X2 K"<N]9";MZ;@Z#?RF
MW>(1R$?A^V9_'>?L4_*3Y\'WNVR$$5G<:XL%81DT:T'4U[EFL*@,\0[C,W&P
MG/%SY8PR9CR3_Q@<CO]$=O2%1LE1!@GP2GV(")AL;?7]@M[OA^E6]!P;\B!Z
M@B$YBU&S<I=:4-V'TX2UUX] S<RG.97Q=O(W_4K.5;-T?GZ<>S17=T?M, _]
MF*UKMM6*W#WSG.(:*\/?5C;;ZKB]7%7V!DYQW0SOGN)N;J_NUOZ?XEH@V7*K
MV0+&()1=[_[]E.7%TO^.\NX)(\J4OHZWR8'>)!G[_7RD7J8Y0-HOU%]=?C2:
MX3MK54/B)IALBGS#&_N6__FMN1"<3DRK3N3!R!&/;66_C<NSK^*XBR15C]6G
M77_&]$5+4K3KK9;D)XP_VVY3RL_/UX<DS<._BR"WS5[D1C\QJ^2ML$-X.F3R
MM&\H==/8"B%]TEB;%<*4%9%OFE5]*[8)R]K$3+JL;T4:-6+M[,]F/W>NWP15
M)S"K=T4=WY*@4;=<7H@:>1(I[S8.IY% \0F3& ##>K[Y<'TX!F'*&[]X#M(G
MXRF 3@"2M3J=%5:* *VZ)"F*(HW=MFJ+5&3D;O.IC#!C;D.D67M.(C;0'GBL
MB;P*%-:F\5$9E3E&("G,,*((!/F7E#FB;2@XR7Z.)%'C79.K!A[8B0.RPM*>
M+MB:8BM2"0K0-45Q.#.#4<*2P& ))$M<0-?EC OB0!CT<Q#&?%Z[B7NVTFPV
MD&TK &21M4W*E3\F6"XL&>CD$T-55'!9C=P]7CZDPRH9VFA;N1 W<E<^^<4L
MC)+XZ2P2MQS[#VJ@YK2P5D$Z#S>^==V'&]E '(CZ;$*U&+X(CF$>1!8;8RZ5
M #H2)]N4%YC51U#X!DN])554@;X?-<G*"Y%\/NML'0F:R3EOD401>QO)':9=
M[KEC%(E_;,4J5J:WP2M?E3^DP4ZY06/LF?X*4'FGL<F2<Z4T*<171%3@"]TL
MC:NL.,IR?M')A+IA*ID@ATRC.Y'X@6LUBD1-<2\HU++'E4"U,-;4<*1AEXVX
MJK0JB#H5=(&</8-4O.'Q)SVQ[UE/ -@Z=\-SWE3C9N-OKMQRJAJ;=V[]8,])
M7B]I"(L9EZBZ,<UL_-VC 6]:EY2VUVF4(KV5Z)P>00,KOH_@ )(OX$^9\9GQ
MKV'^?''*\N1 TU*[5R?J#]2$RO0A*RV)758CLXF5%:TJ(BOYZ+%H[&KO99DZ
M+66#<7SR; )KA=%A7EH!%'MG1IQ.C2.@M@X_]F44RYRW9>3)G7=DL[>P-D6^
MZ^3MT#@ 1X<-F'XL8K&,#\*=!:T;Q7HKP.57OTVVY!)3M.XNC#?,LK/MCD9\
M?4J.@0BK]W$/QH0\"S898(=$I=N4'H-P5TX<KK[PS&VTG.@.7HD;6R$JU2QM
MMJ1>41LIJFFL$.>^2C=U&V>DW:6!5);/&FM"_-.^:8@>IJP+G$$HW!Z1[_A#
M6IO]ITS>CVL&.12J&LCK7A4@;4?8J9^F%:^+BEK.DOT9JT>R<T7DT_3AEMS1
MW6F+%\,S@[WK3@AITIFFXK-U+'B[/!V+7!B&<L_PD75(D#W+L'8+*NIE(#EG
MT%PAEQ@ BL+5E9&B_+=8@YZS!:AL& ** OLAE(#@NS_1KP'<.@% 9&MU[H)B
M,)5VB?BBYW$&"WMS>,+ELT=ASK91%"OG@9OB+97+^2<F8\W0[]+5C'O/;DP;
M^.M2B9<WI'OP->)FM%>)-^VM'+Q\^#;N0>M(Y@Y.&.*5HW29\3/>5>__7N?T
M8)6AP+X.2-HY6*;@L9HN5AE?XUWC_6LACQZN.<7"^]/Q&(FI0A").XU1DIU2
MD3"$57MV8;0^WB?I00P2J)&<SMA5..D*7)B$\N*1J4Q<+I0O.![X1BQ_V(+N
M?C3P<$@0,JW\D U*]' E(-*N<Y$5D4)$2N%P;*HASF\%YHDWSS[; 5')Y6Z%
MP@D//HN]E)W<TMP\YD$8\X'TZLM6!*"_3U)18/,8A4^![J6GL15!/=(\QL;>
MBZ>[8G>?E+7P9Y7+>@BKJ#CE;E2%\)[RC.86-PZ2TMR0+\@*<]FP56PQ)GIS
M(1@V#<>MAXQQ06SU1#'FUX5_35CXO.'!NET,<HNIK5__A@;FD#ND(,US.7/E
M RS[Z)^#E&\:%:%R98R+S$H]\[N]/*^>_3LQH#L^/:A3]GEZ( ="B?-3QMB:
M91?)X9'-KP4Q+=:59C% R@SHWT5H69PTRQM6BY XL?D47=S8? <8U[I]IKL3
MO^Y:JM1X*"@[?VW\ZV$@ULJ]*D@7[6ZGXB6+*KASJO#8K&7%-Q(;OR"_B:I0
MP3GV^RJ.;N3'!76&#25NV"_$?H.%,^P70W"&&OVUSK"%-2XA=]&\\(:F;Z'S
MAJ8/@36J\DQU3W'X=S:_WO$'3_=A4*6D+M]76\>MJR+R";R/-!\W(,_3(NY8
M/E.OV4P#5J1NC#1;*Y?IU>.*?/;:O-!5-+D2F2^]G4O,"4"+:<B<Z'MSG"V*
MP-*VV^@;9:[2=T#D+0IBGQR!=N7Z_O[JX9ZL+_[UT_7=U>77XK'ZZ;>DT^KG
MWAOU6Z#^ZHW[*6C_A!-! M)O#UR3*BV1!Z\E+\>LY5W1FW5!%Z<T90(H,RA-
MVV_40>EZ$LA?%<U_C?,JVYXMNT#Z--2 '#"*+NG:C/Q\>YXNR)Z+=Y!>@F@@
MQ__2#;]5']?7AU .C@?BE:^3%:U_!;[-ID<KTT4H)M7;_V9=G):;B_HW+3'?
MGG-KNFJ,Z=O;=6F=GD.9KKW]9>90-\K5YK8U0_MJO%<?^< F9F_69S5_ [OP
M[&WYC?JO_EX$\F+-7WY-*TZ[3KVY7I]?WXB7*<GZ_O[3AZ]G2]_ S24=FX&8
M;\Z]%4X:S\N9%'BCSL[8I\ SMZ_5]SGU<=D9OCQI $M@@#G>U^T1T3SA5^0!
M43W?5[-P-7=H>_7J2?)0&&K"^KBOR+?99SL%UN.K\7S#^4GA'.'*DU2NV#U>
MOD+POX2/M$PKB\+O-^=!X:>%7\-\$&4B^%5- &UF?@UOQL\NN-C7XM6 IWQ?
MPUSO(P6\&O1F/9/L);BK0&_?$_7W&+_E]!7[GP:9%K[F!)M2.'T*XB*E\442
M9TD4[L0_F':W#(VTR!2RV1=YMH+HGOU&9'.P.2B8J7[(5,4S]8B2%+A1[XJT
M:A;^HEDWOP->U4[JZCVY1C@K:)14Q',BQG\.U9G\'NB7_)QI^/M2=.IMZJTP
MJ[^?%B%9([GB;[PQ(EI#.C(#Z+2'9\JG.<<@EBEXSH,LS'CO-.M_L_[&0+!9
M78^!71-2YUW2;)N&1]DJ^U!5+H-X=W\Z'(+T=;._#]E48Q]N@S@O-EG"^.F6
M*;\U'^;/W0!4JKTY^T1]Y["JFS. IX^JE@*<&T4#(H-4W02IVR!E(\AC]3+H
M:26R\Q,Z5@GN@"'TV(105D,H:T HJ"%T+!J!3X4WDP?DW6CJ/<"ICH,J;V\J
MY-+/2T^5A'<<<HE?RW1J2L?/-\1\!7,R9T^QT)S-V4V N&.GZ9R-$*"+<QHS
M_9L_V7^"+B*'^Q\F]>+4 =C#87.TS_5_8!IOVIL8+J8Y>0]=\_L@3'\)HA.M
MQQ ;YVP6 Z32@/Y=E/'B1)1OS/E\\=$VWZ(+*9L/@08D&_<\((<,)9/'TF$)
MW0=/,.0##7CQ _9M=RLTV7 !QZL65]WY?QK7W2W\ZI @Y$LZ0S9HTR:('QHR
MGKA7NX^BO"IC]47 4-75(]Y]"-+?:<[/Y>_I]I2*4W@;QSNJ-F#\N5O;!\J5
M@LB5P&E=%ZDK\\!_SV=YBX5:D[%).1+3?4P="6@0^MZF_'')_/4VXO-_F0CE
MR$=:BW'!0A:0FC:6=.%8RJR(D*I2"PDY3T8(ZR_4A9[UY\$%FEN0AELU/L#/
M+D[ C$2OHB9FLK1M8F_XIA<T<XAQ& -.J+UN?B.G&1(9[\2[]&ZI"1SK@=T1
M=[)0=V>I&5G, 2JJL+SG#[QU[OY%>W;3W3_GA(";HKVR$?4>DVD$<*X!*F3&
MR2H=[M85UGIS2Z Y_?DL#$P6HD7QN$.R%::#A$>K.)Q)7XW'+?+@>C;CV-63
M#_ZH9%!\3_KE2..,%LO61'S9YAV%_#E@TQ@FM(V"+ OWH7BPLD[_EHO3><IE
MY4%]2H])*F-T:!HF._@(G>+Z)/>"HO."R&90-$I!SD"-VBO3L**T^'IE>4\&
M-XOOH$R]AC_"](%KQ$CEQ=#DZ*G]&WG&&X ]L+B.)%X-'8[=WO#^\+[[CD9!
M3G>W 5M_/:1!G 7BI5H;!SXL"NC%+>SH]G\A0H0,:0IYXL]MOTW7J=M^&%2
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MJ9C*W8$T?#P)@[F41[RS N< \:R0"715A]']5"P?A4L0P]5ZFX<OMJDN'.H
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MGU8M=-;Y\?8[8!3U_!7=3/"<\1,QW9LL?B*@00C](8GIJTR4\/X4[X:IJA,
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MD]"8; ^S%I7M,3:= @_/E#5!3WFXS:YC._!K9(!AK]-<AXYF><($,$>KF4S
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M#$!;+@4-G59^9,X/*'(AD9/X@,?)VP1+Q0?=A#&]SNEA1*Q<0Q0_2JAIAT.
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MD7LBZ^LD)B]0OR9/,-TEZ0GG4.4'I.#RKUS-G\3)HU@:9"-Z0XL/3V+?:A.
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MK5_?/+';*%7PD!W+#81(<SH*)*6+V+PQY8-YAB>3^2:NFHA'3\!%384%$.-
M?R< S2P][G=M^#>F9_GE9;1YU)GGK(R/XA9IYC@KXFVH=^"BYJS\S6MG158Y
M)9#$5V=EHH;*;XR48<-\G.=0D-F#Q%M4.@;W*8931A:=6QR)%(>1#(<'UT]!
MF1/,2$[#2$J#0#!>185*VY!R#*BT <WP0=9Q7 3'*D]KLZN>@*)A/5\/T?:
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M%!9;HOI/2 /6<5AK^1+]( TY-S@1^PEI] &Q@EN+MS%&I[2U)3(KM[;9H3$
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M!.(*\)E(2G9M+B^1:):HUML_B@AOL^Z?GO\E.)W_[<9#U% W"TFD4+<)E^A
MG,EU^)]%EI/G1]4QH#N">TOOX6JZ/5-_NS::EQ8KS3).5L6Q@62MIR>KI+C(
M?]92_#VTUR%%E;3*(2W5$771G F' 2=93@-Y1Z,PA'VM1V6(.1&D]K<\<!+)
MC+JR<&:741MJ++VZ+=FAK%?]<1RVE$HMKF.2<A&D:BH7_A5^"1O\1+_4S_:?
M;^@<'/(+APAFCU#D2(_VM%FN;I2+3N&Z[@$Z\G>A 0.7>>IA!OU8AP)&?]RE
MWVIU.#E=ZM2)DU,D-^: "%B_9>0N3L46&MU<&D*3?EDK -]X)T>U>:;R45F#
M5X;0HT6C5M"C0FY,@/^"KF,J5M#NZ=(0.EQ(V4+Y2]K-63W3Z=RD:)<>%TYO
M124U:M0B^M7)C5'\FB3A]^AX7,>(G!Q)'I^1T#^I6(AP&)?F(N9/RG;X$.28
ML!J$_=V3=46-SQH7'JXR$CHY:F,2"NG(X-(D4S,MVL&I$3&:Y<P%-_9D^S%$
M.'UM+O3<VVJHRKC&U_7$C6[?QT]ILH59IGR;I3Z42WL8YU/*4J(8L'$&KZ(\
M65W4&;X.SA&R,9+W_LO_^&^ 73N18R*_K$Q2:4?M3U)CW5CFI/J'2J.XM$>E
M$H.]INA?V<1Y3(Z4?_/* -7K*DY03$=FA^^XE"R,=G!J3(QF.;O!C7TQD '"
M>VETJ_%UM1A7[KI.N-'CU]Y"2BJ*/32"2TT?Y$I*]5\':D-Y8@W2S#F^8)VH
M<Z-6(U8X9V;$?\?"D*Z3$_XOS7"(0UY;Z>40I/ JR&!8;X!O9Q5M;OYTC@U4
M@[RDK;G\0QDA6!^-;,WXA"M IOQ$YFPVP[/Z@P$&Y/>2)]O?/[T1SK>UYKZA
MARY3DX$:77;F"R[A/6SZ#C-$_'J[38O@F)'_5HGR_0]?Z)_"+_R1E<L,S.%3
M$+SADZP FP;4YO$69:9*B?,(Z3"> XJ2C4P $24#<0,<2CG2OB5!3\O;[;7D
MGI1E?<;Y=\I.#/=!CKZ]$:X>8);]SQH;7F0AST@S]BV/N$9/,RI,+2AKJ*\;
MJQGD1&@SM5[>Q6BI<X2O#H_#2[(C<Q'KF,!8Q IFU53**&4UC[._FP,#&:!?
MWC8T7Z0WEY%7E?MT259Z;M4],PV13@U9A4BA'*X=3RF^W\D_GM GR)&+>/M'
M$2G<LLN-Y'Q=$7$I;TE\%/03'H?LK,J1/'#4)C-\3N$V"KP+XU)14[G%:%1'
M[3Q<O3W L#C"S6X=YU$8'0N<KO@"MT5*J+S]L3T6(0SOD'#P"4]!\W VN]L@
MC:-XGSW!E)P!#57+-C61S6>Q=<NH<_S()L!9D_4I0#4'X), K*:@-@WNQ"<"
M:"9ZC.NRF+99W>H\(6U$L:P8WTR"KS[Z!UC_B$1NI=%9+9JE6>EU#O(&[/(;
M;N_4S"QH4=OF+*B00P-\#$[P)CD%42?==%3J]:[.3:'!AZ0^KP#N!;[1?A[J
M=??CR"EG]\LL >(?!"\MZ)_"N<9.DHLL4BM[4 ^NGH3P04AW;2%ME(7D'BRF
MVYGF%:]C9$L G]%WQS2-OQS8&2PCK0ESW!;]L2*<K!(.; AGVQ0.Y,(Y(^%D
M!&M^BF+Z4_;S@J%&_.295I.R5?,KA:1 RQ&1=DIB0DBVSO,T>D.$HDWU:W(=
M'(^;,Z89W_U_#=(T&*T#-GU4N[7!9G#?^]8?'0W0X2@N9* ^("Z>></MJ:JW
MA6<!;!IR'LPG<E9"3*-DOL)H?\ %EH-WF 9[",XI_+0K<!4\\)UU\P4@-%A$
M3\&QN>9@!0SX9UK3K_18G-Y@NME1:N^SK(#A59!%6X'ERP]AT<P5^!K47-87
MT,[88IEMT_XK0$9P8ZPZ^..6N:7 10W1%YM45<RV :IJI1W_OA,[=UVDJ?C"
M5-#'IA\NH'PHA+)Q_\F:N[KIG$*_)X$#HTK3<4G'-&9&><M-N@_BZ!_\#;,L
M.48A#S%_0M^/U_W;[.ZB.(BW$2V"399"\0.].D:V51I3BQ0Z.8*U04%C5("&
M!?5Q\=E..3*HAG;^(J\^]6C4L/1,-Z0J7)K7D6U#1_ &XES7$>2O[$H=R<JA
M=;V)2F):25'O+,+S?89XA1VR[J'6MBQVD-H.^..&H-82?*-M7;PR/)UJ9P@@
M5HN&55O0"2E+591R4+7494NSL$)TY:1U]$6LKJ([%"TKK./[$P/ZHF^I-:,L
MYI=;::7Q:\FE:27\80W$:,WE1W]#0@O[ZT[/&LW5DBW-[?B2SEYY+)\DP1^R
M-AI@PYDI8JV\ZNMCG)2UKN]K<<PN[N^-NZ"FTD)WPH$^3W(W9G[>FCO"(K#I
MK[A>]WQMK 7VR^-?!]E!<,Y%_VSQ2(O1TZT:EQU<'O?4Q=0^V:G+:,8ZP@]#
M;T_G8_(!8?8,\P M@>'04B'H8&LU$-'<J3Q6'MB7K0%O[@#/IY$.2]+3 =*M
M@?2HOC1PV(ZR2$&M+LGK<N">CL&6N(3K/20Y)*2NU@:_U!K%>Y9S/[B/D^UM
MRR2EN6F+NNP(2$^R^:+O:?'.O!2%Y:MP76P%A"V\^B:$K82SQ:I*9+CNZCF-
MWO%K6V?>S9E]JZEEP]@=Z*24Y=OXB/9=*%+VZ) <0Z3$./TL_WB&[UBAR1]>
MSL?>M\64>MM,TY+BIK?T$^OU7P'MARO6D)Z _!60OFXNYG4P!1E3*6,J(TQE
M?4Q930^3U[Y.SI>\ZKF]B$=(\8BD,?U6OC6 #U?T;9XD[NO=U,Z?S8'O-_:]
MVB5]?=^K6G..$^E$- (-5X!["CY$-_3#[:T="0Y3/*02M"U]=Y*U=G&DITYX
M<F8GSHCP,VV-XTB?@C38N[S?&U&:YI&<#8V1.W33\@'L>WQ/:;)/@],S#F;+
M-F_':$_8%$5B#W>QN!@)Z.YXW+0IH&U!K;$;#TZ!]+L@2L%[<"Q()0!^NHI-
M](R4CF-/-0;XZ3')X;_\EU_^]N=_^ZO3\,HQO6HO2F-*-7\9JJUWPCBQP>:6
M%Z$>>B4<*^<16B/2[H-OHZ)606\%D=<\06VWKQTB'L8B+X1=W.GK@RC/M$]G
M'SR(>9 0_XCRFI']1 66^09SE'C^65/QEL$_"L39[3OZG]%R0;W-;9XF]=/;
M.6DIFP'2SHNZ.P)1=TY2!')VH1<B#!SOXDX_1/;7U1'' "@K^Q%EZ0C>WJ$U
MS;BY*? !^A-,HR2DF3B=8T"A'JF.9/LP6XG+WC-@EEL&Z!B #L)>>LAZC[D=
M[9+F\_L,PV)+=D51#/(#/MW :;1Q>0\;%/DA2<GS?30AS?GAM[H6]QZ$JZNP
MDQ4?3352F6RPA\-UOZ)Z%-9Q6P_J@8W(?<P#: G=E:J,%N 2]'&K+H,EMP84
MQH-26Z/REU :!\6U6E0,I@R-M'>G+H.I(5V7T536$%HBWA*)]7DBX1YI=7_J
MD(QN4!Z0N_L[_1?Z ;\5];_^'U!+ P04    " #LB658!+WC!<.8   +> H
M%0   '-Y<F4M,C R,S$R,S%?<')E+GAM;.R]>W/C.+,W]G^J\ATVF[_W65OR
M]=1[\I:O\SCQ6"[;L_.>I%(J6H(L9BE2RXO'WE2^>]"D+I2$QH4$V81FJ\[9
M9VP#('[=#:#1W>C^;__]8Q;\\L[BQ(_"__SU\%\'O_["PE$T]L.W__PU2R>_
MG?WZW_^W__E_^F__RV^_?6$AB[V4C7]Y_?SE^O;NX9?_<?ET_\M=F*1>.&*_
M7$>C;,;"])???IFFZ?P_?O_]QX\?_QI/_#")@BSE'TC^-8IFO_.__U%\\)>G
M_K\.^(_\7P<GOWWUXM'TM]Y![^B7_^N@]Q\')__1._F_?_E_+[[^?[_]!E,(
M_/#/5R]AO_ IA\E__EKZR,=K'/PKBM]^[QT<]']?-ORU:/D?'XF_T?I'?]GV
M\/?_\?7^>31E,^\W?X%CU0N&$?4[/#\__SW_*V^:^/^1Y/WOHY&7YD14SNL7
MM 7\]-NRV6_PJ]\.>[_U#__UD8Q_!1K$4<">V.27_//_D7[.V7_^FOBS>0#3
MSG\WC=F$_^XSAOZ]_F&OZ/V_7D6<R[_^ @-\>[K;F&4R_\P9 W_[?='N][I?
M Z;[8Q"72R\ NCY/&4L3K1F@?9N:U:,7<\&=LM0?>4&=*6X-9'&^SRG_+RRO
M9# 9S&$APH(RG"LV2./SK$-@K1$;0G 5S>8QF[(P\=_9?934(;A@K*9F/?7"
M-Y;<A;P!7\VI_QJP1SX&BV-H&(W^O B+_YU&P9COQ3=_97[Z60=;U2\V10$O
MF=X&T8]:_%J/47.6JU$'DXLDX=O$Q8C#YY3A1+GWO5<_\%.?)?QO_  =:TS9
M=,":\W^9,A!>+_SDXU]ZB<^IP[F;\ GDBU%CQNHA:L[QFB6CV)_#6(,)_]IE
MEO@A2Q*0NVPV\^+/P>39?PO]"=\PPO1B-(JR,.5JSB/G_8@32P.$A6_4E21;
M4%J:[ZWGQW]X0<:^,B_)XF)I:4P/Z5=WM^ K&C:>=R^ \3C;N,[Y)TL]OEL]
MLU$6YZM&9\O0'*CF?!_CB)]W*2P9^-H<J/# 4HT)HCUKSHB+2)SEV\R G[WQ
M51;#*5S:<C3FIC&&G5E6FI;->3RQ  X5KJJDGR^Q%R;>2%=KP[O6I0V<%_EQ
MD?B:>_=NE[IR[<7>6Q1>O,4L7]DZ KW3I>8<[OG&HB47RX;U-17KJEB;FM9S
M"G?_-W]T[X^X"LM6G- Z;22=Z\Z+;\%<E6!O?_N!%[_Y(>?62W0WXWH//]1T
MYJ88H.;\'J)WKU 8OGIA-N'+F)\.X9L1^33&J,U=+C!<+6-CT-(XBW3U.JQC
M;6UNPC4K/F:8QOYK;CQZY-=L+1T-Z5E[+T_2.%M0GE]WXC>MW4/<K>9<[D(^
M/GOQ/K2FL-&ZKC2S%&ZNCRQ^YEB8CNQN]ZBM ;\F[*^,2_W-N^[NL].E%2W<
MNC9N32NO?8]I\\[4\MWI!71X>SQ;#M? /4I[IK+.K=RHM&=J-EPSMROMR2KZ
M-WW3TIZG]D@-W7:T)ZH:P/+-1Y^ 2$<K-Q#M66PV;_4VHK]^*PW;U,U$?RM7
MC="(=FTP/5GW!O1:@Q6+=[:GXVI/1]#'KKZK/1.D'[7>ICU_:U^R;LDS/?;L
MGW,J5\8UUU?\0&>*VB.UHOD^>#'X5M^9/H"J [>"YUO")EEPS[^;DW576;.-
M4_^#37A5;OW0"T>^%RP\@AN>P$7#\46ZZCL(GT"CAIT[%SU]:C3[^29H4T&T
M-<=I8K8K9_IM%/_PXL*6Q77A)4$_:Z+0'[\)=*4E=!?.LQ26S?@ENDE2?\:U
M,+XGKF5D<LUB_SVGN"WPUC[?*.>OWF/KW!:.V<K]?TG<<8FT>CWYKSE'OL1<
ME_H6QLP+_+_9^(OGA_D&PW_+#/:M+DVV%;I?O/./P:_X0@<WQ_HO=^%%N)YC
MKJI&Q>76-CEKS:$5*E4X'*H.W J>Y7:>><%7+UW\$EQ' N:DN])NFPJVIM.,
MM0^"?\=9[@$4-] G1^TO-(.P@GAKC]2TC5-_ROI#-63EK$!F_:$:FO/-!UB3
M6++X^TM4;OA]ZH^FWUG,UV>:!FS,%0B^WNNCJ_/1ANA0_OWB6I<\>I^P.=7'
MJS.X9<MV!5E4#V%YCML_7T6)P5YK-)KE:"6#?13K:<5S4('+6$<K\UG$YH=O
M?!->6 /"M^)/"Z,6K.?R<PG3B=?X@A6$WYG_-N7?N'CG\WCC0\VX<K^<P@N+
M9WQ>UWZ2K_$GON@3KO/NSID5@YF";^;C5NB2_]=L 6,=6_5K5='\:WZ@57R\
MR6T6CMGX.\P#C'11?!7-9E&8M[U+DH7*E*7P]@T>_35%B3I3:<H_6,7@K3]6
M4[,N/[79,-L9Z<OUAF\T9M, A-XX34=PZD]8?ZA&/,Z5!%YOH$;F>\.[1I^,
M\7WA8?U3WG:0^R8ON(K];F0BM?6A1O'F;G5_E"XW5,LH5<,W@@V94G$9K(M,
M;_!&<&VI9?F3NUQD<L<"W%^#41;D2EC)H'P!?A>C[;JQ;S<3J:T/335  _$M
ME6PU.L,T,-?5>;RP<&VT65QUZL$P^D(S".%_5O:@ERG;:+;8GXS4&TO?L1?#
M!.Z-XL=+-HEBMOK38I.Z_/S?^202KK>8.6'J?\(>Q@K+2MK;WLQN)A,&W%W3
M!&[(3VP4A2.NVQJ&[50=V!X>. 2BL'BF?KVX>_$_B$(O*L&J,K[=2+NMHZVX
M1$*JF3C/,9/<?(R"C%\G;^-HMCKF0+&^]H.,]]L:SD!%;V<>=JFU*7"#"434
MC')[D%5B5/P,==3CJE4]FW-+\Z"FUL5XG$_*"^Y"?HS,##?'AK]O/9[4O@^R
MTN#V<=5CH^F EE_UU9R]V7#YW.>EN-M[/M4-$.PC96"\7,* CZA2:.4IRZ+1
MQC@!) F+XDUJP# )'R=/!9:PT;_>HO??Q\S_'2@$_\A)E9.)_S#,1[]X37+C
MW'*DP'ME03[^<*?-\/#@< &RB?DLT[Z5*)L'6B-3PYH/#\\/SP2\N(@WI^S%
MH^7(_)\[C-C,I[9H\?L\3Q;UVVCJ!RL>3OB)+:78XJN1]MRSA,\EFA>"]NLO
M43QF\7_^RD>:+^WC]P4MT/GFD\T)UB##;OAVFW[R)<&IG.3K&O[QPL>_^/ 3
MA&WR3D" <SKF*?BRRT@M-&)V]KK&SM+DKR/P"2(<W&G'8?8.Z)BFQ8-=UF$P
MQ-SJ=XU;2W4(S%U\I_G*9J\L1C@F; MP#^FXAI%_EU&RV8N9==0U9@GV%:X:
ML+N4S;!]4M8%P/<=VB4UL(@9>=Q51H+8*A@'3?CYW^L4G[;)CO-J/7TQ:TY,
M69.R.&'WK:@D3^S-!P4,O.DSC$^BIASPJ6/\PF&(^7;:8;Z!X3">1_'"%>>E
M[ KN]/'G5326LU':DY.#\$)0@ZL:J,1,/NLPDU^\C[LQIT=NM\EC #*)ZB+M
MPTG0K<N"+F.E>,0L/>\P2Q>ZW.)_@ B'4G8*V@\/#PFO$#58B6)!+O$'3O&Q
M9\C''L=.>*FPRL<%%H2/QM884C[V#?G8Y]A=TUP56! ^&IMAVN?C%?_G('Z)
M?F 6&:0UQ]VM6Z(A#[>1(!PT-LVTS\%<=QO$CW'T[A>5091LW.K"*7#D,B^%
M<!"&&IMOVF?H8Y2D7O!_^G/ES434@:,_=IF9 C (*XT-.*VP$C:6BYAY$N:5
MFW"$)XZQ:W?Z"(.Z:<:!&DC!XS0*F?1RN-V,(W7-?".&@#"KR[:;6S]@\14\
M!8GB3^F.N-%R>-@Q2[;N5BA @7"MR\:8YYD7!$L'BY1K&RTY7C>U$0$*A&M=
MMK?<S!@\4GK[$D<_TNDB\YN4>\(>'+^;:H@$#>)K[[+5Y8K!^[C@+ARSC_^#
MR?FXU99C=M.R+<2!\*Z;EI8+CGP,Z&\#[PV+E"BW&1[V7;-P"N:/\*B;5I1%
MQ, C_U84ABR0> -%38$NKFV0$AP(ZVI%MOR^'>UH/0(2*^%9368F7O*:P\F2
MW]X\;UX(#@O29/F;M00M?C$LU<A;Y:9<)AB3A$^:=!_V#@\.*B^$6J"P$$MQ
M0Y@HD7V_ CTWEX<4D:602PO;6BUN7@5>D@PFQ7-<<1"FL@]0A,CV+V61@IL(
M#$O!ET2,+8-"@S+QQIP&)T0GF"Y_Q%Q%H5B*SJS&SMWG!O";X3.+X5G#0Q3^
M$<$#%#2A"1JD6648( B165+)I4VFUD!G*;Z3?^DULLWP2SL,UQYFV#LY([I!
M5&>X*3I+<:!6U_?F=(N'FAR0I65O9_1A[Y3JX405X; *VE* :IEL7S)^Y\@]
MM11:W.J:IZ.^K>^$O=,#(EMZ';UM>_[="5NMPL/%RW;UM7"S(:P4XN6+,D3,
M/^'\NQ.-6IUWB[>UVBS<:@^4(')"2EDCXZ(80G?B4"O=G+QD>A&.MU.+IU=>
M''_RHR7/822[3.GT!TH1&>!U.(C<K0R0=2B(M=**1FL&7+/7M)1:OB"?;*V;
MC<2UV5/G!*,:Q@[%QU81D8<\.^484I(POA:@L)=:&O!._,RD>E59G?%*.!V*
MG:W"8WYWF'O^>)&^:IE$8X-.$F9K]![VSDZ)56]SKNOCZE#@;6V]3E>?X]#/
MB:W@%79P 0)K0;91Z@7M,V^=8Q04%KY3C91\Q+K @45\R3)0S14H.A1P6VU+
M+BK#0(;.=*L\C'0OQKO!645L'S5@KP:2#H7L5F'QJF9 GIS_"=+?#2;?$I83
M2<)C:3\XD8A"#RLP60=*AV)]*W%YK31H;<["]G!4=4)KUN.J!$*'8H"KJTI*
M'6G8.Z<V5QH;N19SMA;N2Z,.E?/HB<IC:)@M=8< 18/8DFEHDS9$UJ%8X9JB
MH&^SQCOQ)71*K#X9\D\I!&*$'0HSKK1%;Y9^>P'#C<;=%N\%9"$^?)4\0S9V
M):@.A2M7X?5NV6@M8[6L&ZP=XI"PBMS60&4KQ+D3-Z95C6TUP^4=X3I);)VL
MR'(M7 C3*5Z15W)4+LIC???3Z566I-&,Q0:LU^D.-TTW=W@#=(@8&!O$JL8*
MVCC8MS-E+VSRI5_)CWAU?[BF$MM/JA_VVO 067#%<K:EUY13ONNK>.5></<E
MOLK94?$$H!!>NV(_,U+L1(K/^9F;6SN*!6&HN0F-QD(C5%.U3*.*GJ#C$@?\
M6[F@Z\%$I,"5\#-$<]4SD:OZ@N)+[)NV(@FZ0)%'/ZX8ZJ1*K)9$:(X FO ^
MR(497$0Z7+'GZ2GW6SIN=Z[S5@RU"T@()\VM=30G/Y0A]].\FAO$UT9Y-2H6
MCN2<E?0"#9<XBM32>E9!1#COBN'NA<T@37?\61!E&4E],8.[RT5:U*/-3=31
MHZ?8ZXW' K5Y'QPW58$CLN.*_:^2#U="XOX!56XNJ]*@1(BPW9T N/)[1M5K
M%$%KN%R3IVE0\$C,6AP,PE-7['9PSBUJR"N?%VTUA;5 O&PK<A-!@K#2%;/<
MNM#CH^>/[\(K;^YSI;($5F:)57:&BZV;[-;&A@B ,Y%PHU$VR_(*[X71.9KQ
M>4]9F*R*=$.-X@>6#B8OWH?<+F\R$MQJB=6YJJ)1"2@B)ZX8^IZ@^&O(QC=>
M'')M-2D1X9I-_)$O?ZF@Z@PW8_(,/I6D01L;DN/%%>O>+GF,]':X !-;]2LR
M&,6",-3<(-?-$-L:H;5 3^*X:=NF.QE.1!#JV_/(TDX6AH<I2_T11[1O.2B/
M^BWOG%5S4!Z1Z\[:],3V3@&B?W)0EI,#'I&K/0(6*;B)P/C9<U >D2LX<OX@
MA@T,2G=S4+:?DO#PB#BN#.72)E-KH+.4@W(O4HZ>G'4QR:"4W:;H+&6@K)M-
MT/%<E,2>"1,QL0KZGUR4BV>:)^?D1DQS_6U[_F[GHMQRJ/.[ZR#.H8YS1\TC
MBY^GG)3ZL0C8"$!<XC@5E(5:L08*8&ZGM=S"F@-++K)T&L7^WVN+B)K]VSWA
MP'2:[0@@MQ-?"C'>)4EFSNJB%YQL7<DK7(/-&V <SVLI!#C(TB3U0M!=3!E=
MZ@I>N0YF?3#E]BXBQ_-4;NJ<%<YRO0$XL1S;TXUPN9_(LH35X"27=QSVSJG?
M!]=B.H+'\;25(HS*<QSO!$1Q>64+L'2H?KPM!NL=XHJ>X'[MBLF].JMW 3F>
M\[(4(U?A_-;H#61R:XGK@[*5#),LO4,)JL'!+>G%"7/BUJFM!N-X,LP=@,KS
M&ND!Y" /[J_'VPT@CJ?%W &G=TS+NG'"G+EUS]9 8RVYYC:;VPSX6I$E&4P6
M+]3Y7UL,]BI"I5?3T(CO0GH,>X<K+TS70[JH\__*2:CP&Y5!=#"**XG3$O/X
M3VO&\1\@%?DX&Z5<^V+QNS]B2- 6UA1P=^6L*C-BR]4KGWT'0[3TN)8'X!9P
M$C0Z2]J>4Z!/=%M4, 7E( J"-#3+0N3Y"$JQH#$:PG: G$B1T.&(>.<4(>AB
MG-4U>V=!E-=EN&50(^<I^O2"]%,>1B/O!4H6_7K39)@^'M+*O1:S=MV%_.3/
M .N3GZ@"F&7=.%U.NA*GCI^+!D@LQ3:1<WB97NB%?TT9T"SKQ@E*?8?38)N*
MWR@NMZ.?;J/XAQ>/E^@2Y:DJ[@"T(+:I:K!*S&,I(K>#FNK7RNYW_\ZBG+_;
MD4I/7*T(,Z93+7N[*<AP%^ME]W=N+0H$C@<B+5#=<NJ(DO:M@JFA! __O[$\
M4T*%T6#=$ >G(9R5BD$%B(['+ZUR?2[JC>JL>K0/:#9=>1ZHM_Q54!P/3'KB
M/.#T@[KBI<OB NM:J$=_93Y'<A?R2RB_=R974:(HY%EU5%@TQ)<O%<NQ#:(N
M9L?#GKZPD-,MX/@OQC,_](%FH/LN2" 1%T5/(#OQ45%-)/1PT09#(?:S'3D5
MBS=F2-/L#CNO4YRM ,[QV*=K/YE'B1=\B:-L_A"E_.=1G@<V8^.5D_4+O]!"
MAJA!N&PN,\Q4&W'8.W-S%ZB'MW;XU'DA/B%[ Q_Y2T>42!/E<=@[/R!^DUB-
M\Q@2:\%2-'F65K#6J>%TV+EN#3MC!P/@=&X!.R"L!4C1\/(A"J--; M9U;CE
M*?O"%M851XH>GW4A-18OU5:@TCM+\KSN!<@':5UW06NXL1#?XW59)68TCLGQ
MXL(E14+@88(<GH\Q2Z76/-TAAOW^@=-"8 C4\?K#>6I7E&"R$US:$?93XDV^
MGA1HP7.\'G$5MDM(<D8=XUZ/XRIDUJH1T^AT:QUUZ:W@=TT.=1T3?<DF4;S(
M[/SB?;#DYH-3C>/T0R_^S-4DJ-8$?HXH"'(J<<%E4IMO@U^%?,-N.0V;)X:U
MXLF4,LJ!+U;>)0O91)IR&^D!J8N[$A!@(AL8D-K5D#?M/01'#4NU[ (;[: B
MD%M^0='TK54OIEF3RX3ORP><EU[BCR0<%+:'5Y]NV79D,!RO4;P-[=H/LE3Z
MK!'IP<G1F;"K:ES=!&*M5#$-7[\S_VW*T5R\<W7BC3UD$!XXF.R\[E.M8*-Q
M..F.._A(72(#5> Y7KX8@;R0?I,WL(8CP7MAMT[P:@ ;*VE,_U*6JD:"Q6>S
MO3-'*B'TSHAM9G(2BE>,$$0'G\T:Q;_EA8VXZ*>?+[$7)IP&^?7\L_P7Q6,B
M_4& 9EW9)<M,%//;&%<''^-6E 7E\Z+=QIP&U'4]C1FFYOL&-K=?Z99A*1\5
M[38&&I!'K".,4?-Q P/IBUWZ)T0G/7?V8'3^;C_;[6#<>8^^CB_":FQUUP7;
MU+M@JJO,1MW2W/Q,4NBM4*TY6P1U5,UJONF,!*GNSUVP\!\>=Z6PA!%AM<S_
M.3:W;T(ZE7\?HSCG69K&_FN6PN'U$A5F YU787:^ ,G^NY* S8(DV:6*VS<P
MC!:W4<S\M_ JXP#"4?EJPPF?_Q1L1-%?Q'["S[[K+.;_?62Q'XTUZGVW\'78
M*8COB';ES4RF[5/2[1LI1J=O8<R\ -*K_CL*0(M;1RH^LQ&G1E[ UZJ0U_TD
MR /QK8I2LBV1S^V+N8 N&A(IZ05%7[IR*;-PU*N1VKK44];=WKB13;WPC25W
M(5J$3URIG>3>AM=4U[NMR6JR'YXZXI@Z[(P51(.@>FZJ0]S6X<KE; 6I( -L
M)%$(2TRW3K>H'U"F8X;0G%4*KDJ@N'W[V0*F=$$)VP,ENE)"1,(I)&A+@LAM
M37_ST%-ZGT3-@0[$=@\9?\0<E0!Q7M==)M57<G.G+=?VJ>MVF;,20^&V(^IB
M//:+J3]Z_I@KJM[<Y\JSDJ?2?ER;IZ[C9,Y?'41N9Y*]&(VR69;[Q+%[O)KO
MNF,,>V?4M94KR( A.DN99LEJ.SVQE).$C9?1XAIA(:(.P][Y(;%9UYS74BA[
MDF3V*O"29'&1U+TJ;?>!8ZXK990-KDD(#+<SSY9!*>]'NXV'O5YG@M01_B"Z
M%P:%-@TMDCSNF<4^2RX?HO"/"-Y8H\8_>34&PV& (L1*%\JF3:[60$>;3%;*
M[PL[_-8>AB\8ZBQ2YOPV16<KO6R90%\R?^R%(];R?1G@)OSS"WI=?GX+_;\R
M=LV24>SG"!4GM.X0<%?IRBZO/K -43F>)'8'[8,W4]?RD/2"!4=L%3/DH*88
M[$#L9)[8C6G;.09J# F4(KYSJ_DH.!OJ0[:597;,)G[H5STE-(2$8[C-P+'\
MW8MC+Y24=]'M"D'2Q-EA:C-=#LU6"6WJV_A]Q?<:9R==R?YC</_>GK_C%;+O
MPE',O(2?:<7_WH4O;#:/8B_^+$Q/3U$0+.H62=AK,@PLG:XP?IN;8N970.=X
M@>TM?"8)!E1=X9$*\8N!"OP4"X8F5EMI9>=Y;"$7WC@E%XDK?J)]PD.D692%
MJ2CP4E]&U&/!B4FL 38E--K@;66PK2-%B":XO0Y 5[I+DHR-RT&QQ?)X8#_R
M/PE+6E<>C%_"CNE3+]03D-KH'<]DJP?]#R_(F$R(Z@P'_D]BLT-CAY,!?L?3
MXC:JO9P?$GL-6]1><JRVTN86Y\Y-2)"\DEAW.3_>4Y'1!F\KK2VA#.W2<#>.
MO>IE63H2N(RZ\L2ZZGU9!V#M%+E="@4V.7,4/>$22>P0K<90L7#HH;65<Y?T
MREP*K361!UDWN MV3D&M+@P:4&WEZB65!,%;.)FM?+LQW.^(7=\VN8X"M)6_
MMP$3A_0B7A+CBW"\X_5Y8F]^ FG^Q]=^S$;I8,*QB/> QKX%-SOB,"H;(M0T
M?6SE":X:^FPF??GEO1WAJ_,IN$AVSCAG5_8LD,=6"F*RJ'O%LER[Q4NQ#^LL
M"JH#L?+ < 4ECN*W?GC6)08B:\:6XJ[)VF(96A<UO7$Y<<\[9^FQ+FE&M$ $
MS15+<F5/EMD P_[!/AR0E4 C$N)*Y&M=+Y6>6Z9_T"<.F6EK8]G&C(B'*^_)
MI4LA3^*:Y&&9E?>0\AA0Z^1GV48$N!%1<<6 +%L5]21E9P@H>O*3["<"V(B<
MM!1W6\6^M-H4!Z$HZ9/9 )P*9WMP'ZH$&F%]2]&Z%8P[-3B_TY_3X'P/'$E5
M,"-\=R4<5RKFCUD\FG):#B872<+2RIK$]CC#_N'!SZ)-(-@1L7'E6;ULD=27
M&N$P0+B?1+- H"/YKXB?[LN$?Y!/-KGY8/'(3]CX(AS?S.9!],E8WF_P(^1S
MF?KSQ\ 3/>>T_ 5.Q]Y/H9]4H0HB7<2) B2KI$GA,O\ 4'$/'.F-$ 41K;TP
MU6Z 7V[<@+VRMH2/R,G9WZ,0G7I40(1J'ZR[*/:*JA0Z'B?E4>=>S#6C4ZEH
M@(@3>;($>-'/R9AC>(+ZP]=^4@1#\YF^1*7 @ 7)L).NREB<-L?[<J^O@1^1
MC7TP_^:;[26G:UZC@(5)SM^*^XQX,"#B_M_VU01 I,B5I P7X_\G2]*\3,-+
MA*1^%>,O],)";WQBA=&</;/XW1^Q@GA/;!2]%5E$)*+7T@PXNZAS_MF4UW:I
MA@BY*TDK]K^>&&=3YYZ[5Q?N]BB&"+8K=OY]*AS6)R]8T88(6R(3(K>N.!JJ
ME8[ET/?(52#"AM10:,D7T.$GC?W#LSW:'/30(L)@;+HG? /=Q(-&3IP]V@4T
MH")R8)[[ETX.ZCYG[!^>[]'R1P$BG+:3.8.L]J.73&^#Z$="4\UQ]7FS(HX[
MW8:]M0RV#,*X=N-Y=^JB8W3$5H8 B=LE&Z_Y6GSG#( + *= !NB>_$15AD36
M#>A"?-L7,DK,4PTD;M=K7 ,$9P3(^ O_FC*9N:P;T(58R=%@FXK?*"[2&HX&
M3KE[WWOU WX^*Y-3J[H.>WS:76$HRA=-_YH8F]MU'!=ZVY(TZ@I@X@Y<[SON
MS,+5Y+,6(K>K.]9./7YR0NPP-SAPT?F[7;7Q@:6@3#[&T;O/+R67G]\2-KX+
M!_RRX\$6=3'B,E^83]6:OOE@L,MU10:V&8L:&*MAM%3-T2G;<N_PB)B[E=FE
M8UXNX+E=S7'#Y0T^ZG#D!VP#YTMD;XMHXG-\O9X3AZI;%K,&J>1VB<IKQJ<Y
M\G/V\G\';.&FOIA%<>K_K0K(TND.C"&6I@;9C]TNM>E"6Q.SOLYJ',,G#E/C
M^CNQL:AU(9%2HI.E,_-7YS%@YC08L21YXISB5)YRT;YF[RR(YC-QFFF3[L/>
M:9_8C]*:+%2@BZTBFT0;QCJ21&2[2SB-'V.62H-[=(> ;,[$YJS6-Q5#VM0N
MT'E>"%/(WL"C]D*DQ?C)/$J\X$L<9?.'"$+K1[E%,&/C!2'7X7:<,HOF,L6F
MVHC#WOG/I^O4(E7M.J&=$,#\J?3=;.[Y<5XMG9_L;]+\6.(.G"8_W88EI82M
M0J'D9]VS%S HG!EQ*J6?\/0KA9@*3%TR&X 3ZXS8ETYXSFE0IG9)TFYL,J-1
M7%PD2[?(P23?;S-.^"(Y[\S/9LE=^,X6[)!M0I4&'/8/>C_=)E6'4K5KJ6Y*
M'T'\_I)J]Q!3ECM7!Q-.T'SK+E/DY@.NL;(@(-.A(%TB<>[9UH6M(HT<K\V:
M/T5XX,3EE"PHJR%-6!](G?BSG8@J8M0NUTJ]#>T&MZY(M7A*J.$OT1\$TBK^
M+&:HRM2Q5;VU,W7"^4F?G^B<VLQ_5X2TZG0?]@[[G7OTJ."JKG"@:&N7;.W>
M7K/$^NA]YI4 8V]<333* \!B[-QS;\O"(<#K>"'67:Q<^9][_OAZ,?G%P<MO
M!?FAK$Q%6&W 8>^T>TD)+0F/ ?[:A5R[M]<L@QN_^^GTBFL _*R/5^&L1G(D
M'6G8.SOK7 8F2P*D ]Q6^=;.;$.;-\=J$H., 23;UY-*#MGQ J["@SG.^*07
M..%NL-A7UX18_\U4QS$8>M@[/^U<<B9[VH\Y)6R5A^V,J!6G]:8B:+8;"08
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M(DH%;%HN&!ENIUS0S$:$=P0VG;>ZC 0I)A#JZBRN"J-QR&?$YF,MGH@7777
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M:_;.@B@7_IL/<+ SM2A4'8H3YMBM#:,F4K?+WA4/[(J7=?K[@Z07I\JIF]N
M&I3C!=U6"35+KT_N0G#NS[0N%EK].:G.W+Q!F,!SO%C9$]_;PHPM2J'DD8#:
M:U_9EY.(^HE]10G0A6:M4A<5]Y6'G#P62M5[V#^DCDBL+ &ZX*P5LJ*1@768
M<SGF<I%@(AS?Y1=HKOWF,9=*F:@P&B?CH9MZ0G6PUNI&V;PNO+#9/(J]^+-X
M)Z[K1-3NR['WW%((3*$A;&W)<(BP]2Y\C*,15VG%6UIQJ5T]E4KAL;(_7KPW
M-)(!ZQ\"JG:XV ,F,$W1 9$N5VR5@KQ?ZO,$[\2)TG=+.+0Q(8QVQ01YS6+_
M/<]*8&!(P#MQHE 7K*S(:"4FA-$M60WMQ7@;V).1+IP@QVXJ@0I$"(M=L0J"
M8ANS*==MN1074$V#RW2' (*Y&9U@B! )3G+%>+@=M*TO"8J>G#PG;KJ9]8 A
M?'?%5/C ?I3($T<A_^>(E2RB^H)@.A00T,WHQ(I($5&I;U?L?!G8/8C_[IO5
MB].N3V#FJL4[0NW.[MZ<^KMUX(Q@[??SB)>\Q(/#BZ-W>&!C=3R/IFR<!:70
M[_&WA$VR  (U\EKV2,Q/3D#E&K(T/* ESE2F9(5@J=E%[^J"%-4R;7WY-5+0
M].C *!%[?1?32IY6\RJ,H%QV2OOY@L[C0?@$0=Z09"!_N*-<LHU\!\A$[+S6
MX"+BF&J $&X_BUK100/^MS!Z35C\#E2X"^=9"F$ X8CWR@7 J!2OQ<\->\?4
MI0TK"V2#]'#[J9?I^N0-'J(PWB 8]%^09C0-_;\RIK]EMO+]8>^4^B5V?<EM
M@4!-/5;K1@WKUG6GQBI9'[6<)')]G(N+,C]/HSA]8?'L+N3Z>9&TM(+25'5P
M( BQ/4&+8RI=J29^MQ6D:_::KM?JQ;OG!P#R-HHA^_HWOJ-Y@?\WQP"Y?J*B
MWM9J;]06-HM?X<?_&?'=NH;4V2>$VWI0:7%=!5Z2^!.?C2\_\Q2ED!+<"[YZ
MD'<N_;SV4GUYJS,L',K$%\ : F8!N:OJR-(\5;9,/;#V;3?*0O 2P=4H(G]D
M9DAM#DZM5Z8;IRCQ?JY+=/&*TX;HJD%473"=P#FA7PE>[J\PJ2A_=-!R6K25
MBBHHUVVNYZL&X0 [$)!OS!"5>J\)V]75B143;7U1-EI#]NB0RG4AI:_9 M0;
M"L!VOD!MS@_5RC/"2WJ-5GJ;+[T "I FU_P6%EU,)KE56F,7KC(,7.R(\QU7
M$H :6)NZQ#:N&FU7(F][TS4KJF[VX$)6G;W7[[5;5D-(:9WM5]X1@! _5*U$
M>?'6JX75545G4?RY[156N53XH=EM 0L'%+B?BCP5>F>/;G\^7VKE7TA P1%C
M",EM^WQ.%*A+I;WA(3V&O5/JN!8-!NN!<%5=,*OXWOI65[WN.]GM3%SF_+L'
M99'39! _^6]3S7SR5<<$^,0+2\@/U>VL&DQ7M0>T3GSKJVS@1K'XPU76QY:B
M-A8>JN]^.KW*DC2:L;C09]<'_:?V(5AA-(!,_ S-)NO$R[\Z7=Q=^**:MZVO
M^NY6OCVD"FH2I]')^57DTDD6%>;TEWW]P8$@KM>_/=0(>JI)'[<O50]1'B61
M9_M<9 ?/D>=$,9>Z*L/!388XNT6#<E:#(F[',Y6B"DL4!5)"B-=V9>D+T+7?
M%L=WD,\H/]W%BS-GR&4>9U ERK.]^0 GB36I5O;0]DGJ=ED3T>FS)-,/+QZ7
M3Y]5[#S73K/9O*K+U<:'AKVS,V(?0<LJ06U:-566A:(F-T$@19N5N8\.VPTG
M+(<'E.8(.?/B=W;Y^<*_#4*>:,475AB-(R:.-S1DCCK,P@BYVZH[ GM-Q7PO
MK"$ZV$B<>,2I:)H4&SEJ5_TMI2KNK>_B#=1R/VK9)+N6E6):EVP2Q6P]1?X_
M2>J/N.QPS9?Y;U6N)95&!E(07S#4C%*MOSK(]V4/OYE,&&Q?:P(\\3UHZ^&W
MN5"9#PMQ:,1FO_H251GVOMA<KA>SY<A%02(5),EH1'@_17Q1K"]$51"[^F+L
M@:7Y0\M%^L;V RZV\D?JA%X@78;]?LOOPDHO+,+4'_M!!EO/^G'KS<<HR#@K
M;KF0@LTB6_HNMR$8OF*Q]#$@&/$]4,%+U4JU3(E]T2F^,PA<X?>B=Q9[;^PA
MF[VR>&'=JG($&(P'E"2^)-:4*7.PKMX-:V<L_6EB_0]/S\]:7<M-Q?IS(,2K
MLQ+EQ6M6"ZNE/9UO!J\1R:-CRE?&C]YG_DG@$,S&"W0L[Y)>P\/SHQ,J':V5
M%\0<(/'+-37YE6J5'DAWEQ8_[$ Q]$+(E)$G*H/4KNOAKUGJ^<$_(;$[<97]
MWI')ZD5>]$AIGXL:]I9'W1/F2%Q+PR:M-Y>J&0T<O\XL25)$Y@/J*,PI].$G
MLKU:U@\H0V3D-.,=LD5K8'/;DKD%[#J:>7ZH?(>SU9Y3HD_\'D6'4V(>RQ"Y
M'?S$,<T6 ;9?&=RJI:\7MMH"!8@MRS+.B'F)H6@J.*BEG3E[3?RQ[\6?D+%O
M\8Q*M2MC?8:]$ZI7MU9V9 4N,:=;*HM:G]-K3 _>C/^SE E#N36K.\-J('9B
MJ_B'<%T7FIC]KM0M?<R+.$(1YZ)PDW+7%G< 6A"KY-H,$_-;BDO,8U=*EJX4
ME3Q7IN9FCO49]DY/]D&]1G").>U*S=(R*.7FO=L8I)TX/D3%'T0)PZ"(V=E2
M?5(LWQ:+(8SQ(0K_B,#5@N9+0/?B*L, 08BMEBB7!!:0:N@0<XAQ\=$R@;YD
M_AA2?%GC_*4=SFL/P]4<ZA@ <\Z;HD,X[XHE#-Y"@=:B.)7+S8:]LSX16VT<
MQ (H" ]=L6LM$2D/WLV&0"5J=](N+^1,VY@YPK:63%;85COG_X5?%Q:=.[Z!
MAQ!"! @4NZNR)^"F3N8M8H1H,]4%@S#1%7O53G"!?!\5-1_VSJG>OMC83R60
M$-ZZ8J':1J;<7\4=@'K49;9Q'NDQ=0,)PM:6+$^R??=ERF)OSK+4'R5\R]'8
M;X4]0$>D3M4N8P"VW\K ($QKR914Q5E_[X?LCM_)1?NI06\NYT<.;J_F"!$.
MNV)"DCR87,;)+DLV)3>!/X, /S9^Y)>V"/X+^H5D:[8P.AB"B/1E<V$0;^OV
MJ( (&ZV!Z];_8..;C]$4<H(\ 5VPK6.W)5P_'.6N'!$2LV%LFA*$TM7AU?8!
M!\%,/I]:L2V"!Z68V_+^P 6%"^]=DA2U<N ?>2',/'0>8[/5CW#:]SKK3=:0
MD":(@0B7C3C-MMR09<O>HQ</XMP3,,Y+ BZ?>4C=DCH# %<Z:S/3.SN,@")R
MX8Q%;0-KR1!<_#/AL+#CQ70(3K#SSKHUJTB&$BHB&[1FNT&6)JD7C@N]Z%O(
M/KBZXR=L(T$3=LQH=1[V#Z@265LY/DQ (BQVQ:A7CNC8>*)7'(9W82G"0S-(
M234,)]P14<)*6]M !;B(G+AB('R,HQ%CXP0> ^?J43AB0+G-@![I(:$S "?6
ML:,[1R6@B%08VQ?IE,I%AL#%:E@"SG,_R:1!THV3YM3Q_4$#'L)Y6B/E]KVI
M5-EA :DPD.A>0K'^G 9G^W2_5.!$>.V*N?*%S>91[,6?Q76YPLU1<X1A_Y"J
MLI"ME6^&%!$,6M-B^0![\KB$AV]7WMQ/88;B98_WX#@/'=W+]9 A3XF,38YD
MGHC4XU08+Y-]7(Q&V2S++>77;.*/?+FC0=69$\E5.Z(Q2$02].V#YX4DA.P-
M!B<(;/:2*?P_[%SO_((3YAF[GJ=1G+ZP>':7)^+/U1I9P+/V($ V1[T0E<$B
M,M+]'#=ZB6P>H.07A#ZU__!_=S(:K_GQ3I#HW"@)&N;UWY&.KU[\)Z<.>!=6
MF;;D;_7UAX!9$P?-*4DJ<OT;(^S@D_PD3DMRRG]:RRC_8?@$ODHD8F[C[X"0
M-(;#F!E;'!6 Z>!;>AUVX3%5FRTX2C(M1T!MA!\;<^W@"W@%1[YZ'_XLFTEY
MLM$&D%)=/80TW^6+:+YNOVE?96*Y"R'\)J_](0\31GI F1K2FT/-;5 /GMO/
MVI>!%+G2R^)W?MR';Z5L/&O("=202,1_4H8:V_P,+#+BE"9RB4"L2O9)0/JD
M'M&6OSU?>N&?'!I,VD\SF)P\L!GO 3")$YTTP#6!]JPD >G#^EKWHGME6+39
M,+#&B#(HV-&MJV-V_,T]QWQ[?7?%13SC4[V8P1U3887::3_LG9R1VJ(K,0ZW
M/&$ 2=_CUV;UW6SN^3'L?(/)?12^W?OOK,AKF_R;!5#+Y%LB<S5I]>>TI3*4
M6!<%$\"VWNYWU/[(@4ZR  B0FW.C.8M3,/ "J>= H3VP2])5V5L2%-ZUIF6J
M8N9+TR$ 7(?-EUJUT+00=M!\:18*)H98E I4I5=0]P8J$;\B-62H6"KTH7;0
M0&I#( "E.E.#NC>G$I6!U9R7AK*P@Y+4-(M<U_@X40RM/U?SEM_+T0X DKA:
MO3XK!+<O%3#'S;=9'/HIE/H*Q[?^!_PK468KQ#M!43AB:UM59FN#<]N$6]1U
M8K%Z62MZ0/TVXARD=5DM1]9%>^ES-$E_<-HHDC]LM!KVSJ@3^]?:@(5HW,X=
MBM)#9O_4[PP;%;$EO%EU>ANIV[9.%.;2NC&1O]%5]H:UU=53>9N5AI*P [(I
M6VC3]JY;SX_S@/&OS ,+;^X)6GF'1.54%PW'%^FJ[R!\ ELB),#(0QS;MWZM
MIK(N(JMC_Y)U@QP_[1:16\U&1O82K7F#ARB,-TBO,I%9^P:0A]AVHL$]1->V
M3 2WS6PK:EQ^EC:!VYC]E;%P]*D*JU'WYE0Z(K:JV.:X0JZ4M'#;#B<Z-%8H
ME78XC=Y )6)-4I^7"EE0HNQ@B&1-64A6ZTAMT]'H#G0BOO+K<U-?&A"8CAOV
MULMF]<]_^RSFY)Y^WK-W%NB?)Y(!(%$X<9[EUH\4-3G<-A&*KR([H"N=+^@X
ML.B(K51&+#;87A20W2YUM )W%\ZS-,G)=*A_VNSV JH0ETNIPD6%/* XW39D
MBO#U*G&_MRX\T95MH!'N;^)TVW IPM>OQ/W^RO-RTA5;1B/<W\3I=MPFA#1R
M76H[LE&N5>*=@";$L6#M:))*$C06L]F.7.1YF/T1I%X6(A7_5KEMU!D6UBEU
MF2X5U\7"8@&UXT6<OD8A^RR"I6^S<*P6%'$'( ;Q]F*!EV(AD2)VO/Z3Q?>E
M9]1E&%NR5$CQT]:5^CE?H/:I:G3HB818C!H@@>/EL+X]O\3Y(OU<O]A1GD9X
M)TZ48V)O7 ,\%@N3D@J.5].ZBF8SR!CM!8_>G,4Z,96[[<$F0.Q>:4T@9 2@
M+<%E89OX$KVS.,SK+4<Q)(?,TX=SDEZ\L1">&!GM'\:C\0O%Z<^SL50E#VW-
M, L[3@&6749 8FUYDO8#A8#8^MKB#J0F!&W5,;2N7/Y<D</,[Q)/_MLT7=XC
M/N6!X1I=H?8-<:QHXR)@2 O:<F"=B&:\UXA+M_H=(#WQJ[&6XPHL4LU6533*
MTK1KG\LZJ%3G(;VJ+]PW]L#-L,URL7#I4L-6I;.N"4P500&2$.\\NFPS9/H"
MF>/ERTIKI=H6H3< W$7WX #2VR>,2$);XJQA^:DL-["XB/5F(RY6$80%QL8*
MH)&\L2),8=[(8ZG#U6-?=ZX7+3Z6.NQUQ0F(<Z^YFT*9"&X_EMHNR*1P"HN:
M QWV)W8]YZE$(Q2#=_O]TS8PI5]7W %H09V&#&>1'D\WD'0QH]#SG/_W9<IB
M;\ZRU!\E=^%(D<8"[0$PB5WJ4OH+S(U*,&X_-\HKGN5.F,!+EE40%7LRVH>K
MJ*?4.;M;V9A5%'#['5$9E')GWFW,*=<G=F.J^(-XEC HG<PHQ&+(><F%]X\(
M_"&E"N>/&Z7/%7NUV3! $&+K"LHET>9="9VEISUE^GS)_#'4E6UU'5^SO)0Q
MOR*OW6M/?J+:WF7=(+]Q5^YAC>[P&D1P^PW0&B X5.$2JY4#5-8-E@_Q\:_!
M-A6_45QNO_JYC>(?7CQ>HM-(%BGL +0@3BRAP2K$$"-#1/MXARADY.2<^#9F
MS$M#;(Z_H7$T!.2,JGI'NSI"$U2C??6#;$/;-A.^_A*?3RQGZS+JB\^LJ*1^
M%_*/LR2]2Y*,C3EH^$=>+P/JJ:,5@JQ^A//MN"OYCRQ*AV O;()LMMX:\;O6
M:[17ON(3ZM3)S4N5$2ELO0PBDY3\]E^LANL,*/3(-9)H7)!XO:KDYE"](:"R
MSQ[<G?6DQY HMIX1D<G1%ZZPWD=),@A%5]#D@:6/,4N]#XD<Z0[!Z7[ZT\B1
M(5%J/T$Z+^0H9&]>RL8O36I1^1*91@&?XJ/W"7"*-:*K(&']@9[4[U9I=!\%
M16A?#NGJUEXR74S^A7=, (Z97. C#'OGU _,J+1B%4UH7PS9R[906?/5' '(
MM?>;2S6:[,MSHU*0Y7<_G7X+H]>$Q>]P2RPR8G'*1IPL@9]S_FF+L LSW/+@
MO@M'039FX[OPQHM#WDS+#M7T'(;] ^K:*BV*<<M4K?V,2:&$D80;7TV]\(UQ
MT%M>A!59",.0-24H9^,.TS=Y;A+&W,!GH1A(GV;;JP]".QK:TJ> 6(Z9HRK(
M@F)/LTM+MV.K&PGX..K,06F7U57B/HXDQYMS,F(Q[N.(NCR)!MNJQ'T<X:5&
M7'DV9RWNX^B(V*FKP2JSN(\<D:7P;3+#L\7=T2A2P.+GH()<5P(&VCAC&J2A
MVX'G%@ESY06C+"BNL5$0++: =@1;_&W8;[KR.,*^X#4NZ5*B[DDI#D/[3/(D
M-M#D8S5@99-^#SC1E8B;AJ7-KI5-AZJV7B3D'H_GU(M3=Z3<3?MR[_BT*T^4
MG5H-52E=]S&&#;]_UY;(,TO3H+!>M[<F2A\=]D[/NI*R:Q\6P2YIZSY)<5KJ
M.Z;^G%&GWW13UG6H:NMM3J'_W(1C<F_BL_\6^A-_Y(5I091O"5]_T4V2^C.^
M%%^F;-5M,%D;OKK@;+29\^AHE=3'.0,#A;.O*QHESLOVG'5X@23*6W\2IR4Y
MY#^M99#_,'R"& +$&[?Q=T"X/ZI3F6E;P7H"T!WTK^FP%7^.N=D"3E&BA2RB
M-L*/C;EVT .FX,A7[\.?93,I3S;: %*B!2>F^2Y?1//MI/=*Q1L_5/.FW :N
M^$0Q"-J\$<QW3WPQ3=>A/S[K2DAZDP==):KLGUNCA7+T1_VNQ,3IL%C_,JV"
MO'\%R6N6I#ZB+HE3A8L*>4!QNIV,R&*QT-.SKG"]E>-$2@:W,Q8Y63+TB+Q6
MK50BQ%+4  E^RG1*1WUB"UT#C-RZZYC1PO'T2Z5S.]^=@6:*<PGK IZ,KNBE
M;1Q,"CHX7MQ<A$YYT."=8+406WL5_-)G\@8BVJ+ER"FP/>O'.'I=;%Z#R7,V
M&K$$CY(W' 'H0/Q<6LDDP0YO#)"V0K@FHY^8/WO-^ ?RUR%>*C'9&W0':U\'
M%Z\IB^7H'"_SO0T6')A1IA "_<Z@7!-K?H8B8(S-\=K>)9O<2E/-$XGK&[%W
M^T%IMJ[DPFC9=HT2P_'JW!;IN4TD?3MW4]\&[U57[B 2$6H\AD1*G9^R=/CQ
M'AE-I=RM:LTXQLVI[B7X<?FEZ/D>/3(R.''MT]#Q6N."F-AM758BFQJ].5^H
M=?H&N2\6-WVR-%9XG#:WT]5[W(40ZWW*YW1X?.;J*==^B/?A<5?ND\W)0N,G
M79F6'0P1KW3(6<SG='BR=_%V.:M51QI*BP[&FU>2$9MUO(Z)[00:;%/Q&\75
MQ2*[35_P#X^)+_@:?*EZ-\^QN5V%=R^NYB=G^_, 5GVP-$C#/7DXL)])G Z/
MJ0/\FA.\QB5=2M3]>^W@8!:#P^/],7I)I4TAZPU0]9\D3CODR0M$M9B<IO@>
M[';[XT5H4<IUJ.KX0Y2?*TG9Z>$_NWV+E+:;KLGYU4&?G^R,ZEWY7LK_+FEK
MOP)R5>([IM6?G>^/S;\[6GU.55M/G$ARDT%9/"@,_>X%L&HOPO%7+_Z3I7E%
M:,">,VJ9E6Q<RDFFUY/_^F7*OL3\4/P6QLP+_+_9&([)W+/(?\N2]MWL,'7^
M^6T$:D>YO..PUS]NMW31-7M-2[1^YW0$\O,5\<RGIO)>:_0&2,2.("V:8ZX@
M78!N>XDM/I[OT[N)='F&[/129&Y[>IU\#]\G-Y=+)4(L10V0H(,IU$S>3T4A
M^RP.^-LL'*N+"(D[ "WVZH5\']<YI11PVUM]%<UF+ :2/'I<;54*@[#]L'=R
M0.PO;DT69 1PV]E[%<7S*.9W@\L(:+@\N#5$0M)OV#L]):X'U:)HJ GAMF/T
MV_-+G%^[/PWD ^_$K]W4"=Y:$PXE%=S.^?;M^4OTSN(0R+%<!V!UX62]>&.<
M7BPQ$AGCT>#!(;$CL$59JDH>MSUZSZ,I&V<!&TRV;Y-KN#HQ<T;CP-E.+%AU
M;])5\+J=;V[;QI1>>7'\R9=C\2!"SSZH'@"H3OS*HPIO$?7%!#)M3KB&Y:.R
M7'#B4+_(,.)B%4%88+26#BY*O<!:Z/WFS+?\%&C4O;37L'=\3KS&:_!4'R!M
M&C=3AA8.)V..%MW@+D9LKVB,I1L(:^=LH_;9BUU&@N(UQJX^P1AP$2/6]"SM
MWB9P:=.]U9807.M907Z)+F91G,+JN(J2-/?_:ZB -4<&78M8%["G&]JAA>.9
MY[:)L'4MVT%O(%NJH4#I(C:CVA$!/?'2)(>U1':5=-"FY6DTRF80',75M-V@
MFTLVB6)^]?^H+F1ZXX-V2)P2DU#RC&CD>+Z\JJ0 C;-)<=P8'Q1;8AVMB^(H
MHE'M['?4RC].Z$VR7&4Q\*V2*B<<"31CXOMAFT*F1PU;&?,$]>FZ$1J+D^4N
MO @WU]ICE/@PL3V*>#T\Z;6ZNEN(>#T\Z<!U7DES\2+5!_A/Q&NZ3"5#GNE&
MEV=BGLN1_1/QVGK$:^^LJQ&ON42(I:@!$K@=\6HIQK%'G4.T <9B@6PX 5P/
M=VTDQO&$NAY4BZ*A)H3;8;#68QQ/J9]-M"8<2BJX'OU*'N-X=D3\J*M%6:I*
M'K<#::EB''O$FU3=NU,5O&Y'P^(XBU2;690E8JM5R8X,OZ[E"Z_X+5C[Q&ZE
M*A)C:E"M1QVW8W#E*UI%F7N6)"]3+SSL?>4MI_(<V38_!+0GCO=K2IZJ6!HK
MDL_Q^.!Z-%G28A#?1^&;5 NT^R'8I3KKN.J>["+D<[S2M9PF8DI4EE#Q<'#=
M(S:6=4D.I42R%G=-$\2$()_(D&LHG'6&A65,[/BSIUM:( 1MY>Z.Z9%;J[LU
MM7+KNT-XZ=#)&[>)9+6A4(H)5SMJG3JXR:[FTI94*[[+Q>*PFW8D:JG6(USM
M /EN2[66OF59%=TA]"EU(#V1A)J0IW9@_:8<OFRKIMT(^'OPXC@O8[1'47R]
M5798B\\N$?IA,7JF0\"LB=>D%EDW5UU%E/]$ZRTBF'KG1/IO1<89ANSE\/X)
MV6L_9.^<NAR(5"):"=D[1R_]KMSYR][_I;M_4[TQBJ^0#0'TVJ_HK7-40S2D
M"6FL7RW51!8A4648T+N)5!0KQU4-S*31?(@0R&\Z_$X39U"RA7^3)>G%A/_O
M11!$/_B2@397?,Y^"M>=9\[%O() :44M;T8W<.-(?#[LO9^D#U&ZR)S QK>!
M]X;)%?W,@/]$-I@:4B80U\Z0TNVH1049RT\(Q?2[^8 22/Q$VB)Y94--C6\"
M1X@B(*T)=UM$<CL.4M>8M2S49<%LN!P*N$:4N:5E(4.QNQT9*0?]9$MRM@<"
MASY13&/+<H,@W^=X17U]H_JYJ/T)B'0GNK.V?0R:TJ2QP,-N^"S SP@FZ<P+
MOGKIXI>#B3"?0;I;[&N//!U'J_AQZG![D. U,Z 8G1\.0O9?S(M7A*\46Z\S
M,!"B ^E)E9P2+WXKV-UVJ>B2(-_Z. 5>IG&4O4UO_?><&(E-$5-^8]@[I@[L
M;$':=,G@MGN',+W2:1<R*C<B1!A86^Z8MB,I'N-HSN+TDQ,+"#4'.]H#2]?Q
MK4B#]A6-Y40> R],R[/1T#64?<&D<MKJZMRE\,[D5#F2=(< <,1O\709(%Z2
MAD#=UA=0B)>?X!Q4A&-H] 8J=::HA19#Q5*A#]7M<QPG$?^H,OI"HS>$7!-G
MLM;GI:$L[* DC9M W)U\'$A_$,6?JWFCX0_R#@"2.-1.GQ4"GZ *F-O9B6ZS
M./3Y)81QLMSZ'_ O=9P+W@F"RHDO:U69K0W.[5Q#5]%LGO%OJY>UH@?$;7=U
MB]9DM1P9J0\>V9:?HTGZ@]-&OA=OM@(K-?&[KUH;L!"-VY[F>^8E;!H%X[O9
M/([>\U 1];8KZ37LG5._@JJ[&-7HW/80H_2YUTBMI.X,A]->7Z&VD;KM^45A
MYEGVJTA"WA%6&'$PNC8##?E?QN=XJI?2"[AKQF<\\KTBL_L\8#FWPO$B%BO_
M/4H2F7W<TB> 5\3Y_VH*E&5*U,[40OU>%@7XP"K9JWDW4)B[JF'6W'76Z!I+
MFD+D3R%\BMJPWZ3?<EF)5OTF?>H"$[H,J.LWZ>]!H8FE\_[R\R))6'H5>$FB
M>KR*]0&*$#\:,V0>8E]3 '3;,[)"EV/C]U?(3<W&@_ )O/2Q'[[E19.^A=%K
MPN)WH-9=.,]2_N<H'/E!H9R42:-TIS3U2> 'L>JGDA6%A#5#$+>?N:(K5VE^
M4O0$ZE"7+FF6\8:JXP99W/82W85<FV2K5VWW\!%@K?PHD_2"\I7$?B(KAYD:
MHMO>(@2?\DR2]@.*$C-?S3<C?F_@<OOMYA/G!Z<EA"I>LW<61/E*N/F8LS#!
MW4X&O8%*Q*%?.EP4\U\?G]L.JB\L9+$7@&UL//-#'VYV8"O0E0.M_K#2B#6&
MZI)@@O ?QY74+G=ZN@_W6FVD;CNN=&SH$GG0Z0YD)G9E:C-3+ L&*!UW9?$#
M,8VS$3QC"=\XPB>6>UH@@\!#!EL@7U.+Q!?)3>#SG1+^_,AB/X+_CN1>+ NC
MPQ;L@ -+(DSVB.!XE0%.QQ%CX^264QB>P4BV:_F)I#L*L,5MV3$':\W-1:2X
M+M(##$(!7!WQT!L "M1W-:A93S*,<-9.Y[^5G+?MA^Z+)_V<2H-TRN+%.[E[
MWWOU@\4[NK9]H(LIE>:PG%WY5QIETDS&@?"9H[9#76!Z7,:\6.]AI[ #3)QX
M)ZY":#0B!8=(ZO%$HHX7$UXF@F!CL1D$-!(T^Z')&!"J07PEK,_MJJC=]G\N
M //39,*2),=PRPS6/=(18G"(XQZLKW\Y5+>]C#E==BFF%@-Y1PC^)U:[[(F!
M%E2W_89:Q*JKW,#K .K*;[;W!BW$MER+;0<D+@P8CQZ_;N1YJ#E1P'A!&)&(
M34E# 5=U'9[TCEM==&MK-C:UR\^-OVC')AJ,-R2O[JW'%_$JK &Y@Q&+29R6
MY(;_M)89_L-P\"/D'YOZ<R2<8Z<-!]J9V UC_FPIZ6)L'=3!=9F(AF8(6G&P
M5,E#Q727,*<\XRXF3.!RYKU%X0L_J;TYRU)_E-R%(_D[75D?CI3(!X:277"_
M52/H8D$'B!.<15F8WF;A./GJA=Y;X?X/% Q3=AR>]*G2.!MP31-&%\LP+ 2.
M*\7PKSG_U;^C !*2*WFG[CGD<^["?JBWYM1 + 6BO;/X-:+Q+0O/=D74J:07
M%VMBZX$UQ44;K=MQ: @\9?RIM!\G#/%K1277C)A=1D4::H;LV:N-;9E26[Y1
M(\TY/F(+L ;Y!=NU% YI+)CBB'V+&5/G_1*WYNB(W775F"5#0QNIA24$2J/1
MGY#'B'&$BRBS:B'<=8;C!.JFM4?![EIP::.I$'EX8O[L-8L3T!MRK^*WD$_+
M;$F;C,%)060+JL] @4"80Z>-ET*DX*L?\(,F"MFC]RG/+25KS@$2/]2HMJJE
M<&J',C428#&?1SY4B[N,O'A<3%?!,TF78>_DC#A\HAKCU)@0[M&:DYX?_^O@
MH'?OCV"#T=QC97V&?'QB WO%XU0-"F$@K5&IB(#,SY)K-LJG"XT>[QYO%%Q4
M=>2HCYS<0W61(?RDS9)Y%85)%J00+J^W&M$.'.6IDYJM"A'"-U*[D,+%]>2%
M;UBN^8V_#T^H@X2L^B>W<"&<(WU-J,,Y? 5NMN HB:QS F(CW"C/%.$'Z7L^
M!3^^>A_^+)M).;+1AB,ELKT)2;[+%<%L$1^^L;G&KOM#Q1D_5'.FW(9CI:K*
MJ,F9W=DBG''E&9K>EE[-2R48A-.,V)3:EM,*!8\(C"LQ\6501IZKI8YWU$T5
M%.67FNME9 AW70EU+\/2R(^RW9C3H$-W_3)?U%PL(T"X2!JIKCALKR $AL5S
M@/+@S61W"U%3CIOX:F_UFH%#1%A+FL-*=>-@\RP>3;V2&6H;GS104KL_IQ!A
MF![.,\'%Q0P2PG17TEC]P9+<^"'7PDJMAOT#*D]68WK6+CR$JZZ$ RT *96H
MC7;#WA%U_9M=1D@9MC%OA&6N9(]ZGG(*7?)=9[SAIOWAQ6.0;"[R@U"=3\Q@
M%" ;<:"0B(UBAIOC0L3!E?11S]EKXH]]+_XL>1@4NS3:9]CO'Q"O;.M[M@HL
M\O;!V*P5M,_Z-1Y0-@83DX!.=6>@#_&Z5_$.X;@N-(3UQG:S]EG_&/OO? D\
M!MY([HV3=P Z4*<*U&66F-=27 A_C<U<[?,7V?ON-1)$JKH.3X[W;8O7@XQ(
M@RMFL:]^&,5^^KF,>EZ%02]2TGEO[/+S(0I'D!HE"OBGWXHF$EFI/":G:#=C
MQ[=X+I:7FK 10:*-F4+HL4QHF > /3,/SR>D/0 G0C>#X:2\KX(1831M;%5E
MX?TW"\9WX<O4CPL"X,&KEC[ B=C--PMJ0;%, T20:(.ZRL19!'/#6V/(EC/F
M:E44OT1YW8Z+T5^97Z1#U=D[-(?BA.FF$\YL%S%"BXA!2\9"5 R*Z/Z[D,\T
MYP'DSL(Y+6K-X77(YV;(3!P0PB_:QW_E%Q7+R4L3!:(=.,ANAM+J<$V*"6$<
M[3- T;;Q+9Q[OHW=5CH0)PIQ^G>K>ZT&5B1)ACM)X,7/F?,<$\F&C<3<$B :
M97AR0I1FP\9]SA@H(A[$26'SZ;Y$E^R1BW?^3F[E6,:V ED?#M7!.[HF+(2#
MKD2PB=U4QOXZ3@L'E6@=3 A_C8UU9+E6+D:C?/=Y]#Y!22FG29>P6=)KV#\\
M[V:6#2UFJY$A+*<UJSU$>?F/XEJ [<(;C8;]7L]5LX<(",(6ZJQ5^4/DP63U
M-!GCS6Y+CJOOJCJ,HD&XY$IT6;FLREV29%XXRDMH;#KWI/Y-G0$XL:A#3.OL
MH48@$8DP-C:1G:!(*$\<PQL9 'KYN6ZR6!AYH,\@!YU\X0W3Y"XL"C=]B:-$
M&A-C_VN<$2[>NYNG""*:QG8U]T2S7% [FQ5TNOE@\<A/&%_'(VG:Z,8^RME"
M73^81%!U"8/(JS,A@@#^54V?UVWZY/]9Q%X^^6]3KKVOW%\J0;7]/<Z*4X>/
M[B9I@J25)<ZC5G51+IWQ7Z,PG0:?=V&2>D&0IQW"=/PFOL5I>^YJF$.#]$!D
MS96GQA=!/BX;BTFT\##(##1: T#\(7'&C%JV&A.0B$086V(%RAQ5W92EHVGQ
M]Y>HW/#[U!]-O[.8/;,T#=CX+KSRDNF>55@Y.6M70^E&A17J(MEZ?$$4C.J0
M.UAAQ<(Z:"Q[Q"FQI[0&IXW<IRCX#A9SJ2@OE9)'G';S9$?9I69Z&9G;91(;
MJ'!P2OT&JJ7EOD;K=HG$ABH<G';S,KCFFA&SRZBZ6)6F_:S;I]WTV989);CI
MFV.T5,.&:''?A?SRQIXY=XKZ2O 1]?XNZ<6)0AQ!8WU_5Z)UNX(- D^YOTO[
M<<(0.T"47#-B=AD5:04;"\=YE=H;!KTYD8C]"AH\Q YW372D57&Z_1CZE-CF
MTY9ZOP6YD[5WD*GO*#DZ#R-D_8<G9YV/=C_=87 %B(U5U*&RS&]8.#8C2O?,
M G_6^QDM\&?=?+&PQ1>K%O@SU.+RCP4>L6I2%^.IP>GZ%GB\:L]/8X$_ZZ:M
M!F67O@7^#$\6X"!S*V5O/NO0BZ8R6]1,+"/82QMZ'3?*F9NY8(WW[#5:4KMZ
M5]TH9]V,X5QSK9(;Y<Q><7C'W2AGW0RA*3.JMAOE#+6?N&)#;]2B=NYFK3#C
MG7X+LMMF=OO/E7N''76I;O%-S',U,DLV=8*PU^V4*0]>'/-QWPE,:)=9PKF1
M)%?1['7Q\O@B'&]/4,.@9C;0\/!L%<77TOK:FHG*?B9L#],FWEPKT1E98A*(
M;AO$'@,OE-2_$34#W,16+1D_Q!P4 '#;,K4$I+SE;#8$[,1GG8 5<IYMS)S4
MY(2F>(B].?]'\9IX\!KX;SE1Y;<5>2^ 2VQ>$M)?<"71 D)J9<(>_L&LX=<W
M?">!#*KP6)$K%P!<4?Q;V7/8.Z'.5Z_+/VTP;IN)ENB*-+F0E(*-!W&>G(*?
M'I>?+_S;BF-0=XAA[_B<V'ID?D0:@G,[.E,.%J J#U;=(8!>Q*8F0]96D8\=
MO&Z;G?BE81:%>:T/I6MHIRULE\11.X;,$G,< ^:V_6@5O7@5>$FB688*Z\,I
MTB-6T\QW>A4:MV,PRZ"4F_AN8Y!Q:K.P@C_(:L6@=#* \IG%/DLN'J+PCP@2
MAEQ%X3N+4Y_+[N-R5O+MM\HP0!'BS)0HFT2:>25TMD(IZ1*2;MOHY)NSJ/FP
M=]XC/H+-]V4)$(2GKEBKMI$I]V5Q!Q!P8NN5A$=Z3-U @K"5UIR5VP->IBSV
MYBQ+_1%4#-$PAPA[ ,Z.Z4<;#,#,(3(P"--<B9C:IH>.*QWM _L9\8%:?Y_=
M1H,PF#B/\"J7VF!R$8:9%Q1WO#QWY6"RR&3Y$CTN*KT/LC1)O7#,U88\-Q+7
M.4KW.=0H;?4K0$_B,'D5KT7V["9H@,B4*_:R;3)R31044KBC<%KX',S"W>^]
M^@&GE49 1K41@9S$\9EF(F4'+R(^M/6X!)#60/(PEF)F(F/413A>6J.*18/M
M2%8_ B>X4]+3& D0@6HML3$B4J6]E,_\6\@6.6Z+:^YBZ\5$1:LSV% Z=H?0
M$ $3: AK7;'?Z4J[V=DB'()?W Z=TD\J D1"76@M@%9WM0V5:Q!>A!?)PEC&
MQI=>(K0?$<P"^$'L"Z0^?W1IA,BLL15SS"9^F$_[2^:/H0Y%^QG-DX(6>:)V
M?KO(?R?S-F%]AOV#$V+?1+7]2H4(879]\V;; <J[2R5)?YY8Y=/#8U)5H5JH
M\NDAL86R"I7U]((20+?CE&VXA$X/.W;U*W''P"&4PW [>-F6.^CTL&-1=FL&
M&3F#<AQ=C&RVZ@HZ[9KJ6Z:^F2/H%-=0?TXWT&DWO>T&>^L6%K=CG2W=V"R8
M6!1?X,3N[(7F5-^I7PN]I4CJSH3K8,0H/6R%:Y$%X=H:D9.S8[YHJ\(D1$L:
M9HU9]@!+#/5F\C*@22+._HF:Y/2Z<_R=M=T*N&T.S>TP:R@UM(0+56!+=)+%
MX^*].%$Z]NQ4:W4K$37W.K^F=3Z;\4\OW-&^U$&[U9+CZJR'#5V9"(K:P=/G
M!7M"]@89'KI[.MMPIYUV[2V$U?.W@&<M46V4>D&;INKM'$'&9FEDI[B* BXS
M49&7HU2Y46)>UNK'R?TSEG8[[1%920R8@CAYJN-UVSC==E;9T[Z3==UR3HM%
MQQ2\V^;ONEEE3_ONU'7+V:5F>AG9SYU5]K1/;,/ V*)F8AF!V\9Q^UEE3_M.
M%N<SW[/7:-TVH3>35?:TW^'B?#G7C)A=1M7%K+)F^6.1+*JG_6YFARP37V#1
MD*'IHM4X#P@L%V^_",?52FK5&8[3IYMYGQ7<K@77;4MSE1R&IWTGBVE)CN-=
M>&ZG\:B:X/#TB/ARO,L(.</*\^YDJHY&TAN>'A'?847D1TY1%8S&:I?56&E)
MG)96&?]IO<+X#\,G,.PA&^;&WSE"XONHM9U2@*N+:35T.(<OO<T6'"71M5-
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M^>]L/# 7#?4XG'1]XEPCM61#&R&2=<05&^.R4OD"]O*PPXX)G6Z<,.ZXAPP
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M&1HBH$L!)-"N)6,UPO?U%?#;G!,N3!="?/'J!W[Z^1*IC@'M 8" >RT'II1
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M8EWI.9_5#H]*><B2R\]UFV7A/'B_KWKE;.T;0!YB/=@*?\6!%K;)Y/;#Y<?
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M/5)5W\4CMR;QPZ'\9IC#*#M)2BI5Z1S"KDGU1^:4VV<OE#4"(;E*77G>LR
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M0_IYS5+/#Y)?VUN2X'@/HB2+BP>'JRGG%24!19(F.Q$HR<5KDL;>2)9JN=[
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M"MDJNU!DCO>SMK-'W6@44;'\)>B%_.7N_>W0T/%^TBN\;"8FQ^ID+)%,O1>
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M>BN0H!>UCV0,DMGGFJ!VV[M: _\5_S%8J(VY=5X*D2F]L/!T(DE5T&Z[9VO
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MNF!W*:'PG0H>!Q(0G^QDK-%C9@F(NT[''4QJ5Z-P )"!VL&(<T>/G14D5/Y
MQ%?P '9ROA?&WAO+TL!/^!5#[B_ 1P!":B>?C/0"3X$2C-O5F7;)H67\Q\8
M1:C=>8U5ZRX:2_X[>OUZP:_[P2RO;<+IPJ_\R2IO<Q7"R"60)6EA68*"!?P?
MAJ>HFE\ 0E-[$A5"H"<ZS?"[75A*EQ;Y/SU?(_>ZYAN!FL0NQ7:E28S7DC/0
M<KN"'$Z>"V):8\AD.)" VDMGQ/(:X-PN.G7A)2]KO.!-+%%*H@$DHSA5J"MZ
MU%OE:DR62D;1A9_LE1ZYR.)8GBZ)C@&:].RVKJG-%8@:%WZB3H#2W:XL[/!
M,F+#7+M;^@J@K9)0[MG-)[-94,"^#N=1_)I/RMA>CAQ"FL\.-Y#;_0#(P9&%
M8]<T7GAA\+]U+[2$?V:V-B;?E=@^G5\%H1?Z0='6,W<<R]L=-'\S8*2L?6";
M68*3G34B?7$[/953W2X3C2SZN(O]2UGTJ7WE$NX86O1Q=SB917]WKG)KOOAI
M0-8S4V^%Y*+[M@P(J16_&\\+=9DI4WXIP9!FUC1/95]O%A=++TGXF0,RB!3[
M)#H&J$A9-*+ES5*%VY+IO/L=LXQ'N5ON/PSPJ=-G%*Q!K& 8%$MF;&O.;Q;#
MB?\V"O\=P1V R_8[B_.>Y'?K">4@%'K9[#5 "V)[-LH@D:*NA<Z209O,S+D1
M_,*[M^VRJ*O#1>-@9Z/LI=*5'I=@MV3^)DB'KV)2JG/A\T $XD* .DP2LU>&
MR%:C X(]NLBCD&IY]%E 3YU]).$*LCLC**S9IVE.W%"%$I+#%0JZ_!@'?C1@
M?2R :JL_0/?K= U&J7BK#P)N8HTK8(.<7Y69VRJ<;S5@%/Y['?;D<Q($[PPF
MKV&^D(X$R,3J5,@#S'RA X:VS+VB0DB1)CA]7@8+3VTKE(\"O,37&EWF:0%Q
MO("]*"IQ&J^#$L\_'_FW%5NE[BN 8$11'%ULHX9DL%49G^J*@P$%F)JW'O4K
M@%;4.;5F;*TC&WMX;170=^^:=$2='FO&*/V;TQ'>Z\25\,V'[#D)9H$7?SYX
M4"E)RU>!C>$D.1[PG4J%NW'M>[(57L(#9ZCIO!2)KM3[ZL% 'VK3EX)W",=U
MH34N>D]WMXZ#=[X$^/'9S]>!4L.+!P =B*]OVLQ";N R7-9JW--H^8VZVY:S
M5^AX9 208\#'?3EJ1 @<,*"M Y+S4$@6OP=^$"Y*-"IU.8#C4"+^E7(GL/D9
MH#GQ+4$N#6():H$$B-B160%_/YQ[X5\<%DPX2#.U\0@? 1");P<M<$Q@=E*2
M .$RK:VPD;J]D22<6WP[!!T,\-)AGT*(A#F0[YZ?Z5ZB)9]P4ESF[]D[R'G^
MBX>W92#+0-,8#1P@BGFUSV<L0$.7"HB<=)2NCFBBJ^ #^E#[+UZX8/= #$RK
M[#\)N)P-H91S5XX8X61'=:0U8]1KEE8H"M3IAK8W^@A0D[)97]ORTP:Q$-%S
MQ2Q:C6Z\\^)IG)-T!FT/V;K.HM1*HO,"X F18:RK?<>($(C4N),A7T5;"I<M
M_IEP8-CF9?H*(!F1Q8U&=I2D0)*QC(VP=J]0VQ*JG#"_0_;!8C](5IA6M9K1
M&Y+.8$#OK$U.8WLR(0(B J[8:;NMO# >J-34) 4B.QW51^_BM#R=E[S84T[I
M2;)2JD7'@6Z.T\I9 #^(C(+NG;=UJ8E(M[$5><;F09A/^U?&R9)W0N_2%%1J
MDG$7![[.61P= Z09NME'@1T1"^(05;[! _9%WKHKS+QEL11^03>+Z7RUY3]&
M=UGLOW@)*YT0!(L"#6FU^A6@YY"-3*U0"Y$^VA:*G54V'%,6RVE]DS,B R((
MM#;GO5(A\'.R!L9QE$K \=]EKWGO,-TSE-[;.'T.!WK+;TX51&I<Z9-X#SUF
M,S_-XN)J>\^68!B#TJ_K;BQW44&6Y'(9O$+;"+Z+LSB(9BMU+#GU6'@[D'G@
M=T1[5$*$L2.+-Z+"UAC6/:RY%DX]3AB1!4$^ % Z6[1+0Q&I@"/L-39-4Y7I
M+:H^K#K"3>-[:/ZDUP]+-10(--#KNB$)D%)3Q@;H,A5);MGYD8W-$BACG)L;
M^ 2X(MR)D)4Z,71> &0;^/W;B!"(_'1DO<8NX^M)3A;P1SB;IB^@*/E\N.1?
M?KRQ,,$=\7JC ?^@+\\F5$"DP)4^G7D9]' &?X&%X-U; I$FZ057GI\<;>[W
ME6TW.N.!5 ,-R:A#!T1DC(V[9'YS0*F0"8 Z4(.) ";"46.[;#E8L^U:X?N%
M\5?_LU9XJSKYI0>Z;YQYYWV"\P2BO?/9>4M9$7"-44\'9YM",LW,CCFM"D,J
MW#]7W\3MC.+G83[454^4U!(:#*5XW.Z"O@+'3X-SEB0YABMFT#X#&0BTH2Z:
M8LAK(V!N=RSGV!:Q]YI?%I-MI1%IA2ID"-"#N%E*748K(-GJ.DZZKO=[P7 J
MW4:A7[\]3N4%0"OB9+B&ZUP/H*O=Q04G'RMM3_IYVCFV=]HI44S:G 1Y'&9#
MW%]232O\K(/ <;8WR,IY<N?%Z6<I^3XY_RS_1I%YKO\23B[29'0Y%S%_DR$Z
M9UN&E/$H,\?W'P;XQ%N>,:_4+*]@HVH>8I6URGHA^P\#?.*D;Y0G:A96,+C=
M(AP1\'H*>KT.*!TZ%C5R"8ZS?<(1:$;:6%!$Y^R8^,RE9ID1JRNXJ!J.2*JU
M+CBT1<SDY9DD3P,RXEXB.I07^<UD>"PU%+$<.[JK@&Y453 D0T!O47JY3-2I
M)A9+O4%L+:^R7*[=L->%40+"Y:/X,=J-4,3X6.-50!-*EY::70(>U\=IJ?^'
MU06[CDJ^AIR6G/A@A<9Y+'H:]!%E!9J:;)1 L=72PS*K@M?G+$Y !:UG#WXB
M";>0 8"2,NV^)L/D:&A;>!CHU]_AFQ?8T*[2%P%5* /GK>E6'92V6GOL\;YM
MPSF4967_S?C;+M_S\)9^F,WWIJ6VF6-#G@Y.3T>=WOIV9H+9U66/PZ2)W8T*
M>HHO>!(LSAK5=S&I>S<@(X 0Q&8W"7_T&%J%XJQM7 !+768;&P/$(&[8+&>3
M-FLK>)RUCN\ 4QK(A<\#$8BM;"H&:;&U@L:2M9PL2E74.UX6VR%N-7]*W"G)
M6 E+<#AK&A>W+#=@YF8IG!%=_36XH\?."I*>F;_Q3O'815':6_Z,.#!62GK!
M?5 )AM0&;J&N+])A7+9;8F. (M0=*(R/MPHP5-9R6^FFI2;C$I8*.Y*?4=\_
M%:P1,Q2%0M7[&M.K9HW=465KW!_^C#BF!V602/O60F?+=DYVRNVV>^29:R8)
M0VRVS/+=Z_!N6T*>$9LP#-E:1S;V\+K;D;MI2\@S8MN&(:.0S1X!9JMMM\U3
M>1*G);[RG[8\Y3\\W4/K $2I5W[_='#VHP>M_+0TMFCBMEIR6UIR.FS!CV#5
M)P AE<=30&F$%Y6YVNJSW0TW_O ^@M?L5<J/RC. DBI!04CO?9Z(YFNKBW6'
M^NN/(%2SIOP,0*4J9Z7+&L%\;361ILJ(77HA].947!_*CP'PGGFWE%<$P?QM
MM8GN_JBW!J,\[%<?!-S4J7G[;)#SJS)SLF[.DDAP, <7!1*VB=3JB'!\%$ E
MC@P7TEY@C-$"8JL-,V$S]I*BN9&$CJN&@'XB-K4U#?;8Q6*K![.M!>ED([-3
MXN6NX+%@X;=! 5N=G*E*K&T-#S5:DVF,!D.&2X)B#LU64V4RSVG['5'/^A6G
MHB<!^M!H&R[;D8!"R_W,BU<7-:D+-;>'6>Y1-WH3'+6(0U[J2X8Q3%M-DZFD
M!- ]>PE4-'^%?((5JV*P/X!W^_QS^\B=]YG7*/W;BV>7'V]!L<469)+)CZUO
M ,G[Y0W4E"S+!+#5@%G@01;F<_P#4,'D_OE_4$L! A0#%     @ [(EE6-.<
M4QT@ @  & 4  !$              ( !     &0U,3@R.3AD97@R,S$N:'1M
M4$L! A0#%     @ [(EE6!$+>[A  @  3@4  !$              ( !3P(
M &0U,3@R.3AD97@R,S(N:'1M4$L! A0#%     @ [(EE6%$.E]1-"   F!\
M !               ( !O@0  &0U,3@R.3AD97@U,2YH=&U02P$"% ,4
M" #LB6582>RR)+^M! "Y^RH $0              @ $Y#0  9#4Q.#(Y.&1P
M;W-A;2YH=&U02P$"% ,4    " #LB658A;(TZ39@ 0"\M0$ $0
M    @ $GNP0 9S4Q.#(Y.&<P.&TP-RYJ<&=02P$"% ,4    " #LB658N/.S
M0%6# 0!EX0$ $0              @ &,&P8 9S4Q.#(Y.&<T,' U,RYJ<&=0
M2P$"% ,4    " #LB658&5_LA=Y! 0 /E0$ $0              @ $0GP<
M9S4Q.#(Y.&<V,78V,"YJ<&=02P$"% ,4    " #LB658Z1XEBE>9  "A^@
M$0              @ $=X0@ 9S4Q.#(Y.&<V.' X,2YJ<&=02P$"% ,4
M" #LB658;J$"O/<[  "_B   $0              @ &C>@D 9S4Q.#(Y.&<X
M,6DW.2YJ<&=02P$"% ,4    " #LB6588_]+TN$% 0!/60$ $0
M    @ ')M@D 9S4Q.#(Y.&<X,FLS-"YJ<&=02P$"% ,4    " #LB6587.3"
M#40?  #^8P$ $0              @ '9O H <WER92TR,#(S,3(S,2YX<V10
M2P$"% ,4    " #LB658"*[A8(0/  !%Z   %0              @ %,W H
M<WER92TR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ [(EE6"EI^Q???
M)!\( !4              ( ! ^P* '-Y<F4M,C R,S$R,S%?9&5F+GAM;%!+
M 0(4 Q0    ( .R)95B"G3&51+<  ,PS"P 5              "  15I"P!S
M>7)E+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #LB658!+WC!<.8   +
M> H %0              @ &,( P <WER92TR,#(S,3(S,5]P<F4N>&UL4$L%
3!@     /  \ P ,  (*Y#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>d518298dposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:syre="http://www.spy.com/20231231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="syre-20231231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P04_12_2023To06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-04-12</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P04_01_2023To04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="P06_30_2023To06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="P03_10_2015To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2015-03-10</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P05_01_2022To05_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:RestructuringActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:RestructuringActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:RestructuringActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:Spyre2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:FairmountFundsManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonAndParapyreHoldingLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:AssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:USBankingInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-26</startDate>
            <endDate>2023-06-26</endDate>
        </period>
    </context>
    <context id="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-26</instant>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">syre:SpyreTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-21</startDate>
            <endDate>2021-03-21</endDate>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PIPTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syre:GlobalRightsToPegzilarginaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">syre:DevelopmentFeeAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">syre:DevelopmentFeeAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2019_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="P02_01_2023To02_28_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">syre:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syre:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputReimbursementRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">syre:MeasurementInputReimbursementRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreFundedMay2022WarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:PreFundedMay2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:FairmountFundsManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:OwnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">syre:USBankingInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AppointOfBoardMembersMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:AppointOfBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ParapyreWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">syre:DevelopmentFeeAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ReimbursableCostsUnderParagonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:SeveranceLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfPreFundedWarrantsMemberusgaapConversionOfStockByUniqueDescriptionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:StockCompensationAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndEighteenEquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">syre:PeaceTrialAndBLAPackageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syre:ImmedicaPharmaABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:NonEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SaleOfStockDecember2023PIPEMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SaleOfStockDecember2023PIPEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">syre:ParapyreWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2023To12_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="PAsOn12_11_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="P06_23_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-23</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-14</startDate>
            <endDate>2023-12-14</endDate>
        </period>
    </context>
    <context id="PAsOn12_14_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syre:ParagonTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:SPY002LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-14</instant>
        </period>
    </context>
    <context id="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-22</startDate>
            <endDate>2023-11-22</endDate>
        </period>
    </context>
    <context id="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-22</startDate>
            <endDate>2023-11-22</endDate>
        </period>
    </context>
    <context id="PAsOn11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-22</instant>
        </period>
    </context>
    <context id="P05_01_2023To05_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">syre:ParagonAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P12_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P10_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">syre:ConversionOfSeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P12_08_2023To12_08_2023_MinimumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-08</startDate>
            <endDate>2023-12-08</endDate>
        </period>
    </context>
    <context id="P12_08_2023To12_08_2023_MaximumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-08</startDate>
            <endDate>2023-12-08</endDate>
        </period>
    </context>
    <context id="PAsOn12_08_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-08</instant>
        </period>
    </context>
    <context id="P11_01_2023To11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syre:TwoThousandAndSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="PAsOn09_09_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syre:ParapyreOptionObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-09</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:SeveranceLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">syre:SeveranceLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">syre:ContingentValueRightLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syre:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syre:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_BOARDSEAT">
        <measure>syre:BOARDSEAT</measure>
    </unit>
    <unit id="Unit_VOTE">
        <measure>syre:VOTE</measure>
    </unit>
    <unit id="Unit_SUBSIDARY">
        <measure>syre:SUBSIDARY</measure>
    </unit>
    <unit id="Unit_employee">
        <measure>syre:employee</measure>
    </unit>
    <unit id="Unit_installment">
        <measure>syre:installment</measure>
    </unit>
    <dei:DocumentType contextRef="P01_01_2023To12_31_2023" id="hidden103883669">POS AM</dei:DocumentType>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden103882519">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2023To12_31_2023" id="hidden103882520">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityCentralIndexKey contextRef="P01_01_2023To12_31_2023" id="ixv-315">0001636282</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="P01_01_2023To12_31_2023" id="ixv-316">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P01_01_2023To12_31_2023" id="ixv-3216">Spyre Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2023To12_31_2023" id="ixv-3217">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2023To12_31_2023" id="ixv-3218">46-4312787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To12_31_2023" id="ixv-3219">221 Crescent Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2023To12_31_2023" id="ixv-3220">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="P01_01_2023To12_31_2023" id="ixv-3221">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To12_31_2023" id="ixv-3222">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To12_31_2023" id="ixv-3223">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To12_31_2023" id="ixv-3224">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To12_31_2023" id="ixv-3225">651-5940</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3226">Heidy King-Jones</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3227">221 Crescent Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3228">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3229">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3230">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3231">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3232">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-3233">651-5940</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2023To12_31_2023" id="ixv-3234">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2023To12_31_2023" id="ixv-3235">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2023To12_31_2023" id="ixv-3236">false</dei:EntityEmergingGrowthCompany>
    <syre:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag contextRef="P01_01_2023To12_31_2023" id="hidden103883038">Accrued interest receivable on available-for-sale debt securities</syre:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleListNotDisclosedFlag>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis"
      id="hidden103884648">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2023" id="hidden103884635">http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2023" id="hidden103884638">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <syre:OtherCommitmentRoyaltyPercentage
      contextRef="PAsOn04_30_2023"
      decimals="2"
      id="hidden103884640"
      unitRef="Unit_pure">0.01</syre:OtherCommitmentRoyaltyPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12025"
      unitRef="Unit_USD">188893000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12030"
      unitRef="Unit_USD">34863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12038"
      unitRef="Unit_USD">150384000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12043"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12051"
      unitRef="Unit_USD">0</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12056"
      unitRef="Unit_USD">375000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12064"
      unitRef="Unit_USD">2251000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12069"
      unitRef="Unit_USD">6172000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12091"
      unitRef="Unit_USD">341528000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12096"
      unitRef="Unit_USD">62258000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12104"
      unitRef="Unit_USD">322000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12109"
      unitRef="Unit_USD">1553000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12117"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12122"
      unitRef="Unit_USD">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12132"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12137"
      unitRef="Unit_USD">3430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12146"
      unitRef="Unit_USD">9000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12151"
      unitRef="Unit_USD">683000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12173"
      unitRef="Unit_USD">341859000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12178"
      unitRef="Unit_USD">71144000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12216"
      unitRef="Unit_USD">896000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12221"
      unitRef="Unit_USD">677000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12229"
      unitRef="Unit_USD">1390000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12234"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12242"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12247"
      unitRef="Unit_USD">625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12255"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12260"
      unitRef="Unit_USD">517000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12268"
      unitRef="Unit_USD">13108000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12273"
      unitRef="Unit_USD">12837000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12281"
      unitRef="Unit_USD">16584000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12286"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12308"
      unitRef="Unit_USD">31978000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12313"
      unitRef="Unit_USD">14656000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12336"
      unitRef="Unit_USD">41310000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12341"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12350"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12355"
      unitRef="Unit_USD">4004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12363"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12368"
      unitRef="Unit_USD">2179000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12390"
      unitRef="Unit_USD">73288000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12395"
      unitRef="Unit_USD">20839000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-12415"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      id="ixv-12420"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12428"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12429"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12430"
      unitRef="Unit_shares">150000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12431"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12432"
      unitRef="Unit_shares">150000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12433"
      unitRef="Unit_shares">150000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12434"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12435"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-12439"
      unitRef="Unit_USD">84555000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-12444"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12461"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12462"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12465"
      unitRef="Unit_shares">1086341</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12467"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12468"
      unitRef="Unit_shares">437037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12469"
      unitRef="Unit_shares">437037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12470"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12471"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-12475"
      unitRef="Unit_USD">184927000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-12480"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12485"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12486"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12487"
      unitRef="Unit_shares">8763659</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12489"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12490"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12491"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12492"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-12493"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-12497"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022_PreferredStockExcludingSeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-12502"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-12507"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-12508"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-12509"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-12510"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-12511"
      unitRef="Unit_shares">36057109</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-12512"
      unitRef="Unit_shares">36057109</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-12513"
      unitRef="Unit_shares">2614014</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-12514"
      unitRef="Unit_shares">2614014</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12518"
      unitRef="Unit_USD">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12523"
      unitRef="Unit_USD">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12532"
      unitRef="Unit_USD">763191000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12537"
      unitRef="Unit_USD">475971000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12545"
      unitRef="Unit_USD">302000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12550"
      unitRef="Unit_USD">-48000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12558"
      unitRef="Unit_USD">-764414000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12563"
      unitRef="Unit_USD">-425624000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12585"
      unitRef="Unit_USD">184016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12590"
      unitRef="Unit_USD">50305000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-12612"
      unitRef="Unit_USD">341859000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-12617"
      unitRef="Unit_USD">71144000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-12712"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-12717"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-12722"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-12730"
      unitRef="Unit_USD">886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-12735"
      unitRef="Unit_USD">2329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_DevelopmentFeeAndRoyaltyMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-12740"
      unitRef="Unit_USD">6739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-12768"
      unitRef="Unit_USD">886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-12773"
      unitRef="Unit_USD">2329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-12778"
      unitRef="Unit_USD">18739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="Fact_103881978"
      unitRef="Unit_USD">89504000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="Fact_103881979"
      unitRef="Unit_USD">58579000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="Fact_103881980"
      unitRef="Unit_USD">57069000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-12820"
      unitRef="Unit_USD">39946000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-12825"
      unitRef="Unit_USD">28531000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-12830"
      unitRef="Unit_USD">27319000</us-gaap:GeneralAndAdministrativeExpense>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-12839"
      unitRef="Unit_USD">130188000</syre:AcquiredInProcessResearchAndDevelopment>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-12844"
      unitRef="Unit_USD">0</syre:AcquiredInProcessResearchAndDevelopment>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-12849"
      unitRef="Unit_USD">0</syre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-12858"
      unitRef="Unit_USD">16449000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-12863"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-12868"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-12896"
      unitRef="Unit_USD">243189000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-12901"
      unitRef="Unit_USD">87110000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-12906"
      unitRef="Unit_USD">84388000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-12934"
      unitRef="Unit_USD">-242303000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-12939"
      unitRef="Unit_USD">-84781000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-12944"
      unitRef="Unit_USD">-65649000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-12987"
      unitRef="Unit_USD">6147000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-12992"
      unitRef="Unit_USD">837000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-12997"
      unitRef="Unit_USD">111000</us-gaap:InvestmentIncomeNet>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-13005"
      unitRef="Unit_USD">-83530000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-13010"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-13015"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13023"
      unitRef="Unit_USD">-19130000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13028"
      unitRef="Unit_USD">-7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13033"
      unitRef="Unit_USD">-122000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13061"
      unitRef="Unit_USD">-96513000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13066"
      unitRef="Unit_USD">830000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13071"
      unitRef="Unit_USD">-11000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13099"
      unitRef="Unit_USD">-338816000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13104"
      unitRef="Unit_USD">-83951000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13109"
      unitRef="Unit_USD">-65660000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13117"
      unitRef="Unit_USD">-26000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13122"
      unitRef="Unit_USD">-136000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13127"
      unitRef="Unit_USD">141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13155"
      unitRef="Unit_USD">-338790000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13160"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13165"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-13193"
      unitRef="Unit_USD_per_Share">-49.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-13194"
      unitRef="Unit_USD_per_Share">-49.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-13199"
      unitRef="Unit_USD_per_Share">-24.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-13200"
      unitRef="Unit_USD_per_Share">-24.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      id="ixv-13205"
      unitRef="Unit_USD_per_Share">-25.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      id="ixv-13206"
      unitRef="Unit_USD_per_Share">-25.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-13214"
      unitRef="Unit_shares">6897065</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-13215"
      unitRef="Unit_shares">6897065</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-13220"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-13221"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-13226"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-13227"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-13235"
      unitRef="Unit_USD">48500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2022To12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      id="ixv-13236"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2021To12_31_2021_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      id="ixv-13237"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13305"
      unitRef="Unit_USD">-338790000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13310"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13315"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13338"
      unitRef="Unit_USD">37000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13343"
      unitRef="Unit_USD">-35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13348"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13356"
      unitRef="Unit_USD">313000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13361"
      unitRef="Unit_USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13366"
      unitRef="Unit_USD">-30000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-13394"
      unitRef="Unit_USD">-338440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-13399"
      unitRef="Unit_USD">-83843000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13404"
      unitRef="Unit_USD">-65832000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-13615"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-13620"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-13628"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-13633"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13638"
      unitRef="Unit_shares">1918000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13643"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13648"
      unitRef="Unit_USD">415824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13653"
      unitRef="Unit_USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13658"
      unitRef="Unit_USD">-276008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      id="ixv-13663"
      unitRef="Unit_USD">139832000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13691"
      unitRef="Unit_shares">40000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13738"
      unitRef="Unit_shares">16000</syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13747"
      unitRef="Unit_USD">1903000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13760"
      unitRef="Unit_USD">1903000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13795"
      unitRef="Unit_USD">8038000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13808"
      unitRef="Unit_USD">8038000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13847"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13856"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13895"
      unitRef="Unit_USD">-30000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13904"
      unitRef="Unit_USD">-30000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-13947"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-13952"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14024"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14029"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14037"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14042"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14047"
      unitRef="Unit_shares">1974000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14052"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14057"
      unitRef="Unit_USD">425765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14062"
      unitRef="Unit_USD">-20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14067"
      unitRef="Unit_USD">-341809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-14072"
      unitRef="Unit_USD">83941000</us-gaap:StockholdersEquity>
    <syre:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14164"
      unitRef="Unit_shares">430000</syre:StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14169"
      unitRef="Unit_USD">1000</syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14174"
      unitRef="Unit_USD">42873000</syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-14187"
      unitRef="Unit_USD">42874000</syre:StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14215"
      unitRef="Unit_shares">204000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14262"
      unitRef="Unit_shares">6000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14271"
      unitRef="Unit_USD">222000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-14284"
      unitRef="Unit_USD">222000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14319"
      unitRef="Unit_USD">7111000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-14332"
      unitRef="Unit_USD">7111000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14371"
      unitRef="Unit_USD">-35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-14380"
      unitRef="Unit_USD">-35000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14419"
      unitRef="Unit_USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-14428"
      unitRef="Unit_USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14471"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-14476"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14548"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2022_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14553"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14561"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14566"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14571"
      unitRef="Unit_shares">2614000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14576"
      unitRef="Unit_USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14581"
      unitRef="Unit_USD">475971000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14586"
      unitRef="Unit_USD">-48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-14591"
      unitRef="Unit_USD">-425624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-14596"
      unitRef="Unit_USD">50305000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14857"
      unitRef="Unit_shares">721000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14862"
      unitRef="Unit_USD">197364000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-14887"
      unitRef="Unit_USD">197364000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14909"
      unitRef="Unit_shares">365000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14914"
      unitRef="Unit_USD">189741000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-14939"
      unitRef="Unit_USD">189741000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14961"
      unitRef="Unit_shares">-649000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-14966"
      unitRef="Unit_USD">-202178000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"
      decimals="-3"
      id="ixv-14971"
      unitRef="Unit_shares">25972000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"
      decimals="-3"
      id="ixv-14976"
      unitRef="Unit_USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"
      decimals="-3"
      id="ixv-14981"
      unitRef="Unit_USD">202175000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"
      decimals="-3"
      id="ixv-14994"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <syre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-15003"
      unitRef="Unit_shares">150000</syre:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-15008"
      unitRef="Unit_USD">84555000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <syre:StockIssuedDuringPeriodSharesNewIssuesOne
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15074"
      unitRef="Unit_shares">6000000</syre:StockIssuedDuringPeriodSharesNewIssuesOne>
    <syre:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15083"
      unitRef="Unit_USD">84555000</syre:StockIssuedDuringPeriodValueNewIssuesOne>
    <syre:StockIssuedDuringPeriodValueNewIssuesOne
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15096"
      unitRef="Unit_USD">84555000</syre:StockIssuedDuringPeriodValueNewIssuesOne>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15125"
      unitRef="Unit_shares">518000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15130"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15135"
      unitRef="Unit_USD">3767000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15148"
      unitRef="Unit_USD">3768000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfPreFundedWarrantsMemberusgaapConversionOfStockByUniqueDescriptionAxis"
      decimals="-3"
      id="ixv-15178"
      unitRef="Unit_shares">905000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15227"
      unitRef="Unit_shares">48000</syre:StockIssuedDuringPeriodSharesOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15236"
      unitRef="Unit_USD">405000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15249"
      unitRef="Unit_USD">405000</syre:StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan>
    <syre:ContingentValueRightDistributionToCommonStockholders
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15286"
      unitRef="Unit_USD">-29500000</syre:ContingentValueRightDistributionToCommonStockholders>
    <syre:ContingentValueRightDistributionToCommonStockholders
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15299"
      unitRef="Unit_USD">-29500000</syre:ContingentValueRightDistributionToCommonStockholders>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15336"
      unitRef="Unit_USD">14347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15349"
      unitRef="Unit_USD">14347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15386"
      unitRef="Unit_USD">11471000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15399"
      unitRef="Unit_USD">11471000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15440"
      unitRef="Unit_USD">37000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15449"
      unitRef="Unit_USD">37000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15490"
      unitRef="Unit_USD">313000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15499"
      unitRef="Unit_USD">313000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15544"
      unitRef="Unit_USD">-338790000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15549"
      unitRef="Unit_USD">-338790000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-15623"
      unitRef="Unit_shares">150000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-15628"
      unitRef="Unit_USD">84555000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-15638"
      unitRef="Unit_shares">437000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-15643"
      unitRef="Unit_USD">184927000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15648"
      unitRef="Unit_shares">36057000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15653"
      unitRef="Unit_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15658"
      unitRef="Unit_USD">763191000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15663"
      unitRef="Unit_USD">302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-15668"
      unitRef="Unit_USD">-764414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-15673"
      unitRef="Unit_USD">184016000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15824"
      unitRef="Unit_USD">-338790000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-15829"
      unitRef="Unit_USD">-83815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-15834"
      unitRef="Unit_USD">-65801000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15857"
      unitRef="Unit_USD">744000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-15862"
      unitRef="Unit_USD">1567000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-15867"
      unitRef="Unit_USD">1576000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15875"
      unitRef="Unit_USD">25675000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-15880"
      unitRef="Unit_USD">7111000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-15885"
      unitRef="Unit_USD">8038000</us-gaap:ShareBasedCompensation>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15894"
      unitRef="Unit_USD">130188000</syre:AcquiredInProcessResearchAndDevelopment>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-15899"
      unitRef="Unit_USD">0</syre:AcquiredInProcessResearchAndDevelopment>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-15904"
      unitRef="Unit_USD">0</syre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-15912"
      unitRef="Unit_USD">-18986000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-15917"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To12_31_2021_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-15922"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-15930"
      unitRef="Unit_USD">-83530000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-15935"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-15940"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15949"
      unitRef="Unit_USD">16449000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-15954"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-15959"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15967"
      unitRef="Unit_USD">2580000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-15972"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-15977"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-15985"
      unitRef="Unit_USD">-915000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-15990"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-15995"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16003"
      unitRef="Unit_USD">2318000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16008"
      unitRef="Unit_USD">327000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16013"
      unitRef="Unit_USD">-548000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16021"
      unitRef="Unit_USD">220000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16026"
      unitRef="Unit_USD">397000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16031"
      unitRef="Unit_USD">425000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16039"
      unitRef="Unit_USD">-15000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16044"
      unitRef="Unit_USD">-426000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16049"
      unitRef="Unit_USD">335000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16072"
      unitRef="Unit_USD">-3245000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16077"
      unitRef="Unit_USD">1144000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16082"
      unitRef="Unit_USD">1216000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16090"
      unitRef="Unit_USD">218000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16095"
      unitRef="Unit_USD">-2641000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16100"
      unitRef="Unit_USD">1065000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16108"
      unitRef="Unit_USD">575000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16113"
      unitRef="Unit_USD">-880000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16118"
      unitRef="Unit_USD">3576000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16126"
      unitRef="Unit_USD">-375000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16131"
      unitRef="Unit_USD">-440000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16136"
      unitRef="Unit_USD">815000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16144"
      unitRef="Unit_USD">-2326000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16149"
      unitRef="Unit_USD">-435000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16154"
      unitRef="Unit_USD">-404000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16162"
      unitRef="Unit_USD">-4891000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16167"
      unitRef="Unit_USD">-843000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16172"
      unitRef="Unit_USD">-373000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16180"
      unitRef="Unit_USD">-2402000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16185"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16190"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16218"
      unitRef="Unit_USD">-99910000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16223"
      unitRef="Unit_USD">-80144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16228"
      unitRef="Unit_USD">-53716000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16272"
      unitRef="Unit_USD">3035000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16277"
      unitRef="Unit_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16282"
      unitRef="Unit_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16291"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16296"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16301"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16309"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16314"
      unitRef="Unit_USD">38000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16319"
      unitRef="Unit_USD">573000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16327"
      unitRef="Unit_USD">475000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16332"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16337"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16345"
      unitRef="Unit_USD">166803000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16350"
      unitRef="Unit_USD">39500000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16355"
      unitRef="Unit_USD">133079000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16363"
      unitRef="Unit_USD">39900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16368"
      unitRef="Unit_USD">96546000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16373"
      unitRef="Unit_USD">111033000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16401"
      unitRef="Unit_USD">-108393000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16406"
      unitRef="Unit_USD">57008000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16411"
      unitRef="Unit_USD">-22619000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16456"
      unitRef="Unit_USD">197364000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16461"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16466"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16475"
      unitRef="Unit_USD">84555000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16480"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16485"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16493"
      unitRef="Unit_USD">84555000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16498"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16503"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16511"
      unitRef="Unit_USD">5786000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16516"
      unitRef="Unit_USD">0</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16521"
      unitRef="Unit_USD">0</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16530"
      unitRef="Unit_USD">0</syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16535"
      unitRef="Unit_USD">42874000</syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16540"
      unitRef="Unit_USD">0</syre:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16548"
      unitRef="Unit_USD">405000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16553"
      unitRef="Unit_USD">222000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16558"
      unitRef="Unit_USD">1903000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16566"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16571"
      unitRef="Unit_USD">418000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16576"
      unitRef="Unit_USD">510000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16604"
      unitRef="Unit_USD">361077000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16609"
      unitRef="Unit_USD">42678000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16614"
      unitRef="Unit_USD">1393000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16642"
      unitRef="Unit_USD">25000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16647"
      unitRef="Unit_USD">-106000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16652"
      unitRef="Unit_USD">-15000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16680"
      unitRef="Unit_USD">152799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16685"
      unitRef="Unit_USD">19436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16690"
      unitRef="Unit_USD">-74957000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-16714"
      unitRef="Unit_USD">36416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-16719"
      unitRef="Unit_USD">16980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      id="ixv-16724"
      unitRef="Unit_USD">91937000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-16752"
      unitRef="Unit_USD">189215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-16757"
      unitRef="Unit_USD">36416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-16762"
      unitRef="Unit_USD">16980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16808"
      unitRef="Unit_USD">189741000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16813"
      unitRef="Unit_USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16818"
      unitRef="Unit_USD">0</us-gaap:StockIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16827"
      unitRef="Unit_USD">202178000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16832"
      unitRef="Unit_USD">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16837"
      unitRef="Unit_USD">0</us-gaap:ConversionOfStockAmountIssued1>
    <syre:LeasedAssetsObtainedInExchangeForLeaseObligations
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-16845"
      unitRef="Unit_USD">0</syre:LeasedAssetsObtainedInExchangeForLeaseObligations>
    <syre:LeasedAssetsObtainedInExchangeForLeaseObligations
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-16850"
      unitRef="Unit_USD">21000</syre:LeasedAssetsObtainedInExchangeForLeaseObligations>
    <syre:LeasedAssetsObtainedInExchangeForLeaseObligations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-16855"
      unitRef="Unit_USD">872000</syre:LeasedAssetsObtainedInExchangeForLeaseObligations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16873">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. The Company and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc., (&#x201c;Spyre&#x201d; or the &#x201c;Company&#x201d;) is a preclinical stage biotechnology company focused on developing next generation therapeutics for patients living with inflammatory bowel disease. The Company was formed as a Limited Liability Company (&#x201c;LLC&#x201d;) in Delaware on December&#160;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC and was converted from a Delaware LLC to a Delaware corporation on March&#160;10, 2015. On November&#160;27, 2023, the Company completed its corporate rebranding, changing the name of the Company to Spyre Therapeutics, Inc. The Company operates in one segment and has its principal offices in Waltham, Massachusetts. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;8, 2023, the Company effected a reverse stock split of its Common Stock at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-25&lt;/div&gt;&lt;/div&gt; (the &#x201c;Reverse Split&#x201d;). Except as indicated otherwise, all share numbers related to the Company&#x2019;s Common Stock disclosed in these financial statements have been adjusted on a post-Reverse Split basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#x2019;s Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. As a result, in April 2023, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#x2019;s existing headcount. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#x201c;Acquisition Agreement&#x201d;), the assets of Spyre Therapeutics, Inc. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;Pre-Merger&lt;/div&gt; Spyre&#x201d;) as disclosed in Note 7 and 8, a privately held biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease through a research and development option agreement (&#x201c;Paragon Agreement&#x201d;) with Paragon Therapeutics (&#x201c;Paragon&#x201d;). The asset acquisition was accomplished through a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt; reverse triangular merger whereby a wholly owned subsidiary of the Company merged with and into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre, which existed at the time the Acquisition Agreement was entered into, became a wholly owned subsidiary of the Company in accordance with the terms of the Acquisition Agreement. Immediately following this merger, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre merged with an into a second wholly subsidiary of the Company (&#x201c;Merger Sub&#x201d;) in accordance with the terms of the Acquisition Agreement and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre ceased to exist. Subsequently, Aeglea BioTherapeutics, Inc. was renamed Spyre Therapeutics, Inc. and is a different entity than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre, which ceased to exist upon merging with Merger Sub. The transaction was structured as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock-for-stock&lt;/div&gt;&lt;/div&gt; transaction pursuant to which all of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre&#x2019;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from the Company of 517,809 shares of common stock and 364,887 shares of Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock, par value of $0.0001 per share (&#x201c;Series A Preferred Stock&#x201d;) (convertible on a 40 to 1 basis), in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#x201c;Asset Acquisition&#x201d;). The common stock and Series A Preferred Stock related to the Asset Acquisition were issued to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre stockholders on July&#160;7, 2023. For additional information, see Note 8. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock (the &#x201c;Series A PIPE&#x201d;) to a group of investors (the &#x201c;Series A Investors&#x201d;). The Company sold an aggregate of 721,452 shares of Series A Preferred Stock (the &#x201c;Series A PIPE Securities&#x201d;) for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million of placement agent and other offering expenses. For additional information, see Note 11. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-transferable&lt;/div&gt; contingent value right (&#x201c;CVR&#x201d;) was distributed to stockholders of record of the Company as of the close of business on July&#160;3, 2023 (the &#x201c;Legacy Stockholders&#x201d;), but was not distributed to the holders of shares of common stock or Series A Preferred Stock issued to the former stockholders of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre or Investors in the Transactions. Holders of the CVRs will be entitled to receive cash payments from proceeds received by the Company for a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-year&lt;/div&gt; period related to the disposition or monetization of its legacy assets for a period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; following the closing of the Asset Acquisition. For additional information, see Note 3. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;21, 2023, the Company&#x2019;s stockholders approved the conversion of the Company&#x2019;s Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock to Common Stock. For additional information, see Note 11. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2023, the Company completed a private placement of shares of common stock and Series B &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock, par value of $0.0001 per share (&#x201c;Series B Preferred Stock&#x201d;) (convertible on a 40 to 1 basis) (collectively, the &#x201c;December 2023 PIPE&#x201d;) to a group of investors (the &#x201c;December 2023 PIPE Investors&#x201d;). The Company sold an aggregate of 6,000,000 shares of Common Stock and 150,000 shares of Series B Preferred Stock (the &#x201c;December 2023 PIPE Securities&#x201d;) for an aggregate purchase price of approximately $180.0&#160;million before deducting approximately $10.9&#160;million of placement agent and other offering expenses. For additional information, see Note 11. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is a preclinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products. There can be no assurance that profitable operations will ever be achieved, and, if achieved, whether profitability can be sustained on a continuing basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Since its inception and through December&#160;31, 2023, the Company has funded our operations by raising an aggregate of approximately $896.2&#160;million of gross proceeds from the sale and issuance of convertible preferred stock and common stock, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, the collection of grant proceeds, and the licensing of its product rights for commercialization of pegzilarginase in Europe and certain countries in the Middle East. As of December&#160;31, 2023, Spyre had an accumulated deficit of $764.4&#160;million, and cash, cash equivalents, and marketable securities of $339.3&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Based on current operating plans, the Company has sufficient resources to fund operations for at least one year from the issuance date of these financial statements with existing cash, cash equivalents, and marketable securities. Spyre will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If the Company is unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on the Company. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) as defined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_12_2023To06_30_2023"
      decimals="2"
      id="ixv-16881"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <syre:FixedExchangeRatio
      contextRef="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="7"
      id="ixv-16892"
      unitRef="Unit_pure">0.5494488</syre:FixedExchangeRatio>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-16893"
      unitRef="Unit_shares">517809</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-16894"
      unitRef="Unit_shares">364887</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="4"
      id="ixv-16896"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-16897"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <syre:OutstandingAndUnexercisedStockOptions
      contextRef="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-16898"
      unitRef="Unit_shares">2734</syre:OutstandingAndUnexercisedStockOptions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-16901"
      unitRef="Unit_shares">721452</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-16902"
      unitRef="Unit_USD">210000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-16903"
      unitRef="Unit_USD">12700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <syre:AssetAcquisitionStockholderPaymentPeriod
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      id="ixv-16924">P3Y</syre:AssetAcquisitionStockholderPaymentPeriod>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_11_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-16930"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn12_11_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-16931"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_11_2023To12_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-16932"
      unitRef="Unit_shares">6000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-16933"
      unitRef="Unit_shares">150000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-16934"
      unitRef="Unit_USD">180000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-16935"
      unitRef="Unit_USD">10900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <syre:ProceedsFromRaisingCapital
      contextRef="P03_10_2015To12_31_2023"
      decimals="-5"
      id="ixv-16942"
      unitRef="Unit_USD">896200000</syre:ProceedsFromRaisingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-16944"
      unitRef="Unit_USD">-764400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-16945"
      unitRef="Unit_USD">339300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16947">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) as defined by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16953">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#x2019;s financial statements relate to the valuation of consideration transferred in acquiring &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research&#160;&amp;amp; development (&#x201c;IPR&amp;amp;D&#x201d;); the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre was comprised of shares of the Company&#x2019;s Common Stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the Series A PIPE securities, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;which&lt;/div&gt; was a financing event involving a group of accredited investors. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All investments have been classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Any unrealized losses from declines in fair value below the amortized cost basis as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-credit&lt;/div&gt; loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash consisted of money market accounts held by financial institutions as collateral for the Company&#x2019;s obligations under a credit agreement and a facility lease for the Company&#x2019;s corporate headquarters in Austin, Texas. The lease was terminated in August 2023 and the cash was subsequently unrestricted. Remaining restricted cash balances relate to the Company&#x2019;s operations in the United Kingdom. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company&#x2019;s two U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000 per depositor. As of December&#160;31, 2023 and 2022, balances at the Company&#x2019;s U.S. banking institutions exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The useful lives of the property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture and office equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Shorter of remaining lease term or estimated useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. The Company recognized a $2.6&#160;million impairment loss for the year ended December&#160;31, 2023 related to its leased office space in Austin, Texas (see Note 17 for additional information). There were no impairments of long-lived assets for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#x2019;s research and &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;development expenses, with a substantial portion of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-going&lt;/div&gt; research and development activities conducted by third-party service providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations (&#x201c;CMOs&#x201d;), and the Company&#x2019;s related-party Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues for expenses resulting from obligations under the Paragon Agreement and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations. Historically, the Company has not experienced any material deviations between accrued and actual research and development expenses. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prior to the Company&#x2019;s restructuring, as described in Note 17, the Company had lease agreements with lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. As allowed under Topic 842, the Company elected to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for any leases involving real estate and office equipment classes of assets and, as a result, accounted for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component. The Company also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company uses fair value measurements to record fair value adjustments to certain financial and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The three levels of inputs that may be used to measure fair value are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width:9%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td style="width:90%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments carried at fair value include cash equivalents and marketable securities. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;Topic 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in the period of adjustment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s contracts may be modified for changes in the customer&#x2019;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;an adjustment to revenue on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis. The cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#x201c;Topic 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#x2019;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes the cost of stock-based awards granted to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock Issued through PIPE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company classified the Series B Preferred Stock outside of stockholders&#x2019; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock on the last trading day prior to the holder&#x2019;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#x2019;s control. Additionally, the Company determined the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Milestone Proceeds &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contingent milestone proceeds associated from the sale of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development assets in earnings once the achievement of the milestone becomes probable and payment to the Company is contractually required. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;amp;D asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Value Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-cash&lt;/div&gt; settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#x2019;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2023 and 2022, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2023, 2022, or 2021. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#x2019;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#x2019;s functional currency and the reporting currency. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company early adopted the Financial Accounting Standards Board&#x2019;s Accounting Standards Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the cash conversion and beneficial conversion feature models in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20&lt;/div&gt; that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted earnings-per-share for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; requires the if-converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; to all Series A Preferred Stock and Series B Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A Preferred Stock and Series B Preferred Stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023-07,&lt;/div&gt; Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 &#x2013; Segment Reporting. This update is effective beginning with the Company&#x2019;s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023-09,&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. This ASU will have no impact on the Company&#x2019;s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax&lt;/div&gt; disclosures. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2023To12_31_2023" id="ixv-16956">&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company&#x2019;s financial statements relate to the valuation of consideration transferred in acquiring &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research&#160;&amp;amp; development (&#x201c;IPR&amp;amp;D&#x201d;); the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre was comprised of shares of the Company&#x2019;s Common Stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the Series A PIPE securities, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;which&lt;/div&gt; was a financing event involving a group of accredited investors. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16990">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of money market funds and debt securities and are stated at fair value. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-16996">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All investments have been classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase. The Company may hold securities with stated maturities greater than one year until maturity. All &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are considered available to support current operations and are classified as current assets. The Company presents credit losses as an allowance rather than as a reduction in the amortized cost of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized in other income (expense) in the results of operations. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; security is uncollectible or when either of the criteria regarding intent or requirement to sell is met. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Any unrealized losses from declines in fair value below the amortized cost basis as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-credit&lt;/div&gt; loss factors is recognized as a component of accumulated other comprehensive (loss) income, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are included in other income (expense) in the results of operations. The cost of securities sold is based on the specific-identification method. &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17035">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash consisted of money market accounts held by financial institutions as collateral for the Company&#x2019;s obligations under a credit agreement and a facility lease for the Company&#x2019;s corporate headquarters in Austin, Texas. The lease was terminated in August 2023 and the cash was subsequently unrestricted. Remaining restricted cash balances relate to the Company&#x2019;s operations in the United Kingdom. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2023To12_31_2023" id="ixv-17041">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities, and restricted cash. The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s cash, cash equivalents, marketable securities, and restricted cash are held by financial institutions that management believes are of high credit quality. The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits. Accounts at each of the Company&#x2019;s two U.S. banking institutions are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000 per depositor. As of December&#160;31, 2023 and 2022, balances at the Company&#x2019;s U.S. banking institutions exceeded the FDIC limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"
      decimals="0"
      id="ixv-17047"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17048">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance that do not extend the life or improve an asset are expensed as incurred. Upon retirement or sale, the cost of disposed assets and their related accumulated depreciation and amortization are removed from the balance sheet. Any gain or loss is credited or charged to operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The useful lives of the property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture and office equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Shorter of remaining lease term or estimated useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <syre:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17054">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The useful lives of the property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture and office equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Shorter of remaining lease term or estimated useful life&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syre:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-17066">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-17071">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-17076">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-17081">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17086">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the fair value. The Company recognized a $2.6&#160;million impairment loss for the year ended December&#160;31, 2023 related to its leased office space in Austin, Texas (see Note 17 for additional information). There were no impairments of long-lived assets for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-17092"
      unitRef="Unit_USD">2600000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <syre:AccruedResearchAndDevelopmentExpensePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17093">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records the costs associated with research nonclinical studies, clinical trials, and manufacturing development as incurred. These costs are a significant component of the Company&#x2019;s research and &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;development expenses, with a substantial portion of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-going&lt;/div&gt; research and development activities conducted by third-party service providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations (&#x201c;CMOs&#x201d;), and the Company&#x2019;s related-party Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues for expenses resulting from obligations under the Paragon Agreement and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations. Historically, the Company has not experienced any material deviations between accrued and actual research and development expenses. &lt;/div&gt;</syre:AccruedResearchAndDevelopmentExpensePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17124">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. To determine the incremental borrowing rate, the Company uses the lease-term appropriate current treasury bond rates adjusted for collateral and inflation risks combined with quoted bank financing rates. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. Amortization expense for the ROU asset associated with its finance leases is recognized on a straight-line basis over the term of the lease and interest expense associated with its finance leases is recognized on the balance of the lease liability using the effective interest method based on the estimated incremental borrowing rate. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prior to the Company&#x2019;s restructuring, as described in Note 17, the Company had lease agreements with lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. As allowed under Topic 842, the Company elected to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for any leases involving real estate and office equipment classes of assets and, as a result, accounted for the lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components as a single lease component. The Company also elected to not apply the recognition requirement of Topic 842 to leases with a term of 12 months or less for all classes of assets. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17136">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company uses fair value measurements to record fair value adjustments to certain financial and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities and to determine fair value disclosures. The accounting standards define fair value, establish a framework for measuring fair value, and require disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the principal or most advantageous market in which the Company would transact are considered along with assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accounting standard for fair value establishes a fair value hierarchy based on three levels of inputs, the first two of which are considered observable and the last unobservable, that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The three levels of inputs that may be used to measure fair value are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto"&gt;
&lt;tr&gt;
&lt;td style="width:9%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td style="width:90%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="2" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Valuations based on unobservable inputs to the valuation methodology and including data about assumptions that market participants would use in pricing the asset or liability based on the best information available under the circumstances.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments carried at fair value include cash equivalents and marketable securities. The carrying amounts of accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17190">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;Topic 606&#x201d;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses its license arrangements within the scope of Topic 606 in accordance with this framework as follows: &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. In assessing whether a promised good or service is distinct, and therefore a performance obligation, the Company considers factors such as the research, stage of development of the licensed product, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, the Company is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;distinct. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The transaction price is determined and allocated to the identified performance obligations in proportion to their stand-alone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is based on observable prices of the performance obligations or, when such prices are not observable, are estimated. The estimation of SSP may include factors such as forecasted revenues or costs, development timelines, discount rates, probabilities of technical and regulatory success, and considerations such as market conditions and entity-specific factors. In certain circumstances, the Company may apply the residual method to determine the SSP of a good or service if the SSP is considered highly variable or uncertain. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the amount of estimated variable consideration in the transaction price to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in the period of adjustment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If an arrangement includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered likely of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are generally not considered likely of being achieved until those approvals are received. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensee and the transfer of the promised goods or services to the licensees will be one year or less. For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and if the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time, recognition is based on the use of an output or input method. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s contracts may be modified for changes in the customer&#x2019;s requirements. If contract modifications are for additional goods and services that are distinct from the existing contract, the modification will be accounted for as either a separate contract or a termination of the existing contract, depending on whether the additional goods or services reflects the SSP. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the additional goods or services in a contract modification are not distinct from the existing contract, they are accounted for as if they were part of the original contract. The effect of the contract modification on the transaction price and the measure of progress for the performance obligation to which it relates is recognized as &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;an adjustment to revenue on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis. The cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; adjustment is calculated using an updated measure of progress applied to the sum of (1)&#160;the remaining consideration allocated to the partially satisfied performance obligation and (2)&#160;the revenue already recognized on that performance obligation. The revenue recognized for fully satisfied goods or services and distinct from the remaining performance obligations is not altered by the modification. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaborative arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company analyzes its license arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC Topic 808, Collaborative Arrangements (&#x201c;Topic 808&#x201d;). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For arrangements within the scope of Topic 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of Topic 808 and which elements of the collaboration are more reflective of a vendor-customer relationship and therefore within the scope of Topic 606. For elements of collaboration arrangements that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. For those elements of the arrangement that are accounted for pursuant to Topic 606, the Company applies the five-step model described above. &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17263">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, travel, stock-based compensation, consulting costs, contract research service costs, laboratory supplies and facilities, contract manufacturing costs, and costs paid to other third parties that conduct research and development activities on the Company&#x2019;s behalf. Amounts incurred in connection with license agreements are also included in research and development expense. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are recorded as a prepaid asset and expensed as the related goods are delivered or the services are performed. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17270">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes the cost of stock-based awards granted to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; based on the estimated grant-date fair values of the awards. The fair values of stock options are estimated on the date of grant using the Black-Scholes option pricing model. The fair values of restricted stock units (&#x201c;RSUs&#x201d;) are based on the fair value of the Company&#x2019;s common stock on the date of the grant. The value of the award is recognized as compensation expense on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise. Compensation expense for employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based payment awards with performance conditions is recognized when the performance condition is deemed probable. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <syre:TemporaryEquityPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17278">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Preferred Stock Issued through PIPE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records shares of convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The Company classified the Series B Preferred Stock outside of stockholders&#x2019; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock on the last trading day prior to the holder&#x2019;s redemption request. The Company has determined that the conversion and redemption are outside of the Company&#x2019;s control. Additionally, the Company determined the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. &lt;/div&gt;</syre:TemporaryEquityPolicyPolicyTextBlock>
    <syre:InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17303">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Milestone Proceeds &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contingent milestone proceeds associated from the sale of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development assets in earnings once the achievement of the milestone becomes probable and payment to the Company is contractually required. &lt;/div&gt;</syre:InProcessResearchAndDevelopmentAssetsContingentConsiderationPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17312">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;amp;D asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17321">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent Value Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date. Any changes in fair value are recorded as other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-cash&lt;/div&gt; settlement of the derivative instrument is probable within the next 12 months from the balance sheet date. The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet. This value is then remeasured for future expected payout as well as the increase in fair value due to the time value of money. These gains or losses, if any, are recognized in the consolidated statements of operations and comprehensive loss within Other (expense) income, net. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company applies a scenario-based method and weighs them based on the possible achievement of certain milestones. The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), among other events. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in ASC 820, Fair Value Measurement. The key assumptions used include the discount rate, probability of regulatory success, and reimbursement rates from certain government agencies. The estimated value of the CVR consideration is based upon available information and certain assumptions which the Company&#x2019;s management believes are reasonable under the circumstances. The ultimate payout under the CVRs may differ materially from the assumptions used in determining the fair value of the CVR consideration. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17347">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and the tax bases of assets and liabilities. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A valuation allowance is established against the deferred tax assets to reduce their carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the unrecognized tax benefits as a component of income tax expense, if applicable. As of December&#160;31, 2023 and 2022, the Company had no unrecognized tax benefits and there were no interest or penalties incurred by the Company in the years ended December&#160;31, 2023, 2022, or 2021. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17355">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is the change in stockholders&#x2019; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company&#x2019;s other comprehensive income (loss) is currently comprised of changes in unrealized losses and gains on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities and foreign currency translation adjustments reflecting the cumulative effect of changes in exchange rates between the foreign entity&#x2019;s functional currency and the reporting currency. &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17363">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company early adopted the Financial Accounting Standards Board&#x2019;s Accounting Standards Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; effective as of January&#160;1, 2023 using the modified retrospective method. Among other amendments, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the cash conversion and beneficial conversion feature models in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20&lt;/div&gt; that required an issuer of certain convertible debt and preferred stock to separately account for embedded conversion features as a component of equity, as well as changes the accounting for diluted earnings-per-share for convertible instruments and contracts that may be settled in cash or stock. Additionally, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; requires the if-converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. The Company applied ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; to all Series A Preferred Stock and Series B Preferred Stock during fiscal year 2023, and, accordingly, the Company did not apply the cash conversion or beneficial conversion feature models in its analysis of the Series A Preferred Stock and Series B Preferred Stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023-07,&lt;/div&gt; Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance and requires companies to disclose all annual disclosures about segments in interim periods. The ASU also requires companies with a single reportable segment to provide all disclosures required by Topic 280 &#x2013; Segment Reporting. This update is effective beginning with the Company&#x2019;s 2024 fiscal year annual reporting period and interim periods beginning thereafter. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023-09,&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. This ASU will have no impact on the Company&#x2019;s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax&lt;/div&gt; disclosures. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17405">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables sets forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt; hierarchy (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:58%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,843&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,843&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183,491&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;336,953&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CVR liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;&#x2007;&#x2007;&#x2009;&#x2007;&#x2007;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;31,603&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;46,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures the fair value of money market funds on quoted prices in active markets for identical asset or liabilities. The Level&#160;2 assets include U.S. government agency securities, commercial paper and corporate bonds, and are valued based on quoted prices for similar assets in active markets and inputs other than quoted prices that are derived from observable market data. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between Level&#160;1 and Level&#160;2 during the periods presented. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had no financial liabilities outstanding measured at fair value. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Forward Contract Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, the Company entered into a contract for the issuance of 364,887 shares of Series A Preferred Stock as part of the consideration transferred. This forward contract was classified as a liability because the underlying preferred shares were contingently redeemable. Further, the forward contract &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;liability was considered a Level&#160;2 liability based on observable market data for substantially the full term of the liability and was initially measured at its estimated fair value on the transaction date based on the underlying price per share on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis of the Series A PIPE Securities issued in the Series A PIPE. Subsequent remeasurement of the fair value of the forward contract liability through its settlement date was based on the market price of the Company&#x2019;s Common Stock, which represents the redemption value of the Series A Preferred Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the forward contract at the transaction date, June&#160;22, 2023, was $106.2&#160;million. The liability was settled with the issuance of the Series A Preferred Stock on July&#160;7, 2023 for $189.7&#160;million. For the year ended December&#160;31, 2023, $83.5&#160;million was recorded as Other (expense) income in the consolidated statements of operations in connection with the change in fair value of the forward contract liability. There was no similar expense for the year ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the forward contract liability for the periods presented (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward&#160;Contract&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of June&#160;22, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Series A Preferred Stock on July&#160;7, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(189.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;CVR Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-transferable&lt;/div&gt; contingent value right was distributed to the Legacy Stockholders, but was not distributed to holders of shares of Common Stock or Series A Preferred Stock issued to the Investors or former stockholders of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre in connection with the Transactions. Holders of the CVR will be entitled to receive certain cash payments from proceeds received by the Company for a three-year period, if any, related to the disposition or monetization of the Company&#x2019;s legacy assets for a period of one year following the closing of the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the CVR liability was determined using the probability weighted discounted cash flow method to estimate future cash flows associated with the sale of the legacy assets. Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June&#160;22, 2023, as a Common Stock dividend, returning capital to the Legacy Stockholders. Changes in fair value of the liability will be recognized as a component of Other income (expense) in the consolidated statement of operations and comprehensive loss in each reporting period. The liability value is based on significant inputs not observable in the market such as estimated cash flows, estimated probabilities of regulatory success, and discount rates, which represent a Level&#160;3 measurement within the fair value hierarchy. The significant inputs used to estimate the fair value of the CVR liability were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Estimated cash flow dates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2/28/24&#x2009;-&#x2009;06/22/26&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Estimated probability of success&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;39% - 100%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Estimated reimbursement rate compared to reimbursement target&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;81% - 100%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-adjusted discount rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5.91% - 6.32%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The change in fair value between the issuance of the CVR and December&#160;31, 2023 was a $19.0&#160;million increase, and was primarily driven by changes in the expected timing of achievement of certain milestones, changes in the likelihood of certain milestones related to the approval received from the European Medicines Agency by Immedica Pharma AB (&#x201c;Immedica&#x201d;), partially offset by a change in the likelihood of a successful disposition of pegtarviliase and updates to expenses and deductions. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the CVR liability for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CVR&#160;Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at CVR issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in the fair value of the CVR liability since issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17409">The following tables sets forth the fair value of the Company&#x2019;s financial assets and liabilities at fair value on a recurring basis based on the three-tier fair &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;value&lt;/div&gt; hierarchy (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:58%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,843&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,843&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;183,491&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;336,953&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CVR liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Financial Assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;&#x2007;&#x2007;&#x2009;&#x2007;&#x2007;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;31,603&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;46,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17486"
      unitRef="Unit_USD">150648000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17491"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17496"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17501"
      unitRef="Unit_USD">150648000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17509"
      unitRef="Unit_USD">32843000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17514"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17519"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17524"
      unitRef="Unit_USD">32843000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17532"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17537"
      unitRef="Unit_USD">16257000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17542"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17547"
      unitRef="Unit_USD">16257000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17555"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17560"
      unitRef="Unit_USD">104141000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17565"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17570"
      unitRef="Unit_USD">104141000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17578"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17583"
      unitRef="Unit_USD">33064000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17588"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17593"
      unitRef="Unit_USD">33064000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17627"
      unitRef="Unit_USD">183491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17632"
      unitRef="Unit_USD">153462000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17637"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17642"
      unitRef="Unit_USD">336953000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17695"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17700"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17705"
      unitRef="Unit_USD">42700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17710"
      unitRef="Unit_USD">42700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17744"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17749"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17754"
      unitRef="Unit_USD">42700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17759"
      unitRef="Unit_USD">42700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17861"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17866"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17871"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-17876"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17884"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17889"
      unitRef="Unit_USD">23641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17894"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17899"
      unitRef="Unit_USD">23641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17907"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-17912"
      unitRef="Unit_USD">4230000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17928"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17933"
      unitRef="Unit_USD">3732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17938"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17943"
      unitRef="Unit_USD">3732000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17977"
      unitRef="Unit_USD">15250000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17982"
      unitRef="Unit_USD">31603000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17987"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-17992"
      unitRef="Unit_USD">46853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-18023"
      unitRef="Unit_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-18029"
      unitRef="Unit_shares">364887</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      id="ixv-18049"
      unitRef="Unit_USD">106200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-18050"
      unitRef="Unit_USD">189700000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      id="ixv-18051"
      unitRef="Unit_USD">-83500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2021To12_31_2021_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      id="ixv-18052"
      unitRef="Unit_USD">-0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2022To12_31_2022_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      id="ixv-18053"
      unitRef="Unit_USD">-0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18054">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the forward contract liability for the periods presented (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Forward&#160;Contract&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of June&#160;22, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Series A Preferred Stock on July&#160;7, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(189.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the CVR liability for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CVR&#160;Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at CVR issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in the fair value of the CVR liability since issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_22_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      id="ixv-18078"
      unitRef="Unit_USD">106200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P06_23_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      id="ixv-18086"
      unitRef="Unit_USD">-83500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P06_23_2023To12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      id="ixv-18094"
      unitRef="Unit_USD">189700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_ForwardContractsMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      id="ixv-18110"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <syre:AssetAcquisitionStockholderPaymentPeriod
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      id="ixv-18127">P3Y</syre:AssetAcquisitionStockholderPaymentPeriod>
    <syre:AssetAcquisitionCashPaymentThresholdPeriod
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      id="ixv-18128">P1Y</syre:AssetAcquisitionCashPaymentThresholdPeriod>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18130">The significant inputs used to estimate the fair value of the CVR liability were as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Estimated cash flow dates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2/28/24&#x2009;-&#x2009;06/22/26&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Estimated probability of success&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;39% - 100%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Estimated reimbursement rate compared to reimbursement target&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;81% - 100%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-adjusted discount rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5.91% - 6.32%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="0"
      id="ixv-18155"
      unitRef="Unit_pure">39</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      id="ixv-18156"
      unitRef="Unit_pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="0"
      id="ixv-18162"
      unitRef="Unit_pure">81</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputReimbursementRateMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      id="ixv-18163"
      unitRef="Unit_pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-18169"
      unitRef="Unit_pure">5.91</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      id="ixv-18170"
      unitRef="Unit_pure">6.32</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-5"
      id="ixv-18172"
      unitRef="Unit_USD">-19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-18215"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-18223"
      unitRef="Unit_USD">29500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-18231"
      unitRef="Unit_USD">-18986000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2023To12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-18239"
      unitRef="Unit_USD">5786000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_ContingentValueRightLiabilityMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-3"
      id="ixv-18255"
      unitRef="Unit_USD">42700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18265">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Cash Equivalents and Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,955&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,563&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79,186&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;&#x2007;&#x2007;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;20,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2023 and 2022, aggregated by major security type and length of time in a continuous unrealized loss position: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,831&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,831&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect they will be required to sell the securities before recovery of the unamortized cost basis. As of December&#160;31, 2023 and 2022, an allowance for credit losses had &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;not&lt;/div&gt; been recognized. Given the Company&#x2019;s intent and ability to hold such securities until recovery, and the lack of significant change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were $0.3&#160;million unrealized gains on marketable securities for the year ended December&#160;31, 2023. There were no realized gains on marketable securities for the year ended December&#160;31, 2023, 2022 and 2021. Interest on marketable securities is included in interest income. Accrued interest receivable on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt &lt;div style="-sec-ix-hidden:hidden103883038;display:inline;"&gt;securities&lt;/div&gt; totaled $0.9&#160;million and $0.1&#160;million as of December&#160;31, 2023 and 2022, respectively, and is excluded from the estimate of credit losses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in one year or less&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;115,784&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in 1 &#x2013; 2 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may sell investments at any time for use in current operations even if they have not yet reached maturity. As a result, the Company classifies marketable securities, including securities with maturities beyond twelve months as current assets. &lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18268">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the estimated fair value of the Company&#x2019;s cash equivalents and marketable securities and the gross unrealized gains and losses (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,648&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,955&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,563&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;186,569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79,186&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:57%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;&#x2007;&#x2007;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;20,877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2007;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18362"
      unitRef="Unit_USD">150648000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18367"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18372"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2023_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18377"
      unitRef="Unit_USD">150648000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18385"
      unitRef="Unit_USD">24950000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18390"
      unitRef="Unit_USD">5000</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18395"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18400"
      unitRef="Unit_USD">24955000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18408"
      unitRef="Unit_USD">10965000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18413"
      unitRef="Unit_USD">1000</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18418"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18423"
      unitRef="Unit_USD">10966000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18457"
      unitRef="Unit_USD">186563000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18462"
      unitRef="Unit_USD">6000</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18467"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18472"
      unitRef="Unit_USD">186569000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18531"
      unitRef="Unit_USD">79124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18536"
      unitRef="Unit_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18541"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18546"
      unitRef="Unit_USD">79186000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18554"
      unitRef="Unit_USD">32984000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18559"
      unitRef="Unit_USD">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18564"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18569"
      unitRef="Unit_USD">33064000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18577"
      unitRef="Unit_USD">21846000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18582"
      unitRef="Unit_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18587"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18592"
      unitRef="Unit_USD">21877000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18600"
      unitRef="Unit_USD">16147000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18605"
      unitRef="Unit_USD">110000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18610"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2023_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18615"
      unitRef="Unit_USD">16257000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18649"
      unitRef="Unit_USD">150101000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18654"
      unitRef="Unit_USD">284000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18659"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18664"
      unitRef="Unit_USD">150384000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18784"
      unitRef="Unit_USD">15250000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18789"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18794"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18799"
      unitRef="Unit_USD">15250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18807"
      unitRef="Unit_USD">7021000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18812"
      unitRef="Unit_USD">1000</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18817"
      unitRef="Unit_USD">2000</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18822"
      unitRef="Unit_USD">7020000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18830"
      unitRef="Unit_USD">3736000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18835"
      unitRef="Unit_USD">0</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18840"
      unitRef="Unit_USD">1000</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18845"
      unitRef="Unit_USD">3735000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-18879"
      unitRef="Unit_USD">26007000</us-gaap:CashEquivalentsAtCarryingValue>
    <syre:CashEquivalentsUnrealizedGains
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-18884"
      unitRef="Unit_USD">1000</syre:CashEquivalentsUnrealizedGains>
    <syre:CashEquivalentsUnrealizedLosses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-18889"
      unitRef="Unit_USD">3000</syre:CashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-18894"
      unitRef="Unit_USD">26005000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18947"
      unitRef="Unit_USD">16644000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18952"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18957"
      unitRef="Unit_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18962"
      unitRef="Unit_USD">16621000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18970"
      unitRef="Unit_USD">3738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18975"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18980"
      unitRef="Unit_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18985"
      unitRef="Unit_USD">3732000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18993"
      unitRef="Unit_USD">495000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-18998"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19003"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19008"
      unitRef="Unit_USD">495000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19042"
      unitRef="Unit_USD">20877000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19047"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19052"
      unitRef="Unit_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19057"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19105">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December&#160;31, 2023 and 2022, aggregated by major security type and length of time in a continuous unrealized loss position: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,831&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,831&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,738&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:46%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12&#160;Months&#160;or&#160;Longer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,732&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. government agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19208"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19213"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19218"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19223"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19228"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2023_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19233"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19241"
      unitRef="Unit_USD">9907000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19246"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19251"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19256"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19261"
      unitRef="Unit_USD">9907000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2023_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19266"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19274"
      unitRef="Unit_USD">4831000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19279"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19284"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19289"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19294"
      unitRef="Unit_USD">4831000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2023_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19299"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19345"
      unitRef="Unit_USD">14738000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19350"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19355"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19360"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19365"
      unitRef="Unit_USD">14738000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19370"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19509"
      unitRef="Unit_USD">17699000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19514"
      unitRef="Unit_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19519"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19524"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19529"
      unitRef="Unit_USD">17699000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19534"
      unitRef="Unit_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19542"
      unitRef="Unit_USD">3732000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19547"
      unitRef="Unit_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19552"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19557"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19562"
      unitRef="Unit_USD">3732000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19567"
      unitRef="Unit_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19575"
      unitRef="Unit_USD">3735000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19580"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19585"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19590"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19595"
      unitRef="Unit_USD">3735000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19600"
      unitRef="Unit_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19646"
      unitRef="Unit_USD">25166000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19651"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19656"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19661"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19666"
      unitRef="Unit_USD">25166000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19671"
      unitRef="Unit_USD">34000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
      contextRef="PAsOn12_31_2022_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19713"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
      contextRef="PAsOn12_31_2023_USGovernmentAgenciesDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-19714"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-19716"
      unitRef="Unit_USD">300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-19717"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-19718"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-19722"
      unitRef="Unit_USD">900000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      id="ixv-19723"
      unitRef="Unit_USD">100000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19724">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in one year or less&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;115,784&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due in 1 &#x2013; 2 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;150,384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19763"
      unitRef="Unit_USD">115784000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19768"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19776"
      unitRef="Unit_USD">34600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19781"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19803"
      unitRef="Unit_USD">150384000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19808"
      unitRef="Unit_USD">20848000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19836">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2023, 2022, and 2021 was $0.7&#160;million, $1.4&#160;million, and $1.4&#160;million, respectively. All of the Company&#x2019;s long-lived assets were located in the United States. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sale of Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#x2019;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. As a result, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#x2019;s existing headcount by June&#160;30, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $0.5&#160;million. After recording the disposal of all the Company&#x2019;s property and equipment net of proceeds, the Company recorded a $0.7&#160;million and $0.2&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19839">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,220&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19878"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LaboratoryEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19883"
      unitRef="Unit_USD">2257000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19891"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19896"
      unitRef="Unit_USD">520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19904"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19909"
      unitRef="Unit_USD">73000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19917"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_SoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19922"
      unitRef="Unit_USD">121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19930"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-19935"
      unitRef="Unit_USD">4393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19957"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19962"
      unitRef="Unit_USD">7364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19970"
      unitRef="Unit_USD">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-19975"
      unitRef="Unit_USD">4144000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-19997"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20002"
      unitRef="Unit_USD">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To12_31_2023_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"
      decimals="-5"
      id="ixv-20019"
      unitRef="Unit_USD">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"
      decimals="-5"
      id="ixv-20020"
      unitRef="Unit_USD">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021_PropertyPlantAndEquipmentMemberusgaapFairValueByAssetClassAxis"
      decimals="-5"
      id="ixv-20021"
      unitRef="Unit_USD">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_12_2023To06_30_2023"
      decimals="2"
      id="ixv-20027"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P04_01_2023To06_30_2023"
      decimals="-5"
      id="ixv-20029"
      unitRef="Unit_USD">500000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-20030"
      unitRef="Unit_USD">-700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-20031"
      unitRef="Unit_USD">-200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <syre:AccruedAndOtherCurrentLiabilitiesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20032">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Accrued and Other Current Liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contracted research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,474&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syre:AccruedAndOtherCurrentLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20035">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contracted research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,972&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,474&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;946&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;488&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20074"
      unitRef="Unit_USD">4054000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20079"
      unitRef="Unit_USD">4589000</us-gaap:AccruedSalariesCurrent>
    <syre:AccruedContractedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20087"
      unitRef="Unit_USD">7092000</syre:AccruedContractedResearchAndDevelopmentCosts>
    <syre:AccruedContractedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20092"
      unitRef="Unit_USD">6972000</syre:AccruedContractedResearchAndDevelopmentCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20100"
      unitRef="Unit_USD">1474000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20105"
      unitRef="Unit_USD">946000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20113"
      unitRef="Unit_USD">488000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20118"
      unitRef="Unit_USD">330000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20140"
      unitRef="Unit_USD">13108000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20145"
      unitRef="Unit_USD">12837000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20161">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Paragon and Parapyre Holding LLC (&#x201c;Parapyre&#x201d;) each beneficially own less than 5% of the Company&#x2019;s capital stock through their respective holdings of the Company&#x2019;s common stock. Fairmount Funds Management &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;LLC (&#x201c;Fairmount&#x201d;) beneficially owns more than 5% of the Company&#x2019;s capital stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, has two seats on the Board and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount appointed Paragon&#x2019;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, the Company assumed the rights and obligations of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon for its services performed under each research program based on the actual costs incurred with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mark-up&lt;/div&gt; costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, which included the $3.0&#160;million research initiation fee and $16.0&#160;million of reimbursable expenses under the Paragon Agreement for historical costs owed to Paragon. As of the acquisition date, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2023, the Company recognized expenses related to services provided by Paragon subsequent to the Asset Acquisition totaling $48.5&#160;million, which included $11.4&#160;million of stock-based compensation expense, and were recorded as Research and development expenses in the consolidated statements of operations. As of December&#160;31, 2023, $16.6&#160;million was unpaid and was included in Related party accounts payable and other current liabilities on the Company&#x2019;s consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2023, the Company made payments totaling $39.5&#160;million to Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;12, 2023 and December&#160;14, 2023, the Company exercised the Option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expects to enter into the SPY001 License Agreement and the SPY002 License Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, we expect to pay Paragon a $1.5&#160;million fee for nomination of a development candidate, as applicable, and the Company expects to be obligated to make a further milestone payment of&#x2009;$2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of expenses related to the Paragon Agreement recognized within research and development expenses, which were ultimately settled in cash (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parapyre Option Obligation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As part of the Paragon Agreement, the Company is obligated to issue Parapyre a stock option grant on the last business day of 2023 and 2024 (the &#x201c;Parapyre Option Obligation&#x201d;). See Note 15 for additional information. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of Related party accounts payable and other current liabilities (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Related party accounts payable and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;December 2023 PIPE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The December 2023 Investors included Fairmount, a related party. Fairmount&#x2019;s participation in the December 2023 PIPE was approved by the Company&#x2019;s board of directors. Fairmount&#x2019;s investment accounted for $10.0&#160;million of the $180.0&#160;million gross proceeds raised in the December 2023 PIPE. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Mark McKenna Option Grant &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;1, 2024, the Board appointed Mark McKenna as a Class&#160;I director. Mr.&#160;McKenna and the Company are parties to a consulting agreement, pursuant to which Mr.&#160;McKenna agreed to continue to provide consulting services as an independent contractor to the Company, with an effective date of August&#160;1, 2023 (the &#x201c;Vesting Commencement Date&#x201d;). As compensation for Mr.&#160;McKenna&#x2019;s consulting services, on November&#160;22, 2023, he was granted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; stock options to purchase 477,000 shares of the Company&#x2019;s common stock under the Company&#x2019;s equity incentive plan with an exercise price of $10.39 per share, which vest as to 25% on the one year anniversary of the Vesting Commencement Date and thereafter vest and become exercisable in 48th equal monthly installments, subject to Mr.&#160;McKenna&#x2019;s continued service to the Company through each applicable vesting date. For the twelve months ended December&#160;31, 2023, the Company recognized $0.1&#160;million in stock-based compensation expense related to Mr.&#160;McKenna&#x2019;s consulting agreement. There was no such expense for the twelve months ended December&#160;31, 2022 and 2021. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-20165"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn12_31_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-20183"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <syre:RelatedPartyTransactionNumberOfBoardSeats
      contextRef="PAsOn12_31_2023_AppointOfBoardMembersMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-20185"
      unitRef="Unit_BOARDSEAT">2</syre:RelatedPartyTransactionNumberOfBoardSeats>
    <syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty
      contextRef="PAsOn12_31_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-20186"
      unitRef="Unit_pure">0.05</syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty>
    <syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20191"
      unitRef="Unit_USD">19000000</syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition>
    <syre:ResearchInitiationFees
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20192"
      unitRef="Unit_USD">3000000</syre:ResearchInitiationFees>
    <syre:ReimbursableResearchCosts
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20193"
      unitRef="Unit_USD">16000000</syre:ReimbursableResearchCosts>
    <syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition
      contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20194"
      unitRef="Unit_USD">19000000</syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2023To12_31_2023_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20196"
      unitRef="Unit_USD">48500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20197"
      unitRef="Unit_USD">11400000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20198"
      unitRef="Unit_USD">16600000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2023To12_31_2023_MilestonePaymentsMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20200"
      unitRef="Unit_USD">39500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <syre:AmountToBePaidUnderAgreement
      contextRef="PAsOn12_14_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20203"
      unitRef="Unit_USD">22000000</syre:AmountToBePaidUnderAgreement>
    <syre:NominationFee
      contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20204"
      unitRef="Unit_USD">1500000</syre:NominationFee>
    <syre:PaymentOfMilestone
      contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20205"
      unitRef="Unit_USD">2500000</syre:PaymentOfMilestone>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20206">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of expenses related to the Paragon Agreement recognized within research and development expenses, which were ultimately settled in cash (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <syre:RelatedPartyTransactionReimbursableCosts
      contextRef="P01_01_2023To12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-20254"
      unitRef="Unit_USD">37100000</syre:RelatedPartyTransactionReimbursableCosts>
    <syre:RelatedPartyTransactionReimbursableCosts
      contextRef="P01_01_2022To12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="ixv-20259"
      unitRef="Unit_USD">0</syre:RelatedPartyTransactionReimbursableCosts>
    <syre:RelatedPartyTransactionReimbursableCosts
      contextRef="P01_01_2021To12_31_2021_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="ixv-20264"
      unitRef="Unit_USD">0</syre:RelatedPartyTransactionReimbursableCosts>
    <syre:ScheduleOfBalancesDueToAffiliatesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20271">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following is the summary of Related party accounts payable and other current liabilities (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reimbursable costs under the Paragon Agreement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Related party accounts payable and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syre:ScheduleOfBalancesDueToAffiliatesTableTextBlock>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2023_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20305"
      unitRef="Unit_USD">16600000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2022_ReimbursableCostsUnderParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      id="ixv-20310"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20332"
      unitRef="Unit_USD">16600000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="PAsOn12_31_2022_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      id="ixv-20337"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2023To12_31_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SaleOfStockDecember2023PIPEMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20377"
      unitRef="Unit_USD">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-20378"
      unitRef="Unit_USD">180000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-20383"
      unitRef="Unit_shares">477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-20384"
      unitRef="Unit_USD_per_Share">10.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P11_22_2023To11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      decimals="2"
      id="ixv-20385"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments
      contextRef="PAsOn11_22_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-20386"
      unitRef="Unit_installment">48</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMonthlyInstallments>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20387"
      unitRef="Unit_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20388">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Asset Acquisition &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre pursuant to the Acquisition Agreement, by and among the Company, Aspen Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#x201c;First Merger Sub&#x201d;), Sequoia Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (&#x201c;Second Merger Sub&#x201d;), and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre. Pursuant to the Acquisition Agreement, First Merger Sub merged with and into &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre, pursuant to which &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre was the surviving corporation and became the Company&#x2019;s wholly owned subsidiary (the &#x201c;First Merger&#x201d;). Immediately following the First Merger, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre merged with and into Second Merger Sub, pursuant to which Second Merger Sub became the surviving entity. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre was a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; stage biotechnology company that was incorporated on April&#160;28, 2023 under the direction of Peter Harwin, a Managing Member of Fairmount, for the purpose of holding rights to certain intellectual property being developed by Paragon. Fairmount is a founder of Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;With respect to the Asset Acquisition, the Company determined that Aeglea was the acquirer for accounting purposes under ASC 805. The primary factors considered were a) the relative voting rights in the combined entity not resulting in a change of control, b) legacy members of the Company&#x2019;s Board of Directors maintained control of the Board of Directors, and c) the only change in the composition of senior management was the appointment of a new Chief Operating Officer. Next, the Company considered whether the Asset Acquisition should be defined as a business under ASC 805. ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;805-10-55-5A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; through &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;55-5C&lt;/div&gt; describe a screen test to determine whether an acquired set of assets and activities is not a business. We determined that substantially all (greater than 90%) of the fair value of the assets acquired were concentrated in a single asset, Spyre&#x2019;s Option to license intellectual property rights related to SPY001, SPY002, SPY003 and SPY004 pursuant to the Paragon Agreement. Accordingly, the Company treated the Asset Acquisition as an asset acquisition for accounting purposes. Even if the transaction would have failed the screen test, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre lacked the financial resources to have inputs, processes, and outputs to constitute a business under ASC 805. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company completed the Asset Acquisition of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre, in accordance with the terms of the Acquisition Agreement. Under the terms of the Acquisition Agreement, the Company issued 517,809 shares of Common Stock and 364,887 shares of Series A Preferred Stock to former &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre security holders. In addition, outstanding and unexercised stock options to purchase 2,734 shares of common stock were assumed from the Amended and Restated Spyre 2023 Equity Incentive Plan. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At the acquisition date, the Company recorded forward contracts to represent the obligation to issue shares of the Company&#x2019;s Common Stock and shares of Series A Preferred Stock. The forward contract related to the Common Stock was recorded as Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital as the instrument is indexed to the Company&#x2019;s Common Stock. The forward contract related to the Series A Preferred Stock was recorded as a liability, as the underlying stock has a cash redemption feature. On July&#160;7, 2023, both the shares of Common Stock and Series A Preferred Stock were issued and the forward contract liability associated with the Series A Preferred Stock was settled accordingly. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the Option to exclusively license IPR&amp;amp;D. The Company determined that the Option to license IPR&amp;amp;D was a single asset as the Company&#x2019;s strategy relies on developing the entire portfolio of individual treatments to create combination treatments that simultaneously address different mechanisms of irritable bowel disease with a single treatment. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the cost to acquire the asset was $113.2&#160;million which was recorded as acquired IPR&amp;amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of Common Stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis) and 517,809 shares of Common Stock, valued at $291.08 per share and $7.277 per share, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition Costs are shown on the following table (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:89%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by the Company&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The allocation of the purchase price to net assets acquired is as a follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:89%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumed liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTextBlock>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-20407"
      unitRef="Unit_shares">517809</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-20408"
      unitRef="Unit_shares">364887</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <syre:OutstandingAndUnexercisedStockOptions
      contextRef="P06_22_2023To06_22_2023_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-20410"
      unitRef="Unit_shares">2734</syre:OutstandingAndUnexercisedStockOptions>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20431"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-20432"
      unitRef="Unit_shares">364887</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-20433"
      unitRef="Unit_shares">14595480</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      id="ixv-20435"
      unitRef="Unit_shares">517809</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      id="ixv-20436"
      unitRef="Unit_USD_per_Share">291.08</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="3"
      id="ixv-20437"
      unitRef="Unit_USD_per_Share">7.277</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20438">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition Costs are shown on the following table (in millions): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:89%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by the Company&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The allocation of the purchase price to net assets acquired is as a follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:89%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;22,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumed liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20462"
      unitRef="Unit_USD">110000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20470"
      unitRef="Unit_USD">3200000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20486"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20520"
      unitRef="Unit_USD">130200000</syre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20528"
      unitRef="Unit_USD">3000000</us-gaap:CashAcquiredFromAcquisition>
    <syre:AssumedLiabilities
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20536"
      unitRef="Unit_USD">20000000</syre:AssumedLiabilities>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-20552"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <syre:OptionAgreementTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20562">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Paragon Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2023, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre entered into the Paragon Agreement with Paragon and Parapyre. Pursuant to the Paragon Agreement, the Option provided for the right to acquire the intellectual property rights related to four research programs from Paragon in accordance with a license agreement to be entered into following each exercise of the Option. Under the Paragon Agreement, the terms of such license agreement would be consistent with the economics and other terms set out in the Paragon Agreement and, in the event of failure to reach an agreement on the definitive terms, the matter would be resolved via arbitration. In consideration for the Option granted under the Paragon Agreement, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre was obligated to pay Paragon an upfront cash amount of&#x2009;$3.0&#160;million in research initiation fees. In addition, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre was obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mark-up&lt;/div&gt; costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, which included the $3.0&#160;million research initiation fee and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. Furthermore, the Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year, during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of the Asset Acquisition, the Company assumed the rights and obligations of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre under the Paragon Agreement, including the Parapyre Option Obligation. Pursuant to the Paragon Agreement, on a research &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;program-by-research&lt;/div&gt;&lt;/div&gt; program basis following the finalization of the research plan for each respective research program, the Company is required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million. For the year ended December&#160;31, 2023, the Company incurred $48.5&#160;million, in costs reimbursable to Paragon, which were recorded as Research and development expenses in the consolidated statements of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2023, the Company made payments totaling $39.5&#160;million to Paragon. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;12, 2023 and December&#160;14, 2023, the Company exercised the Option available under the Paragon Agreement with respect to the SPY001 and SPY002 research programs, respectively, and expects to enter into the SPY001 License Agreement and the SPY002 License Agreement. Our Option available under the Paragon Agreement with respect to the SPY003 and SPY004 programs remains unexercised. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following the execution of each of the SPY001 License Agreement and SPY002 License Agreement, the Company will be obligated to pay Paragon up to $22.0&#160;million upon the achievement of specific development, regulatory and clinical milestones for the first product under each agreement, respectively, that achieves such specified milestones. Upon execution of each of the SPY001 License Agreement and the SPY002 License Agreement, the Company expects to pay Paragon a $1.5&#160;million fee for nomination of a development candidate, as applicable, and the Company expects to be obligated to make a further milestone payment of&#x2009;$2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. Subject to the execution of the Option with respect to the SPY003 or SPY004 research programs, the Company expects to be obligated to make similar payments upon and following the execution of license agreements with respect to these research programs, respectively. &lt;/div&gt;</syre:OptionAgreementTextBlock>
    <syre:ResearchInitiationFees
      contextRef="P05_01_2023To05_31_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20568"
      unitRef="Unit_USD">3000000</syre:ResearchInitiationFees>
    <syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20592"
      unitRef="Unit_USD">19000000</syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition>
    <syre:ResearchInitiationFees
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20593"
      unitRef="Unit_USD">3000000</syre:ResearchInitiationFees>
    <syre:ReimbursableResearchCosts
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20594"
      unitRef="Unit_USD">16000000</syre:ReimbursableResearchCosts>
    <syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition
      contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20595"
      unitRef="Unit_USD">19000000</syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition>
    <syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn05_31_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-20596"
      unitRef="Unit_pure">0.01</syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <syre:NonrefundableResearchInitiationFeeForOneProgramPaidInCash
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-20601"
      unitRef="Unit_USD">800000</syre:NonrefundableResearchInitiationFeeForOneProgramPaidInCash>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2023To12_31_2023_StockCompensationAndResearchAndDevelopmentExpenseMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20602"
      unitRef="Unit_USD">48500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <syre:LicenseAgreementMilestonePayments
      contextRef="P01_01_2023To12_31_2023_ParagonTherapeuticsIncMembersrtCounterpartyNameAxis"
      decimals="-5"
      id="ixv-20604"
      unitRef="Unit_USD">39500000</syre:LicenseAgreementMilestonePayments>
    <syre:AmountToBePaidUnderAgreement
      contextRef="PAsOn12_14_2023_MaximumMembersrtRangeAxis_ParagonTherapeuticsIncMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20607"
      unitRef="Unit_USD">22000000</syre:AmountToBePaidUnderAgreement>
    <syre:NominationFee
      contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20608"
      unitRef="Unit_USD">1500000</syre:NominationFee>
    <syre:PaymentOfMilestone
      contextRef="P12_14_2023To12_14_2023_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SPY002LicenseAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-20609"
      unitRef="Unit_USD">2500000</syre:PaymentOfMilestone>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20610">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Leases &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prior to the Company&#x2019;s restructuring, as described in Note 17, the Company leased certain office space, laboratory facilities, and equipment. These leases required monthly lease payments that were subject to annual increases throughout the lease term. Certain of these leases also included renewal options at the election of the Company to renew or extend the lease for an additional &lt;div style="-sec-ix-hidden:hidden103884648;display:inline;"&gt;three&lt;/div&gt; to five years. These optional periods were not considered in the determination of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has both operating and finance leases. Variable lease expense for these leases primarily consisted of common area maintenance and other operating costs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2019, the Company entered into a lease agreement (the &#x201c;Las Cimas Lease&#x201d;) for its corporate headquarters and laboratory space located in Austin, Texas. The Las Cimas Lease included approximately 30,000 square feet and commenced on April&#160;30, 2019, with an expiration on April&#160;30, 2028. The Company posted a customary letter of credit in the amount of $1.5&#160;million as security, which is subject to automatic reductions per the terms of the Las Cimas Lease. A tenant allowance of up to $1.0&#160;million was provided by the lessor and fully reimbursed to the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $2.0&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease including terminating the associated letter of credit. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s recognition of its operating and finance leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:31%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="-sec-ix-hidden:hidden103884638;display:inline;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total leased assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="-sec-ix-hidden:hidden103884635;display:inline;"&gt;Accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#x2019;s operating and finance leases: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the lease costs pertaining to the Company&#x2019;s operating leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;519&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,510&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash paid for amounts included in the measurement of operating lease liabilities during the years ended December&#160;31, 2023 and 2022 was $0.5&#160;million and $0.9&#160;million, respectively, and was included within net cash used in operating activities in the cash flows. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company had no operating or finance lease obligations. &lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis"
      id="ixv-20615">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="PAsOn04_30_2019"
      decimals="0"
      id="ixv-20619"
      unitRef="Unit_sqft">30000</us-gaap:AreaOfLand>
    <us-gaap:SecurityDeposit
      contextRef="PAsOn04_30_2019"
      decimals="-5"
      id="ixv-20620"
      unitRef="Unit_USD">1500000</us-gaap:SecurityDeposit>
    <us-gaap:TenantImprovements
      contextRef="PAsOn04_30_2019_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-20621"
      unitRef="Unit_USD">1000000</us-gaap:TenantImprovements>
    <syre:OperatingLeaseTerminationFeeAmount
      contextRef="PAsOn08_31_2023"
      decimals="-5"
      id="ixv-20623"
      unitRef="Unit_USD">2000000</syre:OperatingLeaseTerminationFeeAmount>
    <syre:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20640">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s recognition of its operating and finance leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:31%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td style="width:52%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="-sec-ix-hidden:hidden103884638;display:inline;"&gt;Other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;597&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total leased assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="-sec-ix-hidden:hidden103884635;display:inline;"&gt;Accrued and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; operating lease liabilities&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td colspan="3" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syre:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20705"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20710"
      unitRef="Unit_USD">3430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20722"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20727"
      unitRef="Unit_USD">597000</us-gaap:FinanceLeaseRightOfUseAsset>
    <syre:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20751"
      unitRef="Unit_USD">0</syre:OperatingAndFinanceLeaseRightOfUseAsset>
    <syre:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20756"
      unitRef="Unit_USD">4027000</syre:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20809"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20814"
      unitRef="Unit_USD">625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20825"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20830"
      unitRef="Unit_USD">16000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20855"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20860"
      unitRef="Unit_USD">4004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <syre:OperatingAndFinanceLeaseLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-20884"
      unitRef="Unit_USD">0</syre:OperatingAndFinanceLeaseLiabilities>
    <syre:OperatingAndFinanceLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-20889"
      unitRef="Unit_USD">4645000</syre:OperatingAndFinanceLeaseLiabilities>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20907">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the weighted-average remaining lease term and discount rates for the Company&#x2019;s operating and finance leases: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finance leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the lease costs pertaining to the Company&#x2019;s operating leases (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;455&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;991&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;519&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,510&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-20957">P0Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022" id="ixv-20962">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-20970">P0Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022" id="ixv-20975">P0Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-20994"
      unitRef="Unit_pure">0</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      id="ixv-20999"
      unitRef="Unit_pure">0.106</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-21007"
      unitRef="Unit_pure">0</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      id="ixv-21012"
      unitRef="Unit_pure">0.102</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21061"
      unitRef="Unit_USD">455000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-21066"
      unitRef="Unit_USD">910000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-21071"
      unitRef="Unit_USD">991000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21079"
      unitRef="Unit_USD">471000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-21084"
      unitRef="Unit_USD">472000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-21089"
      unitRef="Unit_USD">519000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21117"
      unitRef="Unit_USD">926000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-21122"
      unitRef="Unit_USD">1382000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-21127"
      unitRef="Unit_USD">1510000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-21150"
      unitRef="Unit_USD">500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-21151"
      unitRef="Unit_USD">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21153">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Convertible Preferred Stock and Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is authorized to issue 410,000,000 shares of capital stock of which 400,000,000 shares are designated as Common Stock and 10,000,000 shares are designated as preferred stock, all with a par value of $0.0001 per share. Each holder of Common Stock is entitled to one vote for each share of Common Stock held. The Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Common Stock are entitled to receive dividends out of funds legally available if the board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that the board of directors may determine. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, no Common Stock dividends had been declared by the board of directors. As of December&#160;31, 2023 there were 437,037 shares of Series A preferred stock and 150,000 shares of Series B preferred stock outstanding. There were no shares of Series A preferred stock or shares of Series B preferred stock outstanding as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registered Direct Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2022, the Company issued and sold 430,107 shares of Common Stock at an offering price of $40.00 per share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase up to 694,892 shares of Common Stock at an offering price of $39.9975 per warrant (representing the price per share of Common Stock sold in the offering minus the $0.0025 exercise price per warrant) in a registered direct offering pursuant to a shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3.&lt;/div&gt; The net proceeds to the Company from this offering were approximately $42.9&#160;million, after deducting placement agent fees and offering costs of $2.1&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;June 2023 PIPE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2023, in connection with the Asset Acquisition, the Company issued and sold 721,452 shares of Series A Preferred Stock at approximately $291.08 per share through a private placement to a group of accredited investors. The net proceeds from this offering were approximately $197.3&#160;million, after deducting placement agent fees and offering costs of $12.7&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;December 2023 PIPE &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the Company issued and sold 6,000,000 shares of Common Stock at an offering price of $15.00 per share and 150,000 shares of Series B Preferred Stock at $600 per share through a private placement to a group of accredited investors. The net proceeds from this offering were approximately $169.1&#160;million, after deducting placement agent fees and offering costs of $10.9&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parapyre Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company settled its 2023 obligations under the Parapyre Option Obligation by issuing Parapyre 684,407 warrants to purchase the Company&#x2019;s common stock, less the $21.52 per share exercise price of each warrant. As of December&#160;31, 2023, none of the warrants issued under the Parapyre Option Obligation have been exercised. See Note 15 for additional information on the Parapyre Option Obligation. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In May 2022, the Company issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase shares of Common Stock in underwritten public offerings at the offering price of the Common Stock, less the $0.0025 per share exercise price of each warrant. The warrants were recorded as a component of stockholders&#x2019; equity within additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and have no expiration date. Per the terms of the warrant agreements, the outstanding warrants to purchase shares of Common Stock may not be exercised if the holder&#x2019;s ownership of the Common Stock would exceed 4.99% (&#x201c;Maximum Ownership Percentage&#x201d;) or 9.99% for certain holders. By written notice to the Company, each holder may increase or decrease the Maximum Ownership Percentage to any other percentage (not in excess of 19.99% for the majority of such warrants). The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase Common Stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:45%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issue Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Warrants&lt;br/&gt; Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Voting&lt;/div&gt; Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware (the &#x201c;Certificate of Designation&#x201d;) in connection with the Asset Acquisition and the PIPE. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Certificate of Designation, holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-if-converted-to-Common&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; Stock basis, and in the same form as, dividends actually paid on shares of Common Stock. Except as provided in the Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#x2019;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b)&#160;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (c)&#160;prior to the stockholder approval of the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with Nasdaq Stock Market Rules (the &#x201c;Conversion Proposal&#x201d;) or at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate (x)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (y)&#160;any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which our stockholders immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction or (d)&#160;enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;winding-up&lt;/div&gt; of the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company held a stockholders&#x2019; meeting to submit the following matters to its stockholders for their consideration: (i)&#160;the approval of the Conversion Proposal, and (ii)&#160;if deemed necessary or appropriate by the Company or as otherwise required by law or contract, the approval of an amendment to the Certificate of Incorporation to authorize sufficient shares of Common Stock for the conversion of the Series A Preferred Stock issued pursuant to the Acquisition Agreement. In connection with these matters, the Company filed with the SEC a definitive proxy statement and other relevant materials. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock automatically converted into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0.0% and 20.0%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;26, 2023, the Company completed a private placement of 721,452 shares of Series A PIPE Securities in exchange for gross proceeds of $210.0&#160;million, or net proceeds of $197.3&#160;million, after deducting placement agent and other offering costs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;7, 2023, the Company issued 364,887 shares of Series A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition that closed on June&#160;22, 2023 which settled the related forward contract liability. For additional information, see Note 3. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;21, 2023, the Company&#x2019;s stockholders approved the Conversion Proposal, among other matters, at a special meeting of stockholders. As a result of the approval of the Conversion Proposal, all conditions that could have required cash redemption of the Series A Preferred Stock were satisfied. Since the Series A Preferred Stock is no longer redeemable, the associated balances of the Series A Preferred Stock were reclassified from mezzanine equity to permanent equity during the fourth quarter of 2023. In addition, 649,302 shares of Series A Preferred Stock automatically converted to 25,972,080 shares of Common Stock; 437,037 shares of Series A Preferred Stock did not automatically convert and remain outstanding as of December&#160;31, 2023 due to beneficial ownership limitations. This conversion was recorded as a reclassification between Series A Preferred Stock and Common Stock based on the historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; contributed capital amount, inclusive of any forward-contract valuation adjustments, of the Series A Preferred Stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series B &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Voting&lt;/div&gt; Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;8, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Voting&lt;/div&gt; Convertible Preferred Stock with the Secretary of State of the State of Delaware (the &#x201c;Series B Certificate of Designation&#x201d;) in connection with the December 2023 PIPE. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Series B Certificate of Designation, holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-if-converted-to-Common&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; Stock basis, and in the same form as, dividends actually paid on shares of Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, or alter or amend the Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Company&#x2019;s Certificate of Incorporation or its Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;winding-up&lt;/div&gt; of the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has agreed to use its best efforts to obtain stockholder approval of the conversion of all issued and outstanding Series B Preferred Stock into shares of Common Stock in accordance with the Nasdaq Stock Market Rules (the &#x201c;Series B Conversion Proposal&#x201d;) at its 2024 annual meeting of stockholders, which the Company agreed to hold no later than May&#160;15, 2024. The Series B Preferred Stock is recorded outside of stockholders&#x2019; equity because, if conversion to Common Stock is not approved by the stockholders, the Series B Preferred Stock will be redeemable at the option of the holders for cash equal to the closing price of the Common Stock per share of Common Stock underlying the Series B Preferred Stock, on the last trading day prior to the holder&#x2019;s redemption request. As of December&#160;31, 2023, the redemption value of the Company&#x2019;s outstanding Series B Preferred Stock was $129.1&#160;million based on the closing stock price of the Company&#x2019;s Common Stock on December&#160;31, 2023 of $21.52 per share. The Company has determined that the Series B Preferred Stock did not contain any embedded derivatives and therefore the conversion and redemption features did not require bifurcation. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Following stockholder approval of the Series B Conversion Proposal, each share of Series B Preferred Stock will automatically convert into 40 shares of the Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 0% and 19.99%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;11, 2023, as part of the December 2023 PIPE, the Company completed a private placement of 150,000 shares of Series B Preferred Stock in exchange for gross proceeds of $90.0&#160;million. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <syre:SharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21157"
      unitRef="Unit_shares">410000000</syre:SharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21158"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21159"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-21160"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <syre:NumberOfCommonStockVotingRightsHeldPerShare
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-21161"
      unitRef="Unit_VOTE">1</syre:NumberOfCommonStockVotingRightsHeldPerShare>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21186"
      unitRef="Unit_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21187"
      unitRef="Unit_shares">437037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21188"
      unitRef="Unit_shares">150000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P05_01_2022To05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-21194"
      unitRef="Unit_shares">430107</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn05_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-21195"
      unitRef="Unit_USD_per_Share">40</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn05_31_2022"
      decimals="INF"
      id="ixv-21197"
      unitRef="Unit_shares">694892</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <syre:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
      contextRef="PAsOn05_31_2022"
      decimals="INF"
      id="ixv-21198"
      unitRef="Unit_USD_per_Share">39.9975</syre:ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2022"
      decimals="INF"
      id="ixv-21199"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P05_01_2022To05_31_2022"
      decimals="-5"
      id="ixv-21201"
      unitRef="Unit_USD">42900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <syre:PlacementAgentFeesAndOfferingCosts
      contextRef="P05_01_2022To05_31_2022"
      decimals="-5"
      id="ixv-21202"
      unitRef="Unit_USD">2100000</syre:PlacementAgentFeesAndOfferingCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-21208"
      unitRef="Unit_shares">721452</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-21209"
      unitRef="Unit_USD_per_Share">291.08</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-21210"
      unitRef="Unit_USD">197300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P06_01_2023To06_30_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-21211"
      unitRef="Unit_USD">12700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-21217"
      unitRef="Unit_shares">6000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-21218"
      unitRef="Unit_USD_per_Share">15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21219"
      unitRef="Unit_shares">150000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21220"
      unitRef="Unit_USD_per_Share">600</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-21221"
      unitRef="Unit_USD">169100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P12_01_2023To12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-21222"
      unitRef="Unit_USD">10900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_ParapyreWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-21228"
      unitRef="Unit_shares">684407</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_ParapyreWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-21229"
      unitRef="Unit_USD_per_Share">21.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2022"
      decimals="INF"
      id="ixv-21237"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <syre:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
      contextRef="P05_01_2022To05_31_2022"
      decimals="INF"
      id="ixv-21239"
      unitRef="Unit_pure">0.0499</syre:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised>
    <syre:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
      contextRef="P05_01_2022To05_31_2022"
      decimals="INF"
      id="ixv-21240"
      unitRef="Unit_pure">0.0999</syre:OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders>
    <syre:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice
      contextRef="P05_01_2022To05_31_2022"
      decimals="INF"
      id="ixv-21241"
      unitRef="Unit_pure">0.1999</syre:MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedUponWrittenNotice>
    <syre:ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice contextRef="P05_01_2022To05_31_2022" id="ixv-21242">P61D</syre:ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21259">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the following &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase Common Stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:45%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issue Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;Warrants&lt;br/&gt; Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;May 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;None&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_PreFundedMay2022WarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-21308"
      unitRef="Unit_USD_per_Share">0.0025</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_PreFundedMay2022WarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-21313"
      unitRef="Unit_shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-21346"
      unitRef="Unit_shares">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <syre:PreferredStockRemainsIssuedAndOutstandingPercentage
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-21375"
      unitRef="Unit_pure">0.30</syre:PreferredStockRemainsIssuedAndOutstandingPercentage>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21379"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <syre:BeneficiallyHoldersOwnedPercentage
      contextRef="P06_22_2023To06_22_2023_MinimumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-21380"
      unitRef="Unit_pure">0</syre:BeneficiallyHoldersOwnedPercentage>
    <syre:BeneficiallyHoldersOwnedPercentage
      contextRef="P06_22_2023To06_22_2023_MaximumMembersrtRangeAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-21381"
      unitRef="Unit_pure">0.20</syre:BeneficiallyHoldersOwnedPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-21403"
      unitRef="Unit_shares">721452</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-21404"
      unitRef="Unit_USD">210000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-21405"
      unitRef="Unit_USD">197300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P07_07_2023To07_07_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21407"
      unitRef="Unit_shares">364887</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P10_01_2023To12_31_2023_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21409"
      unitRef="Unit_shares">-649302</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P10_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConversionOfSeriesANonVotingConvertiblePreferredStockMemberusgaapConversionOfStockByUniqueDescriptionAxis"
      decimals="0"
      id="ixv-21410"
      unitRef="Unit_shares">25972080</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21411"
      unitRef="Unit_shares">437037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockRedemptionAmount
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-21427"
      unitRef="Unit_USD">129100000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="PAsOn12_31_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-21428"
      unitRef="Unit_USD_per_Share">21.52</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn12_08_2023_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21446"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <syre:BeneficiallyHoldersOwnedPercentage
      contextRef="P12_08_2023To12_08_2023_MinimumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-21447"
      unitRef="Unit_pure">0</syre:BeneficiallyHoldersOwnedPercentage>
    <syre:BeneficiallyHoldersOwnedPercentage
      contextRef="P12_08_2023To12_08_2023_MaximumMembersrtRangeAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-21448"
      unitRef="Unit_pure">0.1999</syre:BeneficiallyHoldersOwnedPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-21450"
      unitRef="Unit_shares">150000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P12_11_2023To12_11_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBNonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-21451"
      unitRef="Unit_USD">90000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21452">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Strategic License Agreements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Immedica Pharma AB License and Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;21, 2021, the Company entered into an exclusive license and supply agreement with Immedica Pharma AB (&#x201c;Immedica&#x201d;). By entering into this agreement, the Company agreed to provide Immedica the following goods and services: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;i.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Deliver an exclusive, sublicensable, license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; (the &#x201c;License&#x201d;) to develop and commercialize pegzilarginase (the &#x201c;Product&#x201d;) in the territory comprising the members states of the European Economic Area, United Kingdom, Switzerland, Andorra, Monaco, San Marino, Vatican City, Turkey, Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman (the &#x201c;Territory&#x201d;); &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;ii.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Complete the global pivotal PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) Phase 3 trial (&#x201c;PEACE Trial&#x201d;) and related Biologics License Application (&#x201c;BLA&#x201d;) package to file with the United States Food and Drug Administration (&#x201c;FDA&#x201d;), which will be leveraged by Immedica in obtaining the necessary regulatory approvals in the Territory; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;iii.&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Perform a Pediatric Investigation Plan trial (&#x201c;PIP Trial&#x201d;) in order for Immedica to be able to receive certain regulatory approvals within the Territory. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, the Company and Immedica formed a Joint Steering Committee (&#x201c;JSC&#x201d;) to provide oversight to the activities performed under the agreement; however, the substance of the Company&#x2019;s participation in the JSC does not represent an additional promised service, but rather, a right of the Company to protect its own interests in the arrangement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Further, the Company agreed to supply to Immedica, and Immedica agreed to purchase from the Company, substantially all commercial requirements of the Product. The terms of the agreement do not provide for either (i)&#160;an option to Immedica to purchase the Product from the Company at a discount from the standalone selling price or (ii)&#160;minimum purchase quantities. Finally, Immedica will bear (i)&#160;all costs and expenses for any development or commercialization of the Product in the Territory subject to the License exclusive of the Company&#x2019;s promised goods and services summarized above and (ii)&#160;all costs and fees associated with applying for regulatory approval of the Product in the Territory. In July 2021, the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Phase 3 Trial and BLA package performance obligation in exchange for the reimbursement of up to $3.0&#160;million of the actual costs incurred in relation to such incremental services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; payment of $21.5&#160;million and Immedica agreed to provide payment of 50% of the Company&#x2019;s costs incurred in performing the PIP Trial up to a maximum of $1.8&#160;million. In addition, the Company has the ability to receive additional payments under the agreement of up to approximately $120.8&#160;million in regulatory and commercial milestone payments, assuming an exchange rate of $1.07 to &#x20ac;1.00. The Company is also entitled to receive royalties in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-20&#160;percent&lt;/div&gt; range on net sales of the Product in the Territory. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that Immedica meets the definition to be accounted for as a customer because the Company is delivering intellectual property and other services within the Company&#x2019;s normal course of business, in which the parties are not jointly sharing the risks and rewards. Therefore, the Company concluded that the promises summarized above represent transactions with a customer within the scope of ASC 606. The Company determined that the following promises represent distinct promised services, and therefore, performance obligations: (i)&#160;the License, (ii)&#160;the PEACE Trial and BLA package, and (iii)&#160;the PIP Trial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Specifically, in making these determinations, the Company considered the following factors: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;As of inception of the agreement, the Company had completed the Phase 1/2 clinical trial related to the Product and were conducting the ongoing PEACE Trial. Accordingly, the Company is not promising, nor expecting, to perform additional research and development activities pursuant to the agreement that would either significantly modify, customize or be considered highly interdependent or interrelated with pegzilarginase. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The License represents functional intellectual property given the functionality of the License is not expected to change substantially as a result of the company&#x2019;s ongoing activities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The services necessary to complete the PEACE Trial, BLA package and PIP Trial could be performed by other parties. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Given that Immedica was not obligated to purchase any minimum amount or quantities of the Product, the supply of the Product for commercial use to Immedica was determined to be an option for Immedica, rather than a performance obligation of the Company at contract inception and will be accounted for if and when exercised. The Company also determined that Immedica&#x2019;s option to purchase the Product does not create a material right as the expected pricing is not at a discount. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the upfront fixed payment amount of $21.5&#160;million must be included in the transaction price. Additionally, the Company determined at inception of the arrangement that 50% of the estimated costs to be incurred in relation to the PIP Trial exceeded $1.8&#160;million and included the full reimbursement amount of $1.8&#160;million in the transaction price. Upon subsequent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluation&lt;/div&gt; due to changing facts and circumstances, the Company determined the estimated costs are now less than the maximum allowable reimbursement and a portion of the variable consideration was constrained, which did not materially impact the revenue recognized to date. Additionally, upon the modification of the agreement in July 2021, the Company determined that the estimated costs to perform the additional services related to the PEACE Trial and BLA package exceeds the maximum allowable reimbursement of $3.0&#160;million. Therefore, the Company included an estimated total of $3.6&#160;million that will be due in relation to the PIP Trial, PEACE Trial, and BLA package in the transaction price and it is probable that a significant reversal will not occur in the future. In total, the modified transaction price was determined to be $25.1&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has allocated $9.6&#160;million and $3.5&#160;million of the modified transaction price to the PEACE Trial and BLA package and PIP Trial performance obligations, respectively, based on the stand-alone selling prices (&#x201c;SSP&#x201d;), which was based on the estimated costs that a third-party would charge in performing such services on a stand-alone basis. The SSP for the License was established at inception of the arrangement using a residual value approach due to the uniqueness of and lack of observable data related to the License, and without a specific analog from which to make reliable estimates, resulting in an allocation of $12.0&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The potential regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price, as the milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain regulatory approvals, which might not be achieved. The Company determined that the royalties and commercial milestone payments relate predominantly to the license of intellectual property and are therefore excluded from the transaction price under the sales-&#x2009;or usage-based royalty exception of ASC 606. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price as necessary. The Company &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;will recognize the royalties and commercial milestone payments as revenue when the associated sales occur, and relevant sales-based thresholds are met. The Company assessed the arrangement with Immedica and concluded that a significant financing component does not exist. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized revenue allocated to the License performance obligation at a point in time and upon transfer of the License. The Company completed the transfer of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; necessary for Immedica to benefit from the License in June 2021 and recognized $12.0&#160;million of revenue at that time. The development fee allocated to the PEACE Trial, BLA package and PIP Trial performance obligations will be recognized over time using an input method of costs incurred related to the performance obligations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the years ended December&#160;31, 2023 and 2022, the Company recognized revenue of $0.9&#160;million and $2.3&#160;million, respectively, related to the PEACE Trial and BLA package performance obligation using a cost to cost model. The Company recognized revenue of $6.7&#160;million related to the PEACE Trial and BLA package performance obligation using a cost to cost model and $12.0&#160;million related to the transfer of the License for the year ended December&#160;31, 2021. As of December&#160;31, 2022, the Company recorded deferred revenue of $2.7&#160;million associated with the license and supply agreement with Immedica, of which $0.5&#160;million was classified as current. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was zero as it was internally developed. Accordingly, the Company recognized a $16.4&#160;million gain within Gain on Sale of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development, which is comprised of $15.0&#160;million in upfront cash proceeds and the reimbursement of $1.8&#160;million in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-paid&lt;/div&gt; manufacturing costs that was contingent upon a favorable opinion being received by the CHMP, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities totaling $0.4&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will reduce the CVR liability and will be distributed to CVR holders pursuant to the CVR Agreement resulting from the Asset Acquisition. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contract Balances from Customer Contract &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The timing of revenue recognition, billings and cash collections results in contract assets and contract liabilities on the balance sheets. The Company recognizes license and development receivables based on billed services, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the goods or services is transferred to the customer and all revenue recognition criteria have been met. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the Company&#x2019;s contract liabilities for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deductions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contract liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company had no contract assets during the years ended December&#160;31, 2023 and 2022. &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ReimbursementFromLimitedPartnershipInvestment
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21484"
      unitRef="Unit_USD">3000000</us-gaap:ReimbursementFromLimitedPartnershipInvestment>
    <syre:NonRefundablePaymentReceived
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21487"
      unitRef="Unit_USD">21500000</syre:NonRefundablePaymentReceived>
    <syre:PercentageOfPaymentForCostIncurredInPIPTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-21488"
      unitRef="Unit_pure">0.50</syre:PercentageOfPaymentForCostIncurredInPIPTrial>
    <syre:CostsIncurredInPerformingTheTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21489"
      unitRef="Unit_USD">1800000</syre:CostsIncurredInPerformingTheTrial>
    <syre:AdditionalUpfrontPaymentAbilityToReceived
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21490"
      unitRef="Unit_USD">120800000</syre:AdditionalUpfrontPaymentAbilityToReceived>
    <syre:MilestonePaymentsExchangeRate
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-21491"
      unitRef="Unit_pure">1.07</syre:MilestonePaymentsExchangeRate>
    <syre:UpfrontPayment
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21540"
      unitRef="Unit_USD">21500000</syre:UpfrontPayment>
    <syre:PercentageOfPaymentForCostIncurredInPIPTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-21541"
      unitRef="Unit_pure">0.50</syre:PercentageOfPaymentForCostIncurredInPIPTrial>
    <syre:CostsIncurredInPerformingTheTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21542"
      unitRef="Unit_USD">1800000</syre:CostsIncurredInPerformingTheTrial>
    <syre:CostsIncurredInPerformingTheTrial
      contextRef="P03_21_2021To03_21_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21543"
      unitRef="Unit_USD">1800000</syre:CostsIncurredInPerformingTheTrial>
    <us-gaap:ReimbursementFromLimitedPartnershipInvestment
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21545"
      unitRef="Unit_USD">3000000</us-gaap:ReimbursementFromLimitedPartnershipInvestment>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21546"
      unitRef="Unit_USD">3600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21547"
      unitRef="Unit_USD">25100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <syre:AllocatedAmountOfTransactionPrice
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-21549"
      unitRef="Unit_USD">9600000</syre:AllocatedAmountOfTransactionPrice>
    <syre:AllocatedAmountOfTransactionPrice
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PIPTrialMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-21550"
      unitRef="Unit_USD">3500000</syre:AllocatedAmountOfTransactionPrice>
    <syre:AllocationPriceTotal
      contextRef="P07_01_2021To07_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21551"
      unitRef="Unit_USD">12000000</syre:AllocationPriceTotal>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P06_01_2021To06_30_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-21572"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-21574"
      unitRef="Unit_USD">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-21575"
      unitRef="Unit_USD">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_PeaceTrialAndBLAPackageMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-21576"
      unitRef="Unit_USD">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis_LicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-21577"
      unitRef="Unit_USD">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21578"
      unitRef="Unit_USD">2700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022_ImmedicaPharmaABMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-21579"
      unitRef="Unit_USD">500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21581"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21582"
      unitRef="Unit_USD">100000000</syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-6"
      id="ixv-21583"
      unitRef="Unit_USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21584"
      unitRef="Unit_USD">16400000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21586"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <syre:PrepaidExpenseValueOfExpectedRecoveries
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21587"
      unitRef="Unit_USD">1800000</syre:PrepaidExpenseValueOfExpectedRecoveries>
    <syre:DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21589"
      unitRef="Unit_USD">400000</syre:DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21594">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table presents changes in the Company&#x2019;s contract liabilities for the periods presented (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deductions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Contract liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-21667"
      unitRef="Unit_USD">2696000</us-gaap:ContractWithCustomerLiability>
    <syre:ContractWithCustomerLiabilityAdditions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21672"
      unitRef="Unit_USD">575000</syre:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-21677"
      unitRef="Unit_USD">-3271000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21682"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-21685"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-21686"
      unitRef="Unit_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21698">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Sale of Pegzilarginase to Immedica &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;27, 2023, the Company announced that it had entered into an agreement to sell the global rights to pegzilarginase to Immedica for $15.0&#160;million in upfront cash proceeds and up to $100.0&#160;million in contingent milestone payments. The sale of pegzilarginase to Immedica superseded and terminated the previous license agreement between the Company and Immedica. On July&#160;27, 2023, the carrying value of the asset was zero as it was internally developed. Accordingly the Company recognized a $16.4&#160;million gain within Gain on sale of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development, which is comprised of $15.0&#160;million in upfront cash proceeds and the reimbursement of $1.8&#160;million in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-paid&lt;/div&gt; manufacturing costs that was contingent upon a favorable opinion being received by the Committee for Medicinal Products for Human Use, net of transaction costs and the derecognition of pegzilarginase related nonfinancial assets and liabilities totaling $0.4&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the FDA, among other events. Accordingly, the Company will recognize any future milestone payments once the contingency is resolved and payment is contractually required. The upfront payment and contingent milestone payments if paid, net of expenses and adjustments, will be distributed to CVR holders pursuant to the CVR Agreement resulting from the Asset Acquisition. &lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21704"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21705"
      unitRef="Unit_USD">100000000</syre:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-6"
      id="ixv-21706"
      unitRef="Unit_USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21707"
      unitRef="Unit_USD">16400000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="P07_27_2023To07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21709"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <syre:PrepaidExpenseValueOfExpectedRecoveries
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21710"
      unitRef="Unit_USD">1800000</syre:PrepaidExpenseValueOfExpectedRecoveries>
    <syre:DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet
      contextRef="PAsOn07_27_2023_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberusgaapDisposalGroupClassificationAxis_GlobalRightsToPegzilarginaseMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-5"
      id="ixv-21712"
      unitRef="Unit_USD">400000</syre:DisposalGroupNotDiscontinuedOperationDerecognitionOfNonfinancialAssetsAndLiabilitiesNet>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21714">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Novation of Manufacturing Agreements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to a Novation Agreement dated September&#160;19, 2023 (the &#x201c;Novation Agreement&#x201d;), by and between the Company, Paragon and WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;), the Company novated (i)&#160;a Biologics Master Services Agreement (the &#x201c;WuXi Biologics MSA&#x201d;) and (ii)&#160;a Cell Line License Agreement (the &#x201c;Cell Line License Agreement&#x201d;). &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Biologics Master Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, Paragon and WuXi Biologics entered into the WuXi Biologics MSA, which was subsequently novated to the Company by Paragon on September&#160;19, 2023 pursuant to the Novation Agreement. The WuXi Biologics MSA governs certain development activities and GMP manufacturing and testing for the SPY001 program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, the Company is obligated to pay WuXi Biologics a service fee and all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; obligations in the amount specified in each work order associated with the agreement for the provision of services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The WuXi Biologics MSA terminates on the later of (i)&#160;June&#160;20, 2027 or (ii)&#160;the completion of services under all work orders executed by the parties prior to June&#160;20, 2027, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. The Company can terminate the WuXi Biologics MSA or any work order at any time upon 30 days&#x2019; prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six months prior notice with reasonable cause, provided however that if WuXi Biologics terminates a work order in such manner, no termination or cancellation fees shall be paid by the Company and (ii)&#160;immediately for cause upon (a)&#160;the other party&#x2019;s material breach that remains uncured for 30 days after notice of such breach, (b)&#160;the other party&#x2019;s bankruptcy or (c)&#160;a force majeure event that prevents performance for a period of at least 90 days. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cell Line License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, Paragon and WuXi Biologics entered into the Cell Line License Agreement, which was subsequently novated to the Company by Paragon pursuant to the Novation Agreement. Under the Cell Line License Agreement, the Company received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive,&lt;/div&gt; worldwide, sublicensable license to certain of WuXi Biologics&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; cell line, biological materials (the &#x201c;WuXi Biologics Licensed Technology&#x201d;) and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;cell line licensed by WuXi Biologics under the Cell Line License Agreement (the &#x201c;WuXi Biologics Licensed Products&#x201d;). Specifically, the WuXi Biologics Licensed Technology is used in certain manufacturing activities in support of the SPY001 program. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In consideration for the license, the Company agreed to pay WuXi Biologics a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; license fee of $0.2&#160;million. Additionally, if the Company manufactures all of its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics of less than &lt;div style="-sec-ix-hidden:hidden103884640;display:inline;"&gt;one&lt;/div&gt; percent of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the &#x201c;Royalty&#x201d;). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by the Company upon six months prior written notice and our payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii)&#160;by WuXi Biologics for a material breach by the Company that remains uncured for 60 days after written notice, (iii)&#160;by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#x2019;s bankruptcy. &lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <syre:OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod contextRef="P04_01_2023To04_30_2023" id="ixv-21725">P30M</syre:OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod>
    <syre:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod contextRef="P04_01_2023To04_30_2023" id="ixv-21726">P6M</syre:OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod>
    <syre:OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable
      contextRef="PAsOn04_30_2023"
      decimals="0"
      id="ixv-21727"
      unitRef="Unit_USD">0</syre:OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable>
    <syre:OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod contextRef="P04_01_2023To04_30_2023" id="ixv-21728">P30D</syre:OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod>
    <syre:OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod contextRef="P04_01_2023To04_30_2023" id="ixv-21729">P90D</syre:OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod>
    <syre:OtherCommitmentNonRefundableLicenseFeeAmount
      contextRef="PAsOn04_30_2023"
      decimals="-5"
      id="ixv-21756"
      unitRef="Unit_USD">200000</syre:OtherCommitmentNonRefundableLicenseFeeAmount>
    <syre:OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod contextRef="P04_01_2023To04_30_2023" id="ixv-21759">P6M</syre:OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod>
    <syre:OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod contextRef="P04_01_2023To04_30_2023" id="ixv-21760">P60D</syre:OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod>
    <syre:OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod contextRef="P04_01_2023To04_30_2023" id="ixv-21761">P30D</syre:OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21762">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15. Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2015 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2015, the Company adopted the 2015 Equity Incentive Plan (&#x201c;2015 Plan&#x201d;), administered by the board of directors, and provides for the Company to sell or issue share of Common Stock or restricted Common Stock, or to grant incentive stock options or nonqualified stock options for the purchase of Common Stock, to employees, members of the board of directors and consultants of the Company. Under the terms of the 2015 Plan, the exercise prices, vesting and other restrictions may be determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant, the term of stock options may not be greater than ten years for all grants, and for grantees holding more than 10% of the total combined voting power of all classes of stock, the term may not be greater than five years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company granted options under the 2015 Plan until April 2016 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2015 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, a total of 3,029 shares of Common Stock are subject to options outstanding under the 2015 Plan and will become available under the 2016 Equity Incentive Plan (&#x201c;2016 Plan&#x201d;) to the extent the options are forfeited or lapse unexercised. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2016 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2016 Plan became effective in April 2016 and serves as the successor to the 2015 Plan. Under the 2016 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonuses. The 2016 Plan provides for an initial reserve of 44,000 shares of Common Stock, plus 20,395 shares of Common Stock remaining under the 2015 Plan, and any share awards that subsequently are forfeited or lapse unexercised under the 2015 Plan. The shares reserved exclude shares of Common Stock reserved for issuance under the 2015 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2018, the 2016 Plan was amended to increase the number of shares of Common Stock reserved for issuance thereunder by 70,384 shares, extend the term of the 2016 Plan through August&#160;7, 2028, and provide for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;the remaining term of the plan equal to (a) 4.0% of the number of issued and outstanding shares of Common Stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board each year (the &#x201c;Evergreen Provision&#x201d;). As a result of the operation of each of these provisions, on January&#160;1, 2023, 2022, and 2021, an additional 104,561, 78,968, and 76,735 shares, respectively, became available for issuance under the 2016 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the 2016 Plan was amended to (i)&#160;increase the number of shares of Common Stock reserved for issuance thereunder by 4,481,152 shares, (ii)&#160;revise the annual limit on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; director compensation from 4,000 shares to (a) $750,000 in total value or (b) $1,000,000 in the year of the director&#x2019;s initial service as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; director or in any year a director serves as chairman of the Board of Directors, in either case, applicable to fees paid in both cash and equity, (iii)&#160;remove the fixed termination date of the 2016 Plan and, (iv)&#160;revise the Evergreen Provision from 4% to 5% of issued and outstanding shares of Common Stock on December&#160;31 of the preceding calendar year and to include shares issuable upon the exercise of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants and the conversion of outstanding shares of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock in the calculation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the total number of shares reserved for issuance under the 2016 Plan was 5,019,177, of which 3,294,962 shares were subject to outstanding option awards and restricted unit awards. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2018 Equity Inducement Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2018, the board of directors approved and adopted the 2018 Equity Inducement Plan (&#x201c;2018 Plan&#x201d;), which became effective on the same date. The board of directors approved an initial reserve of 44,000 shares of Common Stock to be used exclusively for individuals who were not previously employees or directors, or following a bona fide period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employment,&lt;/div&gt; as an inducement material to the individual entering into employment with the Company. Nonqualified stock options or restricted stock units may be granted under the 2018 Plan at the discretion of the Compensation Committee or the board of directors. The Company did not seek stockholder approval of the 2018 Plan pursuant to Nasdaq Rule 5635(c)(4). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During 2023, the 2018 Plan was amended to increase the number of shares of Common Stock reserved for issuance by 6,000,000. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under the 2016 Plan and 2018 Plan, the Company may grant stock-based awards with service conditions (&#x201c;service-based&#x201d; awards), performance conditions (&#x201c;performance-based&#x201d; awards), and market conditions (&#x201c;market-based&#x201d; awards). Service-based awards granted under the 2018 Plan, 2016 Plan, and 2015 Plan generally vest over four years and expire after ten years, although awards have been granted with vesting terms less than four years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company granted 153,865 service-based restricted stock units (&#x201c;RSUs&#x201d;) during the year ended December&#160;31, 2023 to certain employees under the 2018 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the total number of shares reserved for issuance under the 2018 Plan was 6,044,000, of which 5,350,595 shares were subject to outstanding awards. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Spyre 2023 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Amended and Restated Spyre 2023 Equity Incentive Plan (the &#x201c;Spyre Equity Plan&#x201d;) and its outstanding and unexercised stock options, which were converted to options to purchase 2,734 shares of Common Stock. The acquisition-date fair value of these grants will be recognized as an expense on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pro-rata&lt;/div&gt; basis over the vesting period. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Parapyre Option Obligation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of warrants for Parapyre to purchase 1% of the then outstanding shares of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Merger&lt;/div&gt; Spyre. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of warrants is based on the outstanding shares of the Company&#x2019;s Common Stock, (ii)&#160;establishing the grant date as the last business day of 2023 and 2024, and (iii)&#160;defining the term of the warrants granted as ten years. The Company determined that the 2023 and 2024 grants are two separate grants, as there would be no obligation for the 2024 grant had the Company exercised or terminated all of the options under the Paragon Agreement prior to December&#160;31, 2023. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, a liability related to the Parapyre Option Obligation was recorded pursuant to the amended Paragon Agreement during 2023 interim periods. The Company determined that the grant date of the award was December&#160;31, 2023, as all terms of the award, including number of shares and exercise price, were known by all parties. Accordingly, the Company measured the grant-date fair value of the warrants granted at approximately $11.5&#160;million as an equity-classified award, of which $0.1&#160;million was recognized as part of the liabilities assumed with the Asset Acquisition on June&#160;22, 2023. For the year ended December&#160;31, 2023, $11.4&#160;million was recognized as stock compensation expense related to the Parapyre Option Obligation. There was no similar expense for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the unamortized expense related to the Parapyre Option Obligation was nil. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock option activity for the year ended December&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Under&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;405,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,776,245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46,246&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(637,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,497,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98,928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,497,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98,928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options exercisable as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,065,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The aggregate intrinsic value of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s Common Stock as of the reporting date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the years ended December&#160;31, 2023, 2022, and 2021, the weighted-average grant date fair value of options granted was $9.67, $1.80, and $4.96, per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2023, and 2021 was $0.4&#160;million and $0.7&#160;million, respectively. No options were exercised in the year ended December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were 477,000 stock options issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; during the years ended December&#160;31, 2023. There were no stock options issued to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; during the years ended December&#160;31, 2022 and 2021. For the years ended December&#160;31, 2023, 2022 and 2021, no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock options vested in the period. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2016 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2016 Employee Stock Purchase Plan (&#x201c;2016 ESPP&#x201d;) became effective in April 2016. A total of 6,600 shares of Common Stock &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;were &lt;/div&gt;reserved for issuance under the 2016 ESPP. Eligible employees may purchase shares of Common Stock under the 2016 ESPP at 85% of the lower of the fair market value of the Common Stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year. The 2016 ESPP will terminate ten years from the first purchase date under the plan, unless terminated earlier by the board of directors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2018, the 2016 ESPP was amended to provide for an automatic annual increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the year equal to (a) 1.0% of the number of issued and outstanding shares of Common Stock on December&#160;31 of the immediately preceding year, or (b)&#160;a lesser amount as approved by the board of directors each year. As a result of the operation of this provision, on January&#160;1, 2023, 2022 and 2021, an additional 26,140, 19,742, and 19,184 shares, respectively, became available for issuance under the 2016 ESPP. As of December&#160;31, 2023, the reserve remaining and available for future issuance under the 2016 ESPP was 72,404 shares. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2023, the 2016 ESPP was amended to increase the maximum shares purchased during any one period from 80 shares to 400 shares or a lesser amount determined by the board of directors. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2023, stock-based compensation expense related to the 2016 ESPP plan was di minimis. For the years ended 2022 and 2021, stock-based compensation expense related to the 2016 ESPP plan was $0.1&#160;million and $0.2&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Common Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In July 2020, the Company granted 9,128 restricted stock units to certain employees, with vesting terms subject to regulatory, commercial, and clinical milestones, in addition to a service condition. As of December&#160;31, 2023 none of these restricted stock units had vested and all restricted stock units were forfeited since the performance milestones were not met within the required time frame. No stock-based compensation expense was recognized on these awards. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company granted 153,865 service-based restricted stock units during the year ended December&#160;31, 2023. There were no restricted stock units granted during the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&#160;Grant&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were no restricted stock units granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; during the years ended December&#160;31, 2023, 2022, and 2021. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation expense recognized from the Company&#x2019;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,237&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;No related tax benefits were recognized for the years ended December&#160;31, 2023, 2022, and 2021 (see Note&#160;18). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; awards contain both performance and service-based vesting conditions. No expense was recognized for the unvested employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; awards with only a performance condition for the years ended December&#160;31, 2023, 2022, and 2021. The performance-based vesting conditions represent specific performance targets. Compensation expense for employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based payment awards with performance conditions is recognized when the performance condition is deemed probable of achievement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company had an aggregate of $64.4&#160;million of unrecognized stock-based compensation expense for options outstanding, which is expected to be recognized over a weighted average period of 3.5 years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Term &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the midpoint between the vesting date and the end of the contractual term). The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company&#x2019;s stock-based awards. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Volatility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Since the Company was privately held through April 2016 and transitioned from a clinical stage company to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; stage company in 2023, it alone does not have the relevant company-specific historical data to support its expected volatility. As such, the Company has used an average of expected volatilities based on the volatilities of a representative group of publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. Subsequent to the Company&#x2019;s initial public offering, it began to consider the Company&#x2019;s own historic volatility. However, due to the transition from a clinical stage company to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; stage company, the Company still uses peer company data to assist in this analysis. For purposes of identifying comparable companies, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards. The Company intends to consistently apply this process using the same or &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt; &lt;/div&gt;similar comparable entities until a sufficient amount of historical information regarding the volatility of the Company&#x2019;s own share price post transition becomes available. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-Free Interest Rate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Dividend &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has never paid dividends on its Common Stock and has no plans to pay dividends on its Common Stock. Therefore, the Company used an expected dividend yield of zero. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Valuation of Stock Options and 2016 ESPP &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the stock options granted under the the Company&#x2019;s equity incentive plans, as well as the shares available for purchase under the 2016 ESPP were determined using the Black-Scholes option-pricing model. The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Options Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2016 ESPP&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21770"
      unitRef="Unit_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P03_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-21771">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <syre:GranteesWithMoreThanFiveYearsVestingTermPercent
      contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21772"
      unitRef="Unit_pure">0.10</syre:GranteesWithMoreThanFiveYearsVestingTermPercent>
    <syre:MaximumVestingTermForMoreThanTenPercentGrantees
      contextRef="P03_01_2015To03_31_2015_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-21773">P5Y</syre:MaximumVestingTermForMoreThanTenPercentGrantees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21776"
      unitRef="Unit_shares">3029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21782"
      unitRef="Unit_shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn04_30_2016_TwoThousandAndFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21783"
      unitRef="Unit_shares">20395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <syre:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21785"
      unitRef="Unit_shares">70384</syre:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares
      contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21807"
      unitRef="Unit_pure">0.04</syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21808"
      unitRef="Unit_shares">104561</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21809"
      unitRef="Unit_shares">78968</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21810"
      unitRef="Unit_shares">76735</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P11_01_2023To11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21812"
      unitRef="Unit_shares">4481152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <syre:ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares
      contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21814"
      unitRef="Unit_shares">4000</syre:ShareBasedPaymentArrangementPlanTermsAnnualLimitForNonEmployeeDirectorCompensationNumberOfShares>
    <syre:ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount
      contextRef="PAsOn11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21815"
      unitRef="Unit_USD">750000</syre:ShareBasedPaymentArrangementPlanModificationAnnualLimitForNonEmployeeDirectorCompensationAmount>
    <syre:ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount
      contextRef="PAsOn11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21816"
      unitRef="Unit_USD">1000000</syre:ShareBasedPaymentArrangementPlanModificationNonEmployeeDirectorCompensationAmount>
    <syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares
      contextRef="P10_01_2018To10_31_2018_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21818"
      unitRef="Unit_pure">0.04</syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares>
    <syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares
      contextRef="P11_01_2023To11_30_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-21819"
      unitRef="Unit_pure">0.05</syre:AnnualPercentageOfAdditionalSharesWhichEqualsToIssuedAndOutstandingShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21823"
      unitRef="Unit_shares">5019177</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21824"
      unitRef="Unit_shares">3294962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn02_28_2018_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21830"
      unitRef="Unit_shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-21833"
      unitRef="Unit_shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      id="ixv-21835">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      id="ixv-21836">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P02_01_2018To02_28_2018_ServiceBasedAwardsMemberusgaapAwardTypeAxis_TwoThousandAndFifteenAndTwoThousandAndSixteenEquityIncentivePlanAndTwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      id="ixv-21837">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-21839"
      unitRef="Unit_shares">153865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21841"
      unitRef="Unit_shares">6044000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_TwoThousandAndEighteenEquityInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-21842"
      unitRef="Unit_shares">5350595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <syre:ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding
      contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-21870"
      unitRef="Unit_pure">0.01</syre:ClassOfWarrantOrRightAnnualGrantPercentageOfCommonStockOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_09_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-21874">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <syre:ClassOfWarrantOrRightGrantDateFairValue
      contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-21875"
      unitRef="Unit_USD">11500000</syre:ClassOfWarrantOrRightGrantDateFairValue>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="P06_22_2023To06_22_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-21876"
      unitRef="Unit_USD">100000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-21877"
      unitRef="Unit_USD">11400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-3"
      id="ixv-21878"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-3"
      id="ixv-21879"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensation>
    <syre:ClassOfWarrantOrRightUnamortizedExpense
      contextRef="PAsOn12_31_2023_ParapyreOptionObligationMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-3"
      id="ixv-21881"
      unitRef="Unit_USD">0</syre:ClassOfWarrantOrRightUnamortizedExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21882">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock option activity for the year ended December&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Under&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;405,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,776,245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(46,246&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(637,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,497,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98,928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options vested and expected to vest as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,497,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.40&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;98,928&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options exercisable as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,065,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-21988"
      unitRef="Unit_shares">405082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      id="ixv-21993"
      unitRef="Unit_USD_per_Share">113.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022" id="ixv-21998">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22003"
      unitRef="Unit_USD">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22011"
      unitRef="Unit_shares">8776245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-22016"
      unitRef="Unit_USD_per_Share">9.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22032"
      unitRef="Unit_shares">46246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-22037"
      unitRef="Unit_USD_per_Share">8.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22053"
      unitRef="Unit_shares">637686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-22058"
      unitRef="Unit_USD_per_Share">43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22095"
      unitRef="Unit_shares">8497395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-22100"
      unitRef="Unit_USD_per_Share">12.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2023To12_31_2023" id="ixv-22105">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22110"
      unitRef="Unit_USD">98928000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22139"
      unitRef="Unit_shares">8497395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-22144"
      unitRef="Unit_USD_per_Share">12.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-22149">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22154"
      unitRef="Unit_USD">98928000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22183"
      unitRef="Unit_shares">1065700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-22188"
      unitRef="Unit_USD_per_Share">24.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-22193">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22198"
      unitRef="Unit_USD">13328000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22222"
      unitRef="Unit_USD_per_Share">9.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22223"
      unitRef="Unit_USD_per_Share">1.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22224"
      unitRef="Unit_USD_per_Share">4.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-22225"
      unitRef="Unit_USD">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-22226"
      unitRef="Unit_USD">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-6"
      id="ixv-22227"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="INF"
      id="ixv-22248"
      unitRef="Unit_shares">477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      id="ixv-22250"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      id="ixv-22251"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      id="ixv-22253"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      id="ixv-22254"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonEmployeesMembersrtTitleOfIndividualAxis"
      decimals="0"
      id="ixv-22255"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22262"
      unitRef="Unit_shares">6600</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-22264"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="PAsOn04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-22265"
      unitRef="Unit_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee
      contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22266"
      unitRef="Unit_USD">25000</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualFairMarketValuePerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      id="ixv-22267">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease
      contextRef="P06_01_2018To06_30_2018_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22269"
      unitRef="Unit_pure">0.01</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalAnnualPercentageIncrease>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22270"
      unitRef="Unit_shares">26140</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22271"
      unitRef="Unit_shares">19742</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_01_2020_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22272"
      unitRef="Unit_shares">19184</syre:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22273"
      unitRef="Unit_shares">72404</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <syre:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan
      contextRef="P04_01_2016To04_30_2016_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22275"
      unitRef="Unit_shares">80</syre:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan>
    <syre:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan
      contextRef="P02_01_2023To02_28_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22276"
      unitRef="Unit_shares">400</syre:MaximumNumberOfSharesPurchasedUnderEmployeeStockPurchasePlan>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-22278"
      unitRef="Unit_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-22279"
      unitRef="Unit_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P07_01_2020To07_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-22285"
      unitRef="Unit_shares">9128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-22286"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandAndSixteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22287"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22289"
      unitRef="Unit_shares">153865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-22290"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-22291"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-22292">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes employee restricted stock activity for the year ended December&#160;31, 2023: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&#160;Grant&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unvested restricted stock units as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;153,865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22331"
      unitRef="Unit_shares">5660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22336"
      unitRef="Unit_USD_per_Share">203.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22344"
      unitRef="Unit_shares">153865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22349"
      unitRef="Unit_USD_per_Share">18.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22357"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-22362"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22370"
      unitRef="Unit_shares">5660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22375"
      unitRef="Unit_USD_per_Share">203.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22396"
      unitRef="Unit_shares">153865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22401"
      unitRef="Unit_USD_per_Share">18.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-22437">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation expense recognized from the Company&#x2019;s equity incentive plans, 2018 Plan, and the 2016 ESPP for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,910&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,237&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22538"
      unitRef="Unit_USD">2910000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22543"
      unitRef="Unit_USD">11328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22548"
      unitRef="Unit_USD">2591000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22553"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22558"
      unitRef="Unit_USD">2723000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22563"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22571"
      unitRef="Unit_USD">11327000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22576"
      unitRef="Unit_USD">109000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22581"
      unitRef="Unit_USD">4520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22586"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22591"
      unitRef="Unit_USD">5315000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22596"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22642"
      unitRef="Unit_USD">14237000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22647"
      unitRef="Unit_USD">11437000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22652"
      unitRef="Unit_USD">7111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22657"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22662"
      unitRef="Unit_USD">8038000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_NonEmployeesMembersrtTitleOfIndividualAxis_TwoThousandEighteenEquityInducementPlanAndTwoThousandSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-22667"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22708"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-22709"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22710"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2023_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-22713"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2021_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-22714"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2022_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-22715"
      unitRef="Unit_USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-22719"
      unitRef="Unit_USD">64400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-22720">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-22767"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-22768"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-22769"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-22775">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Options Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2016 ESPP&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-22839">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-22844">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-22849">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22857"
      unitRef="Unit_pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22862"
      unitRef="Unit_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-22867"
      unitRef="Unit_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-22875"
      unitRef="Unit_pure">0.0437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-22880"
      unitRef="Unit_pure">0.0293</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      id="ixv-22885"
      unitRef="Unit_pure">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22893"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22898"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-22903"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      id="ixv-22927">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      id="ixv-22932">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      id="ixv-22937">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-22945"
      unitRef="Unit_pure">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-22950"
      unitRef="Unit_pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-22955"
      unitRef="Unit_pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      id="ixv-22963"
      unitRef="Unit_pure">0.0499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      id="ixv-22968"
      unitRef="Unit_pure">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="4"
      id="ixv-22973"
      unitRef="Unit_pure">0.0008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22981"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22986"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_TwoThousandAndSixteenEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22991"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-22993">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16. Defined Contribution Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company sponsors a 401(k) retirement plan in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. During the years ended December&#160;31, 2023, 2022, 2021, the Company provided $0.2&#160;million, $0.6&#160;million, and $0.6&#160;million, respectively, in contributions to the plan. &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22997"
      unitRef="Unit_USD">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-22998"
      unitRef="Unit_USD">600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      id="ixv-22999"
      unitRef="Unit_USD">600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23000">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17. Restructuring Charges &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Severance and Stock Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;12, 2023, based on the review of the inconclusive interim results from the Company&#x2019;s Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria and other business considerations, the Company announced that it had initiated a process to explore strategic alternatives to maximize stockholder value and engaged an independent exclusive financial advisor to support this process. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result, the Company implemented a restructuring plan resulting in an approximate 83% reduction of the Company&#x2019;s existing headcount by June&#160;30, 2023. The Company recognized restructuring expenses consisting of cash severance payments and other employee-related costs of $6.4&#160;million during the year ended December&#160;31, 2023. Cash payments for employee related restructuring charges of $5.3&#160;million were paid as of December&#160;31, 2023. In addition, the Company recognized $1.0&#160;million in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; stock-based compensation &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;expense related to the accelerated vesting of stock-based awards for certain employees. The Company recorded these restructuring charges based on each employee&#x2019;s role to the respective research and development and general and administrative operating expense categories on its consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the changes in the Company&#x2019;s accrued restructuring balance (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:53%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Beginning&#160;Balance&lt;br/&gt; December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending&#160;Balance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Severance liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,325&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sale of Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the second quarter of 2023, the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $0.5&#160;million. After recording the disposal of all the Company&#x2019;s property and equipment net of proceeds, the Company recorded a $0.7&#160;million and $0.2&#160;million loss on disposal of long lived assets which is included in Research and development and General and administrative expenses, respectively. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; Asset and Leasehold Improvement Impairment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Effective June&#160;30, 2023, the Company abandoned its leased office space in Austin, Texas. As a result, the Company recognized an impairment loss of $0.9&#160;million related to the operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and $1.7&#160;million related to leasehold improvements. On August&#160;7, 2023, the Company terminated its building lease in Austin, Texas. The negotiated termination agreement obligated the Company to pay the lessor a $2.0&#160;million termination fee in exchange for releasing the Company of all further obligations under the lease. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All charges related to the restructuring activities were recognized during the second quarter of 2023. No further restructuring charges will be incurred under the restructuring plan. A summary of the charges related to the restructuring activities is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Severance&lt;br/&gt; Related&lt;br/&gt; Expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&lt;br/&gt; Compensation&lt;br/&gt; Expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss on&lt;br/&gt; Disposal&#160;of&lt;br/&gt; Long&#160;Lived&lt;br/&gt; Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease Asset&lt;br/&gt; Impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; Restructuring&lt;br/&gt; Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;931&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_12_2023To06_30_2023"
      decimals="2"
      id="ixv-23009"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-23010"
      unitRef="Unit_USD">6400000</us-gaap:SeveranceCosts1>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-23011"
      unitRef="Unit_USD">5300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-23012"
      unitRef="Unit_USD">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23031">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the changes in the Company&#x2019;s accrued restructuring balance (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:53%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Beginning&#160;Balance&lt;br/&gt; December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Charges&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending&#160;Balance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Severance liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,325&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2022_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23085"
      unitRef="Unit_USD">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23090"
      unitRef="Unit_USD">6448000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2023To12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23095"
      unitRef="Unit_USD">5325000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2023_SeveranceLiabilityMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23100"
      unitRef="Unit_USD">1123000</us-gaap:RestructuringReserve>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="PAsOn06_30_2023"
      decimals="-5"
      id="ixv-23107"
      unitRef="Unit_USD">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-23108"
      unitRef="Unit_USD">-700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-23109"
      unitRef="Unit_USD">-200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P06_30_2023To06_30_2023"
      decimals="-5"
      id="ixv-23117"
      unitRef="Unit_USD">900000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold
      contextRef="P06_30_2023To06_30_2023"
      decimals="-5"
      id="ixv-23120"
      unitRef="Unit_USD">1700000</us-gaap:ImpairmentOfLeasehold>
    <syre:OperatingLeaseTerminationFeeAmount
      contextRef="PAsOn08_31_2023"
      decimals="-5"
      id="ixv-23121"
      unitRef="Unit_USD">2000000</syre:OperatingLeaseTerminationFeeAmount>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23123">A summary of the charges related to the restructuring activities is as follows (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Severance&lt;br/&gt; Related&lt;br/&gt; Expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&lt;br/&gt; Compensation&lt;br/&gt; Expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss on&lt;br/&gt; Disposal&#160;of&lt;br/&gt; Long&#160;Lived&lt;br/&gt; Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease Asset&lt;br/&gt; Impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; Restructuring&lt;br/&gt; Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,266&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;931&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23192"
      unitRef="Unit_USD">3182000</us-gaap:SeveranceCosts1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23197"
      unitRef="Unit_USD">123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23202"
      unitRef="Unit_USD">-749000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23207"
      unitRef="Unit_USD">1405000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:RestructuringCosts
      contextRef="P04_01_2023To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23212"
      unitRef="Unit_USD">5459000</us-gaap:RestructuringCosts>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23220"
      unitRef="Unit_USD">3266000</us-gaap:SeveranceCosts1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23225"
      unitRef="Unit_USD">870000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23230"
      unitRef="Unit_USD">-182000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23235"
      unitRef="Unit_USD">1175000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:RestructuringCosts
      contextRef="P04_01_2023To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23240"
      unitRef="Unit_USD">5493000</us-gaap:RestructuringCosts>
    <us-gaap:SeveranceCosts1
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23280"
      unitRef="Unit_USD">6448000</us-gaap:SeveranceCosts1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23285"
      unitRef="Unit_USD">993000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23290"
      unitRef="Unit_USD">-931000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23295"
      unitRef="Unit_USD">2580000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:RestructuringCosts
      contextRef="P04_01_2023To06_30_2023_RestructuringActivitiesMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-3"
      id="ixv-23300"
      unitRef="Unit_USD">10952000</us-gaap:RestructuringCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23334">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:63%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(338,942&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before income tax expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(338,816&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2023, the Company recognized no provision or benefit from income taxes. For both the years ended December&#160;31, 2022 and 2021, the Company recognized an income tax expense of $0.1&#160;million, related to foreign subsidiaries income tax expense and the Texas margins tax. The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax provision derived by applying the federal statutory rate to income before income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(71,151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss on forward contract valuation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,541&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired IPR&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss on CVR revaluation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of tax rate on foreign jurisdiction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in the valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax (benefit) expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the deferred tax assets and liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74,454&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized 174 R&amp;amp;D costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,532&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,246&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125,491&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciable assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(125,491&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(107,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has established a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by $17.8&#160;million, $20.6&#160;million, and $16.9&#160;million during the years ended December&#160;31, 2023, 2022, and 2021, respectively, primarily due to continuing loss from operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, the Company had U.S. net operating loss carryforwards (&#x201c;NOL&#x201d;) of $354.5&#160;million and $328.2&#160;million, respectively. For both the years ended December&#160;31, 2023 and 2022, the Company had U.S. tax credit carryforwards and state tax credit carryforwards of $21.9&#160;million and $1.6&#160;million, respectively. Of the net operating loss and tax credit carryforwards $58.4&#160;million and $21.9&#160;million, respectively, will expire in 2033, if not utilized. Any remaining net operating loss will carry forward indefinitely and can be &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;utilized to offset up to 80% of the taxable income in any tax year. The net operating loss and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or tax credits are utilized. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#x2019;s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. If the Company has experienced an ownership change at any time since its formation, utilization of the NOL or research and development credit carryforwards would be subject to an annual limitation under Section&#160;382 or 383 of the Internal Revenue Code, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-exempt&lt;/div&gt; rate, and then could be subject to additional adjustments, as required. Additionally, the separate return limitation year (&#x201c;SRLY&#x201d;) rules may apply to losses of the Company&#x2019;s eight wholly owned U.S. subsidiary corporations. The SRLY rules limit the consolidated group&#x2019;s use of a subsidiary corporation&#x2019;s net operating losses to the amount of income generated by the subsidiary corporation after it becomes a member of the group. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months. Due to the existence of the valuation allowance, future changes in the Company&#x2019;s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to examination by taxing authorities in its significant jurisdictions for the 2019 and subsequent years. However, due to NOL and tax attribute carryovers, the taxing authorities have the ability to adjust the NOLs and other tax attributes related to closed years. As of December&#160;31, 2023 and 2022, there were no amounts recorded for uncertain tax positions. As of December&#160;31, 2023, undistributed earnings of the Company&#x2019;s incorporated foreign subsidiaries are immaterial. Under the Global Intangible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Low-Taxed&lt;/div&gt; Income (&#x201c;GILTI&#x201d;) provisions of the 2017 Tax Cuts and Jobs Act, U.S. income taxes have been incurred on the undistributed earnings of the foreign subsidiaries and therefore, the tax impact upon distribution is limited to state income and withholding taxes and is not material. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23337">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the (loss) income before income tax expense by jurisdiction for the periods indicated: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:63%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(338,942&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(84,113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before income tax expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(338,816&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(65,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23385"
      unitRef="Unit_USD">-338942000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23390"
      unitRef="Unit_USD">-84113000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23395"
      unitRef="Unit_USD">-65940000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23403"
      unitRef="Unit_USD">126000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23408"
      unitRef="Unit_USD">162000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23413"
      unitRef="Unit_USD">280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23441"
      unitRef="Unit_USD">-338816000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23446"
      unitRef="Unit_USD">-83951000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23451"
      unitRef="Unit_USD">-65660000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-23493"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23494">The difference between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income before income taxes is as follows (in thousands): &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax provision derived by applying the federal statutory rate to income before income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(71,151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss on forward contract valuation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,541&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired IPR&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss on CVR revaluation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of tax rate on foreign jurisdiction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in the valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax (benefit) expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23542"
      unitRef="Unit_USD">-71151000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23547"
      unitRef="Unit_USD">-17630000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23552"
      unitRef="Unit_USD">-13789000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23560"
      unitRef="Unit_USD">17541000</syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount>
    <syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23565"
      unitRef="Unit_USD">0</syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount>
    <syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23570"
      unitRef="Unit_USD">0</syre:EffectiveIncomeTaxRateReconciliationForwardContractLiabilityAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23578"
      unitRef="Unit_USD">27340000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23583"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23588"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23596"
      unitRef="Unit_USD">3987000</syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount>
    <syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23601"
      unitRef="Unit_USD">0</syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount>
    <syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23606"
      unitRef="Unit_USD">0</syre:EffectiveIncomeTaxRateReconciliationContingentValueAddedLiabilityAmount>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23614"
      unitRef="Unit_USD">4472000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23619"
      unitRef="Unit_USD">1042000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23624"
      unitRef="Unit_USD">1002000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <syre:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23632"
      unitRef="Unit_USD">-1000</syre:IncomeTaxReconciliationTaxCostCredit>
    <syre:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23637"
      unitRef="Unit_USD">-3559000</syre:IncomeTaxReconciliationTaxCostCredit>
    <syre:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23642"
      unitRef="Unit_USD">-3815000</syre:IncomeTaxReconciliationTaxCostCredit>
    <syre:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23650"
      unitRef="Unit_USD">0</syre:IncomeTaxReconciliationTaxCostCredit>
    <syre:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2022To12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23655"
      unitRef="Unit_USD">-640000</syre:IncomeTaxReconciliationTaxCostCredit>
    <syre:IncomeTaxReconciliationTaxCostCredit
      contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23660"
      unitRef="Unit_USD">-152000</syre:IncomeTaxReconciliationTaxCostCredit>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23668"
      unitRef="Unit_USD">-53000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23673"
      unitRef="Unit_USD">42000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23678"
      unitRef="Unit_USD">-5000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23686"
      unitRef="Unit_USD">17839000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23691"
      unitRef="Unit_USD">20609000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23696"
      unitRef="Unit_USD">16900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23724"
      unitRef="Unit_USD">-26000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23729"
      unitRef="Unit_USD">-136000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-23734"
      unitRef="Unit_USD">141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23756">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the deferred tax assets and liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforward&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74,454&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized 174 R&amp;amp;D costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,532&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;566&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;668&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,246&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,914&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,631&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125,491&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciable assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(676&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(125,491&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(107,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23806"
      unitRef="Unit_USD">74454000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23811"
      unitRef="Unit_USD">68917000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23819"
      unitRef="Unit_USD">22532000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23824"
      unitRef="Unit_USD">11097000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23832"
      unitRef="Unit_USD">47000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23837"
      unitRef="Unit_USD">52000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23845"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23850"
      unitRef="Unit_USD">566000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23858"
      unitRef="Unit_USD">579000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23863"
      unitRef="Unit_USD">668000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23871"
      unitRef="Unit_USD">4246000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23876"
      unitRef="Unit_USD">3293000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23884"
      unitRef="Unit_USD">21914000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23889"
      unitRef="Unit_USD">21914000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23897"
      unitRef="Unit_USD">1631000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      id="ixv-23902"
      unitRef="Unit_USD">1631000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23910"
      unitRef="Unit_USD">88000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23915"
      unitRef="Unit_USD">190000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23937"
      unitRef="Unit_USD">125491000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23942"
      unitRef="Unit_USD">108328000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23961"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23966"
      unitRef="Unit_USD">676000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23988"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23993"
      unitRef="Unit_USD">676000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-24001"
      unitRef="Unit_USD">125491000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-24006"
      unitRef="Unit_USD">107652000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-24028"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-24033"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-24050"
      unitRef="Unit_USD">17800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-24051"
      unitRef="Unit_USD">20600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      id="ixv-24052"
      unitRef="Unit_USD">16900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-24054"
      unitRef="Unit_USD">354500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      id="ixv-24055"
      unitRef="Unit_USD">328200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-24056"
      unitRef="Unit_USD">21900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-24057"
      unitRef="Unit_USD">1600000</us-gaap:TaxCreditCarryforwardAmount>
    <syre:OperatingLossCarryforwardsSetToExpireIfNotUtilized
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-24058"
      unitRef="Unit_USD">58400000</syre:OperatingLossCarryforwardsSetToExpireIfNotUtilized>
    <syre:TaxCreditCarryforwardsSetToExpireIfNotUtilized
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-24059"
      unitRef="Unit_USD">21900000</syre:TaxCreditCarryforwardsSetToExpireIfNotUtilized>
    <syre:NumberOfDomesticSubsidiaries
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-24079"
      unitRef="Unit_SUBSIDARY">8</syre:NumberOfDomesticSubsidiaries>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-24080"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-24081"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-24083"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24085">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19. Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company computes net loss attributable per common stockholder using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method required for participating securities. The Company considers convertible preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for Common Stock and participating security considering a participating security&#x2019;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock and Series B Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock and the Series B Preferred Stock were excluded from the calculation of basic net loss per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants outstanding during the period, without consideration of potential dilutive securities. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24088">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company computes net loss attributable per common stockholder using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method required for participating securities. The Company considers convertible preferred stock to be participating securities. In the event that the Company paid out distributions, holders of convertible preferred stock would participate in the distribution. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method is an earnings (loss) allocation method under which earnings (loss) per share is calculated for Common Stock and participating security considering a participating security&#x2019;s rights to undistributed earnings (loss) as if all such earnings (loss) had been distributed during the period. The holders of Series A Preferred Stock and Series B Preferred Stock do not have an obligation to fund losses and therefore the Series A Preferred Stock and the Series B Preferred Stock were excluded from the calculation of basic net loss per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants outstanding during the period, without consideration of potential dilutive securities. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants are included in the computation of basic net loss per share as the exercise price is negligible and they are fully vested and exercisable. For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. The Company has generated a net loss for all periods presented, therefore diluted net loss per share is the same as basic net loss per share since the inclusion of potentially dilutive securities would be anti-dilutive. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24104">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;The following weighted-average equity instruments were excluded from the calculation of diluted net loss per share because their effect would have been &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;anti-dilutive&lt;/div&gt; for the periods presented: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 64%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;Options to purchase Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,583,226&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2007;&#x2009;346,331&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2007;&#x2009;264,858&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,240&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,983&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,975&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;Outstanding Parapyre Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,625&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24189"
      unitRef="Unit_shares">2583226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24199"
      unitRef="Unit_shares">346331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24209"
      unitRef="Unit_shares">264858</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24224"
      unitRef="Unit_shares">4240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24234"
      unitRef="Unit_shares">6983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24244"
      unitRef="Unit_shares">7975</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24259"
      unitRef="Unit_shares">5625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24269"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_ParapyreWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-24279"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24283">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;The following is a reconciliation of the shares used as the denominator for the calculation of basic and diluted net loss per share: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 64%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 2%; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;;font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;Weighted average Common Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,201,954&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,307,668&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,956,933&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;Weighted average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;695,111&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,063,563&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;672,851&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;-sec-ix-redline:true;;display:inline;"&gt;Total basic and diluted weighted average shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,897,065&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,371,231&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="-sec-ix-redline:true;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,629,784&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-24368"
      unitRef="Unit_shares">6201954</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-24378"
      unitRef="Unit_shares">2307668</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-24388"
      unitRef="Unit_shares">1956933</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-24403"
      unitRef="Unit_shares">695111</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-24413"
      unitRef="Unit_shares">1063563</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-24423"
      unitRef="Unit_shares">672851</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-24438"
      unitRef="Unit_shares">6897065</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-24439"
      unitRef="Unit_shares">6897065</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-24449"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-24450"
      unitRef="Unit_shares">3371231</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-24460"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-24461"
      unitRef="Unit_shares">2629784</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-24697"
      unitRef="Unit_USD">3035000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-24713"
      unitRef="Unit_USD">3035000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-24729"
      unitRef="Unit_USD">3035000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-24760"
      unitRef="Unit_USD">20047000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-24776"
      unitRef="Unit_USD">20047000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-24792"
      unitRef="Unit_USD">20047000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-24813"
      unitRef="Unit_USD">-17012000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-24843"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Description of the Business and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, Aeglea BioTherapeutics, Inc. (&#x201c;Aeglea&#x201d;, the &#x201c;Company&#x201d;, and &#x201c;our&#x201d;) acquired, in accordance with the terms of the Agreement and Plan of Merger (the &#x201c;Acquisition Agreement&#x201d;), the assets from Spyre Therapeutics, Inc (&#x201c;Spyre&#x201d;), a privately held biotechnology company advancing a pipeline of antibody therapeutics through a research and development option agreement (&#x201c;Paragon Agreement&#x201d;) with Paragon Therapeutics (&#x201c;Paragon&#x201d;). Spyre was incorporated on April&#160;28, 2023, for the purpose of holding rights to certain intellectual property being developed by Paragon. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;8, 2023, Aeglea effected a reverse stock split of its Common Stock at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-25&lt;/div&gt;&lt;/div&gt; (the &#x201c;Reverse Split&#x201d;). Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this statement have been adjusted on a post-Reverse Split basis. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The transaction (the &#x201c;Asset Acquisition&#x201d;) was structured as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock-for-stock&lt;/div&gt;&lt;/div&gt; transaction pursuant to which all of Spyre&#x2019;s outstanding equity interests were exchanged based on a fixed exchange ratio of 0.5494488 to 1 for consideration from Aeglea of 517,809 shares of common stock and 364,887 shares of Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock, par value of $0.0001 per share (&#x201c;Series A Preferred Stock&#x201d;) (convertible on a 40 to 1 basis) in addition to the assumption of outstanding and unexercised stock options to purchase 2,734 shares of common stock from the Amended and Restated Spyre 2023 Equity Incentive Plan. The Aeglea common stock and the Aeglea Series A Preferred Stock related to the Asset Acquisition were issued to the Spyre stockholders on July&#160;7, 2023. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#x2019;s option (the &#x201c;Option&#x201d;) to exclusively license certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;). The Company determined that the Option to license IPR&amp;amp;D was a single asset as the Company&#x2019;s strategy relies on developing a portfolio of combination treatments that simultaneously address different mechanisms of irritable bowel disease. The Company also determined that the pipeline candidates within the portfolio are similar in nature and risk profile. In addition, the Company did not obtain any substantive processes, assembled workforce, or employees capable of producing outputs in connection with the Asset Acquisition. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the cost to acquire the asset was $113.2&#160;million, which was recorded as acquired IPR&amp;amp;D. The fair value of the consideration issued consisted of the 364,887 shares of Series A Preferred Stock (14,595,480 shares of common stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis) and 517,809 shares of common stock, valued at $291.08 per share and $7.277 per share, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Paragon Agreement provided for an annual equity grant of options to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Option, at the fair market value determined by the board of directors of Spyre (the &#x201c;Parapyre Option Obligation&#x201d;). In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement, including the Parapyre Option Obligation. As a result, the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of common stock of the Company on the same terms. For additional information, see Note&#160;3. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition costs are shown on the following table (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by Aeglea&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s allocation of the purchase price to net assets acquired is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,035&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;730-10-25-2(c),&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; intangible assets used in research and developmental activities acquired in an asset acquisition should be expensed at the acquisition date if there is no alternative future use in other R&amp;amp;D projects or otherwise (i.e., if they have no economic value). The Company determined that product candidates pertaining to Spyre had no alternative future use at the time of acquisition and recorded $130.2&#160;million to Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process&lt;/div&gt; Research and Development Expenses as of the date of acquisition. The difference between this amount and the $113.2&#160;million cost to acquire Spyre represents the net liabilities assumed of $17.0&#160;million. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of acquiring Spyre, and based on the criteria in Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; of the Securities and Exchange Commission&#x2019;s (the &#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X,&lt;/div&gt; the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#x2019;s full financial statements are not material to the Company&#x2019;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; and Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#x2019;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#x2019;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#x2019;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#x2019;s option to exclusively license IPR&amp;amp;D. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;amp;D asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#x2019;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#x2019;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, the Board of Directors approved a restructuring of the Company&#x2019;s workforce pursuant to which the Company&#x2019;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#x2019;s clinical programs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#x2019; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#x2019;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of Spyre was comprised of the Company&#x2019;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of June&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;22&lt;/div&gt;, 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;023,&lt;/div&gt; Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#x2019;s insured limit were $2.8&#160;million. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. &lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="P09_08_2023To09_08_2023" id="ixv-24850">1-for-25</us-gaap:StockholdersEquityReverseStockSplit>
    <syre:FixedExchangeRatio
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis"
      decimals="7"
      id="ixv-24854"
      unitRef="Unit_pure">0.5494488</syre:FixedExchangeRatio>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-24855"
      unitRef="Unit_shares">517809</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-24856"
      unitRef="Unit_shares">364887</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-24858"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-24859"
      unitRef="Unit_pure">40</us-gaap:PreferredStockConvertibleConversionRatio>
    <syre:OutstandingAndUnexercisedStockOptions
      contextRef="P06_22_2023To06_22_2023_AssetAcquisitionMemberusgaapAssetAcquisitionAxis_Spyre2023EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-24860"
      unitRef="Unit_shares">2734</syre:OutstandingAndUnexercisedStockOptions>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023"
      decimals="-5"
      id="ixv-24864"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      id="ixv-24865"
      unitRef="Unit_shares">364887</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      id="ixv-24866"
      unitRef="Unit_shares">14595480</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableSharesOfCommonStockOnAnAsConvertedBasis>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P06_22_2023To06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="INF"
      id="ixv-24868"
      unitRef="Unit_shares">517809</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      id="ixv-24869"
      unitRef="Unit_USD_per_Share">291.08</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn06_22_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="3"
      id="ixv-24870"
      unitRef="Unit_USD_per_Share">7.277</us-gaap:SharesIssuedPricePerShare>
    <syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-24872"
      unitRef="Unit_pure">0.01</syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-24893"> &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Asset Acquisition costs are shown on the following table (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Consideration transferred in Series A Preferred Stock and common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transaction costs incurred by Aeglea&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s allocation of the purchase price to net assets acquired is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,188&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash acquired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,035&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cost to acquire asset&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113,176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      id="ixv-24917"
      unitRef="Unit_USD">109979000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      id="ixv-24925"
      unitRef="Unit_USD">3197000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      id="ixv-24941"
      unitRef="Unit_USD">113176000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      id="ixv-24975"
      unitRef="Unit_USD">130188000</syre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      id="ixv-24983"
      unitRef="Unit_USD">3035000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      id="ixv-24991"
      unitRef="Unit_USD">20047000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-3"
      id="ixv-25007"
      unitRef="Unit_USD">113176000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <syre:AcquiredInProcessResearchAndDevelopment
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-25021"
      unitRef="Unit_USD">130200000</syre:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-25023"
      unitRef="Unit_USD">113200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <syre:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="P06_22_2023To06_22_2023_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      id="ixv-25024"
      unitRef="Unit_USD">17000000</syre:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25025"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of acquiring Spyre, and based on the criteria in Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; of the Securities and Exchange Commission&#x2019;s (the &#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X,&lt;/div&gt; the Company would ordinarily be required to file certain historical audited financial statements for Spyre and corresponding pro forma financial information pursuant to Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Further, the historical financial statements could require the inclusion of predecessor entity information, if warranted. However, because the Company believes that Spyre&#x2019;s full financial statements are not material to the Company&#x2019;s shareholders and would be of limited value to investors, the Company requested relief from the SEC from the requirements under Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-05&lt;/div&gt; and Article 11 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; to file audited financial statements and pro forma financial information in connection with the acquisition of Spyre. In response to the waiver request, the SEC provided the Company with a waiver that it could file an audited Statement of Assets Acquired and Liabilities Assumed from Spyre Therapeutics, Inc. on the basis of the allocation of the Company&#x2019;s purchase price as of the acquisition date of June&#160;22, 2023. Stand-alone full financial statements related to the assets acquired have not been prepared previously. This financial statement is not intended to be a complete presentation of the financial position, results of operations, or cash flows of Spyre. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that it was the acquirer of Spyre under ASC 805 due to the relative voting rights in the combined entity, the composition of the governing body of the combined entity, and the composition of the senior management of the combined entity remaining relatively the same before and after the consummation of the transaction. The Company determined that the future conversion of the Series A Preferred Stock, if approved by the Company&#x2019;s voting shareholders, was an independent event based on it being outside of the control of the Company and therefore substantive. The Company did not succeed to substantially all of Paragon&#x2019;s business nor acquire from Paragon any separately identifiable line of business, the Company concluded that Paragon did not meet the definition of predecessor. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company concluded that the arrangement meets the definition of an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, Spyre&#x2019;s option to exclusively license IPR&amp;amp;D. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-acquisition&lt;/div&gt; direct costs recorded in accrued professional and consulting fees. Goodwill is not recognized in asset acquisitions. When a transaction accounted for as an asset acquisition includes an IPR&amp;amp;D asset, the IPR&amp;amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. Otherwise, the cost allocated to acquire an IPR&amp;amp;D asset with no alternative future use is charged to expense at the acquisition date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization of the Company&#x2019;s product candidates will require significant additional financing before a commercial drug can be produced and marketed. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology and market acceptance of the Company&#x2019;s product candidates. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company&#x2019;s future success. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, the Board of Directors approved a restructuring of the Company&#x2019;s workforce pursuant to which the Company&#x2019;s workforce was reduced by approximately 83%, retaining approximately 10 employees. Additionally, the Company announced interim results from its ongoing Phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria. Following a review of the interim results and other business considerations, the Company explored strategic alternatives with the goal of maximizing stockholder value, including possible business combinations and/or a divestiture of the Company&#x2019;s clinical programs. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, the Company acquired the net liabilities from Spyre. Additionally, on June&#160;26, 2023, the Company completed a private placement of shares of Series A Preferred Stock and sold an aggregate of 721,452 shares of Series A Preferred Stock for an aggregate purchase price of approximately $210.0&#160;million before deducting approximately $12.7&#160;million placement agent and other offering expenses. In accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, in connection with the preparation of the statement of assets acquired and liabilities assumed of Spyre, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statement is available to be issued. Our Series A Preferred Stock agreement requires us to seek stockholder approval for the conversion of the Series A Preferred Stock to Common Stock. The Company has agreed to hold a stockholders&#x2019; meeting to submit this matter to its stockholders for their consideration. In connection with this, the Company filed with the SEC a preliminary proxy statement and other relevant materials. The stockholder meeting has not occurred as of October&#160;6, 2023. If our stockholders do not timely approve the conversion of our Series A Preferred Stock, then the holders of our Series A Preferred Stock &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;are entitled to require us to settle their shares of Series A Preferred Stock for cash at a price per share equal to the fair value of the Series A Preferred Stock, as described in our Certificate of Designation relating to the Series&#160;A Preferred Stock. The cash redemption is not in our control and raises substantial doubt about our ability to continue as a going concern. The accompanying financial statement assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. &lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P04_01_2023To04_30_2023"
      decimals="2"
      id="ixv-25064"
      unitRef="Unit_pure">0.83</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <syre:NumberOfEmployeesRetained
      contextRef="P04_01_2023To04_30_2023"
      decimals="0"
      id="ixv-25065"
      unitRef="Unit_employee">10</syre:NumberOfEmployeesRetained>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-25067"
      unitRef="Unit_shares">721452</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-25068"
      unitRef="Unit_USD">210000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <syre:PlacementAgentAndOtherOfferingExpenses
      contextRef="P06_26_2023To06_26_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-25069"
      unitRef="Unit_USD">12700000</syre:PlacementAgentAndOtherOfferingExpenses>
    <us-gaap:UseOfEstimates contextRef="P06_22_2023To06_22_2023" id="ixv-25094"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and certain financial statement disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. Key estimates that management considers in the preparation of the Company&#x2019;s financial statements relate to accrued option costs payable to Paragon and the valuation of consideration transferred. The consideration transferred in acquiring IPR&amp;amp;D in connection with the acquisition of Spyre was comprised of the Company&#x2019;s common stock and shares of Series A preferred stock. To determine the fair value of the equity transferred, the Company considered the per share value of its concurrent private financing transaction, which was an over-subscribed financing event involving a group of investors. &lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25100"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of June&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;22&lt;/div&gt;, 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;023,&lt;/div&gt; Spyre held $3.0&#160;million in cash and cash equivalents, which consisted of a single deposit account denominated in U.S. dollars. At June&#160;22, 2023, U.S. cash deposits in excess of the Federal Deposit Insurance Corporation&#x2019;s insured limit were $2.8&#160;million. &lt;/div&gt; </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_22_2023"
      decimals="-5"
      id="ixv-25108"
      unitRef="Unit_USD">3000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Cash
      contextRef="PAsOn06_22_2023_USBankingInstitutionMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      id="ixv-25109"
      unitRef="Unit_USD">2800000</us-gaap:Cash>
    <syre:AccruedLiabilitiesPolicyTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25110"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities primarily consist of research initiation fees, reimbursable expenses under the Paragon Agreement for historical costs incurred by Paragon, professional and consulting fees, and the fair of assumed Parapyre Option Obligation. &lt;/div&gt; </syre:AccruedLiabilitiesPolicyTextBlock>
    <syre:AccruedLiabilitiesTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25116"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Accrued liabilities &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Asset Acquisition, the Company assumed the rights and obligations of Spyre under the Paragon Agreement. Under the Paragon Agreement, Spyre is obligated to compensate Paragon on a quarterly basis for its services performed under each research program based on the actual costs incurred with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mark-up&lt;/div&gt; costs pursuant to the terms of the Paragon Agreement. As of the date of the Asset Acquisition, Spyre had incurred total expenses of $19.0&#160;million under the Paragon Agreement since inception, inclusive of a $3.0&#160;million research initiation fee that was due upon signing of the Paragon Agreement and $16.0&#160;million of historical reimbursable expenses owed to Paragon. As of June&#160;22, 2023, $19.0&#160;million was unpaid and was assumed by the Company through the Asset Acquisition. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued option cost payable to Paragon&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value of assumed Parapyre Option Obligation (Note&#160;3)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </syre:AccruedLiabilitiesTextBlock>
    <syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-25121"
      unitRef="Unit_USD">19000000</syre:RelatedPartyExpensesIncurredPriorToAssetAcquisition>
    <syre:ResearchInitiationFees
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-25122"
      unitRef="Unit_USD">3000000</syre:ResearchInitiationFees>
    <syre:ReimbursableResearchCosts
      contextRef="P06_22_2023To06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-25123"
      unitRef="Unit_USD">16000000</syre:ReimbursableResearchCosts>
    <syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition
      contextRef="PAsOn06_22_2023_ParagonAgreementMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-25124"
      unitRef="Unit_USD">19000000</syre:RelatedPartyExpensesUnpaidPriorToAssetAcquisition>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25125"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;June&#160;22,&lt;br/&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued option cost payable to Paragon&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,987&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional and consulting fees&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value of assumed Parapyre Option Obligation (Note&#160;3)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <syre:AccruedOptionCostPayable
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-25149"
      unitRef="Unit_USD">18987000</syre:AccruedOptionCostPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-25157"
      unitRef="Unit_USD">917000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ProgramRightsObligations
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-25165"
      unitRef="Unit_USD">143000</us-gaap:ProgramRightsObligations>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn06_22_2023"
      decimals="-3"
      id="ixv-25181"
      unitRef="Unit_USD">20047000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25201"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Parapyre Option Obligation &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2023, in connection with the Asset Acquisition, the Company assumed the Parapyre Option Obligation which provided for an annual equity grant of options for Parapyre to purchase 1% of the then outstanding shares of Spyre&#x2019;s common stock, on a fully diluted basis, on the last business day of each calendar year during the term of the Paragon Agreement, at the fair market value determined by the board of directors of Spyre. As a result of the Asset Acquisition the Parapyre Option Obligation shall continue and Parapyre shall be entitled to receive the equivalent shares of the Company with the same terms. The Parapyre Option Obligation is considered a Level&#160;2 liability based on observable market data for substantially the full term of the liabilities. The Parapyre Option Obligation is measured each period using a Black-Scholes model to estimate the fair value of the option grant. Changes in the fair value of the Parapyre Option Obligation are recorded as stock-based compensation within Research and development expenses for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; who provided &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; testing services within Research and development expenses. As of June&#160;22, 2023, the estimated liability of the Parapyre Option Obligation was $0.1&#160;million and was included in accrued liabilities. &lt;/div&gt; </us-gaap:AssetAcquisitionTextBlock>
    <syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
      contextRef="PAsOn06_22_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-25205"
      unitRef="Unit_pure">0.01</syre:PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="PAsOn06_22_2023"
      decimals="-5"
      id="ixv-25208"
      unitRef="Unit_USD">100000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25209"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Related Party Transactions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Paragon and Parapyre Holding LLC each beneficially owns less than 5% of the Company&#x2019;s capital stock through their respective holdings of Common Stock and Series A Preferred Stock of the Company. Fairmount Funds Management LLC (&#x201c;Fairmount&#x201d;) beneficially owns more than 5% of our capital stock, has two seats on the Company&#x2019;s board of directors and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and Fair Journey Biologics. Fairmount has appointed Paragon&#x2019;s board of directors and has the contractual right to approve the appointment of any executive officers. Parapyre is an entity formed by Paragon as a vehicle to hold equity in Spyre in order to share profits with certain employees of Paragon. &lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn06_22_2023_MaximumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_ParagonAndParapyreHoldingLlcMembersrtOwnershipAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-25213"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-25214"
      unitRef="Unit_pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <syre:RelatedPartyTransactionNumberOfBoardSeats
      contextRef="PAsOn06_22_2023"
      decimals="0"
      id="ixv-25215"
      unitRef="Unit_BOARDSEAT">2</syre:RelatedPartyTransactionNumberOfBoardSeats>
    <syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty
      contextRef="PAsOn06_22_2023_FairmountFundsManagementLlcMembersrtOwnershipAxis_MinimumMembersrtRangeAxis_OwnershipInterestMemberusgaapRelatedPartyTransactionAxis_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      id="ixv-25216"
      unitRef="Unit_pure">0.05</syre:MinorityInterestOwnershipPercentageByNoncontrollingOwnersHeldInThirdParty>
    <us-gaap:SubsequentEventsTextBlock contextRef="P06_22_2023To06_22_2023" id="ixv-25217"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s management has evaluated subsequent events up to October&#160;6, 2023, the date the Statement of Assets Acquired and Liabilities Assumed from Spyre, Inc. was available to be issued. There have been no subsequent events that require recognition or disclosure in this financial statement except for the following described below. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;7, 2023, the Company issued 517,809 shares of common stock and 364,887 shares of Series&#160;A Preferred Stock as part of its consideration transferred in connection with the Asset Acquisition. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;8, 2023, the Company filed a preliminary proxy statement with the SEC to solicit approval of the conversion of the Series A Preferred Stock into shares of Common Stock in connection with the Asset acquisition, among other matters, at a special meeting of stockholders. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;8, 2023, the Company&#x2019;s Board of Directors approved a reverse stock split of the Company&#x2019;s common stock, par value $0.0001 per share, at a ratio of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-25&lt;/div&gt;&lt;/div&gt; and a reduction in the total number of authorized shares of Common Stock from 500,000,000 shares to 20,000,000 shares. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;29, 2023, the Company amended the Paragon Agreement to amend and restate certain terms of the option grant pertaining to the Parapyre Option Obligation, including but not limited to (i)&#160;defining that the annual equity grant of options is based on the outstanding shares of Aeglea&#x2019;s common stock, (ii)&#160;establishing the grant date as the last business day of each applicable calendar year, and (iii)&#160;defining the term of the options granted is ten years. The liability related to the Parapyre Option Obligation will be recorded pursuant to the amended Paragon Agreement on a go forward basis. The Company determined that these amendments would not have materially impacted the liability as of June&#160;22, 2023. &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P07_07_2023To07_07_2023_CommonStockMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-25222"
      unitRef="Unit_shares">517809</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="P07_07_2023To07_07_2023_SeriesANonVotingConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SpyreTherapeuticsIncMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-25223"
      unitRef="Unit_shares">364887</syre:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      id="ixv-25226"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="P09_08_2023To09_08_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-25229">1-for-25</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P09_08_2023To09_08_2023_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-25230"
      unitRef="Unit_shares">500000000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P09_08_2023To09_08_2023_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-25231"
      unitRef="Unit_shares">20000000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P09_29_2023To09_29_2023_ParapyreOptionObligationMemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-25233">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_103881978"
          xlink:label="Fact_103881978"
          xlink:type="locator"/>
        <link:footnote id="FN_363400" xlink:label="FN_363400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $48.5 million in related party expenses for the year ended December 31, 2023 and no related party expenses for the year ended months ended December 31, 2022 and 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_103881978"
          xlink:to="FN_363400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_103881979"
          xlink:label="Fact_103881979"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_103881979"
          xlink:to="FN_363400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_103881980"
          xlink:label="Fact_103881980"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_103881980"
          xlink:to="FN_363400"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
